PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Moldes, M; Feve, B; Pairault, J				Moldes, M; Feve, B; Pairault, J			Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage - Differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADHESION PROTEIN-1 REVEALS; VASCULAR SMOOTH-MUSCLE; HUMAN UMBILICAL ARTERY; BROWN ADIPOSE-TISSUE; INSULIN-RESISTANCE; RAT AORTA; MESSENGER-RNA; GLUCOSE-TRANSPORT; HYDROGEN-PEROXIDE	In an effort to identify novel mRNAs modulated during the course of adipose conversion, we have used a simplified differential display technique and have isolated a cDNA encoding an amine oxidase tremendously expressed in the adipocyte, the semicarbazide-sensitive amine oxidase (SSAO), The predicted amino acid sequence (765 amino acids) is likely to be the homologue of the human placental amine oxidase and of the partially known sequence of the rat adipocyte membrane amine oxidase, SSAO mRNAs are present in several tissues, but strikingly, the highest levels of gene expression are found in adipose tissue and aorta. Enzyme transcript levels are barely detectable in preadipocytes but are induced several hundred-fold during the adipocyte differentiation of 3T3-L1 or 3T3-F442A cells and of rat precursor primary cultures. These changes in transcript levels parallel a sharp increase in SSAO enzyme activity. The biochemical properties of the SSAO present in 3T3-L1 or 3T3-F442A adipocytes closely resemble the features of the SSAO activity previously described in white and brown adipose tissues. Interestingly, SSAO mRNA levels and enzyme activity drop in response to effecters of the cAMP pathway and to the cytokine tumor necrosis factor-alpha, indicating that two major signaling molecules of adipose tissue development and metabolism can control SSAO function, Moreover, the expression of SSAO transcripts and activity are clearly down-regulated in white adipose tissue from obese Zucker rats. Because of its known stimulatory effect on glucose transport, its biochemical properties and its pattern of expression and regulation, SSAO could play an important role in the regulation of adipocyte homeostasis.	Univ Paris 06, Ctr Rech Biomed Cordeliers, UPRES A 7079 CNRS, F-75270 Paris 06, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Pairault, J (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, UPRES A 7079 CNRS, 15 Rue Ecole Med, F-75270 Paris 06, France.	pairault@infobiogen.fr	Moldes-Garnaud, Marthe/E-4817-2017	Moldes-Garnaud, Marthe/0000-0002-9950-2267; Feve, Bruno/0000-0001-6577-9009				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ANTRAS J, 1991, MOL CELL ENDOCRINOL, V82, P183, DOI 10.1016/0303-7207(91)90030-V; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BARRAND MA, 1982, BIOCHEM PHARMACOL, V31, P2177, DOI 10.1016/0006-2952(82)90511-1; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Bono P, 1998, J IMMUNOL, V161, P2953; Bono P, 1998, J IMMUNOL, V160, P5563; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONFORTI L, 1993, BIOCHEM PHARMACOL, V46, P603, DOI 10.1016/0006-2952(93)90544-7; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CZECH MP, 1974, J BIOL CHEM, V249, P1001; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; ELLIOTT J, 1989, BIOCHEM PHARMACOL, V38, P1507, DOI 10.1016/0006-2952(89)90191-3; Enrique-Tarancon G, 1998, J BIOL CHEM, V273, P8025, DOI 10.1074/jbc.273.14.8025; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Frohman Michael A., 1995, P381; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GRUNFELD C, 1991, TRENDS ENDOCRIN MET, V2, P213, DOI 10.1016/1043-2760(91)90027-K; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HYSMITH RM, 1987, J CARDIOVASC PHARM, V9, P668, DOI 10.1097/00005344-198706000-00005; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEWINSOHN R, 1978, BIOCHEM PHARMACOL, V27, P1857, DOI 10.1016/0006-2952(78)90033-3; LEWINSOHN R, 1981, J PHARM PHARMACOL, V33, P569, DOI 10.1111/j.2042-7158.1981.tb13868.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLE SA, 1980, J BIOL CHEM, V255, P888; LIVINGSTON JN, 1977, J BIOL CHEM, V252, P560; Lizcano JM, 1998, BIOCHEM J, V331, P69, DOI 10.1042/bj3310069; Lizcano JM, 1996, BIOCHEM PHARMACOL, V52, P187, DOI 10.1016/0006-2952(96)00132-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYLES GA, 1992, BIOCHEM PHARMACOL, V43, P1409, DOI 10.1016/0006-2952(92)90196-P; LYLES GA, 1995, BIOCHEM PHARMACOL, V49, P416, DOI 10.1016/0006-2952(94)00421-H; LYLES GA, 1985, J PHARM PHARMACOL, V37, P637, DOI 10.1111/j.2042-7158.1985.tb05100.x; MATSUMOTO T, 1982, BIOCHEM PHARMACOL, V31, P2207, DOI 10.1016/0006-2952(82)90520-2; MAY JM, 1979, J BIOL CHEM, V254, P9017; Morris NJ, 1997, J BIOL CHEM, V272, P9388; MU D, 1994, J BIOL CHEM, V269, P9926; MUCHMORE DB, 1982, BIOCHEMISTRY-US, V21, P3886, DOI 10.1021/bi00259a025; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; OKUYAMA T, 1961, ARCH BIOCHEM BIOPHYS, V95, P242, DOI 10.1016/0003-9861(61)90141-2; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; PRECIOUS E, 1988, BIOCHEM PHARMACOL, V37, P707, DOI 10.1016/0006-2952(88)90145-1; RAIMONDI L, 1992, COMP BIOCHEM PHYS B, V102, P953, DOI 10.1016/0305-0491(92)90108-4; RAIMONDI L, 1991, BIOCHEM PHARMACOL, V41, P469, DOI 10.1016/0006-2952(91)90549-K; RODBELL M, 1964, J BIOL CHEM, V239, P375; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; RYDER TA, 1979, HISTOCHEMISTRY, V62, P93, DOI 10.1007/BF00537010; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; Smith DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/jem.188.1.17; SOKOLOV BP, 1994, NUCLEIC ACIDS RES, V22, P4009, DOI 10.1093/nar/22.19.4009; SPIEGELMAN BM, 1981, CELL, V24, P503, DOI 10.1016/0092-8674(81)90341-X; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WIBO M, 1980, EUR J BIOCHEM, V112, P87, DOI 10.1111/j.1432-1033.1980.tb04990.x; Zhang XP, 1996, GENE, V179, P279, DOI 10.1016/S0378-1119(96)00387-3	78	77	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9515	9523		10.1074/jbc.274.14.9515	http://dx.doi.org/10.1074/jbc.274.14.9515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092636	hybrid			2022-12-27	WOS:000079451800055
J	Suhy, DA; Simon, KD; Linzer, DIH; O'Halloran, TV				Suhy, DA; Simon, KD; Linzer, DIH; O'Halloran, TV			Metallothionein is part of a zinc-scavenging mechanism for cell survival under conditions of extreme zinc deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; TRANSCRIPTION FACTOR; DIETARY ZINC; CADMIUM-RESISTANT; CONFERS RESISTANCE; RESPONSE ELEMENT; HEPATOMA-CELLS; MOUSE CELLS; RAT-LIVER; EXPRESSION	Metallothionein (MT) is a small cysteine-rich protein thought to play a critical role in cellular detoxification of inorganic species by sequestering metal ions that are present in elevated concentrations. We demonstrate here that metallothionein can play an important role at the other end of the homeostatic spectrum by scavenging an essential metal in a mouse fibroblast cell line that has been cultured under conditions of extreme zinc deprivation (LZA-LTK-). These cells unexpectedly produce constitutively high levels of metallothionein mRNA; however, the MT protein accumulates only when high concentrations of zinc are provided in the media. Until this MT pool is saturated, no measurable zinc remains in the external media. In this case, zinc deprivation leads to amplification of the MT gene locus in the LZA-LTK- cell line. Furthermore, the intracellular zinc levels in the fully adapted cells remain at the normal level of 0.4 fmol zinc/cell, even when extracellular zinc concentration is decreased by 2 orders of magnitude relative to normal media.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@nwu.edu	Das, Simon Kumar/AAC-4266-2019; O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NCI NIH HHS [P30 CA60553] Funding Source: Medline; NIDDK NIH HHS [R01 DK52627] Funding Source: Medline; NIGMS NIH HHS [R01 GM038784, R01 GM38784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI YB, 1991, METHOD ENZYMOL, V205, P108; BEACH LR, 1981, P NATL ACAD SCI-BIOL, V78, P2110, DOI 10.1073/pnas.78.4.2110; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BLALOCK TL, 1988, J NUTR, V118, P222, DOI 10.1093/jn/118.2.222; BREMNER I, 1993, METALLOTHIONEIN, V3, P111; Brouwer M, 1996, ADV INORG BIOCHEM, P235; CHOPRA A, 1990, J CELL PHYSIOL, V142, P316, DOI 10.1002/jcp.1041420214; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COUSINS RJ, 1992, J NUTR, V122, P56, DOI 10.1093/jn/122.1.56; Cui L, 1998, J NUTR, V128, P1092, DOI 10.1093/jn/128.7.1092; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; CZAJA MJ, 1991, J CELL PHYSIOL, V147, P434, DOI 10.1002/jcp.1041470308; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; FREEDMAN JH, 1986, J BIOL CHEM, V261, P1840; FREEDMAN JH, 1989, BIOCHIM BIOPHYS ACTA, V992, P145, DOI 10.1016/0304-4165(89)90003-2; GALLANT KR, 1986, BIOCHEM CELL BIOL, V64, P8, DOI 10.1139/o86-002; GALLANT KR, 1987, J NUTR, V117, P709, DOI 10.1093/jn/117.4.709; GICK GG, 1982, J BIOL CHEM, V257, P9049; GRAHAM JM, 1992, CELL BIOL LABFAX, P7; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; ISZARD MB, 1995, TOXICOL APPL PHARM, V133, P305, DOI 10.1006/taap.1995.1155; JIN NZ, 1993, BIOL TRACE ELEM RES, V36, P183, DOI 10.1007/BF02783177; Kelly EJ, 1996, J NUTR, V126, P1782; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLAASSEN CD, 1993, METALLOTHIONEIN, V3, P207; KRAKER AJ, 1988, CANCER RES, V48, P3381; LANE LC, 1978, ANAL BIOCHEM, V86, P655, DOI 10.1016/0003-2697(78)90792-3; Lee DK, 1996, MOL REPROD DEV, V43, P158, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;158::AID-MRD4&gt;3.0.CO;2-Q; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MAYO KE, 1982, J BIOL CHEM, V257, P3061; MENARD MP, 1981, J NUTR, V111, P1353, DOI 10.1093/jn/111.8.1353; MESSER HH, 1982, J NUTR, V112, P652, DOI 10.1093/jn/112.4.652; MINKEL DT, 1980, BIOCHEM J, V191, P475, DOI 10.1042/bj1910475; MINKEL DT, 1979, CANCER RES, V39, P2451; MORRISON JN, 1987, J NUTR, V117, P1588, DOI 10.1093/jn/117.9.1588; PALMITER RD, 1995, TOXICOL APPL PHARM, V135, P139, DOI 10.1006/taap.1995.1216; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PATTANAIK A, 1994, J INORG BIOCHEM, V54, P91, DOI 10.1016/0162-0134(94)80023-5; PRASAD AS, 1991, AM J CLIN NUTR, V53, P403, DOI 10.1093/ajcn/53.2.403; PRASAD AS, 1976, TRACE ELEMENTS HUMAN, P1; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RICHARDS MP, 1976, J NUTR, V106, P1591, DOI 10.1093/jn/106.11.1591; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHROEDER JJ, 1991, J NUTR, V121, P844, DOI 10.1093/jn/121.6.844; SCHROEDER JJ, 1991, METHOD ENZYMOL, V205, P575; SELDEN RF, 1987, CURRENT PROTOCOLS MO; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUHY DA, 1996, MET IONS BIOL SYST, V32, P558; TOHOYAMA H, 1992, FEMS MICROBIOL LETT, V95, P81, DOI 10.1111/j.1574-6968.1992.tb05346.x; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WAALKES MP, 1993, METALLOTHIONEIN, V3, P243; WAN M, 1995, EXPERIENTIA, V51, P606, DOI 10.1007/BF02128753; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	67	117	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9183	9192		10.1074/jbc.274.14.9183	http://dx.doi.org/10.1074/jbc.274.14.9183			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092590	hybrid			2022-12-27	WOS:000079451800009
J	Ujita, M; McAuliffe, J; Suzuki, M; Hindsgaul, O; Clausen, H; Fukuda, MN; Fukuda, M				Ujita, M; McAuliffe, J; Suzuki, M; Hindsgaul, O; Clausen, H; Fukuda, MN; Fukuda, M			Regulation of I-branched poly-N-acetyllactosamine synthesis - Concerted actions by i-extension enzyme, I-branching enzyme, and beta 1,4-galactosyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-I; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HUMAN-ERYTHROCYTE-MEMBRANE; EMBRYONAL CARCINOMA-CELLS; LINKED SUGAR CHAINS; L-SELECTIN; LYMPHOCYTE ADHESION; EXPRESSION CLONING; POLYSIALIC ACID; UDP-GALACTOSE	I-branched poly-N-acetyllactosamine is a unique carbohydrate composed of N-acetyllactosamine branches attached to linear poly-N-acetyllactosamine, which is synthesized by I-branching beta 1,6-N-acetylglucosaminyl-transferase. I-branched poly-N-acetyllactosamine can carry bivalent functional oligosaccharides such as sialyl Lewis(x), which provide much better carbohydrate ligands than monovalent functional oligosaccharides. In the present study, we first demonstrate that I-branching beta 1,6-N-acetylglucosaminyltransferase cloned from human PA-1 embryonic carcinoma cells transfers beta 1,6-linked GlcNAc preferentially to galactosyl residues of N-acetyllactosamine close to nonreducing terminals, We then demonstrate that among various beta 1,4-galactosyltransferases (beta 4Gal-Ts), beta 4Gal-TI is most efficient in adding a galactose to linear and branched poly-N-acetyllactosamines. When a beta 1,6-GlcNAc branched poly-N-acetyllactosamine was incubated with a mixture of beta 4Gal-TI and i-extension beta 1,3-N-acetylglucosaminyltransferase, the major product was the oligosaccharide with one N-acetyllactosamine extension on the linear Gal beta 1-->4GlcNAc beta 1-->3 side chain, Only a minor product contained galactosylated I-branch without N-acetyllactosamine extension. This finding was explained by the fact that beta 4Gal-TI adds a galactose poorly to beta 1,6-GlcNAc attached to linear poly-N-acetyllactosamines, while beta 1,3-N-acetylglucosaminyltransferase and beta 4Gal-TI efficiently add N-acetyllactosamine to linear poly-N-acetyllactosamines. Together, these results strongly suggest that galactosylation of I-branch is a rate-limiting step in I-branched poly-N-acetyllactosamine synthesis, allowing poly-N-acetyllactosamine extension mostly along the linear poly-N-acetyllactosamine side chain. These findings are entirely consistent with previous findings that poly-N-acetyllactosamines in human erythrocytes, PA-1 embryonic carcinoma cells, and rabbit erythrocytes contain multiple, short I-branches.	Burnham Inst, Glycobiol Program, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Copenhagen, Sch Dent, DK-2200 Copenhagen, Denmark	Sanford Burnham Prebys Medical Discovery Institute; University of Copenhagen	Fukuda, M (corresponding author), Burnham Inst, Glycobiol Program, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		clausen, henrik/AAD-8016-2021	Clausen, Henrik/0000-0002-0915-5055	NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; FUKUDA MN, 1992, CRC HDB ENDOGLYCOSID, P55; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GU J, 1992, J BIOL CHEM, V267, P2994; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; IMAI Y, 1993, NATURE, V361, P555; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; Kido M, 1998, BIOCHEM BIOPH RES CO, V245, P860, DOI 10.1006/bbrc.1998.8537; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; LEE N, 1990, J BIOL CHEM, V265, P20476; LOWE BJ, 1994, MOL GLYCOBIOLOGY, P163; Mattila P, 1998, J BIOL CHEM, V273, P27633, DOI 10.1074/jbc.273.42.27633; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PILLER F, 1984, J BIOL CHEM, V259, P3385; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; ROMANS DG, 1980, J IMMUNOL, V124, P2807; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Sakamoto Y, 1998, J BIOL CHEM, V273, P27625, DOI 10.1074/jbc.273.42.27625; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SRIVASTAVA G, 1992, CARBOHYD RES, V224, P83, DOI 10.1016/0008-6215(92)84095-A; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WANG WC, 1991, J BIOL CHEM, V266, P23185; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YOSHIMA H, 1980, J BIOL CHEM, V255, P793; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2	52	40	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9296	9304		10.1074/jbc.274.14.9296	http://dx.doi.org/10.1074/jbc.274.14.9296			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092606	hybrid			2022-12-27	WOS:000079451800025
J	Carman, CV; Lisanti, MP; Benovic, JL				Carman, CV; Lisanti, MP; Benovic, JL			Regulation of G protein-coupled receptor kinases by caveolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; SCAFFOLDING DOMAIN; ADENYLYL-CYCLASE; TYROSINE KINASE; BINDING; AGONIST; EXPRESSION; SUBUNITS	G protein-coupled receptor kinases (GRKs) have been principally characterized by their ability to phosphorylate and desensitize G protein-coupled receptors, However, recent studies suggest that GRKs may have more diverse protein/protein interactions in cells. Based on the identification of a consensus caveolin binding motif within the pleckstrin homology domain of GRK2, we tested the direct binding of purified full-length GRK2 to various glutathione S-transferase-caveolin-1 fusion proteins, and we discovered a specific interaction of GRK2 with the caveolin scaffolding domain. Interestingly, analysis of GRK1 and GRK5, which lack a pleckstrin homology domain, revealed in vitro binding properties similar to those of GRK2, Maltose-binding protein caveolin and glutathione S-transferase-GRK fusion proteins were used to map overlapping regions in the N termini of both GRK2 and GRK5 that appear to mediate conserved GRK/caveolin interactions. In vivo association of GRK2 and caveolin was suggested by co-fractionation of GRK2 with caveolin in A431 and NIH-3T3 cells and was further supported by co-immunoprecipitation of GRK2 and caveolin in COS-l cells. Functional significance for the GRK/caveolin interaction was demonstrated by the potent inhibition of GRK-mediated phosphorylation of both receptor and peptide substrates by caveolin-1 and -3 scaffolding domain peptides, These data reveal a novel mode for the regulation of GRKs that is likely to play an important role in their cellular function.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Jefferson University; Jefferson University; Jefferson University; Yeshiva University; Albert Einstein College of Medicine	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu	Carman, Christopher/L-8108-2016; Lisanti, Michael P/C-6866-2013; Carman, Christopher V./AAX-8995-2020; Lisanti, Michael/B-6131-2018	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548; Lisanti, Michael/0000-0003-2034-1382	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM44944, GM50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; KEEN JH, 1990, ADV CELL BIOL, V3, P153; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; KIM CM, 1993, RECEPTOR, V3, P39; Kudej RK, 1997, J MOL CELL CARDIOL, V29, P2735, DOI 10.1006/jmcc.1997.0508; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Oka N, 1997, AM J PHYSIOL-CELL PH, V273, pC1957, DOI 10.1152/ajpcell.1997.273.6.C1957; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Ping PP, 1997, AM J PHYSIOL-HEART C, V273, pH707, DOI 10.1152/ajpheart.1997.273.2.H707; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	50	149	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8858	8864		10.1074/jbc.274.13.8858	http://dx.doi.org/10.1074/jbc.274.13.8858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085129	hybrid			2022-12-27	WOS:000079451600071
J	Eckhardt, M; Gotza, B; Gerardy-Schahn, R				Eckhardt, M; Gotza, B; Gerardy-Schahn, R			Membrane topology of the mammalian CMP-sialic acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; N-ACETYLGLUCOSAMINE TRANSPORTER; UDP-GALACTOSE TRANSPORTER; ALPHA-MANNOSIDASE-II; MOLECULAR-CLONING; GOLGI-APPARATUS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; P-GLYCOPROTEIN	Nucleotide sugar transporters form a family of distantly related membrane proteins of the Golgis apparatus and the endoplasmic reticulum. The first transporter sequences have been identified within the last 2 years. However, information about the secondary and tertiary structure for these molecules has been limited to theoretical considerations. In the present study, an epitope-insertion approach was used to investigate the membrane topology of the CMP-sialic acid transporter. Immunofluorescence studies were carried out to analyze the orientation of the introduced epitopes in semipermeabilized cells. Both an amino-terminally introduced FLAG sequence and a carboxyl-terminal hemagglutinin tag were found to be oriented toward the cytosol. Results obtained with CMP sialic acid transporter variants that contained the hemagglutinin epitope in potential intermembrane loop structures were in good correlation with the presence of 10 transmembrane regions. This building concept seems to be preserved also in other mammalian and nonmammalian nucleotide sugar transporters. Moreover, the functional analysis of the generated mutants demonstrated that insertions in or very close to membrane-spanning regions inactivate the transport process, whereas those in hydrophilic loop structures have no detectable effect on the activity. This study points the way toward understanding structure-function relationships of nucleotide sugar transporters.	Hannover Med Sch, Inst Med Mikrobiol, D-30625 Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	rgs@mikrobio.h.shuttle.de						Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARON MD, 1990, J BIOL CHEM, V265, P19928; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAPASSO JM, 1984, BIOCHIM BIOPHYS ACTA, V777, P133, DOI 10.1016/0005-2736(84)90505-4; CECCHELLI R, 1985, EUR J BIOCHEM, V153, P111, DOI 10.1111/j.1432-1033.1985.tb09275.x; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HARVEY BE, 1993, BIOCHEM BIOPH RES CO, V190, P571, DOI 10.1006/bbrc.1993.1086; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; HIRSCHBERG CB, 1997, GOLGI APPARATUS, P163; Ishida N, 1996, J BIOCHEM, V120, P1074; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KUHN NJ, 1976, BIOCHEM J, V154, P243, DOI 10.1042/bj1540243; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGE Y, 1991, J LIPID RES, V32, P329; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PESSINO A, 1991, J BIOL CHEM, V266, P20213; Reuter G, 1996, BIOL CHEM H-S, V377, P325; ROST B, 1995, PROTEIN SCI, V4, P521; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WHITE SH, 1990, J MEMBRANE BIOL, V115, P145, DOI 10.1007/BF01869453; YAMAGUCHI A, 1992, FEBS LETT, V307, P229, DOI 10.1016/0014-5793(92)80773-A; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	52	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8779	8787		10.1074/jbc.274.13.8779	http://dx.doi.org/10.1074/jbc.274.13.8779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085119	hybrid			2022-12-27	WOS:000079451600061
J	Hanachi, P; Hershey, JWB; Vornlocher, HP				Hanachi, P; Hershey, JWB; Vornlocher, HP			Characterization of the p33 subunit of eukaryotic translation initiation factor-3 from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; RABBIT RETICULOCYTES; PRT1 PROTEIN; FACTOR EIF3; YEAST; COMPLEX; IDENTIFICATION; DIVERSITY; COMPONENT; DOMAIN	Eukaryotic translation initiation factor-3 (eIF3) is a large multisubunit complex that binds to the 40 S ribosomal subunit and promotes the binding of methionyl-tRNA(i) and mRNA. The molecular mechanism by which eIF3 exerts these functions is incompletely understood. We report here the cloning and characterization of TIF35, the Saccharomyces cerevisiae gene encoding the p33 subunit of eIF3. p33 is an essential protein of 30,501 Da that is required in vivo for initiation of protein synthesis. Glucose repression of TIF35 expressed from a GAL1 promoter results in depletion of both the p33 and p89 subunits. Expression of histidine-tagged p33 in yeast in combination with Ni2+ affinity chromatography allows the isolation of a complex containing the p135, p110, p90, p39, and p38 subunits of eIF3. The p33 subunit binds both mRNA and rRNA fragments due to an RNA recognition motif near its C terminus. Deletion of the C-terminal 71 amino acid residues causes loss of RNA binding, but expression of the truncated form as the sole source of p33 nevertheless supports the slow growth of yeast. These results indicate that the p33 subunit of eIF3 plays an important role in the initiation phase of protein synthesis and that its RNA-binding domain is required for optimal activity.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CIGAN AM, 1987, GENE, V59, P1; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; EVANS DRH, 1995, MOL CELL BIOL, V15, P4525; FEINBERG B, 1982, J BIOL CHEM, V257, P846; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; Greenberg JR, 1998, J BIOL CHEM, V273, P23485, DOI 10.1074/jbc.273.36.23485; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Guthrie C, 1991, GUIDE YEAST GENETICS; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Staehelin T, 1979, Methods Enzymol, V60, P136; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	34	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8546	8553		10.1074/jbc.274.13.8546	http://dx.doi.org/10.1074/jbc.274.13.8546			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085088	hybrid			2022-12-27	WOS:000079451600030
J	Pei, DQ				Pei, DQ			Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; GELATINASE-A; CELL-SURFACE; MT-MMPS; DIFFERENTIAL EXPRESSION; HUMAN STROMELYSIN-3; BREAST-CARCINOMA; MESSENGER-RNA; STROMAL CELLS; CANCER CELLS	A new member of the membrane-type matrix metalloproteinase (MT-MMP) subfamily tentatively named MT5-MMP was isolated from mouse brain cDNA library. It is predicted to contain (i) a candidate signal sequence, (ii) a propeptide region with the highly conserved PRCGVPD sequence, (iii) a potential furin recognition motif RRRRNKR, (iv) a zinc-binding catalytic domain, (v) a hemopexin-like domain, (vi) a 24 residue hydrophobic domain as a potential transmembrane domain, and (vii) a short cytosolic domain. Reverse transcriptase-polymerase chain reaction analysis of its transcripts indicates that MT5-MMP is expressed in a brain-specific manner consistent with the origin of its EST clone from cerebellum. It is also highly expressed during embryonic development at stages day 11 and 15. Like other MT-MMPs, MT5-MMP specifically activates progelatinase A when co-expressed in Madin-Darby canine kidney cells. Its ability to activate progelatinase A is dependent on its proteolytic activity since a mutation converting Glu to Ala in the zinc binding motif HE(255)LGH renders MT5-MMP inactive against progelatinase A. In contrast to other MT-MMPs, MT5-MMP tends to shed from cell surface as soluble proteinases, thus offering flexibility as both a cell bound and soluble proteinase for extracellular matrix remodeling processes. Taken together, these properties serve to distinguish MT5-MMP as a versatile MT-MMP playing an important role in extracellular matrix remodeling events in the brain and during embryonic development.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Gilles C, 1996, INT J CANCER, V65, P209; Imai K, 1996, CANCER RES, V56, P2707; Imamura T, 1998, J CANCER RES CLIN, V124, P65, DOI 10.1007/s004320050137; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Li H, 1998, MOL CARCINOGEN, V22, P84; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Nagase H, 1998, Cell Res, V8, P179; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohtani H, 1996, INT J CANCER, V68, P565, DOI 10.1002/(SICI)1097-0215(19961127)68:5<565::AID-IJC2>3.0.CO;2-X; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shofuda K, 1997, J BIOL CHEM, V272, P9749; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueno H, 1997, CANCER RES, V57, P2055; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1996, KIDNEY INT, V49, pS68; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yamamoto M, 1996, CANCER RES, V56, P384	38	215	224	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8925	8932		10.1074/jbc.274.13.8925	http://dx.doi.org/10.1074/jbc.274.13.8925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085137	hybrid			2022-12-27	WOS:000079451600079
J	Soskic, V; Nyakatura, E; Roos, M; Muller-Esterl, W; Godovac-Zimmermann, J				Soskic, V; Nyakatura, E; Roos, M; Muller-Esterl, W; Godovac-Zimmermann, J			Correlations in palmitoylation and multiple phosphorylation of rat bradykinin B-2 receptor in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MASS-SPECTROMETRY; B2 RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BOVINE RHODOPSIN; KINASE; IDENTIFICATION	Rat bradykinin B-2 receptor from unstimulated Chinese hamster ovary cells transfected with the corresponding cDNA has been isolated, and subsequent mass spectrometric analysis of multiple phosphorylated species and of the palmitoylation attachment site is described. Bradykinin B-2 receptor was isolated on oligo(dT)-cellulose using N-(epsilon-maleimidocaproyloxy) succinimide-Met-lys-bradykinin coupled to a protected (dA)(30)-mer. This allowed a one-step isolation of the receptor on an oligo(dT)-cellulose column via variation solely of salt concentration. After enzymatic in-gel digestion, matrix-assisted laser desorption ionization and electrospray ion trap mass spectrometric analysis of the isolated rat bradykinin B-2 receptor showed phosphorylation at Ser(365), Ser(371), Ser(378), Ser(380), and Thr(374). Further phosphorylation at Tyr(362) and Tyr(161) was observed. Rat bradykinin receptor B-2 receptor is also palmitoylated at Cys(356). All of the phosphorylation sites except for Tyr(161) cluster at the carboxyl-terminal domain of the receptor located on the cytoplasmic face of the cell membrane. Surprisingly, many of the post-translational modifications were shown by MSn mass spectroscopic analysis to be correlated pairwise, e.g. diphosphorylation at Ser(365) and Ser(371), at Ser(378) and Ser(380), and at Thr(374) and Ser(380) as well as mutually exclusive phosphorylation at Tyr(352) and palmitoylation at Cys(356). The last correlation may be involved in a receptor internalization motif. Pairwise correlations and mutual exclusion of phosphorylation and palmitoylation suggest critical roles of multiple post-translational modifications for the regulation of activity, coupling to intracellular signaling pathways, and/or sequestration of the bradykinin receptor.	Inst Mol Biotechnol eV, D-07745 Jena, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Godovac-Zimmermann, J (corresponding author), UCL, Ctr Mol Med, 5 Univ St, London WC1E 6JJ, England.	j.godovac-zimmermann@ucl.ac.uk	Zimmermann, Jasminka Godovac/E-6863-2010					AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GODOVACZIMMERMA.J, 1999, IN PRESS ELECTROPHOR; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; KHOUJA A, 1992, J DEV PHYSIOL, V18, P263; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; Minshall RD, 1997, CIRC RES, V81, P848; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Ohguro H, 1996, J BIOL CHEM, V271, P5215; Ottleben H, 1997, EUR J BIOCHEM, V244, P471, DOI 10.1111/j.1432-1033.1997.00471.x; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PARK J, 1994, BRAZ J MED BIOL RES, V27, P1707; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; REGOLI D, 1980, PHARMACOL REV, V32, P1; Roos M, 1998, J BIOL CHEM, V273, P924, DOI 10.1074/jbc.273.2.924; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; Taketo M, 1997, BBA-MOL CELL RES, V1355, P89, DOI 10.1016/S0167-4889(96)00126-7; Taylor JA, 1996, RAPID COMMUN MASS SP, V10, P679, DOI 10.1002/(SICI)1097-0231(199604)10:6<679::AID-RCM528>3.0.CO;2-Q; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61	44	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8539	8545		10.1074/jbc.274.13.8539	http://dx.doi.org/10.1074/jbc.274.13.8539			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085087	hybrid			2022-12-27	WOS:000079451600029
J	Stefaner, I; Praetor, A; Hunziker, W				Stefaner, I; Praetor, A; Hunziker, W			Nonvectorial surface transport, endocytosis via a di-leucine-based motif, and bidirectional transcytosis of chimera encoding the cytosolic tail of rat FcRn expressed in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; GOLGI NETWORK LOCALIZATION; CYTOPLASMIC DOMAIN DETERMINANT; MANNOSE 6-PHOSPHATE RECEPTOR; BASOLATERAL SORTING SIGNAL; KINASE-II PHOSPHORYLATION; COATED PIT LOCALIZATION; MDCK CELLS; HUMAN PLACENTA; CALMODULIN ANTAGONIST	Transfer of passive immunity from the mother to the fetus or newborn involves the transport of IgG across several epithelia, Depending on the species, IgG is transported prenatally across the placenta and yolk sac or is absorbed from colostrum and milk by the small intestine of the suckling newborn. In both cases apical to basolateral transepithelial transport of IgG is thought to be mediated by FcRn, an IgG Fc receptor with homology to major histocompatibility class I antigens, Here, we analyzed the intracellular routing of chimera encoding the rat FcRn tail fused to the ecto- and transmembrane domain of the macrophage Fc gamma RIIb, Newly synthesized chimera were delivered in a nonvectorial manner to the apical and basolateral cell surface, from where the chimera were able to internalize and transcytose, Apical to basolateral and basolateral to apical transcytosis were differently regulated. This intracellular routing of the chimera is similar to that of the native FcRn, indicating that the cytosolic tail of the receptor is necessary and sufficient to endow an unrelated FcR with the intracellular transport behavior of FcRn, Furthermore, the di-leucine motif in the cytosolic domain of FcRn was required for rapid and efficient endocytosis but not for basolateral sorting of the chimera.	Univ Lausanne, BIL Biomed Res Ctr, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Hunziker, W (corresponding author), Univ Lausanne, BIL Biomed Res Ctr, Inst Biochem, 155 Ch des Boveresses, CH-1066 Epalinges, Switzerland.	Walter.Hunziker@ib.unil.ch	Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; Ellinger, Isabella/0000-0001-6335-076X				APODACA G, 1994, J BIOL CHEM, V269, P19005; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BRAMBELL FWR, 1956, PROC R SOC SER B-BIO, V145, P170, DOI 10.1098/rspb.1956.0024; BRAMBELL FWR, 1954, LANCET, V1, P964; Brambell FWR., 1970, N HOLL RES MONOGR FR, V18; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1998, J MAMMARY GLAND BIOL, V3, P287, DOI 10.1023/A:1018715511178; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; Leach JL, 1996, J IMMUNOL, V157, P3317; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MORRIS B, 1974, J PHYSIOL-LONDON, V241, P761, DOI 10.1113/jphysiol.1974.sp010683; Mostov KE, 1995, COLD SPRING HARB SYM, V60, P775, DOI 10.1101/SQB.1995.060.01.083; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Reich V, 1996, J CELL SCI, V109, P2133; RODEWALD R, 1980, J CELL BIOL, V85, P18, DOI 10.1083/jcb.85.1.18; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WHITNEY JA, 1995, CELL, V83, P703	60	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8998	9005		10.1074/jbc.274.13.8998	http://dx.doi.org/10.1074/jbc.274.13.8998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085147	hybrid			2022-12-27	WOS:000079451600089
J	Tamatani, M; Che, YH; Matsuzaki, H; Ogawa, S; Okado, H; Miyake, S; Mizuno, T; Tohyama, M				Tamatani, M; Che, YH; Matsuzaki, H; Ogawa, S; Okado, H; Miyake, S; Mizuno, T; Tohyama, M			Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF kappa B activation in primary hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; RECOMBINANT ADENOVIRUS; PREVENTS APOPTOSIS; GLOBAL-ISCHEMIA; TRANSGENIC MICE; GROWTH-FACTORS; FACTOR-ALPHA; INDUCTION; INHIBITION	Emerging data indicate that tumor necrosis factor (TNF) exerts a neuroprotective effect in response to brain injury. Here we examined the mechanism of TNF in preventing neuronal death in primary hippocampal neurons. TNF protected neurons against hypoxia- or nitric oxide-induced injury, with an increase in the antiapoptotic proteins Bcl-2 and Bcl-x as determined by Western blot and reverse transcriptase-polymerase chain reaction analysis. Treatment of neurons with an antisense oligonucleotide to bcl-2 mRNA or that to bcl-x mRNA blocked the up-regulation of Bcl-2 or Bcl-x expression, respectively, and partially inhibited the neuroprotective effect induced by TNF. Moreover, adenovirus-mediated overexpression of Bcl-2 significantly inhibited hypoxia- or nitric oxide-induced neuronal death. To examine the possible involvement of a transcription factor, NF kappa B, in the regulation of Bcl-2 and Bcl-x expression in TNF-treated neurons, an adenoviral vector capable of expressing a mutated form of I kappa B was used to infect neurons prior to TNF treatment. Expression of the mutant NF kappa B completely inhibited NF kappa B DNA binding activity and inhibited both TNF-induced up-regulation of Bcl-2 and Bcl-x expression and neuroprotective effect. These findings indicate that induction of Bcl-2 and Bcl-x expression through NF kappa B activation is involved in the neuroprotective action of TNF against hypoxia- or nitric oxide-induced injury.	Osaka Univ, Sch Med, Dept Anat & Neurosci, Osaka 5650872, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Tokyo 1838526, Japan	Osaka University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Tamatani, M (corresponding author), Osaka Univ, Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Osaka 5650872, Japan.	tama@anat2.med.osaka-u.ac.jp	MATSUZAKI, HIDEO/AAE-5246-2020	MATSUZAKI, HIDEO/0000-0002-6869-1261				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; FRANKOWSKI H, 1995, NEUROREPORT, V6, P1919; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Isenmann S, 1998, BRAIN PATHOL, V8, P49; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Okuyama T, 1998, GENE THER, V5, P1047, DOI 10.1038/sj.gt.3300704; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SATO T, 1994, P NATL ACAD SCI USA, V94, P5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG ZH, 1995, J IMMUNOL, V155, P3722; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	48	509	542	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8531	8538		10.1074/jbc.274.13.8531	http://dx.doi.org/10.1074/jbc.274.13.8531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085086	hybrid			2022-12-27	WOS:000079451600028
J	Iwata, T; Sato, S; Jimenez, J; McGowan, M; Moroni, M; Dey, A; Ibaraki, N; Reddy, VN; Carper, D				Iwata, T; Sato, S; Jimenez, J; McGowan, M; Moroni, M; Dey, A; Ibaraki, N; Reddy, VN; Carper, D			Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; TYROSINE PHOSPHORYLATION; PROTEASOME ACTIVITIES; RECEPTOR SUBSTRATE-1; KAPPA-B; GENE; EXPRESSION; INHIBITION; PROTEIN; CELLS	Induction of aldose reductase (AR) was observed in human cells treated with tumor necrosis factor-alpha (TNF-alpha). AR protein expression increased severalfold in human liver cells after 1 day of exposure to 100 units/ml TNF-a. An increase in AR transcripts was also observed in human liver cells after 3 h of TNF-alpha treatment, reaching a maximum level of 11-fold at 48 h, Among the three inflammatory cytokines: TNF-alpha, interleukin-1, and interferon-gamma, TNF-alpha (100 units/ml) gave the most induction of AR. Differences in the pattern of AR induction were observed in human liver, lens, and retinal pigment epithelial cells with increasing concentrations of TNF-alpha. A similar pattern of AR promoter response was observed between TNF-alpha and osmotically stressed human liver cells. The deletion of the osmotic response element (ORE) abolished the induction by TNF-alpha and osmotic stress. A point mutation that converts ORE to a nuclear factor-kappa B (NF-kappa B) sequence abolished the osmotic response but maintained the TNF-alpha response. Electrophoretic gel mobility shift assays showed two NF-kappa B proteins, p50 and p52, capable of binding ORE sequence, and gel shift Western assay detected NF-kappa B proteins p50 and p65 in the ORE complex. Inhibitors of NF-kappa B signaling, lactacystin, and MG132 abolished the AR promoter response to TNF-alpha.	NEI, NIH, Lab Mechanisms Ocular Dis, Bethesda, MD 20892 USA; NEI, Lab Ocular Therapeut, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Nippon Med Sch, Dept Ophthalmol, Bunkyo Ku, Tokyo 113, Japan; Univ Michigan, Sch Med, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Nippon Medical School; University of Michigan System; University of Michigan	Carper, D (corresponding author), NEI, NIH, Lab Mechanisms Ocular Dis, 9000 Rockville Pike,Bldg 6,Rm232, Bethesda, MD 20892 USA.				NATIONAL EYE INSTITUTE [Z01EY000312] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Bush KT, 1997, J BIOL CHEM, V272, P9086; CARPENTER GA, 1990, NEURAL NETWORKS, V3, P129, DOI 10.1016/0893-6080(90)90085-Y; Daoudal S, 1997, J BIOL CHEM, V272, P2615, DOI 10.1074/jbc.272.5.2615; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Iwata T, 1997, J BIOL CHEM, V272, P32500, DOI 10.1074/jbc.272.51.32500; IWATA T, 1995, ADV EXP MED BIOL, V372, P373; KADOR PF, 1981, ANAL BIOCHEM, V114, P53, DOI 10.1016/0003-2697(81)90450-4; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KLETZIEN RF, 1994, DIABETES, V43, pA82; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; Nakamura J, 1997, LIFE SCI, V60, P1847, DOI 10.1016/S0024-3205(97)00145-8; ROBISON WG, 1983, SCIENCE, V221, P1170; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sambrook J., 2002, MOL CLONING LAB MANU; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TANAKA M, 1994, J BIOL CHEM, V269, P29379; THOMAS D, 1995, CELL, V80, P529; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VONHEYNINGEN R, 1959, NATURE, V184, P194; Zhou C, 1997, EXP EYE RES, V65, P349, DOI 10.1006/exer.1997.0335	41	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7993	8001		10.1074/jbc.274.12.7993	http://dx.doi.org/10.1074/jbc.274.12.7993			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075698	hybrid			2022-12-27	WOS:000079268100057
J	Sheridan, SD; Benham, CJ; Hatfield, GW				Sheridan, SD; Benham, CJ; Hatfield, GW			Inhibition of DNA supercoiling-dependent transcriptional activation by a distant B-DNA to Z-DNA transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; CONFORMATIONAL TRANSITIONS; DUPLEX DESTABILIZATION; SUPERHELICAL DNA; ILVGMEDA OPERON; PROTEIN; MOLECULES; SEQUENCES; MULTIPLE	Negative DNA superhelicity can destabilize the local B-form DNA structure and can drive transitions to other conformations at susceptible sites. In a molecule containing multiple susceptible sites, superhelicity can couple these alternatives together, causing them to compete. In principle, these superhelically driven local structural transitions can be either facilitated or inhibited by proteins that bind at or near potential transition sites, If a DNA region that is susceptible to forming a superhelically induced alternate structure is stabilized in the B-form by a DNA-binding protein, its propensity for transition will be transferred to other sites within the same domain, If one of these secondary sites is in a promoter region, this transfer could facilitate open complex formation and thereby activate gene expression. We previously proposed that a supercoiling-dependent, DNA structural transmission mechanism of this type is responsible for the integration host factor-mediated activation of transcription from the ilvP(G) promoter of Escherichia coli (Sheridan, S, D,, Benham, C. J, & Hatfield, G, W, (1998) J, Biol, Chem, 273, 21298-21308), In this report we confirm the validity of this mechanism by demonstrating the ability of a distant Z-DNA-forming site to compete with the superhelical destabilization that is required for integration host factor-mediated transcriptional activation, and thereby delay its occurrence.	Univ Calif Irvine, Coll Med, Dept Mol Genet & Microbiol, Irvine, CA 92697 USA; CUNY Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA	University of California System; University of California Irvine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hatfield, GW (corresponding author), Univ Calif Irvine, Coll Med, Dept Mol Genet & Microbiol, Irvine, CA 92697 USA.	gwhatfie@uci.edu	Benham, Craig J/G-1512-2013		NIGMS NIH HHS [GM07311, GM55073, GM47012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1992, J BIOL CHEM, V267, P1776; BARTON JK, 1988, CHEM ENG NEWS, V66, P30, DOI 10.1021/cen-v066n039.p030; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; BENHAM CJ, 1981, J MOL BIOL, V150, P43, DOI 10.1016/0022-2836(81)90324-7; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; Benham CJ, 1996, J MOL BIOL, V255, P425, DOI 10.1006/jmbi.1996.0035; BENHAM CJ, 1980, J CHEM PHYS, V72, P3633, DOI 10.1063/1.439625; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; ELLISON MJ, 1987, EMBO J, V6, P1513, DOI 10.1002/j.1460-2075.1987.tb02394.x; FURLONG JC, 1989, BIOCHEMISTRY-US, V28, P2009, DOI 10.1021/bi00431a008; Herbert JM, 1996, J BIOL CHEM, V271, P25928; KELLEHER RJ, 1986, P NATL ACAD SCI USA, V83, P6342, DOI 10.1073/pnas.83.17.6342; KLUMP HH, 1990, BIOPHYSICS-USSR, V1, P241; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; Parekh BS, 1996, J BIOL CHEM, V271, P20258, DOI 10.1074/jbc.271.34.20258; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Wang ZY, 1997, J MOL BIOL, V271, P499, DOI 10.1006/jmbi.1997.1197	30	37	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8169	8174		10.1074/jbc.274.12.8169	http://dx.doi.org/10.1074/jbc.274.12.8169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075720	hybrid			2022-12-27	WOS:000079268100079
J	Sun, H; Molday, RS; Nathans, J				Sun, H; Molday, RS; Nathans, J			Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; HAMSTER P-GLYCOPROTEIN; DRUG TRANSPORT; FUNCTIONAL RECONSTITUTION; FUNDUS FLAVIMACULATUS; RIM PROTEIN; MACULAR DEGENERATION; PIGMENT EPITHELIUM; CYSTIC-FIBROSIS; VISUAL PIGMENTS	Many substrates for P-glycoprotein, an ABC transporter that mediates multidrug resistance in mammalian cells, have been shown to stimulate its ATPase activity in vitro. In the present study, we used this property as a criterion to search for natural and artificial substrates and/or allosteric regulators of ABCR, the rod photoreceptor-specific ABC transporter responsible for Stargardt disease, an early onset macular degeneration. ABCR was immunoaffinity purified to apparent homogeneity from bovine rod outer segments and reconstituted into liposomes, All-trans-retinal, a candidate ligand, stimulates the ATPase activity of ABCR 3-4-fold, with a half-maximal effect at 10-15 mu M. 11-cis- and 13-cis-retinal show similar activity. All-trans-retinal stimulates the ATPase activity of ABCR with Michaelis-Menten behavior indicative of simple noncooperative binding that is associated with a rate-limiting enzyme-substrate intermediate in the pathway of ATP hydrolysis. Among 37 structurally diverse non-retinoid compounds, including nine previously characterized substrates or sensitizers of P-glycoprotein, only four show significant ATPase stimulation when tested at 20 mu M. The dose-response curves of these four compounds are indicative of multiple binding sites and/or modes of interaction with ABCR, Two of these compounds, amiodarone and digitonin, can act synergistically with all-trans retinal, implying that they interact with a site or sites on ABCR different from the one with which all-trans-retinal interacts, Unlike retinal, amiodarone appears to interact with both free and ATP-bound ABCR, Together with clinical observations on Stargardt disease and the localization of ABCR to rod outer segment disc membranes, these data suggest that retinoids, and most likely retinal, are the natural substrates for transport by ABCR in rod outer segments. These observations have significant implications for understanding the visual cycle and the pathogenesis of Stargardt disease and for the identification of compounds that could modify the natural history of Stargardt disease or other retinopathies associated with impaired ABCR function.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Ophthalmol, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Sch Med, Baltimore, MD 21205 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of British Columbia	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COOK NJ, 1988, J BIOL CHEM, V263, P11382; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; Corson DW, 1996, PHOTOCHEM PHOTOBIOL, V63, P595, DOI 10.1111/j.1751-1097.1996.tb05661.x; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648; Dryja T. P., 1998, SCIENCE, V279; DUNN S, 1994, BIOCHEMISTRY-US, V33, P757; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651; FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GLENN AM, 1994, RETINA-J RET VIT DIS, V14, P27, DOI 10.1097/00006982-199401000-00006; Guymer R, 1998, RETINAL PIGMENT EPIT, P693; HARLOW E, 1988, ANTIBODIES LAB MANUA, P300; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; KLEIN BA, 1967, AM J OPHTHALMOL, V64, P3; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P183; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Rebbeor JF, 1998, BBA-BIOMEMBRANES, V1369, P85, DOI 10.1016/S0005-2736(97)00185-5; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; RODEN DM, 1996, PHARMACOL BASIS THER, P858; RODIECK RW, 1998, 1 STEPS SEEING, P155; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SEGEL IH, 1976, BIOCH CALCULATIONS, P246; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Sharom FJ, 1996, BIOCHEM J, V320, P421, DOI 10.1042/bj3200421; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Thomson JL, 1997, CURR EYE RES, V16, P741, DOI 10.1076/ceyr.16.7.741.5060; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812	68	286	294	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8269	8281		10.1074/jbc.274.12.8269	http://dx.doi.org/10.1074/jbc.274.12.8269			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075733	hybrid			2022-12-27	WOS:000079268100092
J	Coletta, M; Angeletti, M; Ascenzi, P; Bertollini, A; Della Longa, S; De Sanctis, G; Priori, AM; Santucci, R; Amiconi, G				Coletta, M; Angeletti, M; Ascenzi, P; Bertollini, A; Della Longa, S; De Sanctis, G; Priori, AM; Santucci, R; Amiconi, G			Coupling of the oxygen-linked interaction energy for inositol hexakisphosphate and bezafibrate binding to human HbA(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERROUS HUMAN HEMOGLOBIN; T-STATE HEMOGLOBIN; X-RAY; STRUCTURAL-CHANGE; GLOBIN STRUCTURE; DEOXYHEMOGLOBIN; OXYHEMOGLOBIN; COOPERATIVITY; SPECTROSCOPY; TETRAMERS	The energetics of signal propagation between different functional domains (i.e, the binding sites for O-2, inositol hexakisphospate (IHP), and bezafibrate (BZF)) of human HbA(0) was analyzed at different heme ligation states and through the use of a stable, partially heme ligated intermediate. Present data allow three main conclusions to be drawn, and namely: (i) IHP and BZF enhance each others binding as the oxygenation proceeds, the coupling free energy going from close to zero in the deoxy state to -3.4 kJ/mol in the oxygenated form; (ii) the simultaneous presence of IHP and BZF stabilizes the hemoglobin T quaternary structure at very low O-2 pressures, but as oxygenation proceeds it does not impair the transition toward the R structure, which indeed occurs also under these conditions; (iii) under room air pressure (i.e. pO(2) = 150 torr), IHP and BZF together induce the formation of an asymmetric dioxygenated hemoglobin tetramer, whose features appear reminiscent of those suggested for transition state species (i.e. T- and R-like tertiary conformation(s) within a quaternary R-like structure).	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy; Univ Roma 3, Dept Biol, I-00146 Rome, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy; Univ Aquila, Dept Expt Med, Biophys Grp, I-67100 Laquila, Italy	University of Rome Tor Vergata; University of Camerino; Roma Tre University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of L'Aquila	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	coletta@seneca.uniroma2.it	Coletta, Massimiliano/GSN-5927-2022; Priori, Alberto/K-9603-2016; Angeletti, Mauro/AAC-5597-2019; Coletta, Massimo/N-9049-2015	Priori, Alberto/0000-0002-1549-3851; Angeletti, Mauro/0000-0001-6719-5517; della longa, stefano/0000-0002-8157-9530; COLETTA, Massimiliano/0000-0002-5489-9467				ABRAHAM DJ, 1992, J MOL BIOL, V227, P480, DOI 10.1016/0022-2836(92)90902-V; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Adair GS, 1925, J BIOL CHEM, V63, P529; AMICONI G, 1989, BIOCHEMISTRY-US, V28, P8547, DOI 10.1021/bi00447a042; AMICONI G, 1981, J MOL BIOL, V152, P111, DOI 10.1016/0022-2836(81)90097-8; ANTONINI E, 1982, EUR J BIOCHEM, V121, P325, DOI 10.1111/j.1432-1033.1982.tb05789.x; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ASCENZI P, 1993, J INORG BIOCHEM, V50, P263, DOI 10.1016/0162-0134(93)80053-C; BENESCH RE, 1986, J MOL BIOL, V190, P481, DOI 10.1016/0022-2836(86)90016-1; BENESCH RE, 1983, P NATL ACAD SCI-BIOL, V80, P6202, DOI 10.1073/pnas.80.20.6202; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P831, DOI 10.1006/jmbi.1994.1192; COLETTA M, 1993, BIOCHIM BIOPHYS ACTA, V1162, P309, DOI 10.1016/0167-4838(93)90295-3; COLETTA M, 1998, IN PRESS BIOPHYS J; De Sanctis G, 1998, J BIOL INORG CHEM, V3, P135; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; DOYLE ML, 1988, J MOL BIOL, V196, P927; EATON WA, 1991, P NATL ACAD SCI USA, V88, P4472, DOI 10.1073/pnas.88.10.4472; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; Giardina B, 1981, Methods Enzymol, V76, P417; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; GILL SJ, 1989, BIOCHEM BIOPH RES CO, V165, P226, DOI 10.1016/0006-291X(89)91058-9; GRAY RD, 1971, J BIOL CHEM, V245, P2914; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; HOPFIELD JJ, 1973, J MOL BIOL, V77, P207, DOI 10.1016/0022-2836(73)90332-X; IMAI K, 1975, J BIOL CHEM, V250, P2227; JAYARAMAN V, 1995, SCIENCE, V269, P1843, DOI 10.1126/science.7569921; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; Messana I, 1998, J BIOL CHEM, V273, P15329, DOI 10.1074/jbc.273.25.15329; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mouawad L, 1996, J MOL BIOL, V258, P393, DOI 10.1006/jmbi.1996.0257; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PERUTZ MF, 1983, LANCET, V2, P881; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2174, DOI 10.1021/bi00707a027; PIN S, 1994, METHOD ENZYMOL, V232, P266; Riggs A., 1981, Methods in Enzymology, V76, P5; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; SCHONERT H, 1988, EUR J BIOCHEM, V176, P319, DOI 10.1111/j.1432-1033.1988.tb14284.x; SHARMA VS, 1976, J BIOL CHEM, V251, P4267; WILLIAMS RC, 1973, ANAL BIOCHEM, V54, P137, DOI 10.1016/0003-2697(73)90256-X; Wilson J, 1996, J MOL BIOL, V264, P743, DOI 10.1006/jmbi.1996.0674; WYMAN J, 1984, Q REV BIOPHYS, V17, P453, DOI 10.1017/S0033583500004881	46	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6865	6874		10.1074/jbc.274.11.6865	http://dx.doi.org/10.1074/jbc.274.11.6865			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066739	hybrid			2022-12-27	WOS:000079078400011
J	Anandatheerthavarada, HK; Vijayasarathy, C; Bhagwat, SV; Biswas, G; Mullick, J; Avadhani, NG				Anandatheerthavarada, HK; Vijayasarathy, C; Bhagwat, SV; Biswas, G; Mullick, J; Avadhani, NG			Physiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; C6 CELL-LINE; CYTOCHROME-P-450 SYSTEM; ESCHERICHIA-COLI; OXIDATIVE DAMAGE; PRECURSOR FORMS; MULTIPLE FORMS; P-450; REDUCTASE; DNA	Recently, we showed that the major species of beta-naphthoflavone-inducible rat liver mitochondrial P450MT2 consists of N-terminal truncated microsomal P4501A1 (+33/1A1) and that the truncated enzyme exhibits different substrate specificity as compared with intact P4501A1. The results of the present study show that P450MT2 targeted to COS cell mitochondria by transient transfection of P4501A1 cDNA is localized inside the mitochondrial inner membrane in a membrane-extrinsic orientation. Go-expression with wild type P4501A1 and adrenodoxin (Adx) cDNAs resulted in 5-7-fold higher erythromycin N-demethylation (ERND) in the mitochondrial fraction but minimal changes in the microsomal fraction of transfected cells. Erythromycin, a potent inhibitor of bacterial and mitochondrial protein synthesis, caused 8-12-fold higher accumulation of CYP1A1 mRNA, preferential accumulation of P450MT2, and 5-6-fold higher ERND activity in the mitochondrial compartment of rat C6 glioma cells. Consistent with the increased mitochondrial ERND activity, cc-expression with P4501A1 and Adx in COS cells rendered complete protection against erythromycin-mediated mitochondrial translation inhibition. Mutations that specifically affect the mitochondrial targeting of P4501A1 also abolished protection against mitochondrial translation inhibition. These results for the first time suggest a physiological function for the xenobiotic inducible cytochrome P4501A1 against drug-mediated mitochondrial toxicity.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NIGMS NIH HHS [GM34883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; AVADHANI NG, 1971, EXP CELL RES, V69, P226, DOI 10.1016/0014-4827(71)90331-4; AVADHANI NG, 1975, SUB-CELL BIOCHEM, V4, P93; BACHMANN E, 1979, TOXICOL LETT, V3, P29, DOI 10.1016/0378-4274(79)90103-6; BHAGWAT SV, 1995, ARCH BIOCHEM BIOPHYS, V320, P73, DOI 10.1006/abbi.1995.1344; Bhagwat SV, 1998, INT J ONCOL, V13, P281; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; BHAGWAT SV, 1999, IN PRESS BIOCH PHARM; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; BHAT NK, 1985, BIOCHEMISTRY-US, V24, P8107, DOI 10.1021/bi00348a041; BHAT NK, 1982, CANCER RES, V42, P2764; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DEVRIES H, 1973, BIOCHIM BIOPHYS ACTA, V331, P264, DOI 10.1016/0005-2787(73)90439-5; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; Geng J, 1997, BRAIN RES, V774, P11, DOI 10.1016/S0006-8993(97)81681-2; GENG J, 1995, J NEUROCHEM, V65, P554; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONKAKOSKI P, 1988, ARCH BIOCHEM BIOPHYS, V267, P558, DOI 10.1016/0003-9861(88)90063-X; IMAI T, 1993, J BIOL CHEM, V268, P19681; ISCAN M, 1990, BIOCHEM BIOPH RES CO, V169, P858, DOI 10.1016/0006-291X(90)91972-U; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LUDDEN TM, 1985, CLIN PHARMACOKINET, V10, P63, DOI 10.2165/00003088-198510010-00003; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MARTELL R, 1986, ANN INTERN MED, V104, P660, DOI 10.7326/0003-4819-104-5-660; MICHAEL NL, 1984, EMBO J, V3, P3165, DOI 10.1002/j.1460-2075.1984.tb02275.x; Mitsuyama T, 1998, MOL CELL BIOCHEM, V181, P157, DOI 10.1023/A:1006894301389; MIZUNO Y, 1988, J NEUROL SCI, V86, P97, DOI 10.1016/0022-510X(88)90010-X; MUKHOPADHYAY CK, 1994, J BIOL CHEM, V269, P13390; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; NIRANJAN BG, 1980, J BIOL CHEM, V255, P6575; NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; RAZA H, 1988, J BIOL CHEM, V263, P9533; Sakaki T, 1996, J BIOL CHEM, V271, P26209, DOI 10.1074/jbc.271.42.26209; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; SINCLAIR JF, 1981, BIOCHEM PHARMACOL, V30, P2805, DOI 10.1016/0006-2952(81)90418-4; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Tan GT, 1996, J MOL BIOL, V261, P222, DOI 10.1006/jmbi.1996.0454; Vellai T, 1998, J MOL EVOL, V46, P499, DOI 10.1007/PL00006331; VIJAYASARATHY C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P38, DOI 10.1016/0005-2728(93)90213-Y; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATKINS PB, 1989, J CLIN INVEST, V83, P688, DOI 10.1172/JCI113933; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WHATLEY FR, 1981, ANN NY ACAD SCI, V361, P330, DOI 10.1111/j.1749-6632.1981.tb46529.x; WILKIE D, 1977, MOL CELL BIOCHEM, V14, P97, DOI 10.1007/BF01734171; WUNDERLICH V, 1971, CHEM-BIOL INTERACT, V4, P81, DOI 10.1016/0009-2797(72)90001-4; YANG HYL, 1988, MOL PHARMACOL, V34, P67; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	66	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6617	6625		10.1074/jbc.274.10.6617	http://dx.doi.org/10.1074/jbc.274.10.6617			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037757	hybrid			2022-12-27	WOS:000078902800079
J	Fujinaga, J; Tang, XB; Casey, JR				Fujinaga, J; Tang, XB; Casey, JR			Topology of the membrane domain of human erythrocyte anion exchange protein, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; SITE-DIRECTED MUTAGENESIS; PRO-868 -> LEU; TRANSPORT PROTEIN; BAND-3 PROTEIN; MONOCLONAL-ANTIBODIES; INTRACELLULAR PH; CYTOPLASMIC SIDE; TERMINAL REGION; BINDING-SITE	Anion exchanger 1 (AE1) is the chloride/bicarbonate exchange protein of the erythrocyte membrane. By using a combination of introduced cysteine mutants and sulfhydryl-specific chemistry, we have mapped the topology of the human AE1 membrane domain. Twenty-seven single cysteines were introduced throughout the Leu(708)-Val(911) region of human AE1, and these mutants were expressed by transient transfection of human embryonic kidney cells. On the basis of cysteine accessibility to membrane-permeant biotin maleimide and to membrane-impermeant lucifer yellow iodoacetamide, we have proposed a model for the topology of AE1 membrane domain. In this model, AE1 is composed of 13 typical transmembrane segments, and the Asp(807)-His(834) region is membrane-embedded but does not have the usual alpha-helical conformation. To identify amino acids that are important for anion transport, we analyzed the anion exchange activity for all introduced cysteine mutants, using a whole cell fluorescence assay, We found that mutants G714C, S725C, and S731C have very low transport activity, implying that this region has a structurally and/or catalytically important role, We measured the residual anion transport activity after mutant treatment with the membrane-impermeant, cysteine-directed compound, sodium (2-sulfonatoethyl) methanethiosulfonate) (MTSES). Only two mutants, S852C and A858C, were inhibited by MTSES, indicating that these residues may be located in a pore-lining region.	Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Erickson HK, 1997, BIOCHEMISTRY-US, V36, P9958, DOI 10.1021/bi970493t; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH, P503; KANG D, 1992, J BIOL CHEM, V267, P19211; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIEBERMAN DM, 1987, BIOCHIM BIOPHYS ACTA, V903, P37, DOI 10.1016/0005-2736(87)90153-2; LIEBERMAN DM, 1983, BIOCHEMISTRY-US, V22, P4028, DOI 10.1021/bi00286a006; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MAKINO S, 1982, J BIOCHEM-TOKYO, V92, P1069, DOI 10.1093/oxfordjournals.jbchem.a134022; MORI A, 1995, J BIOCHEM-TOKYO, V118, P1192, DOI 10.1093/oxfordjournals.jbchem.a125006; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REITHMEIER RAF, 1996, HDB BIOL PHYSICS, V2; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SALHANY JM, 1995, P NATL ACAD SCI USA, V92, P11844, DOI 10.1073/pnas.92.25.11844; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; XU M, 1993, J BIOL CHEM, V268, P21505	37	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6626	6633		10.1074/jbc.274.10.6626	http://dx.doi.org/10.1074/jbc.274.10.6626			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037758	hybrid			2022-12-27	WOS:000078902800080
J	Gibson, AD; Lamerdin, JA; Zhuang, P; Baburaj, K; Serpersu, EH; Peterson, CB				Gibson, AD; Lamerdin, JA; Zhuang, P; Baburaj, K; Serpersu, EH; Peterson, CB			Orientation of heparin-binding sites in native vitronectin - Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SOMATOMEDIN-B DOMAIN; S-PROTEIN VITRONECTIN; ANTITHROMBIN-III; BLOOD-COAGULATION; STRUCTURAL REQUIREMENTS; MULTIMERIC VITRONECTIN; CONFORMATIONAL CHANGE; PLASMA VITRONECTIN; CRYSTAL-STRUCTURE	A primary heparin-binding site in vitronectin has been localized to a cluster of cationic residues near the C terminus of the protein. More recently, secondary binding sites have been proposed. In order to investigate whether the binding site originally identified on vitronectin functions as an exclusive and independent heparin-binding domain, solution binding methods have been used in combination with NMR and recombinant approaches to evaluate Ligand binding to the primary site. Evaluation of the ionic strength dependence of heparin binding to vitronectin according to classical linkage theory indicates that a single ionic bond is prominent. It had been previously shown that chemical modification of vitronectin using an arginine reactive probe results in a significant reduction in heparin binding (Gibson, A, Baburaj, K, Day, D. E., Verhamme, I., Shore, J, D,, and Peterson, C, B, (1997) J. Biol Chem, 272, 5112-5121), The label has now been localized to arginine residues within the cyanogen bromide fragment-(341-380) that contains the primary heparin-binding site on vitronectin. One- and two-dimensional NMR on model peptides based on this primary heparin-binding site indicate that an arginine residue participates in the ionic interaction and that other nonionic interactions may be involved in forming a complex with heparin, A recombinant polypeptide corresponding to the C-terminal 129 amino acids of vitronectin exhibits heparin-binding affinity that is comparable to that of full-length vitronectin and is equally effective at neutralizing heparin anticoagulant activity. Results from this broad experimental approach argue that the behavior of the primary site is sufficient to account for the heparin binding activity of vitronectin and support an exposed orientation for the site in the structure of the native protein.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.			Serpersu, Engin H./0000-0003-1420-455X	NHLBI NIH HHS [HL50676] Funding Source: Medline; NIGMS NIH HHS [R29 GM42661] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042661] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES DW, 1983, J BIOL CHEM, V258, P2548; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DANIELSSON A, 1981, BIOCHEM J, V193, P427; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HORNER AA, 1988, BIOCHEM J, V251, P141, DOI 10.1042/bj2510141; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Kost C, 1996, EUR J BIOCHEM, V236, P682, DOI 10.1111/j.1432-1033.1996.0682d.x; KOST C, 1992, J BIOL CHEM, V267, P12098; LANE DA, 1987, J BIOL CHEM, V262, P16343; Liang OD, 1997, FEBS LETT, V407, P169, DOI 10.1016/S0014-5793(97)00330-X; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCGUIRE EA, 1988, J BIOL CHEM, V263, P1942; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; Peterson CB, 1998, TRENDS CARDIOVAS MED, V8, P124, DOI 10.1016/S1050-1738(97)00136-9; PETERSON CB, 1985, J BIOL CHEM, V260, P610; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1997, J BIOL CHEM, V272, P9971; SOBEL M, 1992, J BIOL CHEM, V267, P8857; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; YE J, 1991, J BIOL CHEM, V266, P23016; Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n; YONEDA A, 1993, EUR J BIOCHEM, V218, P797, DOI 10.1111/j.1432-1033.1993.tb18434.x; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	57	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6432	6442		10.1074/jbc.274.10.6432	http://dx.doi.org/10.1074/jbc.274.10.6432			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037735	hybrid			2022-12-27	WOS:000078902800057
J	Lindblom, A; Quadt, N; Marsh, T; Aeschlimann, D; Morgelin, M; Mann, K; Maurer, P; Paulsson, M				Lindblom, A; Quadt, N; Marsh, T; Aeschlimann, D; Morgelin, M; Mann, K; Maurer, P; Paulsson, M			The intrinsic factor vitamin B-12 receptor, cubilin, is assembled into trimers via a coiled-coil alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; FACTOR-COBALAMIN; LAMININ; PROTEIN; DOMAIN; STABILIZATION; PURIFICATION; COMPLEX; MATRIX; KIDNEY	A large protein was purified from bovine kidney, using selective extraction with EDTA to solubilize proteins anchored by divalent cation-dependent interactions. An antiserum raised against the purified protein labeled the apical cell surface of the epithelial cells in proximal tubules and the luminal surface of small intestine. Ten peptide sequences, derived from the protein, all matched the recently published sequences for rat (Moestrup, S. K. Kozyraki, R., Kristiansen, M., Kaysen, J. H., Helm Rasmussen, H., Brault, D., Pontillon, F., Goda, F. O., Christensen, E. I., Hammond, T. G., and Verroust, P. J. (1998) J. Biol. Chem. 273, 5235-5242) and human cubilin, a receptor for intrinsic factor-vitamin B-12 complexes, identifying the protein as bovine cubilin. In electron microscopy, a three-armed structure was seen, indicating an oligomerization of three identical subunits. This model was supported by the M-r values of about 1,500,000 for the intact protein and 440,000 for its subunits obtained by analytical ultracentrifugation. In a search for a potential assembly domain, we identified a region of heptad repeats in the N-terminal part of the cubilin sequence. Computer-assisted analysis supported the presence of a coiled-coil alpha-helix between amino acids 103 and 132 of the human cubilin sequence and predicted the formation of a triple coiled-coil. We therefore conclude that cubilin forms a noncovalent trimer of identical subunits connected by an N-terminal coiled-coil alpha-helix.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Univ Lund, Malmo Gen Hosp, Dept Internal Med, S-21401 Malmo, Sweden; Univ Bern, ME Muller Inst Biomech, CH-3010 Bern, Switzerland; Univ Wisconsin, Div Orthoped Surg, Madison, WI 53792 USA; Univ Lund, Dept Mol & Cell Biol, S-22100 Lund, Sweden; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany	University of Cologne; Lund University; University of Bern; University of Wisconsin System; University of Wisconsin Madison; Lund University; Max Planck Society	Paulsson, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.		Mann, Karlheinz/C-4254-2008	Aeschlimann, Daniel/0000-0003-0930-7706				AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; BECK K, 1992, PATTERNS PROTEIN SEQ, P229; *BECKM INSTR INC, 1991, MOD XLA AN ULTR OPT; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHERNYAK VY, 1982, ANAL BIOCHEM, V123, P110, DOI 10.1016/0003-2697(82)90630-3; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; GUEANT JL, 1991, BIOCHIM BIOPHYS ACTA, V1073, P614, DOI 10.1016/0304-4165(91)90238-C; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; Kozyraki R, 1998, BLOOD, V91, P3593; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARCOULLIS G, 1977, BIOCHIM BIOPHYS ACTA, V496, P36, DOI 10.1016/0304-4165(77)90113-1; MARCOULLIS G, 1977, BIOCHIM BIOPHYS ACTA, V496, P309; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; RAMABO MJ, 1997, J MOL BIOL, V274, P650; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1994, ADV T ADDISONS DIS, V2, P393; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	35	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6374	6380		10.1074/jbc.274.10.6374	http://dx.doi.org/10.1074/jbc.274.10.6374			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037728	hybrid			2022-12-27	WOS:000078902800050
J	Pedrajas, JR; Kosmidou, E; Miranda-Vizuete, A; Gustafsson, JA; Wright, APH; Spyrou, G				Pedrajas, JR; Kosmidou, E; Miranda-Vizuete, A; Gustafsson, JA; Wright, APH; Spyrou, G			Identification and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PEROXIDE REDUCTASE; PROTEIN DISULFIDE-ISOMERASE; OXIDATIVE STRESS-RESPONSE; GLUTATHIONE-PEROXIDASE; ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; GENE-EXPRESSION; BUDDING YEAST; DNA-SYNTHESIS; GROWTH	The so-called thioredoxin system, thioredoxin (Trx), thioredoxin reductase (Trr), and NADPH, acts as a disulfide reductase system and can protect cells against oxidative stress. In Saccharomyces cerevisiae, two thioredoxins (Trx1 and Trx2) and one thioredoxin reductase (Trr1) have been characterized, all of them located in the cytoplasm, We have identified and characterized a novel thioredoxin system in S. cerevisiae. The TRX3 gene codes for a 14-kDa protein containing the characteristic thioredoxin active site (WCGPC). The TRR2 gene codes for a protein of 37 kDa with the active-site motif (CAVC) present in prokaryotic thioredoxin reductases and binding sites for NADPH and FAD, We cloned and expressed both proteins in Escherichia coli, and the recombinant Trx3 and Trr2 proteins were active in the insulin reduction assay, Trx3 and Trr2 proteins have N-terminal domain extensions with characteristics of signals for import into mitochondria, By immunoblotting analysis of Saccharomyces subcellular fractions, we provide evidence that these proteins are located in mitochondria, We have also constructed S. cerevisiae strains null in Trx3 and Trr2 proteins and tested them for sensitivity to hydrogen peroxide, The Delta trr2 mutant was more sensitive to H2O2, whereas the Delta trx3 mutant was as sensitive as the wild type. These results suggest an important role of the mitochondrial thioredoxin reductase in protection against oxidative stress in S. cerevisiae.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden.	giannis.spyrou@cbt.ki.se	Pedrajas, José Rafael/M-9758-2015; Miranda-Vizuete, Antonio/D-6927-2012; IBIS, REDOX/J-7473-2017; Wright, Anthony/J-8187-2015	Pedrajas, José Rafael/0000-0003-1998-0638; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Wright, Anthony/0000-0003-1029-9969				BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAMBERLIN M, 1974, J VIROL, V14, P509, DOI 10.1128/JVI.14.3.509-516.1974; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Constantini P., 1996, J BIOL CHEM, V271, P6746; EJIRI SI, 1979, J BACTERIOL, V139, P161, DOI 10.1128/JB.139.1.161-164.1979; Fortuniak A, 1996, BIOCHEM MOL BIOL INT, V38, P901; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GAN ZR, 1991, J BIOL CHEM, V266, P1692; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HARSHMAN KD, 1988, CELL, V14, P211; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, PLASMA MEMBRANE OXID, P295; Inoue Y, 1995, BBA-GEN SUBJECTS, V1245, P325, DOI 10.1016/0304-4165(95)00117-4; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PON L, 1991, MOL BIOL YEAST SACCH, P334; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; ROVERI A, 1994, BBA-PROTEIN STRUCT M, V1208, P211, DOI 10.1016/0167-4838(94)90106-6; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; Sherman F., 1986, METHODS YEAST GENETI; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Treger JM, 1998, BIOCHEM BIOPH RES CO, V243, P13, DOI 10.1006/bbrc.1997.8061; TSANG MLS, 1976, J BACTERIOL, V125, P923, DOI 10.1128/JB.125.3.923-933.1976; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	59	179	186	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6366	6373		10.1074/jbc.274.10.6366	http://dx.doi.org/10.1074/jbc.274.10.6366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037727	hybrid			2022-12-27	WOS:000078902800049
J	Yamada, Y; Chochi, Y; Takamiya, K; Sobue, K; Inui, R				Yamada, Y; Chochi, Y; Takamiya, K; Sobue, K; Inui, R			Modulation of the channel activity of the epsilon 2/zeta 1-subtype N-methyl D-Aspartate receptor by PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-SUPPRESSOR PROTEIN; POSTSYNAPTIC DENSITY; NMDA RECEPTORS; GLUTAMATE RECEPTORS; MOLECULAR DIVERSITY; GUANYLATE KINASES; HIPPOCAMPAL LTP; FAMILY; ACTIVATION	A channel-associated protein PSD-95 has been shown to induce clustering of N-methyl D-aspartate (NMDA) receptors, interacting with the COOH terminus of the epsilon subunit of the receptors. The effects of PSD-95 on the channel activity of the epsilon 2/zeta 1 heteromeric NMDA receptor were examined by injection of PSD-95 cRNA into Xenopus oocytes expressing the NMDA receptors. Expression of PSD-95 decreased the sensitivity of the NMDA receptor channels to L-glutamate. Mutational studies showed that the interaction between the COOH terminus of the epsilon 2 subunit of the NMDA receptor and the second PSD-95/Dlg/Z0-1 domain of PSD-95 is critical for the decrease in glutamate sensitivity. It is known that protein kinase C markedly potentiates the channel activity of the MMDA receptor expressed in oocytes. PSD-95 inhibited the protein kinase C-mediated potentiation of the channels. Thus, we demonstrated that PSD-95 functionally modulates the channel activity of the epsilon 2/zeta 1 NMDA receptor. PSD-95 makes signal transmission more efficient by clustering the channels at postsynaptic sites. In addition to this, our results suggest that PSD-95 plays a protective role against neuronal excitotoxicity by decreasing the glutamate sensitivity of the channels and by inhibiting the protein kinase C mediated potentiation of the channels.	Yamaguchi Univ, Sch Med, Dept Pharmacol, Ube, Yamaguchi 7558505, Japan; Osaka Univ, Sch Med, Dept Neurochem & Neuropharmacol, Osaka 5650871, Japan	Yamaguchi University; Osaka University	Inui, R (corresponding author), Yamaguchi Univ, Sch Med, Dept Pharmacol, 1144 Kogushi, Ube, Yamaguchi 7558505, Japan.							BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Chen SJ, 1996, J NEUROCHEM, V67, P194; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; GERBER G, 1989, J NEUROSCI, V9, P3606; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kawashima N, 1997, FEBS LETT, V418, P301, DOI 10.1016/S0014-5793(97)01399-9; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LAUBE B, 1997, NEURON, V18, P439; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Wagner DA, 1996, NEUROPHARMACOLOGY, V35, P29, DOI 10.1016/0028-3908(95)00177-8; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	46	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6647	6652		10.1074/jbc.274.10.6647	http://dx.doi.org/10.1074/jbc.274.10.6647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037761	hybrid			2022-12-27	WOS:000078902800083
J	Wu, G; Wei, CH; Kulmacz, RJ; Osawa, Y; Tsai, AL				Wu, G; Wei, CH; Kulmacz, RJ; Osawa, Y; Tsai, AL			A mechanistic study of self-inactivation of the peroxidase activity in prostaglandin H synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; MANGANO PROTOPORPHYRIN-IX; ARACHIDONIC-ACID; VESICULAR GLAND; FATTY-ACIDS; CYCLOOXYGENASE; BIOSYNTHESIS; REDUCTION; KINETICS; HYDROPEROXIDES	Prostaglandin H synthase (PGHS) is a self-activating and self-inactivating enzyme. Both the peroxidase and cyclooxygenase activities have a limited number of catalytic turnovers. Sequential stopped-flow measurements were used to analyze the kinetics of PGHS-1 peroxidase self-inactivation during reaction with several different hydroperoxides. The inactivation followed single exponential kinetics, with a first-order rate constant of 0.2-0.5 s(-1) at 24 degrees C. This rate was independent of the peroxide species and concentration used, strongly suggesting that the self-inactivation process originates after formation of Compound I and probably with Intermediate II, which contains an oxyferryl heme and a tyrosyl radical. Kinetic scan and rapid scan experiments were used to monitor the heme changes during the inactivation process. The results from both experiments converged to a simple, linear, two-step mechanism in which Intermediate II is first converted in a faster step (0.5-2 s(-1)) to a new compound, Intermediate III, which undergoes a subsequent slower (0.01-0.05 s(-1)) transition to a terminal species. Rapid-quench and high pressure liquid chromatography analysis indicated that Intermediate III likely retains an intact heme group that is not covalently linked with the PGHS-1 protein.	Univ Texas, Hlth Sci Ctr, Div Hematol, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, Houston, TX 77030 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Div Hematol, POB 20708, Houston, TX 77225 USA.	atsai@heart.med.uth.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030509, R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52170, GM30509, GM44911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EGAN RW, 1979, J BIOL CHEM, V254, P3295; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MACDONALD ID, 1989, ARCH BIOCHEM BIOPHYS, V272, P194, DOI 10.1016/0003-9861(89)90210-5; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; OHKI S, 1979, J BIOL CHEM, V254, P829; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034	31	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9231	9237		10.1074/jbc.274.14.9231	http://dx.doi.org/10.1074/jbc.274.14.9231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092596	hybrid			2022-12-27	WOS:000079451800015
J	Kasahara, J; Fukunaga, K; Miyamoto, E				Kasahara, J; Fukunaga, K; Miyamoto, E			Differential effects of a calcineurin inhibitor on glutamate-induced phosphorylation of Ca2+/calmodulin-dependent protein kinases in cultured rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CEREBELLAR GRANULE CELLS; II MUTANT MICE; CA-2+-INDEPENDENT FORM; DEPENDENT MECHANISM; GENE-EXPRESSION; PHOSPHATASE 2A; CALMODULIN; ACTIVATION; BRAIN	Calcium/calmodulin-dependent protein kinases (CaM kinases) are major multifunctional enzymes that play important roles in calcium-mediated signal transduction. To characterize their regulatory mechanisms in neurons, we compared glutamate-induced phosphorylation of CaM kinase IV and CaM kinase II in cultured rat hippocampal neurons. We observed that dephosphorylation of these kinases followed different time courses, suggesting different regulatory mechanisms for each kinase. Okadaic acid, an inhibitor of protein phosphatase (PP) 1 and PP2A, increased the phosphorylation of both kinases, In contrast, cyclosporin A, an inhibitor of calcineurin, showed different effects: the phosphorylation and activity of CaM kinase IV were significantly increased with this inhibitor, but those of CaM kinase II were not significantly increased. Cyclosporin A treatment of neurons increased phosphorylation of Thr(196) Of CaM kinase TV, the activated form with CaM kinase kinase, which was recognized with an anti-phospho-Thr(196) antibody. Moreover, recombinant CaM kinase TV was dephosphorylated and inactivated with calcineurin as well as with PP1, PP2A, and PP2C in vitro. These results suggest that CaM kinase IV, but not CaM kinase II, is directly regulated with calcineurin.	Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Kumamoto University	Miyamoto, E (corresponding author), Kumamoto Univ, Sch Med, Dept Pharmacol, 2-2-1 Honjo, Kumamoto 8600811, Japan.							BARNES GN, 1995, J NEUROCHEM, V64, P340; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; MATSUMOTO K, 1995, ENDOCRINOLOGY, V136, P3784, DOI 10.1210/en.136.9.3784; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIYANO O, 1992, J BIOL CHEM, V267, P1198; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OHTA Y, 1988, J BIOL CHEM, V263, P11540; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SAITOH Y, 1987, J NEUROCHEM, V49, P1286, DOI 10.1111/j.1471-4159.1987.tb10022.x; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; YAMAKAWA T, 1992, BRAIN RES, V597, P220, DOI 10.1016/0006-8993(92)91477-V; YANAGIHARA N, 1994, MOL PHARMACOL, V46, P423; YANO S, 1994, J BIOL CHEM, V269, P5428	40	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9061	9067		10.1074/jbc.274.13.9061	http://dx.doi.org/10.1074/jbc.274.13.9061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085155	hybrid			2022-12-27	WOS:000079451600097
J	Stecher, H; Gelb, MH; Saari, JC; Palczewski, K				Stecher, H; Gelb, MH; Saari, JC; Palczewski, K			Preferential release of 11-cis-retinol from retinal pigment epithelial cells in the presence of cellular retinaldehyde-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALL-TRANS-RETINOIDS; VITAMIN-A; VISUAL CYCLE; MEMBRANES; ISOMERIZATION; BIOSYNTHESIS	In photoreceptor cells of the retina, photoisomerization of 11-cis-retinal to all-trans-retinal triggers phototransduction. Regeneration of 11-cis-retinal proceeds via a complex set of reactions in photoreceptors and in adjacent retinal pigment epithelial cells where all-trans-retinol is isomerized to 11-cis-retinol. Our results show that isomerization in vitro only occurs in the presence of ape-cellular retinaldehyde-binding protein. This retinoid-binding protein may drive the reaction by mass action, overcoming the thermodynamically unfavorable isomerization, Furthermore, this 11-cis-retinol/11-cis retinal-specific binding protein potently stimulates hydrolysis of endogenous 11-cis-retinyl esters but has no effect on hydrolysis of all-trans-retinyl esters, Ape-cellular retinaldehyde-binding protein probably exerts its effect by trapping the 11-cis-retinol product. When retinoid-depleted retinal pigment epithelial microsomes were preincubated with different amounts of all-trans-retinol to form all-trans-retinyl esters and then [H-3]all-trans-retinol was added, as predicted, the specific radioactivity of [H-3]all-trans-retinyl esters increased during subsequent reaction. However, the specific radioactivity of newly formed 11-cis-retinol stayed constant during the course of the reaction, and it was largely unaffected by expansion of the all-trans-retinyl ester pool during the preincubation. The absence of dilution establishes that most of the ester pool does not participate in isomerization, which in turn suggests that a retinoid intermediate other than all-trans-retinyl ester is on the isomerization reaction pathway.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.			gelb, michael/0000-0001-7000-5219	NATIONAL EYE INSTITUTE [P30EY001730] Funding Source: NIH RePORTER; NEI NIH HHS [EY01730, EY080611, EY02317] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1971, VISION RES, V11, P539, DOI 10.1016/0042-6989(71)90075-7; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BRIDGES CDB, 1980, VISION RES, V20, P355, DOI 10.1016/0042-6989(80)90022-X; BROWN PK, 1956, J BIOL CHEM, V222, P865; Crabb JW, 1998, METH MOL B, V89, P91; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P7938, DOI 10.1021/bi00398a059; GOLDSTEI.EB, 1970, VISION RES, V10, P1065, DOI 10.1016/0042-6989(70)90082-9; GOLDSTEIN EB, 1967, VISION RES, V7, P837, DOI 10.1016/0042-6989(67)90004-1; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; KNOWLES A, 1977, EYE, V28, P118; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS GM, 1988, J CHROMATOGR, V438, P383, DOI 10.1016/S0021-9673(00)90269-3; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1990, METHOD ENZYMOL, V190, P156; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; Saari John C., 1994, P351; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Wald G, 1935, J GEN PHYSIOL, V19, P351, DOI 10.1085/jgp.19.2.351; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3	34	105	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8577	8585		10.1074/jbc.274.13.8577	http://dx.doi.org/10.1074/jbc.274.13.8577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085092	hybrid			2022-12-27	WOS:000079451600034
J	Darnay, BG; Ni, J; Moore, PA; Aggarwal, BB				Darnay, BG; Ni, J; Moore, PA; Aggarwal, BB			Activation of NF-kappa B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappa B-inducing kinase - Identification of a novel TRAF6 interaction motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; TERMINAL KINASE; FAMILY MEMBER; INDUCTION; LIGAND; DOMAIN; CD30; IL-1	Various members of the tumor necrosis factor (TNF) receptor superfamily activate nuclear factor kappa B (NF-kappa B) and the c-Jun N-terminal kinase (JNK) pathways through their interaction with TNF receptor-associated factors (TRAFs) and NF-kappa B-inducing kinase (NIK). We have previously shown that the cytoplasmic domain of receptor activator of NF-kappa B (RANK) interacts with TRAF2, TRAF5, and TRAF6 and that its overexpression activates NF-kappa B and JNK pathways. Through a detailed mutational analysis of the cytoplasmic domain of RANK, we demonstrate that TRAF2 and TRAF5 bind to consensus TRAF binding motifs located in the C terminus at positions 565-568 and 606-611, respectively. In contrast, TRAF6 interacts with a novel motif located between residues 340 and 358 of RANK. Furthermore, transfection experiments with RANK and its deletion mutants in human embryonic 293 cells revealed that the TRAF6-binding region (340-358), but not the TRAF2 or TRAF5-binding region, is necessary and sufficient for RANK-induced NF-kappa B activation. Moreover, a kinase mutant of NIK (NIK-KM) inhibited RANK-induced NF-kappa B activation. However, RANK-mediated JNK activation required a distal portion (427-603) of RANK containing the TRAF2-binding domain. Thus, our results indicate that RANK interacts with various TRAFs through distinct motifs and activates NF-kappa B via a novel TRAF6 interaction motif, which then activates MK, thus leading to NF-kappa B activation, whereas RANK most likely activates JNK through a TRAF2-interacting region in RANK.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	34	315	337	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7724	7731		10.1074/jbc.274.12.7724	http://dx.doi.org/10.1074/jbc.274.12.7724			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075662	hybrid			2022-12-27	WOS:000079268100021
J	Jayadev, S; Petranka, JG; Cheran, SK; Biermann, JA; Barrett, JC; Murphy, E				Jayadev, S; Petranka, JG; Cheran, SK; Biermann, JA; Barrett, JC; Murphy, E			Reduced capacitative calcium entry correlates with vesicle accumulation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; INTRACELLULAR CALCIUM; CA2+ INFLUX; NEOPLASTIC PROGRESSION; CELL-LINE; DNA FRAGMENTATION; STORE DEPLETION; XENOPUS OOCYTES; LEUKEMIA-CELLS	A preneoplastic variant of Syrian hamster embryo cells, sup(+), exhibits decreased endoplasmic reticulum calcium levels and subsequently undergoes apoptosis in low serum conditions (Preston, G, A, Barrett, J, C,, Biermann, J, A, and Murphy, E, (1997) Cancer Res. 57, 537-542). This decrease in endoplasmic reticulum calcium appears to be due, at least in part, to reduced capacitative calcium entry at the plasma membrane. Thus we investigated whether inhibition of capacitative calcium entry per se could reduce endoplasmic reticulum calcium and induce apoptosis of cells. We find that treatment with either SKF96365 (30-100 mu M) Or cell-impermeant 1,2-bis(o-amino-5-bromophenoxy)ethane-N,N,N',N'-tetra-acetic acid (5-10 mM) is able to induce apoptosis of cells in conditions where apoptosis does not normally occur. Because previous work has implicated vesicular trafficking as a mechanism of regulating capacitative calcium entry, we investigated whether disruption of vesicular trafficking could lead to decreased capacitative calcium entry and subsequent apoptosis of cells. Coincident with low serum-induced apoptosis, we observed an accumulation of vesicles within the cell, suggesting deregulated vesicle trafficking, Treatment of cells with bafilomycin (30-100 nM), an inhibitor of the endosomal proton ATPase, produced an accumulation of vesicles, decreased capacitative entry, and induced apoptosis, These data suggest that deregulation of vesicular transport results in reduced capacitative calcium entry which in turn results in apoptosis.	NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jayadev, S (corresponding author), NIEHS, Mol Carcinogenesis Lab, POB 12233,MD D2-03, Res Triangle Pk, NC 27709 USA.	jayadev@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023020, Z01ES050142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Baldwin SA, 1995, BIOSCIENCE REP, V15, P419, DOI 10.1007/BF01204346; BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; BELLOMO G, 1992, CANCER RES, V52, P1342; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; DAVIES EV, 1995, BIOCHEM BIOPH RES CO, V206, P348, DOI 10.1006/bbrc.1995.1048; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; HEMING TA, 1995, J EXP BIOL, V198, P1711; HENOMATSU N, 1993, EUR J CELL BIOL, V62, P127; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; ISEKI R, 1993, J IMMUNOL, V151, P5198; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; MAGNELLI L, 1993, BIOCHEM BIOPH RES CO, V194, P1394, DOI 10.1006/bbrc.1993.1979; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTERO M, 1993, J BIOL CHEM, V268, P13055; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUNKER R, 1992, ANN HEMATOL, V65, P50, DOI 10.1007/BF01715127; MURPHY CT, 1995, CELL CALCIUM, V18, P245, DOI 10.1016/0143-4160(95)90069-1; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRESTON GA, 1994, CANCER RES, V54, P4214; Preston GA, 1997, CANCER RES, V57, P537; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; Shrode LD, 1997, AM J PHYSIOL-CELL PH, V272, pC1968, DOI 10.1152/ajpcell.1997.272.6.C1968; Somasundaram B, 1996, J BIOL CHEM, V271, P26096, DOI 10.1074/jbc.271.42.26096; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TRUMP BF, 1995, GROWTH FACTORS TUMOR, P121; VOLLENWEIDER I, 1991, ELECTRON MICROSC REV, V4, P249, DOI 10.1016/0892-0354(91)90005-W; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, INT REV CYTOL, P755; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T	76	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8261	8268		10.1074/jbc.274.12.8261	http://dx.doi.org/10.1074/jbc.274.12.8261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075732	hybrid			2022-12-27	WOS:000079268100091
J	Li, S; Moy, L; Pittman, N; Shue, G; Aufiero, B; Neufeld, EJ; LeLeiko, NS; Walsh, MJ				Li, S; Moy, L; Pittman, N; Shue, G; Aufiero, B; Neufeld, EJ; LeLeiko, NS; Walsh, MJ			Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein cut homolog, is associated with histone deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY ORGAN IDENTITY; BINDING FACTOR CBF; HOMEODOMAIN PROTEIN; DNA-BINDING; DOWN-REGULATION; SACCHAROMYCES-CEREVISIAE; EPITHELIAL-CELLS; PROMOTER REGION; KINASE-C; EXPRESSION	Human cystic fibrosis transmembrane conductance regulator gene (CFTR) transcription is tightly regulated by nucleotide sequences upstream of the initiator sequences. Our studies of human CFTR transcription focus on identifying transcription factors bound to an inverted CCAAT consensus or "Y-box element." The human homeodomain CCAAT displacement protein/cut homolog (CDP/cut) can bind to the Y-box element through a cut repeat and homeobox, Analysis of stably transfected cell lines with wild-type and mutant human CFTR-directed reporter genes demonstrates that human histone acetyltransferase GCN5 and transcription factor ATF-1 can potentiate CFTR transcription through the Y-box element, We have found 1) that human CDP/cut acts as a repressor of CFTR transcription through the Y-box element by competing for the sites of transactivators hGCN5 and ATF-1;2) that the ability of CDP/cut to repress activities of hGCN5 and ATF-1 activity is contingent on the amount of CDP/cut expression; 3) that histone acetylation may have a role in the regulation of gene transcription by altering the accessibility of the CFTR Y-box for sequence-specific transcription factors; 4) that trichostatin A, an inhibitor of histone deacetylase activity, activates transcription of CFTR through the Y-box element; 5) that the inhibition of histone deacetylase activity leads to an alteration of local chromatin structure requiring an intact Y-box sequence in CFTR; 6) that immunocomplexes of CDP/cut possess an associated histone deacetylase activity; 7) that the carboxyl region of CDP/cut, responsible for the transcriptional repressor function, interacts with the histone deacetylase, HDAC1, We propose that CFTR transcription may be regulated through interactions with factors directing the modification of chromatin and requires the conservation of the inverted CCAAT CY-box) element of the CFTR promoter.	CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Gastroenterol & Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Program Mol Cellular Biochem & Dev Sci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Mol Med, New York, NY 10029 USA; Harvard Univ, Sch Med, Childrens Hosp, Med Div Hematol Oncol, Boston, MA 02115 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital; Harvard Medical School	Walsh, MJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Gastroenterol & Liver Dis, 1 Gustave L Levy Pl, New York, NY 10029 USA.	walsh@msvax.mssm.edu	Neufeld, Ellis J./F-9331-2011; LeLeiko, Neal/GRJ-6855-2022	Neufeld, Ellis J./0000-0001-8092-6281; leleiko, neal/0000-0001-7699-1400				ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BREUER W, 1993, J BIOL CHEM, V268, P13935; BREUER W, 1992, J BIOL CHEM, V267, P10465; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1996, MOL CELL BIOL, V16, P593; CHOU JL, 1991, J BIOL CHEM, V266, P24471; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACK J, 1991, DEVELOPMENT, V113, P735; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; KOH J, 1993, J BIOL CHEM, V268, P15912; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sinha S, 1996, MOL CELL BIOL, V16, P328; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Smith AN, 1996, J BIOL CHEM, V271, P9947, DOI 10.1074/jbc.271.17.9947; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WADE PA, 1997, CURR BIOL, V7, P82; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YANG XJ, 1996, CELL, V87, P953; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	71	114	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7803	7815		10.1074/jbc.274.12.7803	http://dx.doi.org/10.1074/jbc.274.12.7803			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075672	hybrid			2022-12-27	WOS:000079268100031
J	Yuan, G; Bin, JC; McKay, DJ; Snyder, FF				Yuan, G; Bin, JC; McKay, DJ; Snyder, FF			Cloning and characterization of human guanine deaminase - Purification and partial amino acid sequence of the mouse protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; DIHYDROOROTASE; METABOLISM; ENZYMES; MICE	Mouse erythrocyte guanine deaminase has been purified to homogeneity, The native enzyme was dimeric, being comprised of two identical subunits of approximately 50,000 Da, The protein sequence was obtained from five cyanogen bromide cleavage products giving sequences ranging from 12 to 25 amino acids in length and corresponding to 99 residues. Basic Local Alignment Search Tool (BLAST) analysis of expressed sequence databases enabled the retrieval of a human expressed sequence tag cDNA clone highly homologous to one of the mouse peptide sequences. The presumed coding region of this clone was used to screen a human kidney cDNA library and secondarily to polymerase chain reaction-amplify the full-length coding sequence of the human brain cDNA corresponding to an open reading frame of 1365 nucleotides and encoding a protein of 51,040 Da, Comparison of the mouse peptide sequences with the inferred human protein sequence revealed 88 of 99 residues to be identical. The human coding sequence of the putative enzyme was subcloned into the bacterial expression vector pMAL-c2, expressed, purified, and characterized as having guanine deaminase activity with a K-m for guanine of 9.5 +/- 1.7 mu M. The protein shares a 9-residue motif with other aminohydrolases and amidohydrolases (PGX[VI]DXH[TVI]H) that has been shown to be ligated with heavy metal ions, commonly zinc, The purified recombinant guanine deaminase was found to contain approximately 1 atom of zinc per 51-kDa monomer.	Univ Calgary, Fac Med, Dept Med Genet, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Fac Med, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Snyder, FF (corresponding author), Univ Calgary, Fac Med, Dept Med Genet, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	snyder@ucalgary.ca						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERGER SJ, 1985, J NEUROCHEM, V44, P1736, DOI 10.1111/j.1471-4159.1985.tb07162.x; BERGSTROM JD, 1979, ARCH BIOCHEM BIOPHYS, V194, P107, DOI 10.1016/0003-9861(79)90600-3; BOULIEU R, 1984, CLIN CHIM ACTA, V142, P82; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; BROSH S, 1990, J NEUROCHEM, V54, P1776, DOI 10.1111/j.1471-4159.1990.tb01233.x; DAWSON DM, 1971, NEUROLOGY, V21, P621, DOI 10.1212/WNL.21.6.621; FARKAS WR, 1978, SCIENCE, V199, P786, DOI 10.1126/science.622568; GALILEA JM, 1981, INT J BIOCHEM, V13, P773, DOI 10.1016/0020-711X(81)90052-5; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUPTA NK, 1985, ARCH BIOCHEM BIOPHYS, V236, P266, DOI 10.1016/0003-9861(85)90626-5; HENDERSO.JF, 1968, J BIOL CHEM, V243, P2514; ITO S, 1989, J HISTOCHEM CYTOCHEM, V37, P611, DOI 10.1177/37.5.2649557; KANTZ J, 1989, EUR J BIOCHEM, V181, P431; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14231, DOI 10.1073/pnas.94.26.14231; Kim GJ, 1998, BIOCHEM J, V330, P295, DOI 10.1042/bj3300295; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1263; KUMAR S, 1979, NEW ENGL J MED, V330, P1332; KUZMITS R, 1980, ENZYME, V25, P148, DOI 10.1159/000459240; LETISSIER PR, 1994, ANAL BIOCHEM, V222, P168, DOI 10.1006/abio.1994.1469; LEWIS AS, 1974, J BIOL CHEM, V249, P3862; MIYAMOTO S, 1982, J BIOCHEM, V91, P167, DOI 10.1093/oxfordjournals.jbchem.a133673; MOHAMEDALI KA, 1993, J BIOL CHEM, V268, P23728; NARDIELLO S, 1978, ENZYME, V23, P353, DOI 10.1159/000458600; Nygaard P, 1996, J BACTERIOL, V178, P846, DOI 10.1128/jb.178.3.846-853.1996; ROSSI CA, 1978, BIOCHIM BIOPHYS ACTA, V526, P235, DOI 10.1016/0005-2744(78)90308-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLAR EM, 1973, CANCER RES, V33, P94; SITARAMAYYA A, 1974, BIOCHEM J, V138, P143, DOI 10.1042/bj1380143; SNYDER FF, 1994, BBA-MOL BASIS DIS, V1227, P33, DOI 10.1016/0925-4439(94)90103-1; Snyder FF, 1997, P NATL ACAD SCI USA, V94, P2522, DOI 10.1073/pnas.94.6.2522; SOLAINI G, 1982, ITAL J BIOCHEM, V31, P253; TARR GE, 1986, MICROCHARACTERIZATIO, P155; VANWAEG G, 1986, PURINE PYRIMIDINE ME, P425; WILLIAMS NK, 1995, BIOCHEMISTRY-US, V34, P11344, DOI 10.1021/bi00036a007; ZIMMERMANN BH, 1995, BIOCHEMISTRY-US, V34, P7038, DOI 10.1021/bi00021a015	37	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8175	8180		10.1074/jbc.274.12.8175	http://dx.doi.org/10.1074/jbc.274.12.8175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075721	hybrid			2022-12-27	WOS:000079268100080
J	Zerhusen, B; Zhao, JY; Xie, JX; Davis, PB; Ma, JJ				Zerhusen, B; Zhao, JY; Xie, JX; Davis, PB; Ma, JJ			A single conductance pore for chloride ions formed by two cystic fibrosis transmembrane conductance regulator molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL RECONSTITUTION; CFTR; CHANNEL; GENE	The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent protein kinase (PRA)- and ATP-regulated chloride channel, whose gating process involves intra- or intermolecular interactions among the cytosolic domains of the CFTR protein. Tandem linkage of two CFTR molecules produces a functional chloride channel with properties that are similar to those of the native CFTR channel, including trafficking to the plasma membrane, ATP- and PKA-dependent gating, and a unitary conductance of 8 picosiemens (pS), A heterodimer, consisting of a wild type and a mutant CFTR, also forms an 8-pS chloride channel with mixed gating properties of the wild type and mutant CFTR channels. The data suggest that two CFTR molecules interact together to form a single conductance pore for chloride ions.	Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Ma, JJ (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA.	jxm63@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051770] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK51770, R01-DK27556] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; LOO MA, 1997, PEDIATR PULM, V14, P212; MA J, 1997, J BIOL CHEM, V273, P28133; MA J, 1995, J BIOL CHEM, V271, P7351; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; NAREN AP, 1998, PEDIATR PULM, V17, P94; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; XIE JX, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	22	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7627	7630		10.1074/jbc.274.12.7627	http://dx.doi.org/10.1074/jbc.274.12.7627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075649	hybrid			2022-12-27	WOS:000079268100008
J	Eliasson, R; Pontis, E; Jordan, A; Reichard, P				Eliasson, R; Pontis, E; Jordan, A; Reichard, P			Allosteric control of three B-12-dependent (class II) ribonucleotide reductases - Implications for the evolution of ribonucleotide reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; NRDEF ENZYME; PROTEIN; BACTERIOPHAGE-T4; CLONING; BINDING; R1	Three separate classes of ribonucleotide reductases are known, each with a distinct protein structure. One common feature of all enzymes is that a single protein generates each of the four deoxyribonucleotides. Class I and III enzymes contain an allosteric substrate specificity site capable of binding effecters (ATP or various deoxyribonucleoside triphosphates) that direct enzyme specificity, Some (but not all) enzymes contain a second allosteric site that binds only ATP or dATP. Binding of dATP to this site inhibits the activity of these enzymes, X-ray crystallography has localized the two sites within the structure of the Escherichia coli class I enzyme and identified effector-binding amino acids, Here, we have studied the regulation of three class II enzymes, one from the archaebacterium Thermoplasma acidophilum and two from eubacteria (Lactobacillus leichmannii and Thermotoga maritima). Each enzyme has an allosteric site that binds ATP or various deoxyribonucleoside triphosphates and that regulates its substrate specificity according to the same rules as for class I and III enzymes. dATP does not inhibit enzyme activity, suggesting the absence of a second active allosteric site. For the L, leichmannii and T, maritima enzymes, binding experiments also indicate the presence of only one allosteric site, Their primary sequences suggest that these enzymes lack the structural requirements for a second site. In contrast, the T, acidophilum enzyme binds dATP at two separate sites, and its sequence contains putative effector-binding amino acids for a second site. The presence of a second site without apparent physiological function leads to the hypothesis that a functional site was present early during the evolution of ribonucleotide reductases, but that its function was lost from the T, acidophilum enzyme, The other two B-12 enzymes lost not only the function, but also the structural basis for the site, Also a large subgroup (Ib) of class I enzymes, but none of the investigated class III enzymes, has lost this site. This is further indirect evidence that class II and I enzymes may have arisen by divergent evolution from class III enzymes.	Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem 1, S-17177 Stockholm, Sweden; Autonomous Univ Barcelona, Fac Sci, Dept Genet & Microbiol, E-08193 Barcelona, Spain	Karolinska Institutet; Autonomous University of Barcelona	Reichard, P (corresponding author), Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem 1, S-17177 Stockholm, Sweden.	peter.reichard@mbb.ki.se	jordan, albert/ABC-8229-2020; jordan, albert/K-4678-2014	jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693				BECK WS, 1967, J BIOL CHEM, V242, P3148; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; BROWN NC, 1969, EUR J BIOCHEM, V9, P561, DOI 10.1111/j.1432-1033.1969.tb00646.x; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KIM JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P674, DOI 10.1016/0003-9861(77)90548-3; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; ORMO M, 1990, ANAL BIOCHEM, V182, P674; PANAGOU D, 1972, BIOCHEMISTRY-US, V11, P2378, DOI 10.1021/bi00762a025; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Tauer A, 1997, P NATL ACAD SCI USA, V94, P53, DOI 10.1073/pnas.94.1.53; Thelander L, 1978, Methods Enzymol, V51, P227; YOUNG P, 1994, J BIOL CHEM, V269, P27815	29	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7182	7189		10.1074/jbc.274.11.7182	http://dx.doi.org/10.1074/jbc.274.11.7182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066778	hybrid			2022-12-27	WOS:000079078400050
J	Satoh, D; Horii, A; Ochiai, M; Ashida, M				Satoh, D; Horii, A; Ochiai, M; Ashida, M			Prophenoloxidase-activating enzyme of the silkworm, Bombyx mori - Purification, characterization, and cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-VENTRAL PATTERN; HORSESHOE-CRAB HEMOCYTES; BLOOD-COAGULATION FACTOR; SERINE-PROTEASE ZYMOGEN; AMINO-ACID-SEQUENCE; PRO-PHENOL OXIDASE; 4 TANDEM REPEATS; PLASMA PREKALLIKREIN; RECOGNITION PROTEIN; PROCLOTTING ENZYME	Prophenoloxidase-activating enzyme (PPAE) was purified to homogeneity as judged by SDS-polyacrylamide gel electrophoresis from larval cuticles of the silkworm, Bombyx mori. The purified PPAE preparation was shown to be a mixture of the isozymes of PPAE (PPAE-I and PPAE-II), which were eluted at different retention times in reversed-phase high performance liquid chromatography, PPAE-I and PPAE-II seemed to be post translationally modified isozymes and/or allelic variants. Both PPAE isozymes were proteins composed of two polypeptides (heavy and light chains) that are linked by disulfide linkage(s) and glycosylated serine proteases, The results of cDNA cloning, peptide mapping, and amino acid sequencing of PPAE revealed that PPAE is synthesized as prepro-PPAE with 441 amino acid residues and is activated from pro-PPAE: by cleavage of a peptide bond between Lys(152) and Ile(153), The homology search showed 36.9% identity of PPAE to easter, which is a serine protease involved in dorsoventral pattern formation in the Drosophila embryo, and indicated the presence of two consecutive clip-like domains in the light chain. A single copy of the PPAE gene was suggested to be present in the silkworm genome. In the fifth instar larvae, PPAE transcripts were detected in the integument, hemocytes, and salivary glands but not in the fat body or mid gut. A polypeptide cross-reactive to mono-specific anti-PPAE/IgG was transiently detected in the extract of eggs between 1 and 3 h after they were laid.	Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600189, Japan	Hokkaido University	Ashida, M (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600189, Japan.	ashida@pop.lowtem.hokudai.ac.jp	Ochiai, Masanori/A-4372-2012	Ochiai, Masanori/0000-0002-0022-347X				ANDERSSON K, 1989, INSECT BIOCHEM, V19, P629, DOI 10.1016/0020-1790(89)90097-8; ASHIDA M, 1980, INSECT BIOCHEM, V10, P37, DOI 10.1016/0020-1790(80)90036-0; ASHIDA M, 1971, ARCH BIOCHEM BIOPHYS, V144, P749, DOI 10.1016/0003-9861(71)90383-3; ASHIDA M, 1967, ARCH BIOCHEM BIOPHYS, V122, P411, DOI 10.1016/0003-9861(67)90213-5; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; ASHIDA M, 1974, BIOCHEM BIOPH RES CO, V57, P1089, DOI 10.1016/0006-291X(74)90808-0; ASHIDA M, 1988, INSECT BIOCHEM, V18, P11, DOI 10.1016/0020-1790(88)90031-5; Ashida Masaaki, 1998, P135; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHEN CL, 1995, BIOCHEM J, V310, P23, DOI 10.1042/bj3100023; Chosa N, 1997, INSECT BIOCHEM MOLEC, V27, P61, DOI 10.1016/S0965-1748(96)00070-7; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P210, DOI 10.1016/0003-9861(73)90407-4; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FENIMORE JA, 1998, 3 INT S MOL INS SCI; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1982, J BIOL CHEM, V257, P3875; Horii A., 1995, Zoological Science (Tokyo), V12, P44; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Johansson M.W., 1996, Progress in Molecular and Subcellular Biology, V15, P46; KATSUMI Y, 1995, EUR J BIOCHEM, V228, P870, DOI 10.1111/j.1432-1033.1995.tb20334.x; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; KOSHLAND DEJ, 1970, ENZYMES, V1, P348; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON HS, 1965, ANNU REV BIOCHEM, V34, P595, DOI 10.1146/annurev.bi.34.070165.003115; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MURUGASUOEI B, 1995, GENE DEV, V9, P139, DOI 10.1101/gad.9.2.139; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; Peter J, 1998, BBA-GEN SUBJECTS, V1380, P93, DOI 10.1016/S0304-4165(97)00135-9; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P570, DOI 10.1016/0006-3002(55)90280-8; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SMITH C, 1994, GENETICS, V136, P1355; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TISELIUS A, 1956, ARCH BIOCHEM BIOPHYS, V65, P132, DOI 10.1016/0003-9861(56)90183-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559; YASUHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V320, P14, DOI 10.1006/abbi.1995.1337; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	60	205	219	2	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7441	7453		10.1074/jbc.274.11.7441	http://dx.doi.org/10.1074/jbc.274.11.7441			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066809	hybrid			2022-12-27	WOS:000079078400081
J	Annunen, P; Koivunen, P; Kivirikko, KI				Annunen, P; Koivunen, P; Kivirikko, KI			Cloning of the alpha subunit of prolyl 4-hydroxylase from Drosophila and expression and characterization of the corresponding enzyme tetramer with some unique properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOMERASE BETA-SUBUNIT; BACULOVIRUS EXPRESSION; CAENORHABDITIS-ELEGANS; HISTIDINE-RESIDUES; MOLECULAR-CLONING; LYSYL HYDROXYLASE; SEQUENCE; IDENTIFICATION; COLLAGEN; ISOFORM	Prolyl 4-hydroxylase catalyzes the formation of 4-hydroxyproline in collagens. The vertebrate enzymes are alpha(2)beta(2) tetramers, whereas the Caenorhabditis elegans enzyme is an alpha beta dimer, the beta subunit being identical to protein-disulfide isomerase (PDI), We report here that the processed Drosophila melanogaster a subunit is 516 amino acid residues in length and shows 34 and 35% sequence identities to the two types of human alpha subunit and 31% identity to the C, elegans alpha subunit. Its coexpression in insect cells with the Drosophila PDI polypeptide produced an active enzyme tetramer, and small amounts of a hybrid tetramer were also obtained upon coexpression with human PDI, Four of the five recently identified critical residues at the catalytic site were conserved, but a histidine that probably helps the binding of 2-oxoglutarate to the Fe2+ and its decarboxylation was replaced by arginine 490, The enzyme had a higher K-m for 2-oxoglutarate, a lower reaction velocity, and a higher percentage of uncoupled decarboxylation than the human enzymes. The mutation R490H reduced the percentage of uncoupled decarboxylation, whereas R490S increased the K-m for 2-oxoglutarate, reduced the reaction velocity, and increased the percentage of uncoupled decarboxylation. The recently identified peptide-binding domain showed a relatively low identity to those from other species, and the K-m of the Drosophila enzyme for (Pro-Pro-Gly)(10) was higher than that of any other animal prolyl 4-hydroxylase studied. A 1.9-kilobase mRNA coding for this alpha subunit was present in Drosophila larvae.	Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu	Kivirikko, KI (corresponding author), Univ Oulu, Dept Med Biochem, Kajaanintie 52 A, FIN-90220 Oulu, Finland.							Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; GRUENWALD S, 1994, BACULOVIRUS EXPRESSI; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MCKAY RR, 1995, INSECT BIOCHEM MOLEC, V25, P647, DOI 10.1016/0965-1748(95)00001-C; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yasothornsrikul S, 1997, GENE, V198, P17, DOI 10.1016/S0378-1119(97)00274-6	29	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6790	6796		10.1074/jbc.274.10.6790	http://dx.doi.org/10.1074/jbc.274.10.6790			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037780	hybrid			2022-12-27	WOS:000078902800102
J	Li, C; Kraemer, FB; Ahlborn, TE; Liu, JW				Li, C; Kraemer, FB; Ahlborn, TE; Liu, JW			Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LEUKEMIA INHIBITORY FACTOR; GENE-EXPRESSION; HEPG2 CELLS; NUCLEAR-PROTEIN; FACTOR SP1; IDENTIFICATION; SEQUENCE; BINDS; REPRESSION	Oncostatin M (OM) activates the transcription of the human low density lipoprotein receptor (LDLR) in HepG2 cells through a sterol-independent mechanism. Our previous studies showed that mutations within the repeat 3 sequence of the LDLR promoter significantly decreased OM activity on LDLR promoter luciferase reporter constructs that contain the sterol responsive element-1 (repeat 2) and Sp1 binding sites (repeats 1 and 3), In this study, we investigated the signal transduction pathways that are involved in OM-induced LDLR transcription, In HepG2 cells, OM induced a rapid increase in LDLR mRNA expression, with increases detected at 30 min and maximal induction at 1 h, This OM effect was not blocked by protein synthesis inhibitors, inhibitors of p38 kinase, phosphatidylinositol 3-kinase, or c-Jun N-terminal kinase, but OM activity was completely abolished by pretreating cells with inhibitors of the extracellular signal-regulated kinase (ERK) kinase (mitogen/ ERK kinase (MEK)), To investigate whether the repeat 3 sequence of the LDLR promoter is the OM-responsive element that converts ERK activation at the promoter level, three luciferase reporters, pLDLR-TATA containing only the TATA-like elements of the promoter, pLDLR-R3 containing repeat 3 and the TATA-like elements, and pLDLR-234 containing repeats 1, 2, 3 and the TATA-like elements were constructed and transiently transfected into HepG2 cells. OM had no effect on the basal promoter construct pLDLR-TATA; however, including a single copy of repeat 3 sequence in the TATA vector (pLDLR-R3) resulted in a full OM response. The activity of OM on pLDLR-R3 was identical to that of pLDLR-234, Importantly, the ability of OM to increase luciferase activities in both pLDLR-R3- and pLDLR-234-transfected cells was blocked in a dose-dependent manner by inhibition of MEK, These results demonstrate that the mitogen-activated protein kinase MEK/ERK cascade is the essential signaling pathway by which OM activates LDLR gene transcription and provide the first evidence that the repeat 3 element is a new downstream target of ERK activation.	Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, JW (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	liu@icon.palo-alto.med.va.gov	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BLOCK LH, 1993, P NATL ACAD SCI USA, V90, P4097, DOI 10.1073/pnas.90.9.4097; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Faris M, 1998, AIDS, V12, P19, DOI 10.1097/00002030-199801000-00003; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Kumar A, 1997, J LIPID RES, V38, P2240; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Liu JW, 1997, ARTERIOSCL THROM VAS, V17, P2948, DOI 10.1161/01.ATV.17.11.2948; Liu JW, 1997, J LIPID RES, V38, P2035; LIU JW, 1994, CELL GROWTH DIFFER, V5, P1333; Mehta KD, 1996, J BIOL CHEM, V271, P33616, DOI 10.1074/jbc.271.52.33616; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pak YK, 1996, J LIPID RES, V37, P985; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RUDLING M, 1993, P NATL ACAD SCI USA, V90, P8851, DOI 10.1073/pnas.90.19.8851; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; THOMA B, 1994, J BIOL CHEM, V269, P6215; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YIN TG, 1994, J BIOL CHEM, V269, P3731; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449	52	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6747	6753		10.1074/jbc.274.10.6747	http://dx.doi.org/10.1074/jbc.274.10.6747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037774	hybrid			2022-12-27	WOS:000078902800096
J	Turpin, P; Hay, RT; Dargemont, C				Turpin, P; Hay, RT; Dargemont, C			Characterization of I kappa B alpha nuclear import pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; DNA-BINDING; LOCALIZATION SEQUENCES; NUCLEOCYTOPLASMIC TRANSPORT; CYTOPLASMIC RETENTION; TERMINAL DOMAIN; EXPORT PATHWAY; PORE COMPLEX; HNRNP A1; SIGNAL	I kappa B alpha controls the transcriptional activity of nuclear factor (NF)-kappa B by retaining it in the cytoplasm; but, when expressed in the nucleus, it can also inhibit the interaction of NF-kappa B with DNA and promote the export of NF-kappa B from the nucleus to the cytoplasm, Here, we report that I kappa B alpha, when not bound to NF-kappa B, is constitutively transported to the nucleus, and we confirm that the interaction of NF-kappa B with NF-kappa B retains I kappa B alpha in the cytoplasm, Nuclear import of I kappa B alpha does not result from passive diffusion but from a specific energy-dependent transport process that requires the ankyrin repeats of I kappa B alpha. Nuclear accumulation of I kappa B alpha is dependent on importins alpha and beta as well as the small GTPase Ran, which are also responsible for the nuclear import mediated by basic nuclear localization sequences (NLS). However, these proteins are not sufficient to promote I kappa B alpha nuclear translocation. Factor(s) can be removed selectively from cell extracts with ankyrin repeats of I kappa B alpha which strongly reduce import of I kappa B alpha but not of proteins containing basic NLS. These findings indicate that I kappa B alpha is imported in the nucleus by a piggy-back mechanism that involves additional protein(s) containing a basic NLS and able to interact with ankyrin repeats of I kappa B alpha.	Inst Curie, CNRS, Unite Mixte Rech 144, Lab Transport Nucleocytoplasm, F-75248 Paris 05, France; Univ St Andrews, Sch Biomed Sci, Inst Biomol Sci, St Andrews, Fife, Scotland	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; University of St Andrews	Dargemont, C (corresponding author), Inst Curie, CNRS, Unite Mixte Rech 144, Lab Transport Nucleocytoplasm, 26 Rue Ulm, F-75248 Paris 05, France.		Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Aster JC, 1997, J BIOL CHEM, V272, P11336; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mizuno T, 1996, J CELL SCI, V109, P2627; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	83	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6804	6812		10.1074/jbc.274.10.6804	http://dx.doi.org/10.1074/jbc.274.10.6804			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037782	hybrid			2022-12-27	WOS:000078902800104
J	Kim, KH; Carman, GM				Kim, KH; Carman, GM			Phosphorylation and regulation of choline kinase from Saccharomyces cerevisiae by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; ESCHERICHIA-COLI; CYCLIC-AMP; CKI GENE; YEAST; PURIFICATION; CELLS; EXPRESSION; CLONING; METABOLISM	The CK11-encoded choline kinase (ATP:choline phosphotransferase, EC 2.7.1.32) from Saccharomyces cerevisiae was phosphorylated in vivo on multiple serine residues. Activation of protein kinase A activity in vivo resulted in a transient increase in the phosphorylation of choline kinase. This phosphorylation was accompanied by a stimulation in choline kinase activity. In vitro, protein kinase A phosphorylated choline kinase on a serine residue with a stoichiometry (0.44 mol of phosphate/mol of choline kinase) consistent with one phosphorylation site/choline kinase subunit. The major phosphopeptide derived from the enzyme phosphorylated in vitro by protein kinase A was common to one of the major phosphopeptides derived from the enzyme phosphorylated in vivo. Protein kinase A activity was dose- and time-dependent and dependent on the concentrations of ATP (K-m 2.1 mu M) and choline kinase (K-m 0.12 mu M). Phosphorylation of choline kinase with protein kinase A resulted in a stimulation (1.9-fold) in choline kinase activity whereas alkaline phosphatase treatment of choline kinase resulted in a 60% decrease in choline kinase activity. The mechanism of the protein kinase A-mediated stimulation in choline kinase activity involved an increase in the apparent V-max values with respect to ATP (2.6-fold) and choline (2.7-fold). Overall, the results reported here were consistent with the conclusion that choline kinase was regulated by protein kinase A phosphorylation.	Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; ISHIDATE K, 1984, J BIOL CHEM, V259, P4706; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PORTER TJ, 1990, J BIOL CHEM, V265, P414; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Segel IH, 1975, ENZYME KINETICS BEHA; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P63, DOI 10.1016/S0005-2760(97)00104-5	49	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9531	9538		10.1074/jbc.274.14.9531	http://dx.doi.org/10.1074/jbc.274.14.9531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092638	hybrid			2022-12-27	WOS:000079451800057
J	Onate, L; Vicente-Carbajosa, J; Lara, P; Diaz, I; Carbonero, P				Onate, L; Vicente-Carbajosa, J; Lara, P; Diaz, I; Carbonero, P			Barley BLZ2, a seed-specific bZIP protein that interacts with BLZ1 in vivo and activates transcription from the GCN4-like motif of B-hordein promoters in barley endosperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING; MICROPROJECTILE BOMBARDMENT; OPAQUE-2 ENCODES; PROLAMIN GENES; WHEAT; DIMERIZATION; RECOGNIZES; SEQUENCES; TOBACCO	A barley endosperm cDNA, encoding a DNA-binding protein of the bZIP class of transcription factors, BLZ2, has been characterized. The Blz2 mRNA expression is restricted to the endosperm, where it precedes that of the hordein genes. BLZ2, expressed in bacteria, binds specifically to the GCN4-like motif (GLM; 5'-GTGAGT-CAT-3') in a 43-base pair oligonucleotide derived from the promoter region of a Hor-2 gene (B1-hordein), This oligonucleotide also includes the prolamin box (PB; 5'-TGTAAAG-3'). Binding by BLZ2 is prevented when the GLM is mutated to 5'-GTGctTCtc-3' but not when mutations affect the PB, The BLZ2 protein is a potent transcriptional activator in a yeast two-hybrid system where it dimerizes with BLZ1, a barley bZIP protein encoded by the ubiquitously expressed Blz1 gene. Transient expression experiments in co-bombarded developing barley endosperms demonstrate that BLZ2 transactivates transcription from the GLM of the Hor-2 gene promoter and that this activation is also partially dependent on the presence of an intact PB. A drastic decrease in GUS activity is observed in co-bombarded barley endosperms when using as effecters equimolar mixtures of Blz2 and Blz1 in antisense constructs. These results strongly implicate the endosperm-specific BLZ2 protein from barley, either as a homodimer or as a heterodimer with BLZ1, as an important transcriptional activator of seed storage protein genes containing the GLM in their promoters.	Univ Politecn Madrid, Lab Bioquim & Biol Mol, Dept Biotecnol, ETS Ingn Agron, E-28040 Madrid, Spain	Universidad Politecnica de Madrid	Carbonero, P (corresponding author), Univ Politecn Madrid, Lab Bioquim & Biol Mol, Dept Biotecnol, ETS Ingn Agron, E-28040 Madrid, Spain.	pcarbonero@bit.etsia.upm.es	Oñate-Sánchez, Luis J/C-6274-2017; Vicente-Carbajosa, Jesus/A-9368-2008; Diaz, Isabel/I-8840-2014	Oñate-Sánchez, Luis J/0000-0001-7047-5739; Vicente-Carbajosa, Jesus/0000-0002-6332-1712; Diaz, Isabel/0000-0001-9865-902X				ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; Ausubel FA, 1990, CURRENT PROTOCOLS MO; AZAD AA, 1980, NUCLEIC ACIDS RES, V8, P4365, DOI 10.1093/nar/8.19.4365; BEVAN M, 1993, PHILOS T R SOC B, V342, P209, DOI 10.1098/rstb.1993.0149; BRANDT A, 1985, CARLSBERG RES COMMUN, V50, P333, DOI 10.1007/BF02907156; COLOT V, 1987, EMBO J, V6, P3559, DOI 10.1002/j.1460-2075.1987.tb02685.x; DEPATER S, 1994, PLANT J, V6, P133, DOI 10.1046/j.1365-313X.1994.6020133.x; DIAZ I, 1995, MOL GEN GENET, V248, P592, DOI 10.1007/BF02423455; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENTWISTLE J, 1991, PLANT MOL BIOL, V17, P1217, DOI 10.1007/BF00028737; FORDE BG, 1985, NUCLEIC ACIDS RES, V7, P1869; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; Guerin J, 1997, PLANT PHYSIOL, V114, P55, DOI 10.1104/pp.114.1.55; GUILTINAN MJ, 1994, PLANT MOL BIOL, V26, P1041, DOI 10.1007/BF00040687; HAMMONDKOSACK MCU, 1993, EMBO J, V12, P545, DOI 10.1002/j.1460-2075.1993.tb05686.x; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HULL GA, 1991, PLANT MOL BIOL, V17, P1111, DOI 10.1007/BF00037153; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIKKERT JR, 1993, PLANT CELL TISS ORG, V33, P221, DOI 10.1007/BF02319005; Kreis M., 1992, BARLEY GENETICS MOL; LAGRIMINI LM, 1987, P NATL ACAD SCI USA, V84, P7542, DOI 10.1073/pnas.84.21.7542; LEISY DJ, 1990, PLANT MOL BIOL, V14, P41, DOI 10.1007/BF00015653; LOHMER S, 1991, EMBO J, V10, P617, DOI 10.1002/j.1460-2075.1991.tb07989.x; LOHMER S, 1993, PLANT CELL, V5, P65, DOI 10.1105/tpc.5.1.65; Mena M, 1998, PLANT J, V16, P53, DOI 10.1046/j.1365-313x.1998.00275.x; MULLER M, 1995, J PLANT PHYSIOL, V145, P606, DOI 10.1016/S0176-1617(11)81271-X; MULLER M, 1993, PLANT J, V4, P343, DOI 10.1046/j.1365-313X.1993.04020343.x; Nakase M, 1997, PLANT MOL BIOL, V33, P513, DOI 10.1023/A:1005784717782; PIROVANO L, 1994, PLANT MOL BIOL, V24, P515, DOI 10.1007/BF00024119; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; RANDOLPH E, 1992, BIOTECHNIQUES, V13, P18; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SORENSEN MB, 1989, MOL GEN GENET, V217, P195, DOI 10.1007/BF02464881; SUMNERSMITH M, 1985, NUCLEIC ACIDS RES, V13, P3905, DOI 10.1093/nar/13.11.3905; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR MG, 1991, PLANT CELL REP, V10, P120, DOI 10.1007/BF00232041; UENG P, 1988, PLANT PHYSIOL, V86, P1281, DOI 10.1104/pp.86.4.1281; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VASIL V, 1991, BIO-TECHNOL, V9, P743, DOI 10.1038/nbt0891-743; Vicente-Carbajosa J, 1998, PLANT J, V13, P629, DOI 10.1111/j.1365-313X.1998.00068.x; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; YUNES JA, 1994, PLANT CELL, V6, P237, DOI 10.1105/tpc.6.2.237	53	96	107	1	23	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9175	9182		10.1074/jbc.274.14.9175	http://dx.doi.org/10.1074/jbc.274.14.9175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092589	Green Accepted, hybrid			2022-12-27	WOS:000079451800008
J	Perrella, MA; Pellacani, A; Wiesel, P; Chin, MT; Foster, LC; Ibanez, M; Hsieh, CM; Reeves, R; Yet, SF; Lee, ME				Perrella, MA; Pellacani, A; Wiesel, P; Chin, MT; Foster, LC; Ibanez, M; Hsieh, CM; Reeves, R; Yet, SF; Lee, ME			High mobility group-I(Y) protein facilitates nuclear factor-kappa B binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; IFN-BETA GENE; INTERFERON-GAMMA; VIRUS INDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL-PROTEINS; NO SYNTHASE; DNA-BINDING; EXPRESSION	Nitric oxide (NO), a free radical gas whose production is catalyzed by the enzyme NO synthase, participates in the regulation of multiple organ systems. The inducible isoform of NO synthase (iNOS) is transcriptionally upregulated by inflammatory stimuli; a critical mediator of this process is nuclear factor (NF)-kappa B, Our objective was to determine which regulatory elements other than NF-kappa B binding sites are important for activation of the MOS promoter/enhancer. We also wanted to identify transcription factors that may be functioning in conjunction with NF-kappa B (subunits p50 and p65) to drive iNOS transcription. Deletion analysis of the iNOS promoter/enhancer revealed that an AT-rich sequence (-61 to -54) downstream of the NF-kappa B site (-85 to -76) in the 5'-flanking sequence was important for iNOS induction by interleukin-1 beta and endotoxin in vascular smooth muscle cells. This AT-rich sequence, corresponding to an octamer (Oct) binding site, bound the architectural transcription factor high mobility group (HMG)-I(Y) protein. Electrophoretic mobility shift assays showed that HMG-I(Y) and NF-kappa B subunit p50 bound to the iNOS promoter/enhancer to form a ternary complex. The formation of this complex required HMG-I(Y) binding at the Oct site. The location of an HMG-I(Y) binding site typically overlaps that of a recruited transcription factor. In the iNOS promoter/enhancer, however, HMG-I(Y) formed a complex with p50 while binding downstream of the NF-kappa B site. Furthermore, overexpression of HMG-I(Y) potentiated iNOS promoter/enhancer activity by p50 and p65 in transfection experiments, suggesting that HMG-I(Y) contributes to the transactivation of MOS by NF-kappa B.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Brigham & Womens Hosp, Crit Care Div, Boston, MA 02115 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Washington State University	Perrella, MA (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 667 Huntington Ave, Boston, MA 02115 USA.	perrella@cvlab.harvard.edu	Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL03194, HL60788, HL03745] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HELMKE RJ, 1987, IN VITRO CELL DEV B, V23, P567; IGNARRO JJ, 1990, ANN REV PHARM TOXICO, V30, P35; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; REEVES R, 1990, J BIOL CHEM, V265, P8573; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sambrook J., 2002, MOL CLONING LAB MANU; Sawada T, 1997, J IMMUNOL, V158, P5267; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xie QW, 1997, J BIOL CHEM, V272, P14867, DOI 10.1074/jbc.272.23.14867; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	55	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9045	9052		10.1074/jbc.274.13.9045	http://dx.doi.org/10.1074/jbc.274.13.9045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085153	hybrid			2022-12-27	WOS:000079451600095
J	Zhang, LL; Song, LX; Parker, EM				Zhang, LL; Song, LX; Parker, EM			Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase - Evidence that substrate availability limits beta-amyloid peptide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LINKED PRESENILIN-1; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CELLS; GENE; RATIO; VIVO	The calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN) has been reported to have complex effects on the production of the beta-amyloid peptide (A beta), In this study, the effects of ALLN on the processing of the amyloid precursor protein (APP) to A beta were examined in 293 cells expressing APP or the C-terminal 100 amino acids of APP (C100), In cells expressing APP or low levels of C100, ALLN increased A beta 40 and A beta 42 secretion at low concentrations, decreased A beta 40 and A beta 42 secretion at high concentrations, and increased cellular levels of C100 in a concentration-dependent manner by inhibiting C100 degradation. Low concentrations of ALLN increased A beta 42 secretion more dramatically than A beta 40 secretion. ALLN treatment of cells expressing high levels of C100 did not alter cellular C100 levels and inhibited A beta 40 and A beta 42 secretion with similar IC50 values. These results suggest that C100 can be processed both by gamma-secretase and by a degradation pathway that is inhibited by low concentrations of ALLN, The data are consistent with inhibition of gamma-secretase by high concentrations of ALLN but do not support previous assertions that ALLN is a selective inhibitor of the gamma-secretase producing A beta 40. Rather, A beta 42 secretion may be more dependent on C100 substrate concentration than A beta 40 secretion.	Schering Plough Corp, Res Inst, Dept Cent Nervous Syst & Cardiovasc Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Zhang, LL (corresponding author), Schering Plough Corp, Res Inst, Dept Cent Nervous Syst & Cardiovasc Res, K15-3-3600,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	lili.zhang@spcorp.com						Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DYKES T, 1993, FEBS LETT, V335, P89; DYKES T, 1992, FEBS LETT, V309, P20; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Savage MJ, 1998, J NEUROSCI, V18, P1743; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	23	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8966	8972		10.1074/jbc.274.13.8966	http://dx.doi.org/10.1074/jbc.274.13.8966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085142	hybrid			2022-12-27	WOS:000079451600084
J	Calsou, P; Frit, P; Humbert, O; Muller, C; Chen, DJ; Salles, B				Calsou, P; Frit, P; Humbert, O; Muller, C; Chen, DJ; Salles, B			The DNA-dependent protein kinase catalytic activity regulates DNA end processing by means of Ku entry into DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; NUCLEOTIDE EXCISION-REPAIR; ATOMIC-FORCE MICROSCOPY; V(D)J RECOMBINATION; HELICASE-II; BINDING-PROTEIN; CELL-EXTRACTS; DAMAGED DNA; IN-VITRO; AUTOANTIGEN	The DNA-dependent protein kinase (DNA-PK) is required for double-strand break repair in mammalian cells. DNA-PK contains the heterodimer Ku and a 460-kDa serine/threonine kinase catalytic subunit (p460), Ku binds in vitro to DNA termini or other discontinuities in the DNA helix and is able to enter the DNA molecule by an ATP-independent process. It is clear from in vitro experiments that Ku stimulates the recruitment to DNA of p460 and activates the kinase activity toward DNA-binding protein substrates in the vicinity. Here, we have examined in human nuclear cell extracts the influence of the kinase catalytic activity on Ku binding to DNA, We demonstrate that, although Ku can enter DNA from free ends in the absence of p460 subunit, the kinase activity is required for Ku translocation along the DNA helix when the whole Ku/p460 assembles on DNA termini, When the kinase activity is impaired, DNA-PK including Ku and p460 is blocked at DNA ends and prevents their processing by either DNA polymerization, degradation, or ligation. The control of Ku entry into DNA by DNA-PK catalytic activity potentially represents an important regulation of DNA transactions at DNA termini.	Inst Pharmacol & Biol Struct, CNRS UPR 9062, F-31077 Toulouse, France; Univ Calif Los Alamos Natl Lab, DNA Damage & Repair Grp, Div Life Sci, Los Alamos, NM 87545 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); United States Department of Energy (DOE); Los Alamos National Laboratory	Calsou, P (corresponding author), Inst Pharmacol & Biol Struct, CNRS UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		salles, bernard/B-8531-2008; MULLER, Catherine/E-2060-2011; calsou, patrick/AAB-5123-2020; MULLER, Catherine/M-2185-2018	Calsou, Patrick/0000-0001-7951-9806				Anderson CW, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P395; Badie C, 1997, CANCER RES, V57, P4600; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FRANCOEUR AM, 1985, J IMMUNOL, V135, P2378; Frit P, 1998, J MOL BIOL, V284, P963, DOI 10.1006/jmbi.1998.2257; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Labhart P, 1996, FEBS LETT, V386, P110, DOI 10.1016/0014-5793(96)00420-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LeRomancer M, 1996, J CELL SCI, V109, P3121; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lu H, 1998, CANCER RES, V58, P84; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Ono M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Pang DL, 1997, CANCER RES, V57, P1412; POWIS G, 1994, CANCER RES, V54, P2419; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Turchi JJ, 1996, J BIOL CHEM, V271, P13861, DOI 10.1074/jbc.271.23.13861; Tuteja N, 1997, BIOCHEM BIOPH RES CO, V236, P636, DOI 10.1006/bbrc.1997.7021; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhu C, 1996, CANCER SURV, V28, P295	67	89	91	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7848	7856		10.1074/jbc.274.12.7848	http://dx.doi.org/10.1074/jbc.274.12.7848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075677	hybrid			2022-12-27	WOS:000079268100036
J	Fujimoto, N; Yeh, SY; Kang, HY; Inui, S; Chang, HC; Mizokami, A; Chang, CS				Fujimoto, N; Yeh, SY; Kang, HY; Inui, S; Chang, HC; Mizokami, A; Chang, CS			Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN; STEROID-RECEPTORS; HORMONE RECEPTOR; PROTEIN; CANCER; GENE; ACTIVATION; MUTATION; TRANSCRIPTION; CYTOSKELETON	Androgen receptor (AR) is a hormone-activated transcriptional factor that can bind to androgen response elements and that regulates the transcription of target genes via a mechanism that presumably involves cofactors. We report here the cloning of a novel AR coactivator ARA55 using a yeast two-hybrid system. ARA55 consists of 444 amino acids with the predicted molecular mass of 55 kDa and its sequence shows very high homology to mouse hic5, a TGF-beta 1-inducible gene. Yeast and mammalian two-hybrid systems and co immunoprecipitation assays all prove ARA55 can bind to AR in a ligand-dependent manner. Transient transfection assay in prostate cancer DU145 cells further demonstrates that ARA55 can enhance AR transcriptional activity in the presence of 1 nM dihydrotestosterone or its antagonists such as 100 nM 17 beta-estradiol or 1 mu M hydroxyflutamide, Our data also suggest the C-terminal half of ARA55, which includes three LIM motifs, is sufficient to interact with AR. Northern blot and polymerase chain reaction quantitation showed ARA55 can be expressed differently in normal prostate and prostate tumor cells. Together, our data suggests that ARA55 may play very important roles in the progression of prostate cancer by the modulation of AR transactivation.	Univ Rochester, Ctr Med, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Med Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, Ctr Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Ctr Med, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@pathology.rochester.edu	Kang, Hong-Yo/W-9031-2019	Kang, Hong-Yo/0000-0003-0626-5037; CHANG, HONG-CHIANG/0000-0001-5411-6680	NCI NIH HHS [CA55639, CA68568] Funding Source: Medline; NIDDK NIH HHS [DK51346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; ONATE SA, 1995, SCIENCE, V270, P1354; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG C, 1997, THESIS U WISCONSIN M; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	28	226	233	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8316	8321		10.1074/jbc.274.12.8316	http://dx.doi.org/10.1074/jbc.274.12.8316			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075738	hybrid			2022-12-27	WOS:000079268100097
J	Jiang, HL; Okamura, CS; Lucy, MC				Jiang, HL; Okamura, CS; Lucy, MC			Isolation and characterization of a novel promoter for the bovine growth hormone receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC PROMOTER; GH BINDING-PROTEIN; ALDOLASE-A GENE; MESSENGER-RNA; PLACENTAL-LACTOGEN; GENOMIC STRUCTURE; FACTOR-I; EXPRESSION; MOUSE; CLONING	The use of alternative promoters represents an important mechanism for the regulation of growth hormone receptor (GHR) gene expression. Two promoters have been isolated previously for the GHR gene: the pi promoter that drives liver-specific expression, and the P2 promoter that drives ubiquitous expression. In the present study, we isolated a third GHR promoter termed P3, The P3 promoter was GC-rich and TATA-less, The P3 promoter was able to drive the expression of a luciferase reporter gene in cell lines Hep G2, PLC/PRF/5, and BHK-21. In vivo, the P3 promoter initiated transcription from two major sites in exon 1C of the GHR gene in many tissues. In the adult bovine liver, the P3-transcribed GHR mRNA represented only 10% of the total GHR mRNA pool. In non-hepatic tissues such as kidney, skeletal muscle, mammary gland, and uterus, PB-transcribed GHR mRNA represented 30-40% of the total GHR mRNA pool, Within the bovine GHR gene, the P3 promoter was located immediately downstream from the P2 promoter. In transfected cells, the P2 promoter served as an enhancer for the P3 promoter. Existence and co-regulation of two ubiquitous promoters may be a mechanism for achieving a high level of expression of the GHR gene in multiple tissues.	Univ Missouri, Dept Anim Sci, ASRC 164, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Lucy, MC (corresponding author), Univ Missouri, Dept Anim Sci, ASRC 164, Columbia, MO 65211 USA.	lucym@missouri.edu		, Honglin/0000-0001-9540-5788				ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; BARTON DE, 1989, CYTOGENET CELL GENET, V50, P137, DOI 10.1159/000132743; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; Bennett PA, 1996, ENDOCRINOLOGY, V137, P3891, DOI 10.1210/en.137.9.3891; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; Brakebusch C, 1997, J BIOL CHEM, V272, P3674, DOI 10.1074/jbc.272.6.3674; BYATT JC, 1995, P SOC EXP BIOL MED, V210, P20, DOI 10.3181/00379727-210-43919; Chen NY, 1997, ENDOCRINOLOGY, V138, P1988, DOI 10.1210/en.138.5.1988; CIOFFI JA, 1990, NUCLEIC ACIDS RES, V18, P6451, DOI 10.1093/nar/18.21.6451; Clegg CH, 1996, J BIOL CHEM, V271, P1638, DOI 10.1074/jbc.271.3.1638; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; DOMENE HM, 1995, DNA CELL BIOL, V14, P195, DOI 10.1089/dna.1995.14.195; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Edens A, 1998, ENDOCR REV, V19, P559, DOI 10.1210/er.19.5.559; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HEAP D, 1995, J ANIM SCI, V73, P1529; Heap D, 1996, DOMEST ANIM ENDOCRIN, V13, P421, DOI 10.1016/0739-7240(96)00072-0; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Jux C, 1998, ENDOCRINOLOGY, V139, P3296, DOI 10.1210/en.139.7.3296; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li J, 1996, ENDOCRINOLOGY, V137, P1650, DOI 10.1210/en.137.5.1650; Lucy MC, 1998, J DAIRY SCI, V81, P1889, DOI 10.3168/jds.S0022-0302(98)75760-1; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MENON RK, 1995, J BIOL CHEM, V270, P8851, DOI 10.1074/jbc.270.15.8851; Nguyen AP, 1996, ENDOCRINOLOGY, V137, P3659, DOI 10.1210/en.137.9.3659; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P5125, DOI 10.1073/pnas.94.10.5125; PEKHLETSKY RI, 1992, MOL CELL ENDOCRINOL, V90, P103, DOI 10.1016/0303-7207(92)90107-H; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; Silos SA, 1996, J BIOL CHEM, V271, P17504, DOI 10.1074/jbc.271.29.17504; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215; Zou LL, 1997, ENDOCRINOLOGY, V138, P1771, DOI 10.1210/en.138.4.1771	49	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7893	7900		10.1074/jbc.274.12.7893	http://dx.doi.org/10.1074/jbc.274.12.7893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075683	hybrid			2022-12-27	WOS:000079268100042
J	Li, XF; Lytton, J				Li, XF; Lytton, J			A circularized sodium-calcium exchanger exon 2 transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; NA-CA EXCHANGER; NA+/CA2+ EXCHANGER; MOLECULAR-CLONING; TRANSMEMBRANE SEGMENTS; SARCOPLASMIC-RETICULUM; BINDING-PROTEIN; MOUSE TESTIS; GENE; EXPRESSION	Previous reports of Na/Ca exchanger gene 1 (NCX1) expression have revealed a major RNA transcript of 7 kilobase pairs (kb), minor transcripts of similar to 13 and similar to 4 kb, and a relatively abundant 1.8-kb RNA band. In the present report we demonstrate that the 1.8-kb message, which has a tissue and subcellular distribution matching that of full-length NCX1 but is not polyadenylated, corresponds to a perfectly circularized exon 2 species. The circular transcript contained the normal NCX1 start codon, a new stop codon introduced as a consequence of circularization, and encoded a protein corresponding to the NH2-terminal portion of NCX1, terminating just after amino acid 600 in the cytoplasmic loop, A linear version of the circular transcript was prepared and transfected into HEK-293 cells. A protein, matching the predicted size of similar to 70 kDa, was expressed, and the transfected cells possessed Na/Ca exchange activity. Although in native tissue we could not detect a protein corresponding exactly to that predicted from the circular transcript, a prominent band of slightly shorter size, possibly representing further proteolytic processing of circular transcript protein, was observed in membranes from LLC-MK2 cells and rat kidney.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Lytton, Jonathan/0000-0003-4770-2512				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Dolci S, 1997, BIOL REPROD, V57, P1128, DOI 10.1095/biolreprod57.5.1128; Dubin RA, 1995, GENE, V167, P245, DOI 10.1016/0378-1119(95)00639-7; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; Gabellini N, 1996, EUR J BIOCHEM, V239, P897, DOI 10.1111/j.1432-1033.1996.0897u.x; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Lederer WJ, 1996, ANN NY ACAD SCI, V779, P7, DOI 10.1111/j.1749-6632.1996.tb44764.x; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Lytton J, 1996, ANN NY ACAD SCI, V779, P58, DOI 10.1111/j.1749-6632.1996.tb44770.x; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Philipson KD, 1996, ANN NY ACAD SCI, V779, P20, DOI 10.1111/j.1749-6632.1996.tb44766.x; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; RUKNUDIN A, 1998, BIOPHYS J, V74, P193; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 2002, MOL CLONING LAB MANU; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680; Zaphiropoulos PG, 1997, MOL CELL BIOL, V17, P2985, DOI 10.1128/MCB.17.6.2985; Zaphiropoulos PG, 1996, P NATL ACAD SCI USA, V93, P6536, DOI 10.1073/pnas.93.13.6536	40	82	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8153	8160		10.1074/jbc.274.12.8153	http://dx.doi.org/10.1074/jbc.274.12.8153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075718	hybrid			2022-12-27	WOS:000079268100077
J	Cannon, KS; Helenius, A				Cannon, KS; Helenius, A			Trimming and readdition of glucose to N-linked oligosaccharides determines calnexin association of a substrate glycoprotein in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; ATP-COUPLED TRANSPORT; G-PROTEIN; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; QUALITY-CONTROL; BREFELDIN-A; INTERMEDIATE COMPARTMENT; INTRACELLULAR-TRANSPORT; INFLUENZA HEMAGGLUTININ	To analyze the role of glucose trimming and reglucosylation in the binding of substrate proteins to calnexin in the endoplasmic reticulum (ER) of living cells, we made use of the thermosensitive vesicular stomatitis virus tsO45 glycoprotein (Gr protein). At nonpermissive temperature the G protein failed to fold completely and remained bound to calnexin, When the cells were shifted to permissive temperature, complete folding occurred accompanied by glucosidase-mediated elimination of calnexin-G protein complexes. If release from calnexin was blocked during the temperature shift by inhibiting the glucosidases, folding occurred, albeit at a reduced rate. In contrast, when unfolded by a shift from permissive to nonpermissive temperature, the G protein was reglucosylated rapidly and became capable of rebinding to calnexin. The rate at which calnexin binding occurred showed a 20-min delay that was explained by accumulation of the G protein in calnexin-free exit sites of the ER. These contained the glucosyltransferase responsible for reglucosylation of misfolded glycoproteins but had little or no calnexin, After unfolding and reglucosylation, the G proteins moved slowly from these structures back to the ER where they reassociated with the chaperone. Taken together, these results in live cells fully supported the lectin-only model of calnexin function. The ER exit sites emerged as a potentially important location for components of the quality control system.	Swiss Fed Inst Technol, Biochem Lab, CH-8092 Zurich, Switzerland; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Yale University	Helenius, A (corresponding author), Swiss Fed Inst Technol, Biochem Lab, Univ Str 16, CH-8092 Zurich, Switzerland.				NIGMS NIH HHS [GM 52972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052972] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1986, J BIOL CHEM, V261, P4690; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BALCH WE, 1986, J BIOL CHEM, V261, P4681; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LODISH HF, 1983, VIROLOGY, V125, P335, DOI 10.1016/0042-6822(83)90206-4; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; PARODI AJ, 1982, J BIOL CHEM, V257, P7641; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	44	66	66	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7537	7544		10.1074/jbc.274.11.7537	http://dx.doi.org/10.1074/jbc.274.11.7537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066821	hybrid			2022-12-27	WOS:000079078400093
J	Gang, DR; Kasahara, H; Xia, ZQ; Vander Mijnsbrugge, K; Bauw, G; Boerjan, W; Van Montagu, M; Davin, LB; Lewis, NG				Gang, DR; Kasahara, H; Xia, ZQ; Vander Mijnsbrugge, K; Bauw, G; Boerjan, W; Van Montagu, M; Davin, LB; Lewis, NG			Evolution of plant defense mechanisms - Relationships of phenylcoumaran benzylic ether reductases to pinoresinol-lariciresinol and isoflavone reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDICAGO-SATIVA L; PHYTOALEXIN BIOSYNTHESIS; FORSYTHIA-INTERMEDIA; DILIGNOL GLYCOSIDES; PHENOLIC-COMPOUNDS; MOLECULAR-CLONING; STRESS RESPONSES; CONIFER NEEDLES; CELL-DIVISION; PIPER WIGHTII	Pinoresinol-lariciresinol and isoflavone reductase classes are phylogenetically related, as is a third, the so-called "isoflavone reductase homologs," This study establishes the first known catalytic function for the latter, as being able to engender the NADPH-dependent reduction of phenylcoumaran benzylic ethers, Accordingly, all three reductase classes are involved in the biosynthesis of important and related phenylpropanoid-derived plant defense compounds. In this investigation, the phenylcoumaran benzylic ether reductase from the gymnosperm, Pinus taeda, was cloned, with the recombinant protein heterologously expressed in Escherichia coli, The purified enzyme reduces the benzylic ether functionalities of both dehydrodiconiferyl alcohol and dihydrodehydrodiconiferyl alcohol, with a higher affinity for the former, as measured by apparent K-m and V-max values and observed kinetic H-3-isotope effects. It abstracts the 4R-hydride of the required NADPH cofactor in a manner analogous to that of the pinoresinol-lariciresinol reductases and isoflavone reductases. A similar catalytic function was observed for the corresponding recombinant reductase whose gene was cloned from the angiosperm, Populus trichocarpa. Interestingly, both pinoresinol-lariciresinol reductases and isoflavone reductases catalyze enantiospecific conversions, whereas the phenylcoumaran benzylic ether reductase only shows regiospecific discrimination. A possible evolutionary relationship among the three reductase classes is proposed, based on the supposition that phenylcoumaran benzylic ether reductases represent the progenitors of pinoresinol-lariciresinol and isoflavone reductases.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; State Univ Ghent VIB, Genet Lab, B-9000 Ghent, Belgium	Washington State University; Flanders Institute for Biotechnology (VIB); Ghent University	Lewis, NG (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	lewisn@wsu.edu	Boerjan, Wout/Y-4158-2019; Gang, David/B-1001-2013; Kasahara, Hiroyuki/F-6445-2012	Boerjan, Wout/0000-0003-1495-510X; Kasahara, Hiroyuki/0000-0002-4858-0978; Lewis, Norman/0000-0001-5742-032X; Davin, Laurence/0000-0002-3248-6485				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ASAKAW AY, 1997, HETROCYCLES, V46, P795; Attucci S., 1996, PLANT PHYSIOL, V110, P1435; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; BANKS SW, 1982, J CHEM SOC CHEM COMM, P157, DOI 10.1039/c39820000157; BINNS AN, 1987, P NATL ACAD SCI USA, V84, P980, DOI 10.1073/pnas.84.4.980; CHU A, 1993, J BIOL CHEM, V268, P27026; DEWICK PM, 1977, J CHEM SOC CHEM COMM, P338, DOI 10.1039/c39770000338; DEYAMA T, 1987, CHEM PHARM BULL, V35, P1803; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; DIXON RA, 1995, PHYSIOL PLANTARUM, V93, P385, DOI 10.1111/j.1399-3054.1995.tb02243.x; Dong JZ, 1996, PLANT CELL REP, V15, P516, DOI 10.1007/BF00232985; DUMAS B, 1992, PLANT PHYSIOL, V98, P796, DOI 10.1104/pp.98.2.796; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; Freudenberg K, 1968, CONSTITUTION BIOSYNT, P47; Fujita M, 1999, J BIOL CHEM, V274, P618, DOI 10.1074/jbc.274.2.618; Gang DR, 1997, ACS SYM SER, V658, P58; Gang DR, 1998, ACS SYM SER, V697, P389, DOI DOI 10.1021/BK-1998-0697.CH025; GARDNER JAF, 1960, CAN J CHEM, V38, P2387, DOI 10.1139/v60-324; GARDNER JAF, 1966, CAN J CHEMISTRY, V44, P52, DOI 10.1139/v66-009; GARDNER JAF, 1959, CAN J CHEM, V37, P1703, DOI 10.1139/v59-246; *GEN COMP GROUP, 1994, GCG SEQ AN SOFTW PAC; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Ikeda Tomoko, 1994, Natural Medicines, V48, P32; KATAYAMA T, 1993, PHYTOCHEMISTRY, V33, P581, DOI 10.1016/0031-9422(93)85452-W; KESSMANN H, 1990, PLANT PHYSIOL, V94, P227, DOI 10.1104/pp.94.1.227; Kraus C, 1997, PHYTOCHEMISTRY, V44, P59, DOI 10.1016/S0031-9422(96)00388-3; KRAUS R, 1990, PHYTOCHEMISTRY, V29, P1653, DOI 10.1016/0031-9422(90)80140-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lers A, 1998, PLANT MOL BIOL, V36, P847, DOI 10.1023/A:1005996515602; LEWIS NG, 1998, ACS SYM SER, V697, P1; LUNDGREN LN, 1985, ACTA CHEM SCAND B, V39, P241, DOI 10.3891/acta.chem.scand.39b-0241; LUNDGREN LN, 1981, PHYTOCHEMISTRY, V20, P1967, DOI 10.1016/0031-9422(81)84046-0; LYNN DG, 1987, P NATL ACAD SCI USA, V84, P615, DOI 10.1073/pnas.84.3.615; MACLEAN H, 1967, CAN J CHEMISTRY, V45, P305, DOI 10.1139/v67-054; MACLEAN H, 1967, CAN J CHEMISTRY, V45, P739, DOI 10.1139/v67-120; MACLEAN H, 1966, CAN J CHEMISTRY, V44, P1541, DOI 10.1139/v66-229; MACLEAN H., 1956, Forest Products Journal, V6, P510; MACLEAN H, 1966, CAN J CHEMISTRY, V44, P1827, DOI 10.1139/v66-274; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; ORR JD, 1992, PLANT PHYSIOL, V98, P343, DOI 10.1104/pp.98.1.343; Otsuka H, 1996, PHYTOCHEMISTRY, V42, P1435, DOI 10.1016/0031-9422(96)00143-4; PAIVA NL, 1994, ARCH BIOCHEM BIOPHYS, V312, P501, DOI 10.1006/abbi.1994.1338; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; PRASAD AK, 1994, TETRAHEDRON, V50, P2231, DOI 10.1016/S0040-4020(01)85081-X; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; RICE P, 1996, PROGRAM MANUAL EGCG; Sambrook J, 1994, MOL CLONING LAB MANU; SATAKE T, 1978, CHEM PHARM BULL, V26, P1619; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SCHLIEPER D, 1990, PHYTOCHEMISTRY, V29, P1519, DOI 10.1016/0031-9422(90)80112-T; Segel IH, 1975, ENZYME KINETICS BEHA; SHAIN L, 1971, PHYTOPATHOLOGY, V61, P841, DOI 10.1094/Phyto-61-841; SMITE E, 1995, PHYTOCHEMISTRY, V40, P341, DOI 10.1016/0031-9422(95)00057-E; STRACK D, 1989, PHYTOCHEMISTRY, V28, P2071, DOI 10.1016/S0031-9422(00)97922-6; SU WC, 1995, PHYTOCHEMISTRY, V40, P563, DOI 10.1016/0031-9422(95)00269-D; SWAN EP, 1969, PHYTOCHEMISTRY, V8, P345, DOI 10.1016/S0031-9422(00)85430-8; TAN RX, 1990, PLANTA MED, V56, P475, DOI 10.1055/s-2006-961015; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; TYAGI OD, 1994, ACTA CHEM SCAND, V48, P1007, DOI 10.3891/acta.chem.scand.48-1007; vanHeerden PS, 1996, J BIOL CHEM, V271, P12350, DOI 10.1074/jbc.271.21.12350	64	153	161	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7516	7527		10.1074/jbc.274.11.7516	http://dx.doi.org/10.1074/jbc.274.11.7516			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066819	hybrid			2022-12-27	WOS:000079078400091
J	Launay, P; Patry, C; Lehuen, A; Pasquier, B; Blank, U; Monteiro, RC				Launay, P; Patry, C; Lehuen, A; Pasquier, B; Blank, U; Monteiro, RC			Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcR gamma association and protects against degradation of bound ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CYTOPLASMIC DOMAIN HETEROGENEITY; HUMAN SERUM IGA; HUMAN MONOCYTES; EPSILON-RI; MEDIATED PHAGOCYTOSIS; PHYSICAL ASSOCIATION; EXPRESSION; BINDING	IgA is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum because it is catabolized faster than IgG, IgA exists in monomeric and polymeric forms that function through receptors expressed on effector cells. Here, we show that IgA Fc receptor(s) (Fc alpha R) are expressed with or without the gamma chain on monocytes and neutrophils, gamma-less Fc alpha R represent a significant fraction of surface Fc alpha R molecules even on cells overexpressing the gamma chain. The Fc alpha R-gamma 2 association is up-regulated by phorbol esters and interferon-gamma. To characterize gamma-less Fc alpha R functionally, we generated mast cell transfectants expressing wild-type human Fc alpha R or a receptor with a point mutation (Arg --> Leu at position 209) which was unable to associate with the gamma chain. Mutant gamma-less Fc alpha R bound monomeric and polymeric human IgA1 or IgA2 but failed to induce exocytosis after receptor clustering. The two types of transfectant showed similar kinetics of Fc alpha R-mediated endocytosis; however, the endocytosis pathways of the two types of receptor differed. Whereas mutant Fc alpha R were localized mainly in early endosomes, those containing Fc alpha R-gamma 2 were found in endo-lysosomal compartments. Mutant gamma-less Fc alpha R recycled the internalized IgA toward the cell surface and protected against IgA degradation. Cells expressing the two forms of Fc alpha R, associated or unassociated with gamma chains, may thus have differential functions either by degrading IgA antibody complexes or by recycling serum IgA.	Hop Necker Enfants Malad, INSERM, U25, F-75743 Paris 15, France; Inst Curie, CNRS, Unite Mixte Rech, F-75005 Paris, France; Inst Pasteur, Unite Immunoallergie, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Monteiro, RC (corresponding author), Hop Necker Enfants Malad, INSERM, U25, 161 Rue Sevres, F-75743 Paris 15, France.	monteiro@necker.fr	Monteiro, Renato C/U-8633-2017; Launay, Pierre/AAH-7076-2019	Monteiro, Renato C/0000-0001-5202-5646; Blank, Ulrich/0000-0002-2661-2983; Lehuen, Agnes/0000-0002-0450-3321				ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ALBRECHTSEN M, 1988, IMMUNOLOGY, V64, P201; Amigorena S, 1998, J EXP MED, V187, P505, DOI 10.1084/jem.187.4.505; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BROWN TA, 1982, J IMMUNOL, V128, P2183; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; CHEVAILLER A, 1989, J IMMUNOL, V142, P2244; CONLEY ME, 1987, ANN INTERN MED, V106, P892, DOI 10.7326/0003-4819-106-6-892; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; DEWIT TPM, 1995, J IMMUNOL, V155, P1203; GODING JW, 1980, J IMMUNOL, V124, P2082; Gulle H, 1998, BLOOD, V91, P383, DOI 10.1182/blood.V91.2.383.383_383_391; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; KINET JP, 1985, BIOCHEMISTRY-US, V24, P4117, DOI 10.1021/bi00336a046; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Launay P, 1998, J LEUKOCYTE BIOL, V63, P636, DOI 10.1002/jlb.63.5.636; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Mestecky J, 1997, BIOCHEM SOC T, V25, P457, DOI 10.1042/bst0250457; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MONTEIRO RC, 1993, J CLIN INVEST, V92, P1681, DOI 10.1172/JCI116754; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; Morton HC, 1996, IMMUNOGENETICS, V43, P246, DOI 10.1007/s002510050057; MORTON HC, 1995, J BIOL CHEM, V270, P29781; NIKOLOVA EB, 1995, J LEUKOCYTE BIOL, V57, P875, DOI 10.1002/jlb.57.6.875; PATRY C, 1995, IMMUNOLOGY, V86, P1; Patry C, 1996, J IMMUNOL, V156, P4442; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; Pleass RJ, 1996, BIOCHEM J, V318, P771, DOI 10.1042/bj3180771; POLAT GL, 1993, IMMUNOLOGY, V80, P287; Reterink TJF, 1996, GENE, V175, P279, DOI 10.1016/0378-1119(96)00152-7; Reterink TJF, 1997, EUR J IMMUNOL, V27, P2219, DOI 10.1002/eji.1830270915; RIFAI A, 1989, LAB INVEST, V61, P381; Roa M, 1997, J IMMUNOL, V159, P2815; Russell MW, 1997, BIOCHEM SOC T, V25, P466, DOI 10.1042/bst0250466; Saito K, 1995, J ALLERGY CLIN IMMUN, V96, P1152, DOI 10.1016/S0091-6749(95)70200-8; SALISBURY JG, 1981, BIOCHEM J, V194, P351, DOI 10.1042/bj1940351; Saudrais C, 1998, J IMMUNOL, V160, P2597; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Sela, 1974, ANTIGENS, VII, P365; SHEN L, 1994, J IMMUNOL, V152, P4080; SHEN L, 1989, J IMMUNOL, V143, P4117; SILVAIN C, 1995, J IMMUNOL, V155, P1606; Solomon A, 1980, CANCER MARKERS, P57, DOI 10.1007/978-1-4612-6117-9_3; STOCKERT RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6229, DOI 10.1073/pnas.79.20.6229; TADOU G, 1993, INT ARCH ALLERGY IMM, V100, P344; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanDijk TB, 1996, BLOOD, V88, P4229; VANEPPS DE, 1976, J EXP MED, V144, P1227, DOI 10.1084/jem.144.5.1227; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; White S, 1998, J BIOL CHEM, V273, P14355, DOI 10.1074/jbc.273.23.14355; WILTON JMA, 1978, CLIN EXP IMMUNOL, V34, P423; Wolf HM, 1996, CLIN EXP IMMUNOL, V105, P537, DOI 10.1046/j.1365-2249.1996.d01-793.x; WOLF HM, 1994, BLOOD, V83, P1278	62	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7216	7225		10.1074/jbc.274.11.7216	http://dx.doi.org/10.1074/jbc.274.11.7216			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066783	hybrid			2022-12-27	WOS:000079078400055
J	Berger, J; Leibowitz, MD; Doebber, TW; Elbrecht, A; Zhang, B; Zhou, GC; Biswas, C; Cullinan, CA; Hayes, NS; Li, Y; Tanen, M; Ventre, J; Wu, MS; Berger, GD; Mosley, R; Marquis, R; Santini, C; Sahoo, SP; Tolman, RL; Smith, RG; Moller, DE				Berger, J; Leibowitz, MD; Doebber, TW; Elbrecht, A; Zhang, B; Zhou, GC; Biswas, C; Cullinan, CA; Hayes, NS; Li, Y; Tanen, M; Ventre, J; Wu, MS; Berger, GD; Mosley, R; Marquis, R; Santini, C; Sahoo, SP; Tolman, RL; Smith, RG; Moller, DE			Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPAR delta ligands produce distinct biological effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; FATTY-ACIDS; GLUCOSE-TOLERANCE; DIFFERENTIAL ACTIVATION; CONFORMATIONAL CHANGE; NUCLEAR RECEPTORS; 3T3-L1 CELLS; INSULIN; THIAZOLIDINEDIONES	The peroxisome proliferator-activated receptors (PPARs) include three receptor subtypes encoded by separate genes: PPAR alpha; PPAR delta, and PPAR gamma, PPAR gamma has been implicated as a mediator of adipocyte differentiation and the mechanism by which thiazolidinedione drugs exert in vivo insulin sensitization. Here we characterized novel, non-thiazolidinedione agonists for PPAR gamma and PPAR delta that were identified by radioligand binding assays. In transient transactivation assays these ligands were agonists of the receptors to which they bind. Protease protection studies showed that ligand binding produced specific alterations in receptor conformation. Both PPAR gamma and PPAR delta directly interacted with a nuclear receptor co-activator (CREB-binding protein) in an agonist-dependent manner. Only the PPAR gamma agonists were able to promote differentiation of 3T3-L1 preadipocytes, In diabetic db/db mice all PPAR gamma agonists were orally active insulin-sensitizing agents producing reductions of elevated plasma glucose and triglyceride concentrations. In contrast, selective in vivo activation of PPAR delta did not significantly affect these parameters. In vivo PPAR alpha activation with WY-14653 resulted in reductions in elevated triglyceride levels with minimal effect on hyperglycemia, We conclude that: 1) synthetic non-thiazolidinediones can serve as ligands of PPAR gamma and PPAR delta; 2) ligand-dependent activation of PPAR delta involves an apparent conformational change and association of the receptor ligand binding domain with CREB-binding protein; 3) PPAR gamma activation (but not PPAR delta or PPAR alpha activation) is sufficient to potentiate preadipocyte differentiation; 4) non-thiazolidinedione PPAR gamma agonists improve hyperglycemia and hypertriglyceridemia in vivo; 5) although PPAR alpha activation is sufficient to affect triglyceride metabolism, PPAR delta activation does not appear to modulate glucose or triglyceride levels.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Berger, J (corresponding author), Merck Res Labs, Dept Mol Endocrinol, RY80N-C31,126 E Lincoln Ave, Rahway, NJ 07065 USA.	joel_berger@merck.com	Santini, Conrad/N-2615-2018					ALLAN GF, 1992, J BIOL CHEM, V267, P19513; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Brandes R, 1995, BIOCHEM PHARMACOL, V50, P1949, DOI 10.1016/0006-2952(95)02082-9; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gimble JM, 1996, MOL PHARMACOL, V50, P1087; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; INOUE I, 1994, DIABETES RES CLIN PR, V25, P199, DOI 10.1016/0168-8227(94)90009-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KOBAYASHI M, 1988, DIABETES CARE, V11, P495, DOI 10.2337/diacare.11.6.495; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LITHELL H, 1977, EUR J CLIN PHARMACOL, V12, P51, DOI 10.1007/BF00561405; Matsui HR, 1997, DIABETES, V46, P348, DOI 10.2337/diabetes.46.3.348; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	49	352	383	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6718	6725		10.1074/jbc.274.10.6718	http://dx.doi.org/10.1074/jbc.274.10.6718			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037770	hybrid			2022-12-27	WOS:000078902800092
J	Guerrette, S; Acharya, S; Fishel, R				Guerrette, S; Acharya, S; Fishel, R			The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; COLORECTAL-CANCER; ESCHERICHIA-COLI; GENE-PRODUCT; MUTATIONS; YEAST; MSH2; CELLS; MLH1; PMS1	Germline mutations in two human mismatch repair (MMR) genes, hMSH2 and hMLH1, appear to account for approximately 70% of the common cancer susceptibility syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Although the hMLH1 protein has been found to copurify with another MMR protein hPMS2 as a heterodimer, their function in MMR is unknown. In this study, we have identified the physical interaction regions of both hMLH1 with hPMS2. We then examined the effects of hMLH1 missense alterations found in HNPCC kindreds for their interaction with hPMS2. Four of these missense alterations (L574P, K616 Delta, R659P, and A681T) displayed >95% reduction in binding to hPMS2. Two additional missense alterations (K618A and K618T) displayed a >85% reduction in binding to hPMS2, whereas three missense alterations (S44F, V506A, and E578G) displayed 25-65% reduction in binding to hPMS2. Interestingly, two HNPCC missense alterations (Q542L and L582V) contained within the consensus interaction region displayed no effect on interaction with hPMS2, suggesting that they may affect other functions of hMLH1. These data confirm that functional deficiencies in the interaction of hMLH1 with hPMS2 are associated with HNPCC as well as suggest that other unknown functional alteration of the human MutL homologues may lead to tumorigenesis in HNPCC kindreds.	Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Dept Microbiol & Immunol, Genet & Mol Biol Program, 233 S 10th St, Philadelphia, PA 19107 USA.	rfishel@hendrix.jci.tju.edu			NCI NIH HHS [CA67007, R01 CA067007, CA56542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DEMEREC M, 1957, CARNEGIE I WASH YB, V370, P390; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Kallal L, 1997, MOL CELL BIOL, V17, P2897, DOI 10.1128/MCB.17.5.2897; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MIYAKE T, 1960, GENETICS, V45, P755; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RYDBERG B, 1978, MUTAT RES, V52, P11, DOI 10.1016/0027-5107(78)90091-X; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WELSH KM, 1987, J BIOL CHEM, V262, P15624	27	141	148	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6336	6341		10.1074/jbc.274.10.6336	http://dx.doi.org/10.1074/jbc.274.10.6336			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037723	hybrid			2022-12-27	WOS:000078902800045
J	McMurry, JL; Kendall, DA				McMurry, JL; Kendall, DA			An artificial transmembrane segment directs SecA, SecB, and electrochemical potential-dependent translocation of a long amino-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; SECRETION MACHINERY; SIGNAL SEQUENCE; INSERTION; PEPTIDE; HYDROPHOBICITY; CONSTRUCTION; ORIENTATION; RESIDUES; MUTANTS	Many integral membrane proteins contain an aminoterminal segment, often referred to as an N-tail, that is translocated across a membrane. In many cases, translocation of the N-tail is initiated by a cleavable, aminoterminal signal peptide. For N-tail proteins lacking a signal peptide, translocation is initiated by a transmembrane segment that is carboxyl to the translocated segment. The mechanism of membrane translocation of these segments, although poorly understood, has been reported to be independent of the protein secretion machinery. In contrast, here we describe alkaline phosphatase mutants containing artificial transmembrane segments that demonstrate that translocation of a long N-tail across the membrane is dependent upon SecA, SecB, and the electrochemical potential in the absence of a signal peptide. The corresponding mutants containing signal peptides also use the secretion machinery but are less sensitive to inhibition of its components. We present evidence that inhibition of SecA by sodium azide is incomplete even at high concentrations of inhibitor, which suggests why SecA-dependent translocation may not have been detected in other systems. Furthermore, by varying the charge around the transmembrane segment, we find that in the absence of a signal peptide, the orientation of the membrane-bound alkaline phosphatase is dictated by the positive inside rule, However, the presence of a signal peptide is an overriding factor in membrane orientation and renders all mutants in an N-out-C-in orientation.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Kendall, DA (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, Box U-44, Storrs, CT 06269 USA.	kendall@uconnvm.uconn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANC JP, 1984, J BIOL CHEM, V259, P9549; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Francetic O, 1996, J BACTERIOL, V178, P5954, DOI 10.1128/jb.178.20.5954-5959.1996; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; Kim J, 1998, J BACTERIOL, V180, P1396, DOI 10.1128/JB.180.6.1396-1401.1998; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; Miller J. H., 1972, EXPT MOL GENETICS, P431; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WHITLEY P, 1995, J BIOL CHEM, V270, P29831	28	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6776	6782		10.1074/jbc.274.10.6776	http://dx.doi.org/10.1074/jbc.274.10.6776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037778	hybrid			2022-12-27	WOS:000078902800100
J	Dafforn, TR; Mahadeva, R; Elliott, PR; Sivasothy, P; Lomas, DA				Dafforn, TR; Mahadeva, R; Elliott, PR; Sivasothy, P; Lomas, DA			A kinetic mechanism for the polymerization of alpha(1)-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CRYSTAL-STRUCTURE; PROTEINASE-INHIBITORS; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; ANTITHROMBIN-III; REACTIVE LOOP; HINGE REGION; SERPINS; DISEASE	The mutation in the Z deficiency variant of alpha(1)-antitrypsin perturbs the structure of the protein to allow a unique intermolecular linkage. These loop-sheet polymers are retained within the endoplasmic reticulum of hepatocytes to form inclusions that are associated with neonatal hepatitis, juvenile cirrhosis, and hepatocellular carcinoma. The process of polymer formation has been investigated here by intrinsic: tryptophan fluorescence, fluorescence polarization, circular dichroic spectra and extrinsic fluorescence with 8-anilino-1-naphthalenesulfonic acid and tetramethylrhodamine-5-iodoacetamide. These biophysical techniques have demonstrated that alpha(1)-antitrypsin polymerization is a two-stage process and have allowed the calculation of rates for both of these steps. The initial fast phase is unimolecular and likely to represent temperature-induced protein unfolding, while the slow phase is bimolecular and associated with loop-sheet interaction and polymer formation. The naturally occurring Z, S, and I variants and recombinant site-directed reactive loop and shutter domain mutants of alpha(1)-antitrypsin were used to demonstrate the close association between protein stability and rate of alpha(1)-antitrypsin polymerization, Taken together, these data allow us to propose a kinetic mechanism for alpha(1)-antitrypsin polymer formation that involves the generation of an unstable intermediate, which can form polymers or generate latent protein.	Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Med, Resp Med Unit, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Dafforn, TR (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.		Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BUSBY TF, 1981, J BIOL CHEM, V256, P2140; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Kim DY, 1996, BIOCHEM BIOPH RES CO, V226, P378, DOI 10.1006/bbrc.1996.1364; Koloczek H, 1996, PROTEIN SCI, V5, P2226, DOI 10.1002/pro.5560051109; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lomas D, 1997, EUR RESPIR J, V10, P672; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1992, J MOL BIOL, V226, P273, DOI 10.1016/0022-2836(92)90140-F; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	47	197	206	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9548	9555		10.1074/jbc.274.14.9548	http://dx.doi.org/10.1074/jbc.274.14.9548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092640	hybrid			2022-12-27	WOS:000079451800059
J	Hwang, Y; Burgin, A; Bushman, F				Hwang, Y; Burgin, A; Bushman, F			DNA contacts stimulate catalysis by a poxvirus topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSCUM CONTAGIOSUM; NUCLEOTIDE-SEQUENCE; VIRUS TOPOISOMERASE; CRYSTAL-STRUCTURE; SV40 DNA; CLEAVAGE; BINDING; IDENTIFICATION; PREFERENCE; GENOME	Eukaryotic type 1B topoisomerases act by forming covalent enzyme-DNA intermediates that transiently nick DNA and thereby release DNA supercoils. Here we present a study of the topoisomerase encoded by the pathogenic poxvirus molluscum contagiosum, Our studies of DNA sites favored for catalysis reveal a larger recognition site than the 5'-(T/C)CCTT-3' sequence previously identified for poxvirus topoisomerases. Separate assays of initial DNA binding and covalent complex formation revealed that different DNA sequences were important for each reaction step. The location of the protein-DNA contacts was mapped by analyzing mutant sites and inosine-substituted DNAs, Some of the bases flanking the 5'-(T/C)CCTT-3' sequence were selectively important for covalent complex formation but not initial DNA binding. Interactions important for catalysis were probed with 5'-bridging phosphorothiolates at the site of strand cleavage, which permitted covalent complex formation but prevented subsequent religation. Kinetic studies revealed that the flanking sequences that promoted recovery of covalent complexes increased initial cleavage instead of inhibiting resealing of the nicked intermediate. These data 1) indicate that previously unidentified DNA contacts can accelerate a step between initial binding and covalent complex formation and 2) help specify models for conformational changes promoting catalysis.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	Salk Institute; California State University System; San Diego State University	Bushman, F (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; KLEMPERER N, 1995, VIROLOGY, V206, P203, DOI 10.1016/S0042-6822(95)80035-2; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; PETERSEN CS, 1992, DERMATOLOGY, V184, P19, DOI 10.1159/000247492; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SCHWARTZ JJ, 1992, J AM ACAD DERMATOL, V27, P583, DOI 10.1016/0190-9622(92)70226-6; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	31	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9160	9168		10.1074/jbc.274.14.9160	http://dx.doi.org/10.1074/jbc.274.14.9160			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092587	Green Submitted, hybrid			2022-12-27	WOS:000079451800006
J	Li, JP; DeFea, K; Roth, RA				Li, JP; DeFea, K; Roth, RA			Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; 3T3-L1 ADIPOCYTES; MAMMALIAN TARGET; GROWTH-FACTOR; SERINE/THREONINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DIABETES-MELLITUS; IRS-1; ACTIVATION	Serine/threonine phosphorylation of insulin receptor substrate 1 (IRS-1) has been implicated as a negative regulator of insulin signaling. Prior studies have indicated that this negative regulation by protein kinase C involves the mitogen-activated protein kinase and phosphorylation of serine 612 in IRS-1, In the present studies, the negative regulation by platelet-derived growth factor (PDGF) was compared with that induced by endothelin-1, an activator of protein kinase C. In contrast to endothelin-1, the inhibitory effects of PDGF did not require mitogen-activated protein kinase or the phosphorylation of serine 612. Instead, three other serines in the phosphorylation domain of IRS-1 (serines 632, 662, and 731) were required for the negative regulation by PDGF. In addition, the PDGF-activated serine/threonine kinase called Akt was found to inhibit insulin signaling. Moreover, this inhibition required the same IRS-1 serine residues as the inhibition by PDGF, Finally, the negative regulatory effects of PDGF and Akt were inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one of the downstream targets of Akt, These studies implicate the phosphatidylinositol 3-kinase/Akt kinase cascade as an additional negative regulatory pathway for the insulin signaling cascade.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Med Ctr, Dept Mol Pharmacol, Stanford, CA 94305 USA.	roth@cmgm.stanford.edu		DeFea, Kathryn/0000-0001-6056-907X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHOU YC, 1994, BIOCHEM BIOPH RES CO, V202, P688, DOI 10.1006/bbrc.1994.1985; CLERK A, 1994, J BIOL CHEM, V269, P32848; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Ferri C, 1997, EXP CLIN ENDOCR DIAB, V105, P38, DOI 10.1055/s-0029-1211794; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Juan CC, 1996, BIOCHEM BIOPH RES CO, V227, P694, DOI 10.1006/bbrc.1996.1571; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LAM K, 1994, J BIOL CHEM, V269, P20648; Li PM, 1996, BIOCHEM BIOPH RES CO, V223, P80, DOI 10.1006/bbrc.1996.0849; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sarman B, 1998, DIABETES METAB REV, V14, P171, DOI 10.1002/(SICI)1099-0895(199806)14:2<171::AID-DMR207>3.0.CO;2-G; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; White MF, 1998, CURR TOP MICROBIOL, V228, P179	36	187	199	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9351	9356		10.1074/jbc.274.14.9351	http://dx.doi.org/10.1074/jbc.274.14.9351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092613	hybrid			2022-12-27	WOS:000079451800032
J	Harrison, CA; Raftery, MJ; Walsh, J; Alewood, P; Iismaa, SE; Thliveris, S; Geczy, CL				Harrison, CA; Raftery, MJ; Walsh, J; Alewood, P; Iismaa, SE; Thliveris, S; Geczy, CL			Oxidation regulates the inflammatory properties of the murine S100 protein S100A8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; IONIZATION MASS-SPECTROMETRY; LOW-DENSITY-LIPOPROTEIN; HUMAN-NEUTROPHILS; CHEMOTACTIC PROTEIN; HYDROGEN-PEROXIDE; COMPLEX-FORMATION; HL-60 CELLS; IN-VIVO; CP-10	The myeloid cell-derived calcium-binding murine protein, S100A8, is secreted to act as a chemotactic factor at picomolar concentrations, stimulating recruitment of myeloid cells to inflammatory sites, S100A8 may be exposed to oxygen metabolites, particularly hypochlorite, the major oxidant generated by activated neutrophils at inflammatory sites. Here we show that hypochlorite oxidizes the single Cys residue (Cys(41)) of S100A8. Electrospray mass spectrometry and SDS-polyacrylamide gel electrophoresis analysis indicated that low concentrations of hypochlorite (40 mu M) converted 70-80% of S100A8 to the disulfide-linked homodimer, The mass was 20,707 Da, 92 Da more than expected, indicating additional oxidation of susceptible amino acids (possibly methionine). Phorbol 12-myristate 13-acetate activation of differentiated HL-60 granulocytic cells generated an oxidative burst that was sufficient to efficiently oxidize exogenous S100A8 within 10 min, and results implicate involvement of the myeloperoxidase system. Moreover, disulfide-linked dimer was identified in lung lavage fluid of mice with endotoxin-induced pulmonary injury. S100A8 dimer was inactive in chemotaxis and failed to recruit leukocytes in vivo. Positive chemotactic activity of recombinant Ala(41)S100A8 indicated that Cys41 was not essential for function and suggested that covalent dimerization may structurally modify accessibility of the chemotactic hinge domain. Disulfide-dependent dimerization may be a physiologically significant regulatory mechanism controlling S100A8-provoked leukocyte recruitment.	Univ New S Wales, Sch Pathol, Cytokine Res Unit, Kensington, NSW 2052, Australia; Univ Queensland, Ctr Drug Design & Dev, St Lucia, Qld 4072, Australia	University of New South Wales Sydney; University of Queensland	Geczy, CL (corresponding author), Univ New S Wales, Sch Pathol, Cytokine Res Unit, Kensington, NSW 2052, Australia.		Iismaa, Siiri/A-9924-2008; Iismaa, Siiri/C-9300-2013	Iismaa, Siiri/0000-0003-2409-7356; Harrison, Craig/0000-0003-1059-3682				BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BERNTZEN HB, 1991, SCAND J RHEUMATOL, V20, P74, DOI 10.3109/03009749109165280; BRUN JG, 1994, J RHEUMATOL, V21, P733; CLARK RA, 1982, J IMMUNOL, V129, P2725; Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6; Dean RT, 1997, BIOCHEM J, V324, P1; DEVERY JM, 1994, J IMMUNOL, V152, P1888; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Drohat AC, 1997, PROTEIN SCI, V6, P1577, DOI 10.1002/pro.5560060721; GOEBELER M, 1993, J LEUKOCYTE BIOL, V53, P11, DOI 10.1002/jlb.53.1.11; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Golden BE, 1996, ARCH DIS CHILD, V74, P136, DOI 10.1136/adc.74.2.136; Hansson M, 1996, J IMMUNOL, V156, P42; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hu SP, 1996, BLOOD, V87, P3919, DOI 10.1182/blood.V87.9.3919.bloodjournal8793919; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; IISMAA SE, 1994, DNA CELL BIOL, V13, P183, DOI 10.1089/dna.1994.13.183; Johne B, 1997, J CLIN PATHOL-MOL PA, V50, P113; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kocher M, 1996, INFECT IMMUN, V64, P1342, DOI 10.1128/IAI.64.4.1342-1350.1996; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; Kumar RK, 1998, PATHOLOGY, V30, P51, DOI 10.1080/00313029800169665; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; NASKALSKI JW, 1994, ANN BIOL CLIN-PARIS, V52, P451; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Raftery MJ, 1997, RAPID COMMUN MASS SP, V11, P405, DOI 10.1002/(SICI)1097-0231(19970228)11:4<405::AID-RCM823>3.0.CO;2-A; Raftery MJ, 1998, J AM SOC MASS SPECTR, V9, P533, DOI 10.1016/S1044-0305(98)00020-8; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROTH J, 1993, BIOCHEM BIOPH RES CO, V191, P565, DOI 10.1006/bbrc.1993.1255; RYAN J, 1988, J IMMUNOL, V141, P2110; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1998, J BIOL CHEM, V273, P3901, DOI 10.1074/jbc.273.7.3901; SOHNLE PG, 1991, J INFECT DIS, V163, P187, DOI 10.1093/infdis/163.1.187; Szarka RJ, 1997, J IMMUNOL METHODS, V202, P49, DOI 10.1016/S0022-1759(96)00236-0; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WILCKENS T, 1995, TRENDS PHARMACOL SCI, V16, P193, DOI 10.1016/S0165-6147(00)89021-5; Wu SM, 1997, J BIOL CHEM, V272, P20627, DOI 10.1074/jbc.272.33.20627; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	54	109	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8561	8569		10.1074/jbc.274.13.8561	http://dx.doi.org/10.1074/jbc.274.13.8561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085090	hybrid			2022-12-27	WOS:000079451600032
J	Hilton, JC; Temple, CA; Rajagopalan, KV				Hilton, JC; Temple, CA; Rajagopalan, KV			Re-design of Rhodobacter sphaeroides dimethyl sulfoxide reductase - Enhancement of adenosine N-1-oxide reductase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-SP DENITRIFICANS; N-OXIDE REDUCTASE; MOLYBDOPTERIN GUANINE DINUCLEOTIDE; RAY-ABSORPTION SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; FORMATE DEHYDROGENASE-H; LIVER SULFITE OXIDASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLYBDENUM-COFACTOR	The periplasmic DMSO reductase from Rhodobacter sphaeroides f. sp. denitrificans has been expressed in Escherichia coli BL21(DE3) cells in its mature form and with the R. sphaeroides or E. coli N-terminal signal sequence. Whereas the R. sphaeroides signal sequence prevents formation of active enzyme, addition of a 6x Histag at the N terminus of the mature peptide maximizes production of active enzyme and allows for affinity purification. The recombinant protein contains 1.7-1.9 guanines and greater than 0.7 molybdenum atoms per molecule and has a DMSO reductase activity of 3.4-3.7 units/nmol molybdenum, compared with 3.7 units/nmol molybdenum for enzyme purified from R. sphaeroides. The recombinant enzyme differs from the native enzyme in its color and spectrum but is indistinguishable from the native protein after redox cycling with reduced methyl viologen and Me,SO. Substitution of Cys for the molybdenum-ligating Ser-147 produced a protein with DMSO reductase activity of 1.4-1.5 units/nmol molybdenum. The mutant protein differs from wild type in its color and absorption spectrum in both the oxidized and reduced states. This substitution leads to losses of 61-99% of activity toward five substrates, but the adenosine N-1-oxide reductase activity increases by over 400%.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu						AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BAKER KP, 1991, MOL MICROBIOL, V5, P901, DOI 10.1111/j.1365-2958.1991.tb00764.x; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; FINNEGAN MG, 1993, INORG CHEM, V32, P2616, DOI 10.1021/ic00064a005; GARDE J, 1995, J BIOL CHEM, V270, P6644, DOI 10.1074/jbc.270.12.6644; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P12906, DOI 10.1021/ja972109l; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1999, IN PRESS J AM CHEM S; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Hilton JC, 1996, BBA-PROTEIN STRUCT M, V1294, P111, DOI 10.1016/0167-4838(96)00015-5; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; HILTON JC, 1996, THESIS DUKE U; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUCKLESB.DP, 1973, ANAL BIOCHEM, V56, P591, DOI 10.1016/0003-2697(73)90226-1; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Knablein J, 1996, J MOL BIOL, V263, P40, DOI 10.1006/jmbi.1996.0554; Knablein J, 1997, BIOL CHEM, V378, P303; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; Pollock VV, 1997, J BIOL CHEM, V272, P3355, DOI 10.1074/jbc.272.6.3355; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Shaw AL, 1996, BBA-BIOENERGETICS, V1276, P176, DOI 10.1016/0005-2728(96)00092-8; SHIMOKAWA O, 1979, J BIOCHEM, V86, P1709, DOI 10.1093/oxfordjournals.jbchem.a132691; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; Trieber CA, 1996, J BIOL CHEM, V271, P27339, DOI 10.1074/jbc.271.44.27339; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; YAMAMOTO I, 1995, BIOSCI BIOTECH BIOCH, V59, P1850, DOI 10.1271/bbb.59.1850; YOSHIDA Y, 1991, J BACTERIOL, V173, P3277, DOI 10.1128/jb.173.11.3277-3281.1991	49	54	54	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8428	8436		10.1074/jbc.274.13.8428	http://dx.doi.org/10.1074/jbc.274.13.8428			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085074	hybrid			2022-12-27	WOS:000079451600016
J	Rettenberger, PM; Oka, K; Ellgaard, L; Petersen, HH; Christensen, A; Martensen, PM; Monard, D; Etzerodt, M; Chan, L; Andreasen, PA				Rettenberger, PM; Oka, K; Ellgaard, L; Petersen, HH; Christensen, A; Martensen, PM; Monard, D; Etzerodt, M; Chan, L; Andreasen, PA			Ligand binding properties of the very low density lipoprotein receptor - Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of M-r 40,000 receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR-INHIBITOR; LDL-RECEPTOR; 39-KDA PROTEIN; UROKINASE RECEPTOR; APOLIPOPROTEIN-E; VLDL RECEPTOR; MEDIATED ENDOCYTOSIS; MOLECULAR CHAPERONE; TERMINAL DOMAIN; COMPLEXES	The very low density lipoprotein receptor (VLDLR) binds, among other ligands, the M-r 40,000 receptor-associated protein (RAP) and a variety of serine proteinase-serpin complexes, including complexes of the proteinase urokinase-type plasminogen activator (uPA) with the serpins plasminogen activator inhibitor-1 (PAI-1) and protease nexin-1 (PN-1). We have analyzed the binding of RAP, uPA.PAI-1, and uPA.PN-1 to two naturally occurring VLDLR variants, VLDLR-I, containing all eight complement-type repeats, and VLDLR-III, lacking the third complement-type repeat, encoded by exon 4. VLDLR-III displayed similar to 4-fold lower binding of RAP than VLDLR-I and similar to 10-fold lower binding of the most C-terminal one of the three domains of RAP. In contrast, the binding of uPA PAI-1 and uPA PN-1 to the two VLDLR variants was indistinguishable. Surprisingly, uPA PN-1, but not uPA PAI-1, competed RAP binding to both VLDLR variants. These observations show that the third complement-type repeat plays a crucial role in maintaining the contact sites needed for optimal recognition of RAP, but does not affect the proteinase-serpin complex contact sites, and that two ligands can show full cross-competition without sharing the same contacts with the receptor. These results elucidate the mechanisms of molecular recognition of ligands by receptors of the low density lipoprotein receptor family.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Aarhus University; Baylor College of Medicine; Baylor College of Medicine; Friedrich Miescher Institute for Biomedical Research	Andreasen, PA (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, 10C Gustav Wieda Vej, DK-8000 Aarhus C, Denmark.		Ellgaard, Lars/I-9034-2014; Martensen, Pia/I-3996-2012	Ellgaard, Lars/0000-0002-7018-0137; Martensen, Pia Moller/0000-0002-1259-0226	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; ESSER V, 1988, J BIOL CHEM, V263, P13282; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; Kasza A, 1997, EUR J BIOCHEM, V248, P270, DOI 10.1111/j.1432-1033.1997.00270.x; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; MADSEN B, 1999, IN PRESS FIBRINOLYSI; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; NYKJAER A, 1994, J IMMUNOL, V152, P505; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; Rodenburg KW, 1998, BIOCHEM J, V329, P55; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; SOMMER J, 1989, GENE, V85, P453, DOI 10.1016/0378-1119(89)90439-3; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	55	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8973	8980		10.1074/jbc.274.13.8973	http://dx.doi.org/10.1074/jbc.274.13.8973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085143	hybrid			2022-12-27	WOS:000079451600085
J	Yuan, T; Ouyang, H; Vogel, HJ				Yuan, T; Ouyang, H; Vogel, HJ			Surface exposure of the methionine side chains of calmodulin in solution - A nitroxide spin label and two-dimensional NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SEQUENCE-INDEPENDENT RECOGNITION; PROBING PROTEIN-STRUCTURE; CALCIUM-FREE CALMODULIN; NITRIC-OXIDE SYNTHASE; CARDIAC TROPONIN-C; TERMINAL DOMAIN; APO-CALMODULIN; CENTRAL HELIX; PROTEOLYTIC FRAGMENTS	Binding of calcium to calmodulin (CaM) causes a conformational change in this ubiquitous calcium regulatory protein that allows the activation of many target proteins. Met residues make up a large portion of its hydrophobic target binding surfaces. In this work, we have studied the surface exposure of the Met residues in the apo- and calcium-bound states of CaM in solution, Complexes of calcium-CaM with synthetic peptides derived from the CaM-binding domains of myosin light chain kinase, constitutive nitric-oxide synthase, and CaM-dependent protein kinase I were also studied. The surface exposure was measured by NMR by studying the effects of the soluble nitroxide spin label, 4-hydroxyl-2,2,6,6-tetramethylpiperidinyl-1-oxy, on the line widths and relaxation rates of the Met methyl resonances in samples of biosynthetically C-13-methyl-Met-labeled CaM. The Met residues move from an almost completely buried state in apo-CaM to an essentially fully exposed state in Ca2+, CaM. Binding of two Ca2+ to the C-terminal lobe of CaM causes full exposure of the C-terminal Met residues and a partial exposure of the N-terminal Met side chains. Binding of the three target peptides blocks the access of the nitroxide surface probe to nearly all Met residues, although the mode of binding is distinct for the three peptides studied. These data show that calcium binding to CaM controls the surface exposure of the Met residues, thereby providing the switch for target protein binding.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca						BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Beatty EJ, 1996, BIOCHEMISTRY-US, V35, P7635, DOI 10.1021/bi960684g; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; COCCO MJ, 1994, PROTEIN SCI, V3, P267; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Edwards RA, 1998, BIOCHEM J, V331, P149, DOI 10.1042/bj3310149; ESPOSITO G, 1992, J MOL BIOL, V224, P659, DOI 10.1016/0022-2836(92)90551-T; Fabian H, 1996, EUR BIOPHYS J BIOPHY, V24, P195; FESIK SW, 1991, J AM CHEM SOC, V113, P7080, DOI 10.1021/ja00018a080; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; George SE, 1996, BIOCHEMISTRY-US, V35, P8307, DOI 10.1021/bi960495y; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Molinari H, 1997, BIOPHYS J, V73, P382, DOI 10.1016/S0006-3495(97)78078-0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P1179, DOI 10.1021/bi00004a011; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Peters JA, 1996, PROG NUCL MAG RES SP, V28, P283, DOI 10.1016/0079-6565(95)01026-2; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; PETROS AM, 1994, METHOD ENZYMOL, V239, P717; PETROS AM, 1992, J BIOMOL NMR, V2, P11, DOI 10.1007/BF02192797; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; SMITH LJ, 1991, BIOCHEMISTRY-US, V30, P986, DOI 10.1021/bi00218a015; Sorensen BR, 1998, BIOCHEMISTRY-US, V37, P4244, DOI 10.1021/bi9718200; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; VanderSpoel D, 1996, PROTEIN SCI, V5, P2044; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WILLIAMSON MP, 1992, CHEM SOC REV, V21, P227, DOI 10.1039/cs9922100227; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WOLFF J, 1986, BIOCHEMISTRY-US, V25, P7950, DOI 10.1021/bi00372a025; YUAN SX, 1988, EUR J BIOCHEM, V175, P119, DOI 10.1111/j.1432-1033.1988.tb14173.x; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328; YUAN T, 1995, BIOCHEMISTRY-US, V34, P10690, DOI 10.1021/bi00033a045; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901; Zhou N, 1997, BIOCHEMISTRY-US, V36, P2817, DOI 10.1021/bi9625713	64	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8411	8420		10.1074/jbc.274.13.8411	http://dx.doi.org/10.1074/jbc.274.13.8411			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085072	hybrid			2022-12-27	WOS:000079451600014
J	Huang, HB; Horiuchi, A; Watanabe, T; Shih, SR; Tsay, HJ; Li, HC; Greengard, P; Nairn, AC				Huang, HB; Horiuchi, A; Watanabe, T; Shih, SR; Tsay, HJ; Li, HC; Greengard, P; Nairn, AC			Characterization of the inhibition of protein phosphatase-1 by DARPP-32 and inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-REGULATED PHOSPHOPROTEIN; SITE-DIRECTED MUTAGENESIS; RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PHOSPHORYLATION; EXPRESSION; MECHANISM; BINDING; CLONING; TYPE-1	Phospho-DARPP-32 (where DARPP-32 is dopamine-and cAMP-regulated phosphoprotein, M-r 32,000), its homolog, phospho-inhibitor-l, and inhibitor-a are potent inhibitors (IC50 similar to 1 nM) of the catalytic subunit of protein phosphatase-l (PP1), Our previous studies have indicated that a region encompassing residues 6-11 (RKKIQF) and phospho-Thr-34, of phospho-DARPP-32, interacts with PP1, However, little is known about specific regions of inhibitor-a that interact with PP1, We have now characterized in detail the interaction of phospho-DARPP-32 and inhibitor-a with PP1, Mutagenesis studies indicate that within DARPP-32 Phe-11 and Ile-9 play critical roles, with Lys-7 playing a lesser role in inhibition of PP1, Pro-33 and Pro-35 are also important, as is the number of amino acids between residues 7 and 11 and phospho-Thr-34, For inhibitor-a, deletion of amino acids 1-8 (I2-(9-204)) or 100-204 (12-(1-99)) had little effect on the ability of the mutant proteins to inhibit PP1, Further deletion of residues 9-13 (12-(14-204)) resulted in a large decrease in inhibitory potency (IC50 similar to 800 nm), whereas further COOH-terminal deletion (12(1-84)) caused a moderate decrease in inhibitory potency (IC50 similar to 10 nM), Within residues 9-13 (PIKGI), mutagenesis indicated that Ile-10, Lys-11, and Ile-13 play critical roles. The peptide I2-(6-20) antagonized the inhibition of PP-1 by inhibitor-2 but had no effect on inhibition by phospho-DARPP-32, In contrast, the peptide D32-(6-38) antagonized the inhibition of PP1 by phospho-DARPP-32, inhibitor-2, and I2-(1-120) but not I2-(85204), These results indicate that distinct amino acid motifs contained within the NH, termini of phospho-DARPP-32 (KKIQF, where italics indicate important residues) and inhibitor-2 (IKGI) are critical for inhibition of PP1. Moreover, residues 14-84 of inhibitor-a and residues 6-38 of phospho-DARPP-32 share elements that are important for interaction with PP1.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Chi Coll Med & Humanities, Inst Biochem, Hualien 970, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	Rockefeller University; Tzu Chi University; National Yang Ming Chiao Tung University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	nairn@rockvax.rockefeller.edu		Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH 40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yang J, 1998, FASEB J, V12, pA1407; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	42	119	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7870	7878		10.1074/jbc.274.12.7870	http://dx.doi.org/10.1074/jbc.274.12.7870			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075680	hybrid			2022-12-27	WOS:000079268100039
J	Kraner, SD; Rich, MM; Sholl, MA; Zhou, HY; Zorc, CS; Kallen, RG; Barchi, RL				Kraner, SD; Rich, MM; Sholl, MA; Zhou, HY; Zorc, CS; Kallen, RG; Barchi, RL			Interaction between the skeletal muscle type 1 Na+ channel promoter E-box and an upstream repressor element - Release of repression by myogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR EPSILON-SUBUNIT; MONOCLONAL-ANTIBODIES; SODIUM-CHANNELS; GENE; TRANSCRIPTION; EXPRESSION; LOCALIZATION; ADENOVIRUS; ACTIVATION; ENHANCER	We have defined how four elements that regulate expression of the rat skeletal muscle type 1 sodium channel (SkM1) gene cooperate to yield specific expression in differentiated muscle. A basal promoter region containing within it a promoter E-box (-31/-26) is broadly expressed in many cells, including myoblasts and myotubes; mutations within the promoter E-box that disrupt binding of the myogenic basic helix-loop-helix (bHLH) factors reduce expression in all cell types only slightly. Sequential addition of upstream elements to the wildtype promoter confer increasing specificity of expression in differentiated cells, even though all three upstream elements, including a positive element (-85/-57), a repressor E-box (-90/-85), and upstream repressor sequences (-135/-95), bind ubiquitously expressed transcription factors. Mutations in the promoter E-box that disrupt the binding of the bHLH factors counteract the specificity conferred by addition of the upstream elements, with the greatest interaction observed between the upstream repressor sequences and the promoter E-box, Forced expression of myogenin in myoblasts releases repression exerted by the upstream repressor sequences in conjunction with the wild-type, but not mutant, promoter E-box, and also initiates expression of the endogenous SkM1 protein. Our data suggest that particular myogenic bHLH proteins bound at the promoter E-box control expression of SkM1 by releasing repression exerted by upstream repressor sequences in differentiated muscle cells.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Kraner, SD (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 223 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	kraner@mail.med.upenn.edu			NINDS NIH HHS [NS-01852, NS-34954] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001852, R01NS034954] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BARR E, 1994, GENE THER, V1, P51; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; COHEN SA, 1992, J MEMBRANE BIOL, V128, P219; DiRocco G, 1997, MOL CELL BIOL, V17, P1244, DOI 10.1128/MCB.17.3.1244; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; HAIMOVICH B, 1987, J NEUROSCI, V7, P2957; Kraner SD, 1998, J NEUROCHEM, V70, P1628; Kraner SD, 1998, J BIOL CHEM, V273, P11327, DOI 10.1074/jbc.273.18.11327; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LUPA MT, 1993, J NEUROSCI, V13, P1326; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; PRODY CA, 1991, J BIOL CHEM, V266, P22588; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7; YANG JS, 1991, NEURON, V7, P412	25	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8129	8136		10.1074/jbc.274.12.8129	http://dx.doi.org/10.1074/jbc.274.12.8129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075715	hybrid			2022-12-27	WOS:000079268100074
J	Ng, GYK; Clark, J; Coulombe, N; Ethier, N; Hebert, TE; Sullivan, R; Kargman, S; Chateauneuf, A; Tsukamoto, N; McDonald, T; Whiting, P; Mezey, E; Johnson, MP; Liu, QY; Kolakowski, LF; Evans, JF; Bonner, TI; O'Neill, GP				Ng, GYK; Clark, J; Coulombe, N; Ethier, N; Hebert, TE; Sullivan, R; Kargman, S; Chateauneuf, A; Tsukamoto, N; McDonald, T; Whiting, P; Mezey, E; Johnson, MP; Liu, QY; Kolakowski, LF; Evans, JF; Bonner, TI; O'Neill, GP			Identification of a GABA(B) receptor subunit, gb2, required for functional GABA(B) receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; NERVOUS-SYSTEM; RAT-BRAIN; PEPTIDES	G protein-coupled receptors are commonly thought to bind their cognate ligands and elicit functional responses primarily as monomeric receptors. In studying the recombinant gamma-aminobutyric acid, type B (GABA,) receptor (gb1a) and a GABA(B)-like orphan receptor (gb2), we observed that both receptors are functionally inactive when expressed individually in multiple heterologous systems. Characterization of the tissue distribution of each of the receptors by in situ hybridization histochemistry in rat brain revealed co-localization of gb1 and gb2 transcripts in many brain regions, suggesting the hypothesis that gb1 and gb2 may interact in vivo. In three established functional systems (inwardly rectifying K+ channel currents in Xenopus oocytes, melanophore pigment aggregation, and direct cAMP measurements in HEK-293 cells), GABA mediated a functional response in cells coexpressing gb1a and gb2 brit not in cells expressing either receptor individually. This GABA activity could be blocked with the GABA(B) receptor antagonist CGP71872, In COS-7 cells coexpressing gb1a and gb2 receptors, co-immunoprecipitation of gb1a and gb2 receptors was demonstrated, indicating that gb1a and gb2 act as subunits in the formation of a functional GABA(B) receptor.	Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada; Merck Sharp & Dohme Ltd, Res Labs, Harlow CM20 2QR, Essex, England; Banyu Pharmaceut Co Ltd, Tsukuba, Ibaraki 3002611, Japan; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; NINDS, NIH, Bethesda, MD 20892 USA; NIMH, Genet Sect, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Merck & Company; Merck & Company; Merck & Company; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Ng, GYK (corresponding author), Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada.	gordon_ng@merck.com	Clark, Janet/P-4896-2018; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691; Whiting, Paul/0000-0002-4121-1379				Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; HEBERT TE, 1994, P ROY SOC B-BIOL SCI, V256, P253, DOI 10.1098/rspb.1994.0078; HEBERT TE, 1996, J BIOL CHEM, V272, P29229; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; JONES KA, 1998, SOC NEUR ABSTR LOS A; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kolakowski LF, 1998, J NEUROCHEM, V71, P2239; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAIDMENT NT, 1989, NEUROSCIENCE, V33, P549, DOI 10.1016/0306-4522(89)90407-7; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; Ng GYK, 1999, GENOMICS, V56, P288, DOI 10.1006/geno.1998.5706; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	22	181	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7607	7610		10.1074/jbc.274.12.7607	http://dx.doi.org/10.1074/jbc.274.12.7607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075644	hybrid			2022-12-27	WOS:000079268100003
J	Stempien-Otero, A; Karsan, A; Cornejo, CJ; Xiang, H; Eunson, T; Morrison, RS; Kay, M; Winn, R; Harlan, J				Stempien-Otero, A; Karsan, A; Cornejo, CJ; Xiang, H; Eunson, T; Morrison, RS; Kay, M; Winn, R; Harlan, J			Mechanisms of hypoxia-induced endothelial cell death - Role of p53 in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; DNA-DAMAGE; PROTEIN; DEGRADATION; ACTIVATION; GROWTH; PHOSPHORYLATION; UBIQUITINATION; FIBROBLASTS	Endothelial cell death may contribute to tissue injury from ischemia, Little is known, however, about the characteristics of endothelial cell death in response to hypoxia. Using an in vitro model, we found that human umbilical vein endothelial cells were resistant to hypoxia-induced cell death with only a 2% reduction in viability at 24 h and 45% reduction in viability at 48 h. Overexpression of a mutant, I kappa B alpha, via adenoviral vector did not potentiate cell death in hypoxia, indicating that nuclear factor-kappa B activation was not involved in cytoprotection. Cell death in hypoxia was determined to be apoptotic by 3' labeling of DNA using terminal deoxynucleotidyl transferase staining and reversibility of cell death with a caspase inhibitor. Exposure of endothelial cells to hypoxia did not alter levels of proapoptotic and antiapoptotic Bcl-2 family members Bar and Bcl-X-L by immunoblot analysis. In contrast, changes in p53 protein levels correlated with the induction of apoptosis in hypoxic endothelial cells. Inhibition of the proteasome increased p53 protein levels and accelerated cell death in hypoxia. Overexpression of p53 by adenoviral transduction was sufficient to initiate apoptosis of normoxic endothelial cells. These data provide a framework for the study of factors regulating endothelial cell survival and death in hypoxia.	Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ British Columbia, Dept Pathol, Vancouver, BC V6T 2B5, Canada; Stanford Univ, Dept Genet, Palo Alto, CA 94305 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of British Columbia; Stanford University	Stempien-Otero, A (corresponding author), Univ Washington, Med Ctr, Dept Med, Box 357710, Seattle, WA 98195 USA.		Karsan, Aly/K-2067-2015	Kay, Mark/0000-0002-2799-2615				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Amellem O, 1997, EXP CELL RES, V232, P361, DOI 10.1006/excr.1997.3497; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ANTWERP DJV, 1996, SCIENCE, V274, P787; ARNOULD T, 1994, BLOOD, V83, P3705; Arora AS, 1996, J CELL PHYSIOL, V167, P434, DOI 10.1002/(SICI)1097-4652(199606)167:3<434::AID-JCP7>3.0.CO;2-Q; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hagar H, 1996, KIDNEY INT, V49, P355, DOI 10.1038/ki.1996.52; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1997, AM J PATHOL, V151, P1775; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Maki CG, 1996, CANCER RES, V56, P2649; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; POLYAK K, 1997, NATURE, V389, P2307; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSENBAUM DM, 1994, ANN NEUROL, V36, P864, DOI 10.1002/ana.410360610; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHOTT AF, 1995, ONCOGENE, V11, P1389; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Thiagarajan RR, 1997, THROMB HAEMOSTASIS, V78, P310; TRETYAKOV AV, 1995, J CLIN INVEST, V95, P738, DOI 10.1172/JCI117721; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xiang H, 1996, J NEUROSCI, V16, P6753; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zund G, 1996, P NATL ACAD SCI USA, V93, P7075, DOI 10.1073/pnas.93.14.7075	48	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8039	8045		10.1074/jbc.274.12.8039	http://dx.doi.org/10.1074/jbc.274.12.8039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075703	hybrid			2022-12-27	WOS:000079268100062
J	Candi, E; Tarcsa, E; Idler, WW; Kartasova, T; Marekov, LN; Steinert, PM				Candi, E; Tarcsa, E; Idler, WW; Kartasova, T; Marekov, LN; Steinert, PM			Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins - Integration with loricrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; DIFFERENTIATION-SPECIFIC GENES; MALIGNANT KERATINOCYTES; SUBSTRATE-SPECIFICITY; PROTRANSGLUTAMINASE-E; EPITHELIAL-CELLS; BOND FORMATION; RETINOIC ACID; SPR1 GENE; EXPRESSION	Small proline-rich 1 (SPR1) proteins are important for barrier function in stratified squamous epithelia, To explore their properties, we expressed in bacteria a recombinant human SPR1 protein and isolated native SPR1 proteins from cultured mouse keratinocytes. By circular dichroism, they possess no alpha or beta structure but have some organized structure associated with their central peptide repeat domain. The transglutaminase (TGase) 1 and 3 enzymes use the SPR1 proteins as complete substrates in vitro but in different ways: head domain A sequences at the amino terminus were used preferentially for cross-linking by TGase 3, whereas those in head domain B sequences were used for cross-linking by TGase 1. The TGase 2 enzyme cross-linked SPR1 proteins poorly. Together with our data base of 141 examples of in vivo cross-links between SPRs and loricrin, this means that both TGase 1 and 3 are required for cross-linking SPR1 proteins in epithelia in vivo. Double in vitro cross-linking experiments suggest that oligomerization of SPR1 into large polymers can occur only by further TGase 1 cross-linking of an initial TGase 3 reaction. Accordingly, we propose that TGase 3 first cross-links loricrin and SPRs together to form small interchain oligomers, which are then permanently affixed to the developing CE by further cross-linking by the TGase 1 enzyme. This is consistent with the known consequences of diminished barrier function in TGase 1 deficiency models.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425,9000 Rockville Pike, Bethesda, MD 20892 USA.	pemast@helix.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041086, Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AN G, 1993, J CELL PHYSIOL, V157, P562, DOI 10.1002/jcp.1041570316; AN G, 1993, J BIOL CHEM, V268, P10977; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BARRY ELR, 1990, J BIOL CHEM, V265, P9302; BIRCKBICHLER PJ, 1977, BIOCHEM BIOPH RES CO, V78, P1, DOI 10.1016/0006-291X(77)91213-X; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; GANG A, 1992, AM J RESP CELL MOL, V7, P104, DOI 10.1165/ajrcmb/7.1.104; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GILCHREST BA, 1994, ARCH DERMATOL, V130, P82, DOI 10.1001/archderm.130.1.82; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; IshidaYamamoto A, 1997, J INVEST DERMATOL, V108, P12, DOI 10.1111/1523-1747.ep12285611; Jarnik M, 1996, J CELL SCI, V109, P1381; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KILLACKEY JJF, 1989, MOL PHARMACOL, V35, P701; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1994, J BIOL CHEM, V269, P27979; Koizumi H, 1996, BRIT J DERMATOL, V134, P686, DOI 10.1111/j.1365-2133.1996.tb06971.x; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINET N, 1988, BIOCHEM J, V271, P305; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; OWENS DM, 1926, J INVEST DERMATOL, V647, P96; PHILLIPS SB, 1990, COMP BIOCHEM PHYS B, V95, P781, DOI 10.1016/0305-0491(90)90317-M; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1994, KERATINOCYTE HDB, P275; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TESFAIGZI J, 1993, AM J RESP CELL MOL, V9, P434, DOI 10.1165/ajrcmb/9.4.434; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081	58	74	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7226	7237		10.1074/jbc.274.11.7226	http://dx.doi.org/10.1074/jbc.274.11.7226			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066784	hybrid			2022-12-27	WOS:000079078400056
J	Nuber, U; Scheffner, M				Nuber, U; Scheffner, M			Identification of determinants in E2 ubiquitin-conjugating enzymes required for hect E3 ubiquitin protein ligase interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; CELL-CYCLE; DEGRADATION; E6-AP; COMPLEX; ENCODES; SYSTEM; GENE; P53; PROTEOLYSIS	Members of the hect domain protein family are characterized by sequence similarity of their C-terminal regions to the C terminus of EG-AP, an E3 ubiquitin-protein ligase, An essential intermediate step in E6-AP-dependent ubiquitination is the formation of a thioester complex between EG-AP and ubiquitin in the presence of distinct E2 ubiquitin-conjugating enzymes including human UbcH5, a member of the UBC4/UBC5 subfamily of E2s. Similarly, several hect domain proteins, including Saccharomyces cerevisiae RSPB, form ubiquitin thioester complexes, indicating that hect domain proteins in general have E3 activity. We show here, by the use of chimeric E2s generated between UbcH5 and other E2s, that a region of UbcH5 encompassing the catalytic site cysteine residue is critical for its ability to interact with E6-AP and RSP5. Of particular importance is a phenylalanine residue at position 62 of UbcH5 that is con served among the members of the UBC4/UBC5 subfamily but is not present in any of the other known E2s, whereas the N-terminal 60 amino acids do not contribute significantly to the specificity of these interactions. The conservation of this phenylalanine residue throughout evolution underlines the importance of the ability to interact with hect domain proteins for the cellular function of UBC4/UBC5 subfamily members.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Scheffner, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Hershko A, 1996, ADV EXP MED BIOL, V389, P221; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith SE, 1996, BIOL CHEM, V377, P437; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; ZHEN M, 1993, MOL CELL BIOL, V13, P1371, DOI 10.1128/MCB.13.3.1371	37	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7576	7582		10.1074/jbc.274.11.7576	http://dx.doi.org/10.1074/jbc.274.11.7576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066826	hybrid			2022-12-27	WOS:000079078400098
J	Cheng, M; Wang, D; Roussel, MF				Cheng, M; Wang, D; Roussel, MF			Expression of c-Myc in response to colony-stimulating factor-1 requires mitogen-activated protein kinase kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; FACTOR-I RECEPTOR; D-TYPE CYCLINS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; SRC FAMILY; INHIBITOR P27(KIP1); MAMMALIAN-CELLS; GENE-EXPRESSION	The mitogen-inducible gene c-myc is a key regulator of cell proliferation and transformation. Yet, the signaling pathway(s) that regulate its expression have remained largely unresolved. Using the mitogen-activated protein kinase kinase (MEK1/2) inhibitor PD98059 and dominant negative forms of Ras (N17) and ERK1 (K71R), we found that activation of Ras and extracellular signal-regulated kinase (ERK) is necessary for colony-stimulating factor-1 (CSF-1)-mediated c-Myc expression and DNA synthetic (S) phase entry. Quiescent NIH-3T3 cells expressing a partially defective CSF-1 receptor, CSF-1R (Y809F), exhibited impaired ERK1 activation and c-Myc expression and failed to enter the S phase of the cell division cycle in response to CSF-1 stimulation. Ectopic expression of a constitutively active form of MEK1 in cells expressing CSF-1R (Y809F) rescued c-Myc expression and S phase entry, but only in the presence of CSF-1-induced cooperating signals. Therefore, MEK1 participates in an obligate signaling pathway linking CSF-1R to c-Myc expression, but other signals from CSF-1R must cooperate with the MEK/ERK pathway to induce c-Myc expression and S phase entry in response to CSF-1 stimulation.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wang, Demin/AAX-4449-2020; Roussel, Martine F/F-1469-2016	Wang, Demin/0000-0001-5549-3795; Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [T32-CA70089, CA-56819, CA-21705] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070089, R01CA056819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BORTNER DM, 1992, INT J ONCOL, V1, P221; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis JN, 1997, MOL CELL BIOL, V17, P7398, DOI 10.1128/MCB.17.12.7398; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1990, BLOOD, V75, P1780; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEMAITRE JM, 1996, ADV CANCER RES, V70, P96; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALLANCE SJ, 1994, HYBRIDOMA, V13, P37, DOI 10.1089/hyb.1994.13.37; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Winston JT, 1996, ONCOGENE, V12, P127; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	59	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6553	6558		10.1074/jbc.274.10.6553	http://dx.doi.org/10.1074/jbc.274.10.6553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037749	hybrid			2022-12-27	WOS:000078902800071
J	Froesch, BA; Aime-Sempe, C; Leber, B; Andrews, D; Reed, JC				Froesch, BA; Aime-Sempe, C; Leber, B; Andrews, D; Reed, JC			Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; HUMAN FOLLICULAR LYMPHOMA; PROGRAMMED CELL-DEATH; IN-VIVO; BREAST-CANCER; MITOCHONDRIAL-MEMBRANES; P53-DEPENDENT APOPTOSIS; P53-TRIGGERED APOPTOSIS; ENDOPLASMIC-RETICULUM	We show here that the anti-apoptosis protein Bcl-2 potently inhibits p53-dependent transcriptional activation of various p53-responsive promoters in reporter gene co-transfection assays in human embryonic kidney 295 and MCF7 cells, without affecting nuclear accumulation of p53 protein. In contrast, Bcl-2(Delta transmembrane (TM)), which lacks a hydrophobic membrane-anchoring domain, had no effect on p53 activity. Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(Delta TM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53 responsive promoter activity and expression of p21(CIP1/WAF1) were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(Delta TM) or control MCF7 cells. The issue of membrane anchoring was further explored by testing the effects of Bcl-2 chimeric proteins that contained heterologous transmembrane domains from the mitochondrial protein ActA or the endoplasmic reticulum protein cytochrome b5, Both Bcl-2(ActA) and Bcl-2(Cytob5) suppressed p53-mediated transactivation of reporter gene plasmids with efficiencies comparable to wild-type Bcl-2. These results suggest that (a) Bcl-2 not only suppresses p53-mediated apoptosis but also interferes with the transcriptional activation of p53 target genes at least in some cell lines, and (b) membrane anchoring is required for this function of Bcl-2. We speculate that membrane-anchored Bcl-2 may sequester an unknown factor necessary for p53 transcriptional activity.	Burnham Inst, La Jolla, CA 92037 USA; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Biochem, Hamilton, ON, Canada	Sanford Burnham Prebys Medical Discovery Institute; McMaster University; McMaster University	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org		Sempe, Christine/0000-0001-6903-1575; Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157	NCI NIH HHS [CA55164-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAO Y, 1994, CANCER RES, V54, P2468; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FONTANINI G, 1995, BRIT J CANCER, V71, P1003, DOI 10.1038/bjc.1995.193; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JAMAL S, 1995, ONCOGENE, V10, P2095; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lohrum M, 1996, ONCOGENE, V13, P2527; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RENZING J, 1995, ONCOGENE, V10, P1865; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SALVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; SEBAG M, 1994, J INVEST DERMATOL, V103, P323, DOI 10.1111/1523-1747.ep12394802; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UPADHYAY S, 1995, CANCER RES, V55, P4520; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	81	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6469	6475		10.1074/jbc.274.10.6469	http://dx.doi.org/10.1074/jbc.274.10.6469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037739	hybrid			2022-12-27	WOS:000078902800061
J	Kobayashi, A; Ito, E; Toki, T; Kogame, K; Takahashi, S; Igarashi, K; Hayashi, N; Yamamoto, M				Kobayashi, A; Ito, E; Toki, T; Kogame, K; Takahashi, S; Igarashi, K; Hayashi, N; Yamamoto, M			Molecular cloning and functional characterization of a new Cap'n' collar family transcription factor Nrf3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL MAF PROTEINS; GENE-EXPRESSION; FACTOR NF-E2; REGION; FOS; HETERODIMERS; ACTIVATOR; ONCOGENE; LCR-F1; CELLS	The NF-E2-binding sites or Maf recognition elements (MARE) are essential cis-acting elements in the regulatory regions of erythroid-specific genes recognized by the erythroid transcription factor NF-E2, composed of p45 and MafK. Recently, two p45-related factors Nrf1 and Nrf2 were isolated, and they are now collectively grouped as the Cap'n' collar (CNC) family. CNC factors bind to MARE through heterodimer formation with small Maf proteins. We report here the identification and characterization of a novel CNC factor, Nrf3, encoding a predicted 73-kDa protein with a basic region-leucine zipper domain highly homologous to those of other CNC proteins. In vitro and in vivo analyses showed that Nrf3 can heterodimerize with MafK and that this complex binds to the MARE in the chicken beta-globin enhancer and can activate transcription. Nrf3 mRNA is highly expressed in human placenta and B cell and monocyte lineage. Chromosomal localization of human Nrf3 is 7p14-15, which lies near the hoxA gene locus. As the genetic loci of p45, nrf1, and nrf2 have been mapped close to those of hoxC, hoxB, and hoxD, respectively, the present study strongly argues for the idea that a single ancestral gene for the CNC family members may have been localized near the ancestral Hox cluster and have diverged to give rise to four closely related CNC factors through chromosome duplication.	Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan; Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 036, Japan; Hirosaki Univ, Sch Med, Clin Lab, Hirosaki, Aomori 036, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Tohoku University; Hirosaki University; Hirosaki University; University of Tsukuba; University of Tsukuba	Kobayashi, A (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, 2-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	akira-k@mail.cc.tohoku.ac.jp	Yamamoto, Masayuki/A-4873-2010; Takahashi, Shinichiro/AAX-7125-2020; Kobayashi, Akira/AAN-8003-2020	Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475; Ito, Etsuro/0000-0002-0168-2475; Kobayashi, Akira/0000-0001-9727-1218; Takahashi, Shinichiro/0000-0003-0011-6065				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1995, HUM GENET, V95, P265; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; JORDAN SA, 1998, GENE DEV, V12, P2164; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kobayashi A, 1997, J BIOCHEM, V122, P703; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; Ma GT, 1997, DEVELOPMENT, V124, P907; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024	38	233	245	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6443	6452		10.1074/jbc.274.10.6443	http://dx.doi.org/10.1074/jbc.274.10.6443			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037736	hybrid			2022-12-27	WOS:000078902800058
J	Perrin, L; Romby, P; Laurenti, P; Berenger, H; Kallenbach, S; Bourbon, HM; Pradel, J				Perrin, L; Romby, P; Laurenti, P; Berenger, H; Kallenbach, S; Bourbon, HM; Pradel, J			The Drosophila modifier of variegation modulo gene product binds specific RNA sequences at the nucleolus and interacts with DNA and chromatin in a phosphorylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; RIBOSOME; MOLECULE; DOMAIN	modulo belongs to the modifier of Position Effect Variegation class of Drosophila genes, suggesting a role for its product in regulating chromatin structure. Genetics assigned a second function to the gene, in protein synthesis capacity. Bifunctionality is consistent with protein localization in two distinct subnuclear compartments, chromatin and nucleolus, and with its organization in modules potentially involved in DNA and RNA binding. In this study, we examine nucleic acid interactions established by Module at nucleolus and chromatin and the mechanism that controls the distribution and balances the function of the protein in the two compartments. Structure/function analysis and oligomer selection/amplification experiments indicate that, in vitro, two basic terminal domains independently contact DNA without sequence specificity, whereas a central RNA Recognition Motif (RRM)-containing domain allows recognition of a novel sequence-/motif-specific RNA class. Phosphorylation moreover is shown to down-regulate DNA binding, Evidence is provided that in vivo nucleolar Module is highly phosphorylated and belongs to a ribonucleoprotein particle, whereas chromatin-associated protein is not modified. A functional scheme is finally proposed in which modification by phosphorylation modulates Mod subnuclear distribution and balances its function at the nucleolus and chromatin.	CNRS, Inst Biol Dev Marseille, Biol & Genet Dev Lab, F-13288 Marseille 9, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9002, F-67084 Strasbourg, France; Ctr Dev Biol, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pradel, J (corresponding author), CNRS, Inst Biol Dev Marseille, Biol & Genet Dev Lab, Parc Sci Luminy,Case 907, F-13288 Marseille 9, France.		Perrin, Laurent/L-8301-2016; Laurenti, Patrick/I-8785-2012; ROMBY, Pascale/AGP-3328-2022	Perrin, Laurent/0000-0002-4139-8743; Laurenti, Patrick/0000-0002-2903-1148; 				Bellaiche Y, 1996, DEVELOPMENT, V122, P3499; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CLARK RF, 1991, METHOD CELL BIOL, V35, P203; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; GARZINO V, 1992, EMBO J, V11, P4471, DOI 10.1002/j.1460-2075.1992.tb05548.x; GARZINO V, 1987, BIOL CELL, V61, P5, DOI 10.1111/j.1768-322X.1987.tb00563.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Henikoff S, 1996, BIOESSAYS, V18, P401, DOI 10.1002/bies.950180510; KAY MA, 1987, TRENDS GENET, V3, P347, DOI 10.1016/0168-9525(87)90295-2; KREJCI E, 1989, NUCLEIC ACIDS RES, V17, P8101, DOI 10.1093/nar/17.20.8101; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; Lentzen G, 1996, RNA, V2, P244; LINDSLEY DL, 1992, GENOME DROSOPHILA ME, P433; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; NOMURA M, 1984, SCI AM, V250, P102, DOI 10.1038/scientificamerican0184-102; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; Perrin L, 1998, J CELL SCI, V111, P2753; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; Saeboe-Larssen S, 1998, GENETICS, V148, P1215; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Wyatt J. R., 1993, RNA WORLD, P465; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; Zhimulev IF, 1998, ADV GENET, V37, P1; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	37	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6315	6323		10.1074/jbc.274.10.6315	http://dx.doi.org/10.1074/jbc.274.10.6315			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037720	hybrid			2022-12-27	WOS:000078902800042
J	Dikalov, SI; Vitek, MP; Maples, KR; Mason, RP				Dikalov, SI; Vitek, MP; Maples, KR; Mason, RP			Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; SPIN-TRAP; HYDROGEN-PEROXIDE; PROTEIN; NEUROTOXICITY; INHIBITION; TOXICITY; ADDUCT; IRON; DECOMPOSITION	Amyloid beta (A beta) peptides play an important, role in the pathogenesis of Alzheimer's disease. Free radical generation by A beta peptides was suggested to be a key mechanism of their neurotoxicity. Reports that neurotoxic free radicals derived from A beta-(1-40) and A beta-(25-35) peptides react with the spin trap N-tert-butyl-alpha-phenylnitrone (PBN) to form a PBN/*A beta peptide radical adduct with a specific triplet ESR. signal assert that the peptide itself was the source of free radicals. We now report that three A beta peptides, A beta-(1-40), A beta-(25-35), and A beta-(40-1), do not yield radical adducts with PEN from the Oklahoma Medical Research Foundation (OMRF). Incontrast to OMRF PEN, incubation of Sigma PEN in phosphate buffer without A beta peptides produced a three-line ESR spectrum, It was shown that this nitroxide is di-tert-butylnitroxide and is formed in the Sigma PEN solution as a result of transition metal-catalyzed auto-oxidation of the respective hydroxylamine present as an impurity in the Sigma PEN. Under some conditions, incubation of PEN from Sigma with A beta-(1-40) or A beta-(25-35) can stimulate the formation of di-tert-butylnitroxide. It was shown that A beta peptides enhanced oxidation of cyclic hydroxylamine 1-hydroxy-4-oxo-2,2,6,6-tetramethylpiperidine (TEMPONE-H), which was strongly inhibited by the treatment of phosphate buffer with Chelex-100. It was shown that ferric and cupric ions are effective oxidants of TEMPONE-H. The data obtained allow us to conclude that under some conditions toxic A beta peptides A beta-(1-40) and A beta-(25-35) enhance metal-catalyzed oxidation of hydroxylamine derivatives, but do not spontaneously form peptide-derived free radicals.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; Centaur Pharmaceut Inc, Sunnyvale, CA 94086 USA; Novosibirsk Chem Kinet & Combust Inst, Novosibirsk 630090, Russia	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS	Dikalov, SI (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109; Dikalov, Sergey/0000-0003-2976-6184; Vitek, Michael/0000-0001-8140-8048				Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Balakrishnan R, 1998, J PEPT RES, V51, P91; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bondy SC, 1998, BRAIN RES, V799, P91, DOI 10.1016/S0006-8993(98)00461-2; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; Cohen G., 1985, CRC HDB METHODS OXYG, P55; DAVIES MJ, 1997, RADICAL MED PROTEIN, P235; Dikalov S, 1997, BIOCHEM BIOPH RES CO, V230, P54, DOI 10.1006/bbrc.1996.5880; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V295, P205, DOI 10.1016/0003-9861(92)90507-S; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HENSLEY K, 1995, NEUROREPORT, V6, P489, DOI 10.1097/00001756-199502000-00021; HENSLEY K, 1995, NEUROREPORT, V6, P493, DOI 10.1097/00001756-199502000-00022; HINTON RD, 1992, J ORG CHEM, V57, P2646, DOI 10.1021/jo00035a020; KALYANARAMAN B, 1979, TETRAHEDRON LETT, V50, P4809; Kato M, 1997, J NEUROCHEM, V68, P1889; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; LAGERCRANTZ C, 1991, FREE RADICAL RES COM, V14, P395, DOI 10.3109/10715769109093428; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MACKOR A, 1967, TETRAHEDRON LETT, V5, P385; MAKINO K, 1981, RADIAT RES, V86, P294, DOI 10.2307/3575507; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Montine KS, 1998, J NEUROPATH EXP NEUR, V57, P415, DOI 10.1097/00005072-199805000-00005; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sayre LM, 1997, CHEM RES TOXICOL, V10, P518, DOI 10.1021/tx970009n; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHUBERT D, 1995, BIOCHEM BIOPH RES CO, V216, P702, DOI 10.1006/bbrc.1995.2678; SENTJURC M, 1992, FREE RADICAL BIO MED, V13, P151, DOI 10.1016/0891-5849(92)90077-T; Smith MA, 1995, J NEUROL SCI, V134, P92, DOI 10.1016/0022-510X(95)00213-L; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; WERTZ JE, 1986, ELECTRON SPIN RESON, P450; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	39	103	104	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9392	9399		10.1074/jbc.274.14.9392	http://dx.doi.org/10.1074/jbc.274.14.9392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092619	hybrid			2022-12-27	WOS:000079451800038
J	Ye, D; Willhite, DC; Blanke, SR				Ye, D; Willhite, DC; Blanke, SR			Identification of the minimal intracellular vacuolating domain of the Helicobacter pylori vacuolating toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PROTEIN TOXINS; VIRULENCE FACTORS; PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; MAMMALIAN-CELLS; LETHAL FACTOR; HELA-CELLS; CYTOTOXIN; INFECTION; VACA	Helicobacter pylori secretes a cytotoxin (VacA) that induces the formation of large vacuoles originating from late endocytic vesicles in sensitive mammalian cells. Although evidence is accumulating that VacA is an A-B toxin, distinct A and B fragments have not been identified. To localize the putative catalytic A-fragment, we transfected HeLa cells with plasmids encoding truncated forms of VacA fused to green fluorescence protein. By analyzing truncated VacA fragments for intracellular vacuolating activity, we reduced the minimal functional domain to the amino-terminal 422 residues of VacA, which is less than one-half of the full-length protein (953 amino acids). VacA is frequently isolated as a proteolytically nicked protein of two fragments that remain noncovalently associated and retain vacuolating activity. Neither the amino-terminal 311 residue fragment (p33) nor the carboxyl-terminal 642 residue fragment (p70) of proteolytically nicked VacA are able to induce cellular vacuolation by themselves. However, cotransfection of HeLa cells with separate plasmids expressing both p33 and p70 resulted in vacuolated cells. Further analysis revealed that a minimal fragment comprising just residues 312-478 functionally complemented p33. Collectively, our results suggest a novel molecular architecture for VacA, with cytosolic localization of both fragments of nicked toxin required to mediate intracellular vacuolating activity.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston	Blanke, SR (corresponding author), Univ Houston, Dept Biol & Biochem, 430 Houston Sci Ctr,3201 Cullen Blvd, Houston, TX 77204 USA.	sblanke@uh.edu						ARORA N, 1992, J BIOL CHEM, V267, P15542; Atherton JC, 1998, BRIT MED BULL, V54, P105; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Blanke SR, 1996, P NATL ACAD SCI USA, V93, P8437, DOI 10.1073/pnas.93.16.8437; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; Burroni D, 1998, INFECT IMMUN, V66, P5547, DOI 10.1128/IAI.66.11.5547-5550.1998; CATRENICH CE, 1992, J MED MICROBIOL, V37, P389, DOI 10.1099/00222615-37-6-389; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CORRADIN G, 1971, P NATL ACAD SCI USA, V68, P3036, DOI 10.1073/pnas.68.12.3036; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; Cover TL, 1998, TRENDS MICROBIOL, V6, P127, DOI 10.1016/S0966-842X(98)01231-1; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1996, ADV INTERNAL MED, V41, P85; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; KATO I, 1969, J BIOL CHEM, V244, P1004; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Montecucco C, 1996, EXPERIENTIA, V52, P1026, DOI 10.1007/BF01952098; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Pagliaccia C, 1998, P NATL ACAD SCI USA, V95, P10212, DOI 10.1073/pnas.95.17.10212; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; PAPINI E, 1993, FEMS MICROBIOL LETT, V113, P155, DOI 10.1016/0378-1097(93)90262-Z; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; van Doorn LJ, 1998, J CLIN MICROBIOL, V36, P2597, DOI 10.1128/JCM.36.9.2597-2603.1998; Wang HJ, 1998, J INFECT DIS, V178, P207, DOI 10.1086/515600; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	49	100	110	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9277	9282		10.1074/jbc.274.14.9277	http://dx.doi.org/10.1074/jbc.274.14.9277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092603	hybrid			2022-12-27	WOS:000079451800022
J	Mallender, WD; Szegletes, T; Rosenberry, TL				Mallender, WD; Szegletes, T; Rosenberry, TL			Organophosphorylation of acetylcholinesterase in the presence of peripheral site ligands - Distinct effects of propidium and fasciculin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURE; ACTIVE-SITE; INHIBITION; BINDING; DISSOCIATION; SPECIFICITY; HYDROLYSIS; ACYLATION; SUBSTRATE	Structural analysis of acetylcholinesterase (AChE) has revealed two sites of ligand interaction in the active site gorge: an acylation site at the base of the gorge and a peripheral site at its mouth. A goal of our studies is to understand how ligand binding to the peripheral site alters the reactivity of substrates and organophosphates at the acylation site. Kinetic rate constants were determined for the phosphorylation of AChE by two fluorogenic organophosphates, 7-[(diethoxyphosphoryl) oxy]-1-methylquinolinium iodide (DEPQ) and 7-[(methylethoxyphosphonyl)oxy] -4-methylcoumarin (EMPC), by monitoring release of the fluorescent leaving group, Rate constants obtained with human erythrocyte AChE were in good agreement with those obtained for recombinant human AChE produced from a high level Drosophila S2 cell expression system. First-order rate constants k(OP) were 1,600 +/- 300 min(-1) for DEPQ and 150 +/- 11 min(-1) for EMPC, and second-order rate constants k(OP)/K-OP were 193 +/- 13 mu M-1 min(-1) for DEPQ and 0.7-1.0 +/- 0.1 mu M-1 min(-1) for EMPC; Binding of the small ligand propidium to the AChE peripheral site decreased K-OP/K-OP by factors of 2-20 for these organophosphates, Such modest inhibitory effects are consistent with our recently proposed steric blockade model (Szegletes, T,, Mallender, W. D., and Rosenberry, T. L. (1998) Biochemistry 37, 4206-4216), Moreover, the binding of propidium resulted in a clear increase in ho, for EMPC, suggesting that molecular or electronic strain caused by the proximity of propidium to EMPC in the ternary complex may promote phosphorylation, In contrast, the binding of the polypeptide neurotoxin fasciculin to the peripheral site of AChE dramatically decreased phosphorylation rate constants. Values of k(OP)/K-OP were decreased by factors of 10(3) to 10(5), and k(OP) was decreased by factors of 300-4,000, Such pronounced inhibition suggested a conformational change in the acylation site induced by fasciculin binding, As a note of caution to other investigators, measurements of phosphorylation of the fasciculin-AChE complex by AChE inactivation gave misleading rate constants because a small fraction of the AChE was resistant to inhibition by fasciculin.	Mayo Fdn Med Educ & Res, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Dept Res, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Rosenberry, TL (corresponding author), Mayo Fdn Med Educ & Res, Dept Pharmacol, Jacksonville, FL 32224 USA.	rosenberry@mayo.edu			NINDS NIH HHS [NS-16577] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albaret C, 1997, PROTEINS, V28, P543, DOI 10.1002/(SICI)1097-0134(199708)28:4<543::AID-PROT8>3.0.CO;2-A; Aldridge W.N., 1972, FRONT BIOL, p[xvi, 328]; [Anonymous], ENZYMES 3E; BARAK D, 1994, J BIOL CHEM, V269, P6296; BARLOW PN, 1987, J AM CHEM SOC, V109, P253, DOI 10.1021/ja00235a038; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BURGEN ASV, 1949, BRIT J PHARM CHEMOTH, V4, P219, DOI 10.1111/j.1476-5381.1949.tb00540.x; Costagli C, 1998, BIOCHEM PHARMACOL, V55, P1733, DOI 10.1016/S0006-2952(97)00676-X; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GINSBURG S, 1966, J MED CHEM, V9, P632, DOI 10.1021/jm00322a051; GORDON MA, 1978, ANAL BIOCHEM, V85, P519, DOI 10.1016/0003-2697(78)90249-X; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HART GJ, 1973, BIOCHEMISTRY-US, V12, P2940, DOI 10.1021/bi00739a026; Hosea NA, 1996, BIOCHEMISTRY-US, V35, P10995, DOI 10.1021/bi9611220; Incardona JP, 1996, MOL BIOL CELL, V7, P595, DOI 10.1091/mbc.7.4.595; KITZ RJ, 1967, MOL PHARMACOL, V3, P225; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; MAGLOTHIN JA, 1975, BIOCHIM BIOPHYS ACTA, V403, P370, DOI 10.1016/0005-2744(75)90066-2; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P211; RADIC Z, 1999, IN PRESS CHEM BIOL I; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROSENBERRY TL, 1971, BIOCHEMISTRY-US, V10, P4114, DOI 10.1021/bi00798a016; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; WILSON IB, 1951, J BIOL CHEM, V190, P111	37	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8491	8499		10.1074/jbc.274.13.8491	http://dx.doi.org/10.1074/jbc.274.13.8491			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085081	hybrid			2022-12-27	WOS:000079451600023
J	Parent, JL; Labrecque, P; Orsini, MJ; Benovic, JL				Parent, JL; Labrecque, P; Orsini, MJ; Benovic, JL			Internalization of the TXA(2) receptor alpha and beta isoforms - Role of the differentially spliced COOH terminus in agonist-promoted receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; THROMBOXANE A(2) RECEPTOR; PLATELET-ACTIVATING-FACTOR; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC TAIL; ALPHA(2)-ADRENERGIC RECEPTORS; HOMOLOGOUS DESENSITIZATION; INTRACELLULAR TRAFFICKING; CHOLINERGIC RECEPTORS	Thromboxane A(2) (TXA(2)) potently stimulates platelet aggregation and smooth muscle constriction and is thought to play a role in myocardial infarction, atherosclerosis, and bronchial asthma, The TXA(2) receptor (TXA(2)R) is a member of the G protein-coupled receptor family and is found as two alternatively spliced isoforms, alpha (343 residues) and beta (407 residues), which share the first 328 residues. In the present report, we demonstrate by enzyme-linked immunosorbent assay and immunofluorescence microscopy that the TXA(2)R beta, but not the TXA(2)R alpha, undergoes agonist-induced internalization when expressed in HEK293 cells as well as several other cell types. Various dominant negative mutants were used to demonstrate that the internalization of the TXA(2)R beta is dynamin-, GRK-, and arrestin-dependent in HEK293 cells, suggesting the involvement of receptor phosphorylation and clathrin-coated pits in this process. Interestingly, the agonist-stimulated internalization of both the alpha and beta isoforms, but not of a mutant truncated after residue 328, can be promoted by overexpression of arrestin-3, identifying the C-tails of both receptors as necessary in arrestin-3 interaction, Simultaneous mutation of two dileucine motifs in the C-tail of TXA(2)R beta did not affect agonist-promoted internalization. Analysis of various C-tail deletion mutants revealed that a region between residues 355 and 366 of the TXA(2)R beta is essential for agonist-promoted internalization. These data demonstrate that alternative splicing of the TXA(2)R plays a critical role in regulating arrestin binding and subsequent receptor internalization.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu						BARAK LS, 1994, J BIOL CHEM, V269, P2790; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORN GW, 1991, J PHARMACOL EXP THER, V259, P228; DORN GW, 1992, AM J PHYSIOL, V31, pC991; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HALUSHKA PV, 1995, J LIPID MEDIAT CELL, V12, P361, DOI 10.1016/0929-7855(95)00023-J; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hermans E, 1996, MOL PHARMACOL, V49, P365; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; KONG GH, 1994, J BIOL CHEM, V269, P13084; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MORO O, 1993, J BIOL CHEM, V268, P6862; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P379, DOI 10.1016/0929-7855(95)00024-K; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OKWU AK, 1992, J PHARMACOL EXP THER, V262, P238; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Petrou C, 1997, J BIOL CHEM, V272, P2326; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Roettger BF, 1997, MOL PHARMACOL, V51, P357; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Sakai K, 1996, J PHARMACOL EXP THER, V276, P829; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SPURNEY RF, 1994, AM J PHYSIOL, V267, pF467, DOI 10.1152/ajprenal.1994.267.3.F467; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TSUGA H, 1994, J BIOL CHEM, V269, P32522; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; VANKOPPEN CJ, 1995, EUR J BIOCHEM, V234, P536; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; Yukawa M, 1997, CIRC RES, V80, P551, DOI 10.1161/01.RES.80.4.551; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	80	170	176	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8941	8948		10.1074/jbc.274.13.8941	http://dx.doi.org/10.1074/jbc.274.13.8941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085139	hybrid			2022-12-27	WOS:000079451600081
J	Yanaga, F; Morimoto, S; Ohtsuki, I				Yanaga, F; Morimoto, S; Ohtsuki, I			Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; PROTEIN-C GENE; MISSENSE MUTATION; ALPHA-TROPOMYOSIN; SUDDEN-DEATH; MYOSIN; EXPRESSION; REPLACEMENT; COMPONENTS	Human wild-type cardiac troponin T, I, C and five troponin T mutants (I79N, R92Q, F110I, E244D, and R278C) causing familial hypertrophic cardiomyopathy were expressed in Escherichia coli, and then were purified and incorporated into rabbit cardiac myofibrils using a troponin exchange technique. The Ca2+-sensitive ATPase activity of these myofibrillar preparations was measured in order to examine the functional consequences of these troponin mutations. An I79N troponin T mutation was found to cause a definite increase in Ca2+ sensitivity of the myofibrillar ATPase activity without inducing any significant change in the maximum level of ATPase activity. A detailed analysis indicated the inhibitory action of troponin I to be impaired by the I79N troponin T mutation. Two more troponin T mutations (R92Q and R278C) were also found to have a Ca2+-sensitizing effect without inducing any change in maximum ATPase activity. Two other troponin T mutations (F110I and E244D) had no Ca2+-sensitizing effects on the ATPase activity, but remarkably potentiated the maximum level of ATPase activity. These findings indicate that hypertrophic cardiomyopathy-linked troponin T mutations have at least two different effects on the Ca2+-sensitive ATPase activity, Ca2+-sensitization and potentiation of the maximum level of the ATPase activity.	Kyushu Univ, Fac Med, Dept Clin Pharmacol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Yanaga, F (corresponding author), Kyushu Univ, Fac Med, Dept Clin Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yanaga@clipharm.med.kyushu-u.ac.jp		Morimoto, Sachio/0000-0001-9171-3636				BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Bottinelli R, 1998, CIRC RES, V82, P106; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HATAKENAKA M, 1991, BIOCHEM BIOPH RES CO, V181, P1022, DOI 10.1016/0006-291X(91)92039-M; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Marian AJ, 1997, CIRC RES, V81, P76, DOI 10.1161/01.RES.81.1.76; MARIAN AJ, 1995, CIRCULATION, V92, P1336, DOI 10.1161/01.CIR.92.5.1336; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; PAN BS, 1987, J BIOL CHEM, V262, P7839; POTTER K, 1996, NAT GENET, V13, P63; RUEGG JC, 1986, CALCIUM MUSCLE ACTIV, P183; SHIRAISHI F, 1992, J BIOCHEM-TOKYO, V111, P61, DOI 10.1093/oxfordjournals.jbchem.a123719; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; YAMAMOTO K, 1982, J BIOCHEM-TOKYO, V93, P1061	32	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8806	8812		10.1074/jbc.274.13.8806	http://dx.doi.org/10.1074/jbc.274.13.8806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085122	hybrid			2022-12-27	WOS:000079451600064
J	Kroll, M; Margottin, F; Kohl, A; Renard, P; Durand, H; Concordet, JP; Bachelerie, F; Arenzana-Seisdedos, F; Benarous, R				Kroll, M; Margottin, F; Kohl, A; Renard, P; Durand, H; Concordet, JP; Bachelerie, F; Arenzana-Seisdedos, F; Benarous, R			Inducible degradation of I kappa B alpha by the proteasome requires interaction with the F-box protein h-beta TrCP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN PROTEOLYSIS MACHINERY; VIRUS EXPRESSION SYSTEM; PRECURSOR P105; VPU PROTEIN; CELL-CYCLE; ACTIVATION; PHOSPHORYLATION; PATHWAY; COMPLEX; KINASE	Activation of NF-kappa B transcription factors requires phosphorylation and ubiquitin-proteasome-dependent degradation of I kappa B proteins. We provide evidence that a human F-box protein, h-beta TrCP, a component of Skp1-Cullin-F-box protein (SCF) complexes, a new class of E3 ubiquitin ligases, is essential for inducible degradation of I kappa B alpha. beta TrCP associates with Ser(32)-Ser(36) phosphorylated, but not with unmodified I kappa B alpha or Ser(32)-Ser(36) phosphorylation-deficient mutants. Expression of a F-box-deleted beta TrCP inhibits I kappa B alpha degradation, promotes accumulation of phosphorylated Ser(32)-Ser(36) I kappa B alpha, and prevents NF-kappa B-dependent transcription. Our findings indicate that beta TrCP is the adaptor protein required for I kappa B alpha recognition by the SCFbeta TrCP E3 complex that ubiquitinates I kappa B alpha and makes it a substrate for the proteasome.	Inst Cochin Genet Mol, INSERM CJF9703, F-75014 Paris, France; Univ Paris 05, ICGM, U129 INSERM, F-75014 Paris, France; Inst Pasteur, Unite Immunol Virale, F-75724 Paris, France; Inst Pasteur, Grp Bunyavirides, Unite Arbovirus & Virus Fievres Hemorrag, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benarous, R (corresponding author), Inst Cochin Genet Mol, INSERM CJF9703, F-75014 Paris, France.		Arenzana-Seisdedos, Fernando/E-5835-2016; concordet, jean-paul/C-3417-2015; BACHELERIE, FRANCOISE/F-8823-2013; Margottin-Goguet, Florence/F-9272-2013	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Margottin-Goguet, Florence/0000-0002-3124-6690; Durand, Herve/0000-0002-8167-4693; Concordet, Jean-Paul/0000-0001-8924-4316				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Blasey HD, 1997, CYTOTECHNOLOGY, V24, P65, DOI 10.1023/A:1007974121182; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haas AL, 1997, FASEB J, V11, P1257; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Hiscott J, 1997, J LEUKOCYTE BIOL, V62, P82, DOI 10.1002/jlb.62.1.82; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LILJESTROM P, 1995, CURRENT PROTOCOLS MO, V2; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	112	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7941	7945		10.1074/jbc.274.12.7941	http://dx.doi.org/10.1074/jbc.274.12.7941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075690	hybrid			2022-12-27	WOS:000079268100049
J	Jaquemar, D; Schenker, T; Trueb, B				Jaquemar, D; Schenker, T; Trueb, B			An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE ANION-EXCHANGER; MEMBRANE-PROTEINS; SERINE-PROTEASE; MESSENGER-RNA; CELLS; DNA; HYBRIDIZATION; INSITU; ENTRY; CA2+	We have identified a novel transformation-sensitive mRNA, which is present in cultured fibroblasts but is lacking in SV40 transformed cells as well as in many mesenchymal tumor cell lines. The corresponding gene is located on human chromosome 8 in band 8q13, The open reading frame of the mRNA encodes a protein of 1119 amino acids forming two distinct domains. The N-terminal domain consists of 18 repeats that are related to the cytoskeletal protein ankyrin, The C-terminal domain contains six putative transmembrane segments that resemble many ion channels. This overall structure is reminiscent of TRP-like proteins that function as store-operated calcium channels. The novel protein with an M-r of 130 kDa is expressed at a very low level in human fibroblasts and at a moderate level in liposarcoma cells. Overexpression in eukaryotic cells appears to interfere with normal growth, suggesting that it might play a direct or indirect role in signal transduction and growth control.	Univ Bern, ME Muller Inst, CH-3010 Bern, Switzerland	University of Bern	Jaquemar, D (corresponding author), Univ Bern, ME Muller Inst, CH-3010 Bern, Switzerland.		Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; DUBBELMAN TMAR, 1982, BIOCHIM BIOPHYS ACTA, V693, P177, DOI 10.1016/0005-2736(82)90485-0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Harlow E., 1988, ANTIBODIES LAB MANUA; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hynes RO, 1990, FIBRONECTINS; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SCHENKER T, 1994, J BIOL CHEM, V269, P25447; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TAM LY, 1994, J BIOL CHEM, V269, P32542; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	33	222	252	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7325	7333		10.1074/jbc.274.11.7325	http://dx.doi.org/10.1074/jbc.274.11.7325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066796	hybrid			2022-12-27	WOS:000079078400068
J	Rubio, F; Schwarz, M; Gassmann, W; Schroeder, JI				Rubio, F; Schwarz, M; Gassmann, W; Schroeder, JI			Genetic selection of mutations in the high affinity K+ transporter HKT1 that define functions of a loop site for reduced Na+ permeability and increased Na+ tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SALT TOLERANCE; POTASSIUM-TRANSPORT; PLASMA-MEMBRANE; HIGHER-PLANTS; ARABIDOPSIS-THALIANA; CORN ROOTS; YEAST; ATPASE; CHANNELS	Potassium is an important macronutrient required for plant growth, whereas sodium (Na+) can be toxic at high concentrations. The wheat K+ uptake transporter HKT1 has been shown to function in yeast and oocytes as a high affinity K+-Na+ cotransporter, and as a low affinity Na+ transporter at high external Naf, A previous study showed that point mutations in HKT1, which confer enhancement of Na+ tolerance to yeast, can be isolated by genetic selection. Here we report on the isolation of mutations in new domains of HKT1 showing further large increases in Na+ tolerance. By selection in a Na+ ATPase deletion mutant of yeast that shows a high Na+ sensitivity, new HKT1 mutants at positions Gln-270 and Asn-365 were isolated. Several independent mutations were isolated at the Asn-365 site. N365S dramatically increased Naf tolerance in yeast compared with all other HKT1 mutants. Cation uptake experiments in yeast and biophysical characterization in Xenopus oocytes showed that the mechanisms underlying the Na+ tolerance conferred by the N365S mutant were: reduced inhibition of high affinity Rb+ (K+) uptake at high Na+ concentrations, reduced low affinity Na+ uptake, and reduced Na+ to K+ content ratios in yeast. In addition, the N365S mutant could be clearly distinguished from less Na+-tolerant HKT1 mutants by a markedly decreased relative permeability for Na+ at high Na+ concentrations, The new mutations contribute to the identification of new functional domains and an amino acid in a loop domain that is involved in cation specificity of a plant high affinity K+ transporter and will be valuable for molecular analyses of Na+ transport mechanisms and stress in plants.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Schroeder, JI (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	Julian@biomail.ucsd.edu	Rubio, Francisco/ABF-8662-2020; Rubio, Francisco/K-2854-2014	Rubio, Francisco/0000-0001-7640-9548; Rubio, Francisco/0000-0001-7640-9548; Schroeder, Julian/0000-0002-3283-5972; Gassmann, Walter/0000-0002-7527-0385				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEESEMAN JM, 1980, PLANT PHYSIOL, V65, P1139, DOI 10.1104/pp.65.6.1139; Diatloff E, 1998, FEBS LETT, V432, P31, DOI 10.1016/S0014-5793(98)00833-3; Ding L, 1997, PLANT PHYSIOL, V113, P795, DOI 10.1104/pp.113.3.795; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; EPSTEIN E, 1965, P NATL ACAD SCI USA, V53, P1320, DOI 10.1073/pnas.53.6.1320; EPSTEIN E, 1976, TRANSPORT PLANTS B, V2, P70; FERNANDO M, 1992, PLANT PHYSIOL, V100, P1269, DOI 10.1104/pp.100.3.1269; Fersht A., 1985, ENZYME STRUCTURE MEC; Fu HH, 1998, PLANT CELL, V10, P63, DOI 10.1105/tpc.10.1.63; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; GLASS ADM, 1978, CAN J BOT, V56, P1759, DOI 10.1139/b78-209; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEGINBOTHAM L, 1993, BIOPHYS J, V64, pA16; Hille B., 1992, IONIC CHANNELS EXCIT; Kim EJ, 1998, PLANT CELL, V10, P51, DOI 10.1105/tpc.10.1.51; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KOCHIAN LV, 1982, PLANT PHYSIOL, V70, P1723, DOI 10.1104/pp.70.6.1723; Maathuis FJM, 1996, PLANT PHYSIOL, V112, P1609, DOI 10.1104/pp.112.4.1609; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUNNS R, 1993, PLANT CELL ENVIRON, V16, P15, DOI 10.1111/j.1365-3040.1993.tb00840.x; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; OMIELAN JA, 1991, GENOME, V34, P961, DOI 10.1139/g91-149; Quintero FJ, 1997, FEBS LETT, V415, P206, DOI 10.1016/S0014-5793(97)01125-3; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santa-Maria GE, 1997, PLANT CELL, V9, P2281, DOI 10.1105/tpc.9.12.2281; Schachtman DP, 1997, P NATL ACAD SCI USA, V94, P11079, DOI 10.1073/pnas.94.20.11079; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	49	99	110	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6839	6847		10.1074/jbc.274.11.6839	http://dx.doi.org/10.1074/jbc.274.11.6839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066736	hybrid			2022-12-27	WOS:000079078400008
J	Stafforini, DM; Tjoelker, LW; McCormick, SPA; Vaitkus, D; McIntyre, TM; Gray, PW; Young, SG; Prescott, SM				Stafforini, DM; Tjoelker, LW; McCormick, SPA; Vaitkus, D; McIntyre, TM; Gray, PW; Young, SG; Prescott, SM			Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN B100; NECROTIZING ENTEROCOLITIS; TRANSGENIC MICE; ANTAGONIST; EXPRESSION; PAF; ASSOCIATION; MODEL	The platelet-activating factor acetylhydrolases are enzymes that were initially characterized by their ability to hydrolyze platelet-activating factor (PAF). In human plasma, PAF acetylhydrolase (EC 3.1.1.47) circulates in a complex with low density lipoproteins (LDL) and high density lipoproteins (HDL). This association defines the physical state of PAF acetylhydrolase, confers a long half-life, and is a major determinant of its catalytic efficiency in vivo. The lipoprotein-associated enzyme accounts for all of the PAF hydrolysis in plasma but only two-thirds of the protein mass. To characterize the enzyme-lipoprotein interaction, we employed site-directed mutagenesis techniques. Two domains within the primary sequence of human PAF acetylhydrolase, tyrosine 205 and residues 115 and 116, were important for its binding to LDL. Mutation or deletion of those sequences prevented the association of the enzyme with lipoproteins. When residues 115 and 116 from human PAF acetylhydrolase were introduced into mouse PAF acetylhydrolase (which normally does not associate with LDL), the mutant mouse PAF acetylhydrolase associated with lipoproteins, To analyze the role of apolipoprotein (apo) B100 in the formation of the PAF acetylhydrolase-LDL complex, we tested the ability of PAF acetylhydrolase to bind to lipoproteins containing truncated forms of apoB, These studies indicated that the carboxyl terminus of apoB plays a key role in the association of PAF acetylhydrolase with LDL. These data on the molecular basis of the PAF acetylhydrolase-LDL association provide a new level of understanding regarding the pathway for the catabolism of PAF in human blood.	Univ Utah, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Cardiovasc Res & Training Inst, Salt Lake City, UT 84112 USA; ICOS Corp, Bothell, WA 98021 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Icos Corporation; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Stafforini, DM (corresponding author), Univ Utah, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Huntsman Canc Inst, 15 N 2030 East,Rm 2100, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu		McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA42014] Funding Source: Medline; NHLBI NIH HHS [HL41633, HL35828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, R01HL035828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blencowe C, 1995, J BIOL CHEM, V270, P31151, DOI 10.1074/jbc.270.52.31151; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Caplan MS, 1997, PEDIATR RES, V42, P779, DOI 10.1203/00006450-199712000-00010; Caplan MS, 1997, J PEDIATR GASTR NUTR, V24, P296, DOI 10.1097/00005176-199703000-00012; CHIESA GL, 1993, J BIOL CHEM, V268, P23747; Debek W, 1998, EXP TOXICOL PATHOL, V50, P19; Derewenda ZS, 1998, CELL MOL LIFE SCI, V54, P446, DOI 10.1007/s000180050172; FLESS GM, 1986, J BIOL CHEM, V261, P8712; Galloway SW, 1996, PANCREAS, V13, P140, DOI 10.1097/00006676-199608000-00004; Giral M, 1996, BRIT J PHARMACOL, V118, P1223, DOI 10.1111/j.1476-5381.1996.tb15527.x; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; Kim E, 1998, J LIPID RES, V39, P703; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Mathiak G, 1997, SHOCK, V7, P391, DOI 10.1097/00024382-199706000-00001; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Muguruma K, 1997, ADV EXP MED BIOL, V407, P379; Oh SO, 1997, J LAB CLIN MED, V130, P191, DOI 10.1016/S0022-2143(97)90095-0; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TSAOUSSIS V, 1994, J LIPID MEDIAT CELL, V9, P301; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; Wei YY, 1998, STRUCTURE, V6, P511, DOI 10.1016/S0969-2126(98)00052-5; YAMADA Y, 1994, P NATL ACAD SCI USA, V91, P10320, DOI 10.1073/pnas.91.22.10320	32	132	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7018	7024		10.1074/jbc.274.11.7018	http://dx.doi.org/10.1074/jbc.274.11.7018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066756	hybrid			2022-12-27	WOS:000079078400028
J	Brown, LM; Burbach, BJ; McKenzie, BA; Connell, GJ				Brown, LM; Burbach, BJ; McKenzie, BA; Connell, GJ			A cis-acting A-U sequence element induces kinetoplastid U-insertions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA LIGASE ACTIVITIES; MITOCHONDRIAL RIBONUCLEOPROTEIN COMPLEXES; LEISHMANIA-TARENTOLAE MITOCHONDRIA; TRYPANOSOMA-BRUCEI MITOCHONDRIA; CYTOCHROME-B TRANSCRIPTS; MESSENGER-RNA; IN-VITRO; GUIDE RNAS; SECONDARY STRUCTURE; URIDINE INSERTION	A 34-nucleotide A-U sequence located immediately upstream of the editing sites of the Leishmania tarentolae cytochrome b mRNA induces a mitochondrial extract to insert U nucleotides independent of guide RNA. Insertions are localized to positions immediately 5' and 3' of the A-U sequence. When placed within an unedited mammalian transcript, the A-Il sequence is sufficient to induce U-insertions. The sequence has a high degree of similarity with the templating nucleotides of a cytochrome b guide RNA and with a sequence adjacent to the editing sites in ND7 mRNA, the other characterized kinetoplastid mRNA supporting guide RNA-independent U-insertions. At least one protein specifically interacts with the A-U sequence. The reaction is consistent with a mechanism proposed for guide RNA-directed editing.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Connell, GJ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	gconnell@lenti.med.umn.edu		Burbach, Brandon/0000-0003-0922-7722	NIAID NIH HHS [R29-AI41138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; Bohjanen PR, 1996, NUCLEIC ACIDS RES, V24, P3733, DOI 10.1093/nar/24.19.3733; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Connell GJ, 1997, J BIOL CHEM, V272, P4212, DOI 10.1074/jbc.272.7.4212; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HUANG J, 1988, NUCLEIC ACIDS RES, V16, P9737, DOI 10.1093/nar/16.20.9737; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MITTELMEIER TM, 1995, MOL CELL BIOL, V15, P780; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; PAN T, 1993, GENE, V125, P111, DOI 10.1016/0378-1119(93)90317-V; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Puttaraju M, 1995, Nucleic Acids Symp Ser, P49; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; SCHINDEWOLF CA, 1995, NUCLEIC ACIDS RES, V23, P1133, DOI 10.1093/nar/23.7.1133; SCHMID B, 1995, NUCLEIC ACIDS RES, V23, P3093, DOI 10.1093/nar/23.16.3093; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; Sloof P, 1997, TRENDS MICROBIOL, V5, P189, DOI 10.1016/S0966-842X(97)01034-2; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; SUGISAKI H, 1993, J BIOL CHEM, V268, P887; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	42	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6295	6304		10.1074/jbc.274.10.6295	http://dx.doi.org/10.1074/jbc.274.10.6295			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037718	hybrid			2022-12-27	WOS:000078902800040
J	Gasic, S; Tian, B; Green, A				Gasic, S; Tian, B; Green, A			Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing G(i) protein concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; LIPOPROTEIN-LIPASE ACTIVITY; INDUCED INSULIN-RESISTANCE; ADENYLATE-CYCLASE; DOWN-REGULATION; NICOTINIC-ACID; RAT ADIPOCYTES; FAT-CELLS; HETEROLOGOUS DESENSITIZATION; SIGNAL-TRANSDUCTION	Prolonged treatment (12-24 h) of adipocytes with tumor necrosis factor alpha (TNF alpha) stimulates Lipolysis, We have investigated the hypothesis that TNF alpha stimulates lipolysis by blocking the action of endogenous adenosine, Adipocytes were incubated for 48 h with TNF alpha, and lipolysis was measured in the absence or presence of adenosine deaminase, Without adenosine deaminase, the rate of glycerol release was 2-3-fold higher in the TNF alpha-treated cells, but with adenosine deaminase lipolysis increased in the controls to approximately that in the TNF alpha-treated cells. This suggests that TNF alpha blocks adenosine release or prevents its antilipolytic effect. Both N-6-phenylisopropyl adenosine and nicotinic acid were less potent and efficacious inhibitors of lipolysis in treated cells. A decrease in the concentration of alpha-subunits of all three G(i) subtypes was detected by Western blotting without a change in G(s)proteins or beta-subunits. G(i2)alpha was about 50% of control, whereas G(i1)alpha and G(i3)alpha were about 20 and 40% of control values, respectively. The time course of G(i) down-regulation correlated with the stimulation of Lipolysis, Furthermore, dawn-regulation of Gi by an alternative approach (prolonged incubation with N-6-phenylisopropyladenosine) stimulated lipolysis. These findings indicate that TNF alpha stimulates lipolysis by blunting endogenous inhibition of lipolysis. The mechanism appears to be a G(i) protein down-regulation.	Mary Imogene Bassett Hosp, Bassett Res Inst, Cooperstown, NY 13326 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Green, A (corresponding author), Mary Imogene Bassett Hosp, Bassett Res Inst, 1 Atwell Rd, Cooperstown, NY 13326 USA.	allan.green@bassett.org						AKTORIES K, 1980, N-S ARCH PHARMACOL, V312, P167, DOI 10.1007/BF00569726; AKTORIES K, 1983, FEBS LETT, V156, P88, DOI 10.1016/0014-5793(83)80254-3; DOERRLER W, 1994, CYTOKINE, V6, P478, DOI 10.1016/1043-4666(94)90074-4; DORIS R, 1994, BIOCHEM J, V297, P41, DOI 10.1042/bj2970041; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; FRAZE E, 1985, J CLIN ENDOCR METAB, V61, P807, DOI 10.1210/jcem-61-5-807; GARCIASAINZ JA, 1985, BIOCHEM J, V232, P439, DOI 10.1042/bj2320439; GASIC S, 1995, BIOCHEM PHARMACOL, V49, P785, DOI 10.1016/0006-2952(94)00537-V; Green A, 1996, AM J PHYSIOL-ENDOC M, V271, pE271, DOI 10.1152/ajpendo.1996.271.2.E271; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; GREEN A, 1992, J BIOL CHEM, V267, P3223; GREEN A, 1990, J BIOL CHEM, V265, P5206; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Jensen MD, 1998, AM J CLIN NUTR, V67, p531S, DOI 10.1093/ajcn/67.3.531S; KAWAKAMI M, 1981, J EXP MED, V154, P631, DOI 10.1084/jem.154.3.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCUS C, 1989, PEDIATR RES, V26, P255, DOI 10.1203/00006450-198909000-00020; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MILLIGAN G, 1991, TRENDS PHARMACOL SCI, V12, P207, DOI 10.1016/0165-6147(91)90551-3; Mittelman SD, 1997, J CLIN INVEST, V100, P3121, DOI 10.1172/JCI119867; OGAWA H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P131, DOI 10.1016/0005-2760(89)90246-4; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; RANDLE PJ, 1963, LANCET, V1, P785; REITHMANN C, 1991, EUR J PHARM-MOLEC PH, V206, P53, DOI 10.1016/0922-4106(91)90146-9; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schwabe U, 1975, Adv Cyclic Nucleotide Res, V5, P569; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; SPRANG SR, 1990, TRENDS BIOCHEM SCI, V15, P366, DOI 10.1016/0968-0004(90)90228-4; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; WIESER PB, 1975, ENDOCRINOLOGY, V96, P1221, DOI 10.1210/endo-96-5-1221; WILLIAMSON JR, 1966, P NATL ACAD SCI USA, V56, P247, DOI 10.1073/pnas.56.1.247	43	109	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6770	6775		10.1074/jbc.274.10.6770	http://dx.doi.org/10.1074/jbc.274.10.6770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037777	hybrid			2022-12-27	WOS:000078902800099
J	Suzuki, M; Sato, J; Kutsuwada, K; Ooki, G; Imai, M				Suzuki, M; Sato, J; Kutsuwada, K; Ooki, G; Imai, M			Cloning of a stretch-inhibitable nonselective cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVATED ION CHANNELS; PARATHYROID-HORMONE; MDX-MYOTUBES; GADOLINIUM; RECEPTOR; PRESSURE; TUBULE; BLOCK; CELLS	A homologue of the capsaicin receptor-nonselective cation channel was cloned from the rat kidney to investigate a mechanosensitive channel. We found this channel to be inactivated by membrane stretch and have designated it stretch-inactivated channel (SIC), SIC encodes a 563-amino acid protein with putative six transmembrane segments. The cDNA was expressed in mammalian cells, and electophysiological studies were performed. SIG-induced large cation currents were found to be regulated by cell volume, with currents being stimulated by cell shrinkage and inhibited by cell swelling. Single channel analysis showed a conductance of 250 pS with cation permeability (PC1/PNa < 0.1), and the channel possessed some of the characteristics of a stretch-inactivated channel in that it was permeable to calcium, sensitive to membrane stretch, and blocked by Gd3+. Therefore, we cloned one of the mechanosensitive cation channels of mammals, which is considered to regulate Ca2+ influx in response to mechanical stress on the cell membrane.	Jichi Med Sch, Dept Pharmacol, Minamimaki, Tochigi 32904, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minamimaki, Tochigi 32904, Japan.	macsuz@jichi.ac.jp						Bourque CW, 1997, ANNU REV PHYSIOL, V59, P601, DOI 10.1146/annurev.physiol.59.1.601; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FRANCO A, 1991, BIOPHYS J, V59, P1164, DOI 10.1016/S0006-3495(91)82332-3; HILLE B, 1994, ION CHANNELS EXCITAB, P337; HISADA T, 1993, PFLUG ARCH EUR J PHY, V422, P393, DOI 10.1007/BF00374296; HOLSTEINRATHLOU NH, 1986, ACTA PHYSIOL SCAND, V126, P333, DOI 10.1111/j.1748-1716.1986.tb07824.x; Maniatis T., 1982, MOL CLONING; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; MORRIS CE, 1991, SCIENCE, V251, P1246, DOI 10.1126/science.1706535; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SAKMANN B, 1985, NATURE, V318, P538, DOI 10.1038/318538a0; SAKMANN B, 1995, SINGLE CHANNEL RECOR, P3; SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370; TANIGUCHI J, 1994, J MEMBRANE BIOL, V140, P123; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; YANG XC, 1993, NONSELECTIVE CATION	20	99	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6330	6335		10.1074/jbc.274.10.6330	http://dx.doi.org/10.1074/jbc.274.10.6330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037722	hybrid			2022-12-27	WOS:000078902800044
J	George, CH; Kendall, JM; Evans, WH				George, CH; Kendall, JM; Evans, WH			Intracellular trafficking pathways in the assembly of connexins into gap junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CALCIUM ENVIRONMENTS; DEPENDENT TRANSPORT; HELA-CELLS; PROTEIN; COMMUNICATION; GOLGI; CHANNEL; RAT	Trafficking pathways underlying the assembly of connexins into gap junctions were examined using living COS-7 cells expressing a range of connexin-aequorin (Cx-Aeq) chimeras. By measuring the chemiluminescence of the aequorin fusion partner, the translocation of oligomerized connexins from intracellular stores to the plasma membrane was shown to occur at different rates that depended on the connexin isoform. Treatment of COS-7 cells expressing Cx32-Aeq and Cx43-Aeq with brefeldin A inhibited the movement of these chimera to the plasma membrane by 84 +/- 4 and 88 +/- 4%, respectively. Nocodazole treatment of the cells expressing Cx32-Aeq and Cx43-Aeq produced 29 +/- 16 and 4 +/- 7% inhibition, respectively. in contrast, the transport of Cx26 to the plasma membrane, studied using a construct (Cx26/43T-Aeq) in which the short cytoplasmic carboxyl-terminal tail of Cx26 was replaced with the extended carboxyl terminus of Cx43, was inhibited 89 +/- 5% by nocodazole and was minimally affected by exposure of cells to brefeldin A (17 +/- 11%). The transfer of Lucifer yellow across gap junctions between cells expressing wild-type Cx32, Cx43, and the corresponding Cx32-Aeq and Cx43-Aeq chimeras was reduced by nocodazole treatment and abolished by brefeldin A treatment. However, the extent of dye coupling between cells expressing wild-type Cx26 or the Cx26/43T-Aeq chimeras was not significantly affected by brefeldin A treatment, but after nocodazole treatment, transfer of dye to neighboring cells was greatly reduced. These contrasting effects of brefeldin A and nocodazole on the trafficking properties and intercellular dye transfer are interpreted to suggest that two pathways contribute to the routing of connexins to the gap junction.	Univ Wales, Coll Med, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	George, CH (corresponding author), Wales Heart Res Inst, Dept Cardiol, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.			George, Christopher/0000-0001-9852-1135				BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BLENNERHASSETT MG, 1991, AM J PHYSIOL, V261, pC1001, DOI 10.1152/ajpcell.1991.261.6.C1001; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; CHEN L, 1995, J THEOR BIOL, V176, P39, DOI 10.1006/jtbi.1995.0174; CIDARREGUI A, 1995, J NEUROSCI, V15, P4259; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Diez JA, 1998, GAP JUNCTIONS, P130; Draguhn A, 1998, NATURE, V394, P189, DOI 10.1038/28184; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FALK MM, 1997, EMBO J, V16, P2704; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; George CH, 1998, BIOCHEM BIOPH RES CO, V247, P785, DOI 10.1006/bbrc.1998.8835; George CH, 1998, J BIOL CHEM, V273, P29822, DOI 10.1074/jbc.273.45.29822; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HAMMOND C, 1994, J CELL BIOL, V126, P231; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIDDER GM, 1987, P NATL ACAD SCI USA, V84, P3718, DOI 10.1073/pnas.84.11.3718; KOJIMA T, 1994, J CELL SCI, V107, P3579; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Martin PEM, 1998, J BIOL CHEM, V273, P1719, DOI 10.1074/jbc.273.3.1719; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nadarajah B, 1998, J NEUROSCI, V18, P7881; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Nicholson BJ, 1998, GAP JUNCTIONS, P3; NILSSON T, 1997, MOL B INT U, P189; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POUS C, 1992, EUR J BIOCHEM, V203, P277, DOI 10.1111/j.1432-1033.1992.tb19857.x; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; Reimann J, 1997, CURR OPIN IMMUNOL, V9, P462, DOI 10.1016/S0952-7915(97)80096-9; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Torok K, 1997, BIOCHEM J, V326, P479; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; vanDeurs B, 1996, J CELL SCI, V109, P1655; Wacker I, 1997, J CELL SCI, V110, P1453; Wang XG, 1996, PFLUG ARCH EUR J PHY, V431, P844	54	99	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8678	8685		10.1074/jbc.274.13.8678	http://dx.doi.org/10.1074/jbc.274.13.8678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085106	hybrid			2022-12-27	WOS:000079451600048
J	Ito, M; Yu, RN; Jameson, JL; Ito, M				Ito, M; Yu, RN; Jameson, JL; Ito, M			Mutant vasopressin precursors that cause autosomal dominant neurohypophyseal diabetes insipidus retain dimerization and impair the secretion of wild-type proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPHYSIN-II GENE; SINGLE-BASE SUBSTITUTION; CODING REGION; ARGININE-VASOPRESSIN; BIOSYNTHETIC PRECURSOR; MUTATION; OXYTOCIN; IDENTIFICATION; KINDREDS; SIGNAL	Autosomal dominant familial neurohypophyseal diabetes insipidus is caused by mutations in the arginine vasopressin (AVP) gene. We demonstrated recently that mutant AVP precursors accumulate within the endoplasmic reticulum of neuronal cells, leading to cellular toxicity. In this study, the possibility that mutant AVP precursors interact with wild-type (WT) proteins to alter their processing and function was explored. WT and mutant precursors were epitope-tagged to allow them to be distinguished in transfected cells. An in vivo cross-linking reaction revealed homo- and heterodimer formation between WT and mutant precursors. Mutant precursors were also shown to impair intracellular trafficking of WT precursors from the endoplasmic reticulum to the Golgi apparatus. In addition to the cytotoxicity caused by mutant AVP precursors, the interaction between the WT and mutant precursors suggests that a dominant-negative mechanism may also contribute to the pathogenesis of familial neurohypophyseal diabetes insipidus.	Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University	Jameson, JL (corresponding author), Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Tarry 15-709,303 E Chicago Ave, Chicago, IL 60611 USA.	ljameson@nwu.edu		Jameson, James/0000-0001-9538-4059				ANDO S, 1987, J BIOL CHEM, V262, P12962; ANGAL S, 1982, BIOCHEMISTRY-US, V21, P1574, DOI 10.1021/bi00536a017; BAHNSEN U, 1992, EMBO J, V11, P19, DOI 10.1002/j.1460-2075.1992.tb05022.x; BAYLIS PH, 1995, ENDOCRINOLOGY, P406; BERGERON C, 1991, ACTA NEUROPATHOL, V81, P345, DOI 10.1007/BF00305879; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BRESLOW E, 1971, J BIOL CHEM, V246, P5179; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BRESLOW E, 1973, BIOCHEMISTRY-US, V12, P4644, DOI 10.1021/bi00747a016; BRESLOW E, 1972, MOL PHARMACOL, V8, P75; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; Calvo B, 1998, J CLIN ENDOCR METAB, V83, P995, DOI 10.1210/jc.83.3.995; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; Heppner C, 1998, J CLIN ENDOCR METAB, V83, P693, DOI 10.1210/jc.83.2.693; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ITO M, 1991, J CLIN INVEST, V87, P725, DOI 10.1172/JCI115052; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KANMERA T, 1985, J BIOL CHEM, V260, P8474; KRISHNAMANI MRS, 1993, J CLIN ENDOCR METAB, V77, P596, DOI 10.1210/jc.77.3.596; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCLEOD JF, 1993, J CLIN ENDOCR METAB, V77, pA599, DOI 10.1210/jcem.77.3.8370682; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; NAGASAKI H, 1995, J CLIN ENDOCR METAB, V80, P1352, DOI 10.1210/jc.80.4.1352; NICOLAS P, 1978, J BIOL CHEM, V253, P2633; Rauch F, 1996, CLIN ENDOCRINOL, V44, P45, DOI 10.1046/j.1365-2265.1996.628449.x; REPASKE DR, 1994, J CLIN ENDOCR METAB, V79, P421, DOI 10.1210/jc.79.2.421; Rittig S, 1996, AM J HUM GENET, V58, P107; Rutishauser J, 1996, J CLIN ENDOCR METAB, V81, P192, DOI 10.1210/jc.81.1.192; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Ueta Y, 1996, J CLIN ENDOCR METAB, V81, P1787, DOI 10.1210/jc.81.5.1787; YUASA H, 1993, J CLIN ENDOCR METAB, V77, P600, DOI 10.1210/jc.77.3.600	39	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9029	9037		10.1074/jbc.274.13.9029	http://dx.doi.org/10.1074/jbc.274.13.9029			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085151	hybrid			2022-12-27	WOS:000079451600093
J	Nancy, V; Wolthuis, RMF; de Tand, MF; Janoueix-Lerosey, I; Bos, JL; de Gunzburg, J				Nancy, V; Wolthuis, RMF; de Tand, MF; Janoueix-Lerosey, I; Bos, JL; de Gunzburg, J			Identification and characterization of potential effector molecules of the Ras-related GTPase Rap2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION STIMULATOR; NUCLEOTIDE EXCHANGE FACTOR; MAP KINASE ACTIVATION; C-FOS PROMOTER; PROTEIN-KINASE; PLASMA-MEMBRANE; BINDING DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; FACTOR RLF	In search for effecters of the Ras-related GTPase Rapa, we used the yeast two-hybrid method and identified the C-terminal Ras/Rap interaction domain of the Ral exchange factors (RalGEFs) Ral GDP dissociation stimulator (RalGDS), RalGDS-like (RGL), and RalGDS-like factor (Rlf), These proteins, which also interact with activated Ras and Rap1, are effecters of Ras and mediate the activation of Ral in response to the activation of Ras. Here we show that the full-length RalGEFs interact with the GTP-bound form of Rap2 in the two-hybrid system as well as in vitro. When co-transfected in HeLa cells, an activated Rapa mutant (Rap2Val-12) but not an inactive protein (Rap2Ala-35) co-immunoprecipitates with RalGDS and Rlf; moreover, Rap2-RalGEF complexes can be isolated from the particulate fraction of transfected cells and were localized by confocal microscopy to the resident compartment of Rap2, i.e. the endoplasmic reticulum. However, the overexpression of activated Rap2 neither leads to the activation of the Ral GTPase via RalGEFs nor inhibits Ras-dependent Ral activation in vivo. Several hypotheses that could explain these results, including compartmentalization of proteins involved in signal transduction, are discussed. Our results suggest that in cells, the interaction of Rap2 with RalGEFs might trigger other cellular responses than activation of the Ral GTPase.	Inst Curie, INSERM, U248, Sect Rech, Paris 05, France; Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Utrecht University	de Gunzburg, J (corresponding author), Inst Curie, INSERM, U248, Sect Rech, 26 Rue Ulm, Paris 05, France.	gunzburg@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Wolthuis, Rob/0000-0002-3109-1588				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BERANGER F, 1991, ONCOGENE, V6, P1835; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Esser D, 1998, BIOCHEMISTRY-US, V37, P13453, DOI 10.1021/bi9811664; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; Murai H, 1997, J BIOL CHEM, V272, P10483; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	72	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8737	8745		10.1074/jbc.274.13.8737	http://dx.doi.org/10.1074/jbc.274.13.8737			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085114	hybrid			2022-12-27	WOS:000079451600056
J	Pourquier, P; Ueng, LM; Fertala, J; Wang, D; Park, HJ; Essigmann, JM; Bjornsti, MA; Pommier, Y				Pourquier, P; Ueng, LM; Fertala, J; Wang, D; Park, HJ; Essigmann, JM; Bjornsti, MA; Pommier, Y			Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages - 7,8-dihydro-8-oxoguanine and 5-hydroxycytosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; ESCHERICHIA-COLI; ENDONUCLEASE-III; ABASIC SITES; CAMPTOTHECIN; CLEAVAGE; REPAIR; 8-HYDROXYGUANINE	We recently showed that abasic sites, uracil mismatches, nicks, and gaps can trap DNA topoisomerase I (top1) when these lesions are introduced in the vicinity of a top1 cleavage site (Pourquier, P., Ueng, L.-M., Kohlhagen, G., Mazumder, A, Gupta, Ri., Kohn, K. W., and Pommier, Y, (1997) J. Biol. Chem. 272, 7792-7796; Pourquier, P., Pilon, A. A, Kohlhagen, G., Mazumder, A., Sharma, A, and Pommier, Y. (1997) J. Biol. Chem. 26441-26447). In this study, we investigated the effects on top1 of an abundant base damage generated by various oxidative stresses: 7,8-dihydro-8-oxoguanine (8-oxoG). Using purified eukaryotic top1 and oligonucleotides containing the 8-oxoG modification, we found a 3-7-fold increase in top1-mediated DNA cleavage when 8-oxoG was present at the +1 or +2 position relative to the cleavage site. Another oxidative lesion, 8-hydroxycytosine, also enhanced top1 cleavage by a-fold when incorporated at the +1 position of the scissile strand. 8-oxoG at the +1 position enhanced noncovalent top1 DNA binding and had no detectable effect on DNA religation or on the incision step. top1 trapping by 8-oxoG was markedly enhanced when asparagine adjacent to the catalytic tyrosine was mutated to histidine, suggesting a direct interaction between this residue and the DNA major groove immediately downstream from the top1 cleavage site. Altogether, these results demonstrate that oxidative base lesions can increase top1 binding to DNA and induce top1 cleavage complexes.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University; Massachusetts Institute of Technology (MIT)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D02, Bethesda, MD 20892 USA.	pommier@nih.gov	Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005	NATIONAL CANCER INSTITUTE [R01CA058755, R35CA052127] Funding Source: NIH RePORTER; NCI NIH HHS [CA52127, CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; ENG WK, 1989, J BIOL CHEM, V264, P13373; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; FUJIMORI A, 1995, CANCER RES, V55, P1339; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hsieh T, 1994, Adv Pharmacol, V29A, P191; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Morham SG, 1996, MOL CELL BIOL, V16, P6804; Morningstar ML, 1997, CHEM RES TOXICOL, V10, P1345, DOI 10.1021/tx970052a; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1996, SEMIN ONCOL, V23, P3; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Wang D, 1997, BIOCHEMISTRY-US, V36, P8628, DOI 10.1021/bi970341y; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LK, 1997, BIOCHEMISTRY-US, V36, P3909, DOI 10.1021/bi962754p; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053	57	158	162	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8516	8523		10.1074/jbc.274.13.8516	http://dx.doi.org/10.1074/jbc.274.13.8516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085084	hybrid			2022-12-27	WOS:000079451600026
J	Musch, MW; Hubert, EM; Goldstein, L				Musch, MW; Hubert, EM; Goldstein, L			Volume expansion stimulates p72(syk) and p56(lyn) in skate erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN TYROSINE PHOSPHORYLATION; AMINO-ACID-SEQUENCE; BAND-3 PROTEIN; TAURINE EFFLUX; CROSS-LINKING; SYK; KINASE; TRANSPORT; ACTIVATION	Hypotonic volume expansion of skate erythrocytes rapidly stimulates the tyrosine phosphorylation of band 3, the membrane protein thought to mediate the osmotically sensitive taurine efflux, Skate erythrocytes possess numerous tyrosine kinases including p59fyn, p56lyn, pp60(src), and p72(syk), demonstrated by immune complex assays measuring autocatalytic kinase activity. Inclusion of the cytoplasmic domain of band 3 in this assay showed that only Syk and Lyn can directly phosphorylate the cytoplasmic domain of band 3, Upon cell volume expansion, Syk activity was increased as assessed by three different assays (immune complex assay measuring autophosphorylation, assay of the level of phosphotyrosine of the immunoprecipitated kinase, and assay of level of P-32 in the kinase immunoprecipitated from cells prelabeled with (PO4)-P-32 and then volume-expanded). The tyrosine kinase Lyn was also stimulated by volume expansion, most notably when analyzed by the latter two methods. Volume expansion stimulated a large increase in the ability of Syk to phosphorylate band 3 at times that coincide with the stimulation of taurine flux. The stilbene piceatannol inhibited Syk preferentially over Lyn and other tyrosine kinases and inhibited volume-stimulated taurine efflux in a concentration-dependent manner similar to that for the inhibition of Syk, Two major phosphorylation peaks were detected in tryptic digests of cdb3 separated by reverse phase HPLC, Edman degradation demonstrated a phosphotyrosine in a YXXL motif. In conclusion, p72(syk) appears to be a strong candidate as a pivotal signal-transducing step in the volume-activated taurine efflux in skate red cells. The level of band-3 phosphorylation may be regulated, in addition, by a protein-tyrosine phosphatase of the 1B variety.	Brown Univ, Div Biol & Med, Providence, RI 02912 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA; Univ Chicago, Inflammatory Bowel Dis Res Ctr, Chicago, IL 60637 USA	Brown University; Mount Desert Island Biological Laboratory; University of Chicago	Goldstein, L (corresponding author), Brown Univ, Div Biol & Med, Box GB-311, Providence, RI 02912 USA.	Leon_Goldstein@brown.edu			NIDDK NIH HHS [DK-47722, DK-42086, DK-38510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, R37DK047722, R01DK038510, R01DK047722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARI G, 1987, BIOCHEM BIOPH RES CO, V142, P587, DOI 10.1016/0006-291X(87)90314-7; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Fievet B, 1998, P NATL ACAD SCI USA, V95, P10996, DOI 10.1073/pnas.95.18.10996; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; Goldstein L, 1996, KIDNEY INT, V49, P1690, DOI 10.1038/ki.1996.249; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUBNER S, 1992, BIOCHEM J, V285, P17; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Minetti G, 1998, BIOCHEM J, V335, P305, DOI 10.1042/bj3350305; MUSCH MW, 1994, AM J PHYSIOL, V266, pR65, DOI 10.1152/ajpregu.1994.266.1.R65; Musch MW, 1996, J BIOL CHEM, V271, P21221, DOI 10.1074/jbc.271.35.21221; MUSCH MW, 1994, J BIOL CHEM, V269, P19683; Musch MW, 1998, AM J PHYSIOL-REG I, V274, pR1677, DOI 10.1152/ajpregu.1998.274.6.R1677; Peters JD, 1996, J BIOL CHEM, V271, P4755; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; TUY FPD, 1983, NATURE, V305, P435; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wang XY, 1997, J BIOCHEM-TOKYO, V121, P325; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Yan SR, 1997, J IMMUNOL, V158, P1902; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013; Zipser Y, 1996, BIOCHEM J, V314, P881, DOI 10.1042/bj3140881	28	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7923	7928		10.1074/jbc.274.12.7923	http://dx.doi.org/10.1074/jbc.274.12.7923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075687	hybrid			2022-12-27	WOS:000079268100046
J	Prichard, L; Deloulme, JC; Storm, DR				Prichard, L; Deloulme, JC; Storm, DR			Interactions between neurogranin and calmodulin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; BINDING-PROTEIN; NEUROMODULIN GAP-43; 2-HYBRID SYSTEM; SYNAPTIC TRANSMISSION; PHOSPHORYLATION SITE; SELECTIVE INCREASE; DEPENDENT TARGET; ADENYLYL-CYCLASE	Neurogranin is a neural-specific, calmodulin (CaM)binding protein that is phosphorylated by protein kinase C (PKC) within its IQ domain at serine 36. Since CaM binds to neurogranin through the IQ domain, PKC phosphorylation and CaM binding are mutually exclusive. Consequently, we hypothesize that neurogranin may function to concentrate CaM at specific sites in neurons and release free CaM in response to increased Ca2+ and PKC activation. However, it has not been established that neurogranin interacts with CaM in vivo, In this study, we examined this question using yeast two-hybrid methodology. We also searched for additional proteins that might interact with neurogranin by screening brain cDNA libraries. Our data illustrate that CaM binds to neurogranin in vivo and that CaM is the only neurogranin-interacting protein isolated from brain cDNA libraries. Single amino acid mutagenesis indicated that residues within the IQ domain are important for CaM binding to neurogranin in vivo. The Ile-33 --> Gin point mutant completely inhibited and Arg-38 --> Gin and Ser-36 --> Asp point mutants reduced neurogranin/CaM interactions. These data demonstrate that CaM is the major protein that interacts with neurogranin in uiuo and support the hypothesis that phosphorylation of neurogranin at Ser-36 regulates its binding to CaM.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; CENG, BRCE, DBMS, INSERM U244, F-38054 Grenoble 9, France	University of Washington; University of Washington Seattle; Institut National de la Sante et de la Recherche Medicale (Inserm)	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Deloulme, Jean Christophe/P-6858-2017	Deloulme, Jean Christophe/0000-0002-2234-5865				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apel E D, 1992, Perspect Dev Neurobiol, V1, P3; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BIEGALKE BJ, 1990, VIROLOGY, V177, P657, DOI 10.1016/0042-6822(90)90531-U; Brill S, 1996, MOL CELL BIOL, V16, P4869; Chao S, 1996, MOL BRAIN RES, V40, P195, DOI 10.1016/0169-328X(96)00049-6; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; CHAPMAN ER, 1991, PROG BRAIN RES, V89, P37; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DELOULME JC, 1991, FEBS LETT, V282, P183, DOI 10.1016/0014-5793(91)80473-G; FEDOROV NB, 1995, EUR J NEUROSCI, V7, P819, DOI 10.1111/j.1460-9568.1995.tb00685.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; Gerendasy DD, 1997, MOL NEUROBIOL, V15, P131, DOI 10.1007/BF02740632; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; Lu PJ, 1997, J BIOL CHEM, V272, P466; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; NEEL VA, 1994, DEVELOPMENT, V120, P2235; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/0006-8993(96)00786-X; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PAUDEL HK, 1993, J BIOL CHEM, V268, P6207; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; Petrova TV, 1996, J BIOL CHEM, V271, P26646, DOI 10.1074/jbc.271.43.26646; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROBERSON ED, 1995, BEHAV BRAIN SCI, V18, P485, DOI 10.1017/S0140525X0003942X; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; SLEMMON JR, 1994, BIOCHEMISTRY-US, V33, P5653, DOI 10.1021/bi00184a039; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; Villacres EC, 1998, J NEUROSCI, V18, P3186; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x	60	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7689	7694		10.1074/jbc.274.12.7689	http://dx.doi.org/10.1074/jbc.274.12.7689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075657	hybrid			2022-12-27	WOS:000079268100016
J	Asano, S; Matsuda, S; Hoshina, S; Sakamoto, S; Takeguchi, N				Asano, S; Matsuda, S; Hoshina, S; Sakamoto, S; Takeguchi, N			A chimeric gastric H+,K+-ATPase inhibitable with both ouabain and SCH 28080	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; CATALYTIC SUBUNIT; BINDING; ATPASE; IDENTIFICATION; SCH-28080; SENSITIVITY; RESISTANCE; MECHANISM	2-Methyl-8-(phenylmethoxy) imidazo( 1,2-a) pyridine-3-acetonitrile (SCH 28080) is a K+ site inhibitor specific for gastric H+,K+-ATPase and seems to be a counterpart of ouabain for Na+,K+-ATPase from the viewpoint of reaction pattern (i.e. reversible binding, K+ antagonism, and binding on the extracellular side). In this study, we constructed several chimeric molecules between H+,K+-ATPase and Na+,K+-ATPase alpha-subunits by using rabbit H+,K+-ATPase as a parental molecule. We found that the entire extracellular loop 1 segment between the first and second transmembrane segments (M1 and M2) and the luminal half of the M1 transmembrane segment of H+,K+-ATPase alpha-subunit were exchangeable with those of Na+,K+-ATPase, respectively, preserving H+,K+-ATPase activity, and that these segments are not essential for SCH 28080 binding. We found that several amino acid residues, including Glu-822, Thr-825, and Pro-829 in the M6 segment of H+,K+-ATPase alpha-subunit are involved in determining the affinity for this inhibitor. Furthermore, we found that a chimeric H+,K+-ATPase acquired ouabain sensitivity and maintained SCH 28080 sensitivity when the loop I segment and Cys-815 in the loop 3 segment of the H+,K+-ATPase cu-subunit were simultaneously replaced by the corresponding segment and amino acid residue (Thr) of Na+,K+-ATPase, respectively, indicating that the binding sites of ouabain and SCH 28080 are separate. In this H+,K+-ATPase chimera, 12 amino acid residues in M1, M4, and loop 1-4 that have been suggested to be involved in ouabain binding of Na+,K+-ATPase alpha-subunit are present; however, the low ouabain sensitivity indicates the possibility that the sensitivity may be increased by additional amino acid substitutions, which shift the overall structural integrity of this chimeric H+,K+-ATPase toward that of Na+,K+-ATPase.	Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan	University of Toyama; University of Toyama	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.	shinji@ms.toyama-mpu.ac.jp		Asano, Shinji/0000-0003-1443-8970				ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; ASKEW GR, 1994, J BIOL CHEM, V269, P24120; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BEIL W, 1986, BRIT J PHARMACOL, V88, P19, DOI 10.1111/j.1476-5381.1986.tb09466.x; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; Canfield VA, 1998, BIOCHEMISTRY-US, V37, P7509, DOI 10.1021/bi980174h; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; KOELING DJ, 1989, J BIOL CHEM, V264, P5545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyu RM, 1997, AM J PHYSIOL-CELL PH, V272, pC1717, DOI 10.1152/ajpcell.1997.272.5.C1717; MORII M, 1989, GASTROENTEROLOGY, V96, P1453, DOI 10.1016/0016-5085(89)90512-X; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCOTT CK, 1985, EUR J PHARMACOL, V112, P268, DOI 10.1016/0014-2999(85)90508-4; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKEGUCHI M, 1990, GASTROENTEROLOGY, V99, P1339, DOI 10.1016/0016-5085(90)91159-4; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; Yamamoto S, 1996, AM J PHYSIOL-CELL PH, V270, pC457, DOI 10.1152/ajpcell.1996.270.2.C457; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	32	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6848	6854		10.1074/jbc.274.11.6848	http://dx.doi.org/10.1074/jbc.274.11.6848			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066737	hybrid			2022-12-27	WOS:000079078400009
J	Barak, LS; Warabi, K; Feng, X; Caron, MG; Kwatra, MM				Barak, LS; Warabi, K; Feng, X; Caron, MG; Kwatra, MM			Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; ACTIVATION; AGONIST; INTERNALIZATION; PHOSPHOLIPIDS; FIBROBLASTS; HYDROLYSIS; MIGRATION	The substance P receptor (SPR) is a G protein-coupled receptor (GPCR) that plays a key role in pain regulation. The SPR desensitizes in the continued presence of agonist, presumably via mechanisms that implicate G protein coupled receptor kinases (GRKs) and beta-arrestins, The temporal relationship of these proposed biochemical events has never been established for any GPCR other than rhodopsin beyond the resolution provided by biochemical assays. We investigate the real-time activation and desensitization of the human SPR in live HEK293 cells using green fluorescent protein conjugates of protein kinase C, GRK2, and beta-arrestin 2. The translocation of protein kinase C beta II-green fluorescent protein to and from the plasma membrane in response to substance P indicates that the human SPR becomes activated within seconds of agonist exposure, and the response desensitizes within 30 s, This desensitization process coincides with a redistribution of GRK2 from the cytosol to the plasma membrane, followed by a robust redistribution of beta-arrestin 2 and a profound change in cell morphology that occurs after I min of SPR stimulation. These data establish a role for GrRKs and beta-arrestins in homologous desensitization of the SPR and provide the first visual and temporal resolution of the sequence of events underlying homologous desensitization of a GPCR in living cells.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Kwatra, MM (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	kwatr001@mc.duke.edu	Kwatra, Madan/ABD-2008-2020		NHLBI NIH HHS [HL03422] Funding Source: Medline; NINDS NIH HHS [NS19576, NS 33405] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033405, R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Garland AM, 1996, MOL PHARMACOL, V49, P438; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HERSHEY AD, 1991, ANN NY ACAD SCI, V632, P63, DOI 10.1111/j.1749-6632.1991.tb33095.x; HUNTER JC, 1985, BIOCHEM BIOPH RES CO, V127, P616, DOI 10.1016/S0006-291X(85)80205-9; KAHLER CM, 1993, EUR J PHARMACOL, V249, P281, DOI 10.1016/0014-2999(93)90523-K; KIM CM, 1993, J BIOL CHEM, V268, P15412; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; MACCIONI RB, 1986, EUR J BIOCHEM, V154, P427, DOI 10.1111/j.1432-1033.1986.tb09415.x; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V148, P1017, DOI 10.1016/S0006-291X(87)80233-4; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; Nishimura K, 1998, BIOCHEMISTRY-US, V37, P1192, DOI 10.1021/bi972302s; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Parenti A, 1996, N-S ARCH PHARMACOL, V353, P475; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; WEISS SJ, 1982, BIOCHEM J, V206, P555, DOI 10.1042/bj2060555	31	72	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7565	7569		10.1074/jbc.274.11.7565	http://dx.doi.org/10.1074/jbc.274.11.7565			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066824	hybrid			2022-12-27	WOS:000079078400096
J	Couture, M; Das, TK; Lee, HC; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB; Guertin, M				Couture, M; Das, TK; Lee, HC; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB; Guertin, M			Chlamydomonas chloroplast ferrous hemoglobin - Heme pocket structure and reactions with ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; PECTINATA BACTERIA SYMBIOSIS; CYTOCHROME-C PEROXIDASE; AMINO-ACID-SEQUENCE; ASCARIS HEMOGLOBIN; RAMAN-SCATTERING; DISTAL HISTIDINE; LUCINA-PECTINATA; NITRIC-OXIDE; TYROSINE B10	We report the optical and resonance Raman spectral characterization of ferrous recombinant Chlamydomonas LI637 hemoglobin. We show that it is present in three pH dependent equilibrium forms including a 4-coordinate species at acid pH, a 6-coordinate high spin species at neutral pH, and a 6-coordinate low spin species at alkaline pH, The proximal ligand to the heme is the imidazole group of a histidine, Kinetics of the reactions with ligands were determined by stopped-flow spectroscopy. At alkaline pH, combination with oxygen, nitric oxide, and carbon monoxide displays a kinetic behavior that is interpreted as being rate-limited by conversion of the 6-coordinate form to a reactive 5-coordinate form. At neutral pH, combination rates of the 5-coordinate form with oxygen and carbon monoxide were much faster (>10(7) mu M-1 s(-1)). The dissociation rate constant measured for oxygen is among the slowest known, 0.014 s(-1), and is independent of pH, Replacement of the tyrosine 63 (B10) by leucine or of the putative distal glutamine by glycine increases the dissociation rate constant 70- and 30-fold and increases the rate of autoxidation 20- and 90-fold, respectively. These results are consistent with at least two hydrogen bonds stabilizing the bound oxygen molecule, one from tyrosine B10 and the other from the distal glutamine, In addition, the high frequency (232 cm(-1)) of the iron-histidine bond suggests a structure that lacks any proximal strain thus contributing to high ligand affinity.	Univ Laval, Fac Sci & Engn, Dept Biochem, Quebec City, PQ G1K 7P4, Canada; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Laval University; Yeshiva University; Albert Einstein College of Medicine	Guertin, M (corresponding author), Univ Laval, Fac Sci & Engn, Dept Biochem, Quebec City, PQ G1K 7P4, Canada.	mguertin@bcm.ulaval.ca	Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055; Das, Tapan/0000-0002-3641-3988	NIGMS NIH HHS [GM54806, GM40168, GM54812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054812, R01GM040168, R37GM040168, R01GM054806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; APPLEBY CA, 1973, J BIOL CHEM, V248, P3183; ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BISIG DA, 1995, J BIOL CHEM, V270, P20754, DOI 10.1074/jbc.270.35.20754; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; CHEVION M, 1977, BIOCHIM BIOPHYS ACTA, V490, P272, DOI 10.1016/0005-2795(77)90002-2; Coletta M, 1996, EUR J BIOCHEM, V235, P49, DOI 10.1111/j.1432-1033.1996.00049.x; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DEROPP JS, 1985, J AM CHEM SOC, V107, P8268, DOI 10.1021/ja00312a080; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; GAGNE G, 1992, PLANT MOL BIOL, V18, P429, DOI 10.1007/BF00040659; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HENRY Y, 1976, J BIOL CHEM, V251, P1578; HORI H, 1971, BIOCHIM BIOPHYS ACTA, V251, P227, DOI 10.1016/0005-2795(71)90106-1; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; IRIE T, 1980, COMP BIOCHEM PHYS B, V67, P549, DOI 10.1016/0305-0491(80)90413-7; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; Kaneko T, 1996, DNA Res, V3, P109; KEILIN J, 1966, HEMES HEMOPROTEINS, P173; Kiger L, 1998, BIOPHYS J, V75, P990, DOI 10.1016/S0006-3495(98)77587-3; Kloek AP, 1996, J MOL EVOL, V43, P101, DOI 10.1007/BF02337354; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; KRAUS DW, 1990, J BIOL CHEM, V265, P16054; Lamb DC, 1998, J AM CHEM SOC, V120, P2981, DOI 10.1021/ja973781l; MANSELL JB, 1993, BIOCHEM MOL BIOL INT, V30, P643; MCREE DE, 1994, P NATL ACAD SCI USA, V91, P12847, DOI 10.1073/pnas.91.26.12847; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; PEISACH J, 1968, J BIOL CHEM, V243, P1871; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; PRONIEWICZ LM, 1988, J AM CHEM SOC, V110, P4541, DOI 10.1021/ja00222a009; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Tang Q, 1998, BIOCHEMISTRY-US, V37, P7047, DOI 10.1021/bi9729413; Thorsteinsson MV, 1996, BBA-PROTEIN STRUCT M, V1292, P133, DOI 10.1016/0167-4838(95)00178-6; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; VANFLETEREN JR, 1994, MOL PHYLOGENET EVOL, V3, P92, DOI 10.1006/mpev.1994.1012; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WERDAN K, 1975, BIOCHIM BIOPHYS ACTA, V396, P276, DOI 10.1016/0005-2728(75)90041-9; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; YONETANI T, 1972, J BIOL CHEM, V247, P2447; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	62	112	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6898	6910		10.1074/jbc.274.11.6898	http://dx.doi.org/10.1074/jbc.274.11.6898			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066743	hybrid			2022-12-27	WOS:000079078400015
J	Kuroda, K; Tani, S; Tamura, K; Minoguchi, S; Kurooka, H; Honjo, T				Kuroda, K; Tani, S; Tamura, K; Minoguchi, S; Kurooka, H; Honjo, T			Delta-induced notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX FACTORS; BARR-VIRUS EBNA2; J-KAPPA; TRANSCRIPTION FACTOR; DROSOPHILA HOMOLOG; NERVOUS-SYSTEM; BINDING-SITE; MOUSE NOTCH; CELL FATE; GENE	Signaling induced by interaction between the receptor Notch and its ligand Delta plays an important role in cell fate determination in vertebrates as well as invertebrates. Vertebrate Notch signaling has been investigated using its constitutively active form, i.e. the truncated intracellular region which is believed to mimic Notch-Delta signaling by interaction with a DNA-binding protein RBP-J. However, the molecular mechanism for Notch signaling triggered by ligand binding, which leads to inhibition of differentiation, is not clear. We have established a myeloma cell line expressing mouse Deltal on its cell surface which can block muscle differentiation by co-culture with C2C12 muscle progenitor cells. We showed that Delta-induced Notch signaling stimulated transcriptional activation of RBP-J binding motif, containing promoters including the HES1 promoter. Furthermore, ligand-induced Notch signaling up-regulated HES1 mRNA expression within 1 h and subsequently reduced expression of MyoD mRNA, Since cycloheximide treatment did not inhibit induction of HES1 mRNA, the HES1 promoter appears to be a primary target of activated Notch. In addition, a transcriptionally active form of RBP-J, i.e. VP16-RBP-J, inhibited muscle differentiation of C2C12 cells by blocking the expression of MyoD protein. These results suggest that HES1 induction by the Deltal/Notch signaling is mediated by RBP-J and blocks myogenic differentiation of C2C12 cells by subsequent inhibition of MyoD expression.	Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	Kyoto University; University of California System; University of California San Diego	Honjo, T (corresponding author), Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; Aster JC, 1997, J BIOL CHEM, V272, P11336; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; delaPompa J, 1997, DEVELOPMENT, V124, P1139; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; FURUKAWA T, 1995, JPN J GENET, V70, P505, DOI 10.1266/jjg.70.505; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GU Y, 1995, DEVELOPMENT, V121, P855; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kato H, 1997, DEVELOPMENT, V124, P4133; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MATSUDA F, 1993, NAT GENET, V3, P88, DOI 10.1038/ng0193-88; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1994, DEVELOPMENT, V120, P2421; OKA C, 1995, DEVELOPMENT, V121, P3291; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sakai T, 1998, J VIROL, V72, P6034, DOI 10.1128/JVI.72.7.6034-6039.1998; SAKAI T, 1995, J BIOCHEM-TOKYO, V118, P921; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Shawber C, 1996, DEVELOPMENT, V122, P3765; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tsakonas SA, 1995, SCIENCE, V268, P225; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yoshida N, 1998, J CELL SCI, V111, P769	69	215	225	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7238	7244		10.1074/jbc.274.11.7238	http://dx.doi.org/10.1074/jbc.274.11.7238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066785	hybrid			2022-12-27	WOS:000079078400057
J	Ueda, Y; Royer, L; Gong, E; Zhang, JL; Cooper, PN; Francone, O; Rubin, EM				Ueda, Y; Royer, L; Gong, E; Zhang, JL; Cooper, PN; Francone, O; Rubin, EM			Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; SELECTIVE LIPID UPTAKE; APOLIPOPROTEIN-A-I; SR-BI; ADRENAL-GLAND; EXPRESSION; CELLS; GENE; OVEREXPRESSION; DELIVERY	Recent studies have indicated that the scavenger receptor class B type I (SR-BI) may play an important role in the uptake of high density lipoprotein (HDL) cholesteryl ester in liver and steroidogenic tissues. To investigate the in vivo effects of liver-specific SR-BI overexpression on lipid metabolism, we created several lines of SR-BI transgenic mice with an SR-BI genomic construct where the SR-BI promoter region had been replaced by the apolipoprotein (apo)A-I promoter. The effect of constitutively increased SR-BI expression on plasma HDL and non-HDL lipoproteins and apolipoproteins was characterized. There was an inverse correlation between SR-BI expression and apoA-I and HDL cholesterol levels in transgenic mice fed either mouse chow or a diet high in fat and cholesterol. An unexpected finding in the SR-BI transgenic mice was the dramatic impact of the SR-BI transgene on non-HDL cholesterol and apoB whose levels were also inversely correlated with SR-BI expression. Consistent with the decrease in plasma HDL and non-HDL cholesterol was an accelerated clearance of HDL, non-HDL, and their major associated apolipoproteins in the transgenics compared with control animals. These in vivo studies of the effect of SR-BI overexpression on plasma lipoproteins support the previously proposed hypothesis that SR-BI accelerates the metabolism of HDL and also highlight the capacity of this receptor to participate in the metabolism of non-HDL lipoproteins.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Pfizer Inc, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Pfizer	Rubin, EM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, 1 Cyclotron Rd,MS-84-171, Berkeley, CA 94720 USA.		Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [HL-50590, HL-18574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574, R01HL050590] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; GLASS CK, 1983, J BIOL CHEM, V258, P7161; HOGAN B, 1994, MANIPULATING MOUSE E, P217; KEYS A, 1980, LANCET, V2, P603; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHINA PM, 1990, J LIPID RES, V31, P859; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Xu SZ, 1997, J LIPID RES, V38, P1289; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	26	207	214	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7165	7171		10.1074/jbc.274.11.7165	http://dx.doi.org/10.1074/jbc.274.11.7165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066776	hybrid			2022-12-27	WOS:000079078400048
J	Franchimont, N; Durant, D; Rydziel, S; Canalis, E				Franchimont, N; Durant, D; Rydziel, S; Canalis, E			Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE CELL-CULTURES; RAT PARIETAL BONE; PARATHYROID-HORMONE; C-FOS; DEOXYRIBONUCLEIC-ACID; ENRICHED CULTURES; GENE-EXPRESSION; BINDING; ISOFORMS; RECEPTOR	Platelet-derived growth factor (PDGF) BE, a mitogen that stimulates bone resorption, increases the expression of interleukin-6 (IL-6), a cytokine that induces osteoclast recruitment. The mechanisms involved in IL-6 induction by PDGF BE are poorly understood. We examined the effect of PDGF BE on IL-6 expression in cultures of osteoblasts from fetal rat calvariae (Ob cells). PDGF BE increased IL-6 mRNA and heterogeneous nuclear RNA levels, the rate of transcription, and the activity of base pairs (bp) -2906 to +20 IL-6 promoter fragments transiently transfected into Ob cells. Deletion analysis revealed two responsive regions, one containing an activator protein-1 (AP-1) site located between bp -276 and -257, and a second, less well defined, downstream of -257. Targeted mutations of a cyclic AMP-responsive element (CRE), and nuclear factor-IL-6 and nuclear factor-kappa B binding sites in a bp -257 to +20 IL-6 construct that was transfected into Ob cells, revealed that the CRE also contributed to IL-6 promoter induction by PDGF BE. Electrophoretic mobility shift assay revealed AP-1 and CRE nuclear protein complexes that were enhanced by PDGF BE. Supershift assays revealed binding of Jun and Fos to AP-1 and CRE sequences and binding of activating transcription factor-a to CRE. In conclusion, PDGF BE induces IL-6 transcription in osteoblasts by regulating nuclear proteins of the AP-1 complex and activating transcription factor-2.	St Francis Hosp & Med Ctr, Res Dept, Worcester, MA 01605 USA; St Francis Hosp & Med Ctr, Dept Med, Worcester, MA 01605 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	University of Connecticut	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Res Dept, 114 Woodland St, Worcester, MA 01605 USA.	ecanalis@stfranciscare.org			NIAMS NIH HHS [AR21707] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1992, CHEM IMMUNOL, V51, P299; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAFFET G, 1991, MOL BIOL MED, V8, P141; CANALIS E, 1989, J CELL PHYSIOL, V140, P530, DOI 10.1002/jcp.1041400319; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P13, DOI 10.1210/endo-125-1-13; CENTRELLA M, 1991, J CELL PHYSIOL, V147, P420, DOI 10.1002/jcp.1041470306; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLAESSONWELSH L, 1989, ACTA ONCOL, V28, P331, DOI 10.3109/02841868909111202; COCHRAN DL, 1993, BONE, V14, P53, DOI 10.1016/8756-3282(93)90256-A; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; FRANCHIMONT N, 1993, P 1993 4 INT S OST C, P249; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; GIRASOLE G, 1995, J BONE MINER RES, V10, pS160; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENFIELD EM, 1993, J BONE MINER RES, V8, P1163; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1987, J CELL PHYSIOL, P31; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Moore DD, 1995, GLOB MOB SURV; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROODMAN GD, 1992, J BONE MINER RES, V7, P475, DOI 10.1002/jbmr.5650070502; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; RYDZIEL S, 1992, ENDOCRINOLOGY, V130, P1916, DOI 10.1210/en.130.4.1916; Rydziel S, 1996, ENDOCRINOLOGY, V137, P4115, DOI 10.1210/en.137.10.4115; Scott V, 1994, Methods Mol Biol, V31, P339; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; Wall F.J., 1986, STAT DATA ANAL HDB; WANG ZQ, 1992, NATURE, V360, P471	48	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6783	6789		10.1074/jbc.274.10.6783	http://dx.doi.org/10.1074/jbc.274.10.6783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037779	hybrid			2022-12-27	WOS:000078902800101
J	Mukherjee, PK; DeCoster, MA; Campbell, FZ; Davis, RJ; Bazan, NG				Mukherjee, PK; DeCoster, MA; Campbell, FZ; Davis, RJ; Bazan, NG			Glutamate receptor signaling interplay modulates stress-sensitive mitogen-activated protein kinases and neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CYTOSOLIC PHOSPHOLIPASE A(2); FREE FATTY-ACIDS; STRIATAL NEURONS; BRAIN INJURY; INHIBITORY AVOIDANCE; ANTAGONIST BN-52021; AGONIST 1S,3R-ACPD; CORTICAL CULTURES; MAP KINASE	Glutamate receptors modulate multiple signaling pathways, several of which involve mitogen-activated protein (MAP) kinases, with subsequent physiological or pathological consequences. Here we report that stimulation of the N-methyl-D-aspartate (NMDA) receptor, using platelet-activating factor (PAF) as a messenger, activates MAP kinases, including c-Jun NH2-terminal kinase, p38, and extracellular signal-regulated kinase, in primary cultures of hippocampal neurons. Activation of the metabotropic glutamate receptor (mGluR) blocks this NMDA-signaling through PAF and MAP kinases, and the resultant cell death. Recombinant PAF-acetylhydrolase degrades PAF generated by NMDA receptor activation; the hetrazepine BN50730 (an intracellular PAF receptor antagonist) also inhibits both NMDA-stimulated MAP kinases and neuronal cell death. The finding that the NMDA receptor-PAF-MAP kinase signaling pathway is attenuated by mGluR activation highlights the exquisite interplay between glutamate receptors in the decision making process between neuronal survival and death.	Louisiana State Univ, Med Ctr, Sch Med, Ctr Neurosci, New Orleans, LA 70112 USA; Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA	Louisiana State University System; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Bazan, NG (corresponding author), Louisiana State Univ, Med Ctr, Sch Med, Neurosci Ctr Excellence, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	nbazan@lsumc.edu	DeCoster, Mark/AAF-5224-2020; Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23002] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; Bonaccorsi L, 1997, BBA-MOL CELL RES, V1355, P155, DOI 10.1016/S0167-4889(96)00125-5; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; BURKE JP, 1994, J NEUROSCI, V14, P5120; CLAPP LE, 1995, BRAIN RES, V693, P101, DOI 10.1016/0006-8993(95)00720-B; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DECOSTER MA, 1995, BRAIN RES, V671, P45, DOI 10.1016/0006-8993(94)01294-R; DECOSTER MA, 1994, INT J DEV NEUROSCI, V12, P227, DOI 10.1016/0736-5748(94)90044-2; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONDA Z, 1994, J BIOL CHEM, V269, P2307; IZQUIERDO I, 1995, P NATL ACAD SCI USA, V92, P5047, DOI 10.1073/pnas.92.11.5047; JERUSALINSKY D, 1994, BEHAV NEURAL BIOL, V62, P1, DOI 10.1016/S0163-1047(05)80052-4; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KURINO M, 1995, J NEUROCHEM, V65, P1282; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; Marcheselli VL, 1996, J BIOL CHEM, V271, P24794, DOI 10.1074/jbc.271.40.24794; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; Nishida K, 1996, STROKE, V27, P514, DOI 10.1161/01.STR.27.3.514; Nishida K, 1996, J NEUROCHEM, V66, P433; Orlando LR, 1995, NEUROSCI LETT, V202, P109, DOI 10.1016/0304-3940(95)12219-2; Packard MG, 1996, NEUROBIOL LEARN MEM, V66, P176, DOI 10.1006/nlme.1996.0058; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; PREHN JHM, 1993, J NEUROSCI RES, V34, P179, DOI 10.1002/jnr.490340205; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SCHOEPP DD, 1995, NEURODEGENERATION, V4, P71, DOI 10.1006/neur.1995.0008; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Wang YM, 1997, BRAIN RES, V772, P45, DOI 10.1016/S0006-8993(97)00837-8; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS RJ, 1995, J NEUROCHEM, V65, P241; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YUE TL, 1990, J NEUROCHEM, V54, P1809, DOI 10.1111/j.1471-4159.1990.tb01239.x	51	76	85	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6493	6498		10.1074/jbc.274.10.6493	http://dx.doi.org/10.1074/jbc.274.10.6493			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037742	hybrid			2022-12-27	WOS:000078902800064
J	Bittova, L; Sumandea, M; Cho, W				Bittova, L; Sumandea, M; Cho, W			A structure-function study of the C2 domain of cytosolic phospholipase A(2) - Identification of essential calcium ligands and hydrophobic membrane binding residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTERFACIAL CATALYSIS; NUCLEAR-ENVELOPE; HIGH-AFFINITY; TRANSLOCATION; SPECIFICITY; SURFACE; PENETRATION; DIVERSITY	The C2 domain of cytosolic phospholipase A(2) (cPLA(2)) is involved in the Ca2+-dependent membrane binding of this protein. To identify protein residues in the C2 domain of cPLA(2) essential for its Ca2+ and membrane binding, we selectively mutated Ca2+ ligands and putative membrane-binding residues of cPLA(2) and measured the effects of mutations on its enzyme activity, membrane binding affinity, and monolayer penetration. The mutations of five Ca2+ ligands (D40N, D43N, N65A, D93N, N95A) show differential effects on the membrane binding and activation of cPLA(2) indicating that two calcium ions bound to the C2 domain have differential roles. The mutations of hydrophobic residues (F35A, M38A, L39A, Y96A, Y97A, M98A) in the calcium binding loops show that the membrane binding of cPLA(2) is largely driven by hydrophobic interactions resulting from the penetration of these residues into the hydrophobic core of the membrane. Leu(39) and Val(97) are fully inserted into the membrane, whereas Phe(35) and Tyr(96) are partially inserted. Finally, the mutations of four cationic residues in a beta-strand (R57E/K58E/R59E/R61E) have modest and negligible effects on the binding of cPLA(2) to zwitterionic and anionic membranes, respectively, indicating that they are not directly involved in membrane binding. In conjunction with our previous study on the C2 domain of protein kinase C-alpha (Medkova, M,. and Cho, W. (1998) J, Biol Chem, 273, 17544-17552), these results demonstrate that C2 domains are not only a membrane docking unit but also a module that triggers membrane penetration of protein and that individual Ca2+ lions bound to the calcium binding loops play differential roles in the membrane binding and activation of their parent proteins.	Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.		Bittova, Lenka/K-4375-2015	Bittova, Lenka/0000-0002-3556-5234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598, GM53987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c	35	118	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9665	9672		10.1074/jbc.274.14.9665	http://dx.doi.org/10.1074/jbc.274.14.9665			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092653	hybrid			2022-12-27	WOS:000079451800072
J	Kim, HS; Garcia, J; Exley, M; Johnson, KW; Balk, SP; Blumberg, RS				Kim, HS; Garcia, J; Exley, M; Johnson, KW; Balk, SP; Blumberg, RS			Biochemical characterization of CD1d expression in the absence of beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE MOLECULE; IMMUNOGLOBULIN-E PRODUCTION; V(ALPHA)14 NKT CELLS; NK1.1(+) T-CELLS; MOUSE CD1; ANTIGEN; GENE; RECOGNITION; MICE; BETA-2-MICROGLOBULIN	CD1d is a major histocompatibility complex class I-like molecule that exhibits a distinct antigen processing pathway that functions in the presentation of hydrophobic antigens to T cells. CD1d has been previously shown to be expressed on the cell surface of human intestinal epithelial cell lines in vivo and a transfected cell line in vitro independently of beta(2)-microglobulin (beta(2)m). To define the relationship between CD1d and beta(2)m and characterize the biochemical structure of CD1d in the absence of beta(2)m, we have used a newly generated series of CD1d transfectants and CD1d-specific antibodies. These studies show that in the absence of beta(2)m, CD1d is expressed on the cell surface as a 45-kDa glycoprotein that is sensitive to endoglycosidase-H and is reduced to 37-kDa after N-glycanase digestion. In contrast, in the presence of beta(2)m, CD1d is expressed on the cell surface as a 48-kDa endoglycosidase-H-resistant glycoprotein. Pulse-chase metabolic labeling studies demonstrate that acquisition of endoglycosidase-H resistance of CD1d is observed in the presence of beta(2)m but not in the absence of beta(2)m even after a 24-h chase period. Thus, CD1d is able to be transported to the cell surface independently of beta(2)m; however, in the absence of beta(2)m, the glycosylation pattern of CD1d is altered and consistent with an immature glycoprotein.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol,Dept Med, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, 75 Francis St, Boston, MA 02115 USA.	rblumberg@rics.bwh.harvard.edu		Exley, Mark/0000-0002-5088-1032	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002549, R01DK044319, R37DK044319] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09682-02] Funding Source: Medline; NIDDK NIH HHS [K08 DK02549-01, DK-44319] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano M, 1998, J IMMUNOL, V161, P1710; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BALK SP, 1991, J IMMUNOL, V146, P768; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BILSLAND CAG, 1991, EUR J IMMUNOL, V21, P71, DOI 10.1002/eji.1830210112; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; BLUMBERG RS, 1995, IMMUNOL REV, V147, P5, DOI 10.1111/j.1600-065X.1995.tb00085.x; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CANCHIS PW, 1993, IMMUNOLOGY, V80, P561; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Colgan SP, 1996, AM J PHYSIOL-CELL PH, V271, pC276, DOI 10.1152/ajpcell.1996.271.1.C276; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GUSSOW D, 1987, J IMMUNOL, V139, P3132; ICHIMIYA S, 1994, J IMMUNOL, V153, P1112; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kasai K, 1997, CLIN EXP IMMUNOL, V109, P317, DOI 10.1046/j.1365-2249.1997.3661267.x; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; Murakami M, 1998, J IMMUNOL, V160, P2649; PARHAM P, 1983, J BIOL CHEM, V258, P6179; SOMNAYWADGAONKA.K, 1999, IN PRESS INT IMMUNOL; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Sydora BC, 1996, J IMMUNOL, V156, P4209; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teitell M, 1997, J IMMUNOL, V158, P2143; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; ZHENG XX, 1995, J IMMUNOL, V154, P5590	44	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9289	9295		10.1074/jbc.274.14.9289	http://dx.doi.org/10.1074/jbc.274.14.9289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092605	hybrid			2022-12-27	WOS:000079451800024
J	Sui, XM; Bramlett, KS; Jorge, MC; Swanson, DA; von Eschenbach, AC; Jenster, G				Sui, XM; Bramlett, KS; Jorge, MC; Swanson, DA; von Eschenbach, AC; Jenster, G			Specific androgen receptor activation by an artificial coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CARBOXYL-TERMINAL REGIONS; NUCLEAR RECEPTOR; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL COACTIVATORS; TRANSACTIVATION DOMAIN; HORMONE RECEPTOR; FACTOR-TFIIB; BINDING; VP16	Transcription activation of steroid receptors, such as the androgen receptor (AR), is mediated by coactivators, which bridge the receptor to the preinitiation complex. To develop a tool for studying the role of the AR in normal development and disease, we constructed artificial coactivators consisting of the transcription activation domains of VP16 or p65/RelA and the AR hinge and ligand-binding domain (AR(LBD)), which has been shown to interact with the AR N-terminal domain. The artificial VP16-AR(LBD), and AR(LBD)-p65 coactivators interacted with the AR N terminus and wild-type AR in an androgen-dependent and androgen-specific manner. VP16-AR(LBD) and AR(LBD)-p65 enhanced the AR transactivity up to 4- and 13-fold, respectively, without affecting the expression of the AR protein. The coactivators did not enhance the transcription activity of the progesterone receptor (PR) or the glucocorticoid receptor (GR), showing their specificity for the AR. In addition, to construct PR- and GR-specific coactivators, the VP16 activation domain was fused to the PR and GR hinge/ligand-binding domain. Although VP16-PRLBD, and VP16-GR(LBD), interacted with the C-terminal portion of steroid receptor coactivator-l, they did not enhance the transcription activity of their receptor. The presented strategy of directing activation domains or other protein activities into the RNA-hound AR complex provides a novel means of manipulating AR function in vitro and in vivo.	Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Jenster, G (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Urol, 1515 Holcombe Blvd,Box 026, Houston, TX 77030 USA.							BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Gupta R, 1996, NUCLEIC ACIDS RES, V24, P2324, DOI 10.1093/nar/24.12.2324; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; WAGNER LA, 1995, BLOOD, V86, P3265; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J	43	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9449	9454		10.1074/jbc.274.14.9449	http://dx.doi.org/10.1074/jbc.274.14.9449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092626	hybrid			2022-12-27	WOS:000079451800045
J	Bonaventura, C; Bonaventura, J; Shih, DTB; Iben, ET; Friedman, J				Bonaventura, C; Bonaventura, J; Shih, DTB; Iben, ET; Friedman, J			Altered ligand rebinding kinetics due to distal-side effects in hemoglobin Chico (Lys(beta 66)(E10)-> Thr)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLVED RESONANCE RAMAN; GEMINATE RECOMBINATION; HEME-PROTEINS; TERTIARY-STRUCTURE; PROXIMAL CONTROL; POCKET POLARITY; DOCKING SITE; MYOGLOBIN; BINDING; CO	Hb Chico is an unusual human hemoglobin variant that has lowered oxygen affinity, but unaltered cooperativity and anion sensitivity. Previous studies showed these features to be associated with distal-side heme pocket alterations that confer increased structural rigidity on the molecule and that increase water content in the beta-chain heme pocket. We report here that the extent of nanosecond geminate rebinding of oxygen to the variant and its isolated beta-chains is appreciably decreased. Structural alterations in this variant decrease its oxygen recombination rates without significantly altering rates of migration out of the heme pocket. Data analysis indicates that one or more barriers that impede rebinding of oxygen from docking sites in the heme pocket are increased, with less consequence for CO rebinding. Resonance Raman spectra show no significant alterations in spectral regions sensitive to interactions between the heme iron and the proximal histidine residue, confirming that the functional differences in the variant are due to distal-side heme pocket alterations. These effects are discussed in the context of a schematic representation of heme pocket wells and barriers that could aid the design of novel hemoglobins with altered ligand affinity without loss of the normal allosteric responses that facilitate unloading of oxygen to respiring tissues.	Duke Univ, Marine Freshwater Biomed Ctr, Sch Environm, Marine Lab, Beaufort, NC 28516 USA; TMC, Inst Cell & Mol Biol, Taipei 110, Taiwan; IBM Corp, San Jose, CA 95193 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Duke University; International Business Machines (IBM); Yeshiva University; Albert Einstein College of Medicine	Bonaventura, C (corresponding author), Duke Univ, Marine Freshwater Biomed Ctr, Sch Environm, Marine Lab, Beaufort, NC 28516 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004287, P30ES001908, P50ES001908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL5108] Funding Source: Medline; NIEHS NIH HHS [ESO4287, ESO1908] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALPERT B, 1979, CHEM PHYS LETT, V64, P11, DOI 10.1016/0009-2614(79)87265-6; ANTONIMI E, 1971, HEMOGLOBIN MYOGLOBIN; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; BANGCHAROENPAURPONG O, 1984, J AM CHEM SOC, V106, P5688, DOI 10.1021/ja00331a045; BONAVENTURA C, 1991, J BIOL CHEM, V266, P23033; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CHANCE MR, 1990, BIOCHEMISTRY-US, V29, P5537, DOI 10.1021/bi00475a018; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; DUDDELL DA, 1979, J CHEM SOC CHEM COMM, P75, DOI 10.1039/c39790000075; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; GERACI G, 1969, J BIOL CHEM, V244, P4664; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kwiatkowski LD, 1998, BIOCHEMISTRY-US, V37, P4325, DOI 10.1021/bi970866q; LI T, 1994, BIOCHEMISTRY-US, V33, P1438; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; MORRIS RJ, 1980, J BIOL CHEM, V255, P8050; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; SCOTT TW, 1985, J AM CHEM SOC, V107, P3702, DOI 10.1021/ja00298a047; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SHIH DTB, 1987, J MOL BIOL, V195, P453, DOI 10.1016/0022-2836(87)90666-8; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; Spiro TG, 1997, J BIOL INORG CHEM, V2, P516, DOI 10.1007/s007750050164; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SZABO A, 1972, BIOCHEM BIOPH RES CO, V46, P855, DOI 10.1016/S0006-291X(72)80219-5; Tian WD, 1996, BIOCHEMISTRY-US, V35, P3487, DOI 10.1021/bi952474u; TRAYLOR TG, 1980, ADV CHEM SER, V191, P219	56	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8686	8693		10.1074/jbc.274.13.8686	http://dx.doi.org/10.1074/jbc.274.13.8686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085107	hybrid			2022-12-27	WOS:000079451600049
J	Ichikawa, H; Halberg, R; Kroos, L				Ichikawa, H; Halberg, R; Kroos, L			Negative regulation by the Bacillus subtilis GerE protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GENE-EXPRESSION; SIGMA-FACTOR; RNA-POLYMERASE; SPORE COAT; REPRESSES TRANSCRIPTION; SPATIAL CONTROL; SWITCH PROTEIN; SPORULATION; PROMOTER; BINDING	GerE is a transcription factor produced in the mother cell compartment of sporulating Bacillus subtilis. It is a critical regulator of cot genes encoding proteins that form the spore coat late in development. Most cot genes, and the gerE gene, are transcribed by sigma(K) RNA polymerase, Previously, it was shown that the GerE protein inhibits transcription in vitro of the sigK gene encoding sigma(K). Here, we show that GerE binds near the sigK transcriptional start site, to act as a repressor. A sigK-lacZ fusion containing the GerE-binding site in the promoter region was expressed at a a-fold lower level during sporulation of wild-type cells than gerE mutant cells, Likewise, the level of SigK protein (i,e, pro-sigma(K) and sigma(K)) was lower in sporulating wild-type cells than in a gerE mutant. These results demonstrate that sigma(K)-dependent transcription of gerE initiates a negative feedback loop in which GerE acts as a repressor to limit production of di, In addition, GerE directly represses transcription of particular cot genes. We show that GerE binds to two sites that span the -35 region of the cotD promoter. A low level of GerE activated transcription of cotD by sigma(K) RNA polymerase in vitro, but a higher level of GerE repressed cotD transcription. The upstream GerE-binding site was required for activation but not for repression. These results suggest that a rising level of GerE in sporulating cells may first activate cotD transcription from the upstream site then repress transcription as the downstream site becomes occupied. Negative regulation by GerE, in addition to its positive effects on transcription, presumably ensures that dl and spore coat proteins are synthesized at optimal levels to produce a germination-competent spore.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Kroos, L (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.				NIGMS NIH HHS [GM43585] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043585, R01GM043585] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER HL, 1986, P NATL ACAD SCI USA, V83, P9438, DOI 10.1073/pnas.83.24.9438; CUTTING S, 1989, J MOL BIOL, V207, P393, DOI 10.1016/0022-2836(89)90262-3; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DANIEL RA, 1993, J MOL BIOL, V232, P468, DOI 10.1006/jmbi.1993.1403; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; HALBERG R, 1994, J MOL BIOL, V243, P425, DOI 10.1006/jmbi.1994.1670; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; Harwood C.R., 1990, MOL BIOL METHODS BAC; Henriques AO, 1997, J BACTERIOL, V179, P1887, DOI 10.1128/jb.179.6.1887-1897.1997; Henriques AO, 1997, J BACTERIOL, V179, P389, DOI 10.1128/jb.179.2.389-398.1997; HOLLAND SK, 1987, J GEN MICROBIOL, V133, P2381; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; KENNEY TJ, 1991, J BACTERIOL, V173, P3282, DOI 10.1128/jb.173.11.3282-3290.1991; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KROOS L, 1999, IN PRESS MOL MICROBI, V31; KUNKEL B, 1988, J BACTERIOL, V170, P3513, DOI 10.1128/jb.170.8.3513-3522.1988; KUNKEL B, 1989, GENE DEV, V3, P1735, DOI 10.1101/gad.3.11.1735; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Miller J. H, 1972, EXPT MOL GENETICS; MOIR A, 1981, J BACTERIOL, V146, P1106, DOI 10.1128/JB.146.3.1106-1116.1981; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMAN K, 1988, J MOL BIOL, V200, P461, DOI 10.1016/0022-2836(88)90536-0; STEVENS CM, 1990, MOL MICROBIOL, V4, P543, DOI 10.1111/j.1365-2958.1990.tb00622.x; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; Zhang B, 1997, J BACTERIOL, V179, P972, DOI 10.1128/jb.179.3.972-975.1997; Zhang B, 1997, J BACTERIOL, V179, P6138, DOI 10.1128/jb.179.19.6138-6144.1997; ZHANG JK, 1994, J MOL BIOL, V240, P405, DOI 10.1006/jmbi.1994.1456; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	34	29	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8322	8327		10.1074/jbc.274.12.8322	http://dx.doi.org/10.1074/jbc.274.12.8322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075739	hybrid			2022-12-27	WOS:000079268100098
J	Lawinger, P; Rastelli, L; Zhao, ZY; Majumder, S				Lawinger, P; Rastelli, L; Zhao, ZY; Majumder, S			Lack of enhancer function in mammals is unique to oocytes and fertilized eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; PREIMPLANTATION MOUSE EMBRYO; ZYGOTIC GENE ACTIVATION; STAGE-SPECIFIC EXPRESSION; XENOPUS-LAEVIS OOCYTES; TERMINAL DOMAIN CTD; HUMAN CELL-LINE; CHROMATIN STRUCTURE; DNA-REPLICATION; BINDING PROTEIN	Previous studies have shown that the lack of novel coactivator activity in mouse oocytes and one-cell embryos (fertilized eggs) renders them incapable of utilizing Gal4:VP16-dependent enhancers (distal elements) but not promoters (proximal elements) in regulating transcription. This coactivator activity first appears in two- to four-cell embryos coincident with the major activation of zygotic gene expression. Here we show that whereas oocytes and fertilized eggs could utilize Spl-dependent promoters, they could not utilize Spl-dependent enhancers, although they showed promoter repression, which is a requirement for delineating enhancer function. In contrast, both Spl-dependent promoters and enhancers were functional in two- to four-cell embryos. Furthermore, the same embryonic stem cell mRNA that provided the coactivator activity for Gal4: VP16-dependent enhancer function also provided Sp1-dependent enhancer function in oocytes, Therefore, the coactivator activity appears to be a requirement for general enhancer function. To determine whether the absence of enhancer function is a unique property of oocytes or a general property of other terminally differentiated cells, transcription was examined in terminally differentiated hNT neurons and their precursors, undifferentiated NT2 stem cells. The results showed that both cell types could utilize enhancers and promoters. Thus, in mammals, the lack of enhancer function appears to be unique to oocytes and fertilized eggs, suggesting that it provides a safeguard against premature activation of genes prior to zygotic gene expression during development.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Majumder, S (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd,Box 100, Houston, TX 77030 USA.	majumder@audumla.mdacc.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Adenot PG, 1997, DEVELOPMENT, V124, P4615; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; Bagga R, 1997, GENE DEV, V11, P629, DOI 10.1101/gad.11.5.629; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BONI J, 1989, J VIROL, V63, P4088; CHALIFOUR LE, 1987, GENE DEV, V1, P1096, DOI 10.1101/gad.1.10.1096; CHALIFOUR LE, 1986, J VIROL, V59, P619, DOI 10.1128/JVI.59.3.619-627.1986; CHRISTIANS E, 1995, DEVELOPMENT, V121, P113; CONOVER JC, 1991, DEV BIOL, V144, P392, DOI 10.1016/0012-1606(91)90431-2; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEMPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DePamphilis ML, 1997, METHODS, V13, P211, DOI 10.1006/meth.1997.0521; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DOOLEY TP, 1989, DEVELOPMENT, V107, P945; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GREEN J, 1987, VIROLOGY, V159, P339, DOI 10.1016/0042-6822(87)90472-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hagmann M, 1997, J VIROL, V71, P5952, DOI 10.1128/JVI.71.8.5952-5962.1997; HENERY CC, 1995, DEV BIOL, V169, P448, DOI 10.1006/dbio.1995.1160; HOGAN B, 1986, MANIPULATING MOUSE E; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaneko KJ, 1997, DEVELOPMENT, V124, P1963; Kaneko KJ, 1998, DEV GENET, V22, P43, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;43::AID-DVG5&gt;3.0.CO;2-7; Keohane AM, 1998, DEV GENET, V22, P65, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;65::AID-DVG7&gt;3.0.CO;2-5; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LATHAM KE, 1992, DEV BIOL, V149, P457, DOI 10.1016/0012-1606(92)90300-6; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; MAJUMDER S, 1995, BIOESSAYS, V17, P879, DOI 10.1002/bies.950171010; Majumder S, 1997, EMBO J, V16, P1721, DOI 10.1093/emboj/16.7.1721; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; MAJUMDER S, 1994, MOL CELL BIOL, V14, P4258, DOI 10.1128/MCB.14.6.4258; MAJUMDER S, 1997, MICROINJECTION TRANS, P323; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MARTINEZSALAS E, 1989, GENE DEV, V3, P1493, DOI 10.1101/gad.3.10.1493; MARTINEZSALAS E, 1988, GENE DEV, V2, P1115, DOI 10.1101/gad.2.9.1115; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MICHAELI T, 1987, NUCLEIC ACIDS RES, V15, P1579, DOI 10.1093/nar/15.4.1579; MIRANDA M, 1993, METHOD ENZYMOL, V225, P412; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NONCHEV S, 1990, MOL REPROD DEV, V25, P72, DOI 10.1002/mrd.1080250113; Nothias JY, 1996, EMBO J, V15, P5715, DOI 10.1002/j.1460-2075.1996.tb00955.x; Oh B, 1997, DEVELOPMENT, V124, P493; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RASTELLI L, 1998, GENE THERAPY MOL BIO; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; RODMAN TC, 1981, J CELL BIOL, V90, P351, DOI 10.1083/jcb.90.2.351; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCHULTZ GA, 1992, MUTAT RES, V296, P17, DOI 10.1016/0165-1110(92)90029-9; SCHULTZ RM, 1993, BIOESSAYS, V15, P531, DOI 10.1002/bies.950150806; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; SEIPEL K, 1994, MOL REPROD DEV, V39, P215, DOI 10.1002/mrd.1080390215; SESHAGIRI PB, 1992, MOL REPROD DEV, V32, P229, DOI 10.1002/mrd.1080320307; SHIOKAWA K, 1990, ROUX ARCH DEV BIOL, V198, P322, DOI 10.1007/BF00383770; SHIOKAWA K, 1989, CELL DIFFER DEV, V28, P17, DOI 10.1016/0922-3371(89)90019-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Stein P, 1997, MOL REPROD DEV, V47, P421, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;421::AID-MRD8&gt;3.0.CO;2-M; STEINBEISSER H, 1988, NUCLEIC ACIDS RES, V16, P3223, DOI 10.1093/nar/16.8.3223; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TELFORD NA, 1990, MOL REPROD DEV, V26, P90, DOI 10.1002/mrd.1080260113; Temeles GL, 1997, J REPROD FERTIL, V109, P223, DOI 10.1530/jrf.0.1090223; THOMPSON EM, 1995, DEVELOPMENT, V121, P3425; Thompson EM, 1998, DEV GENET, V22, P31, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;31::AID-DVG4&gt;3.0.CO;2-8; TURNER CM, 1995, MOL BIOL CELL, V6, P22; Vermaak D, 1998, DEV GENET, V22, P1, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;1::AID-DVG1&gt;3.0.CO;2-A; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Wang QX, 1997, MOL REPROD DEV, V47, P265, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;265::AID-MRD5&gt;3.0.CO;2-J; WIEKOWSKI M, 1991, DEV BIOL, V147, P403, DOI 10.1016/0012-1606(91)90298-H; WIEKOWSKI M, 1993, DEV BIOL, V159, P366, DOI 10.1006/dbio.1993.1248; WIEKOWSKI M, 1999, IN PRESS J CELL SCI; WIRAK DO, 1985, MOL CELL BIOL, V5, P2924, DOI 10.1128/MCB.5.11.2924; Wolffe AP, 1997, BIOCHEM SOC T, V25, P354, DOI 10.1042/bst0250354; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WORRAD DM, 1995, DEVELOPMENT, V121, P2949; WORRAD DM, 1994, DEVELOPMENT, V120, P2347; Worrad DM, 1997, MOL REPROD DEV, V46, P268, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;268::AID-MRD5&gt;3.0.CO;2-N; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174; Zirkin B. R., 1989, The molecular biology of fertilization., P91	105	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8002	8011		10.1074/jbc.274.12.8002	http://dx.doi.org/10.1074/jbc.274.12.8002			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075699	hybrid			2022-12-27	WOS:000079268100058
J	Meredith, JE; Kiosses, WB; Takada, Y; Schwartz, MA				Meredith, JE; Kiosses, WB; Takada, Y; Schwartz, MA			Mutational analysis of cell cycle inhibition by integrin beta(1C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1 CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; FIBRONECTIN RECEPTOR; MESSENGER-RNA; ALPHA-ACTININ; SUBUNIT; EXPRESSION; ISOFORM; PROLIFERATION; LOCALIZATION	Integrin beta(1C) is an alternatively spliced cytoplasmic variant of the beta 1 subunit that potently inhibits cell cycle progression. In this study, we analyzed the requirements for growth suppression by beta(1C) A chimera containing the extracellular/transmembrane domain of the Tac subunit of the human interleukin 2 receptor (gp55) fused to the cytoplasmic domain of beta(1C) (residues 732-805) strongly inhibited growth in mouse 10T1/2 cells even at low expression levels, whereas chimeras containing the beta(1A), beta(1B), beta(1D), beta(3), and beta(5) cytoplasmic domains had weak and variable effects. The beta(1C) cytoplasmic domain is composed of a membrane proximal region (732-757) common to all beta(1) variants and a COOH-terminal 48-amino acid domain (758-805) unique to beta(1C). The beta(1C)-specific domain (758-805) was sufficient to block cell growth even when expressed as a soluble cytoplasmic green fluorescent protein fusion protein. These results indicate that growth inhibition by beta(1C) does not require the intact receptor and can function in the absence of membrane targeting. Analysis of deletions within the beta(1C)-specific domain showed that the 18-amino acid sequence 775-792 is both necessary and sufficient for maximal growth inhibition, although the 13 COOH-terminal residues (793-805) also had weak activity. Finally, beta(1C) is known to be induced in endothelial cells in response to tumor necrosis factor and is down-regulated in prostate epithelial cells after transformation, The green fluorescent protein/beta(1C) (758-805) chimera blocked growth in the human endothelial cell line EV304 and in the transformed prostate epithelial cell line DU145, consistent with a role for beta(1C) as a growth inhibitor in vivo.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243; takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, GM47157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Baudoin C, 1996, CELL ADHES COMMUN, V4, P1, DOI 10.3109/15419069609010759; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Fornaro M, 1996, AM J PATHOL, V149, P765; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215; TAPLEY P, 1989, ONCOGENE, V4, P325; ZHIDKOVA NI, 1995, BIOCHEM BIOPH RES CO, V214, P279, DOI 10.1006/bbrc.1995.2285	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8111	8116		10.1074/jbc.274.12.8111	http://dx.doi.org/10.1074/jbc.274.12.8111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075712	hybrid			2022-12-27	WOS:000079268100071
J	Park, EI; Garrow, TA				Park, EI; Garrow, TA			Interaction between dietary methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the human gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; CHOLINE; METABOLISM; MITOCHONDRIA; TRANSPORTER; OXIDATION; BALANCES; KINETICS; MAMMALS; CLONING	We previously showed that rat liver betaine-homocysteine methyltransferase (BHMT) mRNA content and activity increased l-fold when rats were fed a methionine-deficient diet containing adequate choline, compared with rats fed the same diet with control levels of methionine (Park, E, I., Renduchintala, M, S,, and Garrow, T, A. (1997) J, Nutr, Biochem. 8, 541-545), A further a-fold increase was observed in rats fed the methionine-deficient diet with supplemental betaine, The nutrition studies reported here were designed to determine whether other methyl donors would induce rat liver BHMT gene expression when added to a methionine-deficient diet and to define the relationship between the degree of methionine restriction and level of methyl donor intake on BHMT expression. Therefore, rats were fed amino acid-defined diets varying in methionine and methyl donor composition. The effect of diet on BHMT expression was evaluated using Northern, Western, and enzyme activity analyses. Similar to when betaine was added to a methionine-deficient diet, choline or sulfonium analogs of betaine induced BHMT expression. The diet-induced induction of hepatic BHMT activity was mediated by increases in the steady-state level of its mRNA and immunodetectable protein. Using methyl donor-free diets, we found that methionine restriction was required but alone not sufficient for the high induction of BHMT expression. Concomitant with methionine restriction, dietary methyl groups were required for high levels of BHMT induction, and a dose-dependent relationship was observed between methyl donor intake and BHMT induction. Furthermore, the severity of methionine restriction influenced the magnitude of BHMT induction, To study the molecular mechanisms that regulate the expression of BHMT, we have cloned the human BHMT gene. This gene spans about 20 kilobases of DNA and contains 8 exons and 7 introns, Using RNA isolated from human liver and hepatoma cells, a major transcriptional start site has been mapped using the 5' rapid amplification of cDNA ends technique, and this start site is 26 nucleotides downstream from a putative TATA box.	Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Garrow, TA (corresponding author), Univ Illinois, Dept Food Sci & Human Nutr, 463 Bevier Hall,905 S Goodwin Ave, Urbana, IL 61801 USA.	t-garro@uiuc.edu			PHS HHS [52501] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Emmert JL, 1998, J ANIM SCI, V76, P606; Emmert JL, 1996, J NUTR, V126, P2050; FENTON WA, 1995, METABOLIC MOL BASIS, P3029; FINKELSTEIN JD, 1986, J NUTR, V116, P985, DOI 10.1093/jn/116.6.985; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1983, J NUTR, V113, P519, DOI 10.1093/jn/113.3.519; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1982, ARCH BIOCHEM BIOPHYS, V218, P169, DOI 10.1016/0003-9861(82)90332-0; FINKELSTEIN JD, 1982, BIOCHEM BIOPH RES CO, V108, P344, DOI 10.1016/0006-291X(82)91872-1; FUNK MA, 1990, NUTR RES, V10, P1029, DOI 10.1016/S0271-5317(05)80044-2; GARCIAMARTINEZ LF, 1993, BIOCHEMISTRY-US, V32, P4671, DOI 10.1021/bi00068a027; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; Garrow TA, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P303; GRZELAKOWSKASZTABERT B, 1980, BIOCHIM BIOPHYS ACTA, V632, P164, DOI 10.1016/0304-4165(80)90074-4; HARPER AE, 1970, PHYSIOL REV, V50, P428, DOI 10.1152/physrev.1970.50.3.428; HAUBRICH DR, 1976, J NEUROCHEM, V27, P1305, DOI 10.1111/j.1471-4159.1976.tb02608.x; IIDA H, 1985, B JPN SOC SCI FISH, V51, P1145; KAPLAN CP, 1993, FEBS LETT, V321, P24, DOI 10.1016/0014-5793(93)80613-Y; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; Mudd SH, 1997, DEV CARDIOVASC MED, P77; Paquet L, 1995, CAN J BOT, V73, P1889, DOI 10.1139/b95-201; Park EI, 1997, J NUTR BIOCHEM, V8, P541, DOI 10.1016/S0955-2863(97)00101-0; PORTER RK, 1992, J BIOL CHEM, V267, P14637; Rao PV, 1998, J BIOL CHEM, V273, P30669, DOI 10.1074/jbc.273.46.30669; REVES PG, 1993, J NUTR, V123, P1939; ROSENBLATT DS, 1995, METABOLIC MOL BASIS, P3011; STORCH KJ, 1991, AM J CLIN NUTR, V54, P386, DOI 10.1093/ajcn/54.2.386; Sunden SLF, 1997, ARCH BIOCHEM BIOPHYS, V345, P171, DOI 10.1006/abbi.1997.0246; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; WEINHOLD PA, 1973, LIFE SCI, V13, P621, DOI 10.1016/0024-3205(73)90055-6; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	34	129	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7816	7824		10.1074/jbc.274.12.7816	http://dx.doi.org/10.1074/jbc.274.12.7816			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075673	hybrid			2022-12-27	WOS:000079268100032
J	Chin, KT; Ohki, S; Tang, DM; Cheng, HC; Wang, JH; Zhang, MJ				Chin, KT; Ohki, S; Tang, DM; Cheng, HC; Wang, JH; Zhang, MJ			Identification and structure characterization of a Cdk inhibitory peptide derived from neuronal-specific Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; DIRECTED PROTEIN-KINASE; CALMODULIN-BINDING DOMAIN; PAIRED HELICAL FILAMENTS; BRAIN-SPECIFIC ACTIVATOR; LIGHT-CHAIN KINASE; REGULATORY SUBUNIT; CDC2-LIKE KINASE; NMR-SPECTROSCOPY; DIFFERENTIATION	The activation of cyclin-dependent kinase 5 (Cdk5) depends on the binding of its neuronal specific activator Nck5a, The minimal activation domain of Nck5a is located in the region of amino acid residues 150 to 291 (Tang, D,, Chun, A. C. S., Zhang, M., and Wang, J. H, (1997) J, Biol. Chem. 272, 12318-12327), In this work we show that a 29-residue peptide, denoted as the alpha(N) peptide, encompassing amino acid residues Gln(145) to Asp(173) of Nck5a is capable of binding Cdk5 to result in kinase inhibition. This peptide also inhibits an active phospho-Cdk2-cyclin A complex, with a similar potency. Direct competition experiments have shown that this inhibitory peptide does not compete with Nck5a or cyclin A for Cdk5 or Cdk2, respectively. Steady state kinetic analysis has indicated that the cu, peptide acts as a non-competitive inhibitor of Cdg5 . Nck5a complex with respect to the peptide substrate. To understand the molecular basis of kinase inhibition by the peptide, we determined the structure of the peptide in solution by circular dichroism and two-dimensional H-1 MMR spectroscopy. The peptide adopts an amphipathic alpha-helical structure from residues Ser(149) to Arg(162) which can be further stabilized by the helix-stabilizing solvent trifluoroethanol, The hydrophobic face of the helix is likely to be the kinase binding surface.	Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	Hong Kong University of Science & Technology; University of Melbourne	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China.	mzhang@uxmail.ust.hk	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521; Cheng, Heung-Chin/0000-0002-4965-7148				Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bazan JF, 1996, PROTEINS, V24, P1; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Cheng HC, 1996, BIOCHEMISTRY-US, V35, P11874, DOI 10.1021/bi9603940; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; FAN JS, 1999, IN PRESS BIOCH BIOPH; HAYES TE, 1991, NEW BIOL, V3, P259; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; LEE EM, 1993, MOL CELL BIOL, V13, P1194; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NUGENT JA, 1991, J CELL SCI, V99, P674; OSHIMA T, 1996, P NATL ACAD SCI USA, V93, P11173; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Reymond MT, 1997, BIOCHEMISTRY-US, V36, P5234, DOI 10.1021/bi970038x; Segel IH, 1975, ENZYME KINETICS BEHA, P101; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114	39	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7120	7127		10.1074/jbc.274.11.7120	http://dx.doi.org/10.1074/jbc.274.11.7120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066770	hybrid			2022-12-27	WOS:000079078400042
J	Houssa, B; de Widt, J; Kranenburg, O; Moolenaar, WH; van Blitterswijk, WJ				Houssa, B; de Widt, J; Kranenburg, O; Moolenaar, WH; van Blitterswijk, WJ			Diacylglycerol kinase theta binds to and is negatively regulated by active RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CYTOSKELETON; FIBROBLASTS; ACTIVATION; GTPASES	Diacylglycerol kinase (DGK) phosphorylates the second messenger diacylglycerol to yield phosphatidic acid. To date, very little is known about the regulation of DGK activity. We have previously identified the DGK theta isotype, which is predominantly expressed in brain (Houssa, B,, Schaap, D., van der Wal, J., Goto, K., Kondo, H., Yamakawa, A., Shibata, M., Takenawa, T., and Van Blitterswijk, W. J. (1997) J. Biol, Chem. 272, 10422-10428), We now report that DGK theta binds specifically to activated RhoA in transfected COS cells as well as in nontransfected neuronal N1E-115 cells. Binding is abolished by a point mutation (Y34N) in the effector loop of RhoA DGK theta does not bind to inactive RhoA, nor to the other Rho-family GTPases, Rac or Cdc42, Like active RhoA, DGK theta localizes to the plasma membrane. Strikingly, the binding of activated RhoA to DGK theta completely inhibits DGK catalytic activity. Our results suggest that DGK theta is a downstream effector of RhoA and that its activity is negatively regulated by RhoA, Through accumulation of newly produced diacylglycerol, RhoA-mediated inhibition of DGK theta may lead to enhanced PKC activity in response to external stimuli.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	van Blitterswijk, WJ (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; van Dijk MCM, 1998, BBA-LIPID LIPID MET, V1391, P273, DOI 10.1016/S0005-2760(98)00016-2; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANBLITTERSWIJK WJ, 1999, IN PRESS CHEM PHYS L; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5	23	75	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6820	6822		10.1074/jbc.274.11.6820	http://dx.doi.org/10.1074/jbc.274.11.6820			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066731	hybrid			2022-12-27	WOS:000079078400003
J	Lorentz, O; Suh, ER; Taylor, JK; Boudreau, F; Traber, PG				Lorentz, O; Suh, ER; Taylor, JK; Boudreau, F; Traber, PG			RETRACTED: cAMP response element-binding protein interacts with the homeodomain protein Cdx2 and enhances transcriptional activity (Retracted Article. See vol 276, pg 10576, 2001)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							HOMEOBOX GENE; EPITHELIAL-CELLS; E1A PROTEINS; DIFFERENTIATION; ACTIVATION; EXPRESSION; CBP/P300; CREB; COACTIVATOR; TARGETS	Cdx-2 encodes for a homeodomain protein that is expressed in intestinal epithelial cells. The Cdx2 protein triggers intestinal differentiation in cell lines and is necessary for maintenance of the intestinal phenotype in mice. CBP (cAMP response element-binding protein) is a transcriptional co-activator that interacts with many transcription factors and components of the basal transcriptional machinery. In this study, we demonstrate that CBP is markedly induced upon differentiation of the Caco-2 intestinal cell line and augments Cdx2-dependent transcriptional activity. Cdx2 interacts with the amino-terminal domain of CBP, and the two proteins coexist in vivo within the same nuclear protein complex. Moreover, expression of the CBP domain that interacts with Cdx2 acts as a dominant-negative inhibitor of transcriptional activation by Cdx2. These findings demonstrate a direct interaction between an intestinal homeodomain protein and CBP and suggest that CBP participates in the network of transcriptional proteins that direct intestinal differentiation.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Traber, PG (corresponding author), Hosp Univ Penn, 100 Centrex,34th & Spruce St, Philadelphia, PA 19104 USA.	traberp@mail.med.upenn.edu			NIDDK NIH HHS [P30-DK50306, R01-DK46704] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK046704] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Basora N, 1998, INT J CANCER, V75, P738, DOI 10.1002/(SICI)1097-0215(19980302)75:5<738::AID-IJC12>3.0.CO;2-2; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Duluc I, 1997, J CELL SCI, V110, P1317; Eckner R, 1996, BIOL CHEM, V377, P685; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; JAMES R, 1994, J BIOL CHEM, V269, P15229; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; PINTO M, 1983, BIOL CELL, V47, P323; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WU GD, 1994, J BIOL CHEM, V269, P17080; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	26	19	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7196	7199		10.1074/jbc.274.11.7196	http://dx.doi.org/10.1074/jbc.274.11.7196			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066780	hybrid			2022-12-27	WOS:000079078400052
J	Ammini, CV; Hauswirth, WW				Ammini, CV; Hauswirth, WW			Mitochondrial gene expression is regulated at the level of transcription during early embryogenesis of Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-METABOLISM; EMBRYOS; EGGS; FROG; CA2+; FERTILIZATION; ACTIVATION; OOCYTES; MOUSE; WAVE	Mitochondrial transcription in the early Xenopus laevis embryo resumes several hours before active mtDNA replication, effectively decoupling mtDNA transcription and replication. This developmental feature makes Xenopus embryogenesis an appealing model system to investigate the regulation of mitochondrial transcription. Studies reported here refine our understanding of the timing, magnitude, and mechanism of this transcriptional induction event. Northern analyses of six mitochondrial mRNAs (normalized to mtDNA) reveal that transcript levels remain basal between fertilization and gastrulation and then undergo a coordinate induction, culminating in a 20-28-fold increase over egg levels by 48 h of development. Measurement of mitochondrial run-on transcription rates demonstrates a good correlation between transcription rates and transcript levels, showing that transcription itself is the primary determinant of transcript abundance. Experimental increases in mitochondrial ATP and energy charge also correlate with patterns of transcript levels and transcription rates, suggesting that developmental changes in the biochemical composition of the mitochondrial matrix could be regulating transcriptional activity. Consistent with this idea, transcriptional run-on rates in mitochondria of early embryos can be stimulated by the addition of tricarboxylic acid cycle intermediates to the run on reaction. However, mitochondria of later stages do not show this response to the addition of metabolite. In combination, these data suggest that mitochondrial transcription is under metabolic regulation during early Xenopus embryogenesis.	Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hauswirth, WW (corresponding author), Univ Florida, J Hillis Miller Hlth Ctr, Dept Mol Genet & Microbiol, Box 100266, Gainesville, FL 32610 USA.							Ammini C V, 1996, Methods Enzymol, V264, P23, DOI 10.1016/S0076-6879(96)64005-1; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAWID IB, 1985, J EMBRYOL EXP MORPH, V89, P113; DWORKIN MB, 1991, TRENDS BIOCHEM SCI, V16, P229, DOI 10.1016/0968-0004(91)90091-9; DWORKIN MB, 1989, DEV BIOL, V132, P512, DOI 10.1016/0012-1606(89)90246-7; DWORKIN MB, 1990, DEV BIOL, V138, P177, DOI 10.1016/0012-1606(90)90187-N; GAINES G, 1987, J BIOL CHEM, V262, P1907; Gaines G L 3rd, 1996, Methods Enzymol, V264, P43, DOI 10.1016/S0076-6879(96)64007-5; GINSBERG L, 1973, J EMBRYOL EXP MORPH, V30, P267; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HOLLINGER TG, 1980, GAMETE RES, V3, P45, DOI 10.1002/mrd.1120030106; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LOVTRUPREIN H, 1982, EXP CELL BIOL, V50, P162; LOVTRUPREIN H, 1982, CELL DIFFER DEV, V11, P125, DOI 10.1016/0045-6039(82)90002-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMACK JG, 1993, DEV NEUROSCI-BASEL, V15, P165, DOI 10.1159/000111332; MCKEE EE, 1990, AM J PHYSIOL, V258, pE492, DOI 10.1152/ajpendo.1990.258.3.E492; MEZIANE AE, 1989, EMBO J, V8, P1649; MILLS RM, 1967, EXP CELL RES, V47, P337, DOI 10.1016/0014-4827(67)90236-4; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop PD, 1967, NORMAL TABLES XENOPU; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; PIKO L, 1973, J CELL BIOL, V58, P357, DOI 10.1083/jcb.58.2.357; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; ROE BA, 1985, J BIOL CHEM, V260, P9759; STERN S, 1971, J EXP ZOOL, V176, P179, DOI 10.1002/jez.1401760206; THOMAN M, 1979, DEV BIOL, V68, P191, DOI 10.1016/0012-1606(79)90253-7; WEBB AC, 1977, DEV BIOL, V56, P219, DOI 10.1016/0012-1606(77)90166-X; WEBB AC, 1975, DEV BIOL, V45, P44, DOI 10.1016/0012-1606(75)90239-0; WEINBERG JM, 1989, J LAB CLIN MED, V113, P612; YOUNG PG, 1973, DEV BIOL, V33, P196, DOI 10.1016/0012-1606(73)90174-7	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6265	6271		10.1074/jbc.274.10.6265	http://dx.doi.org/10.1074/jbc.274.10.6265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037714	hybrid			2022-12-27	WOS:000078902800036
J	Di Bartolo, V; Mege, D; Germain, V; Pelosi, M; Dufour, E; Michel, F; Magistrelli, G; Isacchi, A; Acuto, O				Di Bartolo, V; Mege, D; Germain, V; Pelosi, M; Dufour, E; Michel, F; Magistrelli, G; Isacchi, A; Acuto, O			Tyrosine 319, a newly identified phosphorylation site of ZAP-70, plays a critical role in T cell antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PHOSPHOTYROSINE-BINDING DOMAIN; FOCAL ADHESION KINASE; SH2 DOMAIN; SYK; ACTIVATION; INTERACTS; PROTEINS; SLP-76; TCR	Following T cell antigen receptor (TCR) engagement, the protein tyrosine kinase (PTK) ZAP-70 is rapidly phosphorylated on several tyrosine residues, presumably by two mechanisms: an autophosphorylation and a trans-phosphorylation by the Src-family PTK Lck, These events have been implicated in both positive and negative regulation of ZAP-70 activity and in coupling this PTK to downstream signaling pathways in T cells. We show here that Tyr(315) and Tyr(319) in the interdomain B of ZAP-70 are autophosphorylated in vitro and become phosphorylated in vivo upon TCR triggering. Moreover, by mutational analysis, we demonstrate that phosphorylation of Tyr(319) is required for the positive regulation of ZAP-70 function. Indeed, overexpression in Jurkat cells and in a murine T cell hybridoma of a ZAP-70 mutant in which Tyr(319) was replaced by phenylalanine (ZAP-70-Y319F) dramatically impaired anti-TCR-induced activation of the nuclear factor of activated T cells and interleukin-2 production, respectively. Surprisingly, an analogous mutation of Tyr(315) had little or no effect. The inhibitory effect of ZAP-70-Y319F correlated with a substantial loss of its activation-induced tyrosine phosphorylation and up-regulation of catalytic activity, as well as with a decreased in vivo capacity to phosphorylate known ZAP-70 substrates, such as SLP-76 and LAT, Collectively, our data reveal the pivotal role of Tyr(319) phosphorylation in the positive regulation of ZAP-70 and in TCR-mediated signaling.	Inst Pasteur, Dept Immunol, Mol Immunol Unit, F-75724 Paris 15, France; Pharmacia & Upjohn Inc, Dept Biol, I-20014 Nerviano, Italy	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Pfizer	Acuto, O (corresponding author), Inst Pasteur, Dept Immunol, Mol Immunol Unit, 25 Rue Docteur Roux, F-75724 Paris 15, France.	oacuto@pasteur.fr	Di Bartolo, Vincenzo/AAL-6834-2020	Di Bartolo, Vincenzo/0000-0002-5453-947X; Michel, Frederique/0000-0002-3524-2232				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FURLONG MT, 1997, BIOCHIM BIOPHYS ACTA, P177; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KLOHE EP, 1988, J IMMUNOL, V141, P2158; Kong GH, 1996, MOL CELL BIOL, V16, P5026; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Latour S, 1998, EMBO J, V17, P2584, DOI 10.1093/emboj/17.9.2584; Law CL, 1996, MOL CELL BIOL, V16, P1305; LUO K, 1990, ONCOGENE, V5, P921; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Milia E, 1996, ONCOGENE, V13, P767; MOLL H, 1993, EUR J IMMUNOL, V23, P1595, DOI 10.1002/eji.1830230730; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6285	6294		10.1074/jbc.274.10.6285	http://dx.doi.org/10.1074/jbc.274.10.6285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037717	hybrid			2022-12-27	WOS:000078902800039
J	Rogers, JT; Leiter, LM; McPhee, J; Cahill, CM; Zhan, SS; Potter, H; Nilsson, LNG				Rogers, JT; Leiter, LM; McPhee, J; Cahill, CM; Zhan, SS; Potter, H; Nilsson, LNG			Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5 '-untranslated region sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IRON-RESPONSIVE ELEMENT; FERRITIN MESSENGER-RNA; BETA-PROTEIN; APOLIPOPROTEIN-E; GENE-EXPRESSION; TRANSGENIC MICE; RAT-BRAIN; IN-VITRO; DISEASE	The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-l (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1 alpha and IL-beta increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5'-untranslated region (5'-UTR) conferred translational regulation by IL-l alpha and IL-1 beta to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5'-UTR)/CAT mRNAs were unchanged, whereas both baseline and IL-l-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5'-cap site and is homologous to related translational control elements in the 5'-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Suncoast Gerontol Ctr, Tampa, FL 33612 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Rogers, JT (corresponding author), 604 LMRC,221 Longwood Ave, Boston, MA 02115 USA.	Rogers@calvin.bwh.harvard.edu		nilsson, lars/0000-0002-8362-1042; Rogers, Jack/0000-0003-1262-8578; McPhee, James/0000-0001-9329-3479	NIAMS NIH HHS [AR29I32717] Funding Source: Medline; PHS HHS [6872302] Funding Source: Medline; ADAMHA HHS [AD09665] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ADAMHA HHS		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006-8993(97)01204-3; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ElKhoury J, 1996, NATURE, V382, P716; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Frautschy SA, 1998, AM J PATHOL, V152, P307; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRAY CW, 1993, MOL BRAIN RES, V19, P251, DOI 10.1016/0169-328X(93)90037-P; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HOLZMAN DM, 1992, EMBO J, V11, P619; Janciauskiene S, 1996, NAT STRUCT BIOL, V3, P668, DOI 10.1038/nsb0896-668; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Johnston JA, 1996, MOL BRAIN RES, V43, P85, DOI 10.1016/S0169-328X(96)00161-1; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Machein U, 1995, NEUROREPORT, V6, P2283, DOI 10.1097/00001756-199511270-00004; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Neve RL, 1996, MOL BRAIN RES, V39, P185, DOI 10.1016/0169-328X(96)00007-1; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NILSSON L, 1998, FRONT BIOSCI, V3, P436; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; Rogers JT, 1996, BLOOD, V87, P2525, DOI 10.1182/blood.V87.6.2525.bloodjournal8762525; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wisniewski T, 1996, NEUROREPORT, V7, P667, DOI 10.1097/00001756-199601310-00068; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	67	246	268	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6421	6431		10.1074/jbc.274.10.6421	http://dx.doi.org/10.1074/jbc.274.10.6421			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037734	hybrid			2022-12-27	WOS:000078902800056
J	Banbula, A; Mak, P; Bugno, M; Silberring, J; Dubin, A; Nelson, D; Travis, J; Potempa, J				Banbula, A; Mak, P; Bugno, M; Silberring, J; Dubin, A; Nelson, D; Travis, J; Potempa, J			Prolyl tripeptidyl peptidase from Porphyromonas gingivalis - A novel enzyme with possible pathological implications for the development of periodontitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-GINGIVALIS; CYSTEINE PROTEINASES; GLYCYLPROLYL PROTEASE; ESCHERICHIA-COLI; GENE; PURIFICATION; GENERATION; EXPRESSION; ACTIVATION; GINGIPAIN	Porphyromonas gingivalis possesses a complex proteolytic system, which is essential for both its growth and evasion of host defense mechanisms, In this report we characterized, both at a protein and genomic level, a novel peptidase of this system with prolyl tripeptidyl peptidase activity. The enzyme was purified to homogeneity, and its enzymatic activity and biochemical properties were investigated The amino acid sequence at the amino terminus and of internal peptide fragments enabled identification of the gene encoding this enzyme, which we refer to as PtpA for prolyl tripeptidyl peptidase A. The gene encodes an 82-kDa protein, which contains a GWSYGG motif, characteristic for members of the S9 prolyl oligopeptidase family of serine proteases. However, it does not share any structural similarity to Other tripeptidyl peptidases, which, belong to the subtilisin family. The production of prolyl tripeptidyl peptidase may contribute to the pathogenesis of periodontal tissue destruction through the mutual interaction of this enzyme, host and bacterial collagenases, and, dipeptidyl peptidases in the degradation of collagen during the course of infection.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Jagiellonian Univ, Fac Chem, PL-31120 Krakow, Poland; Jagiellonian Univ, Reg Lab, PL-31120 Krakow, Poland	University System of Georgia; University of Georgia; Jagiellonian University; Jagiellonian University; Jagiellonian University	Potempa, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	potempa@arches.uga.edu	Silberring, Jerzy/AGA-5631-2022; Nelson, Daniel C./I-2198-2012	Silberring, Jerzy/0000-0002-4362-8362; Nelson, Daniel C./0000-0003-3248-4831; Mak, Pawel/0000-0002-5222-3922				ABIKO Y, 1985, J DENT RES, V64, P106, DOI 10.1177/00220345850640020201; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BARUA PK, 1989, INFECT IMMUN, V57, P2522, DOI 10.1128/IAI.57.8.2522-2528.1989; BOURGEAU G, 1992, INFECT IMMUN, V60, P3186, DOI 10.1128/IAI.60.8.3186-3192.1992; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; Cicala C, 1998, LIFE SCI, V62, P1817, DOI 10.1016/S0024-3205(97)01167-3; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; CURTIS MA, 1993, J GEN MICROBIOL, V139, P949, DOI 10.1099/00221287-139-5-949; Dashper SG, 1998, J DENT RES, V77, P1133; Gazi MI, 1997, ORAL MICROBIOL IMMUN, V12, P240, DOI 10.1111/j.1399-302X.1997.tb00386.x; GRENIER D, 1989, INFECT IMMUN, V57, P3265, DOI 10.1128/IAI.57.11.3265-3269.1989; GRENIER D, 1987, INFECT IMMUN, V55, P3131, DOI 10.1128/IAI.55.12.3131-3136.1987; HINODE D, 1992, ARCH ORAL BIOL, V37, P859, DOI 10.1016/0003-9969(92)90120-W; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; IMAMURA T, 1995, INFECT IMMUN, V63, P4877, DOI 10.1128/IAI.63.12.4877-4882.1995; Imamura T, 1997, J BIOL CHEM, V272, P16062, DOI 10.1074/jbc.272.25.16062; IMAMURA T, 1995, INFECT IMMUN, V63, P1999, DOI 10.1128/IAI.63.5.1999-2003.1995; JIN KC, 1989, J ENDODONT, V15, P463, DOI 10.1016/S0099-2399(89)80025-1; KABASHIMA T, 1995, ARCH BIOCHEM BIOPHYS, V320, P123, DOI 10.1006/abbi.1995.1349; KIYAMA M, 1998, BIOCHIM BIOPHYS ACTA, V1369, P39; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PIKE R, 1994, J BIOL CHEM, V269, P406; Potempa Jan, 1995, Perspectives in Drug Discovery and Design, V2, P445, DOI 10.1007/BF02172037; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; SOCRANSKY SS, 1992, J PERIODONTOL, V63, P322, DOI 10.1902/jop.1992.63.4s.322; Stenfors C, 1997, J BIOL CHEM, V272, P5747, DOI 10.1074/jbc.272.9.5747; Travis J, 1997, J PERIODONTAL RES, V32, P120, DOI 10.1111/j.1600-0765.1997.tb01392.x; WALTER R, 1980, MOL CELL BIOCHEM, V30, P111; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	34	78	81	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9246	9252		10.1074/jbc.274.14.9246	http://dx.doi.org/10.1074/jbc.274.14.9246			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092598	hybrid			2022-12-27	WOS:000079451800017
J	Gheber, L; Kuo, SC; Hoyt, MA				Gheber, L; Kuo, SC; Hoyt, MA			Motile properties of the kinesin-related Cin8p spindle motor extracted from Saccharomyces cerevisiae cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PYRUVATE-CARBOXYLASE; MICROTUBULE-BASED MOTILITY; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; PROTEIN KLP61F; FISSION YEAST; DROSOPHILA; GENE; MOVEMENT; DYNEIN	We have developed microtubule binding and motility assays for Cin8p, a kinesin-related mit-otic spindle motor protein from Saccharomyces cerevisiae. The methods examine Cin8p rapidly purified from crude yeast cell extracts. We created a recombinant form of CIN8 that fused the biotin carrying polypeptide from yeast pyruvate carboxylase to the carboxyl terminus of Cin8p, This form was biotinated in yeast cells and provided Cin8p activity in vivo, Avidin-coated glass surfaces were used to specifically bind biotinated Cin8p from crude extracts, Microtubules bound to the Cin8p-coated surfaces and moved at 3.4 +/- 0.5 mu m/min in the presence of ATP. Force production by Cin8p was directed toward the plus ends of microtubules. A mutation affecting the microtubule-binding site within the motor domain (cin8-F467A) decreased Cin8p's ability to bind microtubules to the glass surface by > 10-fold, but reduced gliding velocity by only 35%. The cin8-3 mutant form, affecting the alpha 2 helix of the motor domain, caused a moderate defect in microtubule binding, but motility was severely affected, cin8-F467A cells, but not cin8-3 cells, were greatly impaired in bipolar spindle forming ability, We conclude that microtubule binding by Cin8p is more important than motility for proper spindle formation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Hoyt, MA (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,3400 N Charles St, Baltimore, MD 21218 USA.	hoyt@jhu.edu			NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BELL CW, 1982, METHOD CELL BIOL, V24, P373; BERLINER E, 1994, J BIOL CHEM, V269, P8610; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1994, J BIOL CHEM, V269, P22913; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIBBERD MG, 1984, CURR TOP CELL REGUL, V24, P357; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUO SC, 1991, J CELL SCI, P135; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LIM F, 1988, J BIOL CHEM, V263, P11493; LIM F, 1987, ARCH BIOCHEM BIOPHYS, V258, P259, DOI 10.1016/0003-9861(87)90343-2; Nicolas G, 1997, BIOTECHNIQUES, V22, P430, DOI 10.2144/97223bm11; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SAMBROOKI J, 1989, MOL CLONING LAB MANU; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SHERMAN F, 1983, METHODS YEAST GENETI, P61; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P1575, DOI 10.1021/bi00005a013; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WALKER ME, 1991, BIOCHEM BIOPH RES CO, V176, P1210, DOI 10.1016/0006-291X(91)90414-3; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	47	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9564	9572		10.1074/jbc.274.14.9564	http://dx.doi.org/10.1074/jbc.274.14.9564			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092642	hybrid			2022-12-27	WOS:000079451800061
J	Assefa, Z; Vantieghem, A; Declercq, W; Vandenabeele, P; Vandenheede, JR; Merlevede, W; de Witte, P; Agostinis, P				Assefa, Z; Vantieghem, A; Declercq, W; Vandenabeele, P; Vandenheede, JR; Merlevede, W; de Witte, P; Agostinis, P			The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; TRANSDUCTION PATHWAY; CYTOCHROME-C; MAP KINASE; NH2-TERMINAL KINASE; EPITHELIAL-CELLS; JNK ACTIVATION; GROWTH-FACTOR; STRESS; DEATH	In this study, we elucidate signaling pathways induced by photodynamic therapy (PDT) with hypericin. We show that PDT rapidly activates JNK1 while irreversibly inhibiting ERK2 in several cancer cell lines. In HeLa cells, sustained PDT-induced JNK1 and p38 mitogen-activated protein kinase (MAPK) activations overlap the activation of a DEVD-directed caspase activity, poly(ADP-ribose) polymerase (PARP) cleavage, and the onset of apoptosis, The caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) and benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone (zDEVD-fmk) protect cells against apoptosis and inhibit DEVD-specific caspase activity and PARP cleavage without affecting JNK1 and p38 MAPK activations, Conversely, stable overexpression of CrmA, the serpin-like inhibitor of caspase-1 and caspase-8, has no effect on PDT-induced PARP cleavage, apoptosis, or JNK1/p38 activations. Cell transfection with the dominant negative inhibitors of the c-Jun N-terminal kinase (JNK) pathway, SEK-AL and TAM-67, or pretreatment with the p38 MAPK inhibitor PD169316 enhances PDT-induced apoptosis, A similar increase in PDT-induced apoptosis was observed by expression of the dual specificity phosphatase MKP-1, The simultaneous inhibition of both stress kinases by pretreating cells with PD169316 after transfection with either TAM-67 or SEK-AL produces a more pronounced sensitizing effect. Cell pretreatment with the p38 inhibitor PD169316 causes faster kinetics of DEVD-caspase activation and PARP cleavage and strongly oversensitizes the cells to apoptosis following PDT, These observations indicate that the JNK1 and p38 MAPK pathways play an important role in cellular resistance against PDT-induced apoptosis with hypericin.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Pharm, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium	KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University	Agostinis, P (corresponding author), Katholieke Univ Leuven, Fac Med, Div Biochem, Herestr 49, B-3000 Louvain, Belgium.	Patricia.Agostinis@med.huleuven.ac.be	Assefa, Zerihun/V-5641-2017; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Assefa, Zerihun/0000-0001-7803-5228; Agostinis, Patrizia/0000-0003-1314-2115; Vandenabeele, Peter/0000-0002-6669-8822; de Witte, Peter/0000-0002-9989-9567				AGOSTINIS P, 1995, BIOCHEM PHARMACOL, V49, P1615, DOI 10.1016/0006-2952(95)00097-J; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Alecu M, 1998, ANTICANCER RES, V18, P4651; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DBAIDO GS, 1997, J EXP MED, V3, P481; DOUGHERTY TJ, 1992, EUR J CANCER, V28A, P1734, DOI 10.1016/0959-8049(92)90080-L; Fox FE, 1998, J INVEST DERMATOL, V111, P327, DOI 10.1046/j.1523-1747.1998.00278.x; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harris MS, 1996, CURR EYE RES, V15, P255, DOI 10.3109/02713689609007619; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOU P, 1997, MOL CELL BIOL, V17, P24; KAFMANN SH, 1993, CANCER RES, V53, P3976; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Klotz LO, 1998, CANCER RES, V58, P4297; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARIAS R, 1993, CELL, V73, P381; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; VANDENBOGAERDE AL, 1996, ANTICANCER RES, V16, P1611; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Weller M, 1997, NEUROL RES, V19, P459; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZHANG W, 1995, CANCER LETT, V96, P31, DOI 10.1016/0304-3835(95)03914-I; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	58	187	200	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8788	8796		10.1074/jbc.274.13.8788	http://dx.doi.org/10.1074/jbc.274.13.8788			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085120	hybrid			2022-12-27	WOS:000079451600062
J	Nosek, J; Tomaska, L; Pagacova, B; Fukuhara, H				Nosek, J; Tomaska, L; Pagacova, B; Fukuhara, H			Mitochondrial telomere-binding protein from Candida parapsilosis suggests an evolutionary adaptation of a nonspecific single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SSB; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; YEAST; REPLICATION; PHOSPHORYLATION; RESOLUTION; KINASE; GENES	The mitochondrial genome in a number of organisms is represented by linear DNA molecules with defined terminal structures. The telomeres of linear mitochondrial DNA (mtDNA) of yeast Candida parapsilosis consist of tandem arrays of large repetitive units possessing single-stranded 5' extension of about 110 nucleotides. Recently we identified the first mitochondrial telomere-binding protein (mtTBP) that specifically binds a sequence derived from the extreme end of C, parapsilosis linear mtDNA and protects it from attack, by various DNA-modifying enzymes (Tomaska, L',, Nosek, J,, and Fukuhara, H, (1997) J, Biol, Chem, 272, 3049-3059). Here we report the isolation of MTP1, the gene encoding mtTBP of C. parapsilosis, Sequence analysis revealed that mtTBP shares homology with several bacterial and mitochondrial single-stranded DNA-binding proteins that nonspecifically bind to single-stranded DNA with high affinity, Recombinant mtTBP displays a preference for the telomeric 5' overhang of C, parapsilosis mtDNA. The heterologous expression of a mtTBP-GFP fusion protein resulted in its localization to the mitochondria but was unable to functionally substitute for the loss of the S. cerevisiae homologue Rimlp, Analysis of the MTP1 gene and its translation product mtTBP may provide an insight into the evolutionary origin of linear mitochondrial genomes and the role it plays in their replication and maintenance.	Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; Comenius Univ, Fac Nat Sci, Dept Genet, Bratislava 84215, Slovakia; Ctr Univ Paris 11, Inst Curie, Sect Rech, F-91405 Orsay, France	Comenius University Bratislava; Comenius University Bratislava; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Nosek, J (corresponding author), Comenius Univ, Fac Nat Sci, Dept Biochem, Mlynska Dolina CH-1, Bratislava 84215, Slovakia.	nosek@fns.uniba.sk	Nosek, Jozef/A-7581-2008; Tomaska, Lubomir/I-3071-2014	Nosek, Jozef/0000-0002-1020-5451; Tomaska, Lubomir/0000-0003-4886-1910; Kucejova, Blanka/0000-0002-5058-330X				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CURTH U, 1991, EUR J BIOCHEM, V196, P87, DOI 10.1111/j.1432-1033.1991.tb15789.x; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DINOUEL N, 1993, MOL CELL BIOL, V13, P2315, DOI 10.1128/MCB.13.4.2315; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; FANG G, 1995, TELOMERES, P69; FUKUHARA H, 1993, MOL CELL BIOL, V13, P2309, DOI 10.1128/MCB.13.4.2309; GARRITY PA, 1995, PCR 2 PRACTICAL APPR, P309; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NOSEK J, 1995, MOL GEN GENET, V247, P61, DOI 10.1007/BF00425822; Nosek J, 1998, TRENDS GENET, V14, P184, DOI 10.1016/S0168-9525(98)01443-7; NOSEK J, 1994, J BACTERIOL, V176, P5622, DOI 10.1128/JB.176.18.5622-5630.1994; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Suck D, 1997, NAT STRUCT BIOL, V4, P161, DOI 10.1038/nsb0397-161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; Tomaska L, 1997, J BIOL CHEM, V272, P3049, DOI 10.1074/jbc.272.5.3049; Tomaska L, 1998, BIOCHEM BIOPH RES CO, V242, P457, DOI 10.1006/bbrc.1997.7968; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; Webster G, 1997, FEBS LETT, V411, P313, DOI 10.1016/S0014-5793(97)00747-3; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	35	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8850	8857		10.1074/jbc.274.13.8850	http://dx.doi.org/10.1074/jbc.274.13.8850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085128	hybrid			2022-12-27	WOS:000079451600070
J	Pan, QT; Simpson, RU				Pan, QT; Simpson, RU			c-myc intron element-binding proteins are required for 1,25-dihydroxyvitamin D-3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; KINASE-C; TELOMERASE ACTIVITY; HOMEOBOX GENE; HOMEODOMAIN PROTEINS; TRANSCRIPTIONAL REGULATION; TERMINAL DIFFERENTIATION; TRANSGENIC MICE; IMMORTAL CELLS; MESSENGER-RNA	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) suppresses c-myc expression during differentiation of HL-60 cells along the monocytic pathway by blocking transcriptional elongation at the first exon/intron border of the c-myc gene. In the present study, the physiological relevance of three putative regulatory protein binding sites found within a 280-base pair region in intron 1 of the c-myc gene was explored. HL-60 promyelocytic leukemia cells were transiently transfected with three different c-mye promoter constructs cloned upstream of a chloramphenicol acetyltransferase (CAT) reporter gene. With the wild-type c-myc promoter construct (pMPCAT), which contains MIE1, MIE2, and MIE3 binding sites, 1,25-(OH)(2)D-3 was able to decrease CAT activity by 45.4 +/- 7.9% (mean +/- S.E,, n = 8). The ability of 1,25-(OH)(2)D-3 to inhibit CAT activity was significantly decreased to 18.5 +/- 4.3% (59.3% reversal, p < 0.02) when examined with a MIE1 deletion construct (pMPCAT-MIE1). Moreover, 1,25-(OH)(2)D-3 was completely ineffective at suppressing CAT activity in cells transfected with pMPCAT-287, a construct without MIE1, MIE2, and MIE3 binding sites (-6.5 +/- 10.9%, p < 0.002), MIE1- and MIE2-binding proteins induced by 1,25-(OH)(2)D-3 had similar gel shift mobilities, while MIE3-binding proteins migrated differently. Furthermore, chelerythrine chloride, a selective protein kinase C (PKC) inhibitor, and a PKC beta antisense oligonucleotide completely blocked the binding of nuclear proteins induced by 1,25-(OH)(2)D-3 to MIE1, MIE2, and MIE3, A 1,25-(OH)(2)D-3-inducible MIE1-binding protein was identified to be HOXB4. HOXB4 levels were significantly increased in response to 1,25-(OH)(2)D-3. Taken together, these results indicate that HOXB4 is one of the nuclear phosphoproteins involved in c-mye transcription elongation block during HL-60 cell differentiation by 1,25-(OH)(2)D-3.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Simpson, RU (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.	robsim@umich.edu	Pan, Quintin/E-3808-2011		NCI NIH HHS [CA69568] Funding Source: Medline; NIDCR NIH HHS [DE10337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; BENDAVID L, 1991, VIROLOGY, V182, P382, DOI 10.1016/0042-6822(91)90686-6; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELETTI A, 1993, INT J CANCER, V53, P237, DOI 10.1002/ijc.2910530211; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTELL RE, 1988, BIOCHEM PHARMACOL, V37, P635, DOI 10.1016/0006-2952(88)90136-0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; Pan Q, 1997, BIOCHEM PHARMACOL, V54, P909, DOI 10.1016/S0006-2952(97)00286-4; Pan Q, 1996, ENDOCRINOLOGY, V137, P4154, DOI 10.1210/en.137.10.4154; PATTENGALE P, 1986, CURR TOP MICROBIOL, V132, P9; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SATO Y, 1987, BLOOD, V70, P1654; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Simpson RU, 1998, J BIOL CHEM, V273, P19587, DOI 10.1074/jbc.273.31.19587; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SIMPSON RU, 1986, BIOESSAYS, V4, P65, DOI 10.1002/bies.950040206; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; VALLERGA A, 1991, P AM SOC HEMATOL, V78, pA254; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	48	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8437	8444		10.1074/jbc.274.13.8437	http://dx.doi.org/10.1074/jbc.274.13.8437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085075	hybrid			2022-12-27	WOS:000079451600017
J	Rameh, LE; Cantley, LC				Rameh, LE; Cantley, LC			The role of phosphoinositide 3-kinase lipid products in cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-KINASE-B; PHOSPHOLIPASE C-GAMMA; PLECKSTRIN HOMOLOGY DOMAIN; BRUTONS TYROSINE KINASE; GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; INSULIN STIMULATION; VESICULAR TRANSPORT; TUMOR-SUPPRESSOR		Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Cantley, LC (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FALCK JR, 1993, BIOORG MED CHEM LETT, V3, P717, DOI 10.1016/S0960-894X(01)81261-0; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RODRIGUEZ VP, 1994, NATURE, V370, P527; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WENNSTROM S, 1994, ONCOGENE, V9, P651; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	92	808	893	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8347	8350		10.1074/jbc.274.13.8347	http://dx.doi.org/10.1074/jbc.274.13.8347			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085060	hybrid			2022-12-27	WOS:000079451600002
J	Rodriguez, MS; Thompson, J; Hay, RT; Dargemont, C				Rodriguez, MS; Thompson, J; Hay, RT; Dargemont, C			Nuclear retention of I kappa B alpha protects it from signal-induced degradation and inhibits nuclear factor kappa B transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; EXPORT PATHWAY; P50 PRECURSOR; REV PROTEIN; CELL-CYCLE; PHOSPHORYLATION; UBIQUITINATION; KINASE; FAMILY; CRM1	Transcriptional activation of nuclear factor kappa B (NF-kappa B) is mediated by signal-induced phosphorylation and degradation of its inhibitor, I kappa B alpha. However, NF-kappa B activation induces rapid resynthesis of I kappa B alpha, which is responsible for post-induction repression of transcription. Newly synthesized I kappa B alpha translocates to the nucleus, where it dissociates NF-kappa B from DNA and transports NF-kappa B from the nucleus to the cytoplasm in a nuclear export sequence-dependent process that is sensitive to leptomycin B (LMB), In the present study, LMB was used as a tool to inhibit nuclear export sequence-mediated nuclear protein export and evaluate the consequences for regulation of NF-kappa B-dependent transcriptional activity. Pretreatment of cells with LMB inhibits NF-kappa B-dependent transcriptional activation mediated by interleukin 1 beta or tumor necrosis factor alpha. This is a consequence of the inhibition of signal-induced degradation of I kappa B alpha. Although LMB treatment does not affect the signal transduction pathway leading to I kappa B alpha degradation, it blocks I kappa B alpha nuclear export. I kappa B alpha is thus accumulated in the nucleus, and in this compartment it is resistant to signal-induced degradation. These results indicate that the signal-induced degradation of I kappa B alpha is mainly, if not exclusively, a cytoplasmic process. An efficient nuclear export of I kappa B alpha is therefore essential for maintaining a low level of I kappa B alpha in the nucleus and allowing NF-kappa B to be transcriptionally active upon cell stimulation.	Univ St Andrews, Sch Biomed Sci, Inst Biomol Sci, St Andrews KY16 9TS, Fife, Scotland; Inst Curie, CNRS, Unite Mixte Rech 144, F-75248 Paris 05, France	University of St Andrews; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite	Hay, RT (corresponding author), Univ St Andrews, Sch Biomed Sci, Inst Biomol Sci, N Haugh, St Andrews KY16 9TS, Fife, Scotland.	rth@st-and.ac.uk	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WOJCIK C, 1995, EUR J CELL BIOL, V68, P191; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	61	206	210	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9108	9115		10.1074/jbc.274.13.9108	http://dx.doi.org/10.1074/jbc.274.13.9108			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085161	hybrid			2022-12-27	WOS:000079451600103
J	Armes, NA; Neal, KA; Smith, JC				Armes, NA; Neal, KA; Smith, JC			A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-4; TGF-BETA RECEPTOR; GROWTH-FACTOR-BETA; I RECEPTOR; KINASE; GENE; IDENTIFICATION; DROSOPHILA; DOMAIN; FAMILY	Activin, a member of the transforming growth factor beta (TGF-beta) superfamily, signals through a heteromeric complex of type I and type II serine-threonine kinase receptors, The two activin type I receptors previously identified, ALK-2 (ActR-I) and ALK-4 (ActR-IB), have distinct effects on gene expression, differentiation and morphogenesis in the Xenopus animal cap assay. ALK-4 reproduces the effects of activin treatment including the dose-dependent induction of progressively more dorso-anterior mesodermal and endodermal markers, whereas ALK-2 induces only ventral mesodermal markers and counteracts the effects of ALK-4, To identify regions of the receptors that determine signaling specificity we have generated chimeras of the constitutively active ALK-2 and ALK-4 receptors (termed ALK-2* and ALK-4*), The effects of these chimeric receptors on gene expression and morphogenetic movements implicate the loop between kinase subdomains TV and V in mediating the strong dorsal gene-inducing properties of ALK-4*; when the seven amino acids comprising this loop are transferred from ALK-4* to ALK-2*, the resulting chimeric receptor is capable of inducing the expression of dorsal-specific genes. In contrast, when the equivalent region of ALK-2* is transferred to the ALK-4* backbone it cannot effectively counteract the dorsalizing effects of ALK-4*, suggesting that other regions of type I receptors are also involved in determining signal specificity.	Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England	MRC National Institute for Medical Research	Smith, JC (corresponding author), Natl Inst Med Res, Div Dev Biol, The Ridgeway,Mill Hill, London NW7 1AA, England.			Smith, Jim/0000-0003-2413-9392				ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; Armes NA, 1997, DEVELOPMENT, V124, P3797; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Candia AF, 1997, DEVELOPMENT, V124, P4467; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1992, DEVELOPMENT, V115, P573; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Jones CM, 1996, DEVELOPMENT, V122, P1545; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SARGENT MG, 1990, DEVELOPMENT, V109, P967; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1993, CELLULAR INTERACTION, P181; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	44	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7929	7935		10.1074/jbc.274.12.7929	http://dx.doi.org/10.1074/jbc.274.12.7929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075688	hybrid			2022-12-27	WOS:000079268100047
J	Gu, C; Cooper, DMF				Gu, C; Cooper, DMF			Calmodulin-binding sites on adenylyl cyclase type VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOSOLIC DOMAINS; AUTOINHIBITORY DOMAIN; DISCRETE REGIONS; IN-VITRO; CA2+; IDENTIFICATION; CALCIUM; KINASE; FORSKOLIN	Ca2+ stimulation of adenylyl cyclase type VIII (ACVIII) occurs through loosely bound calmodulin. However, where calmodulin binds in ACVIII and how the binding activates this cyclase have not yet been investigated. We have located two putative calmodulin-binding sites in ACVIII, One site is located at the N terminus as revealed by overlay assays; the other is located at the C terminus, as indicated by mutagenesis studies. Both of these calmodulin-binding sites were confirmed by synthetic peptide studies. The N-terminal site has the typical motif of a Ca2+-dependent calmodulin-binding domain, which is defined by a characteristic pattern of hydrophobic amino acids, basic and aromatic amino acids, and a tendency to form amphipathic cu-helix structures. Functional, mutagenesis studies suggest that this binding makes a minor contribution to the Ca2+ stimulation of ACVIII activity, although it might be involved in calmodulin trapping by ACVIII. The primary structure of the C-terminal site resembles another calmodulin-binding motif, the so-called IQ motif, which is commonly Ca2+-independent. Mutagenesis and functional assays indicate that this latter site is a calcium-dependent calmodulin-binding site, which is largely responsible for the Ca2+ stimulation of ACVIII, Removal of this latter calmodulin-binding region from ACVIII results in a hyperactivated enzyme state and a loss of Ca2+ sensitivity. Thus, Ca2+/calmodulin regulation of ACVIII may be through a disinhibitory mechanism, as is the case for a number of other targets of Ca2+/calmodulin.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.	cooperd@essex.uchsc.edu	Gu, Chen/E-3163-2011		NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CECH SY, 1980, MOL CELL BIOCHEM, V33, P67; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; COOPER DMF, 1994, METHOD ENZYMOL, V238, P71; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; GOLDHAMMER A, 1982, ANAL BIOCHEM, V124, P45, DOI 10.1016/0003-2697(82)90217-2; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUGHES MJ, 1996, BIOTECHNIQUES, V20, P192; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Krupinski John, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P53; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Weitz D, 1998, EMBO J, V17, P2273, DOI 10.1093/emboj/17.8.2273; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	48	63	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8012	8021		10.1074/jbc.274.12.8012	http://dx.doi.org/10.1074/jbc.274.12.8012			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075700	hybrid			2022-12-27	WOS:000079268100059
J	Wood, DE; Newcomb, EW				Wood, DE; Newcomb, EW			Caspase-dependent activation of calpain during drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ICE/CED-3 PROTEASE; INHIBITORS; CLEAVAGE; BAX; PROTEOLYSIS; DEGRADATION; CYTOSOL; ROLES; P53	We have previously demonstrated that calpain is responsible for the cleavage of Bax, a proapoptotic protein, during drug-induced apoptosis of HL-60 cells (Wood, D, E,, Thomas, A., Devi, L, A, Berman, Y,, Beavis, R. C., Reed, J, C,, and Newcomb, E, W, (1998) Oncogene 17, 1069-1078). Here we show the sequential activation of caspases and calpain during drug-induced apoptosis of HL-60 cells. Time course experiments using the topoisomerase I inhibitor 9-amino-20(S)-camptothecin revealed that cleavage of caspase-3 substrates poly(ADP-ribose) polymerase (PARP) and the retinoblastoma protein as well as DNA fragmentation occurred several hours before calpain activation and Bax cleavage. Pretreatment with the calpain inhibitor calpeptin blocked calpain activation and Bax cleavage but did not inhibit PARP cleavage, DNA fragmentation, or 9-amino-20(S)camptothecin-induced morphological changes and cell death. Pretreatment with the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk) inhibited PARP cleavage, DNA fragmentation, calpain activation, and Bax cleavage and increased cell survival by 40%. Interestingly, Z-VAD-fmk-treated cells died in a caspase- and calpain-independent manner that appeared morphologically distinct from apoptosis. Our results suggest that excessive or uncontrolled calpain activity may play a role downstream of and distinct from caspases in the degradation phase of apoptosis.	NYU, Dept Pathol, Ctr Med, New York, NY 10016 USA	New York University	Newcomb, EW (corresponding author), NYU, Dept Pathol, Ctr Med, 550 1St Ave,MSB 531, New York, NY 10016 USA.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chen SJ, 1998, MOL CELL BIOCHEM, V178, P141, DOI 10.1023/A:1006893528428; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCGAHON AJ, 1995, METHODS CELL BIOL CE, V46, P174; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Musleh W, 1997, P NATL ACAD SCI USA, V94, P9451, DOI 10.1073/pnas.94.17.9451; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; Thomas A, 1996, ONCOGENE, V12, P1055; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Ueyama H, 1998, J NEUROL SCI, V155, P163, DOI 10.1016/S0022-510X(97)00309-2; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	49	167	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8309	8315		10.1074/jbc.274.12.8309	http://dx.doi.org/10.1074/jbc.274.12.8309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075737	hybrid			2022-12-27	WOS:000079268100096
J	Lee, RJ; Albanese, C; Stenger, RJ; Watanabe, G; Inghirami, G; Haines, GK; Webster, M; Muller, WJ; Brugge, JS; Davis, RJ; Pestell, RG				Lee, RJ; Albanese, C; Stenger, RJ; Watanabe, G; Inghirami, G; Haines, GK; Webster, M; Muller, WJ; Brugge, JS; Davis, RJ; Pestell, RG			pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways - A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANTS; NIH 3T3 CELLS; V-SRC; GENE-EXPRESSION; RETINOBLASTOMA-PROTEIN; TRANSDUCTION PATHWAY; GROWTH-FACTOR; CELLULAR STRESSES; COLLAGENASE GENE; TYROSINE KINASES	The cyclin D1 gene is overexpressed in breast tumors and encodes a regulatory subunit of cyclin-dependent kinases that phosphorylate the retinoblastoma protein. pp60(c-src) activity is frequently increased in breast tumors; however, the mechanisms governing pp60(c-src) regulation of the cell cycle in breast epithelium are poorly understood. In these studies, pp60(v-src) induced cyclin D1 protein levels and promoter activity (48-fold) in MCF7 cells. Cyclin D1-associated kinase activity and protein levels were increased in mammary tumors from murine mammary tumor virus-pp60(c-src527F) transgenic mice. Optimal induction of cyclin D1 by pp60(v-src) involved the extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase members of the mitogen-activated protein kinase family. Cyclin D1 promoter activation by pps60(v-src) involved a cAMP response element-binding protein (CREB)/activating transcription factor 2 (ATF-2) binding site. Dominant negative mutants of CREB and ATF-2 but not c-Jun inhibited pp60(v-src) induction of cyclin D1, pp60(v-src) induction of CREB was blocked by the p38 inhibitor SB203580 or by mutation of CREB at Ser(133), pp60(v-src) induction of ATF-2 was abolished by the a-Jun N-terminal kinase inhibitor JNK-interacting protein-1 or by mutation of ATF-2 at Thr(69) and Thr(71). CREB and ATF-2, which bind to a common pp60(v-src) response element, are transcriptionally activated by distinct mitogen-activated protein kinases. Induction of cyclin D1 activity by pp60(v-src) may contribute to breast tumorigenesis through phosphorylation and inactivation of the retinoblastoma protein.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York University; Northwestern University; McMaster University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Pestell, RG (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.	pestell@aecom.yu.edu			NCI NIH HHS [R29CA70897, RI1 CA75503] Funding Source: Medline; NHLBI NIH HHS [P50-HL56399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA075503, R01CA075503, R01CA070897] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; IVASHKIV LB, 1992, NEW BIOL, V4, P360; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pende M, 1997, J NEUROSCI, V17, P1291; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHUURING E, 1992, ONCOGENE, V7, P355; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1998, DEV BRAIN RES, V108, P77, DOI 10.1016/S0165-3806(98)00032-7; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	85	202	208	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7341	7350		10.1074/jbc.274.11.7341	http://dx.doi.org/10.1074/jbc.274.11.7341			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066798	hybrid			2022-12-27	WOS:000079078400070
J	Ping, YH; Rana, TM				Ping, YH; Rana, TM			Tat-associated kinase (P-TEFb): a component of transcription preinitiation and elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAIN; PROTEINS SPECIFICALLY ASSOCIATE; IN-VITRO; ACTIVATED TRANSCRIPTION; TRANSACTIVATOR TAT; HIV-1 PROMOTER; INITIATION; PHOSPHORYLATION	Human immunodeficiency virus, type 1 (HIV-1) Tat protein activates transcription from the HIV-1 long terminal repeat. Tat interacts with TFIIH and Tat-associated kinase (a transcription elongation factor P-TEFb) and requires the carboxyl-terminal domain of the largest subunit of RNA polymerase II (pol II) for transactivation. We developed a stepwise RNA pol II walking approach and used Western blotting to determine the role of TFIIH and P-TEFb in HIV-1 transcription elongation. Our results demonstrate the new findings that P-TEFb is a component of the preinitiation complex and travels with the elongating RNA pol II, whereas TFIIH is released from the elongation complexes before the trans-activation responsive region RNA is synthesized. Our results suggest that TFIIH and P-TEFb are involved in the clearance of promoter-proximal pausing of RNA pol II on the HIV-1 long terminal repeat at different stages.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Rutgers State Univ, Mol Biosci Grad Program, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Rana, TM (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.			Ping, Yueh-Hsin/0000-0003-2604-9913	FIC NIH HHS [TW 00702] Funding Source: Medline; NIAID NIH HHS [AI 41404, AI 43198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198, R01AI041404, R56AI041404] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; CAI H, 1987, J BIOL CHEM, V262, P298; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Deissler H, 1996, J BIOL CHEM, V271, P4327; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; SPENCER CA, 1990, ONCOGENE, V5, P777; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	46	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7399	7404		10.1074/jbc.274.11.7399	http://dx.doi.org/10.1074/jbc.274.11.7399			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066804	hybrid			2022-12-27	WOS:000079078400076
J	Shariat-Madar, Z; Mahdi, F; Schmaier, AH				Shariat-Madar, Z; Mahdi, F; Schmaier, AH			Mapping binding domains of kininogens on endothelial cell cytokeratin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; RECEPTOR; PROTEIN; SITE; IDENTIFICATION; ACTIVATION; EXPRESSION; IDENTITY; KERATINS	Human cytokeratin 1 (CK1) in human umbilical vein endothelial cells (HUVEC) is expressed on their membranes and is able to bind high molecular weight kininogen (HK) (Hasan, A. A. K,, Zisman, T., and Schmaier, A.H. (1998) Proc. Natl, Acad, Sci, U. S. A. 95, 3615-3620), New investigations have been performed to demonstrate the HK binding domain on CK1, Four overlapping recombinant (r) CK1 proteins were produced in Escherichia coli by a glutathione S-transferase gene fusion system. Biotin-HK specifically bound to rCK1(28) and rCK1(31) in the presence of Zn2+ but not to (Deleted1-6)rCK1(31). Recombinant CK1(28) and rCK1(31) also inhibited biotin-HK binding to HUVEC with IC50 of 0.4 and 0.5 mu M, respectively. Alternatively, rCK1(14) and (Deleted1-6)rCK1(31) did not inhibit binding at concentrations greater than or equal to 1 mu M. Seven sequential 20 amino acid peptides of CK1 were prepared to cover the protein coded by exons 1-3. Only the first peptide (GYG20) coded by exon 1 significantly inhibited HK binding to HUVEC with an IC50 of 35 mu M. Fine mapping studies isolated two overlapping peptides also coded by exon 1 (GPV15 and PGG15) that inhibited binding to HUVEC with IC50 of 18 and 9 mu M, respectively. A sequence scrambled peptide of PGG15 did not block binding to HUVEC and biotin-GPV20 specifically bound to HK. Peptides GPV15 and PGG15 also blocked prekallikrein activation on endothelial cells. However, inhibition of PK activation by peptide PGG15 occurred at 10-fold lower concentration (IC50 = 1 mu M) than inhibition of biotin-HK binding to HUVEC (IC50 = 10 mu M). These studies indicate that HK binds to a region of 20 amino acids coded by exon 1 on CK1 which is carboxyl-terminal to its glycine-rich amino-terminal globular domain. Furthermore, HK binding to Chi modulates PK activation on HUVEC.	Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Div Hematol & Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schmaier, AH (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol & Oncol, 5301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056416, R43HL055907, R01HL052779, R44HL055907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52779, HL55907, HL56416] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; GARSON JA, 1990, LANCET, V335, P419; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; JOSEPH K, 1997, J INVEST MED, V45, P265; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SCHMAIER AH, 1988, J LAB CLIN MED, V112, P182; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; ZINI JM, 1993, BLOOD, V81, P2936	23	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7137	7145		10.1074/jbc.274.11.7137	http://dx.doi.org/10.1074/jbc.274.11.7137			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066772	hybrid			2022-12-27	WOS:000079078400044
J	Liu, CB; Itoh, T; Arai, K; Watanabe, S				Liu, CB; Itoh, T; Arai, K; Watanabe, S			Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CYTOKINE RECEPTOR SUPERFAMILY; NIH 3T3 CELLS; C-FOS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GROWTH SIGNAL; BETA-SUBUNIT; INTERLEUKIN-5; DOMAIN	The Janus tyrosine kinase 2 (JAK2) plays an essential role of cytokine receptor signaling, including that of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. We reported earlier that the activation of JAK2 is essential for all the examined signals induced by human GM-CSF through the box1 region of pc, such as promotion of cell survival and proliferation. To elucidate the role of JAK2 in cell survival and proliferation, we generated an artificial activation system by constructing a chimeric molecule (beta/JAK2) consisting of pc extracellular and transmembrane regions fused with JAK2, and we analyzed various signaling events in interleukin-3-dependent mouse pro-B cell, BA/F3. The beta/JAK2 was constitutively phosphorylated in the absence of human GM-CSF and murine interleukin-3, and this led to proliferation and cell survival. Western blot analysis showed that STAT5, Shc, and SHP-2 were not phosphorylated in the cells, and the consistent activation of beta-casein and c-fos promoters was not enhanced. In contrast, c-myc transcription was constitutively activated. We propose that the activation of beta/JAK2 suffices for survival and proliferation and that the activation of STAT5 and mitogen-activated protein kinase cascade is not required for these activities in BA/F3 cells.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Watanabe, S (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sumiko@ims.u-tokyo.ac.jp	Itoh, Tohru/GYQ-8698-2022	Itoh, Tohru/0000-0002-6579-1638				Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MIYAJIMA A, 1993, BLOOD, V82, P1960; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Taglialatela G, 1996, NEUROREPORT, V7, P977, DOI 10.1097/00001756-199604100-00004; ULLICH A, 1990, CELL, V61, P203; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6342	6349		10.1074/jbc.274.10.6342	http://dx.doi.org/10.1074/jbc.274.10.6342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037724	hybrid			2022-12-27	WOS:000078902800046
J	Xu, J; Esmon, NL; Esmon, CT				Xu, J; Esmon, NL; Esmon, CT			Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; RABBIT THROMBOMODULIN; HUMAN THROMBIN; HUMAN-PLASMA; EXPRESSION; COMPLEX; ANTICOAGULATION; IDENTIFICATION; COFACTOR; PATHWAY	Blocking protein C binding to the endothelial cell protein C receptor (EPCR) on the endothelium is known to reduce protein C activation rates. Now we isolate human EPCR and thrombomodulin (TM) and reconstitute them into phosphatidylcholine vesicles. The EPCR increases protein C activation rates in a concentration-dependent fashion that does not saturate at 14 EPCR molecules/TM. Without EPCR, the protein C concentration dependence fits a single class of sites (K-m = 2.17 +/- 0.13 mu M). With EPCR, two classes of sites are apparent K-m = 20 +/- 15 nM and K-m = 3.2 +/- 1.7 mu M). Increasing the EPCR concentration at a constant TM concentration increases the percentage of high affinity sites. Holding the TRI: EPCR ratio constant while decreasing the density of these proteins results in a decrease in the EPCR enhancement of protein C activation, suggesting that there is little affinity of the EPCR for TM. Negatively charged phospholipids also enhance protein C activation. EPCR acceleration of protein C activation is blocked by anti-EPCR antibodies, but not by annexin V, whereas the reverse is true with negatively charged phospholipids, Human umbilical cord endothelium expresses approximately 7 times more EPCR than TM, Anti-EPCR antibody reduces protein C activation rates 7-fold over these cells, whereas annexin V is ineffective, indicating that EPCR rather than negatively charged phospholipid provide the surface for protein C activation. EPCR expression Varies dramatically among vascular beds. The present results indicate that the EPCR concentration will determine the effectiveness of the protein C activation complex.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Charles-Esmon@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAUER KA, 1984, J CLIN INVEST, V74, P2033, DOI 10.1172/JCI111626; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BUSCH C, 1982, LAB INVEST, V47, P498; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; Ding W, 1996, CIRCULATION, V94, P4056; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FREYSSINET JM, 1986, BIOCHEM J, V238, P151, DOI 10.1042/bj2380151; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; Houston DS, 1997, J BIOL CHEM, V272, P11778, DOI 10.1074/jbc.272.18.11778; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; Laszik Z, 1997, CIRCULATION, V96, P3633; LIN JH, 1994, J BIOL CHEM, V269, P25021; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OWEN WG, 1974, J BIOL CHEM, V249, P594; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SEEGERS WH, 1981, SEMIN THROMB HEMOST, V7, P177; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; XU J, 1998, VASC BIOL M APR 15 1	40	75	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6704	6710		10.1074/jbc.274.10.6704	http://dx.doi.org/10.1074/jbc.274.10.6704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037768	hybrid			2022-12-27	WOS:000078902800090
J	Chinni, C; de Niese, MR; Tew, DJ; Jenkins, AL; Bottomley, SP; Mackie, EJ				Chinni, C; de Niese, MR; Tew, DJ; Jenkins, AL; Bottomley, SP; Mackie, EJ			Thrombin, a survival factor for cultured myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-DEFICIENT MUSCLE; PROTEIN-COUPLED RECEPTORS; MOUSE MUSCLE; PLATELET ACTIVATION; ENDOTHELIAL-CELLS; ALPHA-THROMBIN; EXPRESSION; APOPTOSIS; DIFFERENTIATION; INHIBITION	Three members of the family of protease-activated receptors (PARs), PARs-1, -3 and -4, have been identified as thrombin receptors, PAR-1 is expressed by primary myoblast cultures, and expression is repressed once myoblasts fuse to form myotubes, The current study was undertaken to investigate the hypothesis that thrombin inhibits myoblast fusion, Primary rodent myoblast cultures were deprived of serum to promote myoblast fusion and then cultured in the presence or absence of thrombin, Thrombin inhibited myoblast fusion, but another notable effect was observed; 50% of control cells were apoptotic within 24 h of serum deprivation, whereas less than 15% of thrombin-treated cells showed signs of apoptosis. Proteolysis was required for the effect of thrombin, but no other serine protease tested mimicked the action of thrombin. Neither a PAR-1- nor a PAR-4-activating peptide inhibited apoptosis or fusion, and myoblast cultures were negative for PAR-3 expression. Myoblasts exposed to thrombin for 1 h and then changed to medium without thrombin accumulated apoptosis inhibitory activity in their medium over the subsequent 20 h, Thus the protective action of thrombin appears to be effected through cleavage of an unidentified thrombin receptor, leading to secretion of a downstream apoptosis inhibitory factor. These results demonstrate that thrombin functions as a survival factor for myoblasts and is likely to play an important role in muscle development and repair.	Univ Melbourne, Sch Vet Sci, Parkville, Vic 3052, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	University of Melbourne; Monash University	Mackie, EJ (corresponding author), Univ Melbourne, Sch Vet Sci, Parkville, Vic 3052, Australia.		Mackie, Eleanor J/B-2045-2008; Jenkins, Alicia/N-2482-2015	Mackie, Eleanor J/0000-0002-8057-5407; 				Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; AUSTIN L, 1992, J NEUROL SCI, V112, P185, DOI 10.1016/0022-510X(92)90149-F; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; Citron BA, 1997, THROMB RES, V87, P303, DOI 10.1016/S0049-3848(97)00132-1; COLLER BS, 1993, J BIOL CHEM, V268, P20741; CRAGO AM, 1995, EXP CELL RES, V219, P650, DOI 10.1006/excr.1995.1275; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Glazner GW, 1997, DEV BRAIN RES, V99, P148, DOI 10.1016/S0165-3806(96)00213-1; Guttridge DC, 1997, J BIOL CHEM, V272, P24117, DOI 10.1074/jbc.272.39.24117; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jenkins Alison L., 1993, Journal of Biological Chemistry, V268, P21432; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; LIM RW, 1984, DEV BIOL, V105, P48, DOI 10.1016/0012-1606(84)90260-4; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; LIU LB, 1994, BRIT J HAEMATOL, V88, P592, DOI 10.1111/j.1365-2141.1994.tb05078.x; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Piccardoni P, 1996, THROMB HAEMOSTASIS, V76, P780; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; Suidan HS, 1996, J BIOL CHEM, V271, P29162, DOI 10.1074/jbc.271.46.29162; Tews DS, 1997, NEUROPATH APPL NEURO, V23, P141; TIDBALL JG, 1995, J CELL SCI, V108, P2197; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	34	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9169	9174		10.1074/jbc.274.14.9169	http://dx.doi.org/10.1074/jbc.274.14.9169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092588	hybrid			2022-12-27	WOS:000079451800007
J	Lee, B; Sharron, M; Blanpain, C; Doranz, BJ; Vakili, J; Setoh, P; Berg, E; Liu, G; Guy, HR; Durell, SR; Parmentier, M; Chang, CN; Price, K; Tsang, M; Doms, RW				Lee, B; Sharron, M; Blanpain, C; Doranz, BJ; Vakili, J; Setoh, P; Berg, E; Liu, G; Guy, HR; Durell, SR; Parmentier, M; Chang, CN; Price, K; Tsang, M; Doms, RW			Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AMINO-TERMINAL DOMAIN; HIV-1 INFECTION; ENVELOPE GLYCOPROTEINS; DISEASE PROGRESSION; EXTRACELLULAR LOOP; CELL-LINES; V3 LOOP; TYPE-1; RECEPTOR	The chemokine receptor CCR5 is the major coreceptor for R5 human immunodeficiency virus type-1 strains. We mapped the epitope specificities of 18 CCR5 monoclonal antibodies (mAbs) to identify domains of CCR5 required for chemokine binding, gp120 binding, and for inducing conformational changes in Env that lead to membrane fusion, We identified mAbs that bound to N-terminal epitopes, extracellular loop 2 (ECL2) epitopes, and multidomain (MD) epitopes composed of more than one single extracellular domain. N-terminal mAbs recognized specific residues that span the first 13 amino acids of CCR5, while nearly all ECL2 mAbs recognized residues Tyr-184 to Phe-189. In addition, all MD epitopes involved ECL2, including at least residues Lys-171. and Glu-172, We found that ECL2-specific mAbs were more efficient than NH2- or MD-antibodies in blocking RANTES or MIP-1 beta binding. By contrast, N-terminal mAbs blocked gp120-CCR5 binding more effectively than ECL2 mAbs. Surprisingly, ECL2 mAbs were more potent inhibitors of viral infection than N-terminal mAbs, Thus, the ability to block virus infection did not correlate with the ability to block gp120 binding. Together, these results imply that chemokines and Env bind to distinct but overlapping sites in CCR5, and suggest that the N-terminal domain of CCR5 is more important for gp120 binding while the extracellular loops are more important for inducing conformational changes in Env that lead to membrane fusion and virus infection. Measurements of individual antibody affinities coupled with kinetic analysis of equilibrium binding states also suggested that there are multiple conformational states of CCR5. A previously described mAb, 2D7, was unique in its ability to effectively block both chemokine and Env binding as well as coreceptor activity. 2D7 bound to a unique antigenic determinant in the first half of ECL2 and recognized a far greater proportion of cell surface CCR5 molecules than the other mAbs examined. Thus, the epitope recognized by 2D7 may represent a particularly attractive target for CCR5 antagonists.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; PDL Inc, Fremont, CA USA; NCI, Math Biol Lab, NIH, Bethesda, MD 20892 USA; R&D Syst, Minneapolis, MN 55413 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Wistar Institute	Doms, RW (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, 806 Abramson,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	doms@mail.med.upenn.edu	Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709; Parmentier, Marc/0000-0001-8081-4685	NHLBI NIH HHS [K08 HL03923-01] Funding Source: Medline; PHS HHS [R01-40880, R44 A141299-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003923] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; ASJO B, 1986, LANCET, V2, P660; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BARDEAU B, 1998, J BIOL CHEM, V72, P7125; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berger EA, 1997, AIDS, V11, pS3; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Broder CC, 1997, J LEUKOCYTE BIOL, V62, P20, DOI 10.1002/jlb.62.1.20; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; DOMS RW, 1998, HUMAN RETROVIRUSES A, V3, P1; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; DRAIC T, 1998, J VIROL, V72, P279; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 1998, J VIROL, V72, P2105, DOI 10.1128/JVI.72.3.2105-2112.1998; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; Frade JMR, 1997, J IMMUNOL, V159, P5576; Guy H R, 1996, Ion Channels, V4, P1; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Paxton WA, 1998, VIROLOGY, V244, P66, DOI 10.1006/viro.1998.9082; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Rizzuto CD, 1997, J VIROL, V71, P4847, DOI 10.1128/JVI.71.6.4847-4851.1997; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	58	307	340	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9617	9626		10.1074/jbc.274.14.9617	http://dx.doi.org/10.1074/jbc.274.14.9617			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092648	hybrid			2022-12-27	WOS:000079451800067
J	Stahl, B; Diehlmann, A; Sudhof, TC				Stahl, B; Diehlmann, A; Sudhof, TC			Direct interaction of Alzheimer's disease-related presenilin 1 with armadillo protein p0071	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STEP PURIFICATION; POLARITY GENE ARMADILLO; BETA-CATENIN; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CLONING; BRAIN; EXPRESSION; HOMOLOG	Alzheimer's disease-related presenilins are thought to be involved in Notch signaling during embryonic development and/or cellular differentiation. Proteins mediating the cellular functions of the presenilins are still unknown. We utilized the yeast two-hybrid system to identify an interacting armadillo protein, termed p0071, that binds specifically to the hydrophilic loop of presenilin 1. In vivo, the presenilins constitutively undergo proteolytic processing, forming two stable fragments. Here, we show that the C-terminal fragment of presenilin 1 directly binds to p0071. Nine out of 10 armadillo repeats in p0071 are essential for mediating this interaction. Since armadillo proteins, like beta-catenin and APC, are known to participate in cellular signaling, p0071 may function as a mediator of presenilin 1 in signaling events.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Ctr Mol Biol, INF 282, D-69120 Heidelberg, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stahl, B (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.							Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; McGeer PL, 1998, REV NEUROSCIENCE, V9, P1; Pari G S, 1997, Methods Mol Biol, V62, P301; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEIFER M, 1993, DEVELOPMENT, V118, P1191; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Pizzuti A, 1996, HUM MOL GENET, V5, P953, DOI 10.1093/hmg/5.7.953; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Rose MD., 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Tanahashi H, 1998, BBA-GENE STRUCT EXPR, V1396, P259, DOI 10.1016/S0167-4781(97)00219-4; Taniguchi T, 1997, GENE, V186, P73, DOI 10.1016/S0378-1119(96)00683-X; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	40	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9141	9148		10.1074/jbc.274.14.9141	http://dx.doi.org/10.1074/jbc.274.14.9141			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092585	hybrid			2022-12-27	WOS:000079451800004
J	Agrawal, RK; Penczek, P; Grassucci, RA; Burkhardt, N; Nierhaus, KH; Frank, J				Agrawal, RK; Penczek, P; Grassucci, RA; Burkhardt, N; Nierhaus, KH; Frank, J			Effect of buffer conditions on the position of tRNA on the 70 S ribosome as visualized by cryoelectron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; ANGSTROM RESOLUTION; ELONGATION CYCLE; MODEL; SITE; REFINEMENT; MOVEMENT	The effect of buffer conditions on the binding position of tRNA on the Escherichia coli 70 S ribosome have been studied by means of three-dimensional (3D) cryoelectron microscopy. Either deacylated tRNA(f)(met) or fMet-tRNA(f)(Met) were bound to the 70 S ribosomes, which were programmed with a 46-nucleotide mRNA having AUG codon in the middle, under two different buffer conditions (conventional buffer: containing Tris and higher Mg2+ concentration [10-15 mM]; and polyamine buffer: containing Hepes, lower Mg2+ concentration [6 mM], and polyamines). Difference maps, obtained by subtracting 3D maps of naked control ribosome in the corresponding buffer from the 3D maps of tRNA ribosome complexes, reveal the distinct locations of tRNA on the ribosome. The position of deacylated tRNA(f)(Met) depends on the buffer condition used, whereas that of fMet-tRNA(f)(Met) remains the same in both buffer conditions. The acylated tRNA binds in the classical P site, whereas deacylated tRNA binds mostly in an intermediate P/E position under the conventional buffer condition and mostly in the position corresponding to the classical P site, i.e. in the P/P state, under the polyamine buffer conditions.	SUNY Albany, Wadsworth Ctr, Dept Biomed Sci, Albany, NY 12201 USA; Howard Hughes Med Inst, Albany, NY 12201 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center; Howard Hughes Medical Institute; Max Planck Society	Agrawal, RK (corresponding author), SUNY Albany, Wadsworth Ctr, Dept Biomed Sci, POB 509, Albany, NY 12201 USA.	agrawal@wadsworth.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM055440] Funding Source: NIH RePORTER; NIGMS NIH HHS [1RO1 GM 55440, 1R37 GM 29169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1996, J BIOL CHEM, V271, P21285, DOI 10.1074/jbc.271.35.21285; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; AGRAWAL RK, 1998, J BIOCH CELL BIOL, V31, P2413; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; Bommer U, 1997, SUBCELLULAR FRACTION, P271; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Frank J, 1998, BIOPHYS J, V74, P589, DOI 10.1016/S0006-3495(98)77817-8; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KUTAY UR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P193, DOI 10.1016/0167-4781(90)90165-X; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Nierhaus KH, 1997, P NATL ACAD SCI USA, V94, P10499, DOI 10.1073/pnas.94.20.10499; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PODKOWINSKI J, 1991, NUCLEIC ACIDS RES, V19, P801, DOI 10.1093/nar/19.4.801; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; Zhu J, 1997, J STRUCT BIOL, V118, P197, DOI 10.1006/jsbi.1997.3845; ZIMMERMANN RA, 1990, RIBOSOME, P331	33	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8723	8729		10.1074/jbc.274.13.8723	http://dx.doi.org/10.1074/jbc.274.13.8723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085112	hybrid			2022-12-27	WOS:000079451600054
J	Jenkins, BJ; Le, F; Gonda, TJ				Jenkins, BJ; Le, F; Gonda, TJ			A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL TRANSDUCTION; HIGH-AFFINITY BINDING; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; NEU ONCOGENE; CHAIN; LIGAND; MUTATIONS; RECONSTITUTION; RESIDUES	The high affinity receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) consists of a cytokine-specific alpha-subunit (hGMR alpha) and a common signal-transducing beta-subunit (hpc) that is shared with the interleukin-3 and -5 receptors, We have previously identified a constitutively active extracellular point mutant of hpc, I374N, that can confer factor independence on murine FDC-P1 cells but not BAF-B03 or CTLL-2 cells (Jenkins, B. J., D'Andrea, R. J., and Gonda, T. J. (1995) EMBO J. 14, 4276-4287), This restricted activity suggested the involvement of cell type-specific signaling molecules in the activation of this mutant. We report here that one such molecule is the mouse GMR alpha (mGMR alpha) subunit, since introduction of mGMR alpha, but not hGMR alpha, into BAF-B03 or CTLL-2 cells expressing the I374N mutant conferred factor independence, Experiments utilizing mouse/human chimeric GMR alpha subunits indicated that the species specificity lies in the extracellular domain of GMRa. Importantly, the requirement for mGMR alpha correlated with the ability of I374N (but not wild-type hpc) to constitutively associate with mGMRa. Expression of I374N in human factor-dependent UT7 cells also led to factor-independent proliferation, with concomitant up-regulation of hGMR alpha surface expression. Taken together, these findings suggest a critical role for association with GMR alpha in the constitutive activity of I374N.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia	Gonda, TJ (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Frome Rd, Adelaide, SA 5000, Australia.		jenkins, brendan/A-2401-2009; jenkins, brendan/J-7854-2012	Jenkins, Brendan/0000-0002-7552-4656				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EDER M, 1994, J BIOL CHEM, V269, P30173; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HUGHES SH, 1979, CELL, V18, P347, DOI 10.1016/0092-8674(79)90054-0; Jenkins BJ, 1996, J BIOL CHEM, V271, P29707, DOI 10.1074/jbc.271.47.29707; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOMATSU N, 1991, CANCER RES, V51, P341; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; Mui Alice L.-F., 1994, Progress in Growth Factor Research, V5, P15, DOI 10.1016/0955-2235(94)90015-9; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; Rapoport AP, 1996, BLOOD, V87, P112; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1997, BLOOD, V90, P3005, DOI 10.1182/blood.V90.8.3005	41	17	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8669	8677		10.1074/jbc.274.13.8669	http://dx.doi.org/10.1074/jbc.274.13.8669			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085105	hybrid			2022-12-27	WOS:000079451600047
J	Pandey, P; Avraham, S; Place, A; Kumar, V; Majumder, PK; Cheng, KD; Nakazawa, A; Saxena, S; Kharbanda, S				Pandey, P; Avraham, S; Place, A; Kumar, V; Majumder, PK; Cheng, KD; Nakazawa, A; Saxena, S; Kharbanda, S			Bcl-x(L) blocks activation of related adhesion focal tyrosine kinase proline-rich tyrosine kinase 2 and stress-activated protein kinase c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; INDUCED APOPTOSIS; DEATH PATHWAY; POLY(ADP-RIBOSE) POLYMERASE; PROTEOLYTIC ACTIVATION; JNK ACTIVATION; BCL-2; CELLS; INDUCTION	The stress-activated protein kinase/c-Jun N-terminal protein kinase (JNK) is induced in response to ionizing radiation and other DNA-damaging agents. Recent studies indicate that activation of JNK is necessary for induction of apoptosis in response to diverse agents. Here we demonstrate that methylnethane sulfonate (MMS)-induced activation of JNK is inhibited by overexpression of the anti-apoptotic protein Bcl-x(L), but not by caspase inhibitors CrmA and p35, By contrast, UV-induced JNK activity is insensitive to Bcl-x(L). The results demonstrate that treatment with MMS is associated with an increase in tyrosine phosphorylation of related adhesion focal tyrosine kinase (RAFTK)/proline-rich tyrosine kinase 2 (PYK2), an upstream effector of JNK and that this phosphorylation is inhibited by overexpression of Bcl-x(L). Furthermore, overexpression of a dominant-negative mutant of RAFTK (RAFTK K-M) inhibits MMS-induced JNK activation, The results indicate that inhibition of RAFTK phosphorylation by MMS in Bcl-x(L) cells is attributed to an increase in tyrosine phosphatase activity in these cells. Hence, treatment of Bcl-x(L) cells with sodium vanadate, a tyrosine phosphatase inhibitor, restores MMS-induced activation of RAFTK and JNK. These findings indicate that RAFTK-dependent induction of JNK in response to MMS is sensitive to Bcl-x(L), but not to CrmA. and p35, by a mechanism that inhibits tyrosine phosphorylation and thereby activation of RAFTK. Taken together, these findings support a novel role for Bcl-x(L) that is independent of the caspase cascade.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Manitoba	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	surender_kharbanda@dfci.harvard.edu		Kumar, Vijay/0000-0001-6477-8274	NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Knowlton K, 1998, J SURG RES, V76, P22, DOI 10.1006/jsre.1998.5277; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NATRAJAN AT, 1984, MUTAT RES, V128, P31; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SALEEM A, 1995, J IMMUNOL, V154, P4150; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SMITH GJ, 1986, AM J PATHOL, V122, P488; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; YAN MH, 1994, NATURE, V372, P798; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	60	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8618	8623		10.1074/jbc.274.13.8618	http://dx.doi.org/10.1074/jbc.274.13.8618			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085098	hybrid			2022-12-27	WOS:000079451600040
J	Elbrecht, A; Chen, YL; Adams, A; Berger, J; Griffin, P; Klatt, T; Zhang, B; Menke, J; Zhou, GC; Smith, RG; Moller, DE				Elbrecht, A; Chen, YL; Adams, A; Berger, J; Griffin, P; Klatt, T; Zhang, B; Menke, J; Zhou, GC; Smith, RG; Moller, DE			L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma - The role of Cys(313) in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; EICOSANOIDS; SUPERFAMILY; HORMONE; MEMBER; AGENTS; ALPHA; J(2)	Insulin-sensitizing thiazolidinedione (TZD) compounds are high affinity ligands for a member of the nuclear receptor family, peroxisome proliferator-activated receptor (PPAR) gamma, A scintillation proximity assay for measurement of H-3-radiolabeled TZD binding to human PPAR gamma under homogeneous conditions was developed. Using this approach, a novel non-TZD compound (L-764406) was shown to be a potent (apparent binding IC50 of 70 nM) PPAR gamma ligand, Preincubation of PPAR gamma with L-764406 prevented binding of the [H-3]TZD, suggesting a covalent interaction with the receptor; in addition, structurally related analogues of L-764406, which would be predicted not to interact with PPAR gamma in a covalent fashion, did not displace [H-3]TZD binding to PPAR gamma, Covalent binding of L-764406 was proven by an observed molecular weight shift of a tryptic PPAR gamma ligand binding domain (LBD) peptide by mass spectrometric analysis. A specific cysteine residue (Cys(313) in, helix 3 of hPPAR gamma 2) was identified as the attachment site for this compound. In protease protection experiments, the liganded receptor adopted a typical agonist conformation. L-764406 exhibited partial agonist activity in cells expressing a chimeric receptor containing the PPAR gamma LED and a cognate reporter gene and also induced the expression of the adipocyte-specific gene aP2 in 3T3-L1 cells. In contrast, L-764406 did not exhibit activity in cells transfected with chimeric receptors containing PPAR alpha or PPAR delta LBDs. The partial agonist properties of L-764406 were also evident in a co-activator association assay, indicating that the increased transcription in cells was co-activator mediated. Thus, L-764406 is a novel non-TZD ligand for PPAR gamma and is also the first known partial agonist for this receptor. The results suggest a critical functional role for Cys(313) and helix 3, in contributing to ligand binding and subsequent agonist-induced conformational changes.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Basic Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Elbrecht, A (corresponding author), Merck Res Labs, Dept Mol Endocrinol, Bldg R80N-C31,126 E Lincoln Ave, Rahway, NJ 07065 USA.	alex_elbrecht@merck.com						ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Bisgaier CL, 1998, J LIPID RES, V39, P17; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LARSEN ML, 1993, CURR OPIN LIPIDOL, V4, P34, DOI 10.1097/00041433-199302000-00007; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marburg S, 1996, BIOCONJUGATE CHEM, V7, P612, DOI 10.1021/bc960053z; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	29	97	102	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7913	7922		10.1074/jbc.274.12.7913	http://dx.doi.org/10.1074/jbc.274.12.7913			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075686	hybrid			2022-12-27	WOS:000079268100045
J	Ichimori, K; Fukahori, M; Nakazawa, H; Okamoto, K; Nishino, T				Ichimori, K; Fukahori, M; Nakazawa, H; Okamoto, K; Nishino, T			Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide - Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPR CHARACTERIZATION; REPERFUSION INJURY; MECHANISM; OXYGEN; CELLS; MACROPHAGES; REDUCTASE; RADICALS; SYSTEM; LIVER	Xanthine oxidase (XO) and xanthine dehydrogenase (XDH) were inactivated by incubation with nitric oxide under anaerobic conditions in the presence of xanthine or allopurinol, The inactivation was not pronounced in the absence of an electron donor, indicating that only the reduced enzyme form was inactivated by nitric oxide. The second-order rate constant of the reaction between reduced XO and nitric oxide was determined to be 14.8 +/- 1.4 M-1 s(-1) at 25 degrees C, The inactivated enzymes lacked xanthine-dichlorophenolindophenol activity, and the oxypurinol-bound form of XO was partly protected from the inactivation. The absorption spectrum of the inactivated enzyme was not markedly different from that of the normal enzyme. The flavin and iron-sulfur centers of inactivated XO were reduced by dithionite and reoxidized readily with oxygen, and inactivated XDH retained electron transfer activities from NADH to electron accepters, consistent with the conclusion that the flavin and iron-sulfur centers of the inactivated enzyme both remained intact. Inactivated XO reduced with 6-methylpurine showed no "very rapid" spectra, indicating that the molybdopterin moiety was damaged. Furthermore, inactivated XO reduced by dithionite showed the same slow Mo(V) spectrum as that derived from the desulfo-type enzyme. On the other hand, inactivated XO reduced by dithionite exhibited the same signals for iron-sulfur centers as the normal enzyme. Inactivated XO recovered its activity in the presence of a sulfide-generating system. It is concluded that nitric oxide reacts with an essential sulfur of the reduced molybdenum center of XO and XDH to produce desulfo-type inactive enzymes.	Nippon Med Sch, Dept Biochem & Mol Biol, Tokyo 1138602, Japan; Tokai Univ, Sch Med, Dept Physiol 2, Isehara, Kanagawa 25911, Japan	Nippon Medical School; Tokai University	Nishino, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, 1-1-5 Sendagi, Tokyo 1138602, Japan.	nishino@nms.ac.jp						ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BENNETT B, 1994, BIOCHEM SOC T, V22, pS285, DOI 10.1042/bst022285s; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; Della Corte E, 1968, Biochem J, V108, P349; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; FUKAHORI M, 1994, FREE RADICAL RES, V21, P203, DOI 10.3109/10715769409056572; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison R, 1997, BIOCHEM SOC T, V25, P786, DOI 10.1042/bst0250786; HASSOUN PM, 1994, AM J PHYSIOL, V266, pL163, DOI 10.1152/ajplung.1994.266.2.L163; HASSOUN PM, 1995, AM J PHYSIOL-LUNG C, V268, pL809, DOI 10.1152/ajplung.1995.268.5.L809; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; MALTHOUSE JPG, 1981, BIOCHEM J, V199, P629, DOI 10.1042/bj1990629; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1983, P NATL ACAD SCI-BIOL, V80, P1826, DOI 10.1073/pnas.80.7.1826; NISHINO T, 1994, J BIOCHEM, V116, P1; NISHINO T, 1991, ADV EXP MED BIOL, V309, P327; Nishino T, 1997, BIOCHEM SOC T, V25, P783, DOI 10.1042/bst0250783; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PALMER G, 1969, J BIOL CHEM, V244, P2614; Riggs A., 1981, Methods in Enzymology, V76, P5; RINALDO JE, 1994, AM J RESP CELL MOL, V11, P625, DOI 10.1165/ajrcmb.11.5.7524568; Rothgeb T M, 1978, Methods Enzymol, V52, P473; SAUGSTAD OD, 1988, PEDIATR RES, V23, P143, DOI 10.1203/00006450-198802000-00001; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAUB NC, 1998, PHYSIOLOGY, P561; Wittenberg J.B., 1981, Methods in Enzymology, V76, P29	43	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7763	7768		10.1074/jbc.274.12.7763	http://dx.doi.org/10.1074/jbc.274.12.7763			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075667	hybrid			2022-12-27	WOS:000079268100026
J	Imaizumi, K; Morihara, T; Mori, Y; Katayama, T; Tsuda, M; Furuyama, T; Wanaka, A; Takeda, M; Tohyama, M				Imaizumi, K; Morihara, T; Mori, Y; Katayama, T; Tsuda, M; Furuyama, T; Wanaka, A; Takeda, M; Tohyama, M			The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR DEPENDENCE; CALCIUM HOMEOSTASIS; CORTICAL-NEURONS; ENDOPLASMIC-RETICULUM; LIPID-PEROXIDATION; PEPTIDE; CA2+; TOXICITY; POLYPEPTIDE; HIPPOCAMPAL	DP5, which contains a BH3 domain, was cloned as a neuronal apoptosis-inducing gene. To confirm that DP5 interacts with members of the Bcl-2 family, 293T cells were transiently co-transfected with DP5 and Bcl-xl cDNA constructs, and immunoprecipitation was carried out. The 30-kDa Bcl-xl was co-immunoprecipitated with Myc-tagged DP5, suggesting that DP5 physically interacts with Bcl-xl in mammalian cells. Previously, we reported that DP5 is induced during neuronal apoptosis in cultured sympathetic neurons. Here, we analyzed DP5 gene expression and the specific interaction of DP5 with Bcl-xl during neuronal death induced by amyloid-beta protein (A beta), DP5 mRNA was induced 6 h after treatment with A beta in cultured rat cortical neurons, The protein encoded by DP5 mRNA showed a specific interaction with Bcl-xl, Induction of DP5 gene expression was blocked by nifedipine, an inhibitor of L-type voltage-dependent calcium channels, and dantrolene, an inhibitor of calcium release from the endoplasmic reticulum, These results suggested that the induction of DP5 mRNA occurs downstream of the increase in cytosolic calcium concentration caused by A beta, Moreover, DP5 specifically interacts with Bcl-xl during neuronal apoptosis following exposure to A beta, and its binding could impair the survival-promoting activities of Bcl-xl, Thus, the induction of DP5 mRNA and the interaction of DP5 and Bcl-xl could play significant roles in neuronal degeneration following exposure to A beta.	Osaka Univ, Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan; Tanabe Seiyaku Co Ltd, Yodogawa Ku, Osaka 5320031, Japan; Fukushima Med Coll, Inst Biomed Sci, Fukushima 9601247, Japan; CREST, Kawaguchi 3320012, Japan	Osaka University; Osaka University; Mitsubishi Tanabe Pharma Corporation; Fukushima Medical University; Japan Science & Technology Agency (JST)	Imaizumi, K (corresponding author), Osaka Univ, Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	imaizumi@anat2.med.osaka-u.ac.jp	Morihara, Takashi/AAK-2709-2021; Wanaka, Akio/GPW-8926-2022; Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/ABE-4671-2020	Wanaka, Akio/0000-0001-9951-9862; 				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; COPANI A, 1995, MOL PHARMACOL, V47, P890; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Estus S, 1997, J NEUROSCI, V17, P7736; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FUKUYAMA R, 1994, BRAIN RES, V667, P269, DOI 10.1016/0006-8993(94)91505-9; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Guo Q, 1997, J NEUROSCI, V17, P4212; Han J, 1996, MOL CELL BIOL, V16, P5857; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kanazawa K, 1998, MOL BRAIN RES, V54, P316, DOI 10.1016/S0169-328X(97)00360-4; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KILLER RJ, 1987, SCIENCE, V235, P46; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, J NEUROCHEM, V68, P255; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; SONG SK, 1993, P NATL ACAD SCI USA, V90, P3933, DOI 10.1073/pnas.90.9.3933; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WEISS JH, 1994, J NEUROCHEM, V62, P372	32	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7975	7981		10.1074/jbc.274.12.7975	http://dx.doi.org/10.1074/jbc.274.12.7975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075695	hybrid			2022-12-27	WOS:000079268100054
J	Paudel, HK; Li, W				Paudel, HK; Li, W			Heparin-induced conformational change in microtubule-associated protein tau as detected by chemical cross-linking and phosphopeptide mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; KINASE PHOSPHORYLATES TAU; IN-VITRO; DISEASE; BRAIN; SITES; IDENTIFICATION; BINDING; SULFATE	In Alzheimer's disease, microtubule-associated protein tau becomes abnormally phosphorylated and aggregates into paired helical filaments. Sulfated glycosaminoglycans such as heparin and heparan sulfate were shown to accumulate in pretangle neurons, stimulate in vitro tau phosphorylation, and cause tan aggregation into paired helical filament-like filaments. The sulfated glycosaminoglycan-tau interaction was suggested to be the central event in the development of neuropathology in Alzheimer's disease brain (Goedert, M,, Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., and Crowther, R, A. (1996) Nature 383, 550-553), The biochemical mechanism by which sulfated glycosaminoglycans stimulate tau phosphorylation and cause tan aggregation remains unclear. In this study, disuccinimidyl suberate (DSS), a bifunctional chemical cross-linker, cross-linked tau dimers, tetramers, high molecular size aggregates, and two tau species of sizes 72 and 83 kDa in the presence of heparin, In the absence of heparin only dimeric tau was cross-linked by DSS, Fast protein liquid chromatography gel filtration revealed that 72- and 83-kDa species were formed by intramolecular cross-linking of tau by DSS, These observations indicate that heparin, in addition to causing aggregation, also induces a conformational change in tau in which reactive groups are unmasked or move closer leading to the DSS crosslinking of 72- and 83-kDa species. Heparin-induced structural changes in tau molecule depended on time of heparin exposure. Dimerization and tetramerization peaked at 48 h, whereas conformational change was completed within 30 min of heparin exposure. Heparin exposure beyond 48 h caused an abrupt aggregation of tau into high molecular size species. Heparin stimulated tau phosphorylation by neuronal cdc2-like kinase (NCLK) and cAMP-dependent protein kinase, Phosphopeptide mapping and phosphopeptide sequencing revealed that tau is phosphorylated by NCLK on Thr(212) and Thr(231) and by cAMP-dependent protein kinase on Ser(262) only in the presence of heparin, Heparin stimulation of tau phosphorylation by NCLK showed dependence on time of heparin exposure and correlated with the heparin-induced conformational change of tau, Our data suggest that heparin-induced conformational change exposes new sites for phosphorylation within tau molecule.	Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Paudel, HK (corresponding author), Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	MDHP@MUSICA.McGILL.CA						ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Beyreuther K, 1996, NATURE, V383, P476, DOI 10.1038/383476a0; BRANDT R, 1994, J BIOL CHEM, V269, P11776; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; DILL KA, 1995, ADV PROTEIN CHEM, V46, P59, DOI 10.1016/S0065-3233(08)60332-0; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Hasegawa M, 1996, FEBS LETT, V384, P25, DOI 10.1016/0014-5793(96)00271-2; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P13383; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PERRY G, 1991, J NEUROSCI, V11, P3679; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Roder HM, 1997, J BIOL CHEM, V272, P4509, DOI 10.1074/jbc.272.7.4509; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; Singh TJ, 1996, FEBS LETT, V387, P145, DOI 10.1016/0014-5793(96)00485-1; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; YANG SD, 1994, J NEUROCHEM, V63, P1416	45	68	73	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8029	8038		10.1074/jbc.274.12.8029	http://dx.doi.org/10.1074/jbc.274.12.8029			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075702	hybrid			2022-12-27	WOS:000079268100061
J	Wei, G; Bai, XM; Sarkar, AK; Esko, JD				Wei, G; Bai, XM; Sarkar, AK; Esko, JD			Formation of HNK-1 determinants and the glycosaminoglycan tetrasaccharide linkage region by UDP-GlcUA : galactose beta 1,3-glucuronosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CARBOHYDRATE EPITOPE; BIOSYNTHESIS; GLUCURONOSYLTRANSFERASE; LOCALIZATION; ANTIBODY; PROTEIN; OLIGOSACCHARIDE; GLYCOSYLATION; PROTEOGLYCANS	While expression-cloning enzymes involved in heparan sulfate biosynthesis, we isolated a cDNA that encodes a protein 65% identical to the UDP-GlcUA:glycoprotein beta 1,3-glucuronosyltransferase (GlcUAT-P) involved in forming HNK-1 carbohydrate epitopes (3OSO(3)GlcUA beta 1, 3Gal-) on glycoproteins. The cDNA contains an open reading frame coding for a protein of 335 amino acids with a predicted type II transmembrane protein orientation. Cotransfection of the cDNA with HNK-1 3-O-sulfotransferase produced HNK-1 carbohydrate epitopes in Chinese hamster ovary (CHO) cells and COS-7 cells. In vitro, a soluble recombinant form of the enzyme transferred GlcUA in beta-linkage to Gal beta 1,3/4GlcNAc beta-O-naphthalenemethanol, which resembles the core oligosaccharide on which the HNK-1 epitope is assembled. However, the enzyme greatly preferred Gal beta 1,3Gal beta-O-naphthalenemethanol, a disaccharide component found in the linkage region tetrasaccharide in chondroitin sulfate and heparan sulfate. During the course of this study, a human cDNA clone was described that was thought to encode UDP-GlcUA:Gal beta 1,3Gal-R glucuronosyltransferase (GlcUAT-I), involved in the formation of the linkage region of glycosaminoglycans (Kitagawa, H,, Tone, Y,, Tamura, J,, Neumann, K. W,, Ogawa, T,, Oka, S,, Kawasaki, T,, and Sugahara, K, (1998) J. Biol. Chem. 273, 6615-6618), The deduced amino acid sequences of the CHO and human cDNAs are 95% identical, suggesting that they are in fact homologues of the same gene. Transfection of a CHO cell mutant defective in GlcUAT-I with the hamster cDNA restored glycosaminoglycan assembly in vivo, confirming its identity. Interestingly, transfection of the mutant with GlcUAT-P also restored glycosaminoglycan synthesis. Thus, both GlcUAT-P and GlcUAT-I have overlapping substrate specificities. However, the expression of the two genes was entirely different, with GlcUAT-I expressed in all tissues tested and GlcUAT-P expressed only in brain. These findings suggest that, in neural tissues, GlcUAT-P may participate in both HNK-1 and glycosaminoglycan production.	Univ Calif San Diego, Div Cellular & Mol Med, Glycobiol Res & Training Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Esko, JD (corresponding author), Univ Calif San Diego, Div Cellular & Mol Med, Glycobiol Res & Training Program, 9500 Gilman Dr,CMM E 1055, La Jolla, CA 92093 USA.	jesko@ucsd.edu			NCI NIH HHS [CA46462] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO T, 1981, J IMMUNOL, V127, P1024; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BERGER EG, 1991, J HISTOCHEM CYTOCHEM, V39, P1439, DOI 10.1177/39.10.1940315; BRANDT AE, 1969, P NATL ACAD SCI USA, V64, P374, DOI 10.1073/pnas.64.1.374; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CURENTON T, 1991, BIOCHEM BIOPH RES CO, V179, P416, DOI 10.1016/0006-291X(91)91386-Q; DAS KK, 1991, J BIOL CHEM, V266, P5238; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HELTING T, 1969, J BIOL CHEM, V244, P2799; HELTING T, 1972, J BIOL CHEM, V247, P4327; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; OKA S, 1992, J BIOL CHEM, V267, P22711; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SPIRO MJ, 1977, J BIOL CHEM, V252, P5424; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; Sugumaran G, 1998, BIOCHEM J, V329, P203, DOI 10.1042/bj3290203; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	38	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7857	7864		10.1074/jbc.274.12.7857	http://dx.doi.org/10.1074/jbc.274.12.7857			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075678	hybrid			2022-12-27	WOS:000079268100037
J	Lawrence, CC; Gerfen, GJ; Samano, V; Nitsche, R; Robins, MJ; Retey, J; Stubbe, J				Lawrence, CC; Gerfen, GJ; Samano, V; Nitsche, R; Robins, MJ; Retey, J; Stubbe, J			Binding of Cob(II)alamin to the adenosylcobalamin-dependent ribonucleotide reductase from Lactobacillus leichmannii - Identification of dimethylbenzimidazole as the axial ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; COENZYME-A MUTASE; C BOND-CLEAVAGE; HISTIDINE RESIDUE; CRYSTAL-STRUCTURE; GLUTAMATE MUTASE; COMPONENT-S; B-12 MODELS; COBALT; VITAMIN-B12	The ribonucleoside triphosphate reductase (RTPR) from Lactobacillus leichmannii catalyzes the reduction of nucleoside 5'-triphosphates to 2'-deoxynucleoside 5'-triphosphates and uses coenzyme B-12, adenosylcobalamin (AdoCbl), as a cofactor. Use of a mechanism-based inhibitor, 2'-deoxy-2'-methylenecytidine 5'-triphosphate, and isotopically labeled RTPR and AdoCbl in conjunction with EPR spectroscopy has allowed identification of the lower axial ligand of cob(II)alamin when bound to RTPR. In common with the AdoCbl-dependent enzymes catalyzing irreversible heteroatom migrations and in contrast to the enzymes catalyzing reversible carbon skeleton rearrangements, the dimethylbenzimidazole moiety of the cofactor is not displaced by a protein histidine upon binding to RTPR.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Karlsruhe, Inst Organ Chem, Lehrstuhl Biochem, D-76128 Karlsruhe, Germany; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Yeshiva University; Albert Einstein College of Medicine; Helmholtz Association; Karlsruhe Institute of Technology; Brigham Young University	Stubbe, J (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	stubbe@it.edu			NIGMS NIH HHS [GM 29595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029595, R37GM029595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abend A, 1998, ANGEW CHEM INT EDIT, V37, P625, DOI 10.1002/(SICI)1521-3773(19980316)37:5<625::AID-ANIE625>3.0.CO;2-4; BAYSTON JH, 1970, BIOCHEMISTRY-US, V9, P2164, DOI 10.1021/bi00812a020; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BOOKER S, 1994, THESIS MIT; Brown KL, 1998, J AM CHEM SOC, V120, P9466, DOI 10.1021/ja981729z; Buckel W, 1996, CHEM SOC REV, V25, P329, DOI 10.1039/cs9962500329; CHEMALY SM, 1980, J CHEM SOC DALTON, P2274, DOI 10.1039/dt9800002274; DeRidder DJA, 1996, J MOL STRUCT, V374, P63, DOI 10.1016/0022-2860(95)09034-7; Dong SL, 1998, J AM CHEM SOC, V120, P9947, DOI 10.1021/ja981584w; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FINKE RG, 1998, VITAMIN B12 B12 PROT, P383; GENO MK, 1987, J AM CHEM SOC, V109, P1238, DOI 10.1021/ja00238a039; Gerfen GJ, 1996, J AM CHEM SOC, V118, P8192, DOI 10.1021/ja960363s; GRATE JH, 1979, J AM CHEM SOC, V101, P4601, DOI 10.1021/ja00510a027; HAMILTON JA, 1971, BIOCHEMISTRY-US, V10, P347, DOI 10.1021/bi00778a023; KRAUTLER B, 1994, INORG CHEM, V33, P4128; KRAUTLER B, 1998, VITAMIN B12 B12 PROT, P3; Lawrence CC, 1998, CURR OPIN CHEM BIOL, V2, P650, DOI 10.1016/S1367-5931(98)80097-5; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; Licht SS, 1999, BIOCHEMISTRY-US, V38, P1221, DOI 10.1021/bi981885i; Licht SS, 1999, BIOCHEMISTRY-US, V38, P1234, DOI 10.1021/bi981886a; LUNN CA, 1984, J BIOL CHEM, V259, P469; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARZILLI LG, 1985, J AM CHEM SOC, V107, P6880, DOI 10.1021/ja00310a023; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; RANDACCIO L, 1981, J AM CHEM SOC, V103, P6347, DOI 10.1021/ja00411a014; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; SAMANO V, 1991, SYNTHESIS-STUTTGART, P283; Sauer K, 1998, EUR J BIOCHEM, V253, P698, DOI 10.1046/j.1432-1327.1998.2530698.x; Sauer K, 1998, FEBS LETT, V436, P401, DOI 10.1016/S0014-5793(98)01180-6; Scheuring E, 1997, J AM CHEM SOC, V119, P12192, DOI 10.1021/ja9635239; STEEPER JR, 1970, ANAL BIOCHEM, V34, P123, DOI 10.1016/0003-2697(70)90092-8; Stubbe J., 1998, VITAMIN B12 B12 PROT, P321; STUPPERICH E, 1990, EUR J BIOCHEM, V193, P105, DOI 10.1111/j.1432-1033.1990.tb19310.x; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; Yamanishi M, 1998, BIOCHEMISTRY-US, V37, P4799, DOI 10.1021/bi972572a; ZELDER O, 1995, FEBS LETT, V369, P252, DOI 10.1016/0014-5793(95)00762-X	43	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7039	7042		10.1074/jbc.274.11.7039	http://dx.doi.org/10.1074/jbc.274.11.7039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066759	hybrid, Green Submitted			2022-12-27	WOS:000079078400031
J	Nordin, BE; Schimmel, P				Nordin, BE; Schimmel, P			RNA determinants for translational editing - Mischarging a minihelix substrate by a tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; ACCEPTOR STEM; SINGLE NUCLEOTIDE; GENETIC-CODE; DNA APTAMER; AMINO-ACIDS; AMINOACYLATION; RECOGNITION	The fidelity of protein synthesis requires efficient discrimination of amino acid substrates by aminoacyl-tRNA synthetases, Accurate discrimination of the structurally similar amino acids, valine and isoleucine, by isoleucyl-tRNA synthetase (IleRS) results, in part, from a hydrolytic editing reaction, which prevents misactivated valine from being stably joined to tRNA(Ile). The editing reaction is dependent on the presence of tRNA(Ile), which contains discrete D-loop nucleotides that are necessary to promote editing of misactivated valine, RNA minihelices comprised of just the acceptor-T Psi C helix of tRNA(Ile) are substrates for specific aminoacylation by IleRS, These substrates lack the aforementioned D-loop nucleotides. Because minihelices contain determinants for aminoacylation, we thought that they might also play a role in editing that has not previously been recognized, Here we show that, in contrast to tRNA(Ile) minihelix(Ile) is unable to trigger the hydrolysis of misactivated valine and, in fact, is mischarged with valine, In addition, mutations in minihelix(Ile) that enhance or suppress charging with isoleucine do the same with valine, Thus, minihelix(Ile) contains signals for charging (by Il-eRS) that are independent of the amino acid and, by itself, minihelix(Ile) provides no determinants for editing. An RNA hairpin that mimics the D-stem/loop of tRNA(Ile) is also unable to induce the hydrolysis of misactivated valine, both by itself and in combination with minihelix(Ile). Thus, the native tertiary fold of tRNA(Ile) is required to promote efficient editing. Considering that the minihelix is thought to be the more ancestral part of the tRNA structure, these results are consistent with the idea that, during the development of the genetic code, RNA determinants for editing were added after the establishment of an aminoacylation system.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,Mail Code BCC-379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander RW, 1998, P NATL ACAD SCI USA, V95, P12214, DOI 10.1073/pnas.95.21.12214; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CRAMER F, 1991, BIOCHIMIE, V73, P1027, DOI 10.1016/0300-9084(91)90144-P; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P355; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Glasfeld E, 1996, BIOCHEMISTRY-US, V35, P4139, DOI 10.1021/bi9527810; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hale SP, 1997, TETRAHEDRON, V53, P11985, DOI 10.1016/S0040-4020(97)00711-4; Hale SP, 1996, P NATL ACAD SCI USA, V93, P2755, DOI 10.1073/pnas.93.7.2755; HAMANN CS, 1995, BIOCHEMISTRY-US, V34, P6527, DOI 10.1021/bi00019a034; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LAPOINTE J, 1991, TRANSLATION EUKARYOT, P35; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martinis Susan A., 1995, P349; Noller H.F., 1993, RNA WORLD, P137; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; NUREKI O, 1993, TRANSLATIONAL APPARATUS, P59; PARK SJ, 1988, J BIOL CHEM, V263, P16527; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT E, 1996, THESIS MIT CAMBRIDGE, P160; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	42	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6835	6838		10.1074/jbc.274.11.6835	http://dx.doi.org/10.1074/jbc.274.11.6835			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066735	hybrid			2022-12-27	WOS:000079078400007
J	Pinto, D; Robine, S; Jaisser, F; El Marjou, F; Louvard, D				Pinto, D; Robine, S; Jaisser, F; El Marjou, F; Louvard, D			Regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of small and large intestines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN GENE; HORMONE FUSION GENES; CYTOSKELETAL PROTEIN; VISCERAL ENDODERM; GUT EPITHELIUM; REPORTER GENE; T-ANTIGEN; MICE; PATTERNS; TISSUE	Villin is an early marker of epithelial cells from the digestive and urogenital tracts. Indeed villin is expressed in the stem cells and the proliferative cells of the intestinal crypts, To investigate the underlying molecular mechanisms and particularly those responsible for the restricted tissue specificity, a large genomic region of the mouse villin gene has been analyzed, A 9-kilobase (kb) regulatory region of the mouse villin gene (harboring 3.5 kb upstream the transcription start site and 5.5 kb-of the first intron) was able to promote transcription of the LacZ reporter gene in the small and large intestines of transgenic mice, in a transmissible manner, and thus efficiently directed subsequent beta-gaIactosidase expression in epithelial cells along the entire crypt-villus axis. In the kidney, the transgene was also expressed in the epithelial cells of the proximal tubules but is likely sensitive to the site of integration. A construct lacking the first intron restricted beta-galactosidase expression to the small intestine, Thus, the 9-kb genomic region contains the necessary cis-acting elements to recapitulate the tissue-specific expression pattern of the endogenous villin gene, Hence, these regulatory sequences can be used to target heterologous genes in immature and differentiated epithelial cells of the small and/or large intestinal mucosa.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Louvard, D (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Jaisser, Frederic/P-4287-2017	Jaisser, Frederic/0000-0001-9051-1901				ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BACCHI CE, 1991, LAB INVEST, V64, P418; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CARBONI JM, 1987, AM J PATHOL, V129, P589; CARTIER N, 1993, J CELL SCI, V104, P695; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Cohen-Tannoudji M, 1998, MOL CELL BIOL, V18, P1444, DOI 10.1128/MCB.18.3.1444; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; HALL PA, 1994, J CELL SCI, V107, P3569; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; MOLL R, 1987, VIRCHOWS ARCH B, V54, P155, DOI 10.1007/BF02899208; PERRET C, 1991, GENE, V108, P227, DOI 10.1016/0378-1119(91)90438-H; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRINGAULT E, 1991, P NATL ACAD SCI USA, V88, P10811, DOI 10.1073/pnas.88.23.10811; ROBINE S, 1993, J BIOL CHEM, V268, P11426; Robine S, 1997, AM J PHYSIOL-GASTR L, V273, pG759; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; Simon TC, 1997, J BIOL CHEM, V272, P10652; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; WEST AB, 1988, GASTROENTEROLOGY, V94, P343, DOI 10.1016/0016-5085(88)90421-0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x	44	122	126	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6476	6482		10.1074/jbc.274.10.6476	http://dx.doi.org/10.1074/jbc.274.10.6476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037740	hybrid			2022-12-27	WOS:000078902800062
J	Thuveson, M; Fries, E				Thuveson, M; Fries, E			Intracellular proteolytic processing of the heavy chain of rat pre-alpha-inhibitor - The COOH-terminal propeptide is required for coupling to bikunin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS EXTRACELLULAR-MATRIX; COVALENTLY CROSS-LINKS; TRYPSIN-INHIBITOR; PRECURSOR PROTEINS; FAMILY; ENDOPROTEASE; BIOSYNTHESIS; HEPATOCYTES; CLEAVAGE; SEQUENCE	Pre-alpha-inhibitor is a serum protein consisting of two polypeptides named bikunin and heavy chain 3 (H3). Both polypeptides are synthesized in hepatocytes and while passing through the Golgi complex, bikunin, which carries a chondroitin sulfate chain, becomes covalently linked to the COOH-terminal amino acid residue of H3 via its polysaccharide. Immediately prior to this reaction, a COOH-terminal propeptide of 33 kDa is cleaved off from the heavy chain. Using COS-1 cells transfected with rat H3, we found that in the absence of bikunin, the cleaved propeptide remained bound to the heavy chain and that H3 lacking the propeptide sequence did not become linked to coexpressed bikunin. Sequencing of H3 secreted from COS-1 cells showed that part of the molecules had a 12-amino acid residue long NH2-terminal propeptide. Cleavage of this propeptide, which occurred in the endoplasmic reticulum, was found to require basic amino acid residues at P-1, P-2, and P-6 suggesting that it is mediated by a Golgi enzyme in transit. Deletion of the NH2-terminal propeptide or blocking of its release affected neither transport nor coupling of the heavy chain to bikunin.	Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden	Uppsala University	Thuveson, M (corresponding author), Box 575, S-75123 Uppsala, Sweden.	Thuveson@medkem.uu.se						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1997, BIOCHEM J, V328, P185; BOURGUIGNON J, 1993, EUR J BIOCHEM, V212, P771, DOI 10.1111/j.1432-1033.1993.tb17717.x; BRATT T, 1994, FEBS LETT, V354, P57, DOI 10.1016/0014-5793(94)01087-0; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; Dayhoff MO, ATLAS PROTEIN SEQUEN; DENG WP, 1992, ANAL BIOCH, V200; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; SWAIM MW, 1988, BIOCHEM J, V254, P171, DOI 10.1042/bj2540171; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wisniewski HG, 1996, J IMMUNOL, V156, P1609	27	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6741	6746		10.1074/jbc.274.10.6741	http://dx.doi.org/10.1074/jbc.274.10.6741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037773	hybrid			2022-12-27	WOS:000078902800095
J	van der Voort, R; Taher, TEI; Wielenga, VJM; Spaargaren, M; Prevo, R; Smit, L; David, G; Hartmann, G; Gherardi, E; Pals, ST				van der Voort, R; Taher, TEI; Wielenga, VJM; Spaargaren, M; Prevo, R; Smit, L; David, G; Hartmann, G; Gherardi, E; Pals, ST			Heparan sulfate-modified CD44 promotes hepatocyte growth factor scatter factor induced signal transduction through the receptor tyrosine kinase c-Met	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; FIBROBLAST GROWTH; CELL-ADHESION; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; EPITHELIAL-CELLS; VARIANT ISOFORMS; BINDING; HYALURONATE; EXPRESSION	CD44 has been implicated in tumor progression and metastasis, but the mechanism(s) involved is as yet poorly understood. Recent studies have shown that CD44 isoforms containing the alternatively spliced exon v3 carry heparan sulfate side chains and are able to bind heparin-binding growth factors. In the present study, we have explored the possibility of a physical and functional interaction between CD44 and hepatocyte growth factor/scatter factor (HGF/SF), the ligand of the receptor tyrosine kinase c-Met. The HGF/SF-c-Met pathway mediates cell growth and motility and has been implicated in tumor invasion and metastasis. We demonstrate that a CD44v3 splice variant efficiently binds HGF/SF via its heparan sulfate side chain. To address the functional relevance of this interaction, Namalwa Burkitt's lymphoma cells were stably co-transfected with c-Met and either CD44v3 or the isoform CD44s, which lacks heparan sulfate. We show that, as compared with CD44s, CD44v3 promotes: (i) HGF/SF-induced phosphorylation of c-Met, (ii) phosphorylation of several downstream proteins, and (iii) activation of the MAP kinases ERK1 and -2, By heparitinase treatment and the use of a mutant HGF/SF with greatly decreased affinity for heparan sulfate, we show that the enhancement of c-Met signal transduction induced by CD44v3 was critically dependent on heparan sulfate moieties, Our results identify heparan sulfate-modified CD44 (CD44-HS) as a functional co-receptor for HGF/SF which promotes signaling through the receptor tyrosine kinase c-Met, presumably by concentrating and presenting HGF/SF. As both CD44-HS and c-Met are overexpressed on several types of tumors, we propose that the observed functional collaboration might be instrumental in promoting tumor growth and metastasis.	Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Univ Leuven, Ctr Human Genet, B-3000 Leuven, Belgium; Univ Leuven VIB, B-3000 Leuven, Belgium; Univ Cambridge, Dept Oncol, Growth Factors Grp, Cambridge CB2 2QH, England	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Cambridge	Pals, ST (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	S.T.Pals@AMC.UVA.NL	Spaargaren, Marcel/AAU-1298-2021; Gherardi, Ermanno/AAB-9608-2022	Spaargaren, Marcel/0000-0002-3135-5109; Pals, Steven/0000-0002-1419-0939; GHERARDI, ERMANNO/0000-0002-0016-2945				ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FOX SB, 1993, LANCET, V342, P548, DOI 10.1016/0140-6736(93)91670-H; FURUKAWA T, 1995, AM J PATHOL, V147, P889; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Herrera R, 1998, J CELL SCI, V111, P1039; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Jiang WG, 1995, BIOCHEM BIOPH RES CO, V217, P1062, DOI 10.1006/bbrc.1995.2877; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KMIECIK TE, 1992, BLOOD, V80, P2454; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LACY BE, 1987, J CELL BIOL, V105, P1395, DOI 10.1083/jcb.105.3.1395; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIU C, 1992, ONCOGENE, V7, P181; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; PALS ST, 1989, J IMMUNOL, V143, P851; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Ropponen KM, 1998, SCAND J GASTROENTERO, V33, P301; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; Tuck AB, 1996, AM J PATHOL, V148, P225; VANDERVOORT R, 1995, BIOCHEM BIOPH RES CO, V214, P137, DOI 10.1006/bbrc.1995.2267; vanderVoort R, 1997, J EXP MED, V185, P2121, DOI 10.1084/jem.185.12.2121; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871; ZOLLER M, 1995, J MOL MED, V73, P425	81	187	198	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6499	6506		10.1074/jbc.274.10.6499	http://dx.doi.org/10.1074/jbc.274.10.6499			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037743	hybrid			2022-12-27	WOS:000078902800065
J	Shimada, H; Nagano, S; Ariga, Y; Unno, M; Egawa, T; Hishiki, T; Ishimura, Y				Shimada, H; Nagano, S; Ariga, Y; Unno, M; Egawa, T; Hishiki, T; Ishimura, Y			Putidaredoxin-cytochrome P450(cam) interaction - Spin state of the heme iron modulates putidaredoxin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN ACTIVATION; P-450CAM; CAMPHOR; MODEL; FERREDOXIN; RESOLUTION; MECHANISM	During the monooxygenase reaction catalyzed by cytochrome P450(cam) (P450(cam)), a ternary complex of P450(cam), reduced putidaredoxin, and d-camphor is formed as an obligatory reaction intermediate. When ligands such as CO, NO, and O-2 bind to the heme iron of P450(cam) in the intermediate complex, the EPR spectrum of reduced putidaredoxin with a characteristic signal at 346 millitesla at 77 K changed into a spectrum having a new signal at 348 millitesla. The experiment with O-2 was carried out by employing a mutant P450(cam) with Asp(251) --> Asn or Gly where the rate of electron transfer from putidaredoxin to oxyferrous P450(cam) is considerably reduced. Such a ligand-induced EPR spectral change of putidaredoxin was also shown in situ in Pseudomonas putida, Mutations introduced into the neighborhood of the iron-sulfur cluster of putidaredoxin revealed that a Ser(44) --> Gly mutation mimicked the ligand-induced spectral change of putidaredoxin. Arg(109) and Arg(112), which are in the putative putidaredoxin binding site of P450(cam), were essential for the spectral changes of putidaredoxin in the complex. These results indicate that a change in the P450(cam) active site that is the consequence of an altered spin state is transmitted to putidaredoxin within the ternary complex and produces a conformational change of the 2Fe-2S active center.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Keio University; Osaka University	Shimada, H (corresponding author), Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	shimada@med.keio.ac.jp		Unno, Masashi/0000-0002-5016-6274				BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; Ishimura Y., 1987, CYTOCHROME P 450 NEW, P151; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; PETERSON JA, 1970, J BACTERIOL, V103, P714, DOI 10.1128/JB.103.3.714-721.1970; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; ROOME PW, 1983, J BIOL CHEM, V258, P2593; SANDS RH, 1974, Q REV BIOPHYS, V7, P443, DOI 10.1017/S0033583500001517; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; SHIMADA H, 1993, CYTOCHROME P450 BIOC, P299; SHIMADA H, 1997, CATAL MET C, V19, P195; SHIMADA H, 1990, INT S OXYGENASES OXY, P133; SHIRO Y, 1989, J AM CHEM SOC, V111, P7707, DOI 10.1021/ja00202a007; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1975, THESIS U ILLINOIS UR; TSIBRIS JCM, 1968, P NATL ACAD SCI USA, V59, P959, DOI 10.1073/pnas.59.3.959; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869	30	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9363	9369		10.1074/jbc.274.14.9363	http://dx.doi.org/10.1074/jbc.274.14.9363			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092615	hybrid			2022-12-27	WOS:000079451800034
J	Karasawa, K; Qiu, XY; Lee, TC				Karasawa, K; Qiu, XY; Lee, TC			Purification and characterization from rat kidney membranes of a novel platelet-activating factor (PAF)-dependent transacetylase that catalyzes the hydrolysis of PAF, formation of PAF analogs, and C(2)-ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; COA-INDEPENDENT TRANSACETYLASE; FACTOR-ACETYLHYDROLASE-II; HL-60 CELLS; SPHINGOSINE; CERAMIDE; STRESS; KINASE; 1-ACYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; SPHINGOMYELINASE	We have previously identified two enzyme activities that transfer the acetyl group from platelet-activating factor (PAF) in a CoA-independent manner to lysoplasmalogen or sphingosine in HL-60 cells, endothelial cells, and a variety of rat tissues. These were termed as PAF: lysoplasmalogen (lysophospholipid) transacetylase and PAF:sphingosine transacetylase, respectively. In the present study, we have solubilized and purified this PAF-dependent transacetylase 13,700-fold from rat kidney membranes (mitochondrial plus microsomal membranes) based on the PAF:lysoplasmalogen transacetylase activity. The mitochondria and microsomes were prepared and washed three times, then solubilized with 0.04% Tween 20 at a detergent/protein (w/w) ratio of 0.1. The solubilized fractions from mitochondria and microsomes were combined and subjected to sequential column chromatographies on DEAE-Sepharose, hydroxyapatite, phenyl Sepharose, and chromatofocusing. The enzyme was further purified by native-polyacrylamide gel electrophoresis (PAGE) and affinity gel matrix in which the competitive inhibitor of the enzyme, 1-O-hexadecyl-2-N-methylcarbamyl-sn-glycero-3-phosphoethanolamine was covalently attached to the CH-Sepharose. On SDS-PAGE, the purified enzyme showed a single homogeneous band with an apparent molecular mass of 40 kDa. The purified enzyme catalyzed transacetylation of the acetyl group not only from PAF to lysoplasmalogen forming plasmalogen analogs of PAF, but also to sphingosine producing N-acetylsphingosine (C(2)-ceramide). In addition, this enzyme acted as a PAF-acetylhydrolase in the absence of lipid acceptor molecules. These results suggest that PAF dependent transacetylase is an enzyme that modifies the cellular functions of PAF through generation of other diverse lipid mediators.	Oak Ridge Associated Univ, Biochem Basic & Appl Res Unit, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Lee, TC (corresponding author), Oak Ridge Associated Univ, Biochem Basic & Appl Res Unit, Oak Ridge, TN 37831 USA.	leetc@orau.gov		Carter, Michelle Qiu/0000-0002-0710-7420	NHLBI NIH HHS [HL-52492] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052492] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balestrieri ML, 1997, J BIOL CHEM, V272, P17431, DOI 10.1074/jbc.272.28.17431; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; Goyal J, 1997, J BIOL CHEM, V272, P16231, DOI 10.1074/jbc.272.26.16231; HANNUM YA, 1987, SCIENCE, V243, P670; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; Lee TC, 1996, ADV EXP MED BIOL, V416, P113; LEE TC, 1992, J BIOL CHEM, V267, P19992; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NIETO ML, 1991, J BIOL CHEM, V266, P18699; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 1997, BBA-LIPID LIPID MET, V1348, P311, DOI 10.1016/S0005-2760(97)00067-2; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; RodriguezLafrasse C, 1997, BIOCHEM J, V325, P787, DOI 10.1042/bj3250787; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	32	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8655	8661		10.1074/jbc.274.13.8655	http://dx.doi.org/10.1074/jbc.274.13.8655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085103	hybrid			2022-12-27	WOS:000079451600045
J	Kim, E; Ambroziak, P; Otto, JC; Taylor, B; Ashby, M; Shannon, K; Casey, PJ; Young, SG				Kim, E; Ambroziak, P; Otto, JC; Taylor, B; Ashby, M; Shannon, K; Casey, PJ; Young, SG			Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-FACTOR; SACCHAROMYCES-CEREVISIAE; PROTEIN PRENYLATION; K-RAS; ISOPRENYLATED PEPTIDES; ENDOPLASMIC-RETICULUM; N-RAS; CARBOXYL; PROTEOLYSIS; METHYLATION	Little is known about the enzyme(s) required for the endoproteolytic processing of mammalian Ras proteins. We identified a mouse gene (designated Rce1) that shares sequence homology with a yeast gene (RCE1) implicated in the proteolytic processing of Ras2p. To define the role of Rce1 in mammalian Ras processing, we generated and analyzed Rce1-deficient mice. Reel deficiency was lethal late in embryonic development (after embryonic day 15.5). Multiple lines of evidence revealed that Rce1-deficient embryos and cells lacked the ability to endoproteolytically process Ras proteins. First, Ras proteins from Rce1-deficient cells migrated more slowly on SDS-polyacrylamide gels than Ras proteins from wild-type embryos and fibroblasts. Second, metabolic labeling of Rce1-deficient cells revealed that the Ras proteins were not carboxymethylated. Finally, membranes from Rce1 deficient fibroblasts lacked the capacity to proteolytically process farnesylated Ha-Ras, N-Ras, and Ki-Ras or geranylgeranylated Ki-Ras. The processing of two other prenylated proteins, the farnesylated G(gamma 1) subunit of transducin and geranylgeranylated Rap1B, was also blocked. The absence of endoproteolytic processing and carboxymethylation caused Ras proteins to be mislocalized within cells. These studies indicate that Reel is responsible for the endoproteolytic processing of the Ras proteins in mammals and suggest a broad role for this gene in processing other prenylated CAAX proteins.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94141 USA; Acacia Biosci Inc, Richmond, CA 94806 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University	Kim, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, P01HL047660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41633, HL-47660] Funding Source: Medline; NIA NIH HHS [AG-15451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Boyartchuk VL, 1998, GENETICS, V150, P95; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; COX AD, 1995, METHOD ENZYMOL, V255, P195; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Farese RV, 1996, J LIPID RES, V37, P347; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; GILBERT BA, 1995, METHOD ENZYMOL, V250, P206; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1993, PHARMACOL THERAPEUT, V59, P281, DOI 10.1016/0163-7258(93)90071-K; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	146	150	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8383	8390		10.1074/jbc.274.13.8383	http://dx.doi.org/10.1074/jbc.274.13.8383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085069	hybrid			2022-12-27	WOS:000079451600011
J	Li, X; Dy, RC; Cance, WG; Graves, LM; Earp, HS				Li, X; Dy, RC; Cance, WG; Graves, LM; Earp, HS			Interactions between two cytoskeleton-associated tyrosine kinases: Calcium-dependent tyrosine kinase and focal adhesion tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; N-TERMINAL KINASE; PROTEIN-COUPLED RECEPTORS; ANGIOTENSIN-II; GROWTH-FACTOR; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; FAMILY MEMBERS; T-LYMPHOCYTES; ACTIVATION	The calcium-dependent tyrosine kinase (CADTK), also known as Pyk2/RAFTK/CAK beta/FAX2, is a cytoskeleton-associated tyrosine kinase. We compared CADTK regulation with that of the highly homologous focal adhesion tyrosine kinase (FAK). First, we generated site-specific CADTK mutants. Mutation of Tyr(402) eliminated autophosphorylation and significantly decreased kinase activity. Mutation of Tyr(881), a putative Src kinase phosphorylation site predicted to bind Grb2, had little effect on CADTK regulation. Src family tyrosine kinases resulted in CADTK tyrosine phosphorylation even when co-expressed with the Tyr(402)/Tyr(881) double mutant, suggesting that Src/Fyn etc. phosphorylate additional tyrosine residues. Interestingly, CADTK tyrosine-phosphorylated FAK when both were transiently expressed, but FAK did not phosphorylate CADTK. Biochemical experiments confirmed direct CADTK phosphorylation of FAK. This phosphorylation utilized tyrosine residues other than Tyr(397), Tyr(925), Or Tyr(576)/Tyr(577), suggesting that new SH2-binding sites might be created by CADTK-dependent FAK phosphorylation. Last, expression of the CADTK carboxyl terminus (CRNK) abolished CADTK but not FAK autophosphorylation. In contrast, FAK carboxyl terminus overexpression inhibited both FAK and CADTK autophosphorylation, suggesting that a FAK-dependent cytoskeletal function may be necessary for CADTK activation. Thus, CADTK and FAK, which both bind to some, but not necessarily the same, cytoskeletal elements, may be involved in coordinate regulation of cytoskeletal structure and signaling.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Earp, HS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	hse@med.unc.edu	Graves, Lee/AAG-5470-2021		NCI NIH HHS [CA65910] Funding Source: Medline; NIGMS NIH HHS [GM54010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cazaubon S, 1997, J NEUROSCI, V17, P6203; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; COBB BS, 1994, MOL CELL BIOL, V15, P2819; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EARP HS, 1995, J BIOL CHEM, V270, P28440; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Guo XYD, 1998, BLOOD, V92, p253A; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SEGER R, 1994, J BIOL CHEM, V269, P25699; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	62	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8917	8924		10.1074/jbc.274.13.8917	http://dx.doi.org/10.1074/jbc.274.13.8917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085136	hybrid, Green Published			2022-12-27	WOS:000079451600078
J	Ranganathan, G; Kaakaji, R; Kern, PA				Ranganathan, G; Kaakaji, R; Kern, PA			Role of protein kinase C in the translational regulation of lipoprotein lipase in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DOWN-REGULATION; HUMAN ADIPOSE-TISSUE; RAT ADIPOCYTES; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; PHORBOL ESTERS; CHRONIC ACTIVATION; THYROID-HORMONE; INSULIN; GLUCOSE	The hypertriglyceridemia of diabetes is accompanied by decreased lipoprotein lipase (LPL) activity in adipocytes, Although the mechanism for decreased LPL is not known, elevated glucose is known to increase diacylglycerol, which activates protein kinase C (PKC), To determine whether PKC is involved in the regulation of LPL, we studied the effect of 12-O-tetradecanoyl phorbol 13-acetate (TPA) on adipocytes, LPL activity was inhibited when TPA was added to cultures of 3T3-F442A and rat primary adipocytes, The inhibitory effect of TPA on LPL activity was observed after 6 h of treatment, and was observed at a concentration of 6 nM. 100 nM TPA yielded maximal (80%) inhibition of LPL. No stimulation of LPL occurred after short term addition of TPA to cultures. To determine whether TPA treatment of adipocytes decreased LPL synthesis, cells were labeled with [S-35]methionine and LPL protein was immunoprecipitated, LPL synthetic rate decreased after 6 h of TPA treatment. Western blot analysis of cell lysates indicated a decrease in LPL mass after TPA treatment. Despite this decrease in LPL synthesis, there was no change in LPL mRNA in the TPA-treated cells. Long term treatment of cells with TPA is known to down-regulate PKC, To assess the involvement of the different PRC isoforms, Western blotting was performed. TPA treatment of 3T3-F442A adipocytes decreased PKC alpha, beta, delta, and epsilon, isoforms, whereas PKC lambda, theta, zeta, mu, iota, and gamma remained unchanged or decreased minimally. To directly assess the effect of PRC inhibition, PKC inhibitors (calphostin C and staurosporine) were added to cultures. The PI(C inhibitors inhibited LPL activity rapidly (within 60 min). Thus, activation of PKC did not increase LPL, but inhibition of PKC resulted in decreased LPL synthesis by inhibition of translation, indicating a constitutive role of PKC in LPL gene expression.	John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Ranganathan, G (corresponding author), John L McClellan Mem Vet Adm Med Ctr, 151LR,4300 W 7th St, Little Rock, AR 72205 USA.	Ranganathangouri@exchange.UAMS.edu			NIDDK NIH HHS [DK 39176] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039176, R01DK039176, R29DK039176] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; Avignon A, 1996, DIABETES, V45, P1396, DOI 10.2337/diabetes.45.10.1396; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Haneda M, 1995, J DIABETES COMPLICAT, V9, P246, DOI 10.1016/1056-8727(95)80013-5; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; Iverius P H, 1986, Methods Enzymol, V129, P691; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Kern PA, 1996, J LIPID RES, V37, P2332; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1989, J BIOL CHEM, V264, P3177; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; PYKALISTO OJ, 1975, J CLIN INVEST, V56, P1108, DOI 10.1172/JCI108185; RAISONNIER A, 1994, COMP BIOCH PHYSL, P385; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, METH MOL B, V109, P329; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; RANGANATHAN G, 1994, CIRCULATION; Rouis M, 1997, ARTERIOSCL THROM VAS, V17, P1400, DOI 10.1161/01.ATV.17.7.1400; SAFFARI B, 1992, J LIPID RES, V33, P241; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; SIMSOLO RB, 1992, J LIPID RES, V33, P89; TASKINEN MR, 1979, DIABETOLOGIA, V17, P351, DOI 10.1007/BF01236268; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; Wijsman EM, 1998, ARTERIOSCL THROM VAS, V18, P215, DOI 10.1161/01.ATV.18.2.215; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	48	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9122	9127		10.1074/jbc.274.13.9122	http://dx.doi.org/10.1074/jbc.274.13.9122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085163	hybrid			2022-12-27	WOS:000079451600105
J	Ackerman, MS; Bhate, M; Shenoy, N; Beck, K; Ramshaw, JAM; Brodsky, B				Ackerman, MS; Bhate, M; Shenoy, N; Beck, K; Ramshaw, JAM; Brodsky, B			Sequence dependence of the folding of collagen-like peptides - Single amino acids affect the rate of triple-helix nucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-Y TRIPLETS; BOND ISOMERIZATION; STABILITY; PROCOLLAGEN; STABILIZATION; MUTATIONS; RESIDUES; NMR	The refolding of thermally denatured model collagenlike peptides was studied for a set of 21 guest triplets embedded in a common host framework: acetyl-(Gly-Pro-Hyp)(3)-Gly-Xaa-Yaa-(Gly-Pro-Hyp)(4)-Gly The results show a strong dependence of the folding rate on the identity of the guest Gly-Xaa-Yaa triplet, with the half-times for refolding varying from 6 to 110 min (concentration = 1 mg/ml). All triplets of the form Gly-Xaa-Hyp promoted rapid folding, with the rate only marginally dependent on the residue in the Xaa position. In contrast, triplets of the form Gly-Pro-Yaa and Gly-Xaa-Yaa were slower and showed a wide range of half-times, varying with the identity of the residues in the triplet. At low concentrations, the folding can be described by third-order kinetics, suggesting nucleation is rate-limiting. Data on the relative nucleation ability of different Gly-Xaa-Yaa triplets support the favorable nature of imino acids, the importance of hydroxyproline, the varying effects of the same residue in the Xaa position versus the Yaa position, and the difficulties encountered when leucine or aspartic acid are in the Yaa position. Information on the relative propensities of different tripeptide sequences to promote nucleation of the triple-helix in peptides will aid in identification of nucleation sites in collagen sequences.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@rwja.umdnj.edu	Beck, Konrad/AAX-1351-2020; Ramshaw, John AM/A-9411-2011	Beck, Konrad/0000-0001-5098-9484; Ramshaw, John A.M./0000-0002-2131-3685	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR19626] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; BANSAL M, 1977, INT J PEPT PROT RES, V9, P224; BANSAL M, 1988, BIOPOLYMERS, V27, P299, DOI 10.1002/bip.360270209; Baum J, 1997, FOLD DES, V2, pR53, DOI 10.1016/S1359-0278(97)00028-X; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BRODSKY B, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P55; Bulleid NJ, 1996, SEMIN CELL DEV BIOL, V7, P667, DOI 10.1006/scdb.1996.0081; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Eberhardt ES, 1996, J AM CHEM SOC, V118, P12261, DOI 10.1021/ja9623119; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Liu XY, 1996, BIOCHEMISTRY-US, V35, P4306, DOI 10.1021/bi952270d; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SUTOH K, 1974, BIOPOLYMERS, V13, P2477, DOI 10.1002/bip.1974.360131207; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; VONHIPPEL PH, 1959, BIOCHIM BIOPHYS ACTA, V36, P427, DOI 10.1016/0006-3002(59)90185-4; WEIDNER H, 1975, BIOPOLYMERS, V17, P763; WEIDNER H, 1974, PEPTIDES POLYPEPTIDE, P419; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	39	70	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7668	7673		10.1074/jbc.274.12.7668	http://dx.doi.org/10.1074/jbc.274.12.7668			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075654	hybrid, Green Accepted			2022-12-27	WOS:000079268100013
J	Heller, R; Munscher-Paulig, F; Grabner, R; Till, U				Heller, R; Munscher-Paulig, F; Grabner, R; Till, U			L-ascorbic acid potentiates nitric oxide synthesis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; VITAMIN-C STATUS; RELAXING FACTOR; CYCLIC-GMP; ANTIOXIDANT; DYSFUNCTION; SYNTHASE; VASODILATION; DISEASE; ADULTS	Ascorbic acid has been shown to enhance impaired endothelium-dependent vasodilation in patients with atherosclerosis by a mechanism that is thought to involve protection of nitric oxide (NO) from inactivation by free oxygen radicals. The present study in human endothelial cells from umbilical veins and coronary arteries investigates whether L-ascorbic acid additionally affects cellular NO synthesis. Endothelial cells were incubated for 24 h with 0.1-100 mu M ascorbic acid and were subsequently stimulated for 15 min with ionomycin (2 mu M) Or thrombin (1 unit/ml) in the absence of extracellular ascorbate. Ascorbate pretreatment led to a 3-fold increase of the cellular production of NO measured as the formation of its co-product citrulline and as the accumulation of its effector molecule cGMP. The effect was saturated at 100 mu M and followed a similar kinetics as seen for the uptake of ascorbate into the cells. The investigation of the precursor molecule L-gulonolactone and of different ascorbic acid derivatives suggests that the enediol structure of ascorbate is essential for its effect on NO synthesis. Ascorbic acid did not induce the expression of the NO synthase (NOS) protein nor enhance the uptake of the NOS substrate L-arginine into endothelial cells. The ascorbic acid effect was minimal when the citrulline formation was measured in cell lysates from ascorbate-pretreated cells in the presence of known cofactors for NOS activity. However, when the cofactor tetrahydrobiopterin was omitted from the assay, a similar potentiating effect of ascorbate pretreatment as seen in intact cells was demonstrated, suggesting that ascorbic acid may either enhance the availability of tetrahydrobiopterin or increase its affinity for the endothelial NOS. Our data suggest that intracellular ascorbic acid enhances NO synthesis in endothelial cells and that this may explain, in part, the beneficial vascular effects of ascorbic acid.	Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany	Friedrich Schiller University of Jena	Heller, R (corresponding author), Univ Jena, Ctr Vasc Biol & Med, Norhauser Str 78, D-99089 Erfurt, Germany.	heller@zmkh.ef.uni-jena.de	Heller, Regine/AAC-9353-2019					ALHEID U, 1987, THROMB RES, V47, P561, DOI 10.1016/0049-3848(87)90361-6; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Bult H, 1996, MOL MED TODAY, V2, P510; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; CUNNINGHAM JJ, 1991, METABOLISM, V40, P146, DOI 10.1016/0026-0495(91)90165-S; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; FLUHARTY AL, 1976, BIOCHIM BIOPHYS ACTA, V429, P508, DOI 10.1016/0005-2744(76)90298-9; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARRY PJ, 1982, AM J CLIN NUTR, V36, P332, DOI 10.1093/ajcn/36.2.332; Heitzer T, 1996, CIRCULATION, V94, P6, DOI 10.1161/01.CIR.94.1.6; HELLER R, 1994, AGENTS ACTIONS, V45, P177; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Hornig B, 1998, CIRCULATION, V97, P363; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHLIN LJ, 1979, AM J CLIN NUTR, V32, P325, DOI 10.1093/ajcn/32.2.325; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P351; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; Ness AR, 1996, J HYPERTENS, V14, P503; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; Solzbach U, 1997, CIRCULATION, V96, P1513, DOI 10.1161/01.CIR.96.5.1513; Som S, 1983, Acta Vitaminol Enzymol, V5, P243; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617; TSUJIMURA M, 1982, J NUTR SCI VITAMINOL, V28, P467, DOI 10.3177/jnsv.28.467; Weber P, 1996, INT J VITAM NUTR RES, V66, P19; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WESTENDORP RGJ, 1994, J VASC RES, V31, P42, DOI 10.1159/000159030; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1	39	174	179	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8254	8260		10.1074/jbc.274.12.8254	http://dx.doi.org/10.1074/jbc.274.12.8254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075731	hybrid			2022-12-27	WOS:000079268100090
J	Teuchert, M; Schafer, W; Berghofer, S; Hoflack, B; Klenk, HD; Garten, W				Teuchert, M; Schafer, W; Berghofer, S; Hoflack, B; Klenk, HD; Garten, W			Sorting of furin at the trans-Golgi network - Interaction of the cytoplasmic tail sorting signals with AP-1 Golgi-specific assembly proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; KINASE-II PHOSPHORYLATION; CLATHRIN-ASSOCIATED PROTEINS; HIGH-AFFINITY INTERACTION; COATED VESICLES; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; INVITRO BINDING; MEDIUM CHAINS	The eukaryotic subtilisin-like endoprotease furin is found predominantly in the trans-Golgi network (TGN) and cycles between this compartment, the cell surface, and the endosomes. There is experimental evidence for endocytosis from the plasma membrane and transport from endosomes to the TGN, but direct exit from the TGN to endosomes via clathrin-coated vesicles has only been discussed but not directly shown so far. Here we present data showing that expression of furin promotes the first step of clathrin-coat assembly at the TGN, the recruitment of the Golgis-specific assembly protein AP-I on Golgi membranes. Further, we report that furin indeed is present in isolated clathrin-coated vesicles, packaging into clathrin-coated vesicles requires signal components in the furin cytoplasmic domain which can be recognized by AP-1 assembly proteins. We found that besides depending on the phosphorylation state of a casein kinase II site, interaction of the furin tail with AP-1 and its mu 1subunit is mediated by a tyrosine motif and to less extent by a leucine-isoleucine signal, whereas a monophenylalanine motif is only involved in binding to the intact AP-1 complex. This study implies that high affinity interaction of AP-1 or mu 1 with the cytoplasmic tail of furin needs a complex interplay of signal components rather than one distinct signal.	Inst Pasteur, Inst Biol, EP 525, CNRS, F-59021 Lille, France; Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Philipps University Marburg	Garten, W (corresponding author), Inst Pasteur, Inst Biol, EP 525, CNRS, BP 447,1 Rue Prof Calmette, F-59021 Lille, France.		HOFLACK, Bernard/AAZ-6668-2020					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AHLE S, 1989, J BIOL CHEM, V264, P20089; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sambrook J., 2002, MOL CLONING LAB MANU; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133	49	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8199	8207		10.1074/jbc.274.12.8199	http://dx.doi.org/10.1074/jbc.274.12.8199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075724	hybrid			2022-12-27	WOS:000079268100083
J	Hunt, AE; Lali, FV; Lord, JD; Nelson, BH; Miyazaki, T; Tracey, KJ; Foxwell, BMJ				Hunt, AE; Lali, FV; Lord, JD; Nelson, BH; Miyazaki, T; Tracey, KJ; Foxwell, BMJ			Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein kinase c-Jun N-terminal kinase) activation - IL-2-driven proliferation is independent of p38 and p54 MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; T-CELL LINE; GROWTH SIGNAL-TRANSDUCTION; MICE LACKING JAK3; IL-2 RECEPTOR; TYROSINE KINASE; TETRAVALENT GUANYLHYDRAZONE; ASSOCIATION; PHOSPHORYLATION; SUPPRESSION	We have shown recently that interleukin (IL)-2 activates the mitogen-activated protein (MAP) kinase family members p38 (HOG1/stress-activated protein kinase II) and p54 (c-Jun N-terminal kinase/stress-activated protein kinase I). Furthermore, the p38 MAP kinase inhibitor SB203580 inhibited IL-2-driven T cell proliferation, suggesting that p38 MAP kinase might be involved in mediating proliferative signals. In this study, using transfected BA/F3 cell lines, it is shown that both the acidic domain and the membrane-proximal serine-rich region of the IL-2R beta chain are required for p38 and p54 MAP kinase activation and that, as for p42/44 MAP kinase, this activation requires the Tyr(338) residue of the acidic domain, the binding site for She. It is well established that the acidic domain of the IL-2R beta chain is dispensable for IL-a-driven proliferation, and thus our observations suggest that neither p38 nor p54 MAP kinase activation is required for IL-a-driven proliferation of BA/F3 cells. In addition, the tetravalent guanylhydrazone inhibitor of proinflammatory cytokine production, CNI-1493, can block the activation of p54 and p38 MAP kinases by IL-2 but has no effect on IL-2-driven proliferation of BA/F3 cells, activated primary T cells, or a cytotoxic T cell line. Furthermore, our observations provide evidence for the existence of an additional, unknown target of the p38 MAP kinase inhibitor SB203580, the activation of which is essential for mitogenic signaling by IL-2.	Kennedy Inst Rheumatol, London W6 8LH, England; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Tokyo, Grad Sch, Dept Immunol, Tokyo 113, Japan; Univ Tokyo, Fac Med, Tokyo 113, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	University of Oxford; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Tokyo; University of Tokyo; Northwell Health	Foxwell, BMJ (corresponding author), Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.		Nelson, Brad H/K-2622-2014; Miyazaki, Tadaaki/D-9368-2012; Lali, Ferdinand/AAD-1946-2019; Ferdinand, Lali/AAH-4867-2020	Ferdinand, Lali/0000-0001-5890-9936; Nelson, Brad/0000-0002-4445-5539; Tracey, Kevin J/0000-0003-1884-6314				AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; BIANCHI M, 1995, MOL MED, V1, P254, DOI 10.1007/BF03401550; Bjork L, 1997, J INFECT DIS, V176, P1303; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen PS, 1997, MOL MED, V3, P339, DOI 10.1007/BF03401812; Cohen PS, 1996, P NATL ACAD SCI USA, V93, P3967, DOI 10.1073/pnas.93.9.3967; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; Kemeny MM, 1998, P NATL ACAD SCI USA, V95, P4561, DOI 10.1073/pnas.95.8.4561; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lord JD, 1998, J IMMUNOL, V161, P4627; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAGE TH, 1993, J IMMUNOL, V151, P4753; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILLCOCKS JL, 1993, EUR J IMMUNOL, V23, P716, DOI 10.1002/eji.1830230322; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	53	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7591	7597		10.1074/jbc.274.11.7591	http://dx.doi.org/10.1074/jbc.274.11.7591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066828	hybrid			2022-12-27	WOS:000079078400100
J	Bookchin, RM; Balazs, T				Bookchin, RM; Balazs, T			Polymer structure and solubility of deoxyhemoglobin S in the presence of high concentrations of volume-excluding 70-kDa dextran - Effects of non-S hemoglobins and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; CRYSTALLIZATION; MICROMETHOD; MUTANT	Earlier observations indicated that volume exclusion by admired non-hemoglobin macromolecules lowered the polymer solubility ("C-sat") of deoxyhemoglobin (Hb) S, presumably by increasing its activity. In view of the potential usefulness of these observations for in vitro studies of sickling-related polymerization, we examined the ultrastructure, solubility behavior, and phase distributions of deoxygenated mixtures of Hb S with 70-kDa dextran, a relatively inert, low ionic strength space-filling macromolecule. Increasing admixture of dextran progressively lowered the C-sat of deoxyHb S, With 12 g/dl dextran, a 5-fold decrease in apparent C-sat ("dextran-C-sat") was obtained together with acceptable sensitivity and proportionality with the standard C-sat when assessing the effects of non-S Hb admixtures (A, C, and F) or polymerization inhibitors (alkylureas or phenylalanine). The volume fraction of dextran excluding Hb was 70-75% of total deoxy Hb-dextran (12 g/dl) volumes. Electron microscopy showed polymer fibers and fiber-to-crystal transitions indistinguishable from those formed without dextran, Thus when Hb quantities are limited, as with genetically engineered recombinant Hbs or transgenic sickle mice, the dextran-C-sat provides convenient and reliable screening of effects of Hb S modifications on polymerization under near-physiological conditions, avoiding problems of high ionic strength.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Cambridge, Physiol Lab, Cambridge CB2 3EG, England	Yeshiva University; Albert Einstein College of Medicine; University of Chicago; University of Cambridge	Bookchin, RM (corresponding author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022654, P01HL058512, R01HL028018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58512, HL28018, HL22654] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1979, J BIOL CHEM, V254, P4079; BEHE MJ, 1978, BIOPHYS J, V23, P129, DOI 10.1016/S0006-3495(78)85438-1; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BOOKCHIN RM, 1986, BLOOD, V67, P887; BOOKCHIN RM, 1994, J MOL BIOL, V244, P100, DOI 10.1006/jmbi.1994.1707; BOOKCHIN RM, 1973, SICKLE CELL DISEASE, P140; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1203; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERRONE FA, 1998, HEMOGLOBINS BIOPHY C, P292; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; ITANO HA, 1953, ARCH BIOCHEM BIOPHYS, V47, P148, DOI 10.1016/0003-9861(53)90444-5; Liao D, 1996, BIOPHYS J, V70, P2442, DOI 10.1016/S0006-3495(96)79815-6; MAGDOFFFAIRCHILD B, 1976, P NATL ACAD SCI USA, V73, P990, DOI 10.1073/pnas.73.4.990; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PERUTZ MF, 1950, NATURE, V166, P677, DOI 10.1038/166677a0; POTEL MJ, 1984, J MOL BIOL, V177, P819, DOI 10.1016/0022-2836(84)90050-0; ROSS PD, 1979, BIOCHEM BIOPH RES CO, V88, P1308, DOI 10.1016/0006-291X(79)91123-9; ROTH EF, 1979, J LAB CLIN MED, V93, P867; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; Sunshine HR, 1979, DEV THERAPEUTIC AGEN, P31; VASSAR RJ, 1982, J MOL BIOL, V157, P395, DOI 10.1016/0022-2836(82)90242-X; VEDVICK TS, 1998, CLIN BIOCHEM, V8, P288; WELLEMS TE, 1979, J MOL BIOL, V135, P651, DOI 10.1016/0022-2836(79)90170-0; WELLEMS TE, 1981, J MOL BIOL, V153, P1011, DOI 10.1016/0022-2836(81)90464-2; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	32	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6689	6697		10.1074/jbc.274.10.6689	http://dx.doi.org/10.1074/jbc.274.10.6689			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037766	hybrid			2022-12-27	WOS:000078902800088
J	Hu, CA; Lin, WW; Obie, C; Valle, D				Hu, CA; Lin, WW; Obie, C; Valle, D			Molecular enzymology of mammalian Delta(1)-pyrroline-5-carboxylate synthase - Alternative splice donor utilization generates isoforms with different sensitivity to ornithine inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMYL-TRANSFERASE KINASE; L-PROLINE TRANSPORTER; FIRST 2 STEPS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PYRROLINE-5-CARBOXYLATE SYNTHASE; CHROMOSOMAL LOCALIZATION; ARABIDOPSIS-THALIANA; SMALL-INTESTINE; GYRATE ATROPHY	Delta(1)-Pyrroline-5-carboxylate synthase (P5CS; EC not assigned), a mitochondrial inner membrane, ATP- and NADPH-dependent, bifunctional enzyme, catalyzes the reduction of glutamate to Delta(1)-pyrroline-5-carboxylate, a critical step in the de novo biosynthesis of proline and ornithine. We utilized published plant P5CS sequence to search the expressed sequence tag data base and cloned two full-length human P5CS cDNAs differing in length by 6 base pairs (bp) in the open reading frame. The short cDNA has a 2379-bp open reading frame encoding a protein of 793 residues; the long cDNA, generated by "exon sliding," a form of alternative splicing, contains an additional 6-bp insert following bp +711 of the short form resulting in inclusion of two additional amino acids in the region predicted to be the gamma-glutamyl kinase active site of P5CS, The long form predominates in all tissues examined except gut. We also isolated the corresponding long and short murine P5CS transcripts. To confirm the identity of the putative P5CS cDNAs, we expressed both human forms in gamma-glutamyl kinase- and gamma-glutamyl phosphate reductase-deficient strains of Saccharomyces cerevisiae and showed that they conferred the proline prototrophy. Additionally, we found expression of the murine putative P5CS cDNAs conferred proline prototrophy to P5CS-deficient Chinese hamster ovary cells (CHO-K1). We utilized stable CHO-K1 cell transformants to compare the biochemical characteristics of the long and short murine P5CS isoforms, We found that both confer P5CS activity and that the short isoform is inhibited by L-ornithine with a K-i of similar to 0.25 mM. Surprisingly, the long isoform is insensitive to ornithine inhibition. Thus, the two amino acid insert in the long isoform abolishes feedback inhibition of P5CS activity by L-ornithine.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Pediat, PCTB 802,725 N Wolfe St, Baltimore, MD 21205 USA.	dvalle@jhmi.edu			NEI NIH HHS [5RO1EY02948] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002948] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aral B, 1996, CR ACAD SCI III-VIE, V319, P171; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BRODY LC, 1992, J BIOL CHEM, V267, P3302; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; De Jonge WJ, 1998, PEDIATR RES, V43, P442, DOI 10.1203/00006450-199804000-00002; DEUTCH AH, 1984, NUCLEIC ACIDS RES, V12, P6337, DOI 10.1093/nar/12.15.6337; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FU XD, 1995, RNA, V1, P663; GarciaRios M, 1997, P NATL ACAD SCI USA, V94, P8249, DOI 10.1073/pnas.94.15.8249; Gilligan DM, 1997, GENOMICS, V43, P141, DOI 10.1006/geno.1997.4802; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HENSLEE JG, 1983, ARCH BIOCHEM BIOPHYS, V226, P693, DOI 10.1016/0003-9861(83)90340-5; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; HIRAMATSU T, 1994, AM J CLIN NUTR, V60, P207, DOI 10.1093/ajcn/60.2.207; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; Hu CA, 1996, J BIOL CHEM, V271, P9795, DOI 10.1074/jbc.271.16.9795; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; JONES C, 1975, SOMAT CELL GENET, V1, P345, DOI 10.1007/BF01538666; JONES ME, 1985, J NUTR, V115, P509, DOI 10.1093/jn/115.4.509; Kamoun P, 1998, B ACAD NAT MED PARIS, V182, P131; KAO F, 1967, GENETICS, V55, P511; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LI W, 1992, J BACTERIOL, V174, P4148, DOI 10.1128/jb.174.12.4148-4156.1992; LODATO RF, 1981, METABOLISM, V30, P908, DOI 10.1016/0026-0495(81)90070-6; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MARTIN D, 1992, EUR J PHARMACOL, V219, P59, DOI 10.1016/0014-2999(92)90580-W; MATSUZAWA T, 1994, J BIOCHEM-TOKYO, V116, P721, DOI 10.1093/oxfordjournals.jbchem.a124587; McRory JE, 1997, DNA CELL BIOL, V16, P95, DOI 10.1089/dna.1997.16.95; MILLER RG, 1995, J PEDIATR SURG, V30, P953, DOI 10.1016/0022-3468(95)90320-8; Miller RG, 1996, J SURG RES, V63, P199, DOI 10.1006/jsre.1996.0247; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NADLER JV, 1988, BRAIN RES, V456, P168; NAGAMINE Y, 1985, BIOCHEM BIOPH RES CO, V132, P563, DOI 10.1016/0006-291X(85)91170-2; NICKOLSON VJ, 1982, J NEUROCHEM, V38, P289, DOI 10.1111/j.1471-4159.1982.tb10885.x; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OMORI K, 1993, J BACTERIOL, V175, P959, DOI 10.1128/JB.175.4.959-965.1993; OMORI K, 1991, J GEN MICROBIOL, V137, P509, DOI 10.1099/00221287-137-3-509; Pearson BM, 1996, YEAST, V12, P1021; Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P197, DOI 10.1093/nar/24.1.197; POL S, 1989, HUM GENET, V83, P159, DOI 10.1007/BF00286710; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RIBY JE, 1990, PEDIATR RES, V28, P261, DOI 10.1203/00006450-199009000-00022; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; ROISE D, 1988, J BIOL CHEM, V263, P4509; SAVOURE A, 1995, FEBS LETT, V372, P13, DOI 10.1016/0014-5793(95)00935-3; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SERINA L, 1995, BIOCHEMISTRY-US, V34, P5066, DOI 10.1021/bi00015a018; SHAFQAT S, 1995, MOL PHARMACOL, V48, P219; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; SMITH LT, 1985, J BACTERIOL, V164, P1088, DOI 10.1128/JB.164.3.1088-1093.1985; SMITH RJ, 1979, J CELL PHYSIOL, V98, P475, DOI 10.1002/jcp.1040980306; SMITH RJ, 1980, P NATL ACAD SCI-BIOL, V77, P5221, DOI 10.1073/pnas.77.9.5221; TOMENCHOK DM, 1987, J BACTERIOL, V169, P5364, DOI 10.1128/jb.169.12.5364-5372.1987; Valle, 1995, METABOLIC MOL BASES, P1125; VALLE D, 1973, BIOCHEM BIOPH RES CO, V53, P1130, DOI 10.1016/0006-291X(73)90582-2; VALLE D, 1973, BIOCHEM BIOPH RES CO, V54, P1418, DOI 10.1016/0006-291X(73)91144-3; Valle D, 1995, METABOLIC MOL BASES, V1, P1147; Velaz-Faircloth M, 1995, J Biol Chem, V270, P15755; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAKABAYASHI Y, 1991, ARCH BIOCHEM BIOPHYS, V291, P1, DOI 10.1016/0003-9861(91)90097-3; WALSH CT, 1979, ENZYMATIC REACTION M; WANG T, 1995, NAT GENET, V11, P185, DOI 10.1038/ng1095-185; WINDMUELLER HG, 1975, ARCH BIOCHEM BIOPHYS, V171, P662, DOI 10.1016/0003-9861(75)90078-8; WU GY, 1994, BIOCHEM J, V299, P115, DOI 10.1042/bj2990115; WU GY, 1995, AM J PHYSIOL-REG I, V269, pR621, DOI 10.1152/ajpregu.1995.269.3.R621; YAMANAKA K, 1994, MOL GEN GENET, V243, P9, DOI 10.1007/BF00283870; YOSHIBA Y, 1995, PLANT J, V7, P751, DOI 10.1046/j.1365-313X.1995.07050751.x; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; ZHANG CS, 1995, J BIOL CHEM, V270, P20491, DOI 10.1074/jbc.270.35.20491; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919	77	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6754	6762		10.1074/jbc.274.10.6754	http://dx.doi.org/10.1074/jbc.274.10.6754			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037775	hybrid			2022-12-27	WOS:000078902800097
J	Thielens, NM; Enrie, K; Lacroix, M; Jaquinod, M; Hernandez, JF; Esser, AF; Arlaud, GJ				Thielens, NM; Enrie, K; Lacroix, M; Jaquinod, M; Hernandez, JF; Esser, AF; Arlaud, GJ			The N-terminal CUB-epidermal growth factor module pair of human complement protease C1r binds Ca2+ with high affinity and mediates Ca2+-dependent interaction with C1s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	XVIIth International Complement Workshop	OCT 11-16, 1998	RHODES, GREECE				CHEMICAL CROSS-LINKING; CATALYTIC REGION; SERINE-PROTEASE; FACTOR-VIIA; DOMAIN-STRUCTURE; COMPONENT C1R; TISSUE FACTOR; EGF DOMAINS; CLR; ACTIVATION	The Ca2+-dependent interaction between complement serine proteases C1r and C1s is mediated by their alpha regions, encompassing the major part of their N-terminal CUB-EGF-CUB (where EGF is epidermal growth factor) module array. In order to define the boundaries of the C1r domain(s) responsible for Ca2+ binding and Ca2+-dependent interaction with C1s and to assess the contribution of individual modules to these functions, the CUB, EGF, and CUB-EGF fragments were expressed in eucaryotic systems or synthesized chemically. Gel filtration studies, as well as measurements of intrinsic Tyr fluorescence, provided evidence that the CUB-EGF pair adopts a more compact conformation in the presence of Ca2+. Ca2+-dependent interaction of intact C1r with C1s was studied using surface plasmon resonance spectroscopy, yielding K-D values of 10.9-29.7 nM. The C1r CUB-EGF pair bound immobilized C1s with a higher K-D (1.5-1.8 mu M), which decreased to 31.4 nM when CUB-EGF was used as the immobilized ligand and C1s was free. Half-maximal binding was obtained at comparable Ca2+ concentrations ranging from 5 mu M With intact C1r to 10-16 mu M for C1r alpha and CUB-EGF, The isolated CUB and EGF fragments or a CUB + EGF mixture did not bind C1s, These data demonstrate that the C1r CUB-EGF module pair (residues 1-175) is the minimal segment required for high affinity Ca2+ binding and Ca2+-dependent interaction with C1s and indicate that Ca2+ binding induces a more compact folding of the CUB-EGF pair.	CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble 1, France; CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Spect Masse Prot, F-38027 Grenoble, France; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Missouri System; University of Missouri Kansas City	Thielens, NM (corresponding author), CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, 41 Ave Martyrs, F-38027 Grenoble 1, France.		Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019478] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI 19478] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLAUD GJ, 1986, BIOCHEMISTRY-US, V25, P5177, DOI 10.1021/bi00366a029; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; AUDE CA, 1988, BIOCHEMISTRY-US, V27, P8641, DOI 10.1021/bi00423a020; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORK P, 1995, TRENDS BIOCH SCI S, V20, pC3; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; BUSBY TF, 1987, BIOCHEMISTRY-US, V26, P5564, DOI 10.1021/bi00391a052; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; Cseh S, 1996, MOL IMMUNOL, V33, P351, DOI 10.1016/0161-5890(95)00160-3; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GAL P, 1989, COMPLEMENT INFLAMMAT, V6, P433; Gu JG, 1997, BIOCHEM BIOPH RES CO, V232, P91, DOI 10.1006/bbrc.1997.6230; Hernandez JF, 1997, J PEPT RES, V49, P221; ILLY C, 1991, BIOCHEMISTRY-US, V30, P7135, DOI 10.1021/bi00243a014; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; Kelly CR, 1997, J BIOL CHEM, V272, P17467, DOI 10.1074/jbc.272.28.17467; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; Lange C, 1997, BIOCHEMISTRY-US, V36, P12019, DOI 10.1021/bi970938d; LUO C, 1992, BIOCHEMISTRY-US, V31, P4254, DOI 10.1021/bi00132a015; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; Persson E, 1997, J BIOL CHEM, V272, P19919, DOI 10.1074/jbc.272.32.19919; PETILLOT Y, 1995, FEBS LETT, V358, P323, DOI 10.1016/0014-5793(94)01429-5; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; RIVAS G, 1994, BIOCHEMISTRY-US, V33, P2341, DOI 10.1021/bi00174a048; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; TARENTINO AL, 1995, BIOCHEMISTRY-US, V34, P4665; THIELENS NM, 1994, BIOCHEM J, V301, P509, DOI 10.1042/bj3010509; THIELENS NM, 1990, BIOCHEMISTRY-US, V29, P3570, DOI 10.1021/bi00466a021; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; THIELENS NM, 1997, 4 INT WORKSH C 1 COL; Tsai SW, 1997, MOL IMMUNOL, V34, P1273, DOI 10.1016/S0161-5890(97)00149-1; VIVAUDOU MB, 1991, J MEMBRANE BIOL, V122, P165, DOI 10.1007/BF01872639; Volanakis J., 1998, COMPLEMENT ENZYMES H, P49; YANG HQ, 1994, J BIOL CHEM, V269, P18977	43	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9149	9159		10.1074/jbc.274.14.9149	http://dx.doi.org/10.1074/jbc.274.14.9149			11	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092586	hybrid			2022-12-27	WOS:000079451800005
J	Komori, H; Ichikawa, S; Hirabayashi, Y; Ito, M				Komori, H; Ichikawa, S; Hirabayashi, Y; Ito, M			Regulation of intracellular ceramide content in B16 melanoma cells - Biological implications of ceramide glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE GLYCOSPHINGOLIPIDS; CANCER-CELLS; ENDOGLYCOCERAMIDASE; SPHINGOMYELIN; DIFFERENTIATION; HYDROLYSIS; METABOLISM; DEATH; GLUCOSYLTRANSFERASE; PHOSPHATIDYLCHOLINE	We previously reported that ceramide released from glycosphingolipids (GSLs) by endoglycoceramidase was directly metabolized to GSLs, and thus the content of GSLs was constantly maintained in B16 melanoma cells (Ito, M., and Komori, H. (1996) J. Biol. Chem. 271, 12655-12660). In this study, the metabolism of ceramide released from sphingomyelin (SM) by bacterial sphingomyelinase (SMase) was examined using B16 cells and their GSL-deficient mutant counterpart GM95 cells. Treatment of B16 melanoma cells with bacterial SMase effectively hydrolyzed SM on the plasma membrane, Under these conditions, NeuAc alpha 2,3Gal beta 1,4Glc beta 1,1ceramide was significantly increased. Interestingly, UDP-glucose: ceramide glucosyltransferase-1 (GlcT-1) activity and GSL synthesis, but not SM synthesis or sphingosine generation, were found to be up-regulated by SMase treatment. The up-regulation of GSL synthesis seemed to occur at both the transcriptional and post-translational steps of GlcT-1 synthesis. Accumulation of ceramide by bacterial SMase was much higher in GM95 cells than in the parental cells. When the enzyme was removed from the culture medium, the intracellular ceramide level in B16 cells, but not that in the mutant cells, normalized, No rapid restoration of SM in either of the cell lines was observed after removal of the enzyme. SMase treatment strongly inhibited DNA synthesis in GM95 cells but not that in B16 cells. In the presence of D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of GlcT-1, SMase treatment markedly increased the ceramide content and thus inhibited DNA synthesis in B16 cells. Our study provides the first evidence that GlcT-1 functions to regulate the level of intracellular ceramide by glycosylation of the ceramide when it is present in excess.	Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, Fukuoka 8128581, Japan; RIKEN, Inst Phys & Chem Res, Frontier Res Program, Lab Cellular Glycobiol, Wako, Saitama 3510198, Japan	Kyushu University; RIKEN	Ito, M (corresponding author), Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.			ito, Makoto/0000-0003-3159-7818; Hirabayashi, Yoshio/0000-0002-5774-7354				BASU S, 1973, J BIOL CHEM, V248, P1388; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Gillard BK, 1998, EXP CELL RES, V242, P561, DOI 10.1006/excr.1998.4126; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hidari KIPJ, 1996, J BIOL CHEM, V271, P14636, DOI 10.1074/jbc.271.24.14636; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; KOMORI H, 1995, FEBS LETT, V374, P299, DOI 10.1016/0014-5793(95)01137-4; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MERRILL AH, 1993, ADV LIPID RES, V26, P215; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PLATT FM, 1994, J BIOL CHEM, V269, P8362; RADIN NS, 1993, ADV LIPID RES, V26, P183; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; YOKOYAMA K, 1995, FEBS LETT, V368, P477, DOI 10.1016/0014-5793(95)00714-K; Zhang P, 1997, J BIOL CHEM, V272, P9609	37	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8981	8987		10.1074/jbc.274.13.8981	http://dx.doi.org/10.1074/jbc.274.13.8981			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085144	hybrid			2022-12-27	WOS:000079451600086
J	Lukiw, WJ; Martinez, J; Pelaez, RP; Bazan, NG				Lukiw, WJ; Martinez, J; Pelaez, RP; Bazan, NG			The interleukin-1 type 2 receptor gene displays immediate early gene responsiveness in glucocorticoid-stimulated human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA DEGRADATION; II RECEPTOR; MOLECULAR MECHANISMS; IL-1 RECEPTORS; DECOY RECEPTOR; AP-1 ACTIVITY; EXPRESSION; DEXAMETHASONE; INHIBITION	Human epidermal keratinocytes (HEKs) in primary culture (P2-P4) were used to study glucocorticoid (GC)mediated transcription of the genes encoding the constitutively expressed interleukin-1 type 1 receptor (IL-1R1) and the inducible interleukin-1 type 2 receptor (IL-1R2). Utilizing Northern dot blot analysis and a quantitative reverse transcription-polymerase chain reaction protocol for IL-1R1 and IL-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidly induce transcription from the IL-IR2 gene when compared with IL-1R1 or beta-actin RNA message levels in the same sample. Southern blot analysis of newly generated IL-1R2 reverse transcription-polymerase chain reaction products using end-labeled IL-1R2 intron probes suggested that GC enhancement of IL-1R2 expression was regulated primarily at the level of de novo transcription. GC-induced IL-1R2 gene transcription displayed features characteristic of a classical immediate early gene response, including a signal transduction function, a relatively low basal abundance, a rapid, transient induction, cycloheximide superinduction, actinomycin D suppression, and a rapid decay of IL-1R2 RNA message. Parallel time course kinetic analysis of IL-1R2 RNA message levels with Western immunoblotting revealed tight coupling of de novo IL-IR2 gene transcription with translation of the IL-1R2 RNA message; a newly synthesized (similar to 46-kDa) IL-1RS protein was detected in the HEK growth medium as early as 1 h after budesonide epimer R treatment. These data indicate that different GC compounds can variably up-regulate the IL-1R2 response in HEKs through transcription-mediated mechanisms and, for the first time, suggest that a gene encoding a soluble cytokine receptor can respond like an immediate early gene.	Louisiana State Univ, Med Ctr, Ctr Neurosci, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Ind Farmaceut & Especialidades SA, ARISTEGUI, Dept Res & Dev, Madrid 28006, Spain	Louisiana State University System; Louisiana State University System	Bazan, NG (corresponding author), Louisiana State Univ, Med Ctr, Ctr Neurosci, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	nbazan@lsumc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	PHS HHS [RY02377] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Brown EA, 1996, CYTOKINE, V8, P828; BURGER D, 1995, J CLIN INVEST, V96, P38, DOI 10.1172/JCI118045; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Fink GW, 1997, CYTOKINE, V9, P1023, DOI 10.1006/cyto.1997.0260; Gabellec MM, 1996, J NEUROIMMUNOL, V66, P65, DOI 10.1016/0165-5728(96)00021-5; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GoppeltStruebe M, 1997, BIOCHEM PHARMACOL, V53, P1389, DOI 10.1016/S0006-2952(97)00018-X; GRANT AJ, 1992, P NATL ACAD SCI USA, V89, P2165, DOI 10.1073/pnas.89.6.2165; GROVES RW, 1994, AM J PATHOL, V145, P1048; GROVES RW, 1995, J IMMUNOL, V154, P4065; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; LUKIW WJ, 1996, ALZHEIMERS RES, V2, P221; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nishiyori A, 1997, MOL BRAIN RES, V50, P237, DOI 10.1016/S0169-328X(97)00195-2; Orlando S, 1997, J IMMUNOL, V158, P3861; Rauschmayr T, 1997, P NATL ACAD SCI USA, V94, P5814, DOI 10.1073/pnas.94.11.5814; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; Re F, 1996, J EXP MED, V183, P1841, DOI 10.1084/jem.183.4.1841; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Smith M, 1996, MOL CELL ENDOCRINOL, V122, P151, DOI 10.1016/0303-7207(96)03878-6; Struhl Kevin, 1997, Genes and Function, V1, P5; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; William R, 1998, J IMMUNOL, V161, P957; Ye K, 1996, CYTOKINE, V8, P421, DOI 10.1006/cyto.1996.0058	47	14	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8630	8638		10.1074/jbc.274.13.8630	http://dx.doi.org/10.1074/jbc.274.13.8630			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085100	hybrid			2022-12-27	WOS:000079451600042
J	Funatsu, N; Miyata, S; Kumanogoh, H; Shigeta, M; Hamada, K; Endo, Y; Sokawa, Y; Maekawa, S				Funatsu, N; Miyata, S; Kumanogoh, H; Shigeta, M; Hamada, K; Endo, Y; Sokawa, Y; Maekawa, S			Characterization of a novel rat brain glycosylphosphatidylinositol-anchored protein (Kilon), a member of the IgLON cell adhesion molecule family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED MEMBRANE SUBDOMAINS; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; OPIOID-BINDING; NERVOUS-SYSTEM; IG SUPERFAMILY; DOMAINS; EXPRESSION; CADHERIN; SURFACE	In the central nervous system, many cell adhesion molecules are known to participate in the establishment and remodeling of the neural circuit. Some of the cell adhesion molecules are known to be anchored to the membrane by the glycosylphosphatidylinositol (GPI) inserted to their C termini, and many GPI-anchored proteins are known to be localized in a Triton-insoluble membrane fraction of low density or so-called "raft," In this study, we surveyed the GPI-anchored proteins in the Triton-insoluble low density fraction from 2-week-old rat brain by solubilization with phosphatidylinositol-specific phospholipase C, By Western blotting and partial peptide sequencing after the deglycosylation with peptide N-glycosidase F, the presence of Thy-1, F3/contactin, and T-cadherin was shown. In addition, one of the major proteins, having an apparent molecular mass of 36 kDa after the peptide N-glycosidase F digestion, was found to be a novel protein, The result of cDNA cloning showed that the protein is an immunoglobulin superfamily member with three C2 domains and has six putative glycosylation sites. Since this protein shows high sequence similarity to IgLON family members including LAMP, OBCAM, neurotrimin, CEPU-1, AvGP50, and GP55, we termed this protein Kilon (a kindred of IgLON). Kilon-specific monoclonal antibodies were produced, and Western blotting analysis showed that expression of Kilon is restricted to brain, and Kilon has an apparent molecular mass of 46 kDa in SDS-polyacrylamide gel electrophoresis in its expressed form, In brain, the expression of Kilon is already detected in E16 stage, and its level gradually increases during development. Kilon immunostaining was observed in the cerebral cortex and hippocampus, in which the strongly stained puncta were observed on dendrites and soma of pyramidal neurons.	Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan; Kyoto Inst Technol, Venture Lab, Kyoto 6068585, Japan	Kyoto Institute of Technology; Kyoto Institute of Technology	Maekawa, S (corresponding author), Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan.							Asou H, 1996, J NEUROSCI RES, V45, P571, DOI 10.1002/(SICI)1097-4547(19960901)45:5<571::AID-JNR7>3.0.CO;2-9; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; CLARKE GA, 1994, J CELL SCI, V107, P3393; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Hachisuka A, 1996, NEUROCHEM INT, V28, P373, DOI 10.1016/0197-0186(95)00108-5; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hancox KA, 1997, MOL BRAIN RES, V44, P273, DOI 10.1016/S0169-328X(96)00228-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; Henke RC, 1997, J NEUROSCI RES, V49, P655, DOI 10.1002/(SICI)1097-4547(19970915)49:6<655::AID-JNR1>3.3.CO;2-0; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; HOSOYA H, 1995, NEUROSCI LETT, V186, P83, DOI 10.1016/0304-3940(95)11287-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P106; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; LIPPMAN DA, 1992, GENE, V117, P249, DOI 10.1016/0378-1119(92)90734-7; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PIMENTA AF, 1995, NEURON, V15, P287, DOI 10.1016/0896-6273(95)90034-9; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spaltmann F, 1996, J NEUROSCI, V16, P1770; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRUYK AF, 1995, J NEUROSCI, V15, P2141, DOI 10.1523/JNEUROSCI.15-03-02141.1995; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; Wick MJ, 1996, MOL BRAIN RES, V36, P322, DOI 10.1016/0169-328X(95)00258-T; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Wilson DJA, 1996, J CELL SCI, V109, P3129; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; ZACCO A, 1990, J NEUROSCI, V10, P73; ZHUKAREVA V, 1995, DEVELOPMENT, V121, P1161	55	102	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8224	8230		10.1074/jbc.274.12.8224	http://dx.doi.org/10.1074/jbc.274.12.8224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075727	hybrid			2022-12-27	WOS:000079268100086
J	Bateson, M; Devenish, RJ; Nagley, P; Prescott, M				Bateson, M; Devenish, RJ; Nagley, P; Prescott, M			Single copies of subunits d, oligomycin-sensitivity conferring protein, and b are present in the Saccharomyces cerevisiae mitochondrial ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; ESCHERICHIA-COLI; H+-ATPASE; CROSS-LINKING; COMPLEX; YEAST; STOICHIOMETRY; OSCP; F1; REGION	In the mitochondrial ATP synthase (mtATPase) of the yeast Saccharomyces cerevisiae, the stoichiometry of subunits d, oligomycin-sensitivity conferring protein (OSCP), and b is poorly defined. We have investigated the stoichiometry of these subunits by the application of hexahistidine affinity purification technology, We have previously demonstrated that intact mtATPase complexes incorporating a Hex(6)-tagged subunit can be isolated via Ni2+-nitrilotriacetic acid affinity chromatography (Bateson, RI., Devenish, R, J., Nagley, P., and Prescott, M, (1996) Anal. Biochem. 238, 14-18), Strains were constructed in which Hex(6)-tagged versions of subunits d, OSCP, and b were coexpressed with the corresponding wild-type subunit. This coexpression resulted in a mixed population of mtATPase complexes containing untagged wild-type and Hex(6)-tagged subunits, The stoichiometry of each subunit was then assessed by determining whether or not the untagged wild-type subunit could be recovered from Ni2+-nitrilotriacetic acid purifications as an integral component of those complexes absorbed by virtue of the Hex(6)-tagged subunit, As only the Hex(6)-tagged subunit was recovered from such purifications, we demonstrate that the stoichiometry of subunits d, OSCP, and b in yeast is 1 in each case.	Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3168, Australia	Monash University	Devenish, RJ (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3168, Australia.	Rodney.Devenish@med.monash.edu.au						ARIS JP, 1983, J BIOL CHEM, V258, P4599; Bateson M, 1996, ANAL BIOCHEM, V238, P14, DOI 10.1006/abio.1996.0242; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Gray R E, 1996, Methods Enzymol, V264, P369, DOI 10.1016/S0076-6879(96)64035-X; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HAMES BD, 1990, GEL ELECTROPHORESIS, P30; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; LIPPE G, 1988, J BIOL CHEM, V263, P18627; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORAIS N, 1991, J BIOL CHEM, V266, P16541; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OVCHINNIKOV YA, 1984, FEBS LETT, V175, P109, DOI 10.1016/0014-5793(84)80580-3; PAPAKONSTANTINOU T, 1993, BIOCHIM BIOPHYS ACTA, V1144, P22, DOI 10.1016/0005-2728(93)90026-C; PENIN F, 1985, BIOCHIM BIOPHYS ACTA, V810, P346, DOI 10.1016/0005-2728(85)90220-8; PRESCOTT M, 1995, BIOCHEM BIOPH RES CO, V207, P943, DOI 10.1006/bbrc.1995.1276; ROBERTS H, 1979, FEBS LETT, V108, P501, DOI 10.1016/0014-5793(79)80597-9; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; ROTT R, 1981, J BIOL CHEM, V256, P9224; Straffon AFL, 1998, BBA-BIOMEMBRANES, V1371, P157, DOI 10.1016/S0005-2736(98)00034-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	29	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7462	7466		10.1074/jbc.274.11.7462	http://dx.doi.org/10.1074/jbc.274.11.7462			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066811	hybrid			2022-12-27	WOS:000079078400083
J	Delhaize, E; Hebb, DM; Richards, KD; Lin, JM; Ryan, PR; Gardner, RC				Delhaize, E; Hebb, DM; Richards, KD; Lin, JM; Ryan, PR; Gardner, RC			Cloning and expression of a wheat (Triticum aestivum L.) phosphatidylserine synthase cDNA - Overexpression in plants alters the composition of phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE SYNTHESIS; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; YEAST; BIOSYNTHESIS; ALUMINUM; MUTANT; GENES; TRANSFORMATION; MEMBRANES	We describe the cloning of a wheat cDNA (TaPSS1) that encodes a phosphatidylserine synthase (PSS) and provides the first strong evidence for the existence of this enzyme in a higher eukaryotic cell, The cDNA was isolated on its ability to confer increased resistance to aluminum toxicity when expressed in yeast, The sequence of the predicted protein encoded by TaPSS1 shows homology to PSS from both yeast and bacteria but is distinct from the animal PSS enzymes that catalyze base-exchange reactions. In wheat, Southern blot analysis identified the presence of a small family of genes that cross-hybridized to TaPSS1, and Northern blots showed that aluminum induced TaPSS1 expression in root apices, Expression of TaPSS1 complemented the yeast cho1 mutant that lacks PSS activity and altered the phospholipid composition of wild type yeast, with the most marked effect being increased abundance of phosphatidylserine (PS). Arabidopsis thaliana leaves overexpressing TaPSS1 showed a marked enhancement in PSS activity, which was associated with increased biosynthesis of PS at the expense of bo th phosphatidylinositol and phosphatidylglycerol, Unlike mammalian cells where PS accumulation is tightly regulated even when the capacity for PS biosynthesis is increased, plant cells accumulated large amounts of PS when TaPSS1 was overexpressed. High levels of TaPSS1 expression in Arabidopsis and tobacco (Nicotiana tabacum) led to the appearance of necrotic lesions on leaves, which may have resulted from the excessive accumulation of PS, The cloning of TaPSS1 now provides evidence that the yeast pathway for PS synthesis exists in some plant tissues and provides a tool for understanding the pathways of phospholipid biosynthesis and their regulation in plants.	CSIRO, Canberra, ACT 2601, Australia; Univ Auckland, Sch Biol Sci, Ctr Gene Technol, Auckland 1, New Zealand	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Auckland	Delhaize, E (corresponding author), CSIRO, GPO Box 1600, Canberra, ACT 2601, Australia.		Ryan, Peter R/I-4651-2012; Gardner, Richard C/C-9002-2009; Delhaize, Emmanuel/I-6536-2013	Ryan, Peter R/0000-0002-1376-9543; Lin, Jian/0000-0002-8362-6951				APPELS R, 1982, THEOR APPL GENET, V63, P361, DOI 10.1007/BF00303907; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Aussel C, 1998, FEBS LETT, V431, P195, DOI 10.1016/S0014-5793(98)00748-0; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHANDLER PM, 1983, PLANT PHYSIOL, V71, P47, DOI 10.1104/pp.71.1.47; Choi SB, 1997, MOL CELLS, V7, P58; DATKO AH, 1988, PLANT PHYSIOL, V88, P1338, DOI 10.1104/pp.88.4.1338; DELHAIZE E, 1993, PLANT PHYSIOL, V103, P695, DOI 10.1104/pp.103.3.695; DELHAIZE E, 1995, PLANT PHYSIOL, V107, P207, DOI 10.1104/pp.107.1.207; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Doyle JJ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Galliard T., 1973, FORM FUNCTION PHOSPH, P253; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Jones DL, 1997, FEBS LETT, V400, P51, DOI 10.1016/S0014-5793(96)01319-1; KINNEY AJ, 1987, PLANT PHYSIOL, V84, P78, DOI 10.1104/pp.84.1.78; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; MacDiarmid CW, 1996, PLANT PHYSIOL, V112, P1101, DOI 10.1104/pp.112.3.1101; MARSHALL MO, 1974, CAN J BIOCHEM CELL B, V52, P469, DOI 10.1139/o74-071; MOORE TS, 1975, PLANT PHYSIOL, V56, P177, DOI 10.1104/pp.56.2.177; MOORE TS, 1982, ANNU REV PLANT PHYS, V33, P235, DOI 10.1146/annurev.pp.33.060182.001315; Nishida I, 1996, PLANT MOL BIOL, V31, P205, DOI 10.1007/BF00021784; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Brien IEW, 1998, PLANT J, V13, P803, DOI 10.1046/j.1365-313X.1998.00087.x; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; Richardson K, 1998, AUST J PLANT PHYSIOL, V25, P125, DOI 10.1071/PP97109; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SNOWDEN KC, 1993, PLANT PHYSIOL, V103, P855, DOI 10.1104/pp.103.3.855; SPERKAGOTTLIEB C, 1990, YEAST, V6, P331, DOI 10.1002/yea.320060406; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; SURIN B, 1912, P 4 AS PAC C AGR BIO; Uchida K, 1998, J BIOCHEM-TOKYO, V123, P1073; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P228, DOI 10.1016/S0005-2760(97)00102-1; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01; [No title captured]	47	71	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7082	7088		10.1074/jbc.274.11.7082	http://dx.doi.org/10.1074/jbc.274.11.7082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066765	hybrid			2022-12-27	WOS:000079078400037
J	Helmerhorst, EJ; Breeuwer, P; van't Hof, W; Walgreen-Weterings, E; Oomen, LCJM; Veerman, ECI; Amerongen, AVN; Abee, T				Helmerhorst, EJ; Breeuwer, P; van't Hof, W; Walgreen-Weterings, E; Oomen, LCJM; Veerman, ECI; Amerongen, AVN; Abee, T			The cellular target of histatin 5 on Candida albicans is the energized mitochondrion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAROTID SECRETION; NEUTROPHIL DEFENSINS; PEPTIDE; IMPORT; MECHANISM; PROTEIN; PRESEQUENCES; RESPIRATION; MODULATION; SURFACE	Histatin 5 is a human basic salivary peptide with strong fungicidal properties in vitro. To elucidate the mechanism of action, the effect of histatin 5 on the viability of Candida albicans cells was studied in relation to its membrane perturbing properties. It was found that both the killing activity and the membrane perturbing activity, studied by the influx of a DNA-specific marker propidium iodide, were inhibited by high salt conditions and by metabolic inhibitors, like sodium azide, In addition, exposure to histatin 5 resulted in a loss of the mitochondrial transmembrane potential in situ, measured by the release of the potential-dependent distributional probe rhodamine 123, Localization studies using tetramethylrhodamine isothiocyanate-labeled histatin 5 or fluorescein isothiocyanate-labeled histatin 5 showed a granular intracellular distribution of the peptide, which co-localized with mitotracker orange, a permeant mitochondria-specific probe. Like the biological effects, uptake of labeled histatin 5 was inhibited by mitochondrial inhibitors and high salt conditions. Our data indicate that histatin 5 is internalized, and targets to the energized mitochondrion.	Free Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent, NL-1081 BT Amsterdam, Netherlands; Wageningen Univ & Res Ctr, Dept Food Technol & Nutr Sci, Food Sci Grp, NL-6703 HD Wageningen, Netherlands; Netherlands Canc Inst, Dept Biophys, NL-1066 CX Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Wageningen University & Research; Netherlands Cancer Institute	Helmerhorst, EJ (corresponding author), Free Univ Amsterdam, Dept Oral Biochem, Acad Ctr Dent, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.			Helmerhorst, Eva/0000-0002-4803-3018				BJERKNES R, 1984, J IMMUNOL METHODS, V72, P229, DOI 10.1016/0022-1759(84)90451-4; Costilow R. N, 1981, MANUAL METHODS GENER, P66; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; Helmerhorst EJ, 1997, BIOCHEM J, V326, P39, DOI 10.1042/bj3260039; HENRY MF, 1975, SUB-CELL BIOCHEM, V4, P1; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; HUGOSSON M, 1994, EUR J BIOCHEM, V223, P1027, DOI 10.1111/j.1432-1033.1994.tb19081.x; IIJIMA R, 1993, J BIOL CHEM, V268, P12055; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Lendenmann Urs, 1998, P198; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; Margulis L, 1996, P NATL ACAD SCI USA, V93, P1071, DOI 10.1073/pnas.93.3.1071; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P2104, DOI 10.1021/bi961870p; McAuliffe O, 1998, APPL ENVIRON MICROB, V64, P439; MCCARTHY DM, 1987, APPL ENVIRON MICROB, V53, P345, DOI 10.1128/AEM.53.2.345-351.1987; NICOLAY K, 1994, J BIOENERG BIOMEMBR, V26, P327, DOI 10.1007/BF00763104; OLSON VL, 1977, CAN J MICROBIOL, V23, P166, DOI 10.1139/m77-024; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; SHEPHERD MG, 1978, ARCH MICROBIOL, V116, P61, DOI 10.1007/BF00408734; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; WESTERHOFF HV, 1989, BIOCHIM BIOPHYS ACTA, V975, P361, DOI 10.1016/S0005-2728(89)80344-5; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5549	33	217	220	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7286	7291		10.1074/jbc.274.11.7286	http://dx.doi.org/10.1074/jbc.274.11.7286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066791	hybrid			2022-12-27	WOS:000079078400063
J	Miura, S; Feng, YH; Husain, A; Karnik, SS				Miura, S; Feng, YH; Husain, A; Karnik, SS			Role of aromaticity of agonist switches of angiotensin II in the activation of the AT(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN; RESIDUES; BINDING; ANTAGONISTS; MUTATION; AFFINITY; SITE	We have shown previously that the octapeptide angiotensin II (Ang II) activates the AT, receptor through an induced-fit mechanism (Noda, K,, Feng, Y. H., Liu, X. P., Saad, Y,, Husain, A., and Karnik, S, S. (1996) Biochemistry 35, 16435-16442). In this activation process, interactions between Tyr(4) and Phe(8) of Ang II with Asn(111) and His(256) Of the AT(1) receptor, respectively, are essential for agonism, Here we show that aromaticity, primarily, and size, secondarily, of the Tyr(4) side chain are important in activating the receptor. Activation analysis of AT(1) receptor position 111 mutants by various Ang II position 4 analogues suggests that an amino-aromatic bonding interaction operates between the residue Asn(111) of the AT(1) receptor and Ty(r)4 of Ang II. Degree and potency of AT(1) receptor activation by Ang II can be recreated by a reciprocal exchange of aromatic and amide groups between positions 4 and 111 of Ang II and the AT(1) receptor, respectively. In several other bonding combinations, set up between Ang II position 4 analogues and receptor mutants, the gain of affinity is not accompanied by gain of function, Activation analysis of position 256 receptor mutants by Ang II position 8 analogues suggests that aromaticity of Phe(8) and His256 Side chains is crucial for receptor activation; however, a stacked rather than an amino-aromatic interaction appears to operate at this switch locus. Interaction between these residues, unlike the Tyr(4):Asn(111) interaction, plays an insignificant role in ligand docking.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Karnik, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	karniks@cesmtp.ccf.org	Karnik, Sadashiva/Y-2477-2019; Husain, Ahsan/J-6861-2012	Karnik, Sadashiva/0000-0003-0746-2753; Husain, Ahsan/0000-0003-3426-3469	NEI NIH HHS [EY09704] Funding Source: Medline; NHLBI NIH HHS [R01 HL064845, HL57470, R01 HL057470] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057470] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG KM, 1993, J MOL BIOL, V230, P284, DOI 10.1006/jmbi.1993.1142; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CREIGHTON TE, 1984, PROTEINS STRUCTURAL, P2; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; GUILLEMETTE G, 1984, J MED CHEM, V27, P315, DOI 10.1021/jm00369a015; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karnik SS, 1996, CLIN EXP PHARMACOL P, V23, pS58, DOI 10.1111/j.1440-1681.1996.tb02815.x; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Nicholls A.J., 1993, GRASP MANUAL; NIKIFOROVICH GV, 1994, BIOCHEMISTRY-US, V33, P3591, DOI 10.1021/bi00178a016; NODA K, 1995, J BIOL CHEM, V270, P28511, DOI 10.1074/jbc.270.48.28511; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; NODA K, 1994, J BIOL CHEM, V269, P6743; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; SAMANEN J, 1989, J MED CHEM, V32, P1366, DOI 10.1021/jm00126a037; SAMANEN J, 1994, ANGIOTENSIN 2 RECEPT, V2, P11; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Underwood D J, 1994, Chem Biol, V1, P211, DOI 10.1016/1074-5521(94)90013-2; WALKSMAN G, 1992, NATURE, V358, P646; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	31	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7103	7110		10.1074/jbc.274.11.7103	http://dx.doi.org/10.1074/jbc.274.11.7103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066768	hybrid			2022-12-27	WOS:000079078400040
J	Strumberg, D; Nitiss, JL; Rose, A; Nicklaus, MC; Pommier, Y				Strumberg, D; Nitiss, JL; Rose, A; Nicklaus, MC; Pommier, Y			Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; ESCHERICHIA-COLI; CLEAVAGE; YEAST; DERIVATIVES; INHIBITORS; MECHANISM; COMPLEX; BINDING; GYRASE	A Ser(740) --> Trp mutation in yeast topoisomerase II (top2) and of the equivalent Ser(83) in gyrase results in resistance to quinolones and confers hypersensitivity to etoposide (VP-16), We characterized the cleavage complexes induced by the top2(S740W) in the human c-myc gene. In addition to resistance to the fluoroquinolone CP-115,953, top2(S740W) induced novel DNA cleavage sites in the presence of VP-16, azatoxin, amsacrine, and mitoxantrone, Analysis of the VP-16 sites indicated that the changes in the cleavage pattern were reflected by alterations in base preference. C at position -2 and G at position +6 were observed for the top(2S740W) in addition to the previously reported C-1 and G+5 for the wildtype top2, The VP-16-induced top(2S740W) cleavage complexes were also more stable. The most stable sites had strong preference for C-l, whereas the most reversible sites showed no base preference at positions -1 or -2, Different patterns of DNA cleavage were also observed in the absence of drug and in the presence of calcium. These results indicate that the Ser(740) --> Trp mutation alters the DNA recognition of top2, enhances its DNA binding, and markedly affects its interactions with inhibitors. Thus, residue 740 of top2 appears critical for both DNA and drug interactions.	NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; NCI, Med Chem Lab, Div Basic Sci, NCI, Bethesda, MD 20892 USA; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, NIH, Blg 37,Rom 5D02, Bethesda, MD 20892 USA.		Nitiss, John/E-9974-2010; Nicklaus, Marc/N-4183-2014	Nitiss, John/0000-0002-1013-4972; Strumberg, Dirk/0000-0001-7053-8365; Nicklaus, Marc/0000-0002-4775-7030	NCI NIH HHS [CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck W T, 1994, Adv Pharmacol, V29B, P145; Beck WT, 1997, ADV ENZYME REGUL, V37, P17, DOI 10.1016/S0065-2571(96)00024-6; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BIGIONI M, 1994, NUCLEIC ACIDS RES, V22, P2274, DOI 10.1093/nar/22.12.2274; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Capranico G, 1997, TRENDS PHARMACOL SCI, V18, P323; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; Capranico G, 1997, CANCER CHEMOTHER BIO, V17, P114; Conrad S, 1996, J ANTIMICROB CHEMOTH, V38, P443, DOI 10.1093/jac/38.3.443; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; D'Arpa P, 1994, Adv Pharmacol, V29B, P127; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; Gmunder H, 1997, NUCLEIC ACIDS RES, V25, P604, DOI 10.1093/nar/25.3.604; Hsiung Y, 1996, CANCER RES, V56, P91; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; Hung F, 1996, FEBS LETT, V380, P127, DOI 10.1016/0014-5793(96)00035-X; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LETEURTRE F, 1994, BIOCHEM BIOPH RES CO, V203, P1259, DOI 10.1006/bbrc.1994.2318; LETEURTRE F, 1994, J BIOL CHEM, V269, P7893; LETEURTRE F, 1992, CANCER RES, V52, P4478; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU L, 1994, DNA TOPOISOMERASES T; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; LIU YX, 1994, CANCER RES, V54, P2943; Neu H C, 1994, Adv Pharmacol, V29A, P227; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Yves, 1997, P153; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROBLEDOLUIGGI C, 1991, BIOPOLYMERS, V31, P907, DOI 10.1002/bip.360310710; SARTORIUS J, 1995, FEBS LETT, V374, P387, DOI 10.1016/0014-5793(95)01158-B; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	48	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7292	7301		10.1074/jbc.274.11.7292	http://dx.doi.org/10.1074/jbc.274.11.7292			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066792	hybrid			2022-12-27	WOS:000079078400064
J	Arner, EC; Pratta, MA; Trzaskos, JM; Decicco, CP; Tortorella, MD				Arner, EC; Pratta, MA; Trzaskos, JM; Decicco, CP; Tortorella, MD			Generation and characterization of aggrecanase - A soluble, cartilage-derived aggrecan-degrading activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; NECROSIS-FACTOR-ALPHA; HUMAN SYNOVIAL-FLUID; C-TERMINAL DOMAIN; INTERGLOBULAR DOMAIN; MATRIX METALLOPROTEINASE; TISSUE INHIBITORS; CLEAVAGE SITE; GELATINASE-A; CATABOLISM	A method was developed for generating soluble, active "aggreeanase" in conditioned media from interleukin-1-stimulated bovine nasal cartilage cultures, Using bovine nasal cartilage conditioned media as a source of the aggrecanase enzyme, an enzymatic assay was established employing purified aggrecan monomers as a substrate and monitoring specific aggrecanase-mediated cleavage products by Western analysis using the monoclonal antibody, BC-3 (which recognizes the new N terminus, ARGS, on fragments produced by cleavage between amino acid residues Glu(373 an)d Ala(374)). Using this assay we have characterized cartilage aggrecanase with respect to assay kinetics, pH; and salt optima, heat sensitivity, and stability upon storage. Aggrecanase activity was inhibited by the metalloprotease inhibitor, EDTA, while a panel of inhibitors of serine, cysteine, and aspartic proteinases had no effect, suggesting that aggrecanase is a metalloproteinase, Sensitivity to known matrix metalloproteinase inhibitors as well as to the endogenous tissue inhibitor of metalloproteinases, TIMP-1, further support the notion that aggrecanase is a metalloproteinase potentially related to the ADAM family or MMP family of proteases previously implicated in the catabolism of the extracellular matrix.	DuPont Pharmaceut Co, Inflammatory Dis Res, Expt Stn E400 4239, Wilmington, DE 19880 USA; DuPont Pharmaceut Co, Chem & Phys Sci, Wilmington, DE 19880 USA	DuPont; DuPont	Arner, EC (corresponding author), DuPont Pharmaceut Co, Inflammatory Dis Res, Expt Stn E400 4239, POB 400, Wilmington, DE 19880 USA.							Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Billington CJ, 1998, BIOCHEM J, V336, P207, DOI 10.1042/bj3360207; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CAMPION C, 1989, PCTGB8901399; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, T ORTHOP RES SOC, V18, P190; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HUANG JJ, 1987, MOL BIOL MED, V4, P169; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LEULAKIS P, 1992, BIOCHEM J, V264, P589; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1997, INFLAMM RES, V46, pS122; TORTORELLA MD, 1996, T ORTHOP RES SOC, V20, P341; TORTORELLA MD, 1996, T ORTHOP RES SOC, V21, P148; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; XUE CB, 1997, Patent No. 9718207	43	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6594	6601		10.1074/jbc.274.10.6594	http://dx.doi.org/10.1074/jbc.274.10.6594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037754	hybrid			2022-12-27	WOS:000078902800076
J	Grainge, I; Sherratt, DJ				Grainge, I; Sherratt, DJ			Xer site-specific recombination - DNA strand rejoining by recombinase XerC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FLP RECOMBINASE; IN-VITRO; BACTERIOPHAGE-LAMBDA; HOLLIDAY STRUCTURES; PROTEIN; RESOLUTION; HOMOLOGY; DIF; INTEGRASE	Xer site-specific recombination functions in the stable maintenance of circular replicons in Escherichia coli. Each of two related recombinase proteins, XerC and XerD, cleaves a specific pair of DNA strands, exchanges them, and rejoins them to the partner DNA molecule during a complete recombination reaction. The rejoining activity of recombinase XerC has been analyzed using isolated covalent XerC-DNA complexes resulting from DNA cleavage reactions upon Holliday junction substrates, These covalent protein-DNA complexes are competent in the rejoining reaction, demonstrating that covalently bound XerC can catalyze strand rejoining in the absence of other proteins. This contrasts with a recombinase-mediated cleavage reaction, which requires the presence of both recombinases, the recombinase mediating catalysis at any given time requiring activation by the partner recombinase, In a recombining nucleoprotein complex, both cleavage and rejoining can occur prior to dissociation of the complex.	Univ Oxford, Dept Biochem, Div Mol Genet, Oxford OX1 3QU, England	University of Oxford	Sherratt, DJ (corresponding author), Univ Oxford, Dept Biochem, Div Mol Genet, S Parks Rd, Oxford OX1 3QU, England.	sherratt@bioch.ox.ac.uk	Grainge, Ian RF/A-9031-2010	Grainge, Ian RF/0000-0001-8268-583X				ARCISZEWSKA L, 1995, EMBO J, V14, P2651, DOI 10.1002/j.1460-2075.1995.tb07263.x; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; BLAKELY GW, 1994, NUCLEIC ACIDS RES, V22, P5613; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Colloms SD, 1997, CELL, V88, P855, DOI 10.1016/S0092-8674(00)81931-5; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CORNET F, 1994, J BACTERIOL, V176, P3188, DOI 10.1128/jb.176.11.3188-3195.1994; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; SUMMERS DK, 1984, CELL, V36, P1097, DOI 10.1016/0092-8674(84)90060-6; SUMMERS DK, 1989, EMBO J, V8, P309, DOI 10.1002/j.1460-2075.1989.tb03378.x; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646	35	7	8	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6763	6769		10.1074/jbc.274.10.6763	http://dx.doi.org/10.1074/jbc.274.10.6763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037776	hybrid			2022-12-27	WOS:000078902800098
J	James, EL; Whisstock, JC; Gore, MG; Bottomley, SP				James, EL; Whisstock, JC; Gore, MG; Bottomley, SP			Probing the unfolding pathway of alpha(1)-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR EXTRAPOLATION METHOD; FLUORESCENCE SPECTROSCOPY; ALPHA-1-PROTEINASE INHIBITOR; FOLDING PATHWAY; HINGE REGION; POLYMERIZATION; MECHANISM; LOOP; SERPINS; ALPHA-1-ANTITRYPSIN	Protein misfolding plays a role in the pathogenesis of many diseases, alpha(1)-Antitrypsin misfolding leads to the accumulation of long chain polymers within the hepatocyte, reducing its plasma concentration and predisposing the patient to emphysema and liver disease, In order to understand the misfolding process, it is necessary to examine the folding of alpha(1)-antitrypsin through the different structures involved in this process. In this study we have used a novel technique in which unique cysteine residues were introduced at various positions into ru,antitrypsin and fluorescently labeled with N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine, The fluorescence properties of each protein were studied in the native state and as a function of guanidine hydrochloride-mediated unfolding. The studies found that alpha(1)-antitrypsin unfolded through a series of intermediate structures. From the position of the fluorescence probes, the fluorescence quenching data, and the molecular modeling, we show that unfolding of alpha(1)-antitrypsin occurs via disruption of the A and C beta-sheets followed by the B beta-sheet, The implications of these data on both alpha(1)-antitrypsin function and polymerization are discussed.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Univ Southampton, Sch Biol Sci, Dept Biochem, Southampton SO16 7PX, Hants, England	Monash University; University of Southampton	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.			Whisstock, James/0000-0003-4200-5611				BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; Bottomley SP, 1998, BIOCHEM BIOPH RES CO, V251, P1, DOI 10.1006/bbrc.1998.9254; BOTTOMLEY SP, 1994, PROTEIN ENG, V7, P1463, DOI 10.1093/protein/7.12.1463; Carrell RW, 1996, CHEST, V110, pS243, DOI 10.1378/chest.110.6_Supplement.243S; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; Kang HA, 1997, J BIOL CHEM, V272, P510; Kim DY, 1996, BIOCHEM BIOPH RES CO, V226, P378, DOI 10.1006/bbrc.1996.1364; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; Koloczek H, 1996, J PROTEIN CHEM, V15, P447, DOI 10.1007/BF01886851; Koloczek H, 1996, PROTEIN SCI, V5, P2226, DOI 10.1002/pro.5560051109; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWON KS, 1994, J BIOL CHEM, V269, P9627; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Lomas DA, 1996, QJM-INT J MED, V89, P807, DOI 10.1093/qjmed/89.11.807; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SMITH CJ, 1991, BIOCHEMISTRY-US, V30, P1028, DOI 10.1021/bi00218a021; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WHISSTOCK J, 1996, THESIS U CAMBRIDGE U; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	47	70	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9482	9488		10.1074/jbc.274.14.9482	http://dx.doi.org/10.1074/jbc.274.14.9482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092631	hybrid			2022-12-27	WOS:000079451800050
J	Matsuno-Yagi, A; Hatefi, Y				Matsuno-Yagi, A; Hatefi, Y			Ubiquinol : cytochrome c oxidoreductase - Effects of inhibitors on reverse electron transfer from the iron-sulfur protein to cytochrome b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BC1 COMPLEX; BOVINE HEART-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; BC(1) COMPLEX; ETHOXYFORMIC ANHYDRIDE; REDOX REACTIONS; Q-CYCLE; MECHANISM; REDUCTASE; BINDING	The effects of inhibitors on the reduction of the bis-heme cytochrome b of ubiquinol: cytochrome c oxidoreductase (complex III, bc(1) complex) has been studied in bovine heart submitochondrial particles (SMP) when cytochrome b was reduced by NADH and succinate via the ubiquinone (Q) pool or by ascorbate plus N,N,N',N'-tetramethyl-p-phenylenediamine via cytochrome c(1) and the iron-sulfur protein of complex III (ISP). The inhibitors used were antimycin (an N-side inhibitor), beta-methoxyacrylate derivatives, stigmatellin (P-side inhibitors), and ethoxyformic anhydride, which modifies essential histidyl residues in ISP, In agreement with our previous findings, the following results were obtained: (i) When ISP/cytochrome c(1) were prereduced or SMP were treated with a P-side inhibitor, the high potential heme b(H) was fully and rapidly reduced by NADH or succinate, whereas the low potential heme b(L) was only partially reduced. (ii) Reverse electron transfer from ISP/c(1) to cytochrome b was inhibited more by antimycin than by the P-side inhibitors. This reverse electron transfer was unaffected when, instead of normal SMP, Q-extracted SMP containing 200-fold less Q (0.06 mol Q/mol cytochrome b or c(1)) were used. (iii) The cytochrome b reduced by reverse electron transfer through the leak of a P-side inhibitor was rapidly oxidized upon subsequent addition of antimycin. This antimycin-induced reoxidation did not happen when Q-extracted SMP were used. The implications of these results on the path of electrons in complex III, on oxidant-induced extra cytochrome b reduction, and on the inhibition of forward electron transfer to cytochrome b by a P-side plus an N-side inhibitor have been discussed.	Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Hatefi, Y (corresponding author), Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIDDK NIH HHS [DK-08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK008126, R37DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HOWELL N, 1993, BIOCHEMISTRY-US, V32, P11162, DOI 10.1021/bi00092a028; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MatsunoYagi A, 1997, J BIOL CHEM, V272, P16928, DOI 10.1074/jbc.272.27.16928; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1987, J BIOL CHEM, V262, P14158; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; OHNISHI T, 1994, FEBS LETT, V353, P103, DOI 10.1016/0014-5793(94)01021-8; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; RIESKE JS, 1967, J BIOL CHEM, V242, P4854; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1987, J BIOL CHEM, V262, P8677; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YAGI T, 1982, BIOCHEMISTRY-US, V21, P4777, DOI 10.1021/bi00262a039; YU CA, 1996, BIOCHIM BIOPHYS ACTA, V127, P47; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9283	9288		10.1074/jbc.274.14.9283	http://dx.doi.org/10.1074/jbc.274.14.9283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092604	hybrid			2022-12-27	WOS:000079451800023
J	Li, SL; Paulsson, KM; Sjogren, HO; Wang, P				Li, SL; Paulsson, KM; Sjogren, HO; Wang, P			Peptide-bound major histocompatibility complex class I molecules associate with tapasin before dissociation from transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ENDOPLASMIC-RETICULUM; TAP TRANSPORTERS; BINDING; CHAPERONE; CALNEXIN; GLYCOPROTEIN; GENERATION; SELECTION; PROTEINS	Major histocompatibility complex (MHC) class I molecules present antigenic peptides to CD8 T cells. The peptides are generated in the cytosol, then translocated across the membrane of the endoplasmic reticulum by the transporter associated with antigen processing (TAP). TAP is a trimeric complex consisting of TAP1, TAP2, and tapasin (TAP-A) as indicated for human cells by reciprocal coprecipitation with anti TAP1/2 and anti-tapasin antibodies, respectively. TAP1 and TAP2 are required for the peptide transport. Tapasin is involved in the association of class I with TAP and in the assembly of class I with peptide. The mechanisms of tapasin function are still unknown. Moreover, there has been no evidence for a murine tapasin analogue, which has led to the suggestion that murine MHC class I binds directly to TAP1/2. In this study, we have cloned the mouse analogue of tapasin. The predicted amino acid sequence showed 78% identity to human tapasin with identical consensus sequences of signal peptide, N-linked glycosylation site, transmembrane domain and double lysine motif. However, there was less homology (47%) found at the predicted cytosolic domain, and in addition, mouse tapasin is 14 amino acids longer than the human analogue at the C terminus. This part of the molecule may determine the species specificity for interaction with MHC class I or TAP1/2. Like human tapasin, mouse tapasin binds both to TAP1/2 and MHC class I. In TAP2-mutated RMA-S cells, both TAP1 and MHC class I were coprecipitated by anti-tapasin antiserum indicative of association of tapasin with TAP1 but not TAP2. With crosslinker-modified peptides and purified microsomes, anti-tapasin coprecipitated both peptide-bound MHC class I and TAP1/2. In contrast, anti-calreticulin only coprecipitated peptide-free MHC class I molecules. This difference in association with peptide-loaded class I suggests that tapasin functions later than calreticulin during MHC class I assembly, and controls peptide loading onto MHC class I molecules in the endoplasmic reticulum.	Univ Lund, S-22007 Lund, Sweden	Lund University	Li, SL (corresponding author), Univ Lund, Box 7031, S-22007 Lund, Sweden.			Wang, Ping/0000-0001-8992-1233				ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHEN AP, 1998, IMMUNITY, V8, P531; DAVID V, 1993, J BIOL CHEM, V268, P9585; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KALTOFT MB, 1992, HYBRIDOMA, V11, P507, DOI 10.1089/hyb.1992.11.507; Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Neisig A, 1996, J IMMUNOL, V156, P3196; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SUCH WK, 1994, SCIENCE, V264, P1322; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANLEEUWEN JE, 1996, P NATL ACAD SCI USA, V24, P13997; Wang P, 1996, J IMMUNOL, V157, P213; Wang P, 1996, J BIOL CHEM, V271, P24830, DOI 10.1074/jbc.271.40.24830; YANG Y, 1992, J BIOL CHEM, V267, P11669	37	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8649	8654		10.1074/jbc.274.13.8649	http://dx.doi.org/10.1074/jbc.274.13.8649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085102	hybrid			2022-12-27	WOS:000079451600044
J	Notbohm, H; Nokelainen, M; Myllyharju, J; Fietzek, PP; Muller, PK; Kivirikko, KI				Notbohm, H; Nokelainen, M; Myllyharju, J; Fietzek, PP; Muller, PK; Kivirikko, KI			Recombinant human type II collagens with low and high levels of hydroxylysine and its glycosylated forms show marked differences in fibrillogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; INSECT CELLS; PROCOLLAGEN; EXPRESSION; CLEAVAGE; PROTEIN; TENDON	Type II collagen is the main structural component of hyaline cartilages where it forms networks of thin fibrils that differ in morphology from the much thicker fibrils of type I collagen. We studied here in vitro the formation of fibrils of pepsin-treated recombinant human type II collagen produced in insect cells. Two kinds of type II collagen preparation were used: low hydroxylysine collagen having 2.0 hydroxylysine residues/1,000 amino acids, including 1.3 glycosylated hydroxylysines; and high hydroxylysine collagen having 19 hydroxylysines/1,000 amino acids, including 8.9 glycosylated hydroxylysines. A marked difference in fibril formation was found between these two kinds of collagen preparation, in that the maximal turbidity of the former was reached within 5 min under the standard assay conditions, whereas the absorbance of the latter increased until about 600 min. The critical concentration with the latter was about 10-fold, and the absorbance/microgram collagen incorporated into the fibrils was about one-sixth. The morphology of the fibrils was also different, in that the high hydroxylysine collagen formed thin fibrils with essentially no interfibril interaction or aggregation, whereas the low hydroxylysine collagen formed thick fibrils on a background of thin ones. The data thus indicate that regulation of the extents of lysine hydroxylation and hydroxylysine glycosylation may play a major role in the regulation of collagen fibril formation and the morphology of the fibrils.	Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland; Univ Lubeck, Inst Med Mol Biol, D-23538 Lubeck, Germany; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland	University of Oulu; University of Lubeck; University of Oulu	Kivirikko, KI (corresponding author), Univ Oulu, Dept Med Biochem, Kajaanintie 52 A, FIN-90220 Oulu, Finland.							Birk DE, 1997, EUR J CELL BIOL, V72, P352; Birk DE, 1996, MATRIX BIOL, V15, P111, DOI 10.1016/S0945-053X(96)90152-3; FERTALA A, 1994, J BIOL CHEM, V269, P11584; Kadler KE, 1996, BIOCHEM J, V316, P1; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; NOTBOHM H, 1993, INT J BIOL MACROMOL, V15, P299, DOI 10.1016/0141-8130(93)90030-P; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1992, INT J BIOL MACROMOL, V14, P292, DOI 10.1016/S0141-8130(05)80043-1; TENNI R, 1984, ITAL J BIOCHEM, V33, P117; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; YANG CLL, 1993, EUR J BIOCHEM, V213, P1297, DOI 10.1111/j.1432-1033.1993.tb17881.x	20	77	81	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8988	8992		10.1074/jbc.274.13.8988	http://dx.doi.org/10.1074/jbc.274.13.8988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085145	hybrid			2022-12-27	WOS:000079451600087
J	Sano, Y; Harada, J; Tashiro, S; Gotoh-Mandeville, R; Maekawa, T; Ishii, S				Sano, Y; Harada, J; Tashiro, S; Gotoh-Mandeville, R; Maekawa, T; Ishii, S			ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; LEUCINE ZIPPER PROTEINS; DNA-BINDING DOMAINS; N-TERMINAL KINASE; CYCLIC-AMP; MAP KINASE; C-JUN; INDUCED TRANSCRIPTION; TRANSDUCTION PATHWAY; CDNA CLONES	Upon transforming growth factor-beta (TGF-beta) binding to its cognate receptor, Smad3 and Smad4 form heterodimers and transduce the TGF-beta signal to the nucleus. In addition to the Smad pathway, another pathway involving a member of the mitogen-activated protein kinase kinase kinase family of kinases, TGF-beta-activated kinase-1 (TAK1), is required for TGF-beta signaling. However, it is unknown how these pathways function together to synergistically amplify TGF-beta signaling. Here we report that the transcription factor ATF-2 (also called CRE-BP1) is bound by a hetero-oligomer of Smad3 and Smad4 upon TGF-beta stimulation. ATF-2 is one member of the ATF/CREB family that binds to the cAMP response element, and its activity is enhanced after phosphorylation by stress-activated protein kinases such as c-Jun N-terminal kinase and p38. The binding between ATF-2 and Smad3/4 is mediated via the MH1 region of the Smad proteins and the basic leucine zipper region of ATF-2. TGF-beta signaling also induces the phosphorylation of ATF-2 via TAK1 and p38. Both of these actions are shown to be responsible for the synergistic stimulation of ATF-2 trans-activating capacity. These results indicate that ATF-2 plays a central role in TGF-beta signaling by acting as a common nuclear target of both Smad and TAK1 pathways.	RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, Ibaraki, Osaka 3050074, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka, Japan	RIKEN; Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, 3-1-1 Koyadai, Ibaraki, Osaka 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NOMURA N, 1993, J BIOL CHEM, V268, P4259; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; TAKEDA J, 1991, ONCOGENE, V6, P1009; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; VANDAM H, 1997, EMBO J, V14, P31798; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	65	304	317	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8949	8957		10.1074/jbc.274.13.8949	http://dx.doi.org/10.1074/jbc.274.13.8949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085140	hybrid			2022-12-27	WOS:000079451600082
J	Gatti, A; Huang, ZD; Tuazon, PT; Traugh, JA				Gatti, A; Huang, ZD; Tuazon, PT; Traugh, JA			Multisite autophosphorylation of p21-activated protein kinase gamma-PAK as a function of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MOLECULAR-CLONING; IDENTIFICATION; CLEAVAGE; GTPASES; FAMILY; PHOSPHORYLATION; RECEPTOR; PEPTIDES; STE20	p21-activated protein kinase (PAK) is a family of serine/threonine kinases whose activity is stimulated by binding to small G-proteins such as Cdc42 and subsequent autophosphorylation, Focusing on the ubiquitous gamma-isoform of PAK in this study, baculovirus-infected insect cells were used to obtain recombinant gamma-PAK, while native gamma-PAK was isolated from rabbit reticulocytes, Two-dimensional gel electrophoresis of gamma-PAK followed by immunoblot analysis revealed a similar profile for native and recombinant gamma-PAK, both consisting of multiple protein spots. Following Cdc42-stimulated autophosphorylation, the two-dimensional profiles of native and recombinant gamma-PAK were characterized by a similar acidic shift, suggesting a common response to Cdc42. To understand the effect of differential phosphorylation on its activation status, gamma-PAK autophosphorylation was conducted in the presence or absence of activators such as Cdc42 and histone II-AS, followed by tryptic digestion and comparative two-dimensional phosphopeptide mapping. The major phosphopeptides were subjected to a combination of manual and automated amino acid sequencing. Overall, eight autophosphorylation sites were identified in Cdc42-activated gamma-PAK, six of which are in common with those previously reported in alpha-PAK, while Ser-19 and Ser-165 appear to be uniquely phosphorylated in the gamma-form, Further, the phosphorylation of Ser-141, Ser-165, and Thr-402 was found to correlate with gamma-PAK activation.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gatti A, 1997, EUR J BIOCHEM, V249, P92, DOI 10.1111/j.1432-1033.1997.t01-1-00092.x; Gatti A, 1999, ANAL BIOCHEM, V266, P198, DOI 10.1006/abio.1998.2955; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; JAKOBI R, 1998, FASEB J, V12, P343; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	39	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8022	8028		10.1074/jbc.274.12.8022	http://dx.doi.org/10.1074/jbc.274.12.8022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075701	hybrid			2022-12-27	WOS:000079268100060
J	Gurrola, GB; Arevalo, C; Sreekumar, R; Lokuta, AJ; Walker, JW; Valdivia, HH				Gurrola, GB; Arevalo, C; Sreekumar, R; Lokuta, AJ; Walker, JW; Valdivia, HH			Activation of ryanodine receptors by imperatoxin A and a peptide segment of the II-III loop of the dihydropyridine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; FK506-BINDING PROTEIN; RELEASE; CHANNEL; CALCIUM; VENOM; ACID; REGIONS; MUTANT	Excitation-contraction coupling in skeletal muscle is believed to be triggered by direct protein-protein interactions between the sarcolemmal dihydropyridine-sensitive Ca2+ channel and the Ca2+ release channel/ryanodine receptor (RyR) of sarcoplasmic reticulum. A 138-amino acid cytoplasmic loop between repeats II and III of the (alpha(1), subunit of the skeletal dihydropyridine receptor (the II-III loop) interacts with a region of the RyR to elicit Ca2+ release. In addition, small segments (10-20 amino acid residues) of the II-III loop retain the capacity to activate Ca2+ release. Imperatoxin A, a 33-amino acid peptide from the scorpion Pandinus imperator, binds directly to the RyR and displays structural and functional homology with an activating segment of the II-III loop (Glu(666)-Leu(690)), Mutations in a structural motif composed of a cluster of basic amino acids followed by Ser or Thr dramatically reduce or completely abolish the capacity of the peptides to activate RyRs, Thus, the Imperatoxin A-RyR interaction mimics critical molecular characteristics of the II-III loop-RyR interaction and may be a useful tool to elucidate the molecular mechanism that couples membrane depolarization to sarcoplasmic reticulum Ca2+ release in vivo.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Valdivia, HH (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	valdivia@physiology.wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055438, P01HL047053] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL47053, HL55438] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BERS DM, 1991, EXCITATION CONTRACTI; Beurg M, 1998, BIOPHYS J, V74, pA235; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HAGIWARA K, 1990, BIOMED RES-TOKYO, V11, P181, DOI 10.2220/biomedres.11.181; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; LINDSAY ARG, 1994, J GEN PHYSIOL, V104, P425, DOI 10.1085/jgp.104.3.425; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; PALADE P, 1987, J BIOL CHEM, V262, P6135; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; Wilson CJ, 1997, BIOCHEMISTRY-US, V36, P4542, DOI 10.1021/bi962299x; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5; Zucchi R, 1997, PHARMACOL REV, V49, P1	36	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7879	7886		10.1074/jbc.274.12.7879	http://dx.doi.org/10.1074/jbc.274.12.7879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075681	hybrid			2022-12-27	WOS:000079268100040
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			The heparin heparan sulfate-binding site on apo serum amyloid A - Implications for the therapeutic intervention of amyloidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL EFFLUX; FIBROBLAST GROWTH-FACTOR; HUMAN ANTITHROMBIN-III; HUMAN APOLIPOPROTEIN-E; ACUTE-PHASE PROTEIN; BASIC-AMINO-ACIDS; CONGO RED; PRP ACCUMULATION; A SAA	Serum amyloid A isoforms, apoSAA1 and apoSAA2, are apolipoproteins of unknown function that become major components of high density lipoprotein (HDL) during the acute phase of an inflammatory response, ApoSAA is also the precursor of inflammation-associated amyloid, and there is strong evidence that the formation of inflammation-associated and other types of amyloid is promoted by heparan sulfate (HS). Data presented herein demonstrate that both mouse and human apoSAA contain binding sites that are specific for heparin and HS, with no binding for the other major glycosaminoglycans detected. Cyanogen bromide-generated peptides of mouse apoSAA1 and apoSAA2 were screened for heparin binding activity. Two peptides, an apoSAA1-derived 80-mer (residues 24-103) and a smaller carboxyl-terminal 27-mer peptide of apoSAA2 (residues 77-103), were retained by a heparin column. A synthetic peptide corresponding to the CNBr-generated 27-mer also bound heparin, and by substituting or deleting one or more of its six basic residues (Arg-83, His-84, Arg-86, Lys-89, Arg-95, and Lys-102), their relative importance for heparin and HS binding was determined. The Lys-102 residue appeared to be required only for HS binding. The residues Arg-86, Lys-89, Arg-95, and Lys-102 are phylogenetically conserved suggesting that the heparin/HS binding activity may be an important aspect of the function of apoSAA HS linked by its carboxyl groups to an Affi-Gel column or treated with carbodiimide to block its carboxyl groups lost the ability to bind apoSAA. HDL-apoSAA did not bind to heparin; however, it did bind to HS, an interaction to which apoA-I contributed. Results from binding experiments with Congo Red-Sepharose 4B columns support the conclusions of a recent structural study which found that heparin binding domains have a common spatial distance of about 20 Angstrom between their two outer basic residues. Our present work provides direct evidence that apoSAA can associate with HS (and heparin) and that the occupation of its binding site by HS, and HS analogs, likely caused the previously reported increase in amyloidogenic conformation (beta-sheet) of apoSAA2 (McCubbin, W. D., Kay, C. M., Narindrasorasak, S., and Kisilevsky, R. (1988) Biochem. J. 256, 775-783) and their amyloid-suppressing effects in vivo (Kisilevsky, R., Lemieux, L. J., Fraser, P. E., Kong, X., Hultin, P. G., and Szarek, W. A. (1995) Not. Med. 1, 143-147), respectively.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Kisilevsky, R (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.	Kisilevsky@cliff.path.queensu.ca						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AILLES L, 1993, LAB INVEST, V69, P443; Ancsin JB, 1997, J BIOL CHEM, V272, P406; AXELRAD MA, 1982, LAB INVEST, V47, P139; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BANKA CL, 1995, J LIPID RES, V36, P1058; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BITTER T, 1966, J CLIN INVEST, V45, P963, DOI 10.1172/JCI105412; BRISSETTE L, 1989, J BIOL CHEM, V264, P19327; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; DALFERES ER, 1967, ARCH BIOCHEM BIOPHYS, V118, P284, DOI 10.1016/0003-9861(67)90350-5; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GITEL SN, 1985, BLOOD, V65, P902; GOLDBERGER G, 1987, J IMMUNOL, V138, P3967; GOLDSMITH MR, 1979, ANAL BIOCHEM, V99, P33, DOI 10.1016/0003-2697(79)90041-1; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIDAKA H, 1992, BIOCHEM J, V284, P161, DOI 10.1042/bj2840161; HIROSE N, 1987, BIOCHEMISTRY-US, V26, P5505, DOI 10.1021/bi00391a044; HUSBY G, 1994, AMYLOID, V1, P119, DOI 10.3109/13506129409148635; HUSBY G, 1973, NATURE, V244, P362, DOI 10.1038/244362a0; HUSHNER I, 1994, CLIN RHEUMATOL, P513; Inoue S, 1996, LAB INVEST, V74, P1081; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jensen LE, 1997, J IMMUNOL, V158, P384; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; KAGAN DZ, 1974, PROBL TUBERK, V40, P72; KAZATCHKINE MD, 1993, B WORLD HEALTH ORGAN, V71, P105; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; KISILEVSKY R, 1992, LAB INVEST, V66, P778; Kisilevsky R, 1996, CIBA F SYMP, V199, P58; KISILEVSKY R, 1997, Patent No. 5643562; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; LEVIN M, 1973, J EXP MED, V138, P373, DOI 10.1084/jem.138.2.373; Linhardt R. J., 1997, CARBOHYDRATES DRUG D, P277; LINKE RP, 1991, BIOCHEM BIOPH RES CO, V176, P1100, DOI 10.1016/0006-291X(91)90397-P; LIU CS, 1987, J BIOL CHEM, V262, P17356; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; Magnus JH, 1997, AMYLOID, V4, P121, DOI 10.3109/13506129708995282; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NICHOLS WC, 1988, BIOCHEM BIOPH RES CO, V156, P534; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PreciadoPatt L, 1996, INT J PEPT PROT RES, V48, P503; PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661; PUCHTLER H, 1983, HISTOCHEMISTRY, V77, P431, DOI 10.1007/BF00495799; ROCKEN C, 1997, INT J EXP CLIN INVES, V4, P259; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCOPES RK, 1986, J CHROMATOGR, V376, P131, DOI 10.1016/S0378-4347(00)80830-0; SERGREST JP, 1976, BIOCHEMISTRY-US, V15, P3187; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1987, LAB INVEST, V57, P687; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SOBEL M, 1992, J BIOL CHEM, V267, P8857; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; SUN XJ, 1989, J BIOL CHEM, V264, P11288; UHLAR CM, 1994, GENOMICS, V19, P228, DOI 10.1006/geno.1994.1052; Van der Westhuyzen D., 1986, AMYLOIDOSIS, P115; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253	87	135	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7172	7181		10.1074/jbc.274.11.7172	http://dx.doi.org/10.1074/jbc.274.11.7172			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066777	hybrid			2022-12-27	WOS:000079078400049
J	Anis, Y; Nurnberg, B; Visochek, L; Reiss, N; Naor, Z; Cohen-Armon, M				Anis, Y; Nurnberg, B; Visochek, L; Reiss, N; Naor, Z; Cohen-Armon, M			Activation of G(o)-proteins by membrane depolarization traced by in situ photoaffinity labeling of G(alpha o)-proteins with [alpha P-32]GTP-azidoanilide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GTP-BINDING PROTEINS; CATALYZED ADP-RIBOSYLATION; ALPHA-SUBUNITS; MUSCARINIC RECEPTORS; SODIUM-CHANNELS; RAT-BRAIN; LIPID MODIFICATIONS; NA+ CHANNELS; PHOSPHOLIPID-VESICLES	Evidence for depolarization-induced activation of G-proteins in membranes of rat brain synaptoneurosomes has been previously reported (Cohen-Armon, RI,, and Sokolovsky, M. (1991) J, Biol, Chem, 266, 2595-2605; Cohen-Armon, RI., and Sokolovsky, M. (1993) J, Biol, Chem, 268, 9824-9838). In the present work we identify the activated G-proteins as G(o)-proteins by tracing their depolarization-induced in situ photoaffinity labeling with [alpha(32)P]GTP-azidoanilide (GTPAA), Labeled GTPAA was introduced into transiently permeabilized rat brainstem synaptoneurosomes. The resealed synaptoneurosomes, while being UV-irradiated, were depolarized. Relative to synaptoneurosomes at resting potential, the covalent binding of [alpha(32)P]GTPAA to G alpha(o1)- and G alpha(o3)-proteins, but not to G alpha(o2)- isoforms, was enhanced by 5- to 7-fold in depolarized synaptoneurosomes, thereby implying an accelerated exchange of GDP for [alpha(32)P]GT-PAA. Their depolarization-induced photoaffinity labeling was independent of stimulation of G(o)-proteincoupled receptors and could be reversed by membrane repolarization, thus excluding induction by transmitters release. It was, however, dependent on depolarization-induced activation of the voltage-gated sodium channels (VGSC), regardless of Na+ current. The alpha subunit of VGSC was cross-linked and co-immunoprecipitated with G alpha(o)-proteins in depolarized brain-stem and cortical synaptoneurosomes. VGSC alpha subunit most efficiently cross-linked with guanosine 5'-O2-thiodiphosphate-bound rather than to guanosine 5'-O-(3-thiotriphosphate)-bound G alpha(o)-proteins in isolated synaptoneurosomal membranes. These findings support a possible involvement of VGSC in depolarization-induced activation of G(o)-proteins.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Cardiac Res Inst, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Free University of Berlin	Cohen-Armon, M (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel.	marmon@post.tau.ac.il		Nurnberg, Bernd/0000-0002-5995-6555				AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHENG K, 1980, J MEMBRANE BIOL, V56, P191, DOI 10.1007/BF01869476; COHEN-ARMON M, 1985, BIOCHEM BIOPH RES CO, V127, P326, DOI 10.1016/S0006-291X(85)80162-5; COHEN-ARMON M, 1986, J BIOL CHEM, V261, P2498; COHEN-ARMON M, 1991, NEUROSCI LETT, V126, P87, DOI 10.1016/0304-3940(91)90378-7; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; DRAPEAU P, 1983, J NEUROSCI, V3, P703; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FERROLUZZI AG, 1976, BIOCHEMISTRY-US, V15, P617; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GURWITZ D, 1985, MOL PHARMACOL, V28, P297; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Klink R, 1997, J NEUROPHYSIOL, V77, P1813, DOI 10.1152/jn.1997.77.4.1813; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA JY, 1994, P NATL ACAD SCI USA, V91, P12351, DOI 10.1073/pnas.91.25.12351; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOORE JW, 1967, J GEN PHYSIOL, V50, P1401, DOI 10.1085/jgp.50.5.1401; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEER EJ, 1994, PROTEIN SCI, V3, P3; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NURNBERG B, 1994, BIOCHEM J, V300, P387; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROMEY G, 1987, P NATL ACAD SCI USA, V84, P896, DOI 10.1073/pnas.84.3.896; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Slutsky I, 1998, EUR J NEUROSCI, V10, P174; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TASAKI I, 1967, AM J PHYSIOL, V213, P1465, DOI 10.1152/ajplegacy.1967.213.6.1465; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trainer VL, 1996, J BIOL CHEM, V271, P11261, DOI 10.1074/jbc.271.19.11261; Urenjak J, 1996, PHARMACOL REV, V48, P21; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WALKER GR, 1995, J NIH RES, V7, P76; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	74	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7431	7440		10.1074/jbc.274.11.7431	http://dx.doi.org/10.1074/jbc.274.11.7431			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066808	hybrid			2022-12-27	WOS:000079078400080
J	Cole, AR; Hall, NE; Treutlein, HR; Eddes, JS; Reid, GE; Moritz, RL; Simpson, RJ				Cole, AR; Hall, NE; Treutlein, HR; Eddes, JS; Reid, GE; Moritz, RL; Simpson, RJ			Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN IL-6 RECEPTOR; SOLUBLE CYTOKINE RECEPTORS; HIGH-AFFINITY BINDING; HUMAN GROWTH-HORMONE; FLAVOBACTERIUM-MENINGOSEPTICUM; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURES; ACETYLGLUCOSAMINIDASE-F	The high affinity interleukin-6 (IL-6) receptor is a hexameric complex consisting of two molecules each of IL-6, IL-6 receptor (IL-6R), and the high affinity converter and signaling molecule, gp130, The extracellular "soluble" part of the IL-GR (sIL-6R) consists of three domains: an amino-terminal Ig-like domain and two fibronectin-type III (FN III) domains. The two FN III domains comprise the cytokine-binding domain defined by a set of 4 conserved cysteine residues and a WSXWS sequence motif. Here, we have determined the disulfide structure of the human sIL-6R by peptide mapping in the absence and presence of reducing agent. Mass spectrometric analysis of these peptides revealed four disulfide bonds and two free cysteines. The disulfides Cys(102)-Cys(113) and Cys(146)-Cys(157),, consistent with known cytokine-binding domain motifs, and Cys(28)-Cys(77) With known Ig superfamily domains. An unusual cysteine connectivity between Cys(6)-Cys(174), which links the Ig-like and NH2-rminal FN III domains causing them to fold back onto each other, has not previously been observed among cytokine receptors, The two free cysteines (Cys(192) and Cys(258)) were detected as cysteinyl-cysteines, although a small proportion of Cys(258) was reactive with the alkylating agent 4-vinylpyridine. Of the four potential N-glycosylation sites, carbohydrate moieties were identified on Asn(36), Asn(74), and Asn(202), but not on Asn(226).	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research	Simpson, RJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Prot Struct Lab, POB 2008, Parkville, Vic 3050, Australia.	Richard.simpson@ludwig.edu.au	Treutlein, Herbert Rudolf/AAC-7648-2021; Eddes, James/F-1670-2011; Cole, Adam/B-9785-2011; Moritz, Robert L/B-9222-2011	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796; Hall, Nathan/0000-0001-8942-0498				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; CHEREL M, 1995, BLOOD, V86, P2534; CLOGSTON CL, 1989, ARCH BIOCHEM BIOPHYS, V272, P144, DOI 10.1016/0003-9861(89)90205-1; Courchesne PL, 1998, ELECTROPHORESIS, V19, P956, DOI 10.1002/elps.1150190611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Elson GCA, 1998, J IMMUNOL, V161, P1371; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUH G, 1990, J BIOL CHEM, V265, P3111; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; Gaillard JP, 1996, IMMUNOLOGY, V89, P135, DOI 10.1046/j.1365-2567.1996.d01-709.x; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Grotzinger J, 1997, PROTEINS, V27, P96; Haniu M, 1996, BIOCHEMISTRY-US, V35, P13040, DOI 10.1021/bi960213u; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRATA Y, 1989, J IMMUNOL, V143, P2900; HONDA M, 1992, J IMMUNOL, V148, P2175; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; JONES SS, 1990, BLOOD, V76, P31; Kalai M, 1996, EUR J BIOCHEM, V238, P714, DOI 10.1111/j.1432-1033.1996.0714w.x; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; Menziani MC, 1997, PROTEINS, V29, P528; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, PROTEINS, P50; SIMPSON RJ, 1988, BIOCHEM BIOPH RES CO, V157, P364, DOI 10.1016/S0006-291X(88)80056-1; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith DK, 1998, PROTEIN SCI, V7, P886; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2423; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WARD LD, 1994, J BIOL CHEM, V269, P23286; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; WARD LD, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P331; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	73	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7207	7215		10.1074/jbc.274.11.7207	http://dx.doi.org/10.1074/jbc.274.11.7207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066782	hybrid			2022-12-27	WOS:000079078400054
J	Lu, ZL; Hulme, EC				Lu, ZL; Hulme, EC			The functional topography of transmembrane domain 3 of the M-1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; CONSTITUTIVELY ACTIVE MUTANTS; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; ANTAGONIST BINDING; ARGININE RESIDUE; ACTIVATION; RHODOPSIN; ASPARTATE	Alanine-scanning mutagenesis has been applied to residues 100-121 in transmembrane domain 3 of the M-1 muscarinic acetylcholine receptor, This study complements a previous investigation of the triad Asp(122)-Arg(123)-Tyr(124) (Lu, Z-L., Curtis, C, A,, Jones, P. G,, Pavia, J., and Hulme, E. C. (1997) Mol. Pharmacol 51, 234-241), The results demonstrate the alpha-helical secondary structure of the domain and suggest its orientation with respect to the other transmembrane domains. The C-terminal part of the helix appears to be largely buried within the receptor structure. On its surface, there is a patch of three residues, Val(113), Leu(116), and Ser(120), which may form intramolecular contacts that help to stabilize the inactive ground state of the receptor. Mutagenic disruption of these increased agonist affinity and signaling efficacy. In two cases (L116A and S120A), this led to constitutive activation of the receptor. Parallel to the helix axis and spanning the whole transmembrane region, a distinct strip of residues on one face of transmembrane domain 3 forms intermolecular (acetylcholine-receptor, receptor-G; protein) or intrareceptor beads that contribute to the activated state. The binding of acetylcholine may destabilize the first set of contacts while favoring the formation of the second.	Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	MRC National Institute for Medical Research	Hulme, EC (corresponding author), Natl Inst Med Res, Div Phys Biochem, Mill Hill, London NW7 1AA, England.			Lu, Zhiliang/0000-0002-3442-1415				Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Hulme EC, 1998, J PHYSIOLOGY-PARIS, V92, P269, DOI 10.1016/S0928-4257(98)80031-4; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; MATSUI H, 1995, MOL PHARMACOL, V47, P88; PAGE KM, 1995, EUR J PHARM-MOLEC PH, V289, P429, DOI 10.1016/0922-4106(95)90151-5; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	32	83	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7309	7315		10.1074/jbc.274.11.7309	http://dx.doi.org/10.1074/jbc.274.11.7309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066794	hybrid			2022-12-27	WOS:000079078400066
J	Sung, JZ; Qian, YM; Chen, Z; Marfurt, J; Hamilton, AD; Sebti, SM				Sung, JZ; Qian, YM; Chen, Z; Marfurt, J; Hamilton, AD; Sebti, SM			The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors - A potential mechanism for GGTI-298 antitumor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GERANYLGERANYLATION; RAS TRANSFORMATION; CDK INHIBITORS; FARNESYLATION; FIBROBLASTS; PRENYLATION; CELLS; G(1); RHO	The geranylgeranyltransferase I inhibitor GGTI-298 has recently been shown to arrest human tumor cells in the G(1) phase of the cell cycle, induce apoptosis, and inhibit tumor growth in nude mice. In the present manuscript, we provide a possible mechanism by which GGTI-298 mediates its tumor growth arrest. Treatment of the human lung carcinoma cell line Calu-1 with GGTI-298 results in inhibition of the phosphorylation of retinoblastoma protein, a critical step for G(1)/S transition. The kinase activities of two G(1)/S cyclin-dependent kinases, CDK2 and CDK4, are inhibited in Calu-1 cells treated with GGTI-298, Furthermore, GGTI-298 has little effect on the expression levels of CDK2, CDK4, CDK6, cyclins D1 and E, but decreases the levels of cyclin A. GGTI-298 increases the levels of the cyclin-dependent kinase inhibitors p21 and p15 and had little effect on those of p27 and p16, Most interesting is the ability of GGTI-298 to induce partner switching for several CDK inhibitors. GGTI-298 promotes binding of p21 and p27 to CDK2 while decreasing their binding to CDK6, Reversal of partner switching and G(1) block was observed after removal of GGTI-298, Furthermore, GGTI-298 treatment results in an increased binding of p15 to CDK4, which is paralleled with decreased binding to p27, The results demonstrate that the GGTI-298-mediated G(1) block in Calu-1 cells involves increased expression and partner switching of CDK inhibitors resulting in inhibition of CDK2 and CDK4, and retinoblastoma protein phosphorylation.	Univ S Florida, Dept Biochem & Mol Biol, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Dept Biochem & Mol Biol, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BOOTA A, 1998, AM J PHYSIOL, V275, pL55; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Miguel K., 1997, CANCER RES, V57, P1846; MUSUNURU K, 1997, CELL CYCLE REGULATOR; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STARK WW, 1999, IN PRESS AM J PHYSL; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zujewski J., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P270	29	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6930	6934						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066746				2022-12-27	WOS:000079078400018
J	Brophy, CM; Dickinson, M; Woodrum, D				Brophy, CM; Dickinson, M; Woodrum, D			Phosphorylation of the small heat shock-related protein, HSP20, in vascular smooth muscles is associated with changes in the macromolecular associations of HSP20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; ALPHA-B-CRYSTALLIN; CONTRACTION; FORM	Cyclic nucleotide-dependent vasorelaxation is associated with increases in the phosphorylation of a small heat shock-related protein, HSP20, We hypothesized that phosphorylation of HSP20 in vascular smooth muscles is associated with alterations in the macromolecular associations of HSP20, Treatment of bovine carotid artery smooth muscles with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, and the adenylate cyclase activator, forskolin, led to increases in the phosphorylation of HSP20 and dissociation of macromolecular aggregates of HSP20, However, 3-isobutyl-1-methylxanthine and forskolin treatment of a muscle that is uniquely refractory to cyclic nucleotide-dependent vasorelaxation, human umbilical artery smooth muscle, did not result in increases in the phosphorylation of HSP20 or to dissociation of macromolecular aggregates. HSP20 can be phosphorylated in vitro by the catalytic subunit of cAMP-dependent protein kinase (PKA) in both carotid and umbilical arteries and this phosphorylation of HSP20 is associated with dissociation of macromolecular aggregates of HSP20. Activation of cyclic nucleotide-dependent signaling pathways does not lead to changes in the macromolecular associations of another small heat shock protein, HSP27. interestingly, the myosin light chains (MLC20) are in similar fractions as the HSP20, and phosphorylation of HSP20 is associated with changes in the macromolecular associations of MLC20. These data suggest that increases in the phosphorylation of HSP20 are associated with changes in the macromolecular associations of HSP20. HSP20 may regulate vasorelaxation through a direct interaction with specific contractile regulatory proteins.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Vet Adm Med Ctr, Augusta, GA 30910 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Brophy, CM (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med, 1120 15th St, Augusta, GA 30912 USA.				NHLBI NIH HHS [R01 HL58027-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058027] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beall AC, 1997, J BIOL CHEM, V272, P11283; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; Brophy CM, 1997, BIOL REPROD, V57, P1354, DOI 10.1095/biolreprod57.6.1354; Brophy CM, 1998, J VASC SURG, V27, P963, DOI 10.1016/S0741-5214(98)70279-4; BROPHY CM, 1999, IN PRESS J VASC SURG; Guay J, 1997, J CELL SCI, V110, P357; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; JERIUS H, 1999, IN PRESS J VASC SURG; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1994, J BIOL CHEM, V269, P15302; LARSEN JK, 1997, AM J PHYSIOL, V273, P930; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Welsh MJ, 1996, BIOL REPROD, V55, P141, DOI 10.1095/biolreprod55.1.141; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	20	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6324	6329		10.1074/jbc.274.10.6324	http://dx.doi.org/10.1074/jbc.274.10.6324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037721	hybrid			2022-12-27	WOS:000078902800043
J	Moss, JM; Reid, GE; Mullin, KA; Zawadzki, JL; Simpson, RJ; McConville, MJ				Moss, JM; Reid, GE; Mullin, KA; Zawadzki, JL; Simpson, RJ; McConville, MJ			Characterization of a novel GDP-mannose : Serine-protein mannose-l-phosphotransferase from Leishmania mexicana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; PROTEOPHOSPHOGLYCAN; AMASTIGOTES; PARASITES; PROMASTIGOTES; PURIFICATION; DONOVANI; EPITOPES	Protozoan parasites of the genus Leishmania secrete a number of glycoproteins and mucin-like proteoglycans that appear to be important parasite virulence factors. We have previously proposed that the polypeptide backbones of these molecules are extensively modified with a complex array of phosphoglycan chains that are linked to Ser/Thr-rich domains via a common Man alpha 1-PO4-Ser Linkage (Ilg, T., Overath, P., Ferguson, M. A J., Rutherford, T,, Campbell, D, G,, and McConville, M, J, (1994) J, Biol. Chem, 269, 24073-24081), In this study, we show that Leishmania mexicana promastigotes contain a peptide-specific mannose-l-phosphotransferase (pep-MPT) activity that adds Man alpha 1-P to serine residues in a range of defined peptides, The presence and location of the Man alpha 1-PO4-Ser linkage in these peptides were determined by electrospray ionization mass spectrometry and chemical and enzymatic treatments. The pep-MPT activity was solubilized in non-ionic detergents, was dependent on Mn2+, utilized GDP-Man as the mannose donor, and was expressed in all developmental stages of the parasite. The pep-MPT activity was maximal against peptides containing Ser/Thr-rich domains of the endogenous accepters and, based on competition assays with oligosaccharide accepters, was distinct from other leishmanial MPTs involved in the initiation and elongation of lipid-linked phosphoglycan chains. In subcellular fractionation experiments, pep-MPT was resolved from the endoplasmic reticulum marker BiP, but had an overlapping distribution with the cis-Golgi marker Rab1, Although Man-PO4 residues in the mature secreted glycoproteins are extensively modified with mannose oligosaccharides and phosphoglycan chains, similar modifications were not added to peptide-linked Man-PO4 residues in the in vitro assays, Similarly, Man-PO4 residues on endogenous polypeptide accepters were also poorly extended, although the elongating enzymes were still active, suggesting that the pep-MPT activity and elongating enzymes may be present in separate subcellular compartments.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	University of Melbourne; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute	McConville, MJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.	m.mcconville@biochemistry.unimelb.edu.au		Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796				Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; BANGS JD, 1993, J CELL SCI, V105, P1101; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; Brown GM, 1996, EUR J BIOCHEM, V242, P410, DOI 10.1111/j.1432-1033.1996.0410r.x; CAPPAI R, 1993, MOL BIOCHEM PARASIT, V62, P73, DOI 10.1016/0166-6851(93)90179-2; CARVER MA, 1991, J BIOL CHEM, V266, P10974; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Haynes PA, 1998, GLYCOBIOLOGY, V8, P1, DOI 10.1093/glycob/8.1.1; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1995, EUR J CELL BIOL, V66, P205; Ilg T, 1998, J BIOL CHEM, V273, P13509, DOI 10.1074/jbc.273.22.13509; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P847, DOI 10.1093/glycob/7.6.847; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P873, DOI 10.1093/glycob/7.7.873-c; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Peters C, 1997, INFECT IMMUN, V65, P783, DOI 10.1128/IAI.65.2.783-786.1997; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; RUSH JS, 1993, J BIOL CHEM, V268, P13110; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; TACK BF, 1980, J BIOL CHEM, V255, P8842; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WEISE M, 1995, EMBO J, V14, P1067; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	38	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6678	6688		10.1074/jbc.274.10.6678	http://dx.doi.org/10.1074/jbc.274.10.6678			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037765	hybrid			2022-12-27	WOS:000078902800087
J	Tsai, WY; Chow, YT; Chen, HR; Huang, KT; Hong, RI; Jan, SP; Kuo, NY; Tsao, TY; Chen, CH; Cheng, SC				Tsai, WY; Chow, YT; Chen, HR; Huang, KT; Hong, RI; Jan, SP; Kuo, NY; Tsao, TY; Chen, CH; Cheng, SC			Cef1p is a component of the Prp19p-associated complex and essential for pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RNAS; PRECURSOR MESSENGER-RNA; PREMESSENGER RNA; SITE REGION; IN-VITRO; C-MYB; SPLICEOSOME; YEAST; PROTEIN; RIBONUCLEOPROTEIN	The Prp19p protein of the budding yeast Saccharomyces cerevisiae is an essential splicing factor and is associated with the spliceosome during the splicing reaction. We have previously shown that Prp19p is not tightly associated with small nuclear ribonucleoprotein particles but is associated with a protein complex consisting of at least eight protein components. By sequencing components of the affinity-purified complex, we have identified Cef1p as a component of the Prp19p-associated complex, Ntc85p, Cef1p could directly interact with Prp19p and was required for pre-mRNA splicing both in vivo and in vitro. The c-Myb DNA binding motif at the amino terminus of Cef1p was required for cellular growth but not for interaction of Cef1p with Prp19p or Cef1p self-interaction. We have identified a small region of 30 amino acid residues near the carboxyl terminus required for both cell viability and protein-protein interactions. Cef1p was associated with the spliceosome in the same manner as Prp19p, i.e. concomitant with or immediately after dissociation of U4, The anti-Cef1p antibody inhibited binding to the spliceosome of Cef1p, Prp19p, and at least three other components of the Prp19p-associated complex, suggesting that the Prp19p-associated complex is likely associated with the spliceosome and functions as an integral complex.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan; Acad Sinica, Inst Mol Biol, Nankang, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Cheng, SC (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan.		Chen, Chun-Hong/E-3990-2010	CHEN, CHUN-HONG/0000-0002-3028-5508				BEGGS JD, 1993, MOL BIOL REP, V18, P99, DOI 10.1007/BF00986763; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHENG SC, 1990, METHOD ENZYMOL, V181, P89; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Guthrie C, 1991, METHODS ENZYMOL, V194; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; Moore M., 1993, RNA WORLD, P303; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PIKIELNY CW, 1986, CELL, V45, P869, DOI 10.1016/0092-8674(86)90561-1; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SAWA H, 1991, NUCLEIC ACIDS RES, V19, P3953, DOI 10.1093/nar/19.14.3953; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506	34	77	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9455	9462		10.1074/jbc.274.14.9455	http://dx.doi.org/10.1074/jbc.274.14.9455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092627	hybrid			2022-12-27	WOS:000079451800046
J	Ellerby, LM; Andrusiak, RL; Wellington, CL; Hackam, AS; Propp, SS; Wood, JD; Sharp, AH; Margolis, RL; Ross, CA; Salvesen, GS; Hayden, MR; Bredesen, DE				Ellerby, LM; Andrusiak, RL; Wellington, CL; Hackam, AS; Propp, SS; Wood, JD; Sharp, AH; Margolis, RL; Ross, CA; Salvesen, GS; Hayden, MR; Bredesen, DE			Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEAT NEURODEGENERATIVE DISEASES; NEURONAL INTRANUCLEAR INCLUSIONS; CAG REPEAT; POLYGLUTAMINE TRACT; GLUTAMINE REPEATS; DRPLA PROTEIN; GENE; HUNTINGTIN; EXPANSION; APOPTOSIS	Dentatorubropallidoluysian atrophy (DRPLA) is one of eight autosomal dominant neurodegenerative disorders characterized by an abnormal CAG repeat expansion which results in the expression of a protein with a polyglutamine stretch of excessive length. We have reported recently that four of the gene products (huntingtin, atrophin-1 (DRPLA), ataxin-3, and androgen receptor) associated with these open reading frame triplet repeat expansions are substrates for the cysteine protease cell death executioners, the caspases, This led us to hypothesize that caspase cleavage of these proteins may represent a common step in the pathogenesis of each of these four neurodegenerative diseases. Here we present evidence that caspase cleavage of atrophin-1 modulates cytotoxicity and aggregate formation. Cleavage of atrophin-1 at Asp(109) by caspases is critical for cytotoxicity because a mutant atrophin-1 that is resistant to caspase cleavage is associated with significantly decreased toxicity. Further, the altered cellular localization within the nucleus and aggregate formation associated with the expanded form of atrophin-1 are completely suppressed by mutation of the caspase cleavage site at Asp(109). These results provide support for the toxic fragment hypothesis whereby cleavage of atrophin-1 by caspases may be an important step in the pathogenesis of DRPLA. Therefore, inhibiting caspase cleavage of the polyglutamine-containing proteins may be a feasible therapeutic strategy to prevent cell death.	Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Burnham Inst, Program Apoptosis, La Jolla, CA 92037 USA; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V52 4H4, Canada; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of British Columbia; Johns Hopkins University; University of California System; University of California San Diego	Bredesen, DE (corresponding author), Burnham Inst, Program Aging, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dbredesen@ljcrf.edu	Wood, Jonathan D/A-5060-2009; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG12282] Funding Source: Medline; NINDS NIH HHS [NS34172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Margolis RL, 1996, MOL BRAIN RES, V36, P219, DOI 10.1016/0169-328X(95)00241-J; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; Nance MA, 1997, BRAIN PATHOL, V7, P881, DOI 10.1111/j.1750-3639.1997.tb00892.x; Nishiyama K, 1997, ANN NEUROL, V41, P599, DOI 10.1002/ana.410410508; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yazawa I, 1997, NEUROSCI LETT, V225, P53, DOI 10.1016/S0304-3940(97)00189-4; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	41	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8730	8736		10.1074/jbc.274.13.8730	http://dx.doi.org/10.1074/jbc.274.13.8730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085113	hybrid			2022-12-27	WOS:000079451600055
J	Pangalos, MN; Neefs, JM; Somers, M; Verhasselt, P; Bekkers, M; van der Helm, L; Fraiponts, E; Ashton, D; Gordon, RD				Pangalos, MN; Neefs, JM; Somers, M; Verhasselt, P; Bekkers, M; van der Helm, L; Fraiponts, E; Ashton, D; Gordon, RD			Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL-L-GLUTAMATE; AEROMONAS-PROTEOLYTICA AMINOPEPTIDASE; TUMOR-SUPPRESSOR GENE; MEMBRANE ANTIGEN; RAT-BRAIN; INSITU HYBRIDIZATION; MOLECULAR-CLONING; ACETYLASPARTYLGLUTAMATE; CELLS; LOCALIZATION	Hydrolysis of the neuropeptide N-acetyl-L-aspartyl-L-glutamate (NAAG) by N-acetylated alpha-linked acidic dipeptidase (NAALADase) to release glutamate may be important in a number of neurodegenerative disorders in which excitotoxic mechanisms are implicated. The gene coding for human prostate-specific membrane antigen, a marker of prostatic carcinomas, and its rat homologue glutamate carboxypeptidase II have recently been shown to possess such NAALADase activity. In contrast, a closely related member of this gene family, rat ileal 100-kDa protein, possesses a dipeptidyl peptidase IV activity. Here, we describe the cloning of human ileal 100-kDa protein, which we have called a NAALADase-"like" (NAALADase L) peptidase based on its sequence similarity to other members of this gene family, and its inability to hydrolyze NAAG in transient transfection experiments. Furthermore, we describe the cloning of a third novel member of this gene family, NAALADase II, which codes for a type II integral membrane protein and which we have localized to chromosome 11 by fluorescent in situ hybridization analysis, Transient transfection of NAALADase II cDNA confers both NAALADase and dipeptidyl peptidase IV activity to COS cells. Expression studies using reverse transcription-polymerase chain reaction and Northern blot hybridization show that NAALADase II is highly expressed in ovary and testis as well as within discrete brain areas.	Janssen Res Fdn, Dept Biotechnol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Biochem, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Neuropsychopharmacol, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson; Johnson & Johnson	Pangalos, MN (corresponding author), SmithKline Beecham Pharmaceut, Neuropharmacol Res, Harlow CM19 5AW, Essex, England.	menelas_n_pangalos@sbphrd.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Banerjee D, 1995, ACTA BIOCHIM POL, V42, P457; BLAKELY RD, 1988, J NEUROCHEM, V50, P1200, DOI 10.1111/j.1471-4159.1988.tb10593.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bzdega T, 1997, J NEUROCHEM, V69, P2270; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CHANDLER CJ, 1986, J BIOL CHEM, V261, P928; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISRAELI RS, 1993, CANCER RES, V53, P227; ISRAELI RS, 1994, CANCER RES, V54, P1807; JAARSMA D, 1994, J NEUROL SCI, V127, P230, DOI 10.1016/0022-510X(94)90077-9; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEEK J, 1995, BRIT J CANCER, V72, P583, DOI 10.1038/bjc.1995.377; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MEYERHOFF JL, 1992, EPILEPSY RES, P163; MEYERHOFF JL, 1985, BRAIN RES, V346, P392, DOI 10.1016/0006-8993(85)90877-7; MISRA BC, 1989, AM J HUM GENET, V45, P565; Passani LA, 1997, BRAIN RES, V772, P9, DOI 10.1016/S0006-8993(97)00784-1; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; PUTTFARCKEN PS, 1993, J PHARMACOL EXP THER, V266, P796; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; ROBINSON MB, 1986, EUR J PHARMACOL, V130, P345, DOI 10.1016/0014-2999(86)90291-8; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; SEKIGUCHI M, 1992, FEBS LETT, V311, P285, DOI 10.1016/0014-5793(92)81121-2; Shneider BL, 1997, J BIOL CHEM, V272, P31006, DOI 10.1074/jbc.272.49.31006; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; SLUSHER S, 1997, SOC NEUR ABSTR; SU SL, 1995, CANCER RES, V55, P1441; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; VALIVULLAH HM, 1994, J NEUROCHEM, V63, P1714; Wroblewska B, 1997, J NEUROCHEM, V69, P174; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x	45	83	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8470	8483		10.1074/jbc.274.13.8470	http://dx.doi.org/10.1074/jbc.274.13.8470			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085079	hybrid			2022-12-27	WOS:000079451600021
J	Qi, HY; Bernstein, HD				Qi, HY; Bernstein, HD			SecA is required for the insertion of inner membrane proteins targeted by the Escherichia coli signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; ER MEMBRANE; 4.5S RNA; TRANSLOCATION; EXPORT; SECRETION; GENE; ATP; RIBONUCLEOPROTEIN	Recent work has demonstrated that the signal recognition particle (SRP) is required for the efficient insertion of many proteins into the Escherichia coli inner membrane (IM), Based on an analogy to eukaryotic SRP, it is likely that bacterial SRP binds to inner membrane proteins (IMPs) co-translationally and then targets them to protein transport channels ("translocons"), Here we present evidence that SecA, which has previously been shown to facilitate the export of proteins targeted in a post-translational fashion, is also required for the membrane insertion of proteins targeted by SRP. The introduction of SecA mutations into strains that have modest SRP deficiencies produced a synthetic lethal effect, suggesting that SecA and SRP might function in the same biochemical pathway. Consistent with this explanation, depletion of SecA by inactivating a temperature-sensitive amber suppressor in a secA(am) strain completely blocked the membrane insertion of AcrB, a protein that is targeted by SRP. In the absence of substantial SecA, pulse-labeled AcrB was retained in the cytoplasm even after a prolonged chase period and was eventually degraded. Although protein export was also severely impaired by SecA depletion, the observation that more than 20% of the OmpA molecules were translocated properly showed that translocons were still active. Taken together, these results imply that SecA plays a much broader role in the transport of proteins across the E. coli IM than has been previously recognized.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D-20, Bethesda, MD 20892 USA.	harris_bernstein@nih.gov						Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Snyders S, 1997, J BIOL CHEM, V272, P11302; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	38	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8993	8997		10.1074/jbc.274.13.8993	http://dx.doi.org/10.1074/jbc.274.13.8993			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085146	hybrid			2022-12-27	WOS:000079451600088
J	Dornberger, U; Leijon, M; Fritzsche, H				Dornberger, U; Leijon, M; Fritzsche, H			High base pair opening rates in tracts of GC base pairs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-EXCHANGE; B-DNA; NMR-SPECTROSCOPY; SEQUENCE; METHYLTRANSFERASE; OLIGONUCLEOTIDES; RESONANCES; EXCITATION; COMPLEXES; CRYSTALS	Sequence-dependent structural features of the DNA double helix have a strong influence on the base pair opening dynamics. Here we report a detailed study of the kinetics of base pair breathing in tracts of GC base pairs in DNA duplexes derived from H-1 NMR measurements of the imino proton exchange rates upon titration with the exchange catalyst ammonia. In the limit of infinite exchange catalyst concentration, the exchange times of the guanine imino protons of the GC tracts extrapolate to much shorter base pair lifetimes than commonly observed for isolated GC base pairs. The base pair lifetimes in the GC tracts are below 5 ms for almost all of the base pairs. The unusually rapid base pair opening dynamics of GC tracts are in striking contrast to the behavior of AT tracts, where very long base pair lifetimes are observed, The implication of these findings for the structural principles governing spontaneous helix opening as well as the DNA-binding specificity of the cytosine-5-methyltransferases, where flipping of the cytosine base has been observed, are discussed.	Stockholm Univ, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden; Univ Jena, Inst Mol Biol, D-07745 Jena, Germany	Stockholm University; Friedrich Schiller University of Jena	Leijon, M (corresponding author), Stockholm Univ, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden.	leijon@biophys.su.se		Leijon, Mikael/0000-0001-8701-9887				BAUER C, 1984, J MAGN RESON, V58, P442, DOI 10.1016/0022-2364(84)90148-3; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; Dornberger U, 1998, J MOL BIOL, V284, P1453, DOI 10.1006/jmbi.1998.2261; Dornberger U, 1997, NUCLEIC ACIDS RES, V25, P822, DOI 10.1093/nar/25.4.822; FOLTASTOGNIEW E, 1994, BIOCHEMISTRY-US, V33, P11016, DOI 10.1021/bi00202a022; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; GMEINER WH, 1995, MAGN RESON CHEM, V33, P449, DOI 10.1002/mrc.1260330607; Gueron M, 1995, METHOD ENZYMOL, V261, P383; GUERON M, 1992, NUCLEIC ACIDS MOL BI, V6, P1; GUERON M, 1990, STRUCTURE METHODS, V3, P113; HEINEMANN U, 1992, EMBO J, V11, P1931, DOI 10.1002/j.1460-2075.1992.tb05246.x; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; HEINEMANN U, 1992, J BIOL CHEM, V267, P7332; KLIMASAUSKAS S, 1995, GENE, V157, P163, DOI 10.1016/0378-1119(94)00624-2; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOCHOYAN M, 1987, J MOL BIOL, V196, P599, DOI 10.1016/0022-2836(87)90036-2; Leijon M, 1996, J MAGN RESON SER B, V112, P181, DOI 10.1006/jmrb.1996.0127; Leijon M, 1997, J MOL BIOL, V271, P438, DOI 10.1006/jmbi.1997.1153; Leijon M, 1997, BIOCHIMIE, V79, P775, DOI 10.1016/S0300-9084(97)86936-2; LEROY JL, 1992, BIOCHEMISTRY-US, V31, P1407, DOI 10.1021/bi00120a017; LEROY JL, 1991, BIOCHEMISTRY-US, V30, P5653, DOI 10.1021/bi00237a003; LEROY JL, 1988, BIOCHEMISTRY-US, V27, P8894, DOI 10.1021/bi00425a004; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Sarkar M, 1997, BIOCHEMISTRY-US, V36, P15463, DOI 10.1021/bi9702243; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	35	121	122	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6957	6962		10.1074/jbc.274.11.6957	http://dx.doi.org/10.1074/jbc.274.11.6957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066749	hybrid			2022-12-27	WOS:000079078400021
J	Huwiler, A; Pfeilschifter, J; van den Bosch, H				Huwiler, A; Pfeilschifter, J; van den Bosch, H			Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; EXTRACELLULAR ATP; INDUCED APOPTOSIS; PROSTAGLANDIN SYNTHESIS; FEEDBACK INHIBITION; ENDOTHELIAL-CELLS; INVOLVEMENT; SYNTHASE; ALPHA	Exogenous NO is able to trigger apoptosis of renal mesangial cells, and thus may contribute to acute lytic phases as well as to resolution of glomerulonephritis. However, the mechanism involved in these events is still unclear. We report here that chronic exposure of renal mesangial cells for 24 h to compounds releasing NO, including spermine-NO, (Z)-1-(N-methyl-N-[6-(N-methylammoniohexyl)-amino])diazen-1-ium-1,2-diolate (MAHMA-NO), S-nitrosoglutathione (GS-NO), and S-nitroso-N-acetyl-D,L-penicillamine (SNAP) results in a potent and dose-dependent increase in the lipid signaling molecule ceramide, Time courses reveal that significant effects occur after 2-4 h of stimulation with NO donors and reach maximal levels after 24 h of stimulation, No acute (within minutes) ceramide production can be detected. When cells were stimulated with NO donors in the presence of phorbol ester, a direct activator of protein kinase C, both ceramide production and DNA fragmentation are completely abolished. Furthermore, addition of exogenous ceramide partially reversed the inhibitory effect of phorbol ester on apoptosis, thus suggesting a negative regulation of protein kinase C on ceramide formation and apoptosis, In contrast to exogenous NO, tumor necrosis factor (TNF)-alpha stimulates a very rapid and transient increase in ceramide levels within minutes but fails to induce the late-phase ceramide formation. Moreover, TNF fails to induce apoptosis in mesangial cells. Interestingly, NO and TNF alpha cause a chronic activation of acidic and neutral sphingomyelinases, the ceramide-generating enzymes, whereas acidic and neutral ceramidases, the ceramide-metabolizing enzymes, are inhibited by NO, but potently stimulated by TNF alpha, Furthermore, in the presence of an acidic ceramidase inhibitor, N-oleoylethanolamine, TNF alpha leads to a sustained accumulation of ceramide and in parallel induces DNA fragmentation. In summary, our data demonstrate that exogenous NO causes a chronic up-regulation of ceramide levels in mesangial cells by activating sphingomyelinases and concomitantly inhibiting ceramidases, and that particularly the late-phase of ceramide generation may be responsible for the further processing of a proapoptotic signal.	Univ Frankfurt Klinikum, Zentrum Pharmakol, Inst Pharmacol & Toxicol, D-60590 Frankfurt, Germany; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Utrecht University	Huwiler, A (corresponding author), Univ Frankfurt Klinikum, Zentrum Pharmakol, Inst Pharmacol & Toxicol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	huwiler@em.uni-frankfurt.de						ALBINA JE, 1993, J IMMUNOL, V150, P5080; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cattell V, 1995, Curr Opin Nephrol Hypertens, V4, P359, DOI 10.1097/00041552-199507000-00013; CATTELL V, 1993, EXP NEPHROL, V1, P265; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Dawson VL, 1996, J NEUROSCI, V16, P2479; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; FEHSEL K, 1995, J IMMUNOL, V155, P2858; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Huwiler A, 1997, KIDNEY INT, V52, P329, DOI 10.1038/ki.1997.338; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; MULSCH A, 1991, METHOD ENZYMOL, V195, P377; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Nitsch DD, 1997, AM J PATHOL, V150, P889; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OCHSNER M, 1993, EUR J PHARM-MOLEC PH, V245, P15, DOI 10.1016/0922-4106(93)90164-5; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PFEILSCHIFTE RJ, 1995, KIDNEY INT, V51, pS50; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PFEILSCHIFTER J, 1990, CELL SIGNAL, V2, P129; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 1998, KIDNEY INT, V54, pS34, DOI 10.1046/j.1523-1755.1998.06707.x; Pfeilschifter J, 1996, FEBS LETT, V396, P67, DOI 10.1016/0014-5793(96)01070-8; Sandau K, 1996, CELL SIGNAL, V8, P173, DOI 10.1016/0898-6568(95)02051-9; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	45	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7190	7195		10.1074/jbc.274.11.7190	http://dx.doi.org/10.1074/jbc.274.11.7190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066779	hybrid			2022-12-27	WOS:000079078400051
J	Kruth, HS; Zhang, WY; Skarlatos, SI; Chao, FF				Kruth, HS; Zhang, WY; Skarlatos, SI; Chao, FF			Apolipoprotein B stimulates formation of monocyte-macrophage surface-connected compartments and mediates uptake of low density lipoprotein-derived liposomes into these compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; RECEPTOR-RELATED PROTEIN; RICH LIPID PARTICLES; HUMAN ATHEROSCLEROTIC LESIONS; UNESTERIFIED CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODIES; HYPERLIPIDEMIC RABBIT; BETA-VLDL; ACCUMULATION	Much of the cholesterol that accumulates in atherosclerotic plaques is found within monocyte-macrophages transforming these cells into "foam cells." Native low density lipoprotein (LDL) does not cause foam cell formation. Treatment of LDL with cholesterol esterase converts LDL into cholesterol-rich liposomes having >90% cholesterol in unesterified form. Similar cholesterol-rich liposomes are found in early developing atherosclerotic plaques surrounding foam cells. We now show that cholesterol-rich liposomes produced from cholesterol esterase-treated LDL can cause human monocyte-macrophage foam cell formation inducing a 3-5-fold increase in macrophage cholesterol content of which >60% is esterified. Although cytochalasin D inhibited LDL liposome-induced macrophage cholesteryl ester accumulation, LDL liposomes did not enter macrophages by phagocytosis. Rather, the LDL liposomes induced and entered surface-connected compartments within the macrophages, a unique endocytic pathway in these cells that we call patocytosis, LDL liposome apoB rather than LDL liposome lipid mediated LDL liposome uptake by macrophages, This was shown by the findings that: 1) protease treatment of the LDL liposomes prevented macrophage cholesterol accumulation; 2) liposomes prepared from LDL lipid extracts did not cause macrophage cholesterol accumulation; and 3) purified apoB induced and accumulated within macrophage surface-connected compartments. Although apoB mediated the macrophage uptake of LDL liposomes, this uptake did not occur through LDL, LDL receptor-related protein, or scavenger receptors, Also, LDL liposome uptake was not sensitive to treatment of macrophages with trypsin or heparinase, Cholesterol esterase-mediated transformation of LDL into cholesterol-rich liposomes is an LDL modification that: 1) stimulates uptake of LDL cholesterol by apoB-dependent endocytosis into surface-connected compartments, and 2) causes human monocyte-macrophage foam cell formation.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002832, ZIAHL002832] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; CAREW TE, 1978, BIOCHIM BIOPHYS ACTA, V529, P171, DOI 10.1016/0005-2760(78)90115-7; CHAO FF, 1988, AM J PATHOL, V131, P73; CHAO FF, 1992, J BIOL CHEM, V267, P4992; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAMBLE W, 1978, J LIPID RES, V19, P1068; GREVE H, 1988, J BIOL CHEM, V263, P12886; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1984, AM J PATHOL, V114, P201; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; LUNDBERG B, 1984, J LIPID RES, V25, P550; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; MORA R, 1990, J LIPID RES, V31, P1793; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; OBUNIKE JC, 1994, J BIOL CHEM, V269, P13129; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Seo T, 1997, J LIPID RES, V38, P765; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; SHECHTER I, 1981, J LIPID RES, V22, P63; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1994, J BIOL CHEM, V269, P22547; TERTOV VV, 1992, CIRC RES, V71, P218, DOI 10.1161/01.RES.71.1.218; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; WALSH MT, 1983, BIOCHEMISTRY-US, V22, P3170, DOI 10.1021/bi00282a021; WIKLUND O, 1985, J BIOL CHEM, V260, P956; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; XU XX, 1991, J BIOL CHEM, V266, P24849; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	46	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7495	7500		10.1074/jbc.274.11.7495	http://dx.doi.org/10.1074/jbc.274.11.7495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066816	hybrid			2022-12-27	WOS:000079078400088
J	Magyar, A; Zhang, XD; Abdi, F; Kohn, H; Widger, WR				Magyar, A; Zhang, XD; Abdi, F; Kohn, H; Widger, WR			Identifying the bicyclomycin binding domain through biochemical analysis of antibiotic-resistant Rho proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; DEPENDENT TRANSCRIPTION TERMINATION; RNP1-LIKE SEQUENCE MOTIF; ESCHERICHIA-COLI; OLIGONUCLEOTIDE COFACTORS; BIOLOGICAL PROPERTIES; MICROCOCCUS-LUTEUS; HELICASE ACTIVITY; ATPASE ACTIVITY; RNA	Mutations M219K, S266A, and G337S in transcription termination factor Rho have been shown to confer resistance to the antibiotic bicyclomycin (BCM). All three His-tagged mutant Rho proteins exhibited similar K-m values for ATP; however, the V-max values at infinite ATP concentrations were one-fourth to one-third that for the His-tagged wild-type enzyme. BCM inhibition kinetics of poly(C)-dependent ATPase activity for the mutant proteins were non-competitive with respect to ATP (altering catalytic function but not ATP binding) and showed increased K-i values compared with His-tagged wildtype Rho, M219K and G337S exhibited increased ratios of poly(U)/poly(C)-stimulated ATPase activity and lower apparent K-m values for ribo(C)(10) in the poly(dC) ribo(C)(10)ependent ATPase assay compared with His-tagged wild-type Rho. The S266A mutation did not show an increased poly(U)/poly(C) ATPase activity ratio and maintained approximately the same K-m for ribo(C)(10) in the poly(dC). ribo(C)(10)- dependent ATPase assay, The kinetic studies indicated that M219K and G337S altered the secondary RNA binding domain in Rho whereas the S266A mutation did not. Transcription termination assays for each mutant showed different patterns of Rho-terminated transcripts. Tyrosine substitution of Ser-266 led to BCM sensitivity intimating that an OH (hydroxyl) moiety at this position is needed for BCM (binding) inhibition. Our results suggest BCM binds to Rho at a site distinct from both the ATP and the primary RNA binding domains but close to the secondary RNA-binding (tracking) site and the ATP hydrolysis pocket.	Univ Houston, Dept Chem, Houston, TX 77204 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Widger, WR (corresponding author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77204 USA.	hkohn@uh.edu; widger@uh.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1191; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Carrano L, 1998, ANTIMICROB AGENTS CH, V42, P571, DOI 10.1128/AAC.42.3.571; Cho HJ, 1997, J ORG CHEM, V62, P5432, DOI 10.1021/jo970575n; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; ISEKI M, 1980, J ANTIBIOT, V33, P488, DOI 10.7164/antibiotics.33.488; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAMIYA T, 1972, J ANTIBIOT, V25, P576, DOI 10.7164/antibiotics.25.576; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MIYAMURA S, 1973, J ANTIBIOT, V26, P479, DOI 10.7164/antibiotics.26.479; MIYAMURA S, 1972, J ANTIBIOT, V25, P610, DOI 10.7164/antibiotics.25.610; MIYOSHI T, 1980, J ANTIBIOT, V33, P480, DOI 10.7164/antibiotics.33.480; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; NISHIDA M, 1972, J ANTIBIOT, V25, P594, DOI 10.7164/antibiotics.25.594; NISHIDA M, 1972, J ANTIBIOT, V25, P582, DOI 10.7164/antibiotics.25.582; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; Nowatzke WL, 1997, J BACTERIOL, V179, P5238, DOI 10.1128/jb.179.16.5238-5240.1997; Park H, 1996, J ORG CHEM, V61, P7764, DOI 10.1021/jo961004i; Park H, 1996, J ORG CHEM, V61, P7750, DOI 10.1021/jo961002y; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; Riba I, 1998, J BIOL CHEM, V273, P34033, DOI 10.1074/jbc.273.51.34033; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; Santillan A, 1998, J MED CHEM, V41, P1185, DOI 10.1021/jm9708386; Santillan A, 1996, J ORG CHEM, V61, P7756, DOI 10.1021/jo961003q; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SHARP JA, 1983, J BIOL CHEM, V258, P3482; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; TSURUSHITA N, 1984, MOL GEN GENET, V196, P458, DOI 10.1007/BF00436193; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG Y, 1993, J BIOL CHEM, V268, P13940; WANG Y, 1993, J BIOL CHEM, V268, P13947; WILLIAMS RM, 1988, CHEM REV, V88, P511, DOI 10.1021/cr00085a004; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YAGER TD, 1998, MOL CELL BIOL E COLI, P1241; ZHANG Z, 1994, J CHEM SOC CHEM COMM, P1334; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	57	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7316	7324		10.1074/jbc.274.11.7316	http://dx.doi.org/10.1074/jbc.274.11.7316			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066795	hybrid			2022-12-27	WOS:000079078400067
J	Woodrow, CJ; Penny, JI; Krishna, S				Woodrow, CJ; Penny, JI; Krishna, S			Intraerythrocytic Plasmodium falciparum expresses a high affinity facilitative hexose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; POLYMERASE-CHAIN-REACTION; EXOFACIAL LIGAND-BINDING; INFECTED ERYTHROCYTES; MALARIA PARASITE; XENOPUS OOCYTES; MEMBRANE; CHANNEL; INVITRO; ACID	Asexual stages of Plasmodium falciparum cause severe malaria and are dependent upon host glucose for energy. We have identified a glucose transporter of P. falciparum (PfHT1) and studied its function and expression during parasite development in vitro. PfHT1 is a saturable, sodium-independent, and stereospecific transporter, which is inhibited by cytochalasin B, and has a relatively high affinity for glucose (K-m = 0.48 mM) when expressed in Xenopus laevis oocytes, Competition experiments with glucose analogues show that hydroxyl groups at positions C-3 and C-4 are important for ligand binding. mRNA levels for PfHT1, assessed by the quantitative technique of tandem competitive polymerase chain reaction, are highest during the small ring stages of infection and lowest in gametocytes. Confocal immunofluorescence microscopy localizes PfHT1 to the region of the parasite plasma membrane and not to host structures. These findings have implications for development of new drug targets in malaria as well as for understanding of the pathophysiology of severe infection. When hypoglycemia complicates malaria, modeling studies suggest that the high affinity of PfHT1 is likely to increase the relative proportion of glucose taken up by parasites and thereby worsen the clinical condition.	St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	St Georges University London	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, Cranmer Terrace, London SW17 0RE, England.			Krishna, Sanjeev/0000-0003-0066-0634; Woodrow, Charles/0000-0002-5134-7165				BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Goodyer ID, 1997, MOL BIOCHEM PARASIT, V84, P229, DOI 10.1016/S0166-6851(96)02802-2; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KIRK K, 1994, J BIOL CHEM, V269, P3339; Kirk K, 1996, MOL BIOCHEM PARASIT, V82, P195, DOI 10.1016/0166-6851(96)02734-X; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; Pardridge William M., 1993, P395; Penny JI, 1998, MOL BIOCHEM PARASIT, V93, P81, DOI 10.1016/S0166-6851(98)00024-3; Pinder JC, 1998, J CELL SCI, V111, P1831; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; Price R, 1997, MOL BIOCHEM PARASIT, V85, P161, DOI 10.1016/S0166-6851(96)02822-8; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; TRAGER W, 1992, P NATL ACAD SCI USA, V89, P5351, DOI 10.1073/pnas.89.12.5351; VIRDI AS, 1992, MOL CELL PROBE, V6, P375, DOI 10.1016/0890-8508(92)90030-2; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; ZOLG JW, 1984, IN VITRO CELL DEV B, V20, P205, DOI 10.1007/BF02618189	26	103	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7272	7277		10.1074/jbc.274.11.7272	http://dx.doi.org/10.1074/jbc.274.11.7272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066789	hybrid, Green Published			2022-12-27	WOS:000079078400061
J	Coccia, EM; Passini, N; Battistini, A; Pini, C; Sinigaglia, F; Rogge, L				Coccia, EM; Passini, N; Battistini, A; Pini, C; Sinigaglia, F; Rogge, L			Interleukin-12 induces expression of interferon regulatory factor-1 via signal transducer and activator of transcription-4 in human T helper type 1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; NF-KAPPA-B; TH2 CELLS; FACTOR-I; IMMUNE-RESPONSES; NATURAL-KILLER; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; FACTOR IRF-1; IL-12	IRF-1-deficient mice show a striking defect in the development of T helper 1 (Th1) cells. In the present report, we investigate the expression of IRF-1 during differentiation of human T helper cells. No significant differences of IRF-1 mRNA expression were found in established Th1 and Th2 cells; however, interleukin 12 (IL-12) induced a strong up-regulation of IRF-1 transcripts in Th1 but not in Th2 cells. We demonstrate that IL-12-induced up-regulation of IRF-1 is mediated by signal transducer and activator of transcription-4, which binds to the interferon (IFN)-gamma-activated sequence present in the promoter of the IRF-1 gene. Strong IL-12-dependent activation of a reporter gene construct containing the IRF-1 IFN-gamma-activated sequence element provides further evidence for the key role of signal transducer and activator of transcription-4 in the IL-12-induced up-regulation of IRF-1 transcripts in T cells. IRF-1 expression was strongly induced after stimulation of naive CD4(+) T cells via the T cell receptor, irrespective of the cytokines present at priming, indicating that this transcription factor does not play a major role in initiating a Th1-specific transcriptional cascade in differentiating helper T cells. However, our finding that IRF-1 is a target gene of IL-12 suggests that some of the IL-12-induced effector functions of Th1 cells may be mediated by IRF-1.	Roche Milano Ric, I-20132 Milan, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy	Roche Holding; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Rogge, L (corresponding author), Roche Milano Ric, Via Olgettina 58, I-20132 Milan, Italy.		BATTISTINI, ANGELA/C-2944-2016; Rogge, Lars/GYJ-6142-2022; Coccia, Eliana M/B-4752-2013	Coccia, Eliana M/0000-0002-1606-2949; Rogge, Lars/0000-0003-1262-9204				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Cho SS, 1996, J IMMUNOL, V157, P4781; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Groux H, 1997, J IMMUNOL, V158, P5627; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; Hilkens CMU, 1996, J IMMUNOL, V157, P4316; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Huang H, 1998, J EXP MED, V187, P1305, DOI 10.1084/jem.187.8.1305; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Rincon M, 1997, CURR BIOL, V7, pR729, DOI 10.1016/S0960-9822(06)00368-X; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rogge L, 1998, J IMMUNOL, V161, P6567; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamamoto K, 1997, BIOCHEM BIOPH RES CO, V233, P126, DOI 10.1006/bbrc.1997.6415; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	59	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6698	6703		10.1074/jbc.274.10.6698	http://dx.doi.org/10.1074/jbc.274.10.6698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037767	hybrid			2022-12-27	WOS:000078902800089
J	Hussein, AS; Chacon, MR; Smith, AM; Tosado-Acevedo, R; Selkirk, ME				Hussein, AS; Chacon, MR; Smith, AM; Tosado-Acevedo, R; Selkirk, ME			Cloning, expression, and properties of a nonneuronal secreted acetylcholinesterase from the parasitic nematode Nippostrongylus brasiliensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM CHOLINESTERASE; CAENORHABDITIS-ELEGANS; TORPEDO-CALIFORNICA; PERIPHERAL SITE; MOLECULAR-FORMS; DISULFIDE BONDS; CDNA SEQUENCE; GENE; PROTEIN; IDENTIFICATION	We have isolated a full-length cDNA encoding an acetylcholinesterase secreted by the nematode parasite Nippostrongylus brasiliensis. The predicted protein is truncated in comparison with acetylcholinesterases from other organisms such that the carboxyl terminus aligns closely to the end of the catalytic domain of the vertebrate enzymes. The residues in the catalytic triad are conserved, as are the six cysteines which form the three intramolecular disulfide bonds. Three of the fourteen aromatic residues which line the active site gorge in the Torpedo enzyme are substituted by nonaromatic residues, corresponding to Tyr-70 (Thr), Trp-279 (Asn), and Phe-288 (Met), High level expression was obtained via secretion from Pichia pastoris. The purified enzyme behaved as a monomeric hydrophilic species. Although of invertebrate origin and possessing the above substitutions in the active site gorge residues, the enzyme efficiently hydrolyzed acetylthiocholine and showed minimal activity against butyrylthiocholine, It displayed excess substrate inhibition with acetylthiocholine at concentrations over 2.5 mM and was highly sensitive to both active site and "peripheral" site inhibitors, Northern blot analysis indicated a progressive increase in mRNA for AChE B in parasites isolated from 6 days postinfection.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	Imperial College London	Selkirk, ME (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.	m.selkirk@ic.ac.uk	Chacón, Matilde R./E-5574-2019	Chacón, Matilde R./0000-0003-1531-2165; Selkirk, Murray/0000-0002-6274-6014	FIC NIH HHS [T37-TW00046] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [T37TW000046] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; AUSTIN L, 1953, BIOCHEM J, V54, P695, DOI 10.1042/bj0540695; BLACKBURN CC, 1992, MOL BIOCHEM PARASIT, V53, P79, DOI 10.1016/0166-6851(92)90009-9; BRADBURY JE, 1980, EUR J PHARMACOL, V68, P417, DOI 10.1016/0014-2999(80)90416-1; BURT JS, 1975, EXP PARASITOL, V38, P75, DOI 10.1016/0014-4894(75)90039-9; COOKE HJ, 1994, AM J PHYSIOL, V266, pG167, DOI 10.1152/ajpgi.1994.266.2.G167; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Cousin X, 1996, FEBS LETT, V387, P196, DOI 10.1016/0014-5793(96)00447-4; CULOTTI JG, 1981, GENETICS, V97, P281; EDWARDS AJ, 1971, PARASITOLOGY, V62, P339, DOI 10.1017/S0031182000071572; EICHLER J, 1994, MOL PHARMACOL, V45, P335; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; Grauso M, 1998, FEBS LETT, V424, P279, DOI 10.1016/S0014-5793(98)00191-4; GRIFFITHS G, 1994, PARASITOLOGY, V108, P579, DOI 10.1017/S0031182000077441; Grigg ME, 1997, MOL BIOCHEM PARASIT, V90, P513, DOI 10.1016/S0166-6851(97)00202-8; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; JOHNSON CD, 1981, GENETICS, V97, P261; JOHNSON CD, 1988, NEURON, V1, P165, DOI 10.1016/0896-6273(88)90201-2; JOHNSON CD, 1983, J NEUROCHEM, V41, P30, DOI 10.1111/j.1471-4159.1983.tb11811.x; JOHNSON CD, 1985, J NEUROSCI, V5, P1984; JONES VE, 1972, IMMUNOLOGY, V22, P119; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; LEE D L, 1970, Tissue and Cell, V2, P225, DOI 10.1016/S0040-8166(70)80017-9; Lee DL, 1996, INT J PARASITOL, V26, P499, DOI 10.1016/0020-7519(96)00040-9; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MACPHEEQUIGLEY K, 1987, FASEB J, V46, P2150; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCLAREN D J, 1974, International Journal for Parasitology, V4, P39, DOI 10.1016/0020-7519(74)90007-1; Morel N, 1997, BIOCHEM J, V328, P121, DOI 10.1042/bj3280121; OGILVIE B M, 1973, International Journal for Parasitology, V3, P589, DOI 10.1016/0020-7519(73)90083-0; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PRITCHARD DI, 1994, EUR J BIOCHEM, V219, P317, DOI 10.1111/j.1432-1033.1994.tb19943.x; PRITCHARD DI, 1991, PARASITE IMMUNOL, V13, P187, DOI 10.1111/j.1365-3024.1991.tb00274.x; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; RHOADS M L, 1984, Tropical Veterinarian, V2, P3; RHOADS ML, 1981, J BIOL CHEM, V256, P9316; RIMELE TJ, 1981, J PHARMACOL EXP THER, V218, P426; Sanderson B E, 1972, Int J Parasitol, V2, P227, DOI 10.1016/0020-7519(72)90010-0; SANDERSON BE, 1972, Z PARASITENK, V40, P1, DOI 10.1007/BF00329610; SANDERSON BE, 1971, PARASITOLOGY, V62, P367, DOI 10.1017/S0031182000077519; SATOH Y, 1992, CELL TISSUE RES, V269, P213, DOI 10.1007/BF00319611; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SEGERBERG MA, 1993, J GEN PHYSIOL, V101, P271, DOI 10.1085/jgp.101.2.271; SOREQ H, 1994, P NATL ACAD SCI USA, V91, P7907, DOI 10.1073/pnas.91.17.7907; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4670; TWEEDIE S, 1993, MOL BIOCHEM PARASIT, V61, P149, DOI 10.1016/0166-6851(93)90168-W; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	56	67	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9312	9319		10.1074/jbc.274.14.9312	http://dx.doi.org/10.1074/jbc.274.14.9312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092608	hybrid			2022-12-27	WOS:000079451800027
J	Brown, NR; Noble, MEM; Lawrie, AM; Morris, MC; Tunnah, P; Divita, G; Johnson, LN; Endicott, JA				Brown, NR; Noble, MEM; Lawrie, AM; Morris, MC; Tunnah, P; Divita, G; Johnson, LN; Endicott, JA			Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; CELL-CYCLE; DUAL PHOSPHORYLATION; PEPTIDE SUBSTRATE; BUDDING YEAST; S-PHASE	We have prepared phosphorylated cyclin-dependent protein kinase 2 (CDK2) for crystallization using the CDK-activating kinase 1 (CAK1) from Saccharomyces cerevisiae and have grown crystals using microseeding techniques. Phosphorylation of monomeric human CDK2 by CAK1 is more efficient than phosphorylation of the binary CDK2-cyclin A complex. Phosphorylated CDK2 exhibits histone H1 kinase activity corresponding to approximately 0.3% of that observed with the fully activated phosphorylated CDK2-cyclin A complex. Fluorescence measurements have shown that Thr(160) phosphorylation increases the affinity of CDK2 for both histone substrate and ATP and decreases its affinity for ADP, By contrast, phosphorylation of CDK2 has a negligible effect on the affinity for cyclin A. The crystal structures of the ATP-bound forms of phosphorylated CDK2 and unphosphorylated CDK2 have been solved at 2.1-Angstrom resolution. The structures are similar, with the major difference occurring in the activation segment, which is disordered in phosphorylated CDK2, The greater mobility of the activation segment in phosphorylated CDK2 and the absence of spontaneous crystallization suggest that phosphorylated CDK2 may adopt several different mobile states. The majority of these states are likely to correspond to inactive conformations, but a small fraction of phosphorylated CDK2 may be in an active conformation and hence explain the basal activity observed.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; CNRS, Ctr Rech Biochem Macromol, F-34293 Montpellier, France	University of Oxford; University of Oxford; Centre National de la Recherche Scientifique (CNRS)	Endicott, JA (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.		MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728; Noble, Martin/0000-0002-3595-9807; Endicott, Jane/0000-0003-4868-0116				BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREK W, 1992, NEW BIOL, V4, P323; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LORCA T, 1992, J CELL SCI, V102, P55; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	57	191	201	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8746	8756		10.1074/jbc.274.13.8746	http://dx.doi.org/10.1074/jbc.274.13.8746			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085115	Green Published, hybrid			2022-12-27	WOS:000079451600057
J	Crass, T; Ames, RS; Sarau, HM; Tornetta, MA; Foley, JJ; Kohl, J; Klos, A; Bautsch, W				Crass, T; Ames, RS; Sarau, HM; Tornetta, MA; Foley, JJ; Kohl, J; Klos, A; Bautsch, W			Chimeric receptors of the human C3a receptor and C5a receptor (CD88)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; EXPRESSION CLONING; ANAPHYLATOXIN; CELLS; ANALOGS; REGION; SITE; C3A-ANAPHYLATOXIN; ACTIVATION; DISTINCT	Chimeras were generated between the human anaphylatoxin C3a and C5a receptors (C3aR and C5aR, respectively) to define the structural requirements for ligand binding and discrimination. Chimeric receptors were generated by systematically exchanging between the two receptors four receptor modules (the N terminus, transmembrane regions 1 to 4, the second extracellular loop, and transmembrane region 5 to the C terminus). The mutants were transiently expressed in HEK293 cells (with or without G alpha-16) and analyzed for cell surface expression, binding of C3a and C5a, and functional responsiveness (calcium mobilization) toward C3a, C5a, and a C3a as well as a C5a analogue peptide. The data indicate that in both anaphylatoxin receptors the transmembrane regions and the second extracellular loop act as a functional unit that is disrupted by any reciprocal exchange. N-terminal substitution confirmed the two-binding site model for the human C5aR, in which the receptor N terminus is required for high affinity binding of the native ligand but not a C5a analogue peptide, In contrast, the human C3a receptor did not require the original N terminus for high affinity binding of and activation by C3a, a result that was confirmed by N-terminal deletion mutants. This indicates a completely different binding mode of the anaphylatoxins to their corresponding receptors. The C5a analogue peptide, but not C5a, was an agonist of the C5aR. Replacement of the C3aR N terminus by the C5aR sequence, however, lead to the generation of a true hybrid C3a/C5a receptor, which bound and functionally responded to both ligands, C3a and C5a.	Hannover Med Sch, Inst Med Microbiol, D-30623 Hannover, Germany; SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA	Hannover Medical School; GlaxoSmithKline; GlaxoSmithKline	Bautsch, W (corresponding author), Hannover Med Sch, Inst Med Microbiol, Carl Neuberg Str 1, D-30623 Hannover, Germany.		Koehl, Joerg/C-8531-2011	Koehl, Joerg/0000-0003-1121-3178				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Ames RS, 1997, IMMUNOPHARMACOLOGY, V38, P87, DOI 10.1016/S0162-3109(97)00079-9; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; CHAZIN WJ, 1988, BIOCHEMISTRY-US, V27, P9139, DOI 10.1021/bi00426a011; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; EMBER JA, 1992, J IMMUNOL, V148, P3165; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HUBER R, 1980, H-S Z PHYSIOL CHEM, V361, P1389, DOI 10.1515/bchm2.1980.361.2.1389; KOHL J, 1993, COMPLEMENT HLTH DIS, P299; Lienenklaus S, 1998, J IMMUNOL, V161, P2089; MERY L, 1994, J BIOL CHEM, V269, P3457; MONK PN, 1995, J BIOL CHEM, V270, P16625, DOI 10.1074/jbc.270.28.16625; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Werfel T, 1996, J IMMUNOL, V157, P1729; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	28	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8367	8370		10.1074/jbc.274.13.8367	http://dx.doi.org/10.1074/jbc.274.13.8367			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085065	hybrid			2022-12-27	WOS:000079451600007
J	Doornbos, RP; Theelen, M; van der Hoeven, PCJ; van Blitterswijk, WJ; Verkleij, AJ; Henegouwen, PMPVE				Doornbos, RP; Theelen, M; van der Hoeven, PCJ; van Blitterswijk, WJ; Verkleij, AJ; Henegouwen, PMPVE			Protein kinase C zeta is a negative regulator of protein kinase B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; BETA-GAMMA-SUBUNITS; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; AKT PROTOONCOGENE; INDUCED APOPTOSIS	Protein kinase B (PKB), also known as Akt or RAC-PK, is a serine/threonine kinase that can be activated by growth factors via phosphatidylinositol 3-kinase. In this article we show that PKC zeta but not PKC alpha and PKC delta can co-immunoprecipitate PKB from CHO cell lysates. Association of PKB with PKC zeta was also found in COS-1 cells transiently expressing PKB and PKC zeta, and moreover we found that this association is mediated by the AH domain of PKB. Stimulation of COS-1 cells with platelet-derived growth factor (PDGF) resulted in a decrease in the PKB-PKC zeta interaction. The use of kinase-inactive mutants of both kinases revealed that dissociation of the complex depends upon PKB activity. Analysis of the activities of the interacting kinases showed that PDGF-induced activation of PKC zeta was not affected by co expression of PKB. However, both PDGF- and p110-CAAX-induced activation of PKB were significantly abolished in cells co-expressing PKC zeta. In contrast, co-expression of a kinase-dead PKC zeta mutant showed an increased induction of PKB activity upon PDGF treatment. Downstream signaling of PKB, such as the inhibition of glycogen synthase kinase-3, was also reduced by coexpression of PKC zeta. A clear inhibitory effect of PKC zeta was found on the constitutively active double PKB mutant (T308D/S473D). In summary, our results demonstrate that PKB interacts with PKC zeta in vivo and that PKC zeta acts as a negative regulator of PKB.	Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Netherlands Canc Inst, Dept Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Netherlands Cancer Institute	Henegouwen, PMPVE (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands.	bergenp@bio.uu.nl	van Bergen en Henegouwen, Paul/B-8870-2011	van Bergen en Henegouwen, Paul/0000-0001-6050-9042				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P244; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHOU MM, 1998, CURR BIOL, V6, P1271; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	42	121	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8589	8596		10.1074/jbc.274.13.8589	http://dx.doi.org/10.1074/jbc.274.13.8589			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085094	hybrid			2022-12-27	WOS:000079451600036
J	Matkovic-Calogovic, D; Loregian, A; D'Acunto, MR; Battistutta, R; Tossi, A; Palu, G; Zanotti, G				Matkovic-Calogovic, D; Loregian, A; D'Acunto, MR; Battistutta, R; Tossi, A; Palu, G; Zanotti, G			Crystal structure of the B subunit of Escherichia coli heat-labile enterotoxin carrying peptides with anti-herpes simplex virus type 1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; CHOLERA-TOXIN; RIBONUCLEOTIDE REDUCTASE; CARBOXY-TERMINUS; FUSION PROTEINS; C-TERMINUS; A-SUBUNIT; INHIBITION; BINDING; VIBRIO	Two chimeric proteins, consisting of the B subunit of Escherichia coli heat-labile enterotoxin with different peptides fused to the COOH-terminal ends, have been crystallized and their three-dimensional structure determined. The two extensions correspond to la) a nonapeptide representing the COOH-terminal sequence of the small subunit of herpes simplex virus type 1 ribonucleotide reductase and (b) a 27-amino acid long peptide, corresponding to the COOH-terminal end of the catalytic subunit (POL) of DNA polymerase from the same virus. Both proteins crystallize in the P4(1)2(1)2 space group with one pentameric molecule per asymmetric unit, corresponding to a solvent content of about 75%. The overall conformation of the B subunit pentamer in the two chimeric proteins, which consists of five identical polypeptide chains, is very similar to that in the native AB complex and conforms strictly to 5-fold symmetry. On the contrary, the peptide extensions are essentially disordered: in the case of the nonapeptide, only 5 and 6 amino acids were, respectively, positioned in two monomers, while in the other three only 2 residues are ordered. The extension is fully confined to the surface of the pentamer opposite to the face that interacts with the membrane and consequently it does not interfere with the ability of the B subunit to interact with membrane receptors, Moreover, the conformational flexibility of the two peptide extensions could be correlated to their propensity for proteolytic processing and consequent release of a biologically active molecule into cultured cells.	Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Padua, Biopolymer Res Ctr, I-35131 Padua, Italy; Univ Padua, Inst Microbiol, I-35121 Padua, Italy; Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy	University of Padua; University of Padua; University of Padua; University of Trieste	Matkovic-Calogovic, D (corresponding author), Univ Padua, Dept Organ Chem, Via Marzolo 1, I-35131 Padua, Italy.		Tossi, Alessandro/U-2474-2017; Tossi, Alessandro/ABC-9061-2020	Tossi, Alessandro/0000-0001-9087-5764; LOREGIAN, ARIANNA/0000-0002-8900-861X; Zanotti, Giuseppe/0000-0002-0945-6501				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; FERGUSSON LF, 1990, BACTERIAL PROTEIN TO, P519; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HIRST TR, 1991, SOURCE BOOK BACTERIA, P75; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Loregian A, 1996, PROTEIN EXPRES PURIF, V8, P381, DOI 10.1006/prep.1996.0114; Loregian A, 1997, MINERVA BIOTECNOL, V9, P61; LOREGIAN A, 1995, BIOCHEM SOC T, V23, pS61, DOI 10.1042/bst023061s; MARCELLO A, 1994, P NATL ACAD SCI USA, V91, P8994, DOI 10.1073/pnas.91.19.8994; MARCELLO A, 1994, FEMS MICROBIOL LETT, V117, P47, DOI 10.1016/0378-1097(94)90169-4; MARSDEN HS, 1994, J GEN VIROL, V75, P3127, DOI 10.1099/0022-1317-75-11-3127; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1995, NAT STRUCT BIOL, V2, P269, DOI 10.1038/nsb0495-269; Merritt EA, 1997, STRUCTURE, V5, P1485, DOI 10.1016/S0969-2126(97)00298-0; MERRITT EA, 1994, FEBS LETT, V337, P88, DOI 10.1016/0014-5793(94)80635-7; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; NASHAR TO, 1993, VACCINE, V11, P235, DOI 10.1016/0264-410X(93)90023-Q; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLSVIK O, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P5; PARADIS H, 1988, J BIOL CHEM, V263, P16045; PIZZA M, 1994, J EXP MED, V180, P2147, DOI 10.1084/jem.180.6.2147; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; TAKEDA Y, 1983, INFECT IMMUN, V41, P50, DOI 10.1128/IAI.41.1.50-53.1983; VandenAkker F, 1996, PROTEIN SCI, V5, P1184; VANDENAKKER F, 1995, BIOCHEMISTRY-US, V34, P10996, DOI 10.1021/bi00035a005; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	41	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8764	8769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085117				2022-12-27	WOS:000079451600059
J	Roy, CN; Penny, DM; Feder, JN; Enns, CA				Roy, CN; Penny, DM; Feder, JN; Enns, CA			The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN HEPATOMA-CELLS; HISTOCOMPATIBILITY ANTIGENS; INTERNALIZATION MOTIF; SURFACE EXPRESSION; INDEPENDENT UPTAKE; INSULIN-RECEPTORS; HLA-H; RELEASE; COMPLEX	HFE is the protein product of the gene mutated in the autosomal recessive disease hereditary hemochromatosis (Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R. J., Ellis, M. C., Fullan, A., Hinton, L. M., Jones, N. L., Kimmel, B. E., Kronmal, G. S., Lauer, P., Lee, V. K., Loeb, D. B., Mapa, F. A., McClelland, E., Meyer, N. C., Mintier, G. A., Moeller, N., Moore, T., Morikang, E., Prasss, C. E., Quintana, L., Starnes, S. M., Schatzman, R. C., Brunke, K. J., Drayna, D. T., Risch, N. J., Bacon, B. R., and Wolff, R. R, (1996) Nat. Genet. 13, 399-408). At the cell surface, HFE complexes with transferrin receptor (TfR), increasing the dissociation constant of transferrin (Tf) for its receptor 10-fold (Gross, C. N., Irrinki, A., Feder, J. N., and Enns, C. A. (1998) J. Biol. Chem. 273, 22068-22074; Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebron, J. A., Watson, N., Tsuchihashi, Z., Sigal, E., Bjorkman, P. J., and Schatzman, R. C. (1998) Proc. Natl. Acad. Sci. U S A 95, 1472-1477). HFE does not remain at the cell surface, but traffics with TfR to Tf-positive internal compartments (Gross ct at, 1998). Using a HeLa cell line in which the expression of HFE is controlled by tetracycline, we show that the expression of HFE reduces Fe-55 uptake from Tf by 33% but does not affect the endocytic or exocytic rates of TfR cycling. Therefore, HFE appears to reduce cellular acquisition of iron from Tf within endocytic compartments. HFE specifically reduces iron uptake from Tf, as non-Tf-mediated iron uptake from Fe-nitrilotriacetic acid is not altered. These results explain the decreased ferritin levels seen in our HeLa cell system and demonstrate the specific control of HFE over the Tf-mediated pathway of iron uptake. These results also have implications for the understanding of cellular iron homeostasis in organs such as the liver, pancreas, heart, and spleen that are iron loaded in hereditary hemochromatotic individuals lacking functional HFE.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Progenitor Inc, Menlo Park, CA 94025 USA	Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, L215,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL00781] Funding Source: Medline; NIDDK NIH HHS [DK 40608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BALI PK, 1992, BIOCHEMISTRY-US, V31, P3963, DOI 10.1021/bi00131a011; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; Enns C.A., 1996, BIOMEMBRANE, V4, P255, DOI [10.1016/S1874-5342(96)80012-2, DOI 10.1016/S1874-5342(96)80012-2]; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; Ferm M, 1996, IMMUNOL INVEST, V25, P37, DOI 10.3109/08820139609059289; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; INMAN RS, 1993, J BIOL CHEM, V268, P8521; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lok CN, 1998, BIOL SIGNAL RECEPT, V7, P157; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PENHALLOW RC, 1986, J CELL PHYSIOL, V128, P251, DOI 10.1002/jcp.1041280217; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P3474, DOI 10.1073/pnas.83.10.3474; PLANASBOHNE F, 1988, INT J RADIAT BIOL, V53, P489, DOI 10.1080/09553008814552611; Ponka P, 1998, SEMIN HEMATOL, V35, P35; SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SHAH D, 1994, J DRUG TARGET, V2, P93, DOI 10.3109/10611869409015897; SIPE DM, 1991, J BIOL CHEM, V266, P8002; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Trinder D, 1996, HEPATOLOGY, V23, P1512, DOI 10.1002/hep.510230631; VERLAND S, 1989, J IMMUNOL, V143, P945; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	43	184	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9022	9028		10.1074/jbc.274.13.9022	http://dx.doi.org/10.1074/jbc.274.13.9022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085150	hybrid			2022-12-27	WOS:000079451600092
J	Xin, XH; Yang, SY; Kowalski, J; Gerritsen, ME				Xin, XH; Yang, SY; Kowalski, J; Gerritsen, ME			Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; ENDOTHELIAL GROWTH-FACTOR; PPAR-GAMMA; CANCER; ALPHA; DIFFERENTIATION; CELLS; REGULATOR; BIOLOGY; J(2)	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that functions as a transcription factor to mediate ligand-dependent transcriptional regulation. Activation of PPAR gamma by the naturally occurring ligand, 15-deoxy-Delta 12,14-prostaglandin J(2) (15d-PGJ(2)), or members of a new class of oral antidiabetic agents, e.g. BRL49653 and ciglitizone, has been linked to adipocyte differentiation, regulation of glucose homeostasis, inhibition of macrophage and monocyte activation, and inhibition of tumor cell proliferation. Here we report that human umbilical vein endothelial cells (HUVEC) express PPAR gamma mRNA and protein. Activation of PPAR gamma by the specific ligands 15d-PGJ(2), BRL49653, or ciglitizone, dose dependently suppresses HUVEC differentiation into tube-like structures in three-dimensional collagen gels. In contrast, specific PPAR alpha and -beta ligands do not affect tube formation although mRNA for these receptors are expressed in HUVEC. PPAR gamma ligands also inhibit the proliferative response of HUVEC to exogenous growth factors. Treatment of HUVEC with 15d-PGJ(2) also reduced mRNA levels of vascular endothelial cell growth factor receptors 1 (Flt-1) and 2 (Flk/KDR) and urokinase plasminogen activator and increased plasminogen activator inhibitor-1 (PAI-1) mRNA. Finally, administration of 15d-PGJ(2) inhibited vascular endothelial cell growth factor-induced angiogenesis in the rat cornea. These observations demonstrate that PPAR gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo, and suggest that PPAR gamma may be an important molecular target for the development of small-molecule inhibitors of angiogenesis.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Gerritsen, ME (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.	meg@gene.com						Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; EISTNER E, 1998, P NATL ACAD SCI USA, V95, P8806; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FOLKMAN J, 1986, CANCER RES, V46, P467; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ilan N, 1998, J CELL SCI, V111, P3621; Inoue I, 1998, BIOCHEM BIOPH RES CO, V246, P370, DOI 10.1006/bbrc.1998.8622; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Johnson W, 1997, J MATER PROCESS TECH, V63, P1, DOI 10.1016/S0924-0136(96)02594-0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kubota T, 1998, CANCER RES, V58, P3344; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237	32	459	502	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9116	9121		10.1074/jbc.274.13.9116	http://dx.doi.org/10.1074/jbc.274.13.9116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085162	hybrid			2022-12-27	WOS:000079451600104
J	Mohana-Borges, R; Silva, JL; de Prat-Gay, G				Mohana-Borges, R; Silva, JL; de Prat-Gay, G			Protein folding in the absence of chemical denaturants - Reversible pressure denaturation of the noncovalent complex formed by the association of two protein fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATE; HYDROPHOBIC CORE; ARC REPRESSOR; DISSOCIATION; FLUORESCENCE; SPECTROSCOPY; EQUILIBRIUM; STABILITY; NUCLEASE	Small monomeric proteins are the best models for studying protein folding, but they are often too stable for denaturation using pressure as the sole perturbant. In the present work we subject [CI-2(1-40).(41-64)], a noncovalent complex formed by the association of two complementary fragments of the chymotrypsin inhibitor-2, to high pressure to investigate the folding mechanism of a model protein. Pressures up to 3.5 kilobar do not affect the intact protein, but it can be unfolded reversibly by pressure in the presence of subdenaturing concentrations of guanidine chloride, with free energy and molar volume changes of 2.5 kcal mol(-1) and 42.5 ml mol(-1), respectively. In contrast, the complex can be reversibly denatured by high pressure without the addition of chemical denaturants. However, the process is clearly independent of the protein concentration, indicating lack of dissociation. We determined a change in the free energy of 1.4 kcal mol(-1) and a molar volume change of 35 ml mol(-1) for the pressure denaturation of the complex. A persistent quenching of the tryptophan adds further evidence for the presence of residual structure in the high pressure-denatured state. This state also appears to be compact as the small volume change indicates, compared with pressure denaturation of naturally occurring dimers, Based on observations of a number of pressure-denatured states and on characteristics of large CI-2 fragments with a solvent accessible core but maintaining tertiary interactions, the structure of the pressure-denatured state of the CI-2 complex could be explained by an ordered molten globule-like conformation.	Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; Univ Fed Rio de Janeiro, Dept Bioquim Med, ICB, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil	Leloir Institute; Universidade Federal do Rio de Janeiro	de Prat-Gay, G (corresponding author), Fdn Campomar, Inst Invest Bioquim, Av Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	pratgay@iris.iib.uba.ar	SILVA, JERSON Lima/GRF-1442-2022; Silva, Jerson/J-8984-2014; Borges, Ronaldo S Mohana/C-5575-2013	SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441; Prat Gay, Gonzalo/0000-0001-5748-6863				de Prat Gay G, 1994, Proc Natl Acad Sci U S A, V91, P10943; DEPRATGAY G, 1996, ARCH BIOCHEM BIOPHYS, V334, P1; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P1193, DOI 10.1021/bi00219a005; Foguel D, 1998, J BIOL CHEM, V273, P9050, DOI 10.1074/jbc.273.15.9050; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7957, DOI 10.1021/bi00191a024; GAY GD, 1995, P NATL ACAD SCI USA, V92, P3683, DOI 10.1073/pnas.92.9.3683; GAY GD, 1995, J MOL BIOL, V254, P968, DOI 10.1006/jmbi.1995.0669; GAY GD, 1994, PROTEIN ENG, V7, P103; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7964, DOI 10.1021/bi00191a025; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; LETILLY V, 1992, EUR J BIOCHEM, V205, P1061; LI TM, 1976, BIOCHEMISTRY-US, V15, P5571, DOI 10.1021/bi00670a023; LUDVIGSEN S, 1991, J MOL BIOL, V222, P621, DOI 10.1016/0022-2836(91)90500-6; MCPHALEN CA, 1987, BIOCHEMISTRY-US, V26, P261, DOI 10.1021/bi00375a036; Mok YK, 1996, PROTEIN SCI, V5, P310; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Neira JL, 1996, FOLD DES, V1, P189, DOI 10.1016/S1359-0278(96)00031-4; Neira JL, 1997, J MOL BIOL, V268, P185, DOI 10.1006/jmbi.1997.0932; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PALADINI AA, 1994, ANAL BIOCHEM, V218, P364, DOI 10.1006/abio.1994.1193; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; Panick G, 1998, J MOL BIOL, V275, P389, DOI 10.1006/jmbi.1997.1454; PENG XD, 1994, BIOCHEMISTRY-US, V33, P8323, DOI 10.1021/bi00193a020; PREVELIGE PE, 1994, BIOPHYS J, V66, P1631, DOI 10.1016/S0006-3495(94)80955-5; ROYER CA, 1993, BIOCHEMISTRY-US, V32, P5222, DOI 10.1021/bi00070a034; Royer CA, 1995, METHOD ENZYMOL, V259, P357; RUIZSANZ J, 1995, BIOCHEMISTRY-US, V34, P1695, DOI 10.1021/bi00005a026; SAMARASINGHE SD, 1992, BIOCHEMISTRY-US, V31, P7773, DOI 10.1021/bi00149a005; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; Weber G., 1992, PROTEIN INTERACTIONS	39	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7732	7740		10.1074/jbc.274.12.7732	http://dx.doi.org/10.1074/jbc.274.12.7732			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075663	hybrid			2022-12-27	WOS:000079268100022
J	Humphreys, DT; Carver, JA; Easterbrook-Smith, SB; Wilson, MR				Humphreys, DT; Carver, JA; Easterbrook-Smith, SB; Wilson, MR			Clusterin has chaperone-like activity similar to that of small heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOPROTEIN-2; HUMAN PLASMA; APOLIPOPROTEIN-J/CLUSTERIN; ALPHA-CRYSTALLIN; EPITHELIAL-CELLS; TESTIS FLUID; COMPLEMENT; STRESS; DEATH; EXPRESSION	Clusterin is a highly conserved protein which is expressed at increased levels by many cell types in response to a broad variety of stress conditions. A genuine physiological function for clusterin has not yet been established. The results presented here demonstrate for the first time that clusterin has chaperone-like activity. At physiological concentrations, clusterin potently protected glutathione S-transferase and catalase from heat-induced precipitation and alpha-lactalbumin and bovine serum albumin from precipitation induced by reduction with dithiothreitol. Enzyme-linked immunosorbent assay data showed that clusterin bound preferentially to heat-stressed glutathione S-transferase and to dithiothreitol-treated bovine serum albumin and alpha-lactalbumin. Size exclusion chromatography and SDS-polyacrylamide gel electrophoresis analyses showed that clusterin formed high molecular weight complexes (HMW) with all four proteins tested. Small heat shock proteins (sHSP) also act in this way to prevent protein precipitation and protect cells from heat and other stresses. The stoichiometric subunit molar ratios of clusterin:stressed protein during formation of HMW complexes (which for the four proteins tested ranged from 1.0:1.3 to 1.0:11) is less than the reported ratios for sHSP-mediated formation of HMW complexes (1.0:1.0 or greater), indicating that clusterin is a very efficient chaperone. Our results suggest that clusterin may play a sHSP-like role in cytoprotection.	Univ Wollongong, Dept Sci Biol, Wollongong, NSW 2522, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Wollongong; University of Wollongong; University of Sydney	Wilson, MR (corresponding author), Univ Wollongong, Dept Sci Biol, Northfields Ave, Wollongong, NSW 2522, Australia.	Mark_Wilson@uow.edu.au	Carver, John Adrian/J-3825-2014; Wilson, Mark R/B-3254-2018	Carver, John Adrian/0000-0002-2441-8108; Wilson, Mark R/0000-0002-9551-7445; Humphreys, David/0000-0003-4140-0089				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; Arrigo AP, 1998, BIOL CHEM, V379, P19; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CHOI NH, 1989, MOL IMMUNOL, V26, P835; Clark AM, 1997, J ANDROL, V18, P257; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; FRITZ IB, 1993, TRENDS ENDOCRIN MET, V4, P41, DOI 10.1016/S1043-2760(05)80013-X; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P1049; Humphreys D, 1997, BIOCHEMISTRY-US, V36, P15233, DOI 10.1021/bi9703507; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Kapron JT, 1997, PROTEIN SCI, V6, P2120; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; Kimura K, 1997, CELL BIOCHEM FUNCT, V15, P251, DOI 10.1002/(SICI)1099-0844(199712)15:4<251::AID-CBF748>3.0.CO;2-3; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Michel D, 1997, J CELL SCI, V110, P1635; OBRYAN MK, 1990, J CLIN INVEST, V85, P1477, DOI 10.1172/JCI114594; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Pankhurst GJ, 1998, BIOCHEMISTRY-US, V37, P4823, DOI 10.1021/bi972367v; Partridge SR, 1996, INFECT IMMUN, V64, P4324, DOI 10.1128/IAI.64.10.4324-4329.1996; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Silkensen JR, 1995, J CLIN INVEST, V96, P2646, DOI 10.1172/JCI118330; SILKENSEN JR, 1994, BIOCHEM CELL BIOL, V72, P483, DOI 10.1139/o94-065; TSCHOPP J, 1993, J IMMUNOL, V151, P2159; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; WILSON MR, 1993, ANAL BIOCHEM, V209, P183, DOI 10.1006/abio.1993.1100; WILSON MR, 1995, MECH INDUCTION FUNCT, P75; [No title captured]	44	359	368	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6875	6881		10.1074/jbc.274.11.6875	http://dx.doi.org/10.1074/jbc.274.11.6875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066740	hybrid			2022-12-27	WOS:000079078400012
J	Malin, G; Iakobashvili, R; Lapidot, A				Malin, G; Iakobashvili, R; Lapidot, A			Effect of tetrahydropyrimidine derivatives on protein nucleic acids interaction - Type II restriction endonucleases as a model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; PRODUCER STREPTOMYCES-PARVULUS; ECO-RI ENDONUCLEASE; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; HALOPHILIC EUBACTERIA; COMPATIBLE SOLUTES; MAGNETIC-RESONANCE; DNA RECOGNITION; STRESS	2-Methyl-4-carboxy,5-hydroxy-3,4,5,6-tetrahydropyrimidine (THP(A) or hydroxyectoine) and 2-methyl,4-carboxy-3, 4,5,6-tetrahydropyrimidine (THP(B) or ectoine) are now recognized as ubiquitous bacterial osmoprotectants, To evaluate the impact of tetrahydropyrimidine derivatives (THPs) on protein-DNA interaction and on restriction-modification systems, we have examined their effect on the cleavage of plasmid DNA by 10 type II restriction endonucleases. THP(A) completely arrested the cleavage of plasmid and bacteriophage A DNA by EcoRI endonuclease at 0.4 mM and the oligonucleotide (d(CGCGAATTCGCG))(2) at about 4.0 mM. THP(B) was 10-fold less effective than THP(A), whereas for betaine and proline, a notable inhibition was observed only at 100 mM, Similar effects of THP(A) were observed for all tested restriction endonucleases, except for SmaI and PvuII, which were inhibited only partially at 50 mM THP(A), No effect of THP(A) on the activity of DNase I, RNase A, and Tag DNA polymerase was noticed. Gel-shift assays showed that THP(A) inhibited the EcoRI-(d-(CGCGAATTCGCG))(2) complex formation, whereas facilitated diffusion of EcoRI along the DNA was not affected. Methylation of the carboxy group significantly decreased the activity of THPs, suggesting that their zwitterionic character is essential for the inhibition effect. Possible mechanisms of inhibition, the role of THPs in the modulation of the protein-DNA interaction, and the in vivo relevance of the observed phenomena are discussed.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Lapidot, A (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.	colapidot@wiccmail.weizmann.ac.il						BAILEY CR, 1986, J GEN MICROBIOL, V132, P2945; BUCHE A, 1993, J BIOMOL STRUCT DYN, V11, P95, DOI 10.1080/07391102.1993.10508712; Canovas D, 1997, J BIOL CHEM, V272, P25794, DOI 10.1074/jbc.272.41.25794; Capp MW, 1996, J MOL BIOL, V258, P25, DOI 10.1006/jmbi.1996.0231; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Connolly B A, 1994, Methods Mol Biol, V30, P371; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P78; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; ENGEL P, 1987, APPL ENVIRON MICROB, V53, P1; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Flock S, 1996, BIOPHYS J, V71, P1519, DOI 10.1016/S0006-3495(96)79354-2; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GALINSKI EA, 1993, EXPERIENTIA, V49, P487, DOI 10.1007/BF01955150; GALINSKI EA, 1985, EUR J BIOCHEM, V149, P135, DOI 10.1111/j.1432-1033.1985.tb08903.x; GALINSKI EA, 1991, NATO ADV SCI I A-LIF, V201, P351; GREENE PJ, 1975, J MOL BIOL, V99, P237, DOI 10.1016/S0022-2836(75)80143-4; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HAMANA K, 1987, FEMS MICROBIOL LETT, V41, P211; HEITMAN J, 1989, P NATL ACAD SCI USA, V86, P2281, DOI 10.1073/pnas.86.7.2281; INBAR L, 1988, J BIOL CHEM, V263, P16014; INBAR L, 1988, J BACTERIOL, V170, P4055, DOI 10.1128/jb.170.9.4055-4064.1988; INBAR L, 1991, J BACTERIOL, V173, P7790, DOI 10.1128/jb.173.24.7790-7801.1991; INBAR L, 1993, EUR J BIOCHEM, V214, P897, DOI 10.1111/j.1432-1033.1993.tb17993.x; JEBBAR M, 1992, J BACTERIOL, V174, P5027, DOI 10.1128/JB.174.15.5027-5035.1992; Jeltsch A, 1996, EMBO J, V15, P5104, DOI 10.1002/j.1460-2075.1996.tb00891.x; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LAI MC, 1991, J BACTERIOL, V173, P5352, DOI 10.1128/jb.173.17.5352-5358.1991; LAPIDOT A, 1998, Patent No. 123256; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; Louis P, 1997, MICROBIOL-UK, V143, P1141, DOI 10.1099/00221287-143-4-1141; Malin G, 1996, J BACTERIOL, V178, P385, DOI 10.1128/jb.178.2.385-395.1996; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PINGOUD A, 1984, BIOCHEMISTRY-US, V23, P5697, DOI 10.1021/bi00319a006; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Rajendrakumar CSV, 1997, FEBS LETT, V410, P201, DOI 10.1016/S0014-5793(97)00588-7; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RODRIGUEZ RJ, 1993, ANAL BIOCHEM, V209, P291, DOI 10.1006/abio.1993.1122; Sambrook J., 1989, MOL CLONING, pA1; SCHAFER A, 1994, J BACTERIOL, V176, P7309; SCHOBERT B, 1978, BIOCHIM BIOPHYS ACTA, V541, P270, DOI 10.1016/0304-4165(78)90400-2; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TALIBART R, 1994, J BACTERIOL, V176, P5210, DOI 10.1128/JB.176.17.5210-5217.1994; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WELLS RD, 1981, ENZYMES A, V14, P157; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WITHERS BE, 1995, J BIOL CHEM, V270, P6496, DOI 10.1074/jbc.270.12.6496; WOHLFARTH A, 1990, J GEN MICROBIOL, V136, P705, DOI 10.1099/00221287-136-4-705	59	33	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6920	6929		10.1074/jbc.274.11.6920	http://dx.doi.org/10.1074/jbc.274.11.6920			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066745	hybrid			2022-12-27	WOS:000079078400017
J	Sutor, SL; Vroman, BT; Armstrong, EA; Abraham, RT; Karnitz, LM				Sutor, SL; Vroman, BT; Armstrong, EA; Abraham, RT; Karnitz, LM			A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; T-CELL LINE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; B-RAF; 3-KINASE; PHOSPHORYLATION; FAMILY; AKT; INHIBITION	Cytokines trigger the rapid assembly of multimolecular signaling complexes that direct the activation of downstream protein kinase cascades. Two protein kinases that have been linked to growth factor-regulated proliferation and survival are mitogen-activated protein/ERK kinase (MEK) and its downstream target Erk, a member of the mitogen-activated protein kinase family. Using complementary pharmacological and genetic ap preaches, we demonstrate that MEK and Erk activation requires a phosphatidylinositol 3-kinase (PI3-K)-generated signal in an interleukin (IL)-3-dependent myeloid progenitor cell line. Analysis of the upstream pathway leading to MEK activation revealed that inhibition of PI3-K did not block c-Raf activation, whereas MEK activation was effectively blocked under these conditions. Furthermore, agents that elevated cAMP suppressed IL-3-induced c-Raf activation but did not inhibit MEK activation. Because c-Raf activation and MEK activation were inversely affected by PI3-K- and cAMP-dependent pathways, we examined whether IL-3 activated the alternative Raf isoforms A-Raf and B-Raf, Although IL-3 did not activate B-Raf, A-Raf was activated by the cytokine, Moreover, A-Raf activation, like MEK activation, was blocked by inhibition of PI3-K but was insensitive to cAMP. Experiments with dominant negative mutants of the Raf isoforms showed that overexpression of dominant negative c-Raf did not prevent MEK activation. However, dominant negative A-Raf effectively blocked MEK activation, suggesting that activation of the MEK-Erk signaling cascade is mediated through A-Raf Taken together, these results suggest that IL-3 receptors engage and activate both c-Raf and A-Raf in hemopoietic cells. However, these intermediates are differentially regulated by upstream signaling cascades and selectively coupled to downstream signaling pathways.	Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Radiat Oncol, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu			NCI NIH HHS [CA73622, CA52995] Funding Source: Medline; NIGMS NIH HHS [GM73161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073622, U19CA052995, U01CA052995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM RT, 1986, J TISSUE CULTURE MET, V10, P93; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; EYCHENE A, 1995, ONCOGENE, V10, P1159; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KARNITZ LM, 1995, CURR OPIN IMMUNOL, V7, P320, DOI 10.1016/0952-7915(95)80105-7; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; OKADA T, 1994, J BIOL CHEM, V269, P3563; POWIS G, 1994, CANCER RES, V54, P2419; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STORM SM, 1990, ONCOGENE, V5, P345; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	44	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7002	7010		10.1074/jbc.274.11.7002	http://dx.doi.org/10.1074/jbc.274.11.7002			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066754	hybrid			2022-12-27	WOS:000079078400026
J	Diaz, V; Rojo, F; Martinez, C; Alonso, JC; Bernad, A				Diaz, V; Rojo, F; Martinez, C; Alonso, JC; Bernad, A			The prokaryotic beta-recombinase catalyzes site-specific recombination in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYOGENES PLASMID PSM19035; DNA RECOMBINATION; BACILLUS-SUBTILIS; CRE RECOMBINASE; TRANSGENIC MICE; PROTEIN HBSU; MOUSE GENOME; T-CELLS; LOX; PURIFICATION	The development of new strategies for the in vivo modification of eukaryotic genomes has become an important objective of current research. Site-specific recombination has proven useful, as it allows controlled manipulation of murine, plant, and yeast genomes, Here we provide the first evidence that the prokaryotic site-specific recombinase (beta-recombinase), which catalyzes only intramolecular recombination, is active in eukaryotic environments. beta-Recombinase, encoded by the beta gene of the Gram-positive broad host range plasmid pSM19035, has been functionally expressed in eukaryotic cell lines, demonstrating high avidity for the nuclear compartment and forming a clear speckled pattern when assayed by indirect immunofluorescence, In simian COS-1 cells, transient beta-recombinase expression promoted deletion of a DNA fragment lying between two directly oriented specific recognition/crossing over sequences (six sites) located as an extrachromosomal DNA substrate. The same result was obtained in a recombination-dependent lacZ activation system tested in a cell Line that stably expresses the beta-recombinase protein. In stable NIH/3T3 clones bearing different number of copies of the target sequences integrated at distinct chromosomal locations, transient beta-recombinase expression also promoted deletion of the intervening DNA, independently of the insertion position of the target sequences. The utility of this new recombination tool for the manipulation of eukaryotic genomes, used either alone or in combination with the other recombination systems currently in use, is discussed.	CSIC, Dept Inmunol & Oncol, E-28049 Madrid, Spain; CSIC, Dept Biotecnol Microbiana, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bernad, A (corresponding author), CSIC, Dept Inmunol & Oncol, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.	abernad@cnb.uam.es	Rojo, Fernando/A-7038-2008; Alonso, Juan Carlos/D-2595-2009; Bernad, Antonio/P-8573-2017	Rojo, Fernando/0000-0003-1848-7745; Alonso, Juan Carlos/0000-0002-5178-7179; Bernad, Antonio/0000-0003-0620-9668				ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ALONSO JC, 1995, MOL MICROBIOL, V18, P471, DOI 10.1111/j.1365-2958.1995.mmi_18030471.x; ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; CEGLOWSKI P, 1993, GENE, V136, P1, DOI 10.1016/0378-1119(93)90441-5; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905, DOI 10.1073/pnas.89.17.7905; Grasser KD, 1997, EUR J BIOCHEM, V249, P70; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Maniatis T., 1982, MOL CLONING; MEDBERRY SL, 1995, NUCLEIC ACIDS RES, V23, P485, DOI 10.1093/nar/23.3.485; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLIGAN RC, 1979, NATURE, V277, P108, DOI 10.1038/277108a0; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; OSBORNE BI, 1995, PLANT J, V7, P687, DOI 10.1046/j.1365-313X.1995.7040687.x; PICHEL JG, 1993, ONCOGENE, V8, P3333; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROJO F, 1995, NUCLEIC ACIDS RES, V23, P3181, DOI 10.1093/nar/23.16.3181; ROJO F, 1993, FEBS LETT, V328, P169, DOI 10.1016/0014-5793(93)80987-6; ROJO F, 1994, J MOL BIOL, V238, P159, DOI 10.1006/jmbi.1994.1278; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1990, New Biologist, V2, P441; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376	35	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6634	6640		10.1074/jbc.274.10.6634	http://dx.doi.org/10.1074/jbc.274.10.6634			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037759	hybrid			2022-12-27	WOS:000078902800081
J	Knapp, JE; Oliveira, MA; Xie, Q; Ernst, SR; Riggs, AF; Hackert, ML				Knapp, JE; Oliveira, MA; Xie, Q; Ernst, SR; Riggs, AF; Hackert, ML			The structural and functional analysis of the hemoglobin D component from chicken	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE REFINEMENT; OXYGEN-AFFINITY; CRYSTAL-STRUCTURE; HUMAN DEOXYHEMOGLOBIN; ORGANIC-PHOSPHATES; AREA DETECTOR; BLOOD; RESOLUTION; BINDING; ASSOCIATION	Oxygen binding by chicken blood shows enhanced cooperativity at high levels of oxygen saturation. This implies that deoxy hemoglobin tetramers self-associate. The crystal structure of an R-state form of chicken hemoglobin D has been solved to 2.3-Angstrom resolution using molecular replacement phases derived from human oxyhemoglobin. The model consists of an alpha(2)beta(2) tetramer in the asymmetric unit and has been refined to a R-factor of 0.222 (R-free = 0.257) for 29,702 reflections between 10,0- and 2.3-Angstrom resolution. Chicken Hb D differs most from human oxyhemoglobin in the AB and GH corners of the alpha subunits and the EF corner of the beta subunits, Reanalysis of published oxygen binding data for chicken Hbs shows that both chicken Hb A and Hb D possess enhanced cooperativity in vitro when inositol hexaphosphate is present. The electrostatic surface potential for a calculated model of chicken deoxy-Hb D tetramers shows a pronounced hydrophobic patch that involves parts of the D and E helices of the beta subunits, This hydrophobic patch is a promising candidate for a tetramer-tetramer interface that could regulate oxygen binding via the distal histidine.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hackert, ML (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.							ANDERSEN ME, 1971, J BIOL CHEM, V246, P4800; ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BALDWIN JM, 1980, J MOL BIOL, V136, P103, DOI 10.1016/0022-2836(80)90308-3; Bardgard A, 1997, COMP BIOCHEM PHYS B, V117, P225, DOI 10.1016/S0305-0491(97)00094-1; BAUMANN R, 1982, J APPL PHYSIOL, V53, P1439, DOI 10.1152/jappl.1982.53.6.1439; BEHLKE J, 1970, FEBS LETT, V7, P177, DOI 10.1016/0014-5793(70)80150-8; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BERNER NJ, 1988, J EXP BIOL, V140, P437; BOLTON W, 1968, J MOL BIOL, V33, P283, DOI 10.1016/0022-2836(68)90294-5; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BRYGIER J, 1975, EUR J BIOCHEM, V60, P379, DOI 10.1111/j.1432-1033.1975.tb21013.x; CHENG B, 1994, INORG CHEM, V33, P1319, DOI 10.1021/ic00085a018; COBB JA, 1992, J BIOL CHEM, V267, P1183; de Bruin S H, 1974, Biochem Biophys Res Commun, V58, P204, DOI 10.1016/0006-291X(74)90912-7; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; GILL SJ, 1978, SCIENCE, V201, P362, DOI 10.1126/science.663663; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; HEIDNER EJ, 1976, J MOL BIOL, V104, P707, DOI 10.1016/0022-2836(76)90130-3; HIRSOWITZ LA, 1977, RESP PHYSIOL, V31, P51, DOI 10.1016/0034-5687(77)90064-0; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOLLAND RAB, 1994, ADV EXP MED BIOL, V345, P159; HOLLAND RAB, 1988, RESP PHYSIOL, V73, P69, DOI 10.1016/0034-5687(88)90128-4; HOLLAND RAB, 1991, P AUST PHYSL PHARM S, V22, pP117; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; ISAACKS RE, 1980, AM ZOOL, V20, P115; ISAACKS RE, 1976, ARCH BIOCHEM BIOPHYS, V173, P114, DOI 10.1016/0003-9861(76)90240-X; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHANSEN K, 1987, PHYSIOL ZOOL, V60, P269, DOI 10.1086/physzool.60.2.30158651; JOHANSEN K, 1980, J COMP PHYSIOL, V136, P71, DOI 10.1007/BF00688625; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KORBER FCF, 1991, J CHEM SOC DALTON, P3291, DOI 10.1039/dt9910003291; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; LAPENNAS GN, 1983, RESP PHYSIOL, V52, P27, DOI 10.1016/0034-5687(83)90134-2; LAPENNAS GN, 1983, RESP PHYSIOL, V52, P13, DOI 10.1016/0034-5687(83)90133-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIAN CY, 1971, BIOCHEM BIOPH RES CO, V45, P151, DOI 10.1016/0006-291X(71)90063-5; LONGMUIR IS, 1970, J APPL PHYSIOL, V28, P343; LUTZ PL, 1974, RESP PHYSIOL, V20, P325, DOI 10.1016/0034-5687(74)90029-2; LYKKEBOE G, 1978, RESP PHYSIOL, V35, P119, DOI 10.1016/0034-5687(78)90017-8; MACMAHON JA, 1975, COMP BIOCHEM PHYS A, V51, P59, DOI 10.1016/0300-9629(75)90413-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MOSS BA, 1969, AUST J BIOL SCI, V22, P1455, DOI 10.1071/BI9691455; MUIRHEAD H, 1963, NATURE, V199, P633, DOI 10.1038/199633a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perutz M. F., 1970, NATURE, V228, P734; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; POWELL MJD, 1976, MATH PROGRAM, V11, P42, DOI 10.1007/BF01580369; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROLLEMA HS, 1979, J BIOL CHEM, V254, P2038; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SILVA MM, 1992, J BIOL CHEM, V267, P17248; SMITH T, 1992, J APPL CRYSTALLOGR, V26, P496; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TAM LT, 1984, J BIOL CHEM, V259, P2610; VORGER P, 1987, COMP BIOCHEM PHYS A, V88, P613, DOI 10.1016/0300-9629(87)90672-4; VORGER P, 1994, COMP BIOCHEM PHYS B, V109, P391, DOI 10.1016/0305-0491(94)90022-1; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; Zhang J, 1996, J MOL BIOL, V255, P484, DOI 10.1006/jmbi.1996.0040	74	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6411	6420		10.1074/jbc.274.10.6411	http://dx.doi.org/10.1074/jbc.274.10.6411			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037733	hybrid			2022-12-27	WOS:000078902800055
J	Paolillo, M; Feliciello, A; Porcellini, A; Garbi, C; Bifulco, M; Schinelli, S; Ventra, C; Stabile, E; Ricciardelli, G; Schettini, G; Avvedimento, EV				Paolillo, M; Feliciello, A; Porcellini, A; Garbi, C; Bifulco, M; Schinelli, S; Ventra, C; Stabile, E; Ricciardelli, G; Schettini, G; Avvedimento, EV			The type and the localization of cAMP-dependent protein kinase regulate transmission of cAMP signals to the nucleus in cortical and cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; C-FOS TRANSCRIPTION; GENE-EXPRESSION; CYCLIC-AMP; II-BETA; CREB PHOSPHORYLATION; ANCHORING PROTEINS; BINDING-PROTEIN; SUBUNIT; NEURONS	cAMP signals are received and transmitted by multiple isoforms of cAMP-dependent protein kinases, typically determined by their specific regulatory subunits. In the brain the major regulatory isoform RII beta and the RII-anchor protein, AKAP150 (rat) or 75 (bovine), are differentially expressed. Cortical neurons express RII beta and AKAP75; conversely, granule cerebellar cells express predominantly RI alpha and RII alpha Cortical neurons accumulate PKA catalytic subunit and phosphorylated cAMP responsive element binding protein very efficiently into nuclei upon cAMP induction, whereas granule cerebellar cells fail to do so. Down-regulation of RII beta synthesis by antisense oligonucleotides inhibited cAMP-induced nuclear signaling in cortical neurons. Expression in cerebellar granule cells of RII beta and ARAP75 genes by microinjection of specific expression vectors, markedly stimulated cAMP-induced transcription of the lacZ gene driven by a cAMP-responsive element promoter. These data indicate that the composition of PKA in cortical and granule cells underlies the differential ability of these cells to transmit cAMP signals to the nucleus.	Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,CEOS, I-80131 Naples, Italy; Univ Pavia, Fac Farm, Ist Farmacol, I-27100 Pavia, Italy; Univ Naples Federico II, Fac Med, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Fac Med, Ist Farmacol, Genoa, Italy; CBA, IST, Serv Farmacol & Neurosci, Genoa, Italy; Univ Catanzaro, Fac Med Catanzaro, Dipartimento Med Sperimentale, Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Pavia; University of Naples Federico II; Magna Graecia University of Catanzaro	Avvedimento, EV (corresponding author), Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,CEOS, Torre Biol 14 Fl,Via S Pansini 5, I-80131 Naples, Italy.		Porcellini, Antonio/AAC-6097-2019; Paolillo, Mayra/N-2615-2015; Porcellini, Antonio/E-1900-2011	Paolillo, Mayra/0000-0002-7751-3336; Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170; stabile, eugenio/0000-0002-4544-3142; Bifulco, Maurizio/0000-0002-1771-4531; stabile, eugenio/0000-0001-9763-6010				Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; BEEBE SJ, 1986, ENZYMES, V17, P43; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brandon EP, 1998, J NEUROSCI, V18, P3639; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1993, J BIOL CHEM, V268, P20729; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; DAY RN, 1989, J BIOL CHEM, V264, P431; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KAANG BK, 1992, P NATL ACAD SCI USA, V89, P1133, DOI 10.1073/pnas.89.3.1133; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCHINELLI S, 1994, J NEUROCHEM, V62, P944; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; Ventra C, 1996, J NEUROCHEM, V66, P1752	47	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6546	6552		10.1074/jbc.274.10.6546	http://dx.doi.org/10.1074/jbc.274.10.6546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037748	hybrid			2022-12-27	WOS:000078902800070
J	El Kouhen, R; Kouhen, OM; Law, PY; Loh, HH				El Kouhen, R; Kouhen, OM; Law, PY; Loh, HH			The absence of a direct correlation between the loss of [D-Ala(2),MePhe(4),Gly(5)-ol]enkephalin inhibition of adenylyl cyclase activity and agonist-induced mu-opioid receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NG108-15 HYBRID-CELLS; INDUCED DESENSITIZATION; DIFFERENTIAL REGULATION; MOLECULAR MECHANISMS; CARBOXYL-TERMINUS; DOWN-REGULATION; KINASES; INTERNALIZATION; RESENSITIZATION	Chronic activation of the mu-opioid receptor (MOR1TAG) results in the loss of agonist response that has been attributed to desensitization and down-regulation of the receptor. It has been suggested that opioid receptor phosphorylation is the mechanism by which this desensitization and down-regulation occurs. When MOR1TAG; was stably expressed in both neuroblastoma neuro2A and human embryonic kidney HEK293 cells, the opioid agonist [D-Ala(2),MePhe(4),Gly(5)-ol]enkephalin (DAMGO) induced a time- and concentration-dependent phosphorylation of the receptor, in both cell lines, that could be reversed by the antagonist naloxone, Protein kinase C can phosphorylate the receptor, but is not involved in DAMGO-induced MOR1TAG phosphorylation. The rapid rate of receptor phosphorylation, occurring within minutes, did not correlate with the rate of the loss of agonist-mediated inhibition of adenylyl cyclase, which occurs in hours. This lack of correlation between receptor phosphorylation and the loss of response was further demonstrated when receptor phosphorylation was increased by either calyculin A or overexpression of the G-protein receptor kinases. Calyculin A increased the magnitude of MOR1TAG phosphorylation without altering the DAMGO-induced loss of the adenylyl cyclase response. Similarly, when mu- and delta-opioid (DOR1TAG) receptors were expressed in the same system, overexpression of beta-adrenergic receptor kinase 2 elevated agonist-induced phosphorylation for both receptors, However, in the same cell lines under the same conditions, overexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 accelerated the rate of DPDPE- but not DAMGO-induced receptor desensitization. Thus, these data show that phosphorylation of MOR1TAG is not an obligatory event for the DAMGO-induced loss in the adenylyl cyclase regulation by the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	El Kouhen, R (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	elkou001@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA-00546, DA-05695, DA-01583] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, R37DA001583, P01DA005695] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bohm SK, 1997, BIOCHEM J, V322, P1; Bot G, 1997, MOL PHARMACOL, V52, P272, DOI 10.1124/mol.52.2.272; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Diviani D, 1996, J BIOL CHEM, V271, P5049; HAGA T, 1994, J NEUROCHEM, V63, P400; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; LAW PY, 1991, J PHARMACOL EXP THER, V256, P710; LAW PY, 1983, MOL PHARMACOL, V24, P413; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; Tiberi M, 1996, J BIOL CHEM, V271, P3771; WHITE AA, 1978, ANAL BIOCHEM, V85, P451, DOI 10.1016/0003-2697(78)90242-7; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	42	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9207	9215		10.1074/jbc.274.14.9207	http://dx.doi.org/10.1074/jbc.274.14.9207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092593	hybrid			2022-12-27	WOS:000079451800012
J	Herr, FM; Li, E; Weinberg, RB; Cook, VR; Storch, J				Herr, FM; Li, E; Weinberg, RB; Cook, VR; Storch, J			Differential mechanisms of retinoid transfer from cellular retinol binding proteins types I and II to phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSFER; APOLIPOPROTEIN-A-I; AIR-WATER-INTERFACE; CYTOCHROME-C; UNILAMELLAR VESICLES; COLLISIONAL TRANSFER; SURFACE-ACTIVITIES; LIPID-COMPOSITION; LYSINE RESIDUES; HIGH-DENSITY	Cellular retinol-binding proteins types I and LI (CRBP-I and CRBP-II) are known to differentially facilitate retinoid metabolism by several membrane-associated enzymes. The mechanism of ligand transfer to phospholipid small unilamellar vesicles was compared in order to determine whether differences in ligand trafficking properties could underlie these functional differences. Unidirectional transfer of retinol from the CRBPs to membranes was monitored by following the increase in intrinsic protein fluorescence that occurs upon ligand dissociation, The results showed that ligand transfer of retinol from CRBP-I was >5-fold faster than transfer from CRBP-II, For both proteins, transfer of the other naturally occurring retinoid, retinaldehyde, was 4-5-fold faster than transfer of retinol, Rates of ligand transfer from CRBP-I to small unilamellar vesicles increased with increasing concentration of acceptor membrane and with the incorporation of the anionic lipids cardiolipin or phosphatidylserine into membranes. In contrast, transfer from CRBP-II was unaffected by either membrane concentration or composition. Preincubation of anionic vesicles with CRBP-I was able to prevent cytochrome c, a peripheral membrane protein, from binding, whereas CRBP-II was ineffective. In addition, monolayer exclusion experiments demonstrated differences in the rate and magnitude of the CRBP interactions with phospholipid membranes. These results suggest that the mechanisms of ligand transfer from CRBP-I and CRBP-II to membranes are markedly different as follows: transfer from CRBP-I may involve and require effective collisional interactions with membranes, whereas a diffusional process primarily mediates transfer from CRBP-II. These differences may help account for their distinct functional roles in the modulation of intracellular retinoid metabolism.	Rutgers State Univ, Cook Coll, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA	Rutgers State University New Brunswick; Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center	Storch, J (corresponding author), Rutgers State Univ, Cook Coll, Dept Nutr Sci, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu		Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANATHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P110; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; FAUCON JF, 1976, BIOCHIM BIOPHYS ACTA, V435, P283; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; Gomori G, 1942, J LAB CLIN MED, V27, P955; HERR FM, 1993, J LIPID RES, V34, P1545; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HO MTP, 1989, J BIOL CHEM, V264, P17759; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; LI E, 1991, J BIOL CHEM, V266, P3622; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; Ong David E., 1994, P283; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; ROISE D, 1993, AMPHIPATHIC HELIX, P258; Rong D, 1997, FEBS LETT, V402, P116, DOI 10.1016/S0014-5793(96)01509-8; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Storch J, 1996, COMP BIOCHEM PHYS B, V115, P333, DOI 10.1016/S0305-0491(96)00180-0; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, PROTEIN ENG, V10, P31, DOI 10.1093/protein/10.1.31; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; Yun CH, 1996, J BIOL CHEM, V271, P31312, DOI 10.1074/jbc.271.49.31312	50	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9556	9563		10.1074/jbc.274.14.9556	http://dx.doi.org/10.1074/jbc.274.14.9556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092641	hybrid			2022-12-27	WOS:000079451800060
J	Neufeld, EB; Wastney, M; Patel, S; Suresh, S; Cooney, AM; Dwyer, NK; Roff, CF; Ohno, K; Morris, JA; Carstea, ED; Incardona, JP; Strauss, JF; Vanier, MT; Patterson, MC; Brady, RO; Pentchev, PG; Blanchette-Mackie, EJ				Neufeld, EB; Wastney, M; Patel, S; Suresh, S; Cooney, AM; Dwyer, NK; Roff, CF; Ohno, K; Morris, JA; Carstea, ED; Incardona, JP; Strauss, JF; Vanier, MT; Patterson, MC; Brady, RO; Pentchev, PG; Blanchette-Mackie, EJ			The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DISEASE TYPE-C; METHYLAMINE ACCUMULATION; CHOLESTEROL HOMEOSTASIS; INTRACELLULAR-TRANSPORT; MEMBRANE GLYCOPROTEIN; KINETIC EVIDENCE; GM2 GANGLIOSIDE; PLASMA-MEMBRANE; CULTURED-CELLS	Niemann-Pick C disease (NP-C) is a neurovisceral lysosomal storage disorder. A variety of studies have highlighted defective sterol trafficking from lysosomes in NP-C cells. However, the heterogeneous nature of additional accumulating metabolites suggests that the cellular lesion may involve a more generalized block in retrograde lysosomal trafficking. Immunocytochemical studies in fibroblasts reveal that the NPC1 gene product resides in a novel set of lysosome-associated membrane protein-2 (LAMPS)(+)/ mannose g-phosphate receptor(-) vesicles that can be distinguished from cholesterol-enriched LAMP2(+) lysosomes, Drugs that block sterol transport out of lysosomes also redistribute NPC1 to cholesterol-laden lysosomes. Sterol relocation from lysosomes in cultured human fibroblasts can be blocked at 21 degrees C, consistent with vesicle-mediated transfer. These findings suggest that NPC1(+) vesicles may transiently interact with lysosomes to facilitate sterol relocation. Independent of defective sterol trafficking, NP-C fibroblasts are also deficient in vesicle-mediated clearance of endocytosed [C-14]sucrose. Compartmental modeling of the observed [C-14]sucrose clearance data targets the trafficking defect caused by mutations in NPC1 to an endocytic compartment proximal to lysosomes, Low density lipoprotein uptake by normal cells retards retrograde transport of [C-14]sucrose through this same kinetic compartment, further suggesting that it may contain the sterol-sensing NPC1 protein. We conclude that a distinctive organelle containing NPC1 mediates retrograde lysosomal transport of endocytosed cargo that is not restricted to sterol.	NIDDK, Lipid Cell Biol Sect, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Dept Pediat, Div Neonatol, Washington, DC 20007 USA; Vet Affairs Med Ctr, Neurobiol Res Lab, Newington, CT 06111 USA; Tottori Univ, Fac Med, Yanago 6838503, Japan; St Marys Hosp, Saccomanno Res Inst, Grand Junct, CO 81502 USA; Univ Washington, Dept Pediat & Biol Struct, Seattle, WA 98195 USA; Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Fac Med Lyon Sud, Dept Biochem, F-69921 Oullins, France; Fac Med Lyon Sud, INSERM U189, F-69921 Oullins, France; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Tottori University; University of Washington; University of Washington Seattle; University of Pennsylvania; Institut National de la Sante et de la Recherche Medicale (Inserm); Mayo Clinic	Blanchette-Mackie, EJ (corresponding author), NIDDK, Lipid Cell Biol Sect, Lab Cell Biochem & Biol, NIH, Bldg 8,Rm 427,8 Ctr Dr,MSC 0850, Bethesda, MD 20892 USA.	joanbm@bdg8.niddk.nih.gov	Neufeld, Edward/R-3819-2019; Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Patterson, Marc/0000-0002-1116-126X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASAKI K, 1993, J BIOCHEM-TOKYO, V114, P598, DOI 10.1093/oxfordjournals.jbchem.a124223; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; BERMAN M, 1978, DHEW PUBLICATION NIH; BERMAN M, 1983, CONSAM USERS GUIDE, P3279; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLOMHOFF R, 1989, BIOCHEM J, V262, P605, DOI 10.1042/bj2620605; Bright NA, 1997, J CELL SCI, V110, P2027; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; COXEY RA, 1993, J LIPID RES, V34, P1165; DENG YP, 1991, J CELL SCI, V99, P571; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; DUNN WA, 1980, J BIOL CHEM, V255, P5971; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GHOSH RN, 1994, J CELL SCI, V107, P2177; Goodman LA, 1996, DEV BRAIN RES, V93, P162, DOI 10.1016/0165-3806(96)00029-6; Greif P, 1998, ADV EXP MED BIOL, V445, P3; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; JAHRAUS A, 1994, J CELL SCI, V107, P145; Kopitz J, 1996, AM J MED GENET, V63, P198; KOPITZ J, 1994, CLIN CHIM ACTA, V227, P121, DOI 10.1016/0009-8981(94)90141-4; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mukherjee Sushmita, 1996, Molecular Biology of the Cell, V7, p266A; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; PATTERSON MC, 1999, IN PRESS METABOLIC M; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; SIEGEL DA, 1994, J NEUROCHEM, V62, P1852; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOKOL J, 1988, J BIOL CHEM, V263, P3411; Storrie Brian, 1996, Bioessays, V18, P895, DOI 10.1002/bies.950181108; Suzuki K, 1999, NEUROCHEM RES, V24, P471, DOI 10.1023/A:1022571410445; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537; WILSON RB, 1993, J BIOL CHEM, V268, P25357; Yano T, 1996, P JPN ACAD B-PHYS, V72, P214, DOI 10.2183/pjab.72.214	52	315	321	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9627	9635		10.1074/jbc.274.14.9627	http://dx.doi.org/10.1074/jbc.274.14.9627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092649	hybrid			2022-12-27	WOS:000079451800068
J	Chavez, RA; Gray, AT; Zhao, BB; Kindler, CH; Mazurek, MJ; Mehta, Y; Forsayeth, JR; Yost, CS				Chavez, RA; Gray, AT; Zhao, BB; Kindler, CH; Mazurek, MJ; Mehta, Y; Forsayeth, JR; Yost, CS			TWIK-2, a new weak inward rectifying member of the tandem pore domain potassium channel family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; RECTIFIER K+ CHANNEL; SUBUNIT STOICHIOMETRY; PH	Potassium channels are found in all mammalian cell types, and they perform many distinct functions in both excitable and non-excitable cells. These functions are subserved by several different families of potassium channels distinguishable by primary sequence features as well as by physiological characteristics. Of these families, the tandem pore domain potassium channels are a new and distinct class, primarily distinguished by the presence of two pore-forming domains within a single polypeptide chain. We have cloned a new member of this family, TWIK-2, from a human brain cDNA library. Primary sequence analysis of TWIK-2 shows that it is most closely related to TWIK-1, especially in the pore-forming domains. Northern blot analysis reveals the expression of TWIK-2 in all human tissues assayed except skeletal muscle. Human TWIK-2 expressed heterologously in Xenopus oocytes is a non-inactivating weak inward rectifier with channel properties similar to TWIK-1, Pharmacologically, TWIK-2 channels are distinct from TWIK-1 channels in their response to quinidine, quinine, and barium. TWIK-2 is inhibited by intracellular, but not extracellular, acidification. This new clone reveals the existence of a subfamily in the tandem pore domain potassium channel family with weak inward rectification properties.	Elan Pharmaceut, Menlo Park, CA 94025 USA; Univ Calif San Francisco, Sch Med, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Yost, CS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anesthesia, 513 Parnassus Ave,Box 0542,Rm S261, San Francisco, CA 94143 USA.			Chavez, Raymond/0000-0002-3006-0325	NIGMS NIH HHS [GM57740, GM51372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Di Stefano A, 1998, CELL PHYSIOL BIOCHEM, V8, P89, DOI 10.1159/000016273; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; GUILLEMARE E, 1995, MOL PHARMACOL, V47, P588; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KIBBLE JD, 1995, AM J PHYSIOL-RENAL, V268, pF778, DOI 10.1152/ajprenal.1995.268.4.F778; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1997, FEBS LETT, V402, P28, DOI 10.1016/S0014-5793(96)01491-3; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lesage F, 1996, J BIOL CHEM, V271, P4183; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Salkoff Lawrence, 1997, Pfluegers Archiv European Journal of Physiology, V434, pR79; SCHMID A, 1995, J PHYSIOL-LONDON, V484, P661, DOI 10.1113/jphysiol.1995.sp020694; Schmid A, 1997, J PHYSIOL-LONDON, V504, P259, DOI 10.1111/j.1469-7793.1997.259be.x; Shepard AR, 1997, NUCLEIC ACIDS RES, V25, P3183, DOI 10.1093/nar/25.15.3183; Slawik M, 1996, PFLUG ARCH EUR J PHY, V432, P112, DOI 10.1007/s004240050112; TABEI K, 1995, AM J PHYSIOL-RENAL, V268, pF490, DOI 10.1152/ajprenal.1995.268.3.F490; TAKANASHI H, 1994, J CELL PHYSIOL, V161, P537, DOI 10.1002/jcp.1041610317; Tare M, 1998, J PHYSIOL-LONDON, V506, P303, DOI 10.1111/j.1469-7793.1998.303bw.x; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	28	111	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7887	7892		10.1074/jbc.274.12.7887	http://dx.doi.org/10.1074/jbc.274.12.7887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075682	hybrid			2022-12-27	WOS:000079268100041
J	Hurley, JH				Hurley, JH			Structure, mechanism, and regulation of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CALMODULIN-BINDING DOMAIN; IN-VIVO; NUCLEOSIDE 3'-POLYPHOSPHATES; CATALYTIC MECHANISM; CYTOSOLIC DOMAINS; PROTEIN-KINASE; GS-ALPHA; INHIBITION; PHOSPHORYLATION; IDENTIFICATION		NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hurley, JH (corresponding author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	jh8e@nih.gov						Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Bol GF, 1997, BIOCHEM BIOPH RES CO, V237, P251, DOI 10.1006/bbrc.1997.7123; Bryant SH, 1997, NATURE, V388, P34, DOI 10.1038/40313; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Cooper DMF, 1998, J BIOL CHEM, V273, P27703, DOI 10.1074/jbc.273.42.27703; COOPER DMF, 1998, ADV 2 MESSENGER PHOS, V32; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Hanoune J, 1997, MOL CELL ENDOCRINOL, V128, P179, DOI 10.1016/S0303-7207(97)04013-6; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; ITOH H, 1991, J BIOL CHEM, V266, P16226; Johnson RA, 1997, J BIOL CHEM, V272, P8962; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Mitterauer T, 1998, BIOCHEMISTRY-US, V37, P16183, DOI 10.1021/bi981441m; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zhang GY, 1997, PROTEIN SCI, V6, P903; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	54	189	192	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7599	7602		10.1074/jbc.274.12.7599	http://dx.doi.org/10.1074/jbc.274.12.7599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075642	hybrid			2022-12-27	WOS:000079268100001
J	Sabo, SL; Lanier, LM; Ikin, AF; Khorkova, O; Sahasrabudhe, S; Greengard, P; Buxbaum, JD				Sabo, SL; Lanier, LM; Ikin, AF; Khorkova, O; Sahasrabudhe, S; Greengard, P; Buxbaum, JD			Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; KINASE-C; CYTOPLASMIC DOMAIN; PEPTIDE; CLEAVAGE; TRAFFICKING; PHOSPHORYLATION; INTERNALIZATION; LOCALIZATION; COMPARTMENT	The principal component of Alzheimer's amyloid plaques, A beta, derives from proteolytic processing of the Alzheimer's amyloid protein precursor (APP), FE65 is a brain-enriched protein that binds to APP, Although several laboratories have characterized the APP-FE65 interaction in vitro, the possible relevance of this interaction to Alzheimer's disease has remained unclear. We demonstrate here that APP and FE65 co-localize in the endoplasmic reticulum/Golgi and possibly in endosomes, Moreover, FE65 increases translocation of APP to the cell surface, as well as both alpha APP(s) and A beta secretion. The dramatic (4-fold) FE65-dependent increase in A beta secretion suggests that agents which inhibit the interaction of FE65 with APP might reduce A beta secretion in the brain and therefore be useful for preventing or slowing amyloid plaque formation.	CUNY Mt Sinai Sch Med, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, Lab Mol Neuropsychiat, New York, NY 10029 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Zachary & Elizabeth M Fisher Ctr, New York, NY 10021 USA; Hoeschst Marion Roussel, Biotechnol Grp, Bridgewater, NJ 08807 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Rockefeller University	Buxbaum, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA.		Buxbaum, Joseph D/G-6001-2010	khorkova, olga/0000-0002-1848-2365; Buxbaum, Joseph/0000-0001-8898-8313; Sabo, Shasta/0000-0001-6386-7443	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009464, R55AG014996, R01AG014996] Funding Source: NIH RePORTER; NIA NIH HHS [AG09464, AG14996] Funding Source: Medline; NIMH NIH HHS [MH15125] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAHAM J, 1994, ANAL BIOCHEM, V220, P367, DOI 10.1006/abio.1994.1351; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; SAMBAMURTI K, 1992, ANN NY ACAD SCI, V674, P118, DOI 10.1111/j.1749-6632.1992.tb27481.x; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; TOMIMOTO H, 1995, ACTA NEUROPATHOL, V90, P608; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yamazaki T, 1996, J CELL SCI, V109, P999; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	45	189	192	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7952	7957		10.1074/jbc.274.12.7952	http://dx.doi.org/10.1074/jbc.274.12.7952			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075692	hybrid			2022-12-27	WOS:000079268100051
J	Saiki, Y; El-Hayek, R; Ikemoto, N				Saiki, Y; El-Hayek, R; Ikemoto, N			Involvement of the Glu(724)-Pro(760) region of the dihydropyridine receptor II-III loop in skeletal muscle-type excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL FOOT PROTEIN; INDUCED CA2+ RELEASE; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; TRANSVERSE TUBULE; CA-2+ RELEASE; DEPOLARIZATION; CHANNEL; ACTIVATION; FIBERS	Our previous study (El-Hayek, R., Antoniu, B,, Wang, J, P,, Hamilton, S, L,, and Ikemoto, N, (1995) J, Biol, Chem, 270, 22116-22118) suggested the hypothesis that skeletal muscle-type excitation-contraction coupling is regulated by two domains (activating and blocking) of the Ii-III loop of the dihydropyridine receptor alpha 1 subunit. We investigated this hypothesis by examining conformational changes in the ryanodine receptor induced by synthetic peptides and by transverse tubular system (T-tubule) depolarization. Peptide A, corresponding to the Thr(671)-Leu(690) region, rapidly changed the ryanodine receptor conformation from a blocked state (low fluorescence of the conformational probe, methyl coumarin acetamide, attached specifically to the ryanodine receptor) to an activated state (high methyl coumarin acetamide fluorescence) as T-tubule depolarization did. Peptide C, corresponding to the Glu(724)-Pro(760) region, blocked both conformational changes induced by peptide A and T-tubule depolarization, Its ability to block peptide A-induced and depolarization-induced activation was considerably impaired by replacing the portion of peptide C corresponding to the Phe(725)-pro(742) region of the loop with cardiac muscle-type sequence. These results are consistent with the model that depolarization-induced activation of excitation-contraction coupling and blocking/repriming are mediated by the peptide A region and the peptide C region (containing the critical phe(725)-Pro(742) sequence) of the II-III loop, respectively.	Boston Biomed Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Ikemoto, N (corresponding author), Boston Biomed Res Inst, 20 Staniford St, Boston, MA 02114 USA.	Ikemoto@bbri.org			NIAMS NIH HHS [AR16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; Ikemoto N, 1996, FEBS LETT, V394, P330, DOI 10.1016/0014-5793(96)00973-8; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3298; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P519, DOI 10.1113/jphysiol.1990.sp018037; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P495, DOI 10.1113/jphysiol.1990.sp018036; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Lu Xiangyang, 1995, Biophysical Journal, V68, pA372; LU XY, 1994, J BIOL CHEM, V269, P6511; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Nakai J., 1995, Biophysical Journal, V68, pA14; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; THEVENIN BJM, 1992, EUR J BIOCHEM, V206, P471, DOI 10.1111/j.1432-1033.1992.tb16949.x; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017	32	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7825	7832		10.1074/jbc.274.12.7825	http://dx.doi.org/10.1074/jbc.274.12.7825			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075674	hybrid			2022-12-27	WOS:000079268100033
J	Chien, MM; Zahradka, KE; Newell, MK; Freed, JH				Chien, MM; Zahradka, KE; Newell, MK; Freed, JH			Fas-induced B cell apoptosis requires an increase in free cytosolic magnesium as an early event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPHOSPHOLIPID TRANSLOCASE; INTRACELLULAR MAGNESIUM; THYMOCYTE APOPTOSIS; RAT HEPATOCYTES; LYMPHOCYTES; CALCIUM; PHOSPHATIDYLSERINE; ANTIGEN; LIGATION; DEATH	Ligation of the Fas molecule expressed on the surface of a cell initiates multiple signaling pathways that result in the apoptotic death of that cell. We have examined Mg2+ mobilization as well as Ca2+ mobilization in B cells undergoing Fas-initiated apoptosis, Our results indicate that cytosolic levels of free (non-complexed) Mg2+ ([M2+](i)) and Ca2+ ([Ca2+](i)) increase in cells undergoing apoptosis, Furthermore, the percentages of cells mobilizing Mg2+, fragmenting DNA, or externalizing phosphatidylserine (PS) increase in parallel as the concentration of anti-Fas monoclonal antibody is raised. Kinetic analysis suggests that Mg2+ mobilization is an early event in apoptosis, clearly preceding DNA fragmentation and probably occurring prior to externalization of PS as well. The source of Mg2+ that produces the increases in [Mg2+](i) is intracellular and most likely is the mitochondria. Extended pretreatment of B cells with carbonyl cyanide m-chlorophenylhydrazone, an inhibitor of mitochondrial oxidative phosphorylation, produces proportional decreases in the percentage of cells mobilizing Mg2+, fragmenting DNA, and externalizing PS in response to anti-Fas monoclonal antibody treatment. These observations are consistent with the hypothesis that elevated [Mg2+](i) is required for apoptosis. Furthermore, we propose that the increases in [Mg2+](i) function not only as cofactors for Mg2+-dependent endonucleases, but also to facilitate the release of cytochrome c from the mitochondria, which drives many of the post-mitochondrial, caspase-mediated events in apoptotic cells.	Natl Jewish Med & Res Ctr, Dept Med, Div Basic Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Freed, JH (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Div Basic Immunol, 1400 Jackson St, Denver, CO 80206 USA.	freedj@njc.org			NIAID NIH HHS [AI37523, AI33470] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033470, R15AI133470, R01AI037523] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BOND M, 1987, J BIOL CHEM, V262, P15630; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; CHEEK TR, 1989, J CELL SCI, V93, P211; Cittadini A, 1991, Magnes Res, V4, P23; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; Dao T, 1997, J IMMUNOL, V159, P4261; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Foote LC, 1996, J IMMUNOL, V157, P1878; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; JUSTEMENT LB, 1990, NONINVASIVE TECHNIQU, P353; KAWABATA H, 1993, BIOCHEM BIOPH RES CO, V191, P247, DOI 10.1006/bbrc.1993.1209; Khodarev NN, 1996, J IMMUNOL, V156, P922; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; LI HY, 1993, BIOCHIM BIOPHYS ACTA, V1181, P307, DOI 10.1016/0925-4439(93)90037-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOTERA P, 1994, PEZ FDN SYM, V5, P97; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; QUAMME GA, 1993, AM J PHYSIOL, V265, pH281, DOI 10.1152/ajpheart.1993.265.1.H281; RIJKERS GT, 1993, BIOCHEM J, V289, P373, DOI 10.1042/bj2890373; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; SEILIEV AA, 1992, RADIAT ENVIRON BIOPH, V31, P123, DOI 10.1007/BF01211210; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; SUN XM, 1994, J BIOL CHEM, V269, P14857; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Yoshida A, 1998, CANCER RES, V58, P2576	48	48	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7059	7066		10.1074/jbc.274.11.7059	http://dx.doi.org/10.1074/jbc.274.11.7059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066762	hybrid			2022-12-27	WOS:000079078400034
J	Lam, MHC; Briggs, LJ; Hu, W; Martin, TJ; Gillespie, MT; Jans, DA				Lam, MHC; Briggs, LJ; Hu, W; Martin, TJ; Gillespie, MT; Jans, DA			Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LOCALIZATION SEQUENCE; CYTOKINE INTERLEUKIN-5; BONE-RESORPTION; IN-VITRO; PEPTIDE; SIGNAL; LINE; RECEPTOR; GROWTH	Parathyroid hormone-related protein (PTHrP), expressed in a range of tumors, has endocrine, autocrine/paracrine, and intracrine actions, some of which relate to its ability to localize in the nucleus. Here we show for the first time that extracellularly added human PTHrP (amino acids 1-108) can be taken up specifically by receptor-expressing UMR106.01 osteogenic sarcoma cells and accumulate to quite high levels in the nucleus and nucleolus within 40 min. Quantitation of recognition by the nuclear localization sequence (NLS)-binding importin subunits indicated that in contrast to proteins containing conventional NLSs, PTHrP is recognized exclusively by importin beta and not by importin alpha. The sequence of PTHrP responsible for binding was mapped to amino acids 66-94, which includes an SV40 large tumor-antigen NLS-like sequence, although sequence determinants amino-terminal to this region were also necessary for high affinity binding (apparent dissociation constant of similar to 2 nM for importin beta), Nuclear import of PTHrP was assessed in vitro using purified components, demonstrating that importin beta, together with the GTP-binding protein Ran, was able to mediate efficient nuclear accumulation in the absence of importin alpha, whereas the addition of nuclear transport factor NTF2 reduced transport, The polypeptide ligand PTHrP thus appears to be accumulated in the nucleus/nucleolus through a novel, NLS-dependent nuclear import pathway independent of importin a and perhaps also of NTF2.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research	Jans, DA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, POB 334, Canberra, ACT 2601, Australia.		Briggs, Lyndall J/A-7549-2011	Gillespie, Matthew/0000-0001-6543-8909; Jans, David/0000-0001-5115-4745				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; BURTIS WJ, 1992, CLIN CHEM, V38, P2171; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P1762, DOI 10.1210/endo-129-4-1762; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; GOERLICH D, 1995, NATURE, V377, P246; GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem-73-6-1309; HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KAISER SM, 1994, MOL ENDOCRINOL, V8, P139, DOI 10.1210/me.8.2.139; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.3.CO;2-D; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Martin TJ, 1997, J ENDOCRINOL, V154, pS23; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; OKANO K, 1995, ENDOCRINOLOGY, V136, P1782, DOI 10.1210/en.136.4.1782; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Roskams T, 1997, AM J PATHOL, V150, P779; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; WATERS MJ, 1994, P SOC EXP BIOL MED, V206, P216; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191	49	173	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7391	7398		10.1074/jbc.274.11.7391	http://dx.doi.org/10.1074/jbc.274.11.7391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066803	hybrid			2022-12-27	WOS:000079078400075
J	Pfister, T; Wimmer, E				Pfister, T; Wimmer, E			Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE-STRAND RNA; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; VIRAL-RNA; ATPASE ACTIVITY; POLYPEPTIDE 2C; MEMBRANE PROLIFERATION; HUMAN PAPILLOMAVIRUS; E1 PROTEIN; CELL-FREE	The highly conserved non-structural protein 2C of picornaviruses is involved in viral genome replication and encapsidation and in the rearrangement of intracellular structures. 2C binds RNA, has nucleoside triphosphatase activity, and shares three motifs with superfamily III helicases, Motifs "A" and "B" are involved in nucleotide triphosphate (NTP) binding and hydrolysis, whereas a function for motif "C" has not yet been demonstrated. Poliovirus RNA replication is inhibited by millimolar concentrations of guanidine hydrochloride (GdnHCl). Resistance and dependence to GdnHCl map to 2C, To characterize the nucleoside triphosphatase activity of 2C, we purified poliovirus recombinant 2C fused to glutathione S-transferase (GST-PC) from Escherichia coli. GST-SC hydrolyzed ATP with a K-m of 0.7 mM. Other NTPs, including GTP, competed with ATP for binding to 2C but were poor substrates for hydrolysis, Mutation of conserved residues in motif A and B abolished ATPase activity, as did mutation of the conserved asparagine residue in motif C, an observation indicating the involvement of this motif in ATP hydrolysis, GdnHCl at millimolar concentrations inhibited ATP hydrolysis. Mutations in 2C that confer poliovirus resistant to or dependent on GdnHCl increased the tolerance to GdnHCl up to 100-fold.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wimmer, E (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI032100, R01AI015122] Funding Source: NIH RePORTER; NIAID NIH HHS [AI3210007, AI1512225] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B., 1994, MOL BIOL CELL; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; BALTIMORE D, 1963, P NATL ACAD SCI USA, V49, P843, DOI 10.1073/pnas.49.6.843; Banerjee R, 1997, J VIROL, V71, P9570, DOI 10.1128/JVI.71.12.9570-9578.1997; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; Barton DJ, 1997, J VIROL, V71, P8482, DOI 10.1128/JVI.71.11.8482-8489.1997; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1980, VIROLOGY, V100, P390, DOI 10.1016/0042-6822(80)90530-9; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; BLANCO L, 1989, J BIOL CHEM, V264, P8935; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; CALIGUIRI LA, 1974, VIROLOGY, V58, P526, DOI 10.1016/0042-6822(74)90086-5; CALIGUIRI LA, 1970, VIROLOGY, V42, P112, DOI 10.1016/0042-6822(70)90243-6; CALIGUIRI LA, 1973, SELECTIVE INHIBITORS, P257; CAO XM, 1993, J VIROL, V67, P5572, DOI 10.1128/JVI.67.9.5572-5578.1993; Castellino AM, 1997, J VIROL, V71, P7549, DOI 10.1128/JVI.71.10.7549-7559.1997; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; CHO MW, 1993, J VIROL, V67, P3010, DOI 10.1128/JVI.67.6.3010-3018.1993; CROWTHER D, 1961, VIROLOGY, V15, P65, DOI 10.1016/0042-6822(61)90078-2; Cuconati A, 1998, J VIROL, V72, P6456, DOI 10.1128/JVI.72.8.6456-6464.1998; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; DALES S, 1965, VIROLOGY, V26, P379, DOI 10.1016/0042-6822(65)90001-2; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Duggal R, 1997, P NATL ACAD SCI USA, V94, P13786, DOI 10.1073/pnas.94.25.13786; ECHEVERRI AC, 1995, VIROLOGY, V208, P540, DOI 10.1006/viro.1995.1185; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; ETCHISON D, 1981, VIROLOGY, V111, P33, DOI 10.1016/0042-6822(81)90651-6; FERNANDEZ A, 1995, NUCLEIC ACIDS RES, V23, P1327, DOI 10.1093/nar/23.8.1327; Georgopoulos C.M., 1994, BIOL HEAT SHOCK PROT; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; Jenkins O, 1996, J GEN VIROL, V77, P1805, DOI 10.1099/0022-1317-77-8-1805; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; Kadare G, 1997, J VIROL, V71, P2583; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Kusov YY, 1998, ARCH VIROL, V143, P931, DOI 10.1007/s007050050343; LAMA J, 1992, J BIOL CHEM, V267, P15932; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LI JP, 1990, J VIROL, V64, P1102, DOI 10.1128/JVI.64.3.1102-1107.1990; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; MELNICK JL, 1996, FIELDS VIROLOGY, V1, P655; MIRZAYAN C, 1994, VIROLOGY, V199, P176, DOI 10.1006/viro.1994.1110; MIRZAYAN C, 1992, VIROLOGY, V189, P547, DOI 10.1016/0042-6822(92)90578-D; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; Nickel W, 1997, FEBS LETT, V413, P395, DOI 10.1016/S0014-5793(97)00939-3; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; PFISTER T, 1996, KEYST S VIR GEN REPL; PINCUS SE, 1987, VIROLOGY, V157, P83, DOI 10.1016/0042-6822(87)90316-3; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; RIGHTSEL WA, 1961, SCIENCE, V134, P558, DOI 10.1126/science.134.3478.558; RODRIGUEZ PL, 1995, J BIOL CHEM, V270, P10105, DOI 10.1074/jbc.270.17.10105; RODRIGUEZ PL, 1993, J BIOL CHEM, V268, P8105; ROY P, 1970, J VIROL, V6, P604, DOI 10.1128/JVI.6.5.604-609.1970; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 2002, MOL CLONING LAB MANU; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TETERINA NL, 1992, J GEN VIROL, V73, P1977, DOI 10.1099/0022-1317-73-8-1977; Teterina NL, 1997, J VIROL, V71, P8962, DOI 10.1128/JVI.71.12.8962-8972.1997; TOLSKAYA EA, 1994, J MOL BIOL, V236, P1310, DOI 10.1016/0022-2836(94)90060-4; Vance LM, 1997, J VIROL, V71, P8759, DOI 10.1128/JVI.71.11.8759-8765.1997; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Woodman PG, 1997, BBA-MOL CELL RES, V1357, P155, DOI 10.1016/S0167-4889(97)00039-6; ZIJDERVELD DC, 1994, J VIROL, V68, P1158, DOI 10.1128/JVI.68.2.1158-1164.1994	79	132	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6992	7001		10.1074/jbc.274.11.6992	http://dx.doi.org/10.1074/jbc.274.11.6992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066753	hybrid			2022-12-27	WOS:000079078400025
J	Rossig, L; Fichtlscherer, B; Breitschopf, K; Haendeler, J; Zeiher, AM; Mulsch, A; Dimmeler, S				Rossig, L; Fichtlscherer, B; Breitschopf, K; Haendeler, J; Zeiher, AM; Mulsch, A; Dimmeler, S			Nitric oxide inhibits caspase-3 by S-nitrosation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IN-VIVO; NITROSYLATION; PROTEASE; DEATH	In cultured human endothelial cells, physiological levels of NO prevent apoptosis and interfere with the activation of the caspase cascade. In vitro data have demonstrated that NO inhibits the activity of caspase-3 by S-nitrosation of the enzyme. Here we present evidence for the in vivo occurrence and functional relevance of this novel antiapoptotic mechanism. To demonstrate that the cysteine residue Cys-163 of caspase-3 is S-nitrosated, cells were transfected with the Myc-tagged p17 subunit of caspase-3. After incubation of the transfected cells with different NO donors, Myc-tagged p17 was immunoprecipitated with anti-Myc antibody. S-Nitroso-thiol was detected in the immunoprecipitate by electron spin resonance spectroscopy after liberation and spin trapping of NO by N-methyl-D-glucamine-dithiocarbamate-iron complex. Transfection of cells with a p17 mutant, where the essential Cys-163 was mutated into alanine, completely prevented S-nitrosation of the enzyme. As a functional correlate, in human umbilical vein endothelial cells the NO donors sodium nitroprusside or PAPA NONOate (50 mu M) significantly reduced the increase in caspase-3-like activity induced by overexpressing caspase-3 by 75 and 70%, respectively. When human umbilical vein endothelial cells were cotransfected with P-galactosidase, morphological analysis of stained cells revealed that cell death induction by overexpression of caspase-3 was completely suppressed in the presence of sodium nitroprusside, PAPA NONOate, or S-nitroso-L-cysteine (50 mu M). Thus, NO supplied by exogenous NO donors serves in vivo as an antiapoptotic regulator of caspase activity via S-nitrosation of the Cys-163 residue of caspase-3.	Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Dimmeler, S (corresponding author), Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				ALBINA JE, 1993, J IMMUNOL, V150, P5080; Arnelle DR, 1997, NITRIC OXIDE-BIOL CH, V1, P56, DOI 10.1006/niox.1996.0107; Burney S, 1997, NITRIC OXIDE-BIOL CH, V1, P130, DOI 10.1006/niox.1996.0114; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Estevez AG, 1998, J NEUROSCI, V18, P3708; GENG YJ, 1995, AM J PATHOL, V147, P251; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mikoyan VD, 1997, BBA-GEN SUBJECTS, V1336, P225, DOI 10.1016/S0304-4165(97)00032-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; MULSCH A, 1995, CIRCULATION, V92, P1876, DOI 10.1161/01.CIR.92.7.1876; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tsuchiya K, 1996, FREE RADICAL BIO MED, V21, P733, DOI 10.1016/0891-5849(96)00221-3; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	33	358	366	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6823	6826		10.1074/jbc.274.11.6823	http://dx.doi.org/10.1074/jbc.274.11.6823			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066732	hybrid			2022-12-27	WOS:000079078400004
J	Gregoire, JM; Romeo, PH				Gregoire, JM; Romeo, PH			T-cell expression of the human GATA-3 gene is regulated by a non-lineage-specific silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; TISSUE-SPECIFIC EXPRESSION; LOOP-HELIX PROTEINS; DNA-BINDING PROTEIN; TRANSGENIC MICE; LYMPHOCYTE DEVELOPMENT; GLOBIN GENE; ELEMENTS; HEMATOPOIESIS; RECEPTOR	The GATA-3 transcription factor is required for development of the T-cell lineage and Th2 cytokine gene expression in CD4 T-cells, We have mapped the DNase-I-hypersensitive (HS) regions of the human GATA-3 gene in T-cells and non-T-cells and studied their transcriptional activities. HS I-III, located 5' from the transcriptional initiation site, were found in hematopoietic and non-hematopoietic cells, whereas HS IV-VII, located 3' from the transcriptional start site, were exclusively observed in T-cells, Among these hypersensitive sites, two transcriptional control elements were found, one in the first intron of the GATA-3 gene and the other between 8.3 and 5.9 kilobases 5' from the GATA-3 transcriptional initiation site. The first intron acted as a strong transcriptional activator in a position-dependent manner and with no cell-type specificity, The upstream regulatory element could confer T-cell specificity to the GATA-3 promoter activity, and analysis of this region revealed a 707-base pair silencer that drastically inhibited GATA-3 promoter activity in non-T-cells. Two CAG-GTG; E-boxes, located at the 5'- and 3'-ends of the silencer, were necessary for this silencer activity. The 3'-CAGGTG E-box could bind USF proteins, the ubiquitous repressor ZEE, or the basic helix-loop-helix proteins E2A and HEB, and we showed that a competition between ZEE and EBA/HEB proteins is involved in the silencer activity.	Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Romeo, PH (corresponding author), Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France.		Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367				Arnone MI, 1997, DEVELOPMENT, V124, P1851; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BIASSONI R, 1993, EUR J IMMUNOL, V23, P1083, DOI 10.1002/eji.1830230516; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GORAYA TY, 1994, NUCLEIC ACIDS RES, V22, P1194, DOI 10.1093/nar/22.7.1194; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; ISHIHARA H, 1995, J BIOCHEM-TOKYO, V3, P499; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; Lieuw KH, 1997, DEV BIOL, V188, P1, DOI 10.1006/dbio.1997.8575; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Meng AM, 1997, P NATL ACAD SCI USA, V94, P6267, DOI 10.1073/pnas.94.12.6267; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V10, P631; ORKIN SH, 1992, BLOOD, V80, P575; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHRODER FH, 1989, PROSTATE, P17; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VITALE M, 1994, BIOCHEM BIOPH RES CO, V204, P413, DOI 10.1006/bbrc.1994.2474; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	44	61	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6567	6578		10.1074/jbc.274.10.6567	http://dx.doi.org/10.1074/jbc.274.10.6567			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037751	hybrid			2022-12-27	WOS:000078902800073
J	Fleming, JF; Spitsen, GM; Hui, TY; Olivier, L; Du, EZ; Raabe, M; Davis, RA				Fleming, JF; Spitsen, GM; Hui, TY; Olivier, L; Du, EZ; Raabe, M; Davis, RA			Chinese hamster ovary cells require the coexpression of microsomal triglyceride transfer protein and cholesterol 7 alpha-hydroxylase for the assembly and secretion of apolipoprotein B containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; HEPG2 CELLS; ABETALIPOPROTEINEMIA GENE; MCA-RH7777 CELLS; DEGRADATION; TRANSLOCATION; DISEASE; EXPRESSION	Due to the absence of microsomal triglyceride transfer protein (MTP), Chinese hamster ovary (CHO) cells lack the ability to translocate apoB into the lumen of the endoplasmic reticulum, causing apoB to be rapidly degraded by an N-acetyl-leucyl-leucyl-norleucinal-inhibitable process. The goal of this study was to examine if expression of MTP, whose genetic deletion is responsible for the human recessive disorder abetalipoproteinemia, would recapitulate the lipoprotein assembly pathway in CHO cells. Unexpectedly, expression of MTP mRNA and protein in CHO cells did not allow apoB-containing lipoproteins to be assembled and secreted by CHO cells expressing apoB53, Although expression of MTP in cells allowed apoB to completely enter the endoplasmic reticulum, it was degraded by a proteolytic process that was inhibited by dithiothreitol (1 mM) and chloroquine (100 mu M), but resistant to N-acetyl-leucylleucyl-norleucinal, In marked contrast, coexpression of the liver-specific gene product cholesterol 7 alpha-hydroxylase with MTP resulted in levels of MTP lipid transfer activity that were similar to those in mouse liver and allowed intact apoB53 to be secreted as a lipoprotein particle. These data suggest that, although MTP-facilitated lipid transport is not required for apoB translocation, it is required for the secretion of apoB-containing lipoproteins. We propose that, in CHO cells, MTP plays two roles in the assembly and secretion of apoB-containing-lipoproteins: 1) it acts as a chaperone that facilitates apoB53 translocation, and 2) its lipid transfer activity allows apoB-containing lipoproteins to be assembled and secreted. Our results suggest that the phenotype of the cell (e.g. expression of cholesterol 7 alpha-hydroxylase by the liver) may profoundly influence the metabolic relationships determining how apoB is processed into lipoproteins and/or degraded.	San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	California State University System; San Diego State University; California State University System; San Diego State University; University of California System; University of California San Francisco; The J David Gladstone Institutes	Davis, RA (corresponding author), San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051648, P01HL047660, R01HL052005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51648, HL-47660, HL-52005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOUMA ME, 1986, J CLIN INVEST, V78, P398, DOI 10.1172/JCI112590; DAVIS RA, 1982, J BIOL CHEM, V257, P2634; DAVIS RA, 1996, N COMP BIOC, V31, P473; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du EZ, 1996, J LIPID RES, V37, P1309; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KANE JP, 1989, METABOLIC BASIS INHE; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; PATEL S, 1994, ATHEROSCLEROSIS, V108, P201, DOI 10.1016/0021-9150(94)90115-5; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PESSAH M, 1991, J CLIN INVEST, V87, P367, DOI 10.1172/JCI114996; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; RADER DJ, 1993, JAMA-J AM MED ASSOC, V270, P865, DOI 10.1001/jama.270.7.865; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TRAWICK JD, 1996, J LIPID RES, V37, P24169; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang L, 1997, J BIOL CHEM, V272, P27644, DOI 10.1074/jbc.272.44.27644; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9509	9514		10.1074/jbc.274.14.9509	http://dx.doi.org/10.1074/jbc.274.14.9509			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092635	hybrid			2022-12-27	WOS:000079451800054
J	Fox, KM; Karplus, PA				Fox, KM; Karplus, PA			The flavin environment in old yellow enzyme - An evaluation of insights from spectroscopic and artificial flavin studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE PROBES; NUCLEAR MAGNETIC-RESONANCE; FLAVOPROTEINS; MONONUCLEOTIDES; 2-THIOFLAVINS; FAMILY	Spectroscopic and chemical modification studies of modified flavins bound to old yellow enzyme have led to predictions about the flavin environment of this enzyme. These studies analyzed solvent accessibility and hydrogen bonding patterns of particular flavin atoms, in addition to suggesting amino acid residues that are in close proximity to those atoms. Here, these studies are evaluated in the light of the crystal structure of old yellow enzyme to reveal that the spectroscopic and modified flavin results are generally consistent with the crystal structure. This highlights the fact that these are useful methods for studying flavin binding site structure. Although several of the inferred properties of the flavin environment are not consistent with the crystal structure, these discrepancies occurred in cases where an incorrect choice was made from among multiple plausible explanations for an experimental result. We conclude that modified flavin studies are powerful probes of flavin environment; however, it is risky to specify details of interactions, especially because of uncertainties due to induced charge delocalization in the flavin.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Union Coll, Dept Chem, Schenectady, NY 12308 USA	Oregon State University; Union College	Karplus, PA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	karplusp@ucs.orst.edu		Karplus, Paul/0000-0001-8725-6292				BEINERT WD, 1985, EUR J BIOCHEM, V152, P573, DOI 10.1111/j.1432-1033.1985.tb09234.x; BEINERT WD, 1985, EUR J BIOCHEM, V152, P581, DOI 10.1111/j.1432-1033.1985.tb09235.x; BIEMANN M, 1983, J BIOL CHEM, V258, P5440; CLAIBORNE A, 1982, J BIOL CHEM, V257, P174; EBERLEIN G, 1983, J AM CHEM SOC, V105, P6679, DOI 10.1021/ja00360a023; FITZPATRICK PF, 1985, J BIOL CHEM, V260, P8483; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8095, DOI 10.1021/bi00372a045; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8103, DOI 10.1021/bi00372a046; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1984, J BIOL CHEM, V259, P9667; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4859, DOI 10.1021/bi00316a007; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAITO K, 1991, J BIOL CHEM, V266, P20720; Schopfer L. M., 1991, STUDY ENZYMES, P247; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; STOTT K, 1993, J BIOL CHEM, V268, P6097; THEORELL H, 1954, ACTA CHEM SCAND, V8, P877, DOI 10.3891/acta.chem.scand.08-0877; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	23	23	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9357	9362		10.1074/jbc.274.14.9357	http://dx.doi.org/10.1074/jbc.274.14.9357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092614	hybrid			2022-12-27	WOS:000079451800033
J	Ma, ZM; Wang, XY; Nowatzke, W; Ramanadham, S; Turk, J				Ma, ZM; Wang, XY; Nowatzke, W; Ramanadham, S; Turk, J			Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A(2) (iPLA(2)) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA(2) gene on chromosome 22q13.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; ARACHIDONIC-ACID MOBILIZATION; P388D(1) MACROPHAGES; SUBCELLULAR MEMBRANES; INSITU HYBRIDIZATION; SUICIDE INHIBITION; MESSENGER-RNA; ALLELIC LOSS; BETA-CELLS; RAT	An 85-kDa Group VI phospholipase A, enzyme (iPLA(2)) that does not require Ca2+ for catalysis has recently been cloned from three rodent species. A homologous 88-kDa enzyme has been cloned from human B-lymphocyte lines that contains a 54-amino acid insert not present in the rodent enzymes, but human cells have not previously been observed to express catalytically active iPLA(2) isoforms other than the 88-kDa protein. We have cloned cDNA species that encode two distinct iPLA(2) isoforms from human pancreatic islet RNA and a human insulinoma cDNA library. One isoform is an 85-kDa protein (short isoform of human iPLA(2) (SH-iPLA(2))) and the other an 88-kDa protein (long isoform of human iPLA, (LH-iPLA(2))). Transcripts encoding both isoforms are also observed in human promonocytic U937 cells. Recombinant SH-iPLA(2) and LH-iPLA(2) are both catalytically active in the absence of Ca2+ and inhibited by a bromoenol lactone suicide substrate, but LH-iPLA(2) is activated by ATP, whereas SH-iPLA(2) is not. The human iPLA(2) gene has been found to reside on chromosome 22 in region q13.1 and to contain 16 exons represented in the LH-iPLA(2) transcript. Exon 8 is not represented in the SH-iPLA(2) transcript, indicating that it arises by an exon-skipping mechanism of alternative splicing. The amino acid sequence encoded by exon 8 of the human iPLA(2) gene is proline-rich and shares a consensus motif of PX(5)PX(8)HHPX(12)NX(4)Q with the proline-rich middle linker domains of the Smad proteins DAF-3 and Smad4, Expression of mRNA species encoding two active iPLA(2) isoforms with distinguishable catalytic properties in two different types of human cells demonstrated here may have regulatory or functional implications about the roles of products of the iPLA(2) gene in cell biologic processes.	Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Turk, J (corresponding author), Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, 660 S Euclid Ave,Box 8127, St Louis, MO 63110 USA.	jturk@imgate.wustl.edu			NCRR NIH HHS [P41 RR000954] Funding Source: Medline; NIDDK NIH HHS [R37 DK034388, R37-DK-34388, R01 DK069455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388, R01DK069455] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BENNETT V, 1992, J BIOL CHEM, V267, P8703; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DAVIS LG, 1994, BASIC METHODS MOL BI, P335; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Iida A, 1998, GENE CHROMOSOME CANC, V21, P108, DOI 10.1002/(SICI)1098-2264(199802)21:2<108::AID-GCC5>3.0.CO;2-4; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Loweth AC, 1998, DIABETES, V47, P727, DOI 10.2337/diabetes.47.5.727; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Miyakawa A, 1998, INT J ONCOL, V13, P705; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	64	88	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9607	9616		10.1074/jbc.274.14.9607	http://dx.doi.org/10.1074/jbc.274.14.9607			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092647	hybrid, Green Accepted			2022-12-27	WOS:000079451800066
J	Kang, HY; Yeh, SY; Fujimoto, N; Chang, CS				Kang, HY; Yeh, SY; Fujimoto, N; Chang, CS			Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER DOMAIN; CANCER DU145 CELLS; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; ZINC FINGER; GENE; SEQUENCE; HORMONE	Androgen receptor (AR) is a member of the steroid receptor superfamily that may require coactivators for proper or maximal transactivation. Using a yeast two-hybrid screening followed by mammalian cell analyses, we identified a novel ligand-dependent AR-associated protein, ARA54, which Consists of 474 amino acids with a molecular mass of 54 kDa. We demonstrated that ARA54 might function as a preferential coactivator for AR-mediated transactivation in human prostate cancer DU145 cells. Interestingly, our data also showed that ARA54 could significantly enhance the transcriptional activity of LNCaP mutant AR (ARt877a) but not wild type AR or another mutant AR (ARe708k) in the presence of 10 nM 17 beta-estradiol or 1 mu M hydroxyflutamide. These results imply that both ARA54 and the positions of the AR mutation (877 versus 708) might contribute to the specificity of AR-mediated transactivation. Our findings further demonstrated that the C-terminal domain of ARA54 can serve as a dominant negative inhibitor and exogenous full-length ARA54 can reverse this squelching effect on AR transcriptional activity. Co-expression of ARA54 with other AR coactivators, such as ARA70 or SRC-1, showed additive stimulation of AR-mediated transactivation, which indicates that these cofactors may function individually as AR coactivators to induce AR target gene expression. Through our findings, we have identified and characterized a novel AR coactivator, ARA54, which may play an important role in the AR signaling pathway in human prostate.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.	chang@pathology.rochester.edu	Kang, Hong-Yo/W-9031-2019	Kang, Hong-Yo/0000-0003-0626-5037	NATIONAL CANCER INSTITUTE [F32CA075732, R29CA055639, R01CA055639] Funding Source: NIH RePORTER; NCI NIH HHS [CA75732, CA55639, CA68568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; ISHIDA A, 1993, GENE, V129, P249, DOI 10.1016/0378-1119(93)90275-8; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; MCLEOD DG, 1993, CANCER, V71, P1046, DOI 10.1002/1097-0142(19930201)71:3+<1046::AID-CNCR2820711424>3.0.CO;2-M; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; MIYAMOTO H, 1998, MOL BASIS HORMONE RE, P42; ONATE SA, 1995, SCIENCE, V270, P1354; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG C, 1997, THESIS U MADISON WIS; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	40	175	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8570	8576		10.1074/jbc.274.13.8570	http://dx.doi.org/10.1074/jbc.274.13.8570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085091	hybrid			2022-12-27	WOS:000079451600033
J	Peschel, A; Otto, M; Jack, RW; Kalbacher, H; Jung, G; Gotz, F				Peschel, A; Otto, M; Jack, RW; Kalbacher, H; Jung, G; Gotz, F			Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL TEICHOIC-ACID; LIPOTEICHOIC ACID; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; D-ALANINE; BIOSYNTHESIS; EPIDERMIN; BACTERIA; GENES	Positively charged antimicrobial peptides with membrane-damaging activity are produced by animals and humans as components of their innate immunity against bacterial infections and also by many bacteria to inhibit competing microorganisms. Staphylococcus aureus and Staphylococcus xylosus, which tolerate high concentrations of several antimicrobial peptides, were mutagenized to identify genes responsible for this insensitivity. Several mutants with increased sensitivity were obtained, which exhibited an altered structure of teichoic acids, major components of the Gram-positive cell wall. The mutant teichoic acids lacked D-alanine, as a result of which the cells carried an increased negative surface charge. The mutant cells bound fewer anionic, but more positively charged proteins, They were sensitive to human defensin HNP1-3, animal-derived protegrins, tachyplesins, and magainin II, and to the bacteria-derived peptides gallidermin and nisin, The mutated genes shared sequence similarity with the dlt genes involved in the transfer of D-alanine into teichoic acids from other Gram-positive bacteria. Wild-type strains bearing additional copies of the dlt operon produced teichoic acids with higher amounts of D-alanine esters, bound cationic proteins less effectively and were less sensitive to antimicrobial peptides. We propose a role of the D-alanine-esterified teichoic acids which occur in many pathogenic bacteria in the protection against human and animal defense systems.	Univ Tubingen, D-72076 Tubingen, Germany; ECHAZ Microcollect, D-72070 Tubingen, Germany	Eberhard Karls University of Tubingen	Peschel, A (corresponding author), Univ Tubingen, Waldhauser Str 70-8, D-72076 Tubingen, Germany.	mikrogen@uni-tuebingen.de		Otto, Michael/0000-0002-2222-4115				AUGUSTIN J, 1990, FEMS MICROBIOL LETT, V66, P203, DOI 10.1016/0378-1097(90)90283-V; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BERKOWITZ BA, 1990, BIOCHEM PHARMACOL, V39, P625, DOI 10.1016/0006-2952(90)90138-B; BIERBAUM G, 1987, J BACTERIOL, V169, P5452, DOI 10.1128/jb.169.12.5452-5458.1987; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRUCKNER R, 1992, GENE, V122, P187, DOI 10.1016/0378-1119(92)90048-T; Bruckner R, 1997, FEMS MICROBIOL LETT, V151, P1; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DEBABOV DV, 1996, J BACTERIOL, V178, P2869; FISCHER W, 1988, ADV MICROB PHYSIOL, V29, P233, DOI 10.1016/S0065-2911(08)60349-5; Franklin MJ, 1996, J BACTERIOL, V178, P2186, DOI 10.1128/jb.178.8.2186-2195.1996; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; GOTZ F, 1981, J BACTERIOL, V145, P74; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; HEATON MP, 1992, J BACTERIOL, V174, P4707, DOI 10.1128/JB.174.14.4707-4717.1992; HEPTINSTALL S, 1970, NATURE, V225, P519, DOI 10.1038/225519a0; IORDANESCU S, 1976, J GEN MICROBIOL, V96, P277, DOI 10.1099/00221287-96-2-277; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Jack RW, 1996, APPL ENVIRON MICROB, V62, P2897, DOI 10.1128/AEM.62.8.2897-2903.1996; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KOCH HU, 1984, EUR J BIOCHEM, V138, P357, DOI 10.1111/j.1432-1033.1984.tb07923.x; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; MURPHY E, 1985, EMBO J, V4, P3357, DOI 10.1002/j.1460-2075.1985.tb04089.x; Nes IF, 1996, ANTON LEEUW INT J G, V70, P113, DOI 10.1007/BF00395929; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Otto M, 1998, FEMS MICROBIOL LETT, V166, P203, DOI 10.1016/S0378-1097(98)00333-4; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Peschel A, 1996, FEMS MICROBIOL LETT, V137, P279; Peschel A, 1997, MOL GEN GENET, V254, P312, DOI 10.1007/s004380050421; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; POLLACK JH, 1994, J BACTERIOL, V176, P7252, DOI 10.1128/JB.176.23.7252-7259.1994; POOLEY HM, 1994, BACTERIAL CELL WALL; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WU T, 1994, ANTIMICROB AGENTS CH, V38, P729, DOI 10.1128/AAC.38.4.729; YOUNGMAN P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P65	40	762	787	0	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8405	8410		10.1074/jbc.274.13.8405	http://dx.doi.org/10.1074/jbc.274.13.8405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085071	hybrid			2022-12-27	WOS:000079451600013
J	Prescott, SM				Prescott, SM			A thematic series on kinases and phosphatases that regulate lipid signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.								0	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8345	8345		10.1074/jbc.274.13.8345	http://dx.doi.org/10.1074/jbc.274.13.8345			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085059	hybrid			2022-12-27	WOS:000079451600001
J	Stempka, L; Schnolzer, M; Radke, S; Rincke, G; Marks, F; Gschwendt, M				Stempka, L; Schnolzer, M; Radke, S; Rincke, G; Marks, F; Gschwendt, M			Requirements of protein kinase C delta for catalytic function - Role of glutamic acid 500 and autophosphorylation on serine 643	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; TYROSINE PHOSPHORYLATION; PHORBOL ESTER; PKC-DELTA; ADDITIONAL MEMBERS; ENZYMATIC-ACTIVITY; MASS-SPECTROMETRY; IMMUNOGLOBULIN-E; IN-VIVO; ACTIVATION	Recently, we reported that, in contrast to protein kinase C (PKC) alpha and beta(II), PKC delta does not require phosphorylation of a specific threonine (Thr(505)) in the activation loop for catalytic competence (Stempka ct al, (1997) J, Biol, Chem, 272, 6805-6811). Here, we show that the acidic residue glutamic acid 500 (Glu(500)) in the activation loop is important for the catalytic function of PKC delta, A Glu(500) to valine mutant shows 76 and 73% reduced kinase activity toward autophosphorylation and substrate phosphorylation, respectively. With regard to thermal stability and inhibition by the inhibitors Go6976 and Go6983 the mutant does not differ from the wild type, indicating that the general conformation of the molecule is not altered by the site directed mutagenesis. Thus, Glu(500) in the activation loop of PKC delta might take over at least part of the role of the phosphate groups on Thr(497) and Thr(500) Of PKC alpha and beta(II), respectively. Accordingly, PKC delta exhibits kinase activity and is able to autophosphorylate probably without posttranslational modification. Autophosphorylation of PKC delta in vitro occurs on Ser(643), as demonstrated by matrix-assisted laser desorption ionization mass spectrometry of tryptic peptides of autophosphorylated PKC delta wild type and mutants. A peptide containing this site is phosphorylated also in vivo, i.e, in recombinant PKC delta purified from baculovirus-infected insect cells. A Ser(643) to alanine mutation indicates that autophosphorylation of Ser(643) is not essential for the kinase activity of PKC delta, Probably additional (auto)phosphorylation site(s) exist that have not yet been identified.	German Canc Res Ctr, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gschwendt, M (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	gschwendt@dbfi-heidelberg.de						Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Blobe GC, 1996, CANCER SURV, V27, P213; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GSCHWENDT M, 1986, BIOCHEM BIOPH RES CO, V137, P766, DOI 10.1016/0006-291X(86)91145-9; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hunn M, 1997, FEBS LETT, V400, P226, DOI 10.1016/S0014-5793(96)01395-6; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; LIEBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MAIZELS ET, 1992, J BIOL CHEM, V267, P17061; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; ORR JW, 1994, J BIOL CHEM, V269, P27715; PARKER PJ, 1997, PROTEIN KINASE C; Schnolzer M, 1997, INT J MASS SPECTROM, V169, P263, DOI 10.1016/S0168-1176(97)00233-4; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1994, J BIOL CHEM, V269, P19578	54	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8886	8892		10.1074/jbc.274.13.8886	http://dx.doi.org/10.1074/jbc.274.13.8886			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085132	hybrid			2022-12-27	WOS:000079451600074
J	Wong, L; Deb, TB; Thompson, SA; Wells, A; Johnson, GR				Wong, L; Deb, TB; Thompson, SA; Wells, A; Johnson, GR			A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC-CANCER; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; KINASE-ACTIVITY; AUTOPHOSPHORYLATION SITES; HEPARAN-SULFATE; HUMAN-PLACENTA; ERBB-2 KINASE; FACTOR FAMILY; FACTOR-ALPHA	The epidermal growth factor receptor (EGFR) mediates the actions of a family of bioactive peptides that include epidermal growth factor (EGF) and amphiregulin (AR). Here we have studied AR and EGF mitogenic signaling in EGFR devoid NR6 fibroblasts that ectopically express either wild type EGFR (WT) or a truncated EGFR that lacks the three major sites of autophosphorylation (c'1000). COOH-terminal truncation of the EGFR significantly impairs the ability of AR to (i) stimulate DNA synthesis, (ii) elicit Elk-1 transactivation, and (iii) generate sustained enzymatic activation of mitogen-activated protein kinase. EGFR truncation had no significant effect on AR binding to receptor but did result in defective GRB2 adaptor function. In contrast, EGFR truncation did not impair EGF mitogenic signaling, and in c'1000 cells EGF was able to stimulate the association of ErbB2 with GRB2 and SHC. Elk-1 transactivation was monitored when either ErbB2 or a truncated dominant-negative ErbB2 mutant (ErbB2-(1-813)) was overexpressed in cells. Overexpression of full-length ErbB2 resulted in a strong constitutive transactivation of Elk-1 in c'1000 but only slightly stimulated Elk-1 in WT or parental NR6 cells. Conversely, overexpression of ErbB2-(1-813) inhibited EGF-stimulated Elk-1 transactivation in c'1000 but not in WT cells. Thus, the cytoplasmic tail of the EGFR plays a critical role in AR mitogenic signaling but is dispensable for EGF, since EGF-activated truncated EGFRs can signal through ErbB2.	US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA; Berlex Biosci, Dept Prot Chem & Biophys, Richmond, CA 94804 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35294 USA	US Food & Drug Administration (FDA); University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Johnson, GR (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bldg 29A,Rm 3B-16,8800 Rockville Pike, Bethesda, MD 20892 USA.			Wells, Alan/0000-0002-1637-8150	PHS HHS [R01-54739] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; EBERT M, 1994, CANCER RES, V54, P3959; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANES PW, 1994, ONCOGENE, V9, P3601; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI NX, 1994, ONCOGENE, V9, P3457; LYSIAK JJ, 1995, PLACENTA, V16, P359, DOI 10.1016/0143-4004(95)90093-4; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PIPEKORN M, 1994, J CELL PHYSL, V159, P114; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Qian XL, 1996, ONCOGENE, V13, P2149; RICCI A, 1995, ONCOGENE, V11, P1519; Saeki T, 1995, JPN J CLIN ONCOL, V25, P240; SAEKI T, 1992, CANCER RES, V52, P3467; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEHGAL I, 1994, MOL BIOL CELL, V5, P339, DOI 10.1091/mbc.5.3.339; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SOLER C, 1994, ONCOGENE, V9, P2207; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YOKOYAMA M, 1995, INT J ONCOL, V6, P625	69	17	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8900	8909		10.1074/jbc.274.13.8900	http://dx.doi.org/10.1074/jbc.274.13.8900			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085134	hybrid			2022-12-27	WOS:000079451600076
J	Bessette, PH; Cotto, JJ; Gilbert, HF; Georgiou, G				Bessette, PH; Cotto, JJ; Gilbert, HF; Georgiou, G			In vivo and in vitro function of the Escherichia coli periplasmic cysteine oxidoreductase DsbG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; PANCREATIC TRYPSIN-INHIBITOR; IN-VIVO; BOND FORMATION; REDOX PROPERTIES; CELL-ENVELOPE; C-TYPE; THIOREDOXIN; STATES; BIOGENESIS	We have characterized in vivo and in vitro the recently identified DsbG from Escherichia coli, In addition to sharing sequence homology with the thiol disulfide exchange protein DsbC, DsbG: likewise was shown to form a stable periplasmic dimer, and it displays an equilibrium constant with glutathione comparable with DsbA and DsbC, DsbG was found to be expressed at approximately 25% the level of DsbC. In contrast to earlier results (Andersen, C, L,, Matthey-Dupraz, A., Missiakas, D., and Raina, S. (1997) Mel. Microbiol. 26, 121-132), we showed that dsbG is not essential for growth and that dsbG null mutants display no defect in folding of multiple disulfide-containing heterologous proteins. Overexpression of DsbG:, however, was able to restore the ability of dsbC mutants to express heterologous multidisulfide proteins, namely bovine pancreatic trypsin inhibitor, a protein with three disulfides, and to a lesser extent, mouse urokinase (12 disulfides), As in DsbC, the putative active site thiols in DsbG are completely reduced in vivo in a dsbD-dependent fashion, as would be expected if DsbG is acting as a disulfide isomerase or reductase. However, the latter is not likely because DsbG could not catalyze insulin reduction in vitro. Overall, our results indicate that DsbC functions primarily as a periplasmic disulfide isomerase with a narrower substrate specificity than DsbC.	Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	University of Texas System; University of Texas Austin; Baylor College of Medicine	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, Dean Keaton & Speedway, Austin, TX 78758 USA.	gg@che.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047520] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-47520] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; BERGLUND O, 1975, J BIOL CHEM, V250, P2778; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DUVOISIN RM, 1986, GENE, V45, P193, DOI 10.1016/0378-1119(86)90254-4; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Joly JC, 1998, P NATL ACAD SCI USA, V95, P2773, DOI 10.1073/pnas.95.6.2773; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Missiakas D, 1997, TRENDS BIOCHEM SCI, V22, P59, DOI 10.1016/S0968-0004(96)10072-4; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; OSTERMEIER MA, 1996, THESIS U TEXAS AUSTI; Page MD, 1997, MOL MICROBIOL, V24, P977, DOI 10.1046/j.1365-2958.1997.4061775.x; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; Sone M, 1997, J BIOL CHEM, V272, P10349; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Zander T, 1998, METHOD ENZYMOL, V290, P59, DOI 10.1016/S0076-6879(98)90007-6; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	45	137	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7784	7792		10.1074/jbc.274.12.7784	http://dx.doi.org/10.1074/jbc.274.12.7784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075670	hybrid			2022-12-27	WOS:000079268100029
J	Fazio, S; Linton, MF; Hasty, AH; Swift, LL				Fazio, S; Linton, MF; Hasty, AH; Swift, LL			Recycling of apolipoprotein E in mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; HEPARAN-SULFATE PROTEOGLYCANS; BONE-MARROW TRANSPLANTATION; E-DEFICIENT MICE; LIPOPROTEIN RECEPTOR; PERITONEAL-MACROPHAGES; GOLGI-APPARATUS; HEPATIC GOLGI; APOPROTEIN-E; BETA-VLDL	Following the internalization of low density lipoprotein (LDL) by the LDL receptor within cells, both the lipid and the protein components of LDL are completely degraded within the lysosomes. Remnant lipoproteins are also internalized by cells via the LDL receptor as well as other receptors, but the events following the internalization of these complexes, which use apolipoprotein E (apoE) as their ligand for receptor capture, have not been defined. There is evidence that apoE-containing beta-very low density lipoproteins follow differential intracellular routing depending on their size and apoE content and that apoE internalized with lipoproteins can be resecreted by cultured hepatocytes and fibroblasts. In the present studies, we addressed the question of apoE sparing or recycling as a physiologic phenomenon. Remnant lipoproteins (d < 1.019 g/ml) from normal mouse plasma were iodinated and injected into normal C57BL/6 mice. Livers were collected at 10, 30, 60, and 120 min after injection, and hepatic Golgi fractions were prepared for gel electrophoresis analysis. Golgi preparations were analyzed for galactosyltransferase enrichment (>40-fold above cell homogenate) and by appearance of the Golgis stacks and vesicles on electron microscopy. Iodinated apoE was consistently found in the Golgi fractions peaking at 10 min and disappearing by 2 h after injection. Although traces of apoB48 were present in the Golgi fractions, the apoE/apoB ratio in the Golgi was 50-fold higher compared with serum. Quantitatively similar results were obtained when the very low density lipoprotein remnants were injected into mice deficient in either apoE or the LDL receptor, indicating that the phenomenon of apoE recycling is not influenced by the production of endogenous apoE and is not dependent on the presence of LDL receptors. In addition, radioactive apoE in the Golgi fractions was part of d = 1.019-1.21 g/ml complexes, indicating an association of recycled apoE with either newly formed lipoproteins or the internalized complexes. These studies show that apoE recycling is a physiologic phenomenon in vivo and establish the presence of a unique pathway of intracellular processing of apoE-containing remnant lipoproteins.	Vanderbilt Univ, Ctr Med, Div Endocrinol & Diabet,Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Fazio, S (corresponding author), Vanderbilt Univ, Ctr Med, Div Endocrinol & Diabet,Sch Med, Dept Med, 715 MRB 2, Nashville, TN 37232 USA.	sergio.fazio@mcmail.vanderbilt.edu	Hasty, Alyssa/AAA-2757-2020	Hasty, Alyssa/0000-0001-7302-8045	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057984, R01HL057986] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57986, HL57984, R01 HL057986] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1995, CIRCULATION S, V92, P691; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BROWN MS, 1978, MICROENVIRONMENTS ME, P87; BROWN MS, 1907, J SUPRAMOL STRUCT, V6, P85; CHEN CM, 1995, CIRCULATION S, V92, P691; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DAVIS RA, 1989, J BIOL CHEM, V264, P8970; ECK MV, 1997, ARTERIOSCLER THROMB, V17, P3117; FAZIO S, 1992, J BIOL CHEM, V267, P6941; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; HAMILTON RL, 1991, J LIPID RES, V32, P529; HARRISON JC, 1988, J LIPID RES, V29, P1439; HASTY AH, 1997, CIRCULATION S, V96, P104; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HORNICK CA, 1985, J CELL BIOL, V100, P1558, DOI 10.1083/jcb.100.5.1558; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MORRE DJ, 1969, BIOCHEM BIOPH RES CO, V37, P813; PALMITER RD, 1969, BIOCHIM BIOPHYS ACTA, V178, P35, DOI 10.1016/0005-2744(69)90129-6; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; SWIFT LL, 1987, J LIPID RES, V28, P207; SWIFT LL, 1980, J CLIN INVEST, V66, P415, DOI 10.1172/JCI109871; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WONG L, 1989, J CELL PHYSIOL, V141, P441, DOI 10.1002/jcp.1041410227; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	44	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8247	8253		10.1074/jbc.274.12.8247	http://dx.doi.org/10.1074/jbc.274.12.8247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075730	hybrid			2022-12-27	WOS:000079268100089
J	Kapus, A; Szaszi, K; Sun, JG; Rizoli, S; Rotstein, OD				Kapus, A; Szaszi, K; Sun, JG; Rizoli, S; Rotstein, OD			Cell shrinkage regulates Src kinases and induces tyrosine phosphorylation of cortactin, independent of the osmotic regulation of Na+/H+ exchangers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; THICK ASCENDING LIMB; HAMSTER OVARY CELLS; C-SRC; ACTIN CYTOSKELETON; OXIDATIVE STRESS; FAMILY KINASES; SUBSTRATE; TRANSLOCATION	The signaling pathways by which cell volume regulates ion transporters, e.g. Na+/H+ exchangers (NHEs), and affects cytoskeletal organization are poorly understood, We have previously shown that shrinkage induces tyrosine phosphorylation in CHO cells, predominantly in an 85-kDa band. To identify volume-sensitive kinases and their substrates, we investigated the effect of hypertonicity on members of the Src kinase family. Hyperosmolarity stimulated Fyn and inhibited Src, Fyn activation was also observed in nystatin-permeabilized cells, where shrinkage cannot induce intracellular alkalinization, In contrast, osmotic inhibition of Src was prevented by permeabilization or by inhibiting NHE-1, PPI, a selective Src family inhibitor, strongly reduced the hypertonicity-induced tyrosine phosphorylation. We identified one of the major targets of the osmotic stress-elicited phosphorylation as cortactin, an 85-kDa actin-binding protein and well known Src family substrate. Cortactin phosphorylation was triggered by shrinkage and not by changes in osmolarity or pH(i) and was abrogated by PP1, Hyperosmotic cortactin phosphorylation was reduced in Fyn-deficient fibroblasts but remained intact in Src-deficient fibroblasts, To address the potential role of the Src family in the osmotic regulation of NHEs, we used PP1. The drug affected neither the hyperosmotic stimulation of NHE-1 nor the inhibition of NHE-3, Thus, members of the Src family are volume-sensitive enzymes that may participate in the shrinkage-related reorganization of the cytoskeleton but are probably not responsible for the osmotic regulation of NHE.	Toronto Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Semmelweis Univ Med, Dept Physiol, H-1444 Budapest 8, Hungary; Univ Toronto, Toronto, ON M5G 1L7, Canada; Semmelweis Univ Med, Lab Cellular & Mol Physiol, H-1444 Budapest, Hungary	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Semmelweis University; University of Toronto; Semmelweis University	Kapus, A (corresponding author), Toronto Hosp, Dept Surg, Rm CCRW 2-850,101 Coll St, Toronto, ON M5G 1L7, Canada.	akapus@transplantunit.org	Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; DeFranceschi L, 1997, J CLIN INVEST, V99, P220, DOI 10.1172/JCI119150; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GOOD DW, 1995, J BIOL CHEM, V270, P9883, DOI 10.1074/jbc.270.17.9883; HALLOWS KR, 1991, AM J PHYSIOL, V261, pC1154, DOI 10.1152/ajpcell.1991.261.6.C1154; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haussinger D, 1996, BIOCHEM J, V313, P697; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MAA MC, 1992, ONCOGENE, V7, P2429; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; NADA S, 1994, ONCOGENE, V9, P3571; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; Okazaki T, 1997, J BIOL CHEM, V272, P32274, DOI 10.1074/jbc.272.51.32274; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1998, BIOCHEMISTRY-US, V37, P5481, DOI 10.1021/bi9729460; Rivero F, 1996, J CELL SCI, V109, P2679; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SARTOR O, 1993, J BIOL CHEM, V268, P21014; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; Shrode LD, 1997, J BIOL CHEM, V272, P13653, DOI 10.1074/jbc.272.21.13653; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; Susztak K, 1997, BIOCHEM J, V325, P501, DOI 10.1042/bj3250501; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; WATTS BA, 1994, J BIOL CHEM, V269, P20250; Weed SA, 1998, J CELL SCI, V111, P2433; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wiese S, 1998, BIOL CHEM, V379, P667, DOI 10.1515/bchm.1998.379.6.667; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; Yamaji Y, 1997, AM J PHYSIOL-CELL PH, V272, pC886, DOI 10.1152/ajpcell.1997.272.3.C886; ZHAN X, 1994, J BIOL CHEM, V269, P20221	68	140	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8093	8102		10.1074/jbc.274.12.8093	http://dx.doi.org/10.1074/jbc.274.12.8093			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075710	hybrid			2022-12-27	WOS:000079268100069
J	Pellaud, J; Schote, U; Arvinte, T; Seelig, J				Pellaud, J; Schote, U; Arvinte, T; Seelig, J			Conformation and self-association of human recombinant transforming growth factor-beta 3 in aqueous solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; CRYSTAL-STRUCTURE; BIOLOGICAL-ACTIVITIES; RECEPTOR-BINDING; GROWTH-FACTOR-BETA-2; ACTIVATION; EXPRESSION; REPAIR; BONE; PURIFICATION	The transforming growth factors-beta (TGF-beta) are important regulatory peptides for cell growth and differentiation with therapeutic potential for wound healing. Among the several TGF-beta isoforms TGF-beta 3 has a particularly low solubility at physiological pH and easily forms aggregates. A spectroscopic structural analysis of TGF-beta 3 in solution has thus been difficult. In this study, circular dichroism spectroscopy was used to determine the secondary structural elements of TGF-beta 3, In addition, the aggregation of TGF-beta 3 was investigated systematically as a function of pH and salt concentration using a rapid screening method, Sedimentation equilibrium and sedimentation velocity analysis revealed that TGF-beta S exists predominantly in two major forms: (i) monomers in solution at low pH and (ii) large precipitating aggregates at physiological pH, Under acidic conditions (pH < 3.8) the protein was not aggregated, At pH similar to 3.9, a monomer reversible arrow dimer equilibrium could be detected that transformed into larger aggregates at pH > 4.1, Aggregation was pronounced in the pH range of 4.3 < pH < 9.8 with the aggregation maximum between pH 6.5 and 8.5. The aggregation process was accompanied by a structural change of the protein, The CD spectra were characterized by an isodichroic point at 209.5 nm indicating a two-state equilibrium between TGF-beta 3 dissolved in solution and aggregated TGF-beta 3. Aggregated TGF-beta S showed a higher beta-sheet content and lower beta-turn and random coil contributions compared with monomeric TGF-beta 3, Both the solution structure and the aggregate structure of TGF-beta 3 were different from the crystal structure. This was in contrast to TGF-beta 2, which showed very similar crystal and solution structures. Under alkaline conditions (pH > 9.8) the turbidity disappeared and a further conformational change was induced, The pH dependence of the TGF-beta S conformation in solution in the range of 2.3 < pH < 11.0 was reversible. Aggregation of TGF-beta S was, furthermore, influenced by the presence of salt. For pH > 3.8 the addition of salt greatly enhanced the tendency to aggregate, even in the very basic domain. Under physiological conditions (pH 7,4, c(NaCl) = 164 mM) TGF-beta 3 has almost the highest tendency to aggregate and will remain in solution only at nanomolar concentrations.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Novartis Pharma AG, Pharmaceut & Analyt Dev, CH-4002 Basel, Switzerland	University of Basel; Novartis	Seelig, J (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	seelig1@ubaclu.unibas.ch						Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Bonewald LF, 1997, ENDOCRINOLOGY, V138, P657, DOI 10.1210/en.138.2.657; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Chambaz EM, 1996, HORM RES, V45, P222; CHERVENKA CH, 1970, MANUAL METHODS ANAL; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kloen P, 1997, CANCER, V80, P2230; KOPPA SD, 1994, DRUG THER, V24, P34; LEBERMAN R, 1991, FEBS LETT, V284, P293, DOI 10.1016/0014-5793(91)80707-A; LEVINE JH, 1993, AM J PATHOL, V143, P368; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIHALYI E, 1968, J CHEM ENG DATA, V13, P179, DOI 10.1021/je60037a011; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Naef M, 1997, INT J CANCER, V71, P131; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; Roth DA, 1997, PLAST RECONSTR SURG, V99, P300, DOI 10.1097/00006534-199702000-00002; RUNSER S, 1995, BIOTECHNOL APPL BIOC, V22, P39; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHMID P, 1993, J PATHOL, V171, P191, DOI 10.1002/path.1711710307; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TENDIJKE P, 1990, MOL CELL BIOL, V10, P4473, DOI 10.1128/MCB.10.9.4473; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075	40	50	51	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7699	7704		10.1074/jbc.274.12.7699	http://dx.doi.org/10.1074/jbc.274.12.7699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075659	hybrid			2022-12-27	WOS:000079268100018
J	Buse, P; Tran, SH; Luther, E; Phu, PT; Aponte, GW; Firestone, GL				Buse, P; Tran, SH; Luther, E; Phu, PT; Aponte, GW; Firestone, GL			Cell cycle and hormonal control of nuclear-cytoplasmic localization of the serum- and glucocorticoid-inducible protein kinase, Sgk, in mammary tumor cells - A novel convergence point of anti-proliferative and proliferative cell signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-ALPHA; RAT HEPATOMA-CELLS; GENE-EXPRESSION; 3T3 FIBROBLASTS; TRANSCRIPTION FACTORS; ANCHORING PROTEINS; PROMOTER ACTIVITY; DNA-BINDING; S6 KINASE; RECEPTOR	The serum- and glucocorticoid-inducible kinase (sgk) is a novel serine/threonine protein kinase that is transcriptionally regulated in rat mammary tumor cells by serum under proliferative conditions or by glucocorticoids that induce a G(1) cell cycle arrest, Our results establish that the subcellular distribution of Sgk is under stringent cell cycle and hormonal control. Sgk is localized to the perinuclear or cytoplasmic compartment as a 50-kDa hypophosphorylated protein in cells arrested in G(1) by treatment with the synthetic glucocorticoid dexamethasone, In serum-stimulated cells, Sgk was transiently hyperphosphorylated and resided in the nucleus. Laser scanning cytometry, which monitors Sgk localization and DNA content in individual mammary tumor cells of an asynchronously growing population, revealed that Sgk actively shuttles between the nucleus (in S and G(2)/M) and the cytoplasm (in G(1)) in synchrony with the cell cycle. In cells synchronously released from the G(1)/S boundary, Sgk localized to the nucleus during progression through S phase. The forced retention of exogenous Sgk in either the cytoplasmic compartment, using a wild type sgk gene, or the nucleus, using a nuclear localization signal-containing sgk gene (NLS-Sgk), suppressed the growth and DNA synthesis of serum-stimulated cells, Thus, our study implicates the nuclear-cytoplasmic shuttling of sgk as a requirement for cell cycle progression and represents a novel convergence point of anti-proliferative and proliferative signaling in mammary tumor cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; CompuCyte Corp, Cambridge, MA 02139 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.		Luther, Ed/AAO-7064-2020; Luther, Ed/AAA-2536-2021		NATIONAL CANCER INSTITUTE [R01CA071514] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER DB, 1993, CANCER RES, V53, P1808; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; Almawi WY, 1996, J LEUKOCYTE BIOL, V60, P563, DOI 10.1002/jlb.60.5.563; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; CHOI KY, 1994, CELL, V78, P499; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dowd DR, 1997, MOL CELL ENDOCRINOL, V128, P29, DOI 10.1016/S0303-7207(96)04012-9; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fode C, 1996, MOL CELL BIOL, V16, P4665; GERADTS J, 1986, CANCER RES, P1920; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Hansson A, 1996, CELL BIOCHEM FUNCT, V14, P121; HARAGUCHI T, 1991, J BIOL CHEM, V266, P18299; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IRESTONE GL, 1995, HORMONES AGING, P325; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Koli K, 1996, ADV CANCER RES, V70, P63, DOI 10.1016/S0065-230X(08)60872-6; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monfar M, 1996, MOL ENDOCRINOL, V10, P1107, DOI 10.1210/me.10.9.1107; MURPHY LJ, 1994, J STEROID BIOCHEM, V48, P419, DOI 10.1016/0960-0760(94)90189-9; MUSGROVE EA, 1994, SEMIN CANCER BIOL, V5, P381; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; RHEE K, 1995, CANCER RES, V55, P4188; Rider LG, 1996, J IMMUNOL, V157, P2374; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SEGER R, 1995, FASEB J, V9, P727; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; WEBSTER MK, 1991, CANCER RES, V51, P6031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	74	113	124	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7253	7263		10.1074/jbc.274.11.7253	http://dx.doi.org/10.1074/jbc.274.11.7253			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066787	hybrid			2022-12-27	WOS:000079078400059
J	Fillebeen, C; Descamps, L; Dehouck, MP; Fenart, L; Benaissa, M; Spik, G; Cecchelli, R; Pierce, A				Fillebeen, C; Descamps, L; Dehouck, MP; Fenart, L; Benaissa, M; Spik, G; Cecchelli, R; Pierce, A			Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR; HYDROXYL-RADICAL PRODUCTION; VASCULAR SMOOTH-MUSCLE; ENDOTHELIAL-CELLS; LDL-RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; CAPILLARY-PERMEABILITY; PLASMINOGEN-ACTIVATOR; CEREBROSPINAL-FLUID	Lactoferrin (Lf) is an iron-binding protein involved in host defense against infection and severe inflammation; it accumulates in the brain during neurodegenerative disorders. Before determining Lf function in brain tissue, we investigated its origin and demonstrate here that it crosses the blood-brain barrier. An in vitro model of the blood-brain barrier was used to examine the mechanism of Lf transport to the brain. We report that differentiated bovine brain capillary endothelial cells exhibited specific high (K-d = 37.5 nM; n = 90,000/cell) and low (K-d = 2 mu M; n = 900,000 sites/cell) affinity binding sites. Only the latter were present on nondifferentiated cells. The surface-bound Lf was internalized only by the differentiated cell population leading to the conclusion that Lf receptors were acquired during cell differentiation. A specific unidirectional transport then occurred via a receptor-mediated process with no apparent intraendothelial degradation. We further report that iron may cross the bovine brain capillary endothelial cells as a complex with Lf, Finally, we show that the low density lipoprotein receptor-related protein might be involved in this process because its specific antagonist, the receptor-associated protein, inhibits 70% of Lf transport.	Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; Inst Pasteur, Serv Etud & Rech Lipoprot & Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Artois, Fac Jean Perrin, F-62307 Lens, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite d'Artois	Pierce, A (corresponding author), Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France.			Fenart, Laurence/0000-0001-9285-0579				AMBRUSO DR, 1981, J CLIN INVEST, V67, P352, DOI 10.1172/JCI110042; Bi BY, 1996, EUR J CELL BIOL, V69, P288; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; BORSTEIN MB, 1958, LAB INVEST, V7, P134; BRITIGAN BE, 1989, BIOCHEM J, V264, P447, DOI 10.1042/bj2640447; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHERON A, 1977, CR ACAD SCI D NAT, V284, P585; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; CONNOR JR, 1992, ANN NEUROL S, V32, P51; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; DEHOUCK B, 1994, J CELL BIOL, V126, P465, DOI 10.1083/jcb.126.2.465; DEHOUCK M-P, 1990, Circulation et Metabolisme du Cerveau, V7, P151; Descamps L, 1997, J NEUROIMMUNOL, V74, P173, DOI 10.1016/S0165-5728(96)00226-3; Descamps L, 1996, AM J PHYSIOL-HEART C, V270, pH1149, DOI 10.1152/ajpheart.1996.270.4.H1149; FAUCHEUX BA, 1995, P NATL ACAD SCI USA, V92, P9603, DOI 10.1073/pnas.92.21.9603; FAUCHEUX BA, 1993, J NEUROCHEM, V60, P2338, DOI 10.1111/j.1471-4159.1993.tb03527.x; FILLEBEEN C, 1998, ADV LACTOFERRIN RES, P296; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GOAVEC M, 1985, CR ACAD SCI III-VIE, V301, P689; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HALLGREN R, 1982, INFLAMMATION, V6, P291, DOI 10.1007/BF00916410; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUTTINGER M, 1992, J BIOL CHEM, V267, P18551; JENNER P, 1996, NEUROLOGY S3, V47, P161; KAWAMATA T, 1993, AM J PATHOL, V142, P1574; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Legrand D, 1997, BIOCHEM J, V327, P841, DOI 10.1042/bj3270841; LEVEUGLE B, 1994, BRAIN RES, V650, P20, DOI 10.1016/0006-8993(94)90202-X; Leveugle B, 1996, ACTA NEUROPATHOL, V91, P566, DOI 10.1007/s004010050468; LEVEUGLE B, 1993, EUR J BIOCHEM, V213, P1205, DOI 10.1111/j.1432-1033.1993.tb17871.x; Masson P., 1970, LACTOFERRINE PROTEIN, P93; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MAZURIER J, 1989, EUR J BIOCHEM, V179, P481, DOI 10.1111/j.1432-1033.1989.tb14578.x; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; MERESSE S, 1989, J NEUROCHEM, V53, P1363, DOI 10.1111/j.1471-4159.1989.tb08526.x; MIKOGAMI T, 1995, BIOCHEM J, V308, P391, DOI 10.1042/bj3080391; MIKOGAMI T, 1994, AM J PHYSIOL, V267, P308; MILICI AJ, 1987, J CELL BIOL, V105, P2303; MONTREUIL J, 1960, BIOCHIM BIOPHYS ACTA, V45, P413, DOI 10.1016/0006-3002(60)91478-5; NILLESSE N, 1994, BIOL CELL, V82, P149, DOI 10.1016/S0248-4900(94)80017-0; Nuijens JH, 1996, J MAMMARY GLAND BIOL, V1, P285, DOI 10.1007/BF02018081; OSMAND AP, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P219; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SEVERS NJ, 1986, LAB INVEST, V55, P295; Siebert PD, 1997, P NATL ACAD SCI USA, V94, P2198, DOI 10.1073/pnas.94.6.2198; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; SPIK G, 1993, NEW PERSPECTIVES INF, P77; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TERENT A, 1981, STROKE, V12, P40, DOI 10.1161/01.STR.12.1.40; TOOYAMA I, 1995, BRAIN RES, V691, P235, DOI 10.1016/0006-8993(95)00735-9; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; Warshawsky I, 1996, EUR J CELL BIOL, V69, P156; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Ziere GJ, 1996, BIOCHEM J, V313, P289, DOI 10.1042/bj3130289; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069	62	291	330	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7011	7017		10.1074/jbc.274.11.7011	http://dx.doi.org/10.1074/jbc.274.11.7011			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066755	hybrid			2022-12-27	WOS:000079078400027
J	Shi, Y; Wang, SL; Krueger, S; Schwarz, FP				Shi, Y; Wang, SL; Krueger, S; Schwarz, FP			Effect of mutations at the monomer-monomer interface of cAMP receptor protein on specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CYCLIC-AMP RECEPTOR; ESCHERICHIA-COLI; REGULATORY PROTEIN; THERMODYNAMICS; COMPLEX; SITE; CAP; TRANSCRIPTION; ASSOCIATION	To determine the thermodynamic role of binding of an operon to cAMP receptor protein (CRP) in the activation of transcription, isothermal titration calorimetry measurements were performed on the binding of three 40-base pair DNA sequences to the cyclic nucleoside complexes of CRP and its mutants at 296 K, The three 40-base pair sequences consisted of a consensus DNA (conDNA) duplex derived from the CRP-binding site sequences of the operons activated by CRP and two DNA sequences based on the CRP-binding site sequences of the lac operon (lacDNA) and of the gal operon (galDNA), The mutants of CRP consisted of a T127L mutant, a S128A mutant, and a mutant containing both mutations (CRP*) which not only alter the transcriptional activity of the CRP complexes but also are involved in the monomer-monomer interfacial interactions of the CRP dimer, The binding reactions of the DNA duplexes to the fully cNMP-ligated CRP-mutant complexes were endothermic with binding constants as high as 6.6 +/- 1.1 x 10(6) M-1 (conDNA . CRP(cAMP)(2)). ConDNA binding to the unligated T127L and CRP* mutants was observed as well as conDNA and lacDNA binding to CRP with cAMP bound to only one monomer. The reduction of the binding constants with increase in KCl concentration indicated the formation of two ion pairs for the cAMP-ligated CRP and S128A complexes and four ion pairs for the cAMP-ligated T127L and CRP* complexes. Reduction of the DNA binding constants upon substitution of D2O for H2O in the buffer, the large heat capacity changes, and the enthalpy-entropy compensation exhibited by the binding reactions indicate the importance of dehydration in the binding reaction. Small angle neutron scattering measurements on the lacDNA . CRP(cAMP)(2) complex in D2O/ H2O mixtures show that the DNA is bent around the cAMP-ligated protein in solution.	Natl Inst Stand & Technol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	National Institute of Standards & Technology (NIST) - USA	Schwarz, FP (corresponding author), Natl Inst Stand & Technol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.							ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; CONNELLY PR, 1993, BIOCHEMISTRY-US, V32, P5583, DOI 10.1021/bi00072a013; CROMBRUGGHE B, 1984, SCIENCE, V224, P831; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Krueger S, 1998, J BIOL CHEM, V273, P20001, DOI 10.1074/jbc.273.32.20001; Krueger S, 1997, PHYSICA B, V241, P1131, DOI 10.1016/S0921-4526(97)00809-0; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lundback T, 1996, P NATL ACAD SCI USA, V93, P4754, DOI 10.1073/pnas.93.10.4754; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; MOORE JL, 1993, THESIS G WASHINGTON; MULLER N, 1991, J SOLUTION CHEM, V20, P669, DOI 10.1007/BF00650715; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; PORTE D, 1995, J BIOL CHEM, V270, P22721, DOI 10.1074/jbc.270.39.22721; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; Vossen KM, 1997, BIOCHEMISTRY-US, V36, P11640, DOI 10.1021/bi971193e; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; ZHANG XP, 1992, J BIOL CHEM, V267, P8136	34	22	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6946	6956		10.1074/jbc.274.11.6946	http://dx.doi.org/10.1074/jbc.274.11.6946			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066748	hybrid			2022-12-27	WOS:000079078400020
J	Miyata, S; Ruggeri, ZM				Miyata, S; Ruggeri, ZM			Distinct structural attributes regulating von Willebrand factor A1 domain interaction with platelet glycoprotein Ib alpha under flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; ACUTE CORONARY SYNDROMES; BOTHROPS-JARARACA; ARTERY DISEASE; RNA-POLYMERASE; FACTOR VWF; BOTROCETIN; VENOM; COMPLEX	We have used recombinant von Willebrand factor (vWF) fragments to investigate the properties regulating A1 domain interaction with platelet glycoprotein (GP) Ib alpha. One fragment, rvWF(508-704), represented the main portion of domain Al (mature subunit residues 497-716) within the Cys(509)-Cys(695) disulfide loop. The other, rvWF(445-733), included the carboxyl-terminal region of domain D3, preceding A1, and corresponded to the proteolytic fragment originally identified as the GP Ib alpha-binding site (residues 449-728), Conformational changes were induced by reduction and alkylation of the Cys509-Cys695 bond and/or exposure to acidic pH, The cyclic, rvWF(445-733) fragment exhibited the function of native VWF A1 domain. When immobilized onto a surface, it tethered platelets at shear rates up to 6,300 s(-1) mediating low velocity translocation but not stable attachment; in solution, it exhibited limited interaction with GP Ib alpha. In contrast, fragments with perturbed conformation could not tether platelets at high shear rates but promoted stable adhesion at lower shear and bound tightly to GP Ib alpha. Only in the presence of the exogenous modulator, botrocetin, did cyclic rvWF(445-733) mediate irreversible adhesion. Thus, conformational transitions in the VWF A1 domain may influence differentially the efficiency of bond formation with GP Ib alpha and the stability of binding.	Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Ruggeri, ZM (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, SBR-8,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950, R01HL042846, R37HL042846] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42846, HL-48728, HL-31950] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P17; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DEGROOT PG, 1988, J CLIN INVEST, V82, P65, DOI 10.1172/JCI113602; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; DISE CA, 1982, J BIOL CHEM, V257, P4701; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; KATAYAMA M, 1995, J BIOCHEM-TOKYO, V117, P331, DOI 10.1093/jb/117.2.331; Kawasaki T, 1996, J BIOL CHEM, V271, P10635, DOI 10.1074/jbc.271.18.10635; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; NIIYA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PRIOR CP, 1993, BIO-TECHNOL, V11, P709, DOI 10.1038/nbt0693-709; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; READ MS, 1989, BLOOD, V74, P1031; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; USAMI Y, 1993, P NATL ACAD SCI USA, V90, P928, DOI 10.1073/pnas.90.3.928; ZIMMERMAN TS, 1986, J CLIN INVEST, V77, P947, DOI 10.1172/JCI112394	45	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6586	6593		10.1074/jbc.274.10.6586	http://dx.doi.org/10.1074/jbc.274.10.6586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037753	hybrid			2022-12-27	WOS:000078902800075
J	Torres, GE; Egan, TM; Voigt, MM				Torres, GE; Egan, TM; Voigt, MM			Hetero-oligomeric assembly of P2X receptor subunits - Specificities exist with regard to possible partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; SENSORY NEURONS; ATP; RAT; PURINOCEPTORS; EXPRESSION; CLONING	P2X receptors are a distinct family of Ligand-gated ion channels activated by extracellular ATP, Each of the seven identified subunit proteins (P2X(1) through P2X(7)) has been reported to form functional homo-oligomeric channels when expressed in heterologous systems. Functional studies of native receptors, together with patterns of subunit gene expression, suggest that hetero-oligomeric assembly among members of this family may also occur. This prediction is supported by reports describing hetero-oligomeric assembly for three different recombinant subunit combinations. In this report, we systematically examined the ability of all members of the P2X receptor family to interact using a co-immunoprecipitation assay. The seven P2X receptor subunits were differentially epitope-tagged and expressed in various combinations in human embryonic kidney 293 cells. It was found that six of the seven subunits formed homooligomeric complexes, the exception being P2X(6). When co-assembly between pairs of subunits was examined, all were able to form hetero-oligomeric assemblies with the exception of P2X(7). Whereas P2X(1), P2X(2), P2X(5), and P2X(6) were able to assemble with most subunits, P2X(3) and P2X(4) presented a more restricted pattern of co-association, These results suggest that hetero-oligomeric assembly might underlie functional discrepancies observed between P2X responses seen in the native and recombinant settings, while providing for an increased diversity of signaling by ATP.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Voigt, MM (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	voigtm@slu.edu		Egan, Terrance/0000-0002-7249-3161	NHLBI NIH HHS [HL56236] Funding Source: Medline; NINDS NIH HHS [NS35534] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035534] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bardoni R, 1997, J NEUROSCI, V17, P5297; Barnard EA, 1998, PHARMACOL REV, V50, P291; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Burnstock G, 1996, CIBA F SYMP, V198, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Cario-Toumaniantz C, 1998, CIRC RES, V83, P196, DOI 10.1161/01.RES.83.2.196; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Collo G, 1996, J NEUROSCI, V16, P2495; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; KHAKH BS, 1995, BRIT J PHARMACOL, V115, P177, DOI 10.1111/j.1476-5381.1995.tb16336.x; Le KT, 1998, J NEUROSCI, V18, P7152; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Radford KM, 1997, J NEUROSCI, V17, P6529; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Soto M, 1996, BIOCHEM BIOPH RES CO, V223, P456, DOI 10.1006/bbrc.1996.0915; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1997, NEUROPHARMACOLOGY, V36, P1229, DOI 10.1016/S0028-3908(97)00126-3; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Xiang ZH, 1998, NEUROSCI LETT, V256, P105, DOI 10.1016/S0304-3940(98)00774-5; Zhong Y, 1998, BRIT J PHARMACOL, V125, P771, DOI 10.1038/sj.bjp.0702118	30	348	354	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6653	6659		10.1074/jbc.274.10.6653	http://dx.doi.org/10.1074/jbc.274.10.6653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037762	hybrid			2022-12-27	WOS:000078902800084
J	Mahajan, S; Ghosh, S; Sudbeck, EA; Zheng, YG; Downs, S; Hupke, M; Uckun, FM				Mahajan, S; Ghosh, S; Sudbeck, EA; Zheng, YG; Downs, S; Hupke, M; Uckun, FM			Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; CRYSTAL-STRUCTURE; CELL-DEATH; APOPTOSIS; RECEPTOR; COMPLEX; INHIBITORS; REGULATOR; PROTEINS	In a systematic effort to design potent inhibitors of the anti-apoptotic tyrosine kinase BTK (Bruton's tyrosine kinase) as anti-leukemic agents with apoptosis-promoting and chemosensitizing properties, we have constructed a three-dimensional homology model of the BTK kinase domain. Our modeling studies revealed a distinct rectangular binding pocket near the hinge region of the BTK kinase domain with Leu(460), Tyr(476) Arg(525), and Asp(539) residues occupying the corners of the rectangle. The dimensions of this rectangle are approximately 18 x 8 x 9 x 17 Angstrom, and the thickness of the pocket is approximately 7 Angstrom. Advanced docking procedures were employed for the rational design of leflunomide metabolite (LFM) analogs with a high likelihood to bind favorably to the catalytic site within the kinase domain of BTK. The lead compound LFM-A13, for which we calculated a K-i value of 1.4 mu M, inhibited human BTK in vitro with an IC50 value of 17.2 +/- 0.8 mu M. Similarly, LFRIA13 inhibited recombinant BTK expressed in a baculovirus expression vector system with an IC50 value of 2.5 mu M, The energetically favorable position of LFM-A13 in the binding pocket is such that its aromatic ring is close to Tyr(476), and its substituent group is sandwiched between residues Arg(525) and Asp(539). In addition, LFM-A13 is capable of favorable hydrogen bonding interactions with BTK via Asp(539) and Arg(525) residues. Besides its remarkable potency in BTK kinase assays, LFM-A13 was also discovered to be a highly specific inhibitor of BTK, Even at concentrations as high as 100 mu g/ml (similar to 278 mu M), this novel inhibitor did not affect the enzymatic activity of other protein tyrosine kinases, including JAK1, JAK3, HCK, epidermal growth factor receptor kinase, and insulin receptor kinase, In accordance with the anti-apoptotic function of BTK, treatment of BTK+ B-lineage leukemic cells with LFM-A13 enhanced their sensitivity to ceramide- or vincristine-induced apoptosis, To our knowledge, LFM-A13 is the first BTK-specific tyrosine kinase inhibitor and the first anti-leukemic agent targeting BTK.	Huges Inst, Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Huges Inst, Dept Biol Struct, St Paul, MN 55113 USA; Huges Inst, Dept Chem, St Paul, MN 55113 USA; Huges Inst, Dept Biochem, St Paul, MN 55113 USA; Huges Inst, Dept Expt Oncol, St Paul, MN 55113 USA; Huges Inst, Drug Discovery Program, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Huges Inst, Parker Hughes Canc Ctr, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.	Fatih_Uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743; BRUNGER AT, 1992, X PLOR VERSION 3 1; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo EA, 1996, J MED CHEM, V39, P4608, DOI 10.1021/jm9604437; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; *MOL SIM INC, 1996, INS 2; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SAOUAF SJ, 1995, J BIOL CHEM, V270, P27072, DOI 10.1074/jbc.270.45.27072; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SJOGREN EB, 1991, J MED CHEM, V34, P3295, DOI 10.1021/jm00115a020; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; WHYLLIE AH, 1980, INT REV CYTOL, V68, P251; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; [No title captured]	40	185	245	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9587	9599		10.1074/jbc.274.14.9587	http://dx.doi.org/10.1074/jbc.274.14.9587			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092645	hybrid			2022-12-27	WOS:000079451800064
J	Snyders, S; Kohorn, BD				Snyders, S; Kohorn, BD			TAKs, thylakoid membrane protein kinases associated with energy transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; PHOSPHORYLATION; SPECIFICITY; ACTIVATION; RECEPTOR	The phosphorylation of proteins within the eukaryotic photosynthetic membrane is thought to regulate a number of photosynthetic processes in land plants and algae. Both light quality and intensity influence protein kinase activity via the levels of reductants produced by the thylakoid electron transport chain. We have isolated a family of proteins called TAKs, Arabidopsis thylakoid membrane threonine kinases that phosphorylate the light harvesting complex proteins. TAK activity is enhanced by reductant and is associated with the photosynthetic reaction center II and the cytochrome b(6)f complex. TAKs are encoded by a gene family that has striking similarity to transforming growth factor beta receptors of metazoans. Thus thylakoid protein phosphorylation may be regulated by a cascade of reductant-controlled membrane-bound protein kinases.	Duke Univ, Dev Cell & Mol Biol Grp, Dept Bot, Durham, NC 27708 USA	Duke University	Kohorn, BD (corresponding author), Duke Univ, Dev Cell & Mol Biol Grp, Dept Bot, Box 91000, Durham, NC 27708 USA.	kohorn@acpub.duke.edu						Allen J. F., 1981, NATURE, V291, P21; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GAL A, 1995, PHOTOSYNTHESIS LIGHT, V3, P341; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; He ZH, 1996, J BIOL CHEM, V271, P19789, DOI 10.1074/jbc.271.33.19789; HENRIK N, 1997, PROTEIN ENG, V10, P1; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KEREN N, 1995, PHOTOSYNTHESIS LIGHT, V4, P299; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	22	87	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9137	9140		10.1074/jbc.274.14.9137	http://dx.doi.org/10.1074/jbc.274.14.9137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092584	hybrid			2022-12-27	WOS:000079451800003
J	Cascieri, MA; Koch, GE; Ber, E; Sadowski, SJ; Louizides, D; de Laszlo, SE; Hacker, C; Hagmann, WK; MacCoss, M; Chicchi, GG; Vicario, PP				Cascieri, MA; Koch, GE; Ber, E; Sadowski, SJ; Louizides, D; de Laszlo, SE; Hacker, C; Hagmann, WK; MacCoss, M; Chicchi, GG; Vicario, PP			Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; BINDING; HYPERGLYCEMIA; DELETION	We have identified a series of potent, orally bioavailable, non-peptidyl, triarylimidazole and triarylpyrrole glucagon receptor antagonists. 2-(4-Pyridyl)-5-(4-chlorophenyl)-3-(5-bromo-2-propyloxyphenyl)pyrrole (L-168,049), a prototypical member of this series, inhibits binding of labeled glucagon to the human glucagon receptor with an IC50 = 3.7 +/- 3.4 nM (n = 7) but does not inhibit binding of labeled glucagon-like peptide to the highly homologous human glucagon-like peptide receptor at concentrations up to 10 mu M. The binding affinity of L-168,049 for the human glucagon receptor is decreased 24-fold by the inclusion of divalent cations (5 mM), L-168,049 increases the apparent EC50 for glucagon stimulation of adenylyl cyclase in Chinese hamster ovary cells expressing the human glucagon receptor and decreases the maximal glucagon stimulation observed, with a K-b (concentration of antagonist that shifts the agonist dose-response 2-fold) of 25 nM. These data suggest that L-168,049 is a noncompetitive antagonist of glucagon action. Inclusion of L-168,049 increases the rate of dissociation of labeled glucagon from the receptor 4-fold, confirming that the compound is a noncompetitive glucagon antagonist, In addition, we have identified two putative transmembrane domain residues, phenylalanine 184 in transmembrane domain 2 and tyrosine 239 in transmembrane domain 3, for which substitution by alanine reduces the affinity of L-168,049 46- and 4.5-fold, respectively. These mutations do not alter the binding of labeled glucagon, suggesting that the binding sites for glucagon and L-168,049 are distinct.	Merck Res Labs, Dept Mol Pharmacol & Biochem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Cascieri, MA (corresponding author), Merck Res Labs, Dept Mol Pharmacol & Biochem, 80M-213,POB 2000, Rahway, NJ 07065 USA.							BRAND CL, 1994, DIABETOLOGIA, V37, P985, DOI 10.1007/BF00400461; Burcelin R, 1996, DIABETES METAB, V22, P373; Cascieri Margaret A., 1996, Drugs of the Future, V21, P521; Chicchi GG, 1997, J BIOL CHEM, V272, P7765, DOI 10.1074/jbc.272.12.7765; COLLINS JL, 1992, BIOORG MED CHEM LETT, V2, P915, DOI 10.1016/S0960-894X(00)80587-9; DELASZLO SE, 1999, IN PRESS BIOORG MED; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; GYSIN B, 1987, J MED CHEM, V30, P1409, DOI 10.1021/jm00391a024; JELENEK LJ, 1993, SCIENCE, V259, P1614; JOHNSON DG, 1982, SCIENCE, V215, P1115, DOI 10.1126/science.6278587; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; Roden M, 1996, J CLIN INVEST, V97, P642, DOI 10.1172/JCI118460; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310	15	85	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8694	8697		10.1074/jbc.274.13.8694	http://dx.doi.org/10.1074/jbc.274.13.8694			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085108	hybrid			2022-12-27	WOS:000079451600050
J	Franke, CM; Tiemersma, J; Venema, G; Kok, J				Franke, CM; Tiemersma, J; Venema, G; Kok, J			Membrane topology of the lactococcal bacteriocin ATP-binding cassette transporter protein LcnC - Involvement of LcnC in lactococcin A maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIS SUBSP LACTIS; ESCHERICHIA-COLI; STREPTOCOCCUS-LACTIS; ALKALINE-PHOSPHATASE; P-GLYCOPROTEIN; ABC TRANSPORTERS; IMMUNITY PROTEIN; CLONING VECTORS; PLASMID; FUSION	Many non-lantibiotic bacteriocins of lactic acid bacteria are produced as precursors with N-terminal leader peptides different from those present in preproteins exported by the general sec-dependent (type II) secretion pathway. These bacteriocins utilize a dedicated (type I) secretion system for externalization. The secretion apparatus for the lactococcins A, B, and M/N (LcnA, B, and M/N) from Lactococcus lactis is composed of the two membrane proteins LcnC and LcnD, LcnC belongs to the ATP-binding cassette transporters, whereas LcnD is a protein with similarities to other accessory proteins of type I secretion systems, This paper shows that the N-terminal part of LcnC is involved in the processing of the precursor of LcnA By making translational fusions of LcnC to the reporter proteins beta-galactosidase (LacZ) and alkaline phosphatase (PhoA*), it was shown that both the N- and C-terminal parts of LcnC are located in the cytoplasm, As the N terminus of LcnC is required for LcnA maturation and is localized in the cytoplasm, we conclude that the processing of the bacteriocin LcnA to its mature form takes place at the cytosolic side of the cytoplasmic membrane.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Kok, J (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	J.Kok@biol.rug.nl	Kok, Jan/C-9972-2012					AXELSSON L, 1995, J BACTERIOL, V177, P2125, DOI 10.1128/jb.177.8.2125-2137.1995; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHOPIN A, 1984, PLASMID, V11, P260, DOI 10.1016/0147-619X(84)90033-7; DANIELSEN S, 1995, MICROBIOL-SGM, V141, P2905, DOI 10.1099/13500872-141-11-2905; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DIAZGUERRA L, 1989, J BACTERIOL, V171, P2906, DOI 10.1128/jb.171.5.2906-2908.1989; DIEP DB, 1994, APPL ENVIRON MICROB, V60, P160, DOI 10.1128/AEM.60.1.160-166.1994; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DOVER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Franke CM, 1996, J BACTERIOL, V178, P1766, DOI 10.1128/jb.178.6.1766-1769.1996; GASSON MJ, 1983, J BACTERIOL, V154, P1; GILMORE MS, 1994, J BACTERIOL, V176, P7335, DOI 10.1128/JB.176.23.7335-7344.1994; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; Hwang JW, 1997, J BACTERIOL, V179, P6264, DOI 10.1128/jb.179.20.6264-6270.1997; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KOK J, 1993, BACTERIOCINS LACTIC, P121; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; NEWTON G, 1991, MOL MICROBIOL, V5, P2511, DOI 10.1111/j.1365-2958.1991.tb02097.x; PEARCE SR, 1992, MOL MICROBIOL, V6, P47, DOI 10.1111/j.1365-2958.1992.tb00836.x; PRINZ WA, 1994, J BACTERIOL, V176, P6410, DOI 10.1128/jb.176.20.6410-6413.1994; QUADRI LEN, 1994, J BIOL CHEM, V269, P12204; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RINCE A, 1994, APPL ENVIRON MICROB, V60, P1652, DOI 10.1128/AEM.60.5.1652-1657.1994; ROTTLANDER E, 1970, MOL GEN GENET, V108, P47, DOI 10.1007/BF00343184; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON D, 1988, BIOCHIMIE, V70, P559, DOI 10.1016/0300-9084(88)90093-4; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VANBELKUM MJ, 1989, APPL ENVIRON MICROB, V55, P1187, DOI 10.1128/AEM.55.5.1187-1191.1989; VANDEGUCHTE M, 1989, APPL ENVIRON MICROB, V55, P224, DOI 10.1128/AEM.55.1.224-228.1989; VENEMA K, 1994, MOL MICROBIOL, V14, P521, DOI 10.1111/j.1365-2958.1994.tb02186.x; Venema K, 1996, APPL ENVIRON MICROB, V62, P1689, DOI 10.1128/AEM.62.5.1689-1692.1996; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; VENEMA K, 1995, THESIS U GRONINGEN G; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WU JH, 1992, J BIOL CHEM, V267, P12570; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	58	39	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8484	8490		10.1074/jbc.274.13.8484	http://dx.doi.org/10.1074/jbc.274.13.8484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085080	hybrid			2022-12-27	WOS:000079451600022
J	Martin, V; Ronde, P; Unett, D; Wong, A; Hoffman, TL; Edinger, AL; Doms, RW; Funk, CD				Martin, V; Ronde, P; Unett, D; Wong, A; Hoffman, TL; Edinger, AL; Doms, RW; Funk, CD			Leukotriene binding, signaling, and analysis of HIV coreceptor function in mouse and human leukotriene B-4 receptor-transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PLATELET-ACTIVATING-FACTOR; ACTIVE ULCERATIVE-COLITIS; PROTEIN-COUPLED RECEPTORS; CHEMOKINE RECEPTORS; POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR-CLONING; DIVERSE HUMAN; IN-VIVO; GENE	The mouse leukotriene B-4 receptor (m-BLTR) gene was cloned. Membrane fractions of human embryonic kidney 293 cells stably expressing m-BLTR demonstrated a high affinity and specific binding for leukotriene B-4 (LTB4, K-d = 0.24 +/- 0.03 nM). In competition binding experiments, LTB4 was the most potent competitor (K-i = 0.23 +/- 0.05 nM) followed by 20-hydroxy-LTB4 (K-i = 1.1 +/- 0.2 mu M) and by 6-trans-12-epi-LTB4 and LTD4 (K-i > 1 mu M). In stably transfected Chinese hamster ovary cells, LTB4 inhibited forskolin-activated cAMP production and induced an increase of intracellular calcium, suggesting that this receptor is coupled to G(i)- and G(o)-like proteins. In Xenopus laevis melanophores transiently expressing m-BLTR, LTB4 induced the aggregation of pigment granules, confirming the inhibition of cAMP production induced by LTB4. BLT receptors share significant sequence homology with chemokine receptors (CCR5 and CXCR4) that act as human immunodeficiency virus (HIV) coreceptors. However, among the 16 HIV/SIV strains tested, the human BLT receptor did not act as a coreceptor for virus entry into CD4-expressing cells based on infection and cell-cell fusion assays. In 5-lipoxygenase-deficient mice, the absence of leukotriene B-4 biosynthesis did not detectably alter m-BLT receptor binding in membranes obtained from glycogen-elicited neutrophils. Isolation of the m-BLTR gene will form the basis of future experiments to elucidate the selective role of LTB4, as opposed to cysteinyl-leukotrienes, in murine models of inflammation.	Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 806, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Dept Pharmacol, Philadelphia, PA 19129 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Drexel University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 806, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58464] Funding Source: Medline; NIAID NIH HHS [AI40880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; BOUCHELOUCHE PN, 1995, EUR J GASTROEN HEPAT, V7, P349; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; DRYDEN P, 1992, PROSTAGLANDINS, V44, P11, DOI 10.1016/0090-6980(92)90103-Z; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Edinger AL, 1998, VIROLOGY, V249, P367, DOI 10.1006/viro.1998.9306; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; FISHER AR, 1997, THORAX, V52, P1074; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; GRAMINSKI GF, 1993, J BIOL CHEM, V268, P5957; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HILLINGSO J, 1995, CLIN PHARMACOL THER, V57, P335, DOI 10.1016/0009-9236(95)90159-0; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; KJELDSEN J, 1995, PHARMACOL TOXICOL, V77, P371, DOI 10.1111/j.1600-0773.1995.tb01044.x; LEDERER ED, 1993, CELL SIGNAL, V5, P735, DOI 10.1016/0898-6568(93)90034-J; LERNER MR, 1994, TRENDS NEUROSCI, V17, P142, DOI 10.1016/0166-2236(94)90087-6; MCCLINTOCK TS, 1993, ANAL BIOCHEM, V209, P298, DOI 10.1006/abio.1993.1123; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; MIKI I, 1990, BIOCHEM BIOPH RES CO, V166, P342, DOI 10.1016/0006-291X(90)91951-N; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Owman C, 1996, GENOMICS, V37, P187, DOI 10.1006/geno.1996.0541; Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530; Owman C, 1997, BIOCHEM BIOPH RES CO, V241, P390, DOI 10.1006/bbrc.1997.7822; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Rucker J, 1997, METHOD ENZYMOL, V288, P118; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Shindo K, 1997, THORAX, V52, P1024, DOI 10.1136/thx.52.12.1024; Teixeira MM, 1997, BLOOD, V89, P4566, DOI 10.1182/blood.V89.12.4566; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOSHIKAWA D, 1992, CIRC SHOCK, V38, P29	48	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8597	8603		10.1074/jbc.274.13.8597	http://dx.doi.org/10.1074/jbc.274.13.8597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085095	hybrid			2022-12-27	WOS:000079451600037
J	Montaner, S; Perona, R; Saniger, L; Lacal, JC				Montaner, S; Perona, R; Saniger, L; Lacal, JC			Activation of serum response factor by RhoA is mediated by the nuclear factor-kappa B and C/EBP transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TERNARY COMPLEX-FORMATION; TATA-BINDING PROTEIN; DNA-BINDING; SIGNALING PATHWAYS; RAS TRANSFORMATION; LEUCINE-ZIPPER; GROWTH-FACTOR; CELL-DEATH; ALPHA PROTEOLYSIS; INDUCED APOPTOSIS	The activity of the transcription factor NF-kappa B can be modulated by members of the Rho family of small GT-Pases (Perona, R,, Montaner, S,, Saniger, L., Sanchez-Perez, I., Brave, R,, and Lacal, J. C, (1997) Genes Dev, 11, 463-475), Ectopic expression of RhoA, Rac1, and Cdc42Hs proteins induces the translocation of NF-kappa B dimers to the nucleus, triggering the transactivation of the NF-kappa B-dependent promoter from the human immunodeficiency virus. Here, we demonstrate that activation of NF-kappa B by RhoA does not exclusively promote its nuclear translocation and binding to the specific kappa B sequences, NF-kappa B is also involved in the regulation of the transcriptional activity of the c-fos serum response factor (SRF), since the activation of a SRE-dependent promoter by RhoA can be efficiently interfered by the double mutant I kappa B alpha S32A/S36A, an inhibitor of the NF-kappa B activity. We also present evidence that RelA. and p50 NF-kappa B subunits cooperate with the transcription factor C/EBP beta in the transactivation of the 4 x SRE-CAT reporter. Furthermore, RhoA increases the levels of C/EBP beta protein, facilitating the functional cooperation between NF-kappa B, C/EBP beta, and SRF proteins. These results strengthen the pivotal importance of the Rho family of small GTPases in signal transduction pathways which modulate gene expression and reveal that NF-kappa B and C/EBP beta transcription factors are accessory proteins for the RhoA-linked regulation of the activity of the SRF.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; del Peso L, 1997, ONCOGENE, V15, P3047; delPeso L, 1997, BIOCHEM J, V322, P519; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; Esteve P, 1995, ONCOGENE, V11, P2657; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JIMENEZ B, 1995, ONCOGENE, V10, P811; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim BC, 1997, FEBS LETT, V415, P325, DOI 10.1016/S0014-5793(97)01152-6; Kim BC, 1997, FEBS LETT, V407, P7, DOI 10.1016/S0014-5793(97)00289-5; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; Kim JH, 1997, BIOCHEM BIOPH RES CO, V232, P223, DOI 10.1006/bbrc.1997.6261; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P6339; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	112	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8506	8515		10.1074/jbc.274.13.8506	http://dx.doi.org/10.1074/jbc.274.13.8506			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085083	hybrid			2022-12-27	WOS:000079451600025
J	Pryzdial, ELG; Lavigne, N; Dupuis, N; Kessler, GE				Pryzdial, ELG; Lavigne, N; Dupuis, N; Kessler, GE			Plasmin converts factor X from coagulation zymogen to fibrinolysis cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RECEPTOR; FACTOR-VA; ANNEXIN-II; HUMAN-PROTHROMBIN; ACTIVATION; BINDING; PROTEINS; PATHWAY; PURIFICATION; INACTIVATION	Known anticoagulant pathways have been shown to exclusively inhibit blood coagulation cofactors and enzymes. In the current work, we first investigated the possibility of a novel anticoagulant mechanism that functions at the level of zymogen inactivation. Utilizing both clotting and chromogenic assays, the fibrinolysis protease plasmin was found to irreversibly inhibit the pivotal function of factor X (FX) in coagulation, This was due to cleavage at several sites, the location of which were altered by association of FX with procoagulant phospholipid (proPL), The final products were similar to 28 and similar to 47 kDa for proPL-bound and unbound FX, respectively, which did not have analogues when activated FX (FXa) was cleaved instead. We next investigated whether the FX derivatives could interact with the plasmin precursor plasminogen, and we found that plasmin exposed a binding site only on proPL-bound FX, The highest apparent affinity was for the 28-kDa fragment, which was identified as the light subunit disulfide linked to a small fragment of the heavy subunit (Met-296 to similar to Lys-330). After cleavage by plasmin, proPL-bound FX furthermore was observed to accelerate plasmin generation by tissue plasminogen activator. Thus, a feedback mechanism localized by proPL is suggested in which plasmin simultaneously inhibits FX clotting function and converts proPL-bound FX into a fibrinolysis cofactor. These data also provide the first evidence for an anticoagulant mechanism aimed directly at the zymogen FX.	Canadian Blood Serv, Dept Res & Dev, Ottawa, ON K1G 4J5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1G 4J5, Canada	Canadian Blood Services; University of Ottawa	Pryzdial, ELG (corresponding author), Canadian Blood Serv, Dept Res & Dev, 1800 Alta Vista Dr, Ottawa, ON K1G 4J5, Canada.	ed.pryzdial@bloodservices.ca						BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; DUDANI AK, 1993, THROMB RES, V69, P185, DOI 10.1016/0049-3848(93)90044-O; DUDANI AK, 1994, BIOCHEM CELL BIOL, V72, P126, DOI 10.1139/o94-019; EBY CS, 1992, BLOOD S, V80, pA306; ESMON CT, 1995, SEMIN CELL BIOL, V6, P259, DOI 10.1006/scel.1995.0035; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HOJRUP P, 1987, BIOCHEM J, V245, P887, DOI 10.1042/bj2450887; JESTY J, 1974, J BIOL CHEM, V249, P5614; Jesty J, 1976, Methods Enzymol, V45, P95; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KELM RJ, 1994, J BIOL CHEM, V269, P30147; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LIJNEN HR, 1993, METHOD ENZYMOL, V223, P197; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OMAR MN, 1987, J BIOL CHEM, V262, P9750; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P17871, DOI 10.1074/jbc.270.30.17871; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; REINARTZ J, 1995, J IMMUNOL, V154, P844; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	38	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8500	8505		10.1074/jbc.274.13.8500	http://dx.doi.org/10.1074/jbc.274.13.8500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085082	hybrid			2022-12-27	WOS:000079451600024
J	Stennicke, HR; Deveraux, QL; Humke, EW; Reed, JC; Dixit, VM; Salvesen, GS				Stennicke, HR; Deveraux, QL; Humke, EW; Reed, JC; Dixit, VM; Salvesen, GS			Caspase-9 can be activated without proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; PLASMINOGEN-ACTIVATOR; CELL-DEATH; PROTEASE; APOPTOSIS; OLIGOMERIZATION; COMPLEX; CED-4; FADD; DATP	The recombinant form of the proapoptotic caspase-9 purified following expression in Escherichia coli is processed at Asp(315), but largely inactive; however, when added to cytosolic extracts of human 293 cells it is activated 2000-fold in the presence of cytochrome c and dATP. Thus, the characteristic activities of caspase-9 are context-dependent, and its activation may not recapitulate conventional caspase activation mechanisms. To explore this hypothesis we produced recombinant forms of procaspase-9 containing mutations that disabled one or both of the interdomain processing sites of the zymogen. These mutants were able to activate downstream caspases, but only in the presence of cytosolic factors. The mutant with both processing sites abolished had 10% of the activity of wild-type, and was able to support apoptosis, with equal vigor to wild-type, when transiently expressed in 293 cells. Thus caspase-9 has an unusually active zymogen that does not require proteolytic processing, but instead is dependent on cytosolic factors for expression of its activity.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Genentech Inc, San Francisco, CA 94080 USA; Univ Michigan, Sch Med, Dept Cellular & Mol Biol, Ann Arbor, MI 48109 USA	Sanford Burnham Prebys Medical Discovery Institute; Roche Holding; Genentech; University of Michigan System; University of Michigan	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gsalvesen@burnham-inst.org	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA72994] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07863] Funding Source: Medline; NINDS NIH HHS [NS37878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bode W, 1997, CURR OPIN STRUC BIOL, V7, P865, DOI 10.1016/S0959-440X(97)80159-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Krajewska M, 1997, CANCER RES, V57, P1605; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WARE CF, 1998, CYTOKINE HDB; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	28	384	405	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8359	8362		10.1074/jbc.274.13.8359	http://dx.doi.org/10.1074/jbc.274.13.8359			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085063	hybrid			2022-12-27	WOS:000079451600005
J	Herman, A; Helman, D; Livnah, O; Gertler, A				Herman, A; Helman, D; Livnah, O; Gertler, A			Ruminant placental lactogens act as antagonists to homologous growth hormone receptors and as agonists to human or rabbit growth hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED RECOMBINANT ANALOGS; MESSENGER-RIBONUCLEIC-ACID; SITE-DIRECTED MUTAGENESIS; EXTRACELLULAR DOMAIN; SELECTIVE MODIFICATION; SOMATOGENIC ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MAMMARY-GLAND; OVINE	Growth hormone receptor (GHR)-mediated activity of ruminant placental lactogens (PLs) and ovine (o) GH was compared, using cells transfected with full size human (h), rabbit (rb), and oGHRs, All three PLs acted as agonists in heterologous bioassays, whereas in homologous bioassays in cells transfected with oGHRs they antagonized the oGH activity. Despite these differences, oGH and PLs bound with similar affinity to the oGHR extracellular domain (oGHR-ECD), indicating that the binding occurs through hormone site I. Gel filtration of complexes between oPL and oGHR-ECD showed a 1:1 stoichiometry, confirming this conclusion. The oPL T185D and bPL T188D, which exhibited weak biological activity mediated through GHRs, behaved as site I antagonists, whereas oPL G130R and bPL G133R formed a 1:1 complex with GHR-ECDs and bound to h/rb/oGHR-ECDs with affinity similar to that of wild-type oPL, They had no agonistic activity in all models transfected with h/rb and oGHRs, but were antagonistic to all of them. In conclusion, ruminant PLs antagonize the activity of oGH in homologous systems, because they cannot homodimerize oGHRs, whereas in heterologous systems they act as agonists, The structural analysis hints that minor differences in the sequence of the GHR-ECDs may account for this difference. Since the initial step in the activity transduced through cytokine/hemapoietic receptors family is receptor homodimerization or heterodimerization, we suggest that the question of homologous versus heterologous interactions should be reexamined.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol,Fac Life Sci, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	gertler@agri.huji.ac.il						ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; ANTHONY RV, 1995, J ANIM SCI, V73, P1861; ANTHONY RV, 1995, J REPROD FERTIL, P83; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BREIER BH, 1994, ENDOCRINOLOGY, V135, P919, DOI 10.1210/en.135.3.919; BYATT JC, 1992, J ANIM SCI, V70, P2911, DOI 10.2527/1992.7092911x; Christinger HW, 1998, ACTA CRYSTALLOGR D, V54, P1408, DOI 10.1107/S0907444998005794; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; COLLIER RJ, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P13; COLOSI P, 1989, MOL ENDOCRINOL, V3, P1462, DOI 10.1210/mend-3-9-1462; CURIE JC, 1990, REPROD FERTIL, V90, P25; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DURIEZ B, 1993, MOL ENDOCRINOL, V7, P806, DOI 10.1210/me.7.6.806; FORSYTH IA, 1986, J DAIRY SCI, V69, P886, DOI 10.3168/jds.S0022-0302(86)80479-9; FREEMARK M, 1993, END SOC 73 ANN M ABS; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GALOSY SS, 1991, MOL CELL ENDOCRINOL, V78, P229, DOI 10.1016/0303-7207(91)90127-E; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1992, J BIOL CHEM, V267, P12655; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; GERTLER A, 1985, ENDOCRINOLOGY, V116, P1636, DOI 10.1210/endo-116-4-1636; *GRAPHP, 1994, PRISM VERS 2 0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Helman D, 1998, J BIOL CHEM, V273, P16067, DOI 10.1074/jbc.273.26.16067; Helman D, 1997, ENDOCRINOLOGY, V138, P4069, DOI 10.1210/en.138.10.4069; KANN G, 1997, PLACENTA, V18; KESSLER MA, 1991, ENDOCRINOLOGY, V129, P1885, DOI 10.1210/endo-129-4-1885; KLEMPT M, 1993, ENDOCRINOLOGY, V132, P1071, DOI 10.1210/en.132.3.1071; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KRIVI GG, 1991, END SOC 71 ANN M ABS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTAL J, 1975, BIOCHEM BIOPH RES CO, V65, P770, DOI 10.1016/S0006-291X(75)80212-9; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Min S. H., 1994, Proceedings of the New Zealand Society of Animal Production, V54, P59; Min SH, 1997, J DAIRY SCI, V80, P640, DOI 10.3168/jds.S0022-0302(97)75982-4; MURTHY GS, 1982, ENDOCRINOLOGY, V111, P2117, DOI 10.1210/endo-111-6-2117; OBUKOWICZ MG, 1992, APPL ENVIRON MICROB, V58, P1511, DOI 10.1128/AEM.58.5.1511-1523.1992; OGAWA E, 1995, J ENDOCRINOL, V145, P87, DOI 10.1677/joe.0.1450087; PRATT SL, 1995, DOMEST ANIM ENDOCRIN, V12, P337, DOI 10.1016/0739-7240(95)00030-I; PRATT SL, 1995, ENDOCRINOLOGY, V136, P2150, DOI 10.1210/en.136.5.2150; Rowlinson SW, 1996, ENDOCRINOLOGY, V137, P90, DOI 10.1210/en.137.1.90; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; Sakal E, 1998, J ENDOCRINOL, V159, P509, DOI 10.1677/joe.0.1590509; Sakal E, 1997, J ENDOCRINOL, V152, P317, DOI 10.1677/joe.0.1520317; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STATEN NR, 1993, J BIOL CHEM, V268, P18467; STATEN NR, 1997, END SOC 79 ANN M ABS; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; TARTOF KD, 1987, FOCUS, V9, P12; Tchelet A, 1997, MOL CELL ENDOCRINOL, V130, P141, DOI 10.1016/S0303-7207(97)00084-1; TCHELET A, 1993, PEDIAT AD E, V24, P114; VashdiElberg D, 1996, J BIOL CHEM, V271, P5558, DOI 10.1074/jbc.271.10.5558; VASHDIELBERG D, 1995, ENDOCRINOLOGY, V136, P1258, DOI 10.1210/en.136.3.1258; WARREN WC, 1990, J ENDOCRINOL, V126, P141, DOI 10.1677/joe.0.1260141; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	59	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7631	7639		10.1074/jbc.274.12.7631	http://dx.doi.org/10.1074/jbc.274.12.7631			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075650	hybrid			2022-12-27	WOS:000079268100009
J	McClure, RF; Heppelmann, CJ; Paya, CV				McClure, RF; Heppelmann, CJ; Paya, CV			Constitutive Fas ligand gene transcription in Sertoli cells is regulated by Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; IMMUNE PRIVILEGE; SP1-MEDIATED TRANSCRIPTION; NEGATIVE REGULATOR; MEDIATED APOPTOSIS; DEATH FACTOR; IN-VIVO; EXPRESSION; ACTIVATION; PROMOTER	The transcriptional regulation of the Fas ligand (FasL) gene in Sertoli cells was investigated, as these cells are known to have constitutive expression of FasL and hence maintain an "immune privileged" environment within the testicle, Using the Sertoli cell line TM4, it was demonstrated that a gene segment of the 5'-untranslated region located between -318 and -237 relative to the translation start site is required for constitutive Fast transcription. Deletion and mutation analysis demonstrate that an Sp1 rather than an NFAT or NFKB-like DNA binding motif present within this region is necessary and sufficient for constitutive Fast gene transcription. Nuclear extracts of Sertoli cells contain Sp1 and Sp3 that specifically binds to the Sp1 motif present in the Fast gene, and overexpression of Sp1 but not Sp3 leads to a further increase of transcription from the Fast promoter-enhancer region. The data presented demonstrates that constitutive Fast gene transcription in Sertoli cells is regulated by Sp1. In addition, it is shown that basal Fast expression in Jurkat T cells is also controlled by Sp1 and this is in contrast to induced Fast expression, which is NFAT-dependent.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, 200 1st St SW,Guggenheim 501, Rochester, MN 55905 USA.	paya@mayo.edu						BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1993, TRANSCRIPTIONAL REGU, V2, P743; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Guller S, 1997, ANN NY ACAD SCI, V828, P268, DOI 10.1111/j.1749-6632.1997.tb48547.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Korbutt GS, 1997, DIABETES, V46, P317, DOI 10.2337/diabetes.46.2.317; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LUI MZ, 1996, J BIOL CHEM, V271, P2731; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OYAIZU N, 1995, BIOCHEM BIOPH RES CO, V213, P994, DOI 10.1006/bbrc.1995.2227; Perzova R, 1997, BRIT J HAEMATOL, V97, P123, DOI 10.1046/j.1365-2141.1997.d01-2113.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Sugihara A, 1997, ANTICANCER RES, V17, P3861; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; UCKMAN D, 1997, MOL HUM REPROD, V3, P655; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Walker PR, 1997, J IMMUNOL, V158, P4521; Xerri L, 1997, LEUKEMIA, V11, P1868, DOI 10.1038/sj.leu.2400815; Xerri L, 1997, J CLIN PATHOL-MOL PA, V50, P87, DOI 10.1136/mp.50.2.87; Yano H, 1996, J HEPATOL, V25, P454, DOI 10.1016/S0168-8278(96)80204-2	59	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7756	7762		10.1074/jbc.274.12.7756	http://dx.doi.org/10.1074/jbc.274.12.7756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075666	hybrid			2022-12-27	WOS:000079268100025
J	Portois, L; Maget, B; Tastenoy, M; Perret, J; Svoboda, M				Portois, L; Maget, B; Tastenoy, M; Perret, J; Svoboda, M			Identification of a glucose response element in the promoter of the rat glucagon receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; PYRUVATE-KINASE GENE; MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; PARATHYROID-HORMONE; PANCREATIC-ISLETS; ENCODING GENE; EXPRESSION; CLONING; TRANSCRIPTION	We cloned the 5' upstream region of the rat glucagon receptor gene, demonstrating that the 5' noncoding domain of the glucagon receptor mRNA contained two untranslated exons of 131 and 166 nucleotides (nt), respectively, separated by two introns of 0.6 and 3.2 kilobase pairs. We also observed an alternative splicing involving the 166-base pair exon, Cloning of up to 2 kilobase pairs of the newly identified genomic domain and transfection of various constructs driving a reporter gene, in pancreatic islet cell line INS-I, uncovered a strong glucose regulation of the promoter activity of plasmids containing up to nucleotide -868, or more, upstream from the transcriptional start point. This promoter activity displayed threshold-like behavior, with low activity of the promoter below 5 mM glucose, and maximal activation as of 10 mM glucose. This glucose regulation was mapped to a highly palindromic 19-nucleotide region between nt -545 and -527, Indeed, deletion or mutation of this sequence abolished the glucose regulation. This domain contained two palindromic "E-boxes" CACGTG and CAGCTG separated by 3 nt, a feature similar to the "L4 box" found in the pyruvate kinase L gene promoter. This is the first description of a G protein-coupled receptor gene promoter regulated by glucose.	Free Univ Brussels, Dept Biochem & Nutr, Sch Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Svoboda, M (corresponding author), Free Univ Brussels, Dept Biochem & Nutr, Sch Med, 808 Route Lennik,Bldg G-E CP 611, B-1070 Brussels, Belgium.							ABRAHAMSEN N, 1995, J BIOL CHEM, V270, P15853, DOI 10.1074/jbc.270.26.15853; ABRAHAMSEN N, 1995, ENDOCRINOLOGY, V136, P1572, DOI 10.1210/en.136.4.1572; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BUGGY J, 1995, BIOCHEM BIOPH RES CO, V208, P339, DOI 10.1006/bbrc.1995.1343; BURCELIN R, 1995, GENE, V164, P305, DOI 10.1016/0378-1119(95)00472-I; Burcelin R, 1998, J BIOL CHEM, V273, P8088, DOI 10.1074/jbc.273.14.8088; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; Chatterjee TK, 1997, J BIOL CHEM, V272, P12122, DOI 10.1074/jbc.272.18.12122; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Dupriez VJ, 1997, DNA CELL BIOL, V16, P1075, DOI 10.1089/dna.1997.16.1075; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; HANSEN LH, 1995, PEPTIDES, V16, P1163, DOI 10.1016/0196-9781(95)00078-X; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Kahn A, 1997, BIOCHIMIE, V79, P113, DOI 10.1016/S0300-9084(97)81501-5; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kieffer TJ, 1996, ENDOCRINOLOGY, V137, P5119, DOI 10.1210/en.137.11.5119; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; LankatButtgereit B, 1997, PEPTIDES, V18, P617, DOI 10.1016/S0196-9781(97)00001-6; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; MAGET B, 1994, FEBS LETT, V351, P271, DOI 10.1016/0014-5793(94)00875-2; MARIE S, 1993, J BIOL CHEM, V268, P23881; Marine JC, 1996, ENDOCRINOLOGY, V137, P4108, DOI 10.1210/en.137.10.4108; MCCUAIG KA, 1995, NUCLEIC ACIDS RES, V23, P1948, DOI 10.1093/nar/23.11.1948; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; PEI L, 1995, BIOCHEM J, V308, P716; Qvist H, 1998, BIOL CHEM, V379, P75; Sambrook J., 2002, MOL CLONING LAB MANU; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V192, P135, DOI 10.1006/bbrc.1993.1392; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V191, P479, DOI 10.1006/bbrc.1993.1243; SVOBODA M, 1994, MOL CELL ENDOCRINOL, V105, P131, DOI 10.1016/0303-7207(94)90162-7; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	44	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8181	8190		10.1074/jbc.274.12.8181	http://dx.doi.org/10.1074/jbc.274.12.8181			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075722	hybrid			2022-12-27	WOS:000079268100081
J	Dell'Angelica, EC; Mullins, C; Bonifacino, JS				Dell'Angelica, EC; Mullins, C; Bonifacino, JS			AP-4, a novel protein complex related to clathrin adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE FORMATION; GOLGI MEMBRANES; SORTING SIGNALS; COAT PROTEINS; CELL-SURFACE; BINDING; RECEPTOR; SUBUNIT; IDENTIFICATION; RECRUITMENT	Here we report the identification and characterization of AP-4, a novel protein complex related to the heterotetrameric AP-1, AP-2, and AP-3 adaptors that mediate protein sorting in the endocytic and late secretory pathways. The key to the identification of this complex was the cloning and sequencing of two widely expressed, mammalian cDNAs encoding new homologs of the adaptor beta and a subunits named beta 4 and sigma 4, respectively. An antibody to beta 4 recognized in human cells an similar to 83-kDa polypeptide that exists in both soluble and membrane-associated forms. Golgi filtration, sedimentation velocity, and immunoprecipitation experiments revealed that beta 4 is a component of a multisubunit complex (AP-4) that also contains the sigma 4 polypeptide and two additional adaptor subunit homologs named mu 4 (mu-ARP2) and epsilon. Immunofluorescence analyses showed that AP-4 is associated with the trans-Golgis network or an adjacent structure and that this association is sensitive to the drug brefeldin A. We propose that, like the related AP-1, AP-2, and AP-3 complexes, AP-4 plays a role in signal-mediated trafficking of integral membrane proteins in mammalian cells.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.			Bonifacino, Juan S./0000-0002-5673-6370				AHLE S, 1989, J BIOL CHEM, V264, P20089; BNIFACINO JS, 1998, CURRENT PROTOCOLS CE; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Keller P, 1997, J CELL SCI, V110, P3001; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MARKS MS, 1998, CURRENT PROTOCOLS CE; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; REST B, 1994, PROTEINS, V20, P216; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1	41	209	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7278	7285		10.1074/jbc.274.11.7278	http://dx.doi.org/10.1074/jbc.274.11.7278			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066790	hybrid			2022-12-27	WOS:000079078400062
J	Kovoor, A; Celver, J; Abdryashitov, RI; Chavkin, C; Gurevich, VV				Kovoor, A; Celver, J; Abdryashitov, RI; Chavkin, C; Gurevich, VV			Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; THYROTROPIN RECEPTOR; RHODOPSIN; BINDING; MUTATIONS	Arrestin proteins play a key role in the desensitization of G protein-coupled receptors (GPCRs), Recently we proposed a molecular mechanism whereby arrestin preferentially binds to the activated and phosphorylated form of its cognate GPCR. To test the model, we introduced two different types of mutations into beta-arrestin that were expected to disrupt two crucial elements that make beta-arrestin binding to receptors phosphorylation-dependent. We found that two beta-arrestin mutants (Arg(169) --> Glu and Asp(383) --> Ter) (Ter, stop codon) are indeed "constitutively active." In vitro these mutants bind to the agonist-activated beta(2)-adrenergic receptor (beta(2)AR) regardless of its phosphorylation status. When expressed in Xenopus oocytes these beta-arrestin mutants effectively desensitize beta(2)AR in a phosphorylation-independent manner. Constitutively active beta-arrestin mutants also effectively desensitize delta opioid receptor (DOR) and restore the agonist-induced desensitization of a truncated DOR lacking the critical G protein-coupled receptor kinase (GRK) phosphorylation sites. The kinetics of the desensitization induced by phosphorylation-independent mutants in the absence of receptor phosphorylation appears identical to that induced by wild type beta-arrestin + GRK3. Either of the mutations could have occurred naturally and made receptor kinases redundant, raising the question of why a more complex two-step mechanism (receptor phosphorylation followed by arrestin binding) is universally used.	Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; University of Washington; University of Washington Seattle	Gurevich, VV (corresponding author), Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA.		Gurevich, Vsevolod/A-3236-2008; Chavkin, Charles/G-2797-2010	Gurevich, Vsevolod/0000-0002-3950-5351; 	NEI NIH HHS [EY 11500] Funding Source: Medline; NIDA NIH HHS [DA 04123, R37 DA011672] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123, R37DA011672] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; PEARCE S, 1995, J CLIN INVEST, V52, P736; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349	22	150	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6831	6834		10.1074/jbc.274.11.6831	http://dx.doi.org/10.1074/jbc.274.11.6831			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066734	hybrid			2022-12-27	WOS:000079078400006
J	Langenbach, KJ; Sottile, J				Langenbach, KJ; Sottile, J			Identification of protein-disulfide isomerase activity in fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-INSOLUBLE GLOBULIN; MATRIX ASSEMBLY SITES; CROSS-LINKING; LYSOPHOSPHATIDIC ACID; PLASMA FIBRONECTIN; HUMAN-FIBROBLASTS; SELF-ASSOCIATION; COLLAGEN-BINDING; RIBONUCLEASE-A; IONIC-STRENGTH	Assembly and degradation of fibronectin-containing extracellular matrices are dynamic processes that are up-regulated during wound healing, embryogenesis, and metastasis. Although several of the early steps leading to fibronectin deposition have been identified, the mechanisms leading to the accumulation of fibronectin in disulfide-stabilized multimers are largely unknown, Disulfide-stabilized fibronectin multimers are thought to arise through intra- or intermolecular disulfide exchange. Several proteins involved in disulfide exchange reactions contain the sequence Cys-X-X-Cys in their active sites, including thioredoxin and protein-disulfide isomerase, The twelfth type I module of fibronectin (I-12) contains a Cys-X-X-Cys motif, suggesting that fibronectin may have the intrinsic ability to catalyze disulfide bond rearrangement. Using an established protein refolding assay, we demonstrate here that fibronectin has protein-disulfide isomerase activity and that this activity is localized to the carboxyl-terminal type I module I-12. I-12 was as active on an equal molar basis as intact fibronectin, indicating that most of the protein-disulfide isomerase activity of fibronectin is localized to I-12. Moreover, the protein-disulfide isomerase activity of fibronectin appears to be partially cryptic since limited proteolysis of I-10-I-12 increased its isomerase activity and dramatically enhanced the rate of RNase refolding, This is the first demonstration that fibronectin contains protein disulfide isomerase activity and suggests that cross-linking of fibronectin in the extracellular matrix may be catalyzed by a disulfide isomerase activity contained within the fibronectin molecule.	Albany Med Coll, Dept Physiol & Cell Biol A134, Albany, NY 12208 USA	Albany Medical College	Sottile, J (corresponding author), Albany Med Coll, Dept Physiol & Cell Biol A134, Neil Hellman Med Res Bldg,47 New Scotland Ave, Albany, NY 12208 USA.	jsottile@ccgateway.amc.edu			NHLBI NIH HHS [HL50549, T732-HL07194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; ALI IU, 1978, BIOCHIM BIOPHYS ACTA, V510, P140, DOI 10.1016/0005-2736(78)90136-0; ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BALIAN G, 1979, J BIOL CHEM, V254, P1429; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Chen F, 1996, J BIOL CHEM, V271, P9084, DOI 10.1074/jbc.271.15.9084; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; CHIVERS PT, 1996, PROLYL 4 HYDROXYLASE, P487; CHOI MG, 1979, J BIOL CHEM, V254, P2050; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; COLVIN RB, 1989, FIBRONECTIN, P213; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DARRIBERE R, 1993, DEV DYNAM, V194, P63; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; HANTGAN RR, 1974, BIOCHEMISTRY-US, V13, P3421, DOI 10.1021/bi00714a001; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HEDMAN D, 1989, FIBRONECTIN, P123; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes RO, 1990, FIBRONECTINS; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; KESKIOJA J, 1976, CELL, V9, P29, DOI 10.1016/0092-8674(76)90049-0; KOEDAM JA, 1994, BIOCHEM BIOPH RES CO, V198, P1225, DOI 10.1006/bbrc.1994.1173; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARKOVIC Z, 1983, H-S Z PHYSIOL CHEM, V364, P1795, DOI 10.1515/bchm2.1983.364.2.1795; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1983, ANN NY ACAD SCI, V408, P583, DOI 10.1111/j.1749-6632.1983.tb23275.x; NOVOKHATNY VV, 1994, J MOL BIOL, V238, P833, DOI 10.1006/jmbi.1994.1337; Okada N, 1997, J BIOL CHEM, V272, P26978, DOI 10.1074/jbc.272.43.26978; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schor SL, 1996, J CELL SCI, V109, P2581; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; SOMMERS CE, 1993, J BIOL CHEM, V268, P22277; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; Sottile J, 1998, J CELL SCI, V111, P2933; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; VUORI K, 1992, J BIOL CHEM, V267, P7211; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	72	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7032	7038		10.1074/jbc.274.11.7032	http://dx.doi.org/10.1074/jbc.274.11.7032			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066758	hybrid			2022-12-27	WOS:000079078400030
J	McLaughlin, SH; Conn, SN; Bulleid, NJ				McLaughlin, SH; Conn, SN; Bulleid, NJ			Folding and assembly of type X collagen mutants that cause metaphyseal chondrodysplasia-type Schmid - Evidence for co-assembly of the mutant and wild-type chains and binding to molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; DISULFIDE BONDS; ALPHA-1(X) NC1; IN-VITRO; DOMAIN; MUTATIONS; CELLS; PROCOLLAGEN; INVITRO; MATRIX	Schmid metaphyseal chondrodysplasia results from mutations within the COOH-terminal globular domain (NC1) of type X collagen, a short chain collagen expressed in the hypertrophic region of the growth plate cartilage. Previous in vitro studies have proposed that mutations prevent the association of the NC1 domain of constituent chains of the trimer based upon a lack of formation of a trimeric structure that is resistant to dissociation with sodium dodecyl sulfate. To examine the effect of mutations on folding and assembly within a cellular context, bovine type X cDNAs containing analogous disease causing mutations Y598D, N617K, W651R, and wild-type were expressed in semi-permeabilized cells, We assessed trimerization of the mutant chains by their ability to form a collagen triple helix. Using this approach, we demonstrate that although there is an apparent lower efficiency of association of the mutant NC1 domains, they can drive the formation of correctly aligned triple helices with the same thermal stability as the wild-type collagen. When epitope-tagged mutant and wild-type collagen were co-expressed, heterotrimers could be detected by sequential immunoprecipitation. Both wild-type and mutant type X chains were found in association with the molecular chaperones protein disulfide isomerase and Hsp 47, The implications of these findings on the likely mechanism of Schmid metaphyseal chondrodysplasia will be discussed.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			McLaughlin, Stephen/0000-0001-9135-6253; Bulleid, Neil/0000-0002-9839-5279				ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BONAVENTURE J, 1995, HUM GENET, V96, P58, DOI 10.1007/BF00214187; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Pokharel RK, 1995, BIOCHEM BIOPH RES CO, V217, P1157, DOI 10.1006/bbrc.1995.2890; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; THOMAS JT, 1991, BIOCHEM J, V273, P141, DOI 10.1042/bj2730141; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	33	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7570	7575		10.1074/jbc.274.11.7570	http://dx.doi.org/10.1074/jbc.274.11.7570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066825	hybrid			2022-12-27	WOS:000079078400097
J	Mo, XM; Bailin, T; Sadofsky, MJ				Mo, XM; Bailin, T; Sadofsky, MJ			RAG1 and RAG2 cooperate in specific binding to the recombination signal sequence in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; V(D)J RECOMBINATION; SUBSTITUTED RNA; PROTEINS; CLEAVAGE; DEFINITION; COMPLEX; REGION; DNA; RECOGNITION	An essential step in the development of the vertebrate immune system is the DNA level rearrangement of the antigen receptor genes. This process, termed "V(D)J recombination," beans with DNA cleavage at the appropriate sites mediated by the two proteins RAG1 and RAG2. We report here that the two proteins cooperate to bind DNA with significantly higher specificity than either protein alone. Gel purification of the triple complex is performed in the absence of any cross-linking agents. Both proteins remain present in the complex, and UV cross-linking using iodouridine-containing probes shows that RAG1 makes close contacts in both the heptamer and nonamer motifs, The two proteins are also shown to associate with each other in the absence of any DNA. These findings refine our understanding of the protein-DNA interactions that accompany cleavage at the recombination signals.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Sadofsky, MJ (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.			Sadofsky, Moshe/0000-0002-6893-629X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041711, R29AI041711] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41711] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1997, NUCLEIC ACIDS RES, V25, P1375, DOI 10.1093/nar/25.7.1375; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; Meisenheimer KM, 1996, NUCLEIC ACIDS RES, V24, P981, DOI 10.1093/nar/24.5.981; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369	26	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7025	7031		10.1074/jbc.274.11.7025	http://dx.doi.org/10.1074/jbc.274.11.7025			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066757	hybrid			2022-12-27	WOS:000079078400029
J	Tang, DM; Lahti, JM; Grenet, J; Kidd, VJ				Tang, DM; Lahti, JM; Grenet, J; Kidd, VJ			Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CONTAINING RECEPTOR; SIGNALING COMPLEX; PROTEIN-SYNTHESIS; CD95 FAS/APO-1; CYTOCHROME-C; ACTIVATION; LIGAND; FLICE; FADD	Cycloheximide (CHX) can contribute to apoptotic processes, either in conjunction with another agent (e.g. tumor necrosis factor-alpha) or on its own. However, the basis of this CHX-induced apoptosis has not been clearly established. In this study, the molecular mechanisms of CHX-induced cell death were examined in two different human T-cell lines. In T-cells undergoing CHX-induced apoptosis (Jurkat), but not in T-cells resistant to the effects of CHX (CEM C7), caspase-8 and caspase-3 were activated. However, the Fas ligand was not expressed in Jurkat cells either before or after treatment with CHX suggesting that the activation of these caspases does not involve the Fas receptor. To determine whether CHX-induced apoptosis was mediated by a Fas-associated death domain (FADD)-dependent mechanism, a FADD-DN protein was expressed in cells prior to CHX treatment. Its expression effectively inhibited CHX-induced cell death, suggesting that CHX-mediated apoptosis primarily involves a FADD-dependent mechanism. Since CHX treatment did not result in the induction of Fas or Fast, and neutralizing anti-Fas and anti-tumor necrosis factor receptor-1 antibodies did not block CHX-mediated apoptosis, these results may also indicate that FADD functions in a receptor-independent manner. Surprisingly, death effector filaments containing FADD and caspase-8 were observed during CHX treatment of Jurkat, Jurkat-FADD-DN, and CEM C7 cells, suggesting that their formation may be necessary, but not sufficient, for cell death.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.	vincent.kidd@stjude.org	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam A, 1997, J EXP MED, V186, P1503, DOI 10.1084/jem.186.9.1503; Armstrong RC, 1997, J NEUROSCI, V17, P553; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Fulda S, 1997, CANCER RES, V57, P3823; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Loyer P, 1998, J CELL SCI, V111, P1495; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; WALLACH D, 1984, J IMMUNOL, V132, P2464; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	49	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7245	7252		10.1074/jbc.274.11.7245	http://dx.doi.org/10.1074/jbc.274.11.7245			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066786	hybrid			2022-12-27	WOS:000079078400058
J	Tian, H; White, S; Yu, L; Yu, CA				Tian, H; White, S; Yu, L; Yu, CA			Evidence for the head domain movement of the Rieske iron-sulfur protein in electron transfer reaction of the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-SOLUBLE FRAGMENT; MITOCHONDRIAL	The three-dimensional structure of the mitochondrial cytochrome bc(1) complex suggests that movement of the extramembrane domain (head) of the Rieske iron-sulfur protein (ISP) may play an important role in electron transfer. Such movement requires flexibility in the neck region of ISP, since the head and transmembrane domains of the protein are rather rigid. To test this hypothesis, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc(1) complexes with cysteine substitution at various positions in the ISP neck (residues 39-48) were generated and characterized. The mutants with a single cysteine substitution at Ala(42) or Val(44) and a double cysteine substitution at Val(44) and Ala(46) (VQA-CQC) or at Ala(42) and Ala(46) (ADVQA-CDVQC) have photosynthetic growth rates comparable with that of complement cells, Chromatophore membrane and intracytoplasmic membrane (ICM) prepared from these mutants have cytochrome bc(1) complex activity similar to that in the complement membranes, indicating that flexibility of the neck region of ISP was not affected by these cysteine substitutions. Mutants with a double cysteine substitution at Ala(42) and Val(44) (ADV-CDC) or at Pro(40) and Ala(42) (PSA-CSC) have a retarded (50%) or no photosynthetic growth rate, respectively. The ADV-CDC or PSA-CSC mutant ICM contains 20 or 0% of the cytochrome bc(1) complex activity found in the complement ICM, However, activity can be restored by the treatment with beta-mercaptoethanol (beta-ME), The restored activity is diminished upon removal of beta-ME but is retained if the beta-ME-treated membrane is treated with the sulfhydryl reagent N-ethylmaleimide or p-chloromercuribenzoic acid, These results indicate that the loss of bc(1) complex activity in the ADV-CDC or PSA-CSC mutant membranes is due to disulfide bond formation, which increases the rigidity of ISP neck and, in turn, decreases the mobility of the head domain, Using the conditions developed for the isolation of His-tagged complement cytochrome bc(1) complex, a two-subunit complex (cytochromes b and c(1)) is obtained from all of the double cysteine-substituted mutants. This suggests that introduction of two cysteines in the neck region of ISP weakens the interactions between cytochromes b, ISP, and subunit TV.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okway.okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; CROFTS AR, 1982, BIOCHEM SOC T, V10, P201, DOI 10.1042/bst0100201; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kim H, 1997, FASEB J, V11, pA1084; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; PEMBERTON JM, 1981, J BACTERIOL, V147, P110, DOI 10.1128/JB.147.1.110-117.1981; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1987, J BIOL CHEM, V262, P8677; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	23	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7146	7152		10.1074/jbc.274.11.7146	http://dx.doi.org/10.1074/jbc.274.11.7146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066773	hybrid			2022-12-27	WOS:000079078400045
J	Moechars, D; Dewachter, I; Lorent, K; Reverse, D; Baekelandt, V; Naidu, A; Tesseur, I; Spittaels, K; Van Den Haute, C; Checler, F; Godaux, E; Cordell, B; Van Leuven, F				Moechars, D; Dewachter, I; Lorent, K; Reverse, D; Baekelandt, V; Naidu, A; Tesseur, I; Spittaels, K; Van Den Haute, C; Checler, F; Godaux, E; Cordell, B; Van Leuven, F			Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; NEUROFIBRILLARY TANGLES; SENILE PLAQUES; NEURONAL LOSS; IN-VIVO; MOUSE; DEFICITS; TERMINUS; DEATH	Transgenic mice overexpressing different forms of amyloid precursor protein (APP), i.e. wild type or clinical mutants, displayed an essentially comparable early phenotype in terms of behavior, differential glutamatergic responses, deficits in maintenance of long term potentiation, and premature death. The cognitive impairment, demonstrated in F1 hybrids of the different APP transgenic lines, was significantly different from nontransgenic littermates as early as 3 months of age. Biochemical analysis of secreted and membrane-bound APP, C-terminal "stubs," and A beta(40) and A beta(42) peptides in brain indicated that no single intermediate can be responsible for the complex of phenotypic dysfunctions. As expected, the A beta(42) levels were most prominent in APP/London transgenic mice and correlated directly with the formation of amyloid plaques in older mice of this line, Plaques were associated with immunoreactivity for hyperphosphorylated tau, eventually signaling some form of tau pathology. In conclusion, the different APP transgenic mouse lines studied display cognitive deficits and phenotypic traits early in life that dissociated in time from the formation of amyloid plaques and will be good models for both early and late neuropathological and clinical aspects of Alzheimer's disease.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, B-3000 Leuven, Belgium; Scios Inc, Sunnyvale, CA 94086 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR411, F-06560 Valbonne, France; Univ Mons, Neurosci Lab, B-7000 Mons, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Scios; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Mons	Van Leuven, F (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Campus Gasthuisberg ON 06, B-3000 Leuven, Belgium.	fredvl@med.kuleuven.ac.be	Checler, Frederic/C-1241-2009; Wyss-Coray, Tony/AAF-3380-2019	Checler, Frederic/0000-0003-2098-1750; Wyss-Coray, Tony/0000-0001-5893-0831; , Ilse Dewachter/0000-0001-7202-515X				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Carlson GA, 1997, HUM MOL GENET, V6, P1951, DOI 10.1093/hmg/6.11.1951; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GARVEY W, 1991, J HISTOTECHNOL, V14, P39, DOI 10.1179/his.1991.14.1.39; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Moechars D, 1998, BEHAV BRAIN RES, V95, P55, DOI 10.1016/S0166-4328(97)00210-6; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; MOECHARS D, 1998, IN PRESS NEUROSCIENC; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Suh YH, 1997, J NEUROCHEM, V68, P1781; Yankner BA, 1998, NAT MED, V4, P394, DOI 10.1038/nm0498-394; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	38	577	636	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6483	6492		10.1074/jbc.274.10.6483	http://dx.doi.org/10.1074/jbc.274.10.6483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037741	hybrid			2022-12-27	WOS:000078902800063
J	Fukumoto, S; Miyazaki, H; Goto, G; Urano, T; Furukawa, K; Furukawa, K				Fukumoto, S; Miyazaki, H; Goto, G; Urano, T; Furukawa, K; Furukawa, K			Expression cloning of mouse cDNA of CMP-NeuAc : lactosylceramide alpha 2,3-sialyltransferase, an enzyme that initiates the synthesis of gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; SYNTHASE GENE; GOLGI VESICLES; RAT-LIVER; MONOCLONAL-ANTIBODIES; MEDIATED MODULATION; CELL-ADHESION; G(M3); BRAIN	Expression cloning of a cDNA for the alpha 2,3-sialyltransferase (GM3 synthase) (EC 2.4.99.-) gene was performed using a GM3-lacking mouse fibroblast line L cell and anti-GM3 monoclonal antibody. Plasmids from a cDNA library generated with poly(A)(+) RNA of a mouse fibrosarcoma line CMS5j and pdl3027 (polyoma T antigen) were co-transfected into L cells. The isolated cDNA clone pM3T-7 predicted a type II membrane protein with 13 amino acids of cytoplasmic domain, 17 amino acids of transmembrane region, and a large catalytic domain with 329 amino acids. Introduction of the cDNA clone into L cells resulted in the neo-synthesis of GM3 and high activity of alpha 2,3-sialyltransferase. Among glycosphingolipids, only lactosylceramide showed significant activity as an acceptor, indicating that this gene product is a sialyltransferase specific for the synthesis of GM3. An amino acid sequence deduced from the cloned cDNA showed the typical sialyl motif with common features among alpha 2,3-sialyltransferases. Among various mouse tissues, brain, liver, and testis showed relatively high expression of a 2,3-kilobase mRNA, whereas all tissues, more or less, expressed this gene.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528102, Japan	Nagoya University; Nagasaki University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.			Urano, Takeshi/0000-0003-3383-3554; Fukumoto, Satoshi/0000-0002-5046-6891				BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IBER H, 1989, FEBS LETT, V254, P124, DOI 10.1016/0014-5793(89)81022-1; IBER H, 1989, FEBS LETT, V248, P18, DOI 10.1016/0014-5793(89)80423-5; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; KAUFMAN B, 1967, INBORN DISORDERS SPH, P193; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PREUSS U, 1993, J BIOL CHEM, V268, P26273; RUAN S, 1992, CANCER RES, V52, P5725; Sasaki K, 1996, TRENDS GLYCOSCI GLYC, V8, P195, DOI 10.4052/tigg.8.195; SONG WX, 1993, BIOCHEMISTRY-US, V32, P8602, DOI 10.1021/bi00084a030; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; WAKABAYASHI S, 1984, J INVEST DERMATOL, V83, P128, DOI 10.1111/1523-1747.ep12263312; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; Yamamoto A, 1996, J NEUROCHEM, V66, P26; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YAMASHIRO S, 1995, GLYCOCONJUGATE J, V12, P894, DOI 10.1007/BF00731251; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YAMASHIRO S, 1993, CANCER RES, V53, P5305; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	48	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9271	9276		10.1074/jbc.274.14.9271	http://dx.doi.org/10.1074/jbc.274.14.9271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092602	hybrid			2022-12-27	WOS:000079451800021
J	Ghahremani, MH; Cheng, PH; Lembo, PMC; Albert, PR				Ghahremani, MH; Cheng, PH; Lembo, PMC; Albert, PR			Distinct roles for G alpha(i)2, G alpha(i)3, and G beta gamma in modulation of forskolin- or G(s)-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAMMALIAN ADENYLYL CYCLASES; HETEROTRIMERIC G-PROTEINS; PITUITARY-CELLS; POTASSIUM CHANNELS; INHIBITION; EXPRESSION; ACTIVATION; FIBROBLASTS; STIMULATION	Previous studies have shown that a single G protein-coupled receptor can regulate different effector systems by signaling through multiple subtypes of heterotrimeric G proteins. In LD2S fibroblast cells, the dopamine D2S receptor couples to pertussis toxin (PTX)-sensitive G(i)/G(o) proteins to inhibit forskolin- or prostaglandin E-1-stimulated cAMP production and to stimulate calcium mobilization, To analyze the role of distinct G alpha(i/o) protein subtypes, LD2S cells were stably transfected with a series of PTX-insensitive G alpha(i/o) protein Cys --> Ser point mutants and assayed for D2S receptor signaling after PTX treatment, The level of expression of the transfected G alpha mutant subunits was similar to the endogenous level of the most abundant G alpha(i/o) proteins (G alpha(o), G alpha(i)3). D2S receptor-mediated inhibition of forskolin-stimulated cAMP production was retained only in clones expressing mutant G alpha(i)2. In contrast, the D2S receptor utilized G alpha(i)3 to inhibit PGE(i)-induced (G(s)-coupled) enhancement of cAMP production. Following stable or transient transfection, no single or pair set of mutant G alpha(i/o) subtypes rescued the D2S-mediated calcium response following PTX pretreatment. On the other hand, in LD2S cells stably transfected with GRK-CT, a receptor kinase fragment that specifically antagonizes G beta gamma subunit activity, D2S receptor-mediated calcium mobilization was blocked. The observed specificity of G alpha(i)2 and G alpha(i)3 for different states of adenylyl cyclase activation suggests a higher level of specificity for interaction of G alpha(i) subunits with forskolin- versus G(s)-activated states of adenylyl cyclase than has been previously appreciated.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; McGill University	Albert, PR (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd,Rm 2464, Ottawa, ON K1H 8M5, Canada.	palbert@uottawa.ca	Ghahremani, Mohammad H/F-1615-2013; Albert, Paul/E-4804-2010	Ghahremani, Mohammad H/0000-0001-5051-6214; Albert, Paul/0000-0002-1809-3554				ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CAMPS M, 1992, EUR J BIOCHEM, V206, P23066; CASTELLANO MA, 1993, MOL PHARMACOL, V44, P649; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; EINHORN LC, 1991, J NEUROSCI, V11, P3727; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; GHAHREMANI MH, 1995, P SOC NEUROSCI, V21, P1863; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAYES G, 1992, MOL ENDOCRINOL, V6, P920, DOI 10.1210/me.6.6.920; HUFF RM, 1994, J CELL BIOCH B, V18, P220; HUNT TW, 1994, J BIOL CHEM, V269, P29565; IZENWASSER S, 1995, J NEUROCHEM, V64, P1614; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAJINESS ME, 1993, J PHARMACOL EXP THER, V267, P1573; Lembo PMC, 1999, MOL ENDOCRINOL, V13, P138, DOI 10.1210/me.13.1.138; LEW AM, 1995, J BIOL CHEM, V270, P7156, DOI 10.1074/jbc.270.13.7156; LIU YF, 1992, J NEUROCHEM, V59, P2311; LIU YF, 1991, J BIOL CHEM, V266, P23689; LIU YF, 1994, J BIOL CHEM, V269, P13880; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MALEK D, 1993, FEBS LETT, V325, P215; MEMO M, 1992, J NEUROCHEM, V59, P1829, DOI 10.1111/j.1471-4159.1992.tb11016.x; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORRIS SJ, 1996, P SOC NEUR, V22; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nevo I, 1998, MOL PHARMACOL, V54, P419, DOI 10.1124/mol.54.2.419; RAYMOND JR, 1995, AM J PHYSIOL, V28, pF141; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SENOGLES SE, 1994, ENDOCRINOLOGY, V134, P783, DOI 10.1210/en.134.2.783; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VALLAR L, 1990, J BIOL CHEM, V265, P10320; YAMANE HK, 1993, ANNU REV PHARMACOL, V33, P201, DOI 10.1146/annurev.pharmtox.33.1.201; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	48	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9238	9245		10.1074/jbc.274.14.9238	http://dx.doi.org/10.1074/jbc.274.14.9238			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092597	hybrid			2022-12-27	WOS:000079451800016
J	Coon, SL; Begay, V; Deurloo, D; Falcon, J; Klein, DC				Coon, SL; Begay, V; Deurloo, D; Falcon, J; Klein, DC			Two arylalkylamine N-acetyltransferase genes mediate melatonin synthesis in fish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PINEAL-GLAND; MESSENGER-RNA; CIRCADIAN REGULATION; RETINA; RHYTHM; EXPRESSION; METABOLISM; CLONING; ENZYME; ORGAN	Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT, EC 2.3.1.87) is the first enzyme in the conversion of serotonin to melatonin, Large changes in AANAT activity play an important role in the daily rhythms in melatonin production. Although a single AANAT gene has been found in mammals and the chicken, we have now identified two AANAT genes in fish. These genes are designated AANAT-1 and AANAT-2; all known AANATs belong to the AANAT-1 subfamily. PikeAANAT-1 is nearly exclusively expressed in the retina and AANAT-2 in the pineal gland. The abundance of each mRNA changes on a circadian basis, with retinal AANAT-1 mRNA peaking in late afternoon and pineal AANAT-2 mRNA peaking 6 h later. The pike AANAT-1 and AANAT-2 enzymes (66% identical amino acids) exhibit marked differences in their affinity for serotonin, relative affinity for indoleethylamines versus phenylethylamines and temperature-activity relationships. Two AANAT genes also exist in another fish, the trout. The evolution of two AANATs may represent a strategy to optimally meet tissue-related requirements for synthesis of melatonin: pineal melatonin serves an endocrine role and retinal melatonin plays a paracrine role.	NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA; Lab Neurobiol Cellulaire, Dept Neurosci, CNRS, UMR 6558, F-86022 Poitiers, France	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Klein, DC (corresponding author), NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bldg 49,Rm 6A-82, Bethesda, MD 20892 USA.	klein@helix.nih.gov	FALCON, Jack/I-5302-2013	FALCON, Jack/0000-0002-7572-6581; Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000095, Z01HD000095] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arendt J., 1995, MELATONIN MAMMALIAN, p[201, 27]; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; Begay V, 1998, ENDOCRINOLOGY, V139, P905, DOI 10.1210/en.139.3.905; Bernard M, 1997, J NEUROCHEM, V68, P213; BESHARSE JC, 1983, SCIENCE, V219, P1341, DOI 10.1126/science.6828862; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISTRIA M, 1994, GEN COMP ENDOCR, V96, P6, DOI 10.1006/gcen.1994.1153; Falcon J, 1996, PFLUG ARCH EUR J PHY, V432, P386, DOI 10.1007/s004240050149; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Iuvone P. Michael, 1995, P25; Iuvone PM, 1996, RETINAL DEGENERATION AND REGENERATION, P3; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1985, CIBA F SYMP, V117, P38; Klein DC, 1996, TRENDS ENDOCRIN MET, V7, P106, DOI 10.1016/1043-2760(96)00033-1; Klein DC, 1998, HDB BEHAV STATE CONT, P45; Mizusawa K, 1998, ZOOL SCI, V15, P345, DOI 10.2108/zsj.15.345; Morgan IG, 1996, VISUAL NEUROSCI, V13, P399, DOI 10.1017/S0952523800008087; O'Brien PJ, 1986, PINEAL RETINAL RELAT; OKSCHE A, 1965, Prog Brain Res, V10, P3; RODRIGUEZ IR, 1994, J BIOL CHEM, V269, P31969; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Sakamoto K, 1998, NEUROSCI LETT, V245, P113, DOI 10.1016/S0304-3940(98)00189-X; SKENE DJ, 1992, BIOCHEM SOC T, V20, P312, DOI 10.1042/bst0200312; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; WALLS GL, 1942, VERTEBRATE EYE ITS A; ZAWILSKA JB, 1992, NEUROCHEM INT, V20, P23, DOI 10.1016/0197-0186(92)90122-8	35	93	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9076	9082		10.1074/jbc.274.13.9076	http://dx.doi.org/10.1074/jbc.274.13.9076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085157	hybrid			2022-12-27	WOS:000079451600099
J	Oppermann, M; Mack, M; Proudfoot, AEI; Olbrich, H				Oppermann, M; Mack, M; Proudfoot, AEI; Olbrich, H			Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTERLEUKIN-8 RECEPTOR; C5A ANAPHYLATOXIN; EXPRESSION VECTOR; MOLECULAR-CLONING; AMINO-ACIDS; DESENSITIZATION; INTERNALIZATION; SPECIFICITY; PEPTIDE	The binding of CC chemokines to CC chemokine receptor 5 (CCR5) triggers cellular responses that, generally, are only transient in nature. To explore the potential role of G protein coupled receptor kinases (GRKs) in the regulation of CCR5, we performed phosphorylation experiments in a rat basophilic leukemia cell line stably expressing CCR5, The ability of various CCR5 ligands to stimulate calcium mobilization in these cells correlated with their ability to induce receptor phosphorylation, desensitization, internalization, and GRK association with the receptor. Aminooxypentane-RANTES, a potent inhibitor of human immunodeficiency virus infection, has been proposed to act through enhanced CCR5 internalization and inhibition of receptor recycling. Aminooxypentane-RANTES profoundly induced CCR5 phosphorylation, but had no effect on CCR1, In permeabilized rat basophilic leukemia CCR5 cells, monoclonal antibodies with specificity for GRK2/3 inhibited RANTES-induced receptor phosphorylation, Consistent with a role for these kinases in CCR5 regulation, 1-2 x 10(5) copies of GRK2 or GRK3 were found to be expressed in peripheral blood leukocytes. Phosphoamino acid analysis revealed that RANTES-induced CCR5 phosphorylation selectively occurs on serine residues. Our findings with receptor mutants indicate that serine residues at positions 336, 337, 342, and 349 represent GRK phosphorylation sites on CCR5, This study demonstrates that chemokines differ in their ability to induce CCR5 phosphorylation and desensitization and provides a molecular mechanism for the agonist-induced attenuation of CCR5 signaling.	Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany; Univ Munich, Med Policlin, D-80336 Munich, Germany; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	University of Gottingen; University of Munich	Oppermann, M (corresponding author), Univ Kliniken Gottingen, Dept Immunol, Kreuzbergring 57, D-37075 Gottingen, Germany.	mopperm@gwdg.de						AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Franci C, 1996, J IMMUNOL, V157, P5606; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Solari R, 1997, J BIOL CHEM, V272, P9617; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4	41	165	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8875	8885		10.1074/jbc.274.13.8875	http://dx.doi.org/10.1074/jbc.274.13.8875			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085131	hybrid			2022-12-27	WOS:000079451600073
J	Pickard, RT; Strifler, BA; Kramer, RM; Sharp, JD				Pickard, RT; Strifler, BA; Kramer, RM; Sharp, JD			Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; LIPID-BINDING DOMAIN; PRECURSOR TRANSCRIPTS; GENE-EXPRESSION; THEMATIC SERIES; ACID; IDENTIFICATION; CONTAINS; CELLS; PHOSPHORYLATION	Two new cloned human cDNAs encode paralogs of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)). We propose to call these cPLA(2)beta (114 kDa) and cPLA(2)gamma (61 kDa), giving the name cPLA(2)alpha to the well known 85-kDa enzyme. cPLA(2)beta mRNA is expressed more highly in cerebellum and pancreas and cPLA(2)gamma more highly in cardiac and skeletal muscle, Sequence-tagged site mapping places cPLA(2)beta on chromosome 15 in a region near a phosphoinositol bisphosphate phosphatase. The mRNA for cPLA(2)beta is spliced only at a very low level, and Northern blots in 24 tissues show exclusively the unspliced form. cPLA(2)beta has much lower activity on 2-arachidonoyl-phosphatidylcholine liposomes than either of the other two enzymes. Its sequence contains a histidine motif characteristic of the catalytic center of caspase proteases of the apoptotic cascade but no region characteristic of the catalytic cysteine, Sequence-tagged site mapping places cPLA(2)gamma on chromosome 19 near calmodulin, cPLA(2)gamma lacks the C2 domain, which gives cPLA(2)alpha its Ca(2+) sensitivity, and accordingly cPLA(2)gamma has no dependence upon calcium, although cPLA(2)beta does, cPLA(2)gamma contains a prenyl group-binding site motif and appears to be largely membrane-bound. cPLA(2)alpha residues activated by phosphorylation do not appear to be well conserved in either new enzyme. In contrast, all three previously known catalytic residues, as well as one additional essential arginine, Arg-566 in cPLA(2)alpha, are conserved in both new enzyme sequences. Mutagenesis shows strong dependence on these residues for catalytic activity of all three enzymes.	Eli Lilly & Co, Lilly Res Lab, Indianapolis, IN 46285 USA	Eli Lilly	Sharp, JD (corresponding author), Millennium Biotherapeut, 620 Mem Dr, Cambridge, MA 02139 USA.	sharp@mpi.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; *GEN COMP GROUP, 1996, WISC PACK VERS 8 1 9; GEREZ L, 1995, J BIOL CHEM, V270, P19569, DOI 10.1074/jbc.270.33.19569; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; JARROUS N, 1994, J BIOL CHEM, V269, P23141; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; KRAMER JM, 1996, BIOCHIM BIOPHYS ACTA, V959, P269; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Prescott SM, 1997, J BIOL CHEM, V272, P15043, DOI 10.1074/jbc.272.24.15043; QIU ZH, 1993, J BIOL CHEM, V268, P24506; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Srinivasan SR, 1996, ATHEROSCLEROSIS, V123, P33, DOI 10.1016/0021-9150(95)05762-5; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989	47	172	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8823	8831		10.1074/jbc.274.13.8823	http://dx.doi.org/10.1074/jbc.274.13.8823			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085124	hybrid			2022-12-27	WOS:000079451600066
J	Ritty, TM; Broekelmann, T; Tisdale, C; Milewicz, DM; Mecham, RP				Ritty, TM; Broekelmann, T; Tisdale, C; Milewicz, DM; Mecham, RP			Processing of the fibrillin-1 carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; MARFAN-SYNDROME; ENDOPLASMIC-RETICULUM; CALCIUM-BINDING; FBN1 MUTATIONS; BREFELDIN-A; RETROGRADE TRANSPORT; PRECURSOR PROTEINS; GOLGI-APPARATUS; CELL-LINE	To investigate the processing and general properties of the fibrillin-1 carboxyl-terminal domain, three protein expression constructs have been developed as follows: one without the domain, one with the domain, and one with a mutation near the putative proteolytic processing site. The constructs have been expressed in two eukaryotic model systems, baculoviral and CHO-K1, Post-translational modifications that normally occur in fibrillin-1, including glycosylation, signal peptide cleavage, and carboxyl-terminal processing, occur in the three constructs in both cell systems. Amino-terminal sequencing of secreted protein revealed leader sequence processing at two sites, a primary site between Gly-24/Ala-25 and a secondary site of Ala-27/Asn-28. Processing of the carboxyl-terminal domain could be observed by migration differences in SDS-polyacrylamide gel electrophoresis and was evident in both mammalian and insect cells. Immunological identification by Western blotting confirmed the loss of the expected region. The failure of both cell systems to process the mutant construct shows that the multi-basic sequence is the site of proteolytic processing, Cleavage of the fibrillin-1 carboxyl-terminal domain occurred intracellularly in CHO-K1 cells in an early secretory pathway compartment as demonstrated by studies with secretion blocking agents, This finding, taken with the multi-basic nature of the cleavage site and observed calcium sensitivity of cleavage, suggests that the processing enzyme is a secretory pathway resident furin-like protease.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA	Washington University (WUSTL); University of Texas System	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041926, P01HL029594, R37HL053325, R01HL053325] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41926, HL29594, HL53325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECCARI T, 1992, BIOCHEM INT, V27, P783; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; COUKELL MB, 1992, J CELL SCI, V103, P371; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; CROUCH E, 1994, J BIOL CHEM, V269, P15808; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HALBAN PA, 1994, BIOCHEM J, V299, P1; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HAYWARD C, 1994, HUM MUTAT, V3, P159, DOI 10.1002/humu.1380030212; HU SL, 1987, J VIROL, V61, P3617, DOI 10.1128/JVI.61.11.3617-3620.1987; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LISSITZKY JCS, 1988, BIOCHEM J, V250, P843, DOI 10.1042/bj2500843; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; Milewicz DM, 1996, CIRCULATION, V94, P2708, DOI 10.1161/01.CIR.94.11.2708; MILEWICZ DM, 1995, J CLIN INVEST, V95, P2373, DOI 10.1172/JCI117930; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; ODA K, 1992, J BIOL CHEM, V267, P17465; OREILLY DO, 1992, BACULOVIRUS EXPRESSI, P218; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PRESSMAN BC, 1982, ANNU REV PHARMACOL, V22, P465, DOI 10.1146/annurev.pa.22.040182.002341; RAGHUNATH M, 1995, J MOL BIOL, V248, P901, DOI 10.1006/jmbi.1995.0270; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REDICK SD, 1995, J CELL SCI, V108, P1761; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; Sood S, 1996, NAT GENET, V12, P209, DOI 10.1038/ng0296-209; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; ZHANG CY, 1995, BIOCHEM BIOPH RES CO, V207, P238, DOI 10.1006/bbrc.1995.1178	48	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8933	8940		10.1074/jbc.274.13.8933	http://dx.doi.org/10.1074/jbc.274.13.8933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085138	hybrid			2022-12-27	WOS:000079451600080
J	Strahl-Bolsinger, S; Scheinost, A				Strahl-Bolsinger, S; Scheinost, A			Transmembrane topology of Pmt1p, a member of an evolutionarily conserved family of protein O-mannosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-LINKED OLIGOSACCHARIDE; PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; INNER MEMBRANE-PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GENE FAMILY; GLCNAC-1-P TRANSFERASE; CANDIDA-ALBICANS; N-GLYCOSYLATION; PIG-B	The identification of the evolutionarily conserved family of dolichyl-phosphate-D-mannose:protein O-mannosyltransferases (Pmts) revealed that protein O-mannosylation plays an essential role in a number of physiologically important processes, Strikingly, all members of the Pmt protein family share almost identical hydropathy profiles; a central hydrophilic domain is flanked by amino- and carboxyl-terminal sequences containing several putative transmembrane helices, This pattern is of particular interest because it diverges from structural models of all glycosyltransferases characterized so far. Here, we examine the transmembrane topology of Pmt1p, an integral membrane protein of the endoplasmic reticulum, from Saccharomyces cerevisiae. Structural predictions were directly tested by site-directed mutagenesis of endogenous N-glycosylation sites, by fusing a topology-sensitive monitor protein domain to carboxyl-terminal truncated versions of the Pmt1 protein and, in addition, by N-glycosylation scanning. Based on our results we propose a seven-transmembrane helical model for the yeast Pmt1p mannosyltransferase. The Pmt1p amino terminus faces the cytoplasm, whereas the carboxyl terminus faces the lumen of the endoplasmic reticulum, A large hydrophilic segment that is oriented toward the lumen of the endoplasmic reticulum is flanked by five amino-terminal and two carboxyl-terminal membrane spanning domains. We could demonstrate that this central loop is essential for the function of Pmt1p.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Strahl-Bolsinger, S (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany.	sabine.strahl-bolsinger@biologie.uni-regensburg.de	Scheinost, Andreas C/D-2275-2010	Scheinost, Andreas C/0000-0002-6608-5428				Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1996, P NATL ACAD SCI USA, V93, P7160, DOI 10.1073/pnas.93.14.7160; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Eckert V, 1998, GLYCOBIOLOGY, V8, P77, DOI 10.1093/glycob/8.1.77; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUEIRREIRO P, 1996, YEAST, V12, P273; Harlow E., 1988, ANTIBODIES LAB MANUA; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARRIBA G, 1976, FEBS LETT, V71, P316, DOI 10.1016/0014-5793(76)80960-X; Lehle L., 1995, GLYCOPROTEINS A, V29a, P475; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARRIOTT M, 1979, J BACTERIOL, V139, P565, DOI 10.1128/JB.139.2.566-572.1979; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Menon AK, 1997, BIOCHEM SOC T, V25, P861, DOI 10.1042/bst0250861; NILSSON I, 1993, J BIOL CHEM, V268, P5798; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; Roemer T, 1996, GENE DEV, V10, P777, DOI 10.1101/gad.10.7.777; Rothe C, 1998, EUR J BIOCHEM, V252, P16, DOI 10.1046/j.1432-1327.1998.2520016.x; SAKAGUCHI M, 1997, MOL B INT U, P135; Sambrook J., 2002, MOL CLONING LAB MANU; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SENTANDREU R, 1969, CARBOHYD RES, V10, P584, DOI 10.1016/S0008-6215(00)80126-3; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STRAHLBOLSINGER S, 1991, THESIS U REGENSBURG; Sutterlin C, 1998, BIOCHEM J, V332, P153; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; VONHEIJNE G, 1997, MOL B INT U, P55; WESTON A, 1993, EUR J BIOCHEM, V215, P845, DOI 10.1111/j.1432-1033.1993.tb18101.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZHU XY, 1990, J BIOL CHEM, V265, P14250; [No title captured]	60	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9068	9075		10.1074/jbc.274.13.9068	http://dx.doi.org/10.1074/jbc.274.13.9068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085156	hybrid			2022-12-27	WOS:000079451600098
J	Yang, WN; Lin, Q; Guan, JL; Cerione, RA				Yang, WN; Lin, Q; Guan, JL; Cerione, RA			Activation of the Cdc42-associated tyrosine kinase-2 (ACK-2) by cell adhesion via integrin beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; BINDING PROTEINS RAC1; N-TERMINAL KINASE; FOCAL ADHESIONS; SIGNALING PATHWAY; CDC42HS BINDING; V-SRC; IDENTIFICATION	Activated Cdc42-associated kinase-2 (ACK-2) is a nonreceptor tyrosine kinase that appears to be a highly specific target for the Rho-related GTP-binding protein Cdc42. In order to understand better how ACK-2 activity is regulated in cells, we have expressed epitope-tagged forms of this tyrosine kinase in COS-7 and NIH3T3 cells. We find that ACK-2 can be activated by cell adhesion in a Cdc42-dependent manner. However, unlike the focal adhesion kinase, which also is activated by cell adhesion, the activation of ACK-2 is F-actin-independent and does not require cell spreading. In addition, overexpression of ACK-2 in COS-7 cells did not result in the stimulation of extracellular signal-regulated kinase activity but rather activated the c-Jun kinase. Both anti-integrin beta(1) antibody and RGD peptides inhibited the activation of ACR-S by cell adhesion. In addition, ACK-2 was coimmunoprecipitated with integrin beta(1). Overall, these findings suggest that AGK-2 interacts with integrin complexes and mediates cell adhesion signals in a Cdc42-dependent manner.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Nutr Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM40654, GM47458, GM52890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890, R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Brill S, 1996, MOL CELL BIOL, V16, P4869; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8481; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rudel T, 1998, J IMMUNOL, V160, P7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	55	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8524	8530		10.1074/jbc.274.13.8524	http://dx.doi.org/10.1074/jbc.274.13.8524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085085	hybrid			2022-12-27	WOS:000079451600027
J	Betto, R; Senter, L; Ceoldo, S; Tarricone, E; Biral, D; Salviati, G				Betto, R; Senter, L; Ceoldo, S; Tarricone, E; Biral, D; Salviati, G			Ecto-ATPase activity of alpha-sarcoglycan (adhalin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED PROTEINS; RECESSIVE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; GLYCOPROTEIN-COMPLEX; TRANSVERSE TUBULES; PLASMA-MEMBRANE; BINDING SITE; RECEPTOR; GENE; SARCOLEMMA	alpha-Sarcoglycan is a component of the sarcoglycan complex of dystrophin-associated proteins. Mutations of any of the sarcoglycan genes cause specific forms of muscular dystrophies, collectively termed sarcoglycanopathies. Importantly, a deficiency of any specific sarcoglycan affects the expression of the others. Thus, it appears that the lack of sarcoglycans deprives the muscle cell of an essential, yet unknown function. In the present study, we provide evidence for an ecto-ATPase activity of alpha-sarcoglycan. alpha-Sarcoglycan binds ATP in a Mg2+-dependent and Ca2+-independent manner. The binding is inhibited by 3'-O-(4-benzoyl)benzoyl ATP and ADP, Sequence analysis reveals the existence of a consensus site for nucleotide binding in the extracellular domain of the protein, An antibody against this sequence inhibits the binding of ATP, A dystrophin dystrophin-associated protein preparation demonstrates a Mg-ATPase activity that is inhibited by the antibody but not by inhibitors of endo-ATPases. In addition, we demonstrate the presence in the sarcolemmal membrane of a P2X-type purinergic receptor. These data suggest that alpha-sarcoglycan may modulate the activity of P2X receptors by buffering the extracellular ATP concentration. The absence of a-sarcoglycan in sarcoglycanopathies leaves elevated the concentration of extracellular ATP and the persistent activation of P2X receptors, leading to intracellular Ca2+ overload and muscle fiber death.	Univ Padua, Sch Med, CNR, Unit Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Padua, Sch Med, Dept Biomed Sci, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Betto, R (corresponding author), Univ Padua, Sch Med, CNR, Unit Muscle Biol & Physiopathol, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	betto@civ.bio.unipd.it	Salviati, Giancarlo/F-4947-2016	Salviati, Giancarlo/0000-0002-9828-6371	Telethon [692] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; Barbacci E, 1996, BIOCHEM BIOPH RES CO, V222, P273, DOI 10.1006/bbrc.1996.0734; Beckmann JS, 1996, CURR OPIN NEUROL, V9, P389, DOI 10.1097/00019052-199610000-00013; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Burnstock G, 1996, CIBA F SYMP, V198, P1; Carlson CG, 1998, NEUROBIOL DIS, V5, P3, DOI 10.1006/nbdi.1998.0188; CUSACK NJ, 1993, DRUG DEVELOP RES, V28, P244, DOI 10.1002/ddr.430280310; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; KAWAI H, 1995, J CLIN INVEST, V96, P1202, DOI 10.1172/JCI118152; Kennedy C, 1996, SEMIN NEUROSCI, V8, P195, DOI 10.1006/smns.1996.0025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LIN SH, 1988, J BIOL CHEM, V263, P12253; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; LUISE M, 1993, BIOCHEM J, V293, P243, DOI 10.1042/bj2930243; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Michalak M, 1997, CURR OPIN NEUROL, V10, P436, DOI 10.1097/00019052-199710000-00014; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; PAL PK, 1992, J BIOL CHEM, V267, P25003; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; PIZZO P, 1992, J IMMUNOL, V149, P3372; PLESNER L, 1991, BIOCHIM BIOPHYS ACTA, V1067, P191, DOI 10.1016/0005-2736(91)90043-8; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; SALVATORI S, 1990, BIOCHEM J, V267, P679, DOI 10.1042/bj2670679; SALVIATI G, 1982, BIOCHEM J, V202, P289, DOI 10.1042/bj2020289; SENTER L, 1995, BIOCHEM BIOPH RES CO, V206, P57, DOI 10.1006/bbrc.1995.1009; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; TURNER PR, 1988, NATURE, V335, P535; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; Winder SJ, 1997, J MUSCLE RES CELL M, V18, P617, DOI 10.1023/A:1018627705273; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z; [No title captured]	56	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7907	7912		10.1074/jbc.274.12.7907	http://dx.doi.org/10.1074/jbc.274.12.7907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075685	hybrid			2022-12-27	WOS:000079268100044
J	Dai, P; Akimaru, H; Tanaka, Y; Maekawa, T; Nakafuku, M; Ishii, S				Dai, P; Akimaru, H; Tanaka, Y; Maekawa, T; Nakafuku, M; Ishii, S			Sonic hedgehog-induced activation of the Gli1 promoter is mediated by GLI3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CUBITUS-INTERRUPTUS PROTEIN; RUBINSTEIN-TAYBI SYNDROME; SAETHRE-CHOTZEN SYNDROME; KINESIN-RELATED PROTEIN; ZINC-FINGER PROTEINS; LONG TERMINAL REPEAT; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; LIMB DEVELOPMENT	Drosophila transcription factor cubitus interruptus (Ci) and its co-activator CRE (cAMP response element)binding protein (CBP) activate a group of target genes on the anterior-posterior border in response to hedgehog protein (Hh) signaling. In the anterior region, in contrast, the carboxyl-truncated form of Ci generated by protein processing represses Hh expression. In vertebrates, three Ci-related transcription factors (glioblastoma gene products (GLIs) 1, 2, and 3) were identified, but their functional difference in Hh signal transduction is unknown. Here, we report distinct roles for GLI1 and GLIB in Sonic hedgehog (Shh) signaling. GLIB containing both repression and activation domains acts both as an activator and a repressor, as does Ci, whereas GLI1 contains only the activation domain. Consistent with this, GLIB, but not GLI1, is processed to generate the repressor form. Transcriptional co-activator CBP binds to GLIB, but not to GLI1. The trans-activating capacity of GLIB is positively and negatively regulated by Shh and cAMP-dependent protein kinase, respectively, through a specific region of GLI3, which contains the CBP-binding domain and the phosphorylation sites of cAMP-dependent protein kinase. GLI3 directly binds to the Gli1 promoter and induces Gli1 transcription in response to Shh. Thus, GLI3 may act as a mediator of Shh signaling in the activation of the target gene Gli1.	RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan; Univ Tokyo, Grad Sch Med, Div Neurobiol, Dept Neurosci,Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016; Nakafuku, Masato/J-3068-2013	Ishii, Shunsuke/0000-0002-6530-2478; Nakafuku, Masato/0000-0001-7783-9005				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ElGhouzzi V, 1997, NAT GENET, V15, P42; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HENNEKAM RCM, 1990, AM J MED GENET, P17; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; Lee J, 1997, DEVELOPMENT, V124, P2537; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; VORTKAMP A, 1995, HUM GENET, V95, P82; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0	62	429	436	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8143	8152		10.1074/jbc.274.12.8143	http://dx.doi.org/10.1074/jbc.274.12.8143			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075717	hybrid			2022-12-27	WOS:000079268100076
J	Shiojima, I; Komuro, I; Oka, T; Hiroi, Y; Mizuno, T; Takimoto, E; Monzen, K; Aikawa, R; Akazawa, H; Yamazaki, T; Kudoh, S; Yazaki, Y				Shiojima, I; Komuro, I; Oka, T; Hiroi, Y; Mizuno, T; Takimoto, E; Monzen, K; Aikawa, R; Akazawa, H; Yamazaki, T; Kudoh, S; Yazaki, Y			Context-dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx-2.5 and GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; DNA-BINDING SPECIFICITY; SERUM RESPONSE FACTOR; HEART TUBE FORMATION; VENTRAL MORPHOGENESIS; HOMEODOMAIN FACTOR; DROSOPHILA; TINMAN; PROTEINS; EXTRADENTICLE	Although the cardiac homeobox gene Csx/Nkx-2.5 is essential for normal heart development, little is known about its regulatory mechanisms. In a search for the downstream target genes of Csx/Nkx-2.5, we found that the atrial natriuretic peptide (ANP) gene promoter was strongly transactivated by Csx/Nkx-2.5. Deletion and mutational analyses of the ANP promoter revealed that the Csx/Nkx-2.5-binding element (NKE2) located at -240 was required for high level transactivation by Csx/Nkx-2.5. We also found that Csx/Nkx-2.5 and GATA-4 displayed synergistic transcriptional activation of the ANP promoter, and in contrast to previous reports (Durocher, D., Charron, F., Warren, R., Schwartz, R. J., and Namer, M. (1997) EMBO J. 16, 5687-5696; Lee, Y., Shioi, T., Kasahara, H., Jobe, S. M., Wiese, R. J., Markham, B., and Izumo, S (1998) Mel; Cell. Biol. 18, 3120-3129), this synergism was dependent on binding of Csx/Nkx-2.5 to NKE2, but not on GATA-4-DNA interactions. Although GATA-4 also potentiated the Csx/Nkx-2.5-induced transactivation of the artificial promoter that contains multimerized Csx/Nkx-2.5-binding sites, Csx/Nkx-2.5 reduced the GATA-4-induced transactivation of the GATA-4-dependent promoters. These findings indicate that the cooperative transcriptional regulation mediated by Csx/Nkx-2.5 and GATA-4 is promoter context-dependent and suggest that the complex cis-trans interactions may fine-tune gene expression in cardiac myocytes.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Komuro, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	komuro-tky@umin.ac.jp	Takimoto, Eiki/AAC-5100-2021	Akazawa, Hiroshi/0000-0002-3574-9607				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BODMER R, 1995, TRENDS CARDIOVAS MED, V5, P21, DOI 10.1016/1050-1738(94)00032-Q; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen JN, 1996, DEVELOPMENT, V122, P3809; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LU QA, 1995, MOL CELL BIOL, V15, P3786; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zou YM, 1997, DEVELOPMENT, V124, P793	39	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8231	8239		10.1074/jbc.274.12.8231	http://dx.doi.org/10.1074/jbc.274.12.8231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075728	hybrid			2022-12-27	WOS:000079268100087
J	Tillotson, LG				Tillotson, LG			RIN ZF, a novel zinc finger gene, encodes proteins that bind to the CACC element of the gastrin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; INSULINOMA CELLS; LEUCINE-ZIPPER; DNA; SP1; EXPRESSION; SEQUENCES; KRUPPEL	Expression of gastrin, a gut hormone and growth factor, has tissue-specific transcriptional regulation and can be induced in some tumors. Previous studies have shown that a CACC cis-regulatory element is important for transcriptional activation in pancreatic insulinoma cells, To identify CACC-binding proteins, a lambda phage cDNA library derived from a rat insulinoma cell line, RIN 38A, was screened by a Southwestern method. A novel member of the Cys(2)-His(2) zinc finger gene family was cloned and designated RIN ZF, having a cDNA sequence of 3.8 kilobases, One full-length and a shorter splice variant were sequenced and had predicted protein masses of 91.6 and 88.7 kDa, Expression of both splice forms were ubiquitous in fetal and adult rat tissues. Recombinant RIN ZF protein exhibited sequence specific binding to the gastrin CACC element in a gel mobility shift assay. In transient transfections, both splice variants appeared to have only weak activating effects on gastrin-luciferase reporter gene transcription, Furthermore, RIN ZF coexpression with Spl appeared to block the strongly activating effects of Spl mediated through the CACC element. These findings suggest that a novel set of zinc finger proteins may help regulate gastrin gene expression by interfering with Spl transactivation.	Univ N Carolina, Div Digest Dis & Nutr, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Tillotson, LG (corresponding author), Univ N Carolina, Div Digest Dis & Nutr, Dept Med, Rm 148,Glaxo Bldg,CB7038, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [R29 DK49860] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049860] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHUNG DC, 1995, J BIOL CHEM, V270, P8829, DOI 10.1074/jbc.270.15.8829; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEMEDIUK BH, 1992, GASTROENTEROLOGY, V102, P728; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARADA R, 1994, J BIOL CHEM, V269, P2062; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LUTTICHAU HR, 1993, GASTROENTEROLOGY, V104, P1092; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MERCHANT JL, 1993, GASTROENTEROLOGY, V104, P283; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1997, CURRENT PROTOCOLS MO; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Stuempfle KJ, 1997, BIOTECHNIQUES, V22, P260, DOI 10.2144/97222bm13; SUTERCRAZZOLARA C, 1995, BIOTECHNIQUES, V19, P202; TILLOTSON L, 1993, GASTROENTEROLOGY, V104, P456; TILLOTSON LG, 1994, J BIOL CHEM, V269, P2234; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VONSOLINGE WW, 1993, GASTROENTEROLOGY, V104, P1099; WANG TC, 1990, J BIOL CHEM, V265, P8908; WANG TC, 1995, AM J PHYSIOL-GASTR L, V268, pG1025, DOI 10.1152/ajpgi.1995.268.6.G1025; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	52	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8123	8128		10.1074/jbc.274.12.8123	http://dx.doi.org/10.1074/jbc.274.12.8123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075714	Green Published, hybrid			2022-12-27	WOS:000079268100073
J	Wang, TH; Popp, DM; Wang, HS; Saitoh, M; Mural, JG; Henley, DC; Ichijo, H; Wimalasena, J				Wang, TH; Popp, DM; Wang, HS; Saitoh, M; Mural, JG; Henley, DC; Ichijo, H; Wimalasena, J			Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIVATION; PROTEIN-KINASES; BCL-2; PHOSPHORYLATION; TAXOL; STRESS; DEATH; PROGRESSION; CASPASES; GENE	The antineoplastic agent paclitaxel (Taxol(TM)), a microtubule stabilizing agent, is known to arrest cells at the G(2)/M phase of the cell cycle and induce apoptosis. We and others have recently demonstrated that paclitaxel also activates the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signal transduction pathway in various human cell types, however, no clear role has been established for JNK/SAPK in paclitaxel-induced apoptosis. To further examine the role of JNK/SAPK signaling cascades in apoptosis resulting from microtubular dysfunction induced by paclitaxel, we have coexpressed dominant negative (dn) mutants of signaling proteins of the JNK/SAPK pathway (Ras, ASK1, Rac, JNKK, and JNK) in human ovarian cancer cells with a selectable marker to analyze the apoptotic characteristics of cells expressing dn vectors following exposure to paclitaxel, Expression of these dn signaling proteins had no effect on Bcl-2 phosphorylation, yet inhibited apoptotic changes induced by paclitaxel up to 16 h after treatment. Coexpression of these dn signaling proteins had no protective effect after 48 h of paclitaxel treatment. Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Univ Tennessee, Dept Obstet & Gynecol, Ctr Med, Grad Sch Med, Knoxville, TN 37920 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37831 USA; Chang Gung Mem Hosp, Chang Gung Med Sch, Dept Obstet & Gynecol, Taipei 10591, Taiwan; Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Tokyo 1138549, Japan	University of Tennessee System; University of Tennessee Health Science Center; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; Chang Gung Memorial Hospital; Tokyo Medical & Dental University (TMDU)	Wimalasena, J (corresponding author), Univ Tennessee, Dept Obstet & Gynecol, Ctr Med, Grad Sch Med, 1924 Alcoa Highway, Knoxville, TN 37920 USA.			Ichijo, Hidenori/0000-0002-5005-6438	NCI NIH HHS [CA-68538] Funding Source: Medline; NIAAA NIH HHS [AA-08328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Amato SF, 1998, CANCER RES, V58, P241; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COSA OA, 1995, CELL, V81, P1137; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1998, CANCER RES, V58, P1609; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Heimbrook DC, 1998, CURR OPIN CELL BIOL, V10, P284, DOI 10.1016/S0955-0674(98)80152-X; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Huang TS, 1997, CANCER RES, V57, P2974; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee YJ, 1998, J BIOL CHEM, V273, P29857, DOI 10.1074/jbc.273.45.29857; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LONG BH, 1994, CANCER RES, V54, P4355; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MILAS L, 1995, CANCER CHEMOTH PHARM, V35, P297, DOI 10.1007/BF00689448; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; PRESTON GA, 1994, CANCER RES, V54, P4214; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang TH, 1996, J FORMOS MED ASSOC, V95, P509; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WIMALASENA J, 1991, GYNECOL ONCOL, V41, P56, DOI 10.1016/0090-8258(91)90255-4; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Zanke BW, 1998, CANCER RES, V58, P2801	74	196	205	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8208	8216		10.1074/jbc.274.12.8208	http://dx.doi.org/10.1074/jbc.274.12.8208			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075725	hybrid			2022-12-27	WOS:000079268100084
J	Kaplan, DL; Steitz, TA				Kaplan, DL; Steitz, TA			DnaB from Thermus aquaticus unwinds forked duplex DNA with an asymmetric tail length dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI CHROMOSOME; PROTEIN ACTION; BINDING-PROTEINS; REPLICATION FORK; RNA-POLYMERASE; HELICASE; PRIMASE; MECHANISM; BACTERIOPHAGE-T4	DnaB helicase is a ring-shaped hexamer of 300 kDa that is essential for replication of the bacterial chromo some. The dnaB gene from Thermus aquaticus was isolated and cloned, and its gene product was expressed and purified to homogeneity, A helicase assay was developed, and optimal conditions for T, aquaticus DnaB activity were determined using a forked duplex DNA substrate. The activity required a hydrolyzable nucleoside triphosphate and both 5'- and 3'-single-stranded DNA tail regions, Under conditions of single enzymatic turnover, the lengths of the 5'- and S'-single-stranded regions were varied, and 6-10 nucleotides of the 5'-single-stranded tail and 21-30 nucleotides of the 3'-single-stranded tail markedly stimulated the unwinding rate. These data suggest that DnaB from T, aquaticus interacts with both DNA single-stranded tails during unwinding and that a greater portion of the 3'-tail is in contact with the protein. Two models are consistent with these data. In one model, the 5'-single stranded region passes through the central hole of the DnaB ring, and the 3'-tail makes extensive contact with the outside of the protein. In the other model, the 3'-single-stranded region passes through the DnaB ring, and the outside of the protein contacts the 5'-tail.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009	Kaplan, Daniel/0000-0003-2760-7745				Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Dalphin ME, 1996, NUCLEIC ACIDS RES, V24, P216, DOI 10.1093/nar/24.1.216; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Jezewska MJ, 1997, BIOCHEMISTRY-US, V36, P10320, DOI 10.1021/bi970712a; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWER FC, 1989, J BIOL CHEM, V264, P6427; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; MARTIN MCS, 1995, J STRUCT BIOL, V114, P167; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MOK M, 1987, J BIOL CHEM, V262, P16644; PETERSON MG, 1993, METHOD ENZYMOL, V218, P493; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; Sambrook J., 2002, MOL CLONING LAB MANU; Silver J., 1991, PCR PRACTICAL APPROA, P137; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WU CA, 1992, J BIOL CHEM, V267, P4030; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	39	33	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6889	6897		10.1074/jbc.274.11.6889	http://dx.doi.org/10.1074/jbc.274.11.6889			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066742	hybrid			2022-12-27	WOS:000079078400014
J	Kimura, M; Matsuda, Y; Yoshioka, T; Okano, Y				Kimura, M; Matsuda, Y; Yoshioka, T; Okano, Y			Cell cycle-dependent expression and centrosome localization of a third human Aurora/Ip11-related protein kinase, AIK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; COLLAGEN GENE COL2A1; POLO-LIKE KINASE; BREAST-CANCER; DNA CONTENT; CHROMOSOME SEGREGATION; INSITU HYBRIDIZATION; YEAST; CARCINOMA; TUMORS	We earlier isolated cDNAs encoding novel human protein kinases AIK and AIK2 sharing high amino acid sequence identities with Drosophila Aurora and Saccharomyces cerevisiae Ipl1 kinases whose mutations cause abnormal chromosome segregation. In the present study, a third human cDNA (AIK3) highly homologous to artrora/IPL1 was isolated, and the nucleotide sequence was determined. This cDNA encodes 309 amino acids with a predicted molecular mass of 35.9 kDa, C-terminal kinase domain of AIK3 protein shares high amino acid sequence identities with those of Aurora/Ipl1 family protein kinases including human AIK, human AIK2, Xenopus pEg2, Drosophila Aurora, and yeast Ipl1, whereas the N-terminal domain of AIK3 protein shares little homology with any other Aurora/Ipl1 family members. AIK3 gene was assigned to human chromosome 19q13.43, which is a frequently deleted or rearranged region in several tumor tissues, by fluorescence in situ hybridization, somatic cell hybrid panel, and radiation hybrid cell panel. Northern blot analyses revealed that AIK3 expression was limited to testis, The expression levels of AIK3 in several cancer cell lines were elevated severalfold compared with normal fibroblasts. In HeLa cells, the endogenous AIK3 protein level is low in G(1)/S, accumulates during G(2)/M, and reduces after mitosis, Immunofluorescence studies using a specific antibody have shown that AIK3 is localized to centrosome during mitosis from anaphase to cytokinesis, These results suggest that AIK3 may play a role(s) in centrosome function at later stages of mitosis.	Gifu Univ, Sch Med, Dept Mol Pathobiochem, Gifu 5008705, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Genet, Chikusa Ku, Nagoya, Aichi 4640814, Japan	Gifu University; Nagoya University	Okano, Y (corresponding author), Gifu Univ, Sch Med, Dept Mol Pathobiochem, Tsukasamachi 40, Gifu 5008705, Japan.	bunbyo@cc.gifu-u.ac.jp						Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BRINGUIER PP, 1993, CYTOMETRY, V14, P559, DOI 10.1002/cyto.990140516; BUNN PA, 1982, BLOOD, V59, P528; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CHAN CSM, 1993, GENETICS, V135, P677; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Gopalan G, 1998, MAMM GENOME, V9, P86, DOI 10.1007/s003359900688; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; ISOLA JJ, 1995, AM J PATHOL, V147, P905; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kimura M, 1997, CYTOGENET CELL GENET, V78, P107, DOI 10.1159/000134639; Kimura M, 1997, CYTOGENET CELL GENET, V79, P201, DOI 10.1159/000134721; Kimura M, 1998, CYTOGENET CELL GENET, V82, P147, DOI 10.1159/000015089; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KIMURA M, 1991, J BIOCHEM, V109, P399, DOI 10.1093/oxfordjournals.jbchem.a123393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; McDonald JM, 1998, CANCER RES, V58, P1387; McManus DT, 1996, J PATHOL, V179, P177, DOI 10.1002/(SICI)1096-9896(199606)179:2<177::AID-PATH561>3.0.CO;2-2; MELCHIORRI C, 1993, CANCER, V72, P165, DOI 10.1002/1097-0142(19930701)72:1<165::AID-CNCR2820720131>3.0.CO;2-V; MERTENS F, 1994, CANCER GENET CYTOGEN, V73, P147, DOI 10.1016/0165-4608(94)90199-6; MOLENAAR WM, 1994, GENE CHROMOSOME CANC, V10, P66, DOI 10.1002/gcc.2870100111; Niwa H, 1996, GENE, V169, P197, DOI 10.1016/0378-1119(95)00809-8; Roghi C, 1998, J CELL SCI, V111, P557; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SAXENA A, 1992, CANCER RES, V52, P6716; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; TAKAHASHI E, 1989, JPN J HUM GENET, V34, P307, DOI 10.1007/BF01929213; TAKAHASHI E, 1990, HUM GENET, V86, P14; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	42	221	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7334	7340		10.1074/jbc.274.11.7334	http://dx.doi.org/10.1074/jbc.274.11.7334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066797	hybrid			2022-12-27	WOS:000079078400069
J	Walowsky, C; Fitzhugh, DJ; Castano, IB; Ju, JY; Levin, NA; Christman, MF				Walowsky, C; Fitzhugh, DJ; Castano, IB; Ju, JY; Levin, NA; Christman, MF			The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; DNA TOPOISOMERASES; ESCHERICHIA-COLI; YEAST-CELLS; TRANSFORMATION; RESISTANCE; MUTANTS; COMPLEX; DRUGS	Camptothecin is an antitumor agent that kills cells by converting DNA topoisomerase I into a DNA-damaging poison. Although camptothecin derivatives are now being used to treat tumors in a variety of clinical protocols, the cellular factors that influence sensitivity to the drug are only beginning to be understood. We report here that two genes required for sister chromatid cohesion, TRF4 and MCD1/SCC1, are also required to repair camptothecin-mediated damage to DNA. The hypersensitivity to camptothecin in the trf4 mutant does not result from elevated expression of DNA topoisomerase I. We show that Trf4 is a nuclear protein whose expression is cell cycle-regulated at a post-transcriptional level. Suppression of camptothecin hypersensitivity in the trf4 mutant by gene overexpression resulted in the isolation of three genes: another member of the TRF4 gene family, TRF5, and two genes that may influence higher order chromosome structure, ZDS1 and ZDS2, We have isolated and sequenced two human TRF4 family members, hTRF4-1 and hTRF4-2. The hTRF4-1 gene maps to chromosome 5p15, a region of frequent copy number alteration in several tumor types. The evolutionary conservation of TRF4 suggests that it may also influence mammalian cell sensitivity to camptothecin.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Christman, MF (corresponding author), Univ Virginia, Dept Microbiol, Box 441,Jordan Hall,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	mfc3f@virginia.edu	Levin, Nikki/AAE-7397-2022	Castano, Irene/0000-0002-5968-2101				Bi EF, 1996, MOL CELL BIOL, V16, P5264; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Castano IB, 1996, NUCLEIC ACIDS RES, V24, P2404, DOI 10.1093/nar/24.12.2404; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ENG WK, 1988, MOL PHARMACOL, V34, P755; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; IWABUCHI H, 1995, CANCER RES, V55, P6172; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LEVIN NA, 1993, GENETICS, V133, P799; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss J L, 1994, Adv Pharmacol, V29B, P201; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Pommier Y, 1996, ANN NY ACAD SCI, V803, P60, DOI 10.1111/j.1749-6632.1996.tb26377.x; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; RINE J, 1991, METHOD ENZYMOL, V194, P239; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SADOFF BU, 1995, GENETICS, V141, P465; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; Yu YX, 1996, MOL CELL BIOL, V16, P5254	38	60	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7302	7308		10.1074/jbc.274.11.7302	http://dx.doi.org/10.1074/jbc.274.11.7302			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066793	hybrid			2022-12-27	WOS:000079078400065
J	Watanabe, A; Takio, K; Ihara, Y				Watanabe, A; Takio, K; Ihara, Y			Deamidation and isoaspartate formation in smeared tan in paired helical filaments - Unusual properties of the microtubule-binding domain of tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-LIKE FILAMENTS; D-ASPARTYL RESIDUES; NEUROFIBRILLARY TANGLES; PROTEIN-TAU; AMINO-ACID; GROWTH-HORMONE; DISEASE; SEQUENCE; BRAIN; PHOSPHORYLATION	An extensive loss of a selected population of neurons in Alzheimer's disease is closely related to the formation of paired helical filaments (PHFs), The most striking characteristic of PHFs upon Western blotting is their smearing. According to a previously described protocol (Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M,, Titani, K,, and Ihara, Y, (1993) Neuron 10, 1151-1160), smeared tau was purified, and its peptide map was compared with that of soluble (normal) tau, A CNBr fragment from soluble tau (CN5; residues 251-419 according to the 441-residue isoform) containing the microtubule-binding domain migrated at 15 and 18 kDa on SDS-polyacrylamide gel electrophoresis, whereas that from smeared tau exhibited two larger, unusually broad bands at similar to 30 and similar to 45 kDa, presumably representing dimers and trimers of CN5, In the peptide map of smeared tau-derived CN5, distinct peaks eluting at unusual locations were noted, Amino acid sequence and mass spectrometric analyses revealed that these distinct peptides bear isoaspartate at Asn-381 and Asp-387, Because no unusual peptides other than aspartyl or isoaspartyl peptide were found in the digests of smeared tau-derived CN5, it is likely that site-specific deamidation and isoaspartate formation are involved in its dimerization and trimerization and thus in PHF formation in vivo.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST)	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; Aswad D.W., 1995, DEAMIDATION ISOASPAR, P1; ASWAD DW, 1995, DEAMIDATION ISOASPAR, P7; Bornstein P, 1977, Methods Enzymol, V47, P132; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; BRENNAN TV, 1995, DEAMIDATION ISOASPAR, P65; BRUNAUER LS, 1986, J BIOL CHEM, V261, P2538; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; EINARSSON S, 1987, ANAL CHEM, V59, P1191, DOI 10.1021/ac00135a025; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fisher GH, 1991, BRAIN RES B, V28, P127; FLATMARK T, 1966, ACTA CHEM SCAND, V20, P1487, DOI 10.3891/acta.chem.scand.20-1487; GEIGER T, 1987, J BIOL CHEM, V262, P785; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GRAYSON S, 1990, ANAL BIOCHEM, V189, P192, DOI 10.1016/0003-2697(90)90106-J; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYASHI T, 1993, ANAL BIOCHEM, V209, P163, DOI 10.1006/abio.1993.1097; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; IHARA Y, 1990, GERONTOLOGY, V36, P15; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KENESSEY A, 1995, BRAIN RES, V675, P183, DOI 10.1016/0006-8993(95)00061-T; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LEWIS UJ, 1981, J BIOL CHEM, V256, P1645; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MIDELFORT CF, 1972, J BIOL CHEM, V247, P3618; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; NAKIHARA K, 1992, PEPTIDE CHEM, P203; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; PAYAN IL, 1992, NEUROCHEM RES, V17, P187, DOI 10.1007/BF00966798; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; SECCHI C, 1986, INT J PEPT PROT RES, V28, P298; SVASTI J, 1972, BIOCHEM J, V128, P427, DOI 10.1042/bj1280427; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WILSON JM, 1982, J BIOL CHEM, V257, P4830; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WRIGHT HT, 1995, DEAMIDATION ISOASPAR, P229	52	101	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7368	7378		10.1074/jbc.274.11.7368	http://dx.doi.org/10.1074/jbc.274.11.7368			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066801	hybrid			2022-12-27	WOS:000079078400073
J	Burner, U; Obinger, C; Paumann, M; Furtmuller, PG; Kettle, AJ				Burner, U; Obinger, C; Paumann, M; Furtmuller, PG; Kettle, AJ			Transient and steady-state kinetics of the oxidation of substituted benzoic acid hydrazides by myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDASE COMPOUND-I; HYDROGEN-PEROXIDE; SALICYLHYDROXAMIC ACID; HYPOCHLOROUS ACID; ASCORBIC-ACID; SUPEROXIDE; INHIBITION; MECHANISM; NEUTROPHILS; CHLORIDE	Myeloperoxidase is the most abundant, protein in neutrophils and catalyzes the production of hypochlorous acid. This potent oxidant plays a central role in microbial killing and inflammatory tissue damage. 4-Aminobenzoic acid hydrazide (ABAH) is a mechanism-based inhibitor of myeloperoxidase that is oxidized to radical intermediates that cause enzyme inactivation. We have investigated the mechanism by which benzoic acid hydrazides (BAH) are oxidized by myeloperoxidase, and we have determined the features that enable them to inactivate the enzyme. BAHs readily reduced compound I of myeloperoxidase, The rate constants for these reactions ranged from 1 to 3 x 10(6) M-1 s(-1) (15 degrees C, pH 7.0) and were relatively insensitive to the substituents on the aromatic ring. Rate constants for reduction of compound II varied between 6.5 x 10(5) M-1 s(-1) for ABAH and 1,3 x 10(3) M-1 s(-1) for 4-nitrobenzoic acid hydrazide (15 degrees C, pH 7.0). Reduction of both compound I and compound II by BAHs adhered to the Hammett rule, and there were significant correlations with Brown-Okamoto substituent constants. This indicates that the rates of these reactions were simply determines by the ease of oxidation of the substrates and that the incipient free radical carried a positive charge. ABAH was oxidized by myeloperoxidase without added hydrogen peroxide because it underwent auto-oxidation, Although BAHs generally reacted rapidly with compound II, they should be poor peroxidase substrates because the free radicals formed during peroxidation converted myeloperoxidase to compound III. We found that the reduction of ferric myeloperoxidase by BAH radicals was strongly influenced by Hansch's hydrophobicity constants. BAHs containing more hydrophilic substituents were more effective at converting the enzyme to compound III, This implies that BAH radicals must hydrogen bond to residues in the distal heme pocket before they can reduce the ferric enzyme. Inactivation of myeloperoxidase by BAHs was related to how readily they were oxidized, but there was no correlation with their rate constants for reduction of compounds I or II. We propose that BAHs destroy the heme prosthetic groups of the enzyme by reducing a ferrous myeloperoxidase-hydrogen peroxide complex.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; Christchurch Sch Med, Dept Pathol, Free Rad Res Grp, Christchurch, New Zealand	University of Natural Resources & Life Sciences, Vienna; University of Otago	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.		Obinger, Christian/AAV-3173-2021; Furtmüller, Paul G./Y-5819-2018; Kettle, Anthony J/A-8520-2008	Furtmüller, Paul G./0000-0002-1199-2469; Kettle, Anthony J/0000-0002-8218-7766; Obinger, Christian/0000-0002-7133-3430				BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; Candeias LP, 1996, BIOCHEMISTRY-US, V35, P102, DOI 10.1021/bi9514424; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DAVIES B, 1989, BIOCHEM J, V258, P801, DOI 10.1042/bj2580801; DUNFORD HB, 1986, ARCH BIOCHEM BIOPHYS, V251, P536, DOI 10.1016/0003-9861(86)90361-9; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; Hansch C, 1979, SUBSTITUENT CONSTANT; HAZEN SL, 1996, J CLIN INVEST, V98, P1238; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; HURST JK, 1991, EUR J BIOCHEM, V202, P1275, DOI 10.1111/j.1432-1033.1991.tb16500.x; HURST JK, 1991, PEROXIDASES CHEM BIO, P37; IKEDASAITO M, 1991, J BIOL CHEM, V266, P3611; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KETTLE AJ, 1994, J BIOL CHEM, V269, P17146; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; MARCH J, 1977, ADV ORGANIC CHEM REA, P273; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; Marquez LA, 1997, BIOCHEMISTRY-US, V36, P9349, DOI 10.1021/bi970595j; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MARQUEZ LA, 1990, J BIOL CHEM, V265, P6074; MISRA HP, 1976, BIOCHEMISTRY-US, V15, P681, DOI 10.1021/bi00648a036; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; SVENSSON BE, 1988, BIOCHEM J, V249, P521, DOI 10.1042/bj2490521; UTRECHT JP, 1992, DRUG METAB REV, V24, P299; vanDalen CJ, 1997, BIOCHEM J, V327, P487; VANDERWALT BJ, 1994, BIOCHEM PHARMACOL, V47, P1039, DOI 10.1016/0006-2952(94)90415-4; VANZYL JM, 1989, BIOCHEM PHARMACOL, V38, P2363, DOI 10.1016/0006-2952(89)90477-2; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583	37	64	64	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9494	9502		10.1074/jbc.274.14.9494	http://dx.doi.org/10.1074/jbc.274.14.9494			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092633	hybrid			2022-12-27	WOS:000079451800052
J	Kieber-Emmons, T; Lin, CM; Foster, MH; Kleyman, TR				Kieber-Emmons, T; Lin, CM; Foster, MH; Kleyman, TR			Antiidiotypic antibody recognizes an amiloride binding domain within the alpha subunit of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; CONFORMATIONAL SEARCH; NEUTRALIZING ANTIBODY; INDUCED HYPERKALEMIA; MEMBRANE TOPOLOGY; CELL-LINE; PEPTIDE; PROTEIN; ANTIGEN; IDENTIFICATION	We previously raised an antibody (RA6.3) by an antidiotypic approach which was designed to be directed against an amiloride binding domain on the epithelial Na+ channel (ENaC). This antibody mimicked amiloride in that it inhibited transepithelial Na+ transport across A6 cell monolayers. RA6.3 recognized a 72-kDa polypeptide in A6 epithelia treated with tunicamycin, consistent with the size of nonglycosylated Xenopus laevis alpha ENaC. RA6.3 specifically recognized an amiloride binding domain within the alpha-subunit of mouse and bovine ENaC. The deduced amino acid sequence of RA6.3 was used to generate a three-dimensional model structure of the antibody. The combining site of RA6.3 was epitope mapped using a novel computer-based strategy. Organic residues that potentially interact with the RA6.3 combining site were identified by data base screening using the program LUDI. Selected residues docked to the antibody in a manner corresponding to the ordered linear array of amino acid residues within an amiloride binding domain on the alpha-subunit of ENaC, A synthetic peptide spanning this domain inhibited the binding of RA6.3 to alpha ENaC. This analysis provided a novel approach to develop models of antibody-antigen interaction as well as a molecular perspective of RA6.3 binding to an amiloride binding domain within alpha ENaC.	Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Kleyman, TR (corresponding author), Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	kleyman@mail.med.upenn.edu			NIDDK NIH HHS [DK50268] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALABAN RS, 1979, J MEMBRANE BIOL, V49, P363, DOI 10.1007/BF01868992; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFANT ML, 1993, AM J PHYSIOL, V264, pC1480, DOI 10.1152/ajpcell.1993.264.6.C1480; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; CoupayeGerard B, 1996, AM J PHYSIOL-CELL PH, V271, pC1639, DOI 10.1152/ajpcell.1996.271.5.C1639; CoupayeGerard B, 1997, AM J PHYSIOL-CELL PH, V272, pC1781, DOI 10.1152/ajpcell.1997.272.6.C1781; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FINE R M, 1986, Proteins Structure Function and Genetics, V1, P342, DOI 10.1002/prot.340010408; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOTTLIEB GP, 1978, BIOPHYS J, V22, P125, DOI 10.1016/S0006-3495(78)85477-0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILLAUME T, 1990, J IMMUNOL, V145, P1934; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KARP SL, 1993, J IMMUNOL, V150, P867; KIEBEREMMONS T, 1995, KIDNEY INT, V48, P956, DOI 10.1038/ki.1995.377; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1995, ANN INTERN MED, V122, P103, DOI 10.7326/0003-4819-122-2-199501150-00004; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KLEYMAN TR, 1992, J BIOL CHEM, V267, P9622; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LEVY S, 1987, GENE, V54, P167, DOI 10.1016/0378-1119(87)90484-7; LI JHY, 1985, J MEMBRANE BIOL, V83, P45, DOI 10.1007/BF01868737; LI JHY, 1982, BASIC MECHANISMS ACT, P28; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LIN CM, 1994, J BIOL CHEM, V269, P2805; Ling BN, 1997, J BIOL CHEM, V272, P594; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOHMAN KL, 1993, MOL IMMUNOL, V30, P1295, DOI 10.1016/0161-5890(93)90046-E; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; MAS MT, 1992, PROTEINS, V14, P483, DOI 10.1002/prot.340140409; Murali R, 1997, J MOL RECOGNIT, V10, P269, DOI 10.1002/(SICI)1099-1352(199711/12)10:6<269::AID-JMR370>3.0.CO;2-9; NELL LJ, 1992, BIOPOLYMERS, V32, P11, DOI 10.1002/bip.360320104; NISONOFF A, 1991, J IMMUNOL, V147, P2429; NOVOTNY J, 1990, PROTEINS, V7, P93, DOI 10.1002/prot.340070109; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PEDEMONTE CH, 1995, J MEMBRANE BIOL, V147, P223; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SHENKIN PS, 1987, BIOPOLYMERS, V26, P2053, DOI 10.1002/bip.360261207; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TORMO J, 1994, EMBO J, V13, P2247, DOI 10.1002/j.1460-2075.1994.tb06506.x; VANDRIESSCHE W, 1983, PFLUG ARCH EUR J PHY, V398, P179, DOI 10.1007/BF00657149; Verdaguer N, 1996, J MOL BIOL, V256, P364, DOI 10.1006/jmbi.1996.0092; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; WILSON IA, 1994, RES IMMUNOL, V145, P73, DOI 10.1016/S0923-2494(94)80049-9; WORRELL RT, 1995, FASEB J, V9, pA309; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407	68	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9648	9655		10.1074/jbc.274.14.9648	http://dx.doi.org/10.1074/jbc.274.14.9648			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092651	hybrid			2022-12-27	WOS:000079451800070
J	Medvedev, AE; Blanco, JCG; Qureshi, N; Vogel, SN				Medvedev, AE; Blanco, JCG; Qureshi, N; Vogel, SN			Limited role of ceramide in lipopolysaccharide-mediated mitogen-activated protein kinase activation, transcription factor induction, and cytokine release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; DIPHOSPHORYL LIPID-A; LPS BINDING-PROTEIN; MURINE MACROPHAGES; BACTERIAL LIPOPOLYSACCHARIDE; RHODOPSEUDOMONAS-SPHAEROIDES; ACID SPHINGOMYELINASE; INDUCED APOPTOSIS	The involvement of ceramide in lipopolysaccharide-mediated activation of mouse macrophages was studied. Lipopolysaccharide cell-permeable ceramide analogs, and bacterial sphingomyelinase led to phosphorylation of the extracellular signal-regulated kinases, c-Jun NH2-terminal kinases, and p38 kinase and induced AP-1 DNA binding in C3H/OuJ (Lps(n)) but not in C3H/HeJ (Lps(d)) macrophages. Lipopolysaccharide and ceramide mimetics showed distinct kinetics of mitogen-activated protein kinase phosphorylation and AP-1 induction and activated AP-1 complexes with different subunit compositions. Lipopolysaccharide-activated AP-1 consisted of c-Fos, Jun-E, Jun-D, and c-Jun, while C-2-ceramide induced Jun-D and c-Jun only. Lipopolysaccharide and, less potently, C-2-ceramide or sphingomyelinase, stimulated AP-1-dependent reporter gene transcription in RAW 264.7 cells. Unlike lipopolysaccharide, C-2-ceramide failed to activate NF-kappa B and did not induce production of tumor necrosis factor or interleukin-6. The lipopolysaccharide antagonist, Rhodobacter sphaeroides diphosphoryl lipid A, inhibited lipopolysaccharide activation of NF-kappa B and AP-1 but did not block C-2-ceramide-induced AP-1. Pretreatment of C3H/OuJ macrophages with C-2-ceramide greatly diminished AP-1 induction following subsequent C-2-ceramide stimulation. However, lipopolysaccharide-induced transcription factor activation and cytokine release were not influenced, In contrast, lipopolysaccharide pretreatment inhibited both lipopolysaccharide- and C-2-ceramide-mediated responses. Thus, ceramide partially mimics lipopolysaccharide in activating the mitogen-activated protein kinases and AP-1 but not in mediating NF-kappa B induction or cytokine production, suggesting a limited role in lipopolysaccharide signaling.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA	Uniformed Services University of the Health Sciences - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Vogel, SN (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vogel@bob.usuf2.usuhs.mil	Blanco, Jorge/AAW-3752-2020	Blanco, Jorge/0000-0002-6173-0213	NIAID NIH HHS [AI-18797] Funding Source: Medline; NIGMS NIH HHS [GM-50870] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018797, R37AI018797, R01AI018797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050870] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barber SA, 1996, INFECT IMMUN, V64, P3397, DOI 10.1128/IAI.64.8.3397-3400.1996; BARBER SA, 1995, J IMMUNOL, V155, P2303; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P2380, DOI 10.1073/pnas.90.6.2380; GODAMBE SA, 1994, J IMMUNOL, V153, P143; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; HENRICSON BE, 1992, INFECT IMMUN, V60, P4285, DOI 10.1128/IAI.60.10.4285-4290.1992; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIRKLAND TN, 1991, INFECT IMMUN, V59, P131, DOI 10.1128/IAI.59.1.131-136.1991; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Lakics V, 1998, J IMMUNOL, V161, P2490; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEE WY, 1994, J BIOL CHEM, V269, P17971; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MANTHEY CL, 1993, J EXP MED, V178, P695, DOI 10.1084/jem.178.2.695; Manthey CL, 1998, CYTOKINE, V10, P654, DOI 10.1006/cyto.1998.0344; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P18994; MCINTIRE FC, 1967, BIOCHEMISTRY-US, V6, P2363, DOI 10.1021/bi00860a011; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OTTERLEI M, 1991, J IMMUNOTHER, V10, P286, DOI 10.1097/00002371-199108000-00007; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perera PY, 1997, J IMMUNOL, V158, P4422; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; QURESHI N, 1991, J BIOL CHEM, V266, P6532; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SERKKOLA E, 1993, EUR J BIOCHEM, V213, P243, DOI 10.1111/j.1432-1033.1993.tb17754.x; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Thieblemont N, 1997, J EXP MED, V185, P2095, DOI 10.1084/jem.185.12.2095; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WRIGHT SD, 1990, J IMMUNOL, V144, P2566; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	74	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9342	9350		10.1074/jbc.274.14.9342	http://dx.doi.org/10.1074/jbc.274.14.9342			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092612	hybrid			2022-12-27	WOS:000079451800031
J	Mohr, S; Hallak, H; de Boitte, A; Lapetina, EG; Brune, B				Mohr, S; Hallak, H; de Boitte, A; Lapetina, EG; Brune, B			Nitric oxide induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; NITROSYLATION; PROTEIN; THIOLATION; CELLS; BIOCHEMISTRY; INHIBITION; CYSTEINE; ENZYME	S-Nitrosylation of protein thiol groups by nitric oxide (NO) is a widely recognized protein modification. In this study we show that nitrosonium tetrafluoroborate (BF4NO), a NO+ donor, modified the thiol groups of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by S-nitrosylation and caused enzyme inhibition. The resultant protein-S-nitrosothiol was found to be unstable and to decompose spontaneously, thereby restoring enzyme activity. In contrast, the NO-releasing compound S-nitrosoglutathione (GSNO) promoted S-glutathionylation of a thiol group of GAPDH both in vitro and under cellular conditions. The GSH-mixed protein disulfide formed led to a permanent enzyme inhibition, but upon dithiothreitol addition a functional active GAPDH was recovered. This S-glutathionylation is specific for GSNO because GSH itself was unable to produce protein-mixed disulfides. During cellular nitrosative stress, the production of intracellular GSNO might channel signaling responses to form protein-mixed disulfide that can regulate intracellular function.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany; Case Western Reserve Univ, Sch Med, Mol Cardiovasc Res Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	University of Erlangen Nuremberg; Case Western Reserve University; University Hospitals of Cleveland; Cleveland Clinic Foundation	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestr 8, D-91054 Erlangen, Germany.	mfm423@rzmail.uni-erlangen.de						AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BUTLER J, 1976, ANAL BIOCHEM, V75, P674, DOI 10.1016/0003-2697(76)90129-9; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; Knight RJ, 1996, CARDIOVASC RES, V32, P1016, DOI 10.1016/S0008-6363(96)00137-X; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Mohr S, 1996, J BIOL CHEM, V271, P4209; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167	26	267	279	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9427	9430		10.1074/jbc.274.14.9427	http://dx.doi.org/10.1074/jbc.274.14.9427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092623	hybrid			2022-12-27	WOS:000079451800042
J	Nett, JH; Trumpower, BL				Nett, JH; Trumpower, BL			Intermediate length Rieske iron-sulfur protein is present and functionally active in the cytochrome bc(1) complex of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; YEAST MITOCHONDRIA; PROCESSING PEPTIDASE; IMPORT; CLEAVAGE; SUBUNIT; PURIFICATION; PRESEQUENCE; PRECURSOR; INSERTION	To investigate the relationship between post-translational processing of the Rieske iron-sulfur protein of Saccharomyces cerevisiae and its assembly into the mitochondrial cytochrome bc(1) complex we used iron-sulfur proteins in which the presequences had been changed by site-directed mutagenesis of the cloned iron-sulfur protein gene, so that the recognition sites for the matrix processing peptidase or the mitochondrial intermediate peptidase (MIP) had been destroyed. When yeast strain JPJ1, in which the gene for the iron-sulfur protein is deleted, was transformed with these constructs on a single copy expression vector, mitochondrial membranes and bc(1) complexes isolated from these strains accumulated intermediate length iron-sulfur proteins in vivo. The cytochrome bc(1) complex activities of these membranes and bc(1) complexes indicate that intermediate iron-sulfur protein (i-ISP) has full activity when compared with that of mature sized iron-sulfur protein (m-ISP). Therefore the iron-sulfur cluster must have been inserted before processing of i-ISP to m-ISP by MIP, When iron-sulfur protein is imported into mitochondria in vitro, i-ISP interacts with components of the bc(1) complex before it is processed to m-ISP. These results establish that the iron-sulfur cluster is inserted into the apoprotein before MIP cleaves off the second part of the presequence and that this second processing step takes place after i-ISP has been assembled into the bc(1) complex.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.				NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHNI PC, 1983, J BIOL CHEM, V258, P4937; Boumans H, 1997, EUR J BIOCHEM, V249, P762, DOI 10.1111/j.1432-1033.1997.t01-3-00762.x; Boumans H, 1997, J BIOL CHEM, V272, P16753, DOI 10.1074/jbc.272.27.16753; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; BRANDT U, 1994, J BIOL CHEM, V269, P12947; BRANDT U, 1993, J BIOL CHEM, V268, P8387; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; FU W, 1991, J BIOL CHEM, V266, P16212; FU W, 1990, J BIOL CHEM, V265, P16541; GLICK B, 1994, ANNU REV GENET, V25, P21; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GRAHAM LA, 1994, BIOCHEM SOC T, V22, P188, DOI 10.1042/bst0220188; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P631; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; Luciano P, 1996, EXPERIENTIA, V52, P1077, DOI 10.1007/BF01952105; MCADA PC, 1982, J BIOL CHEM, V257, P3177; Nett JH, 1997, J BIOL CHEM, V272, P2212; Nett JH, 1996, J BIOL CHEM, V271, P26713, DOI 10.1074/jbc.271.43.26713; Nett JH, 1998, J BIOL CHEM, V273, P8652, DOI 10.1074/jbc.273.15.8652; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; RAMABADRAN RS, 1992, ARCH BIOCHEM BIOPHYS, V296, P279, DOI 10.1016/0003-9861(92)90573-F; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG XH, 1986, METHOD ENZYMOL, V126, P316; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	31	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9253	9257		10.1074/jbc.274.14.9253	http://dx.doi.org/10.1074/jbc.274.14.9253			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092599	hybrid			2022-12-27	WOS:000079451800018
J	Bianco, C; Kannan, S; De Santis, M; Seno, M; Tang, CK; Martinez-Lacaci, I; Kim, N; Wallace-Jones, B; Lippman, ME; Ebert, AD; Wechselberger, C; Salomon, DS				Bianco, C; Kannan, S; De Santis, M; Seno, M; Tang, CK; Martinez-Lacaci, I; Kim, N; Wallace-Jones, B; Lippman, ME; Ebert, AD; Wechselberger, C; Salomon, DS			Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; SIGNALING NETWORK; PROTEIN; GENE; ACTIVATION; EXPRESSION; FAMILY	Cripto-1 (CR-1) is a recently discovered protein of the epidermal growth factor family that fails to directly bind to any of the four known erb B type 1 receptor tyrosine kinases. The present study demonstrates that CR-1 indirectly induces tyrosine phosphorylation of erb B-4 but not of the epidermal growth factor-related receptors erb B-2 and erb B-3 in different mouse and human mammary epithelial cell lines. In addition, downregulation of erb B-4 in NMuMG mouse mammary epithelial cells and in T47D human breast cancer cells, using an anti-erb B-4 blocking antibody or a hammerhead ribozyme vector targeted to erb B-4 mRNA, impairs the ability of CR-1 to fully activate mitogen-activated protein kinase. Finally, chemical cross-linking of I-125-CR-1 to mouse and human mammary epithelial cell membranes results in the labeling of two specific bands with a molecular weight of 130 and 60 kDa, suggesting that the CR-1 receptor represents a novel receptor structurally unrelated to any of the known type I receptor tyrosine kinases. In conclusion, these data demonstrate that CR-1, upon binding to an unknown receptor, can enhance the tyrosine kinase activity of erb B-4 and that a functional erb B-4 receptor is required for CR-1-induced MAPK activation.	NCI, Tumor Growth Factor Sect, Lab Tumor Immunol & Biol, NIH, Bethesda, MD 20892 USA; Macmaster Univ, Hamilton, ON L8S 4K1, Canada; Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Biochem, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); McMaster University; Okayama University; Georgetown University	Salomon, DS (corresponding author), NCI, Tumor Growth Factor Sect, Lab Tumor Immunol & Biol, NIH, Bldg 10,Room 5B39, Bethesda, MD 20892 USA.	davetgfa@helix.nih.gov		Wechselberger, Christian/0000-0002-2164-3019				BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DESANTIS LM, 1997, CELL GROWTH DIFFER, V8, P1257; DONO R, 1991, AM J HUM GENET, V49, P555; DONO R, 1993, DEVELOPMENT, V118, P1157; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8131; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HELDIN CH, 1996, GROWTH FACTOR REV, V7, P33; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; Shen MM, 1997, DEVELOPMENT, V124, P429; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tang CK, 1998, CANCER RES, V58, P3415; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; XU C, 1999, IN PRESS P NATL ACAD; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yang DJ, 1998, CLIN CANCER RES, V4, P993; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	39	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8624	8629		10.1074/jbc.274.13.8624	http://dx.doi.org/10.1074/jbc.274.13.8624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085099	hybrid			2022-12-27	WOS:000079451600041
J	Ching, TT; Wang, DS; Hsu, AL; Lu, PJ; Chen, CS				Ching, TT; Wang, DS; Hsu, AL; Lu, PJ; Chen, CS			Identification of multiple phosphoinositide-specific phospholipases D as new regulatory enzymes for phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TUMOR-SUPPRESSOR; BIOCHEMICAL-CHARACTERIZATION; CELL-SURVIVAL; 4,5-BISPHOSPHATE; 3-KINASE; BRAIN; ACTIVATION; PHOSPHATES; PKB/AKT	In the course of delineating the regulatory mechanism underlying phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) metabolism, we have discovered three distinct phosphoinositide-specific phospholipase D (PI-PLD) isozymes from rat brain, tentatively designated as PI-PLD, PI-PLDb, and PI-PLDc. These enzymes convert [H-3]PI(3,4,5)P-3 to generate a novel inositol phosphate, D-myo [H-3]inositol 3,4,5-trisphosphate ([H-3]Ins(3,4,5)P-3) and phosphatidic acid. These isozymes are predominantly associated with the cytosol, a notable difference from phosphatidylcholine PLDs. They are partially purified by a three-step procedure consisting of DEAE, heparin, and Sephacryl S-200 chromatography. PI-PLDa and PI-PLDb display a high degree of substrate specificity for PI(3,4,5)P-3, with a relative potency of PI(3,4,5)P-3 >> phosphatidylinositol 3-phosphate (PI(3)P) or phosphatidylinositol 4-phosphate (PI(4)P) > phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-3) > phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-3). In contrast, PI-PLDc preferentially utilizes PI(3)P as substrate, followed by, in sequence, PI(3,4,5)P-3, PI(C)P, PI(3,4)P-2, and PI(4,5)P-2. Both PI(3,4)P-2 and PI(4,5)P-2 are poor substrates for all three isozymes, indicating that the regulatory mechanisms underlying these phosphoinositides are different from that of PI(3,4,5)P-3. None of these enzymes reacts with phosphatidylcholine, phosphatidylserine, or phosphatidylethanolamine. All three PI-PLDs are Ca2+-dependent. Among them, PI-PLDb and PI-PLDc show maximum activities within a sub-mu M range (0.3 and 0.9 mu M Ca2+ respectively), whereas PI-PLDa exhibits an optimal [Ca2+] at 20 mu M. In contrast to PC-PLD, Mg2+ has no significant effect on the enzyme activity. All three enzymes require sodium deoxycholate for optimal activities; other detergents examined including Triton X-100 and Nonidet P-40 are, however, inhibitory. In addition, PI(4,5)P-2 stimulates these isozymes in a dose-dependent manner. Enhancement in the enzyme activity is noted only when the molar ratio of PI(4,5)P-2 to PI(3,4,5)P-3 is between 1:1 and 2:1.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, ASTeCC Facil, Lexington, KY 40506 USA	University of Kentucky	Chen, CS (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, ASTeCC Facil, Rm 323B, Lexington, KY 40506 USA.	cchen1@pop.uky.edu	Hsu, Ao-Lin Allen/AAX-1856-2020	Ching, Tsui-Ting/0000-0001-7650-1766; Hsu, Ao-Lin/0000-0002-2864-3134	NIGMS NIH HHS [R01 GM53448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; HUANG CF, 1992, J BIOL CHEM, V267, P16859; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LU PJ, 1994, BIOCHEMISTRY-US, V33, P11586, DOI 10.1021/bi00204a021; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Pennisi E, 1997, SCIENCE, V275, P1876, DOI 10.1126/science.275.5308.1876; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WANG P, 1991, J BIOL CHEM, V266, P14877; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, J BIOL CHEM, V272, P9625	36	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8611	8617		10.1074/jbc.274.13.8611	http://dx.doi.org/10.1074/jbc.274.13.8611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085097	hybrid			2022-12-27	WOS:000079451600039
J	Lynch, CN; Wang, YC; Lund, JK; Chen, YW; Leal, JA; Wiley, SR				Lynch, CN; Wang, YC; Lund, JK; Chen, YW; Leal, JA; Wiley, SR			TWEAK induces angiogenesis and proliferation of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; HUMAN T-LYMPHOCYTES; DIABETIC-RETINOPATHY; GENE-EXPRESSION; EMERGING FAMILY; IN-VIVO; LIGAND; ACTIVATION	TWEAK is a recently described member of the Tumor Necrosis Factor (TNF) ligand family whose transcripts are present in a wide variety of human tissues (Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu Y. M., Scott, H., Hession, C., Garcia, I., and Browning, J. L. (1997) J. Biol. Chem. 272, 32401-32410). TWEAK is a weak inducer of apoptosis in transformed cells when administered with interferon-gamma or cycloheximide (Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu Y. M., Scott, H., Hession, C., Garcia, I,, and Browning, J. L. (1997) J. Biol. Chem. 272, 32401-32410; Masters, S. A., Sheridan, J. P., Pitti, R. M., Brush, A. G., and Ashkenazi, A. (1998) Curr. Biol. 8, 525-528) and also promotes IL-8 secretion in cultured cells. We report here that picomolar concentrations of recombinant soluble TWEAK induce proliferation in a variety of normal human endothelial cells and in aortic smooth muscle cells and reduce culture requirements for serum and growth factors. Blocking antibodies to Vascular Endothelial Growth Factor (VEGF) do not significantly inhibit TWEAK-induced proliferation, indicating that TWEAK does not function indirectly through up-regulation of VEGF. Pellets containing TWEAK induce a strong angiogenic response when implanted in rat corneas, suggesting a role for TWEAK in vasculature formation in vivo.	Abbott Labs, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wiley, SR (corresponding author), 51 Univ St, Seattle, WA 98101 USA.							AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; BIKFALVI A, 1995, EUR J CANCER, V31A, P1101, DOI 10.1016/0959-8049(95)00169-J; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BROWN LF, 1995, J IMMUNOL, V154, P2801; Bussolino F, 1996, EUR J CANCER, V32A, P2401, DOI 10.1016/S0959-8049(96)00390-5; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P89; Carpenter G, 1993, CURR OPIN CELL BIOL, V5, P261, DOI 10.1016/0955-0674(93)90113-5; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HELDIN CH, 1991, J CELL BIOCHEM, V47, P208, DOI 10.1002/jcb.240470304; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MASTERS SA, 1998, CURR BIOL, V8, P525; Montrucchio G, 1997, AM J PATHOL, V151, P557; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Paques M, 1997, DIABETES METAB, V23, P125; Pels K, 1997, JPN CIRC J, V61, P893, DOI 10.1253/jcj.61.893; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; ROBAYE B, 1991, AM J PATHOL, V138, P447; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P997, DOI 10.1016/0006-291X(87)90350-0; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Van Belle E, 1998, CIRCULATION, V97, P381; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	42	216	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8455	8459		10.1074/jbc.274.13.8455	http://dx.doi.org/10.1074/jbc.274.13.8455			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085077	hybrid			2022-12-27	WOS:000079451600019
J	Thakur, S; Croce, CM				Thakur, S; Croce, CM			Positive regulation of the BRCA1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE BRCA1; SPORADIC BREAST-CANCER; CYCLIC-AMP; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; SOMATOSTATIN GENE; NUCLEAR FACTOR; CELL-CYCLE; EXPRESSION; REGION	Inherited mutations in the BRCA1 gene, presumably leading to loss of function, confer susceptibility to breast and ovarian neoplasms and are thought to be responsible for approximately 2.5-5% of all breast cancers. It has been suggested that alternative mechanisms, such as disruption of transcription, may also be involved in the suppression of BRCA1 gene expression/ function in breast cancers. Therefore, we initiated studies on the BRCA1 transcriptional promoter. Utilizing systematic promoter deletions and transient transfection assays, a 36-base pair region was determined to be important for the positive regulation of BRCA1 transcription. Deletion of this positive regulatory region resulted in a significant loss of promoter activity. Utilizing DNA binding assays, proteins with specific affinities for the positive regulatory region were detected. Disruption of the DNA-protein complexes could affect normal BRCA1 transcription and may contribute to breast cancer susceptibility.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Croce, CM (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [5-T32-CA09678-05, CA76780-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009678, F32CA076780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Dobrovic A, 1997, CANCER RES, V57, P3347; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; SANTRA M, 1994, J BIOL CHEM, V269, P579; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; THAKUR S, 1994, ONCOGENE, V9, P2335; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	31	44	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8837	8843		10.1074/jbc.274.13.8837	http://dx.doi.org/10.1074/jbc.274.13.8837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085126	hybrid			2022-12-27	WOS:000079451600068
J	Makino, R; Matsuda, H; Obayashi, E; Shiro, Y; Iizuka, T; Hori, H				Makino, R; Matsuda, H; Obayashi, E; Shiro, Y; Iizuka, T; Hori, H			EPR characterization of axial bond in metal center of native and cobalt-substituted guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; RESOLUTION CRYSTAL-STRUCTURES; LIGAND-BINDING PROPERTIES; NITRIC-OXIDE; BOVINE LUNG; MOLECULAR STEREOCHEMISTRY; PROXIMAL HISTIDINE; CARBON-MONOXIDE; RAMAN-SPECTROSCOPY; HYBRID HEMOGLOBINS	The nature of the metal-proximal base bond of soluble guanylate cyclase from bovine lung was examined by EPR spectroscopy. When the ferrous enzyme was mixed with NO, a new species was transiently produced and rapidly converted to a five-coordinate ferrous NO complex. The new species exhibited the EPR signal of six-coordinate ferrous NO complex with a feature of histidine-ligated heme, The histidine ligation was further examined by using the cobalt protoporphyrin M-substituted enzyme. The Co2+-substituted enzyme exhibited EPR signals of a broad g(perpendicular to) component and a g(parallel to) component with a poorly resolved triplet of N-14 superhyperfine splittings, which was indicative of the histidine ligation. These EPR features were analogous to those of Lu-subunits of Co2+-hemoglobin in tense state, showing a tension on the iron-histidine bond of the enzyme. The binding of NO to the Co2+-enzyme markedly stimulated the cGMP production by forming the five-coordinate NO complex. We found that N-3(-) elicited the activation of the ferric enzyme by yielding five-coordinate high spin N-3(-) heme. These results indicated that the activation of the enzymes was initiated by NO binding to the metals and proceeded via breaking of the metal-histidine bonds, and suggested that the iron-histidine bond in the ferric enzyme heme was broken by N-3(-) binding.	Rikkyo Univ, Coll Sci, Dept Chem, Toshima Ku, Tokyo 1710021, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigoori, Hyogo 6781201, Japan; Chuo Univ, Dept Appl Chem, Bunkyo Ku, Tokyo 1120003, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510100, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Rikkyo University; University of Hyogo; Chuo University; RIKEN; Osaka University	Makino, R (corresponding author), Rikkyo Univ, Coll Sci, Dept Chem, Toshima Ku, Nishi Ikebukuro 3-34-1, Tokyo 1710021, Japan.	rmakino@rikkyo.ac.jp	Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327				ADAMS KM, 1979, INORG CHEM, V18, P1892, DOI 10.1021/ic50197a034; ASCENZI P, 1989, BIOCHEM J, V258, P473, DOI 10.1042/bj2580473; Barker R, 1974, Methods Enzymol, V34, P479; BREAD DS, 1989, P NATL ACAD SCI USA, V86, P9030; Brucker EA, 1996, J BIOL CHEM, V271, P25419, DOI 10.1074/jbc.271.41.25419; BURSTYN JN, 1995, BIOCHEMISTRY-US, V34, P5896, DOI 10.1021/bi00017a019; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Dierks EA, 1997, J AM CHEM SOC, V119, P7316, DOI 10.1021/ja9603057; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; FERMI G, 1982, J MOL BIOL, V155, P495, DOI 10.1016/0022-2836(82)90483-1; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HENRY Y, 1973, J MOL BIOL, V73, P469, DOI 10.1016/0022-2836(73)90094-6; HOARD JL, 1971, SCIENCE, V174, P1295, DOI 10.1126/science.174.4016.1295; HORI H, 1983, J BIOL CHEM, V258, P2368; HU SZ, 1993, INORG CHEM, V32, P1081, DOI 10.1021/ic00059a010; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1984, J BIOL CHEM, V259, P5923; IIZUKA T, 1969, BIOCHIM BIOPHYS ACTA, V194, P351, DOI 10.1016/0005-2795(69)90096-8; IIZUKA T, 1969, BIOCHIM BIOPHYS ACTA, V181, P275, DOI 10.1016/0005-2795(69)90250-5; IKEDASAITO M, 1977, J BIOL CHEM, V252, P8639; IKEDASAITO M, 1977, J BIOL CHEM, V252, P620; INUBUSHI T, 1983, BIOCHEMISTRY-US, V22, P2904, DOI 10.1021/bi00281a019; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; KON H, 1969, BIOCHEMISTRY-US, V8, P4757, DOI 10.1021/bi00840a016; MASUYA F, 1994, J BIOCHEM, V116, P1146, DOI 10.1093/oxfordjournals.jbchem.a124641; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; MCCOY S, 1970, BIOCHEMISTRY-US, V9, P2387, DOI 10.1021/bi00814a001; MESSANA C, 1978, BIOCHEMISTRY-US, V17, P3652, DOI 10.1021/bi00610a035; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; Paoli M, 1997, J MOL BIOL, V271, P161, DOI 10.1006/jmbi.1997.1180; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; REISBERG P, 1976, J BIOL CHEM, V251, P4379; SCHEIDT WR, 1976, J AM CHEM SOC, V98, P1913, DOI 10.1021/ja00423a044; SCHEIDT WR, 1983, INORG CHEM, V22, P1516, DOI 10.1021/ic00152a019; SCHEIDT WR, 1974, J AM CHEM SOC, V96, P84, DOI 10.1021/ja00808a013; SCHEIDT WR, 1973, J AM CHEM SOC, V95, P8281, DOI 10.1021/ja00806a013; SCHEIDT WR, 1975, J AM CHEM SOC, V97, P17, DOI 10.1021/ja00834a005; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Tomita T, 1997, J BIOCHEM-TOKYO, V122, P531; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WAGNER GC, 1981, J BIOL CHEM, V256, P6266; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WANG MYR, 1977, J BIOL CHEM, V252, P6268; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; WOODRUFF WH, 1974, P NATL ACAD SCI USA, V71, P1065, DOI 10.1073/pnas.71.4.1065; YONETANI T, 1974, J BIOL CHEM, V249, P682; YONETANI T, 1972, J BIOL CHEM, V247, P2447; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YOSHIMURA T, 1979, ARCH BIOCHEM BIOPHYS, V193, P301, DOI 10.1016/0003-9861(79)90035-3; YU AE, 1994, J AM CHEM SOC, V116, P4117, DOI 10.1021/ja00088a073; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; [No title captured]	72	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7714	7723		10.1074/jbc.274.12.7714	http://dx.doi.org/10.1074/jbc.274.12.7714			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075661	hybrid			2022-12-27	WOS:000079268100020
J	Natochin, M; Granovsky, AE; Muradov, KG; Artemyev, NO				Natochin, M; Granovsky, AE; Muradov, KG; Artemyev, NO			Roles of the transducin alpha-subunit alpha 4-helix/alpha 4-beta 6 loop in the receptor and effector interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTERASE GAMMA-SUBUNIT; CYCLIC-GMP PHOSPHODIESTERASE; HETEROTRIMERIC G-PROTEIN; CGMP-PHOSPHODIESTERASE; INHIBITORY SUBUNIT; CATALYTIC SUBUNITS; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; ADP-RIBOSYLATION; RHODOPSIN	The visual GTP-binding protein, transducin, couples light-activated rhodopsin (R*) with the effector enzyme, cGMP phosphodiesterase in vertebrate photoreceptor cells. The region corresponding to the alpha 4-helix and alpha 4-beta 6 loop of the transducin alpha-subunit (G(t)alpha) has been implicated in interactions with the receptor and the effector. Ala-scanning mutagenesis of the alpha 4-beta 6 region has been carried out to elucidate residues critical for the functions of transducin. The mutational analysis supports the role of the alpha 4-beta 6 loop in the R*-G(t)alpha interface and suggests that the G(t)alpha residues Arg(310) and Asp(311) are involved in the interaction with R*. These residues are likely to contribute to the specificity of the R* recognition. Contrary to the evidence previously obtained with synthetic peptides of G(t)alpha, our data indicate that none of the (alpha 4-beta 6 residues directly or significantly participate in the interaction with and activation of phosphodiesterase. However, Ile(299), Phe(303), and Leu(306) form a network of interactions with the alpha 3-helix of G(t)alpha, which is critical for the ability of G(t)alpha to undergo an activational conformational change. Thereby, Ile(299), Phe303 and Leu(306) play only an indirect role in the effector function of G(t)alpha.	Univ Iowa, Coll Med, Dept Phys & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Phys & Biophys, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEST RE, 1985, J BIOL CHEM, V260, P4428; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	37	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7865	7869		10.1074/jbc.274.12.7865	http://dx.doi.org/10.1074/jbc.274.12.7865			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075679	hybrid			2022-12-27	WOS:000079268100038
J	Saito, F; Masaki, T; Kamakura, K; Anderson, LVB; Fujita, S; Fukuta-Ohi, H; Sunada, Y; Shimizu, T; Matsumura, K				Saito, F; Masaki, T; Kamakura, K; Anderson, LVB; Fujita, S; Fukuta-Ohi, H; Sunada, Y; Shimizu, T; Matsumura, K			Characterization of the transmembrane molecular architecture of the dystroglycan complex in Schwann cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; PERIPHERAL-NERVE; GLYCOPROTEIN-COMPLEX; MEMBRANE ORGANIZATION; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; CHAIN GENE; LAMININ-M; MEROSIN; BINDING	We have demonstrated previously 1) that the dystroglycan complex, but not the sarcoglycan complex, is expressed in peripheral nerve, and 2) that alpha-dystroglycan is an extracellular laminin-a-binding protein anchored to beta-dystroglycan in the Schwann cell membrane. In the present study, we investigated the transmembrane molecular architecture of the dystroglycan complex in Schwann cells. The cytoplasmic domain of beta-dystroglycan was co-localized with Dp116, the Schwann cell-specific isoform of dystrophin, in the abaxonal Schwann cell cytoplasm adjacent to the outer membrane, beta-dystroglycan bound to Dp116 mainly via the 15 C-terminal amino acids of its cytoplasmic domain, but these amino acids were not solely responsible for the interaction of these two proteins. Interestingly, the beta-dystroglycan-precipitating antibody precipitated only a small fraction of alpha-dystroglycan and did not precipitate laminin and Dp116 from the peripheral nerve extracts. Our results indicate 1) that Dp116 is a component of the submembranous cytoskeletal system that anchors the dystroglycan complex in Schwann cells, and 2) that the dystroglycan complex in Schwann cells is fragile compared with that in striated muscle cells. We propose that this fragility may be attributable to the absence of the sarcoglycan complex in Schwann cells.	Teikyo Univ, Sch Med, Dept Neurol & Neurosci, Tokyo 1738605, Japan; Natl Def Med Coll, Dept Internal Med 3, Tokorozawa, Saitama 3598513, Japan; Newcastle Univ, Sch Neurosci & Muscular Dystrophy Grp Labs, Reg Neurosci Ctr, Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Teikyo University; National Defense Medical College - Japan; Newcastle General Hospital; Newcastle University - UK	Matsumura, K (corresponding author), Teikyo Univ, Sch Med, Dept Neurol, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	k-matsu@med.teikyo-u.ac.jp						ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Chiba A, 1997, J BIOL CHEM, V272, P2156; COMI GP, 1995, HUM MOL GENET, V4, P2171, DOI 10.1093/hmg/4.11.2171; CULLEN MJ, 1994, ACTA NEUROPATHOL, V87, P349; DEYST KA, 1995, J BIOL CHEM, V270, P25956, DOI 10.1074/jbc.270.43.25956; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; GEE SH, 1993, J BIOL CHEM, V268, P14972; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yuasa K, 1998, FEBS LETT, V425, P329, DOI 10.1016/S0014-5793(98)00251-8	40	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8240	8246		10.1074/jbc.274.12.8240	http://dx.doi.org/10.1074/jbc.274.12.8240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075729	hybrid			2022-12-27	WOS:000079268100088
J	Yamaguchi, Y; Wada, T; Watanabe, D; Takagi, T; Hasegawa, J; Handa, H				Yamaguchi, Y; Wada, T; Watanabe, D; Takagi, T; Hasegawa, J; Handa, H			Structure and function of the human transcription elongation factor DSIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; P-TEFB; GENE IMPORTANT; MESSENGER-RNA; HUMAN HOMOLOG; IN-VITRO; PROTEIN; ACTIVATION; SPT5	5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) is a classic inhibitor of transcription elongation by RNA polymerase II (pol II). We have previously identified and purified a novel transcription elongation factor, termed DSIF (for DRB sensitivity-inducing factor), that makes transcription sensitive to DRB. DSIF is composed of 160- and 14-kDa subunits, which are homologs of the Saccharomyces cerevisiae transcription factors Spt5 and Spt4. DSIF may either repress or stimulate transcription in vitro, depending on conditions, but its physiological function remains elusive. Here we characterize the structure and function of DSIF p160. p160 is shown to be a ubiquitous nuclear protein that forms a stable complex with p14 and interacts directly with the pol II largest subunit, Mutation analysis of p160 is used to identify structural features essential for its in vitro activity and to map the domains required for its interaction with p14 and pol II. Finally, a p160 mutant that represses DSIF activity in a dominant-negative manner is identified and used to demonstrate that DSIF represses transcription from various promoters in vivo.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	hhanda@bio.titech.ac.jp	Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X				Chiang PW, 1996, GENOMICS, V38, P421, DOI 10.1006/geno.1996.0646; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 1996, MOL CELL BIOL, V16, P2848; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MALONE EA, 1993, MOL GEN GENET, V237, P449, DOI 10.1007/BF00279450; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Moore DD, 1995, GLOB MOB SURV; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Stachora AA, 1997, FEBS LETT, V409, P74, DOI 10.1016/S0014-5793(97)00486-9; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; SWANSON MS, 1992, GENETICS, V132, P325; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WADA T, 1991, J VIROL, V65, P557, DOI 10.1128/JVI.65.2.557-564.1991; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; WINSTON F, 1984, GENETICS, V107, P179; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamaguchi Y, 1998, GENES CELLS, V3, P9, DOI 10.1046/j.1365-2443.1998.00162.x; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	39	115	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8085	8092		10.1074/jbc.274.12.8085	http://dx.doi.org/10.1074/jbc.274.12.8085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075709	hybrid			2022-12-27	WOS:000079268100068
J	Luker, GD; Nilsson, KR; Covey, DF; Piwnica-Worms, D				Luker, GD; Nilsson, KR; Covey, DF; Piwnica-Worms, D			Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; ACYL-COENZYME-A; ENDOPLASMIC-RETICULUM; IN-VIVO; SPHINGOMYELIN DEGRADATION; HUMAN-FIBROBLASTS; CYSTIC-FIBROSIS; CELLS; TRANSPORT; GENE	Class I P-glycoproteins (Pgp) confer multidrug resistance in tumors, but the physiologic function of Pgp in normal tissues remains uncertain. In cells derived from tissues that normally express Pgp, recent data suggest a possible role for Pgp in cholesterol trafficking from the plasma membrane to the endoplasmic reticulum, We investigated the esterification of plasma membrane cholesterol under basal conditions and in response to sphingomyelinase treatment in transfected and drug-selected cell lines expressing differing amounts of functional class I Pgp. Compared with parental NIH 3T3 fibroblasts, cells transfected with human multidrug resistance (MDR1) Pgp esterified more cholesterol both without and with sphingomyelinase. Esterification also was greater in drug-selected Dox 6 myeloma cells than parental 8226 cells, which express low and non-immunodetectable amounts of Pgp, respectively. However, no differences in total plasma membrane cholesterol were detected. Transfection of fibroblasts with the multidrug resistance-associated protein (MRP) did not alter esterification, showing that cholesterol trafficking was not generally affected by ATP-binding cassette transporters. Steroidal (progesterone, dehydroepiandrosterone) and non-steroidal antagonists (verapamil, PSC 833, LY335979, and GF120918) were evaluated for effects on both cholesterol trafficking and the net content of Tc-99m-Sestamibi, a reporter of drug transport activity mediated by Pgp, In Pgp-expressing cells treated with nonselective and selective inhibitors, both the kinetics and efficacy of inhibition of cholesterol esterification differed from the antagonism of drug transport mediated by Pgp, Thus, although the data show that greater expression of class I Pgp within a given cell type is associated with enhanced esterification of plasma membrane cholesterol in support of a physiologic function for Pgp in facilitating cholesterol trafficking, the molecular mechanism is dissociated from the conventional drug transport activity of Pgp.	Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Lab Mol Radiopharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Lab Mol Radiopharmacol, 510 S Kingshighway Blvd, St Louis, MO 63110 USA.	piwnica-worms@mirlink-wustl.edu		luker, gary/0000-0001-6832-2581	NHLBI NIH HHS [K08 HL03683] Funding Source: Medline; NIGMS NIH HHS [GM47696] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM047696] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY JD, 1995, LEUKEMIA, V9, P799; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Barnes KM, 1996, BIOCHEMISTRY-US, V35, P4820, DOI 10.1021/bi952380k; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; Bosch I, 1997, LEUKEMIA, V11, P1131, DOI 10.1038/sj.leu.2400695; Bosch I, 1996, BBA-REV CANCER, V1288, pF37, DOI 10.1016/0304-419X(96)00022-4; Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; Crankshaw C, 1996, J NUCL MED, V37, P1110; DALTON WS, 1986, CANCER RES, V46, P5125; Dantzig AH, 1996, CANCER RES, V56, P4171; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; Ehlhardt WJ, 1998, DRUG METAB DISPOS, V26, P42; ELYANDOUZI E, 1994, BIOCHEMISTRY-US, V33, P2329, DOI 10.1021/bi00174a046; FIELD FJ, 1995, J LIPID RES, V36, P1533; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1994, J BIOL CHEM, V269, P30745; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hendrikse NH, 1998, BRIT J CANCER, V77, P353, DOI 10.1038/bjc.1998.57; HYAFIL F, 1993, CANCER RES, V53, P4595; Jacobs NL, 1997, J LIPID RES, V38, P1973; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Kim H, 1997, AM J PHYSIOL-CELL PH, V273, pC687, DOI 10.1152/ajpcell.1997.273.2.C687; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; Luker GD, 1997, BIOCHEMISTRY-US, V36, P14218, DOI 10.1021/bi971931z; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; Nilsson KR, 1998, J MED CHEM, V41, P2604, DOI 10.1021/jm980148h; PIWNICAWORMS D, 1993, CANCER RES, V53, P977; PIWNICAWORMS D, 1995, BIOCHEMISTRY-US, V34, P12210, DOI 10.1021/bi00038a015; PORN MI, 1990, BIOCHEM J, V271, P121, DOI 10.1042/bj2710121; RAO V, 1998, P AM ASSOC CANC RES, V38, P76; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; Sharom FJ, 1998, BIOCHEM J, V333, P621, DOI 10.1042/bj3330621; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; Winegar DA, 1996, J LIPID RES, V37, P179; YANG CPH, 1989, J BIOL CHEM, V264, P782	63	104	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6979	6991		10.1074/jbc.274.11.6979	http://dx.doi.org/10.1074/jbc.274.11.6979			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066752	hybrid			2022-12-27	WOS:000079078400024
J	Nadanaciva, S; Weber, J; Senior, AE				Nadanaciva, S; Weber, J; Senior, AE			Binding of the transition state analog MgADP-fluoroaluminate to F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BETA-SUBUNIT; CATALYTIC SITES; ATP SYNTHASE; MITOCHONDRIAL F1-ATPASE; ACTIVE CONFORMATIONS; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; COMPLEX	Escherichia coli F-1-ATPase from mutant beta Y331W was potently inhibited by fluoroaluminate plus MgADP but not by MgADP alone. beta-Trp-331 fluorescence was used to measure MgADP binding to catalytic sites. Fluoroaluminate induced a very large increase in MgADP binding affinity at catalytic site one, a smaller increase at site two, and no effect at site three. Mutation of either of the critical catalytic site residues beta-Lys-155 or beta-Glu-181 to Gin abolished the effects of fluoroaluminate on MgADP binding, The results indicate that the MgADP-fluoroaluminate complex is a transition state analog and independently demonstrate that residues beta-Lys-155 and (particularly) beta-Glu-181 are important for generation and stabilization of the catalytic transition state. Dicyclohexylcarbodiimide-inhibited enzyme, with 1% residual steady-state ATPase, showed normal transition state formation as judged by fluoroaluminate-induced MgADP binding affinity changes, consistent with a proposed mechanism by which dicyclohexylcarbodiimide prevents a conformational interaction between catalytic sites but does not affect the catalytic step per se. The fluorescence technique should prove valuable for future transition state studies of F-1-ATPase.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Nadanaciva, S (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; RAO R, 1988, J BIOL CHEM, V263, P5569; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; SENIOR AE, 1993, J BIOL CHEM, V268, P6989; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; [No title captured]	39	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7052	7058		10.1074/jbc.274.11.7052	http://dx.doi.org/10.1074/jbc.274.11.7052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066761	hybrid			2022-12-27	WOS:000079078400033
J	Stierum, RH; Croteau, DL; Bohr, VA				Stierum, RH; Croteau, DL; Bohr, VA			Purification and characterization of a mitochondrial thymine glycol endonuclease from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; OXIDATIVE DNA-DAMAGE; ESCHERICHIA-COLI; ULTRAVIOLET-RADIATION; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; POLYMERASE-I; BASE DAMAGE; REPAIR; GLYCOSYLASE	Mitochondrial DNA is exposed to oxygen radicals produced during oxidative phosphorylation, Accumulation of several kinds of oxidative lesions in mitochondrial DNA may lead to structural genomic alterations, mitochondrial dysfunction, and associated degenerative diseases. The pyrimidine hydrate thymine glycol, one of many oxidative lesions, can block DNA and RNA polymerases and thereby exert negative biological effects. Mitochondrial DNA repair of this lesion is important to ensure normal mitochondrial DNA metabolism. Here, we report the purification of a novel rat liver mitochondrial thymine glycol endonuclease (mtTGendo), By using a radiolabeled oligonucleotide duplex containing a single thymine glycol lesion, damage-specific incision at the modified thymine was observed upon incubation with mitochondrial protein extracts. After purification using cation exchange, hydrophobic interaction, and size exclusion chromatography, the most pure active fractions contained a single band of similar to 37 kDa on a silver-stained gel. MtTGendo is active within a broad KCI concentration range and is EDTA-resistant. Furthermore, mtTGendo has an associated apurinic/apyrimidiniclyase activity. MtTGendo does not incise 8-oxodeoxyguanosine or uracil-containing duplexes or thymine glycol in single-stranded DNA. Based upon functional similarity, we conclude that mtTGendo may be a rat mitochondrial homolog of the Escherichia coli endonuclease III protein.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Genet Mol Lab, NIH, Box 01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020; Croteau, Deb/AAP-5933-2020	Croteau, Deborah/0000-0002-6094-4084				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Bozner P, 1997, J NEUROPATH EXP NEUR, V56, P1356, DOI 10.1097/00005072-199712000-00010; CLARK JM, 1986, NUCLEIC ACIDS RES, V14, P737, DOI 10.1093/nar/14.2.737; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; CUMMINGS OW, 1987, J BIOL CHEM, V262, P2005; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; GERSCHENSON M, 1995, NUCLEIC ACIDS RES, V23, P88, DOI 10.1093/nar/23.1.88; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; HIGGINS SA, 1987, BIOCHEMISTRY-US, V26, P1683, DOI 10.1021/bi00380a029; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; HTUN H, 1992, METHOD ENZYMOL, V212, P272; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Jen J, 1997, PHOTOCHEM PHOTOBIOL, V65, P323, DOI 10.1111/j.1751-1097.1997.tb08565.x; Kung HC, 1997, J BIOL CHEM, V272, P9227; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; Lyras L, 1997, J NEUROCHEM, V68, P2061; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; RAGAN CI, 1987, PRACTICAL APPROACH S, P80; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; WANG YJ, 1995, CHEM-BIOL INTERACT, V94, P135, DOI 10.1016/0009-2797(94)03327-5; Wei HC, 1997, FREE RADICAL BIO MED, V23, P148, DOI 10.1016/S0891-5849(96)00526-6; You HJ, 1998, BIOCHEMISTRY-US, V37, P6033, DOI 10.1021/bi973042h; Zastawny TH, 1998, FREE RADICAL BIO MED, V24, P722, DOI 10.1016/S0891-5849(97)00331-6; Zhang XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119, DOI 10.1111/j.1751-1097.1997.tb01886.x; Zhang XS, 1997, FREE RADICAL BIO MED, V23, P980, DOI 10.1016/S0891-5849(97)00126-3	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7128	7136		10.1074/jbc.274.11.7128	http://dx.doi.org/10.1074/jbc.274.11.7128			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066771	hybrid			2022-12-27	WOS:000079078400043
J	Leal, SM; Huang, SS; Huang, JS				Leal, SM; Huang, SS; Huang, JS			Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-P receptor in mink lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; FACTOR (IGF)-BINDING PROTEIN-3; BREAST-CANCER CELLS; TGF-BETA; IGF-I; TARGETED DISRUPTION; OSTEOBLASTIC CELLS; FIBROBLASTS; GROWTH-FACTOR-BETA-1; IDENTIFICATION	High affinity insulin-like growth factor-binding proteins (IGFBP-1 to -6) are a family of structurally homologous proteins that induce cellular responses by insulin-libe growth factor (IGF)-dependent and -independent mechanisms. The IGFBP-3 receptor, which mediates the IGF-independent growth inhibitory response, has recently been identified as the type V transforming growth factor-beta receptor (T beta R-V) (Leal, S.M, Liu, Q,L,, Huang, S.S., and Huang, J, S, (1997) J, Biob Chem, 272, 20572-20576), To characterize the interactions of high affinity IGFBPs with T beta R-V, mink lung epithelial cells (Mv1Lu cells) were incubated with I-125-labeled recombinant human IGFBPs (I-125-IGFBP-1 to -6) in the presence of the cross-linking agent disuccinimidyl suberate and analyzed by 5% SDS-polyacrylamide gel electrophoresis and autoradiography. I-125-IGFBP-3, -4, and -5 but not I-125-IGFBP-1, -2, and -6 bound to T beta R-V as demonstrated by the detection of the similar to 400-kDa I-125-IGFBP T beta R-V cross-linked complex in the cell lysates and immunoprecipitates. The analyses of 125I-labeled Ligand binding competition and DNA synthesis inhibition revealed that IGFBP-3 was a more potent Ligand for TPR-V than IGFBP-4 or -5, Most of the high affinity I-125-IGFBPs formed dimers at the cell surface. The cell-surface dimer of I-125-IGFBP-3 preferentially bound to and was cross-linked to TPR-V in the presence of disuccinimidyl suberate, IGFBP-3 did not stimulate the cellular phosphorylation of Smad2 and Smad3, key transducers of the transforming growth factor-beta type I/type II receptor (T beta R-IT beta R-II) heterocomplex-mediated signaling. These results suggest that IGFBP-3, -4, and -5 are specific ligands for T beta R-V, which mediates the growth inhibitory response through a signaling pathway(s) distinct from that mediated by the T beta R-I and T beta R-II heterocomplex.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@wpogate.slu.edu			NCI NIH HHS [CA38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BACH LA, 1992, BIOCHEM BIOPH RES CO, V186, P301, DOI 10.1016/S0006-291X(05)80807-1; BACH LA, 1992, DIABETES METAB REV, V8, P229, DOI 10.1002/dmr.5610080304; BAKER JB, 1979, NATURE, V278, P743, DOI 10.1038/278743a0; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; Fowlkes JL, 1997, ENDOCRINOLOGY, V138, P2280, DOI 10.1210/en.138.6.2280; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HODGKINSON S, 1995, J ENDOCRINOL, V145, pR2; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; Huang SS, 1998, J BIOL CHEM, V273, P26036, DOI 10.1074/jbc.273.40.26036; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LINSLEY PS, 1979, NATURE, V278, P743; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; LOKESHWAR VB, 1989, J BIOL CHEM, V264, P19318; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Neumann GM, 1998, BIOCHEMISTRY-US, V37, P6572, DOI 10.1021/bi972894e; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OH Y, 1993, J BIOL CHEM, V268, P26045; RAINES EW, 1991, PEPTIDE GROWTH FACTO, V1, P173; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SINGH P, 1994, CANCER RES, V54, P6563; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	42	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6711	6717		10.1074/jbc.274.10.6711	http://dx.doi.org/10.1074/jbc.274.10.6711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037769	hybrid			2022-12-27	WOS:000078902800091
J	Schrem, A; Lange, C; Beyermann, M; Koch, KW				Schrem, A; Lange, C; Beyermann, M; Koch, KW			Identification of a domain in guanylyl cyclase-activating protein 1 that interacts with a complex of guanylyl cyclase and tubulin in photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; RETINAL RODS; CALMODULIN; EXPRESSION; PHOTOTRANSDUCTION; LOCALIZATION; PURIFICATION; RECOGNITION; MODULATION	The membrane-bound guanylyl cyclase in rod photoreceptors is activated by guanylyl cyclase-activating protein 1 (GCAP-1) at low free [Ca(2+)]. GCAP-1 is a Ca(2+)- binding protein and belongs to the superfamily of EF-hand proteins. We created an oligopeptide library of overlapping peptides that encompass the entire amino acid sequence of GCAP-1, Peptides were used in competitive screening assays to identify interaction regions in GCAP-1 that directly bind the guanylyl cyclase in bovine photoreceptor cells. We found four regions in GCAP-1 that participate in regulating guanylyl cyclase. A 15-amino acid peptide located adjacent to the second EF-hand motif (Phe(73)-Lys(87)) was identified as the main interaction domain. Inhibition of GCAP-1-stimulated guanylyl cyclase activity by the peptide Phe(73)-Lys(87) was completely relieved when an excess amount of GCAP-1 was added. An affinity column made from this peptide was able to bind a complex of photoreceptor guanylyl cyclase and tubulin. Using an anti-GCAP-1 antibody, we coimmunoprecipitated GCAP-1 with guanylyl cyclase and tubulin. Complex formation between GCAP-1 and guanylyl cyclase was observed independent of [Ca(2+)]. Our experiments suggest that there exists a tight association of guanylyl cyclase and tubulin in rod outer segments.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany	Helmholtz Association; Research Center Julich	Koch, KW (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	k.w.koch@fz-juelich.de	Koch, Karl-Wilhelm/C-9551-2015	Koch, Karl-Wilhelm/0000-0003-1501-0044				DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Duda T, 1998, BIOCHEM BIOPH RES CO, V242, P118, DOI 10.1006/bbrc.1997.7921; FLEISCHMAN D, 1979, BIOCHEMISTRY-US, V18, P5060, DOI 10.1021/bi00590a006; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; Goraczniak R, 1997, BIOCHEM BIOPH RES CO, V234, P666, DOI 10.1006/bbrc.1997.6579; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Hallett MA, 1996, J CELL SCI, V109, P1803; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KOCH KW, 1995, CELL CALCIUM, V18, P314, DOI 10.1016/0143-4160(95)90027-6; KOCH KW, 1994, EUR J BIOCHEM, V222, P589, DOI 10.1111/j.1432-1033.1994.tb18901.x; KOCH KW, 1991, J BIOL CHEM, V266, P8634; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PODZDNYAKOV N, 1997, BIOCHEMISTRY-US, V36, P14327; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	33	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6244	6249		10.1074/jbc.274.10.6244	http://dx.doi.org/10.1074/jbc.274.10.6244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037711	hybrid			2022-12-27	WOS:000078902800033
J	Baxter, GT; Kuo, RC; Jupp, OJ; Vandenabeele, P; MacEwan, DJ				Baxter, GT; Kuo, RC; Jupp, OJ; Vandenabeele, P; MacEwan, DJ			Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; SIGNAL-TRANSDUCTION; VIRAL-PROTEINS; C-MYC; ACTIVATION; BCL-2; CYTOTOXICITY; MECHANISM; BINDING; DOMAIN	The TF-1 human erythroleukemic cell line exhibits opposing physiological responses toward tumor necrosis factor-alpha (TNF) treatment, dependent upon the mitotic state of the cells. Mitotically active cells in log growth respond to TNF by rapidly undergoing apoptosis whereas TNF exposure stimulates cellular proliferation in mitotically quiescent cells, The concentration-dependent TNF-induced apoptosis was monitored by cellular metabolic activity and confirmed by both DNA epifluorescence and DNA fragmentation. Moreover, these responses could be detected by measuring extracellular acidification activity, enabling rapid prediction (within similar to 1.5 h of TNF treatment) of the fate of the cell in response to TNF. Growth factor resupplementation of quiescent cells, resulting in reactivation of cell cycling, altered TNF action from a proliferative stimulus to an apoptotic signal. Expression levels of the type II TNF receptor subtype (p75TNFR) were found to correlate with sensitivity to TNF-induced apoptosis. Pretreatment of log growth TF-1 cells with a neutralizing anti-p75TNFR monoclonal antibody inhibited TNF-induced apoptosis by greater than 80%. Studies utilizing TNF receptor subtype-specific TNF mutants and neutralizing antisera implicated p75TNFR in TNF-dependent apoptotic signaling. These data show a bifunctional physiological role for TNF in TF-1 cells that is dependent on mitotic activity and controlled by the p75TNFR.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA; Cornell Univ, Cornell Nanofabricat Facil, Ithaca, NY 14853 USA; State Univ Ghent VIB, Dept Biol Mol, B-9000 Ghent, Belgium	University of Aberdeen; Stanford University; Cornell University; Flanders Institute for Biotechnology (VIB); Ghent University	MacEwan, DJ (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	david.macewan@abdn.ac.uk	MacEwan, David/F-7044-2011; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; MacEwan, David/0000-0002-2879-0935				ABDOLRASULNIA R, 1992, AM J RESP CELL MOL, V7, P42, DOI 10.1165/ajrcmb/7.1.42; ALAOUI SE, 1992, FEBS LETT, V311, P174; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Declercq W, 1998, J IMMUNOL, V161, P390; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fiers W, 1996, J INFLAMM, V47, P67; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HELLER RA, 1992, CELL, V70, P47; HIGUCHI M, 1993, FEBS LETT, V331, P252, DOI 10.1016/0014-5793(93)80347-W; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; Martelli AM, 1998, J CELL BIOCHEM, V71, P11, DOI 10.1002/(SICI)1097-4644(19981001)71:1<11::AID-JCB2>3.0.CO;2-4; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PERROS P, 1991, CELL PROLIFERAT, V24, P517, DOI 10.1111/j.1365-2184.1991.tb01179.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VOLLAND S, 1994, INT J CANCER, V56, P698, DOI 10.1002/ijc.2910560515; WALLENOHMAN M, 1993, CANCER LETT, V75, P103, DOI 10.1016/0304-3835(93)90194-E; WARREN DJ, 1990, EUR J HAEMATOL, V45, P158; Weiss T, 1997, J IMMUNOL, V158, P2398; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	61	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9539	9547		10.1074/jbc.274.14.9539	http://dx.doi.org/10.1074/jbc.274.14.9539			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092639	hybrid			2022-12-27	WOS:000079451800058
J	Ho, IHM; Murrell-Lagnado, RD				Ho, IHM; Murrell-Lagnado, RD			Molecular determinants for sodium-dependent activation of G protein-gated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; POTASSIUM CHANNELS; BINDING; G(BETA-GAMMA); EXPRESSION; CLONING; NEURONS; REGIONS; CELLS	G protein-gated inwardly rectifying K+ channels (GIRKs) are activated by a direct interaction with G beta gamma subunits and also by raised internal [Na+]. Both processes require the presence of phosphatidylinositol bisphosphate (PIP2). Here we show that the proximal C-terminal region of GIRK2 mediates the Na+-dependent activation of both the GIRK2 homomeric channels and the GIRK1/GIRK2 heteromeric channels. Within this region, GIRK2 has an aspartate at position 226, whereas GIRK1 has an asparagine at the equivalent position (217), A single point mutation, D226N, in GIRK2, abolished the Na+-dependent activation of both the homomeric and heteromeric channels, Neutralizing a nearby negative charge, E234S had no effect. The reverse mutation in GIRK1, N217D, was sufficient to restore Na+-dependent activation to the GIRK1N217D/GIRK2D226N heteromeric channels. The D226N mutation did not alter either the single channel properties or the ability of these channels to be activated via the m2-muscarinic receptor. PIP2 dramatically increased the open probability of GIRK1/GIRK2 channels in the absence of Na+ or G beta gamma but did not preclude further activation by Na+, suggesting that Na+ is not acting simply to promote PIP2 binding to GIRKs. We conclude that aspartate 226 in GIRK2 plays a crucial role in Na+ dependent gating of GIRK1/GIRK2 channels.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Murrell-Lagnado, RD (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.	rdm1003@cus.cam.ac.uk		Murrell-Lagnado, Ruth/0000-0003-2743-7977				BOND CT, 1995, FEBS LETT, V367, P61, DOI 10.1016/0014-5793(95)00497-W; Callaway JC, 1997, J NEUROPHYSIOL, V77, P145, DOI 10.1152/jn.1997.77.1.145; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; NEVE KA, 1991, MOL PHARMACOL, V39, P733; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Stevens EB, 1997, J PHYSIOL-LONDON, V503, P547, DOI 10.1111/j.1469-7793.1997.547bg.x; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877	23	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8639	8648		10.1074/jbc.274.13.8639	http://dx.doi.org/10.1074/jbc.274.13.8639			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085101	hybrid			2022-12-27	WOS:000079451600043
J	Koticha, DK; Huddleston, SJ; Witkin, JW; Baldini, G				Koticha, DK; Huddleston, SJ; Witkin, JW; Baldini, G			Role of the cysteine-rich domain of the t-SNARE component, SYNDET, in membrane binding and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; PLASMA-MEMBRANE; DIRECTED MUTAGENESIS; CELL-SURFACE; CDNA CLONES; SNAP-25; PALMITOYLATION; TRANSPORT; FUSION; INSULIN	Wild-type syndet is efficiently recruited at the plasma membrane in transfected AtT-20 cells. A deletion at the cysteine-rich domain abolishes palmitoylation, membrane binding, and plasma membrane distribution of syndet. Syndet, SNAP-25A, and SNAP-25B share four cysteine residues, of which three, Cys(2), Cys(4), and Cys(5), are absolutely conserved in all three homologs, Mutations at any pair of cysteines within cysteines 2, 4, and 5 shift syndet from the cell surface into the cytoplasm, Thus, at least two cysteines within the conserved triplet are necessary for plasma membrane localization. Syndet C1S/C3S, with substitutions at the pair Cys(1) and Cys(3), distributes to the plasma membrane, a Gels-like compartment, and the cytosol, We conclude that Cys(1) and Cys(3) are not absolutely necessary for membrane binding or plasma membrane localization. Our results show that the cysteine-rich domain of syndet plays a major role in its subcellular distribution.	Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University	Baldini, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.			Huddleston, Stephen/0000-0002-9244-9854	NIDDK NIH HHS [R01-DK53293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053293] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; DECAMILLI P, 1993, NATURE, V364, P387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HESS DT, 1992, J NEUROSCI, V12, P4634; Hidajat R, 1997, BIOTECHNIQUES, V22, P32, DOI 10.2144/97221bm04; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lane SR, 1997, J NEUROCHEM, V69, P1864; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; RISINGER C, 1993, J BIOL CHEM, V268, P24408; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884	37	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9053	9060		10.1074/jbc.274.13.9053	http://dx.doi.org/10.1074/jbc.274.13.9053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085154	hybrid			2022-12-27	WOS:000079451600096
J	Stathakis, P; Lay, AJ; Fitzgerald, M; Schlieker, C; Matthias, LJ; Hogg, PJ				Stathakis, P; Lay, AJ; Fitzgerald, M; Schlieker, C; Matthias, LJ; Hogg, PJ			Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR; ENDOTHELIAL-CELLS; BINDING; GLUTATHIONE; GROWTH; CANCER; PURIFICATION; MICROPLASMIN; SENSITIVITY; GENERATION	Plasmin is processed in the conditioned medium of HT1080 fibrosarcoma cells producing fragments with the domain structures of the angiogenesis inhibitor, angiostatin, and microplasmin, Angiostatin consists of kringle domains 1-4 and part of kringle 5, while microplasmin consists of the remainder of kringle 5 and the serine proteinase domain. Our findings indicate that formation of angiostatin/microplasmin involves reduction of plasmin by a plasmin reductase followed by proteolysis of the reduced enzyme. We present evidence that the Cys(461)-Cys(540) and Cys(511)-Cys(535) disulfide bonds in kringle 5 of plasmin were reduced by plasmin reductase, Plasmin reductase activity was secreted by HT1080 and Chinese hamster ovary cells and the human mammary carcinoma cell lines MCF-7, MDA231, and BT20 but not by the monocyte/macrophage cell line THP-1. Neither primary foreskin fibroblasts, blood monocyte/ macrophages, nor macrovascular or microvascular endothelial cells secreted detectable plasmin reductase. In contrast, cultured bovine and rat vascular smooth muscle cells secreted small but reproducible levels of plasmin reductase. Reduction of the kringle 5 disulfide bonds triggered cleavage at either Arg(529)-Lys(530) Or two other positions C-terminal of Cys(461) in kringle 5 by a serine proteinase. Plasmin autoproteolysis could account for the cleavage, although another proteinase was mostly responsible in HT1080 conditioned medium. Three serine proteinases with apparent M-r of 70, 50, and 39 were purified from HT1080 conditioned medium, one or more of which could contribute to proteolysis of reduced plasmin.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Hogg, PJ (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179; Hogg, Philip/0000-0001-6486-2863				BANNAI S, 1979, J BIOL CHEM, V254, P3444; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Dudman NPB, 1996, CLIN CHEM, V42, P2028; Field SL, 1996, J CELL PHYSIOL, V168, P322, DOI 10.1002/(SICI)1097-4652(199608)168:2<322::AID-JCP11>3.0.CO;2-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HASSAN NF, 1986, J IMMUNOL METHODS, V95, P273, DOI 10.1016/0022-1759(86)90415-1; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; HOGG PJ, 1992, J BIOL CHEM, V267, P703; JACKSON CJ, 1990, J CELL SCI, V96, P257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lannutti BJ, 1997, CANCER RES, V57, P5277; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; LITTLE PJ, 1986, AM J PHYSIOL, V251, pC707, DOI 10.1152/ajpcell.1986.251.5.C707; MARTIN GM, 1973, TISSUE CULTURE METHO, P39; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Sim BKL, 1997, CANCER RES, V57, P1329; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793	31	78	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8910	8916		10.1074/jbc.274.13.8910	http://dx.doi.org/10.1074/jbc.274.13.8910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085135				2022-12-27	WOS:000079451600077
J	Beggah, AT; Beguin, P; Bamberg, K; Sachs, G; Geering, K				Beggah, AT; Beguin, P; Bamberg, K; Sachs, G; Geering, K			beta-subunit assembly is essential for the correct packing and the stable membrane insertion of the H,K-ATPase alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSLATION; NA,K-ATPASE; TOPOLOGY; TRANSMEMBRANE; TRANSLOCATION; NA,K-PUMPS; SYSTEM	The alpha-subunits of H,K-ATPase (HKA alpha) and Na,K-ATPase require a beta-subunit for maturation. We investigated the role of the beta-subunit in the membrane insertion and stability of the HKA alpha expressed in Xenopus oocytes, Individual membrane segments M1, M2, M3, M4, and M9 linked to a glycosylation reporter act as signal anchor (SA) motifs, and M10 acts as a partial stop transfer motif. In combined HKA alpha constructs, M2 acts as an efficient stop transfer sequence, and M3 acts as a SA sequence. However, M5 and M9 have only partial SA function, and M7 has no SA function. Consistent with the membrane insertion properties of segments in combined a constructs, M1-3 alpha-proteins are resistant to cellular degradation, and M1-5 up to M1-10 alpha-proteins are not resistant to cellular degradation. However, co-expression with beta-subunits increases the membrane insertion of M9 in a M1-9 alpha-protein and completely protects M1-10 alpha-proteins against cellular degradation. Our results indicate that HKA alpha N-terminal (M1-M4) membrane insertion and stabilization are mediated by intrinsic molecular characteristics; however, the C-terminal (M5-M10) membrane insertion and thus the stabilization of the entire alpha-subunit depend on intramolecular and intermolecular beta-subunit interactions that are similar but not identical to data obtained for the Na,K-ATPase alpha-subunit.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Astra Hassle AB, S-43183 Molndal, Sweden; W Los Angeles Wadsworth Vet Adm Med Ctr, Los Angeles, CA 90073 USA	University of Lausanne; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.							BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; Beguin P, 1997, ANN NY ACAD SCI, V834, P540, DOI 10.1111/j.1749-6632.1997.tb52312.x; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; Beguin P, 1996, BIOCHEMISTRY-US, V35, P14098, DOI 10.1021/bi960516o; Chen PX, 1998, AM J PHYSIOL-CELL PH, V275, pC139, DOI 10.1152/ajpcell.1998.275.1.C139; Claeys D, 1997, GASTROENTEROLOGY, V113, P1136, DOI 10.1053/gast.1997.v113.pm9322508; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; DEBER CM, 1997, MOL B INT U, P25; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; High S, 1997, TRENDS CELL BIOL, V7, P206; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Karlish SJD, 1997, ANN NY ACAD SCI, V834, P30, DOI 10.1111/j.1749-6632.1997.tb52223.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	26	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8217	8223		10.1074/jbc.274.12.8217	http://dx.doi.org/10.1074/jbc.274.12.8217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075726	hybrid			2022-12-27	WOS:000079268100085
J	Meade, EA; McIntyre, TM; Zimmerman, GA; Prescott, SM				Meade, EA; McIntyre, TM; Zimmerman, GA; Prescott, SM			Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN-H SYNTHASE-2; FATTY-ACIDS; COLON-CANCER; COLORECTAL ADENOMAS; TISSUE DISTRIBUTION; NUCLEAR RECEPTOR; GENE-EXPRESSION; ASPIRIN USE	The formation of prostaglandins requires the catalytic activity of cyclooxygenase (COX) which converts arachidonic acid to the prostaglandin endoperoxide PGH(2), from which all other prostaglandins are formed. COX-2 is the highly inducible isozyme of COX which is responsible for much of the prostaglandin production in inflammation and is a key factor in colon carcinogenesis. Because COX-2 activity can be rate-limiting in prostaglandin formation, COX-2 expression must be regulated tightly. Numerous factors, including mitogens, tumor promoters, and cytokines have been found to stimulate the transcription of COX-2. We show that fatty acids, prostaglandins, and non-steroidal anti-inflammatory drugs, compounds that are substrates, products, and inhibitors, respectively, of COX enzymatic activity, also increase its expression. These compounds are members of a heterogeneous group of compounds known as peroxisome proliferators, and the prototypical peroxisome proliferator, WY-14,643, also enhanced COX-2 expression. We demonstrate that these compounds increase COX-2 transcription, and we identify a region of the COX-2 promoter containing a peroxisome proliferator response element that is responsible for the enhancement of COX-2 expression seen with these compounds.	Univ Utah, Huntsman Canc Inst, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Nora Eccles Harrison Cardiovasc Training & Res In, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Eccles Program Human Mol Biol & Genet, 15 N 2030 E Rm 4220, Salt Lake City, UT 84112 USA.				NCI NIH HHS [CA 42014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANDYOPADHYAY GK, 1987, J BIOL CHEM, V262, P2750; CARTER CA, 1983, CANCER RES, V43, P3559; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HABIB A, 1993, J BIOL CHEM, V268, P23448; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MEADE EA, 1992, HDB LIPID RES, V8, P285; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; POTTER JD, 1992, JAMA-J AM MED ASSOC, V268, P1573; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	40	263	274	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8328	8334		10.1074/jbc.274.12.8328	http://dx.doi.org/10.1074/jbc.274.12.8328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075740	hybrid			2022-12-27	WOS:000079268100099
J	Micheau, O; Solary, E; Hammann, A; Dimanche-Boitrel, MT				Micheau, O; Solary, E; Hammann, A; Dimanche-Boitrel, MT			Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; MONOCLONAL-ANTIBODY; CD95 FAS/APO-1; LEUKEMIA-CELLS; EXPRESSION; RECEPTOR; CERAMIDE; CHEMOTHERAPY; INVOLVEMENT	Trimerization of the Fas receptor (CD95, APO-1), a membrane bound protein, triggers cell death by apoptosis. The main death pathway activated by Fas receptor involves the adaptor protein FADD (for Fas-associated death domain) that connects Fas receptor to the caspase cascade. Anticancer drugs have been shown to enhance both Fas receptor and Fas ligand expression on tumor cells. The contribution of Fas ligand-Fas receptor interactions to the cytotoxic activity of these drugs remains controversial. Here, we show that neither the antagonistic anti-Fas antibody ZB4 nor the Fas-IgG molecule inhibit drug-induced apoptosis in three different cell lines. The expression of Fas ligand on the plasma membrane, which is identified in untreated U937 human leukemic cells but remains undetectable in untreated HT29 and HCT116 human colon cancer cell lines, is not modified by exposure to various cytotoxic agents. These drugs induce the clustering of Fas receptor, as observed by confocal laser scanning microscopy, and its interaction with FADD, as demonstrated by co-immunoprecipitation, Overexpression of FADD by stable transfection sensitizes tumor cells to drug-induced cell death and cytotoxicity, whereas down-regulation of FADD by transient transfection of an antisense construct decreases tumor cell sensitivity to drug-induced apoptosis, These results were confirmed by transient transfection of constructs encoding either a FADD dominant negative mutant or MC159 or E8 viral proteins that inhibit the FADD/caspase-8 pathway. These results suggest that drug-induced cell death involves the Fas/FADD pathway in a Fas ligand-independent fashion.	Fac Med & Pharm, U517, Pole Biol & Therapie Canc, JE515,INSERM, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Dimanche-Boitrel, MT (corresponding author), Fac Med & Pharm, U517, Pole Biol & Therapie Canc, JE515,INSERM, 7 Blvd Jeanne dArc, F-21033 Dijon, France.	mtboitre@u-bourgogne.fr	micheau, olivier/C-3574-2011; Dimanche-Boitrel, Marie-Therese M/I-4642-2015	micheau, olivier/0000-0001-8499-7984; Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Smith D, 1998, J IMMUNOL, V160, P4159; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Villunger A, 1997, CANCER RES, V57, P3331; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	31	288	302	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7987	7992		10.1074/jbc.274.12.7987	http://dx.doi.org/10.1074/jbc.274.12.7987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075697	hybrid			2022-12-27	WOS:000079268100056
J	Pagano, A; Letourneur, F; Garcia-Estefania, D; Carpentier, JL; Orci, L; Paccaud, JP				Pagano, A; Letourneur, F; Garcia-Estefania, D; Carpentier, JL; Orci, L; Paccaud, JP			Sec24 proteins and sorting at the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; TRANSPORT VESICLES; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; MEMBRANE-PROTEIN; COATED VESICLES; NEW-GENERATION; COPII; ER; YEAST	COPII proteins are necessary to generate secretory vesicles at the endoplasmic reticulum, In yeast, the Sec24p protein is the only COPII component in which two close orthologues have been identified. By using gene knock-out in yeast, we found that the absence of one of these Sec24 orthologues resulted in a selective secretion defect for a subset of proteins released into the medium. Data base searches revealed the existence of an entire family of Sec24-related proteins in humans, worms, flies, and plants. We identified and cloned two new human cDNAs encoding proteins homologous to yeast Sec24p, in addition to two human cDNAs already present within the data bases. The entire Sec24 family identified to date is characterized by clusters of highly conserved residues within the 2/3 carboxyl-terminal domain of all the proteins and a divergent amino terminus domain. Human (h) Sec24 orthologues co-immunoprecipitate with hSec23Ap and migrate as a complex by size exclusion chromatography. Immunofluorescence microscopy confirmed that these proteins co-localize with hSec23p and hSec13p. Together, our data suggest that in addition to its role in the shaping up of the vesicle, the Sec23-24p complex may be implicated in cargo selection and concentration.	Univ Geneva, Med Ctr, Dept Morphol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland; CNRS, Inst Biol & Chem Prot, F-69367 Lyon, France	University of Geneva; University of Geneva; Centre National de la Recherche Scientifique (CNRS)	Paccaud, JP (corresponding author), Univ Geneva, Med Ctr, Dept Morphol, CH-1211 Geneva, Switzerland.			Letourneur, Francois/0000-0003-2232-6127				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guthrie C, 1991, METHODS ENZYMOL, V194; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; James P, 1996, GENETICS, V144, P1425; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; MIZUNO M, 1994, J CELL SCI, V107, P1321; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377	46	100	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7833	7840		10.1074/jbc.274.12.7833	http://dx.doi.org/10.1074/jbc.274.12.7833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075675	hybrid			2022-12-27	WOS:000079268100034
J	Saucedo, LJ; Myers, CD; Perry, ME				Saucedo, LJ; Myers, CD; Perry, ME			Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; BINDING DOMAIN; P53; TRANSLATION; EXPRESSION; CELLS; AMPLIFICATION; TRANSCRIPTS	The mdm2 (murine double minute 2) oncogene encodes several proteins, the largest of which (p90) binds to and inactivates the p53 tumor suppressor protein. Multiple MDM2 proteins have been detected in tumors and in cell lines expressing high levels of mdm2 mRNAs, Here we show that one of these proteins (p76) is expressed, along with p90, in wild-type and p53-null mouse embryo fibroblasts, indicating that it may have an important physiological role in normal cells. Expression of this protein is induced, as is that of p90, by UV light in a p53-dependent manner. The p76 protein is synthesized via translational initiation at AUG codon 50 and thus lacks the N terminus of p90 and does not bind p53, In cells, p90 and p76 can be synthesized from mdm2 mRNAs transcribed from both the P1 (constitutive) and P2 (p53-responsive) promoters. Site-directed mutagenesis reveals that these RNAs give rise to p76 via internal initiation of translation. In addition, mdm2 mRNAs lacking exon 3 give rise to p76 exclusively, and such mRNAs are induced by p53 in response to UV light. These data indicate that p76 may be an important product of the mdm2 gene and a downstream effector of p53.	Univ Wisconsin, Mcardle Lab Canc Res 207A, Sch Med, Cell & Mol Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Perry, ME (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res 207A, Sch Med, Cell & Mol Biol Program, 1400 Univ Ave, Madison, WI 53706 USA.	perry@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [P30CA007175, T32CA009135] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09135, CA-70718, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kirchmaier AL, 1998, J VIROL, V72, P4657, DOI 10.1128/JVI.72.6.4657-4666.1998; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lane DP, 1996, ONCOGENE, V12, P2461; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McMasters KM, 1996, ONCOGENE, V13, P1731; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PAPWORTH C, 1995, STRATEGIES, V9, P3; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	41	34	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8161	8168		10.1074/jbc.274.12.8161	http://dx.doi.org/10.1074/jbc.274.12.8161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075719	hybrid			2022-12-27	WOS:000079268100078
J	Chapman, TL; You, I; Joseph, IM; Bjorkmann, PJ; Morrison, SL; Raghavan, M				Chapman, TL; You, I; Joseph, IM; Bjorkmann, PJ; Morrison, SL; Raghavan, M			Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL PROTEIN-A; C-GAMMA-2-C-GAMMA-3 INTERFACE REGION; RHEUMATOID-FACTOR BINDING; GLYCOPROTEIN-I; SUBCLASS SPECIFICITY; CRYSTAL-STRUCTURE; GENETIC CONTENT; INFECTED-CELLS; CHIMERIC IGG; COMPLEX	Herpes simplex virus type I (HSV-1) virions and HSV-1-infected cells bind to human immunoglobulin G (hIgG) via its Fc region. A complex of two surface glycoproteins encoded by HSV-1, gE and gI, is responsible for Fc binding. We have co-expressed soluble truncated forms of gE and gf in Chinese hamster ovary cells. Soluble gE-gI complexes can be purified from transfected cell supernatants using a purification scheme that is based upon the Fc receptor function of gE-gI. Using gel filtration and analytical ultracentrifugation, we determined that soluble gE-gI is a heterodimer composed of one molecule of gE and one molecule of gI and that gE-gI heterodimers bind hIgG with a 1:1 stoichiometry. Biosensor-based studies of the binding of wild type or mutant IgG proteins to soluble gE-gI indicate that histidine 435 at the C(H)2-C(H)3 domain interface of IgG is a critical residue for IgG binding to gE-gI, We observe many similarities between the characteristics of IgG binding by gE-gI and by rheumatoid factors and bacterial Fc receptors such as Staphylococcus aureus protein A. These observations support a model for the origin of some rheumatoid factors, in which they represent anti-idiotypic antibodies directed against antibodies to bacterial and viral Fc receptors.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 15629, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	University of Michigan System; University of Michigan; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of California System; University of California Los Angeles	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.	malinir@umich.edu						ADLER R, 1978, INFECT IMMUN, V21, P442, DOI 10.1128/IAI.21.2.442-447.1978; ALLEN JC, 1966, ARTHRITIS RHEUM, V9, P758, DOI 10.1002/art.1780090603; ARTANDI SE, 1991, J IMMUNOL, V146, P603; BALAN P, 1994, J GEN VIROL, V75, P1245, DOI 10.1099/0022-1317-75-6-1245; BANKS TA, 1992, CLIN INFECT DIS, V14, P933, DOI 10.1093/clinids/14.4.933; BAUCKE RB, 1979, J VIROL, V32, P779, DOI 10.1128/JVI.32.3.779-789.1979; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BELL S, 1990, J VIROL, V64, P2181, DOI 10.1128/JVI.64.5.2181-2186.1990; BONAGURA VR, 1993, J IMMUNOL, V151, P3840; BONAGURA VR, 1992, DNA CELL BIOL, V11, P245, DOI 10.1089/dna.1992.11.245; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; COOKE A, 1984, LANCET, V2, P723; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; COSTA JC, 1975, LANCET, V1, P77; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DINGWELL KS, 1994, J VIROL, V68, P834, DOI 10.1128/JVI.68.2.834-845.1994; DINGWELL KS, 1995, J VIROL, V69, P7087, DOI 10.1128/JVI.69.11.7087-7098.1995; DOWLER KW, 1984, J MED VIROL, V13, P251, DOI 10.1002/jmv.1890130307; DUBIN G, 1991, J VIROL, V65, P7046, DOI 10.1128/JVI.65.12.7046-7050.1991; DUBIN G, 1990, J VIROL, V64, P2725, DOI 10.1128/JVI.64.6.2725-2731.1990; DUBIN G, 1992, CURR TOP MICROBIOL, V179, P111; Favoreel HW, 1997, J VIROL, V71, P8254, DOI 10.1128/JVI.71.11.8254-8261.1997; FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODING LR, 1992, CELL, V71, P5; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Hashido M, 1997, MICROBIOL IMMUNOL, V41, P415, DOI 10.1111/j.1348-0421.1997.tb01872.x; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JOHANSSON PJH, 1994, IMMUNOLOGY, V83, P631; JOHANSSON PJH, 1984, J VIROL, V50, P796, DOI 10.1128/JVI.50.3.796-804.1984; JOHANSSON PJH, 1989, IMMUNOLOGY, V66, P8; JOHANSSON PJH, 1985, J VIROL, V56, P489, DOI 10.1128/JVI.56.2.489-494.1985; JOHANSSON PJH, 1990, APMIS, V98, P685, DOI 10.1111/j.1699-0463.1990.tb04989.x; JOHNSON DC, 1987, J VIROL, V61, P2208, DOI 10.1128/JVI.61.7.2208-2216.1987; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kimura H, 1997, VIROLOGY, V233, P382, DOI 10.1006/viro.1997.8625; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRONVALL G, 1969, J IMMUNOL, V103, P828; Lange H, 1996, EUR J IMMUNOL, V26, P2234, DOI 10.1002/eji.1830260940; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LEHNER T, 1975, LANCET, V2, P60; LEISBON PJ, 1997, IMMUNITY, V6, P655; LITWIN V, 1992, J VIROL, V66, P3643, DOI 10.1128/JVI.66.6.3643-3651.1992; LONGNECKER R, 1987, P NATL ACAD SCI USA, V84, P4303, DOI 10.1073/pnas.84.12.4303; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MCGEOCH DJ, 1987, J GEN VIROL, V68, P19, DOI 10.1099/0022-1317-68-1-19; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; METCALF JF, 1988, INTERVIROLOGY, V29, P39, DOI 10.1159/000150027; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; NARDELLA FA, 1985, J EXP MED, V162, P1811, DOI 10.1084/jem.162.6.1811; PARA MF, 1980, J VIROL, V34, P512, DOI 10.1128/JVI.34.2.512-520.1980; PETROVSKIS EA, 1986, J VIROL, V60, P185, DOI 10.1128/JVI.60.1.185-193.1986; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; PLOTZ PH, 1983, LANCET, V2, P824; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; STONE GC, 1989, J IMMUNOL, V143, P565; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; Sutton BJ, 1998, ADV EXP MED BIOL, V435, P41; Tirabassi RS, 1997, J VIROL, V71, P6455, DOI 10.1128/JVI.71.9.6455-6464.1997; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSUCHIYA N, 1990, J IMMUNOL, V144, P4742; WESTMORELAND D, 1974, J GEN VIROL, V24, P167, DOI 10.1099/0022-1317-24-1-167; WHEALY ME, 1993, J VIROL, V67, P3786, DOI 10.1128/JVI.67.7.3786-3797.1993; WIGER D, 1985, IMMUNOLOGY, V54, P565; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004	75	41	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6911	6919		10.1074/jbc.274.11.6911	http://dx.doi.org/10.1074/jbc.274.11.6911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066744	hybrid, Green Accepted			2022-12-27	WOS:000079078400016
J	Charles, AC; Piros, ET; Evans, CJ; Hales, TG				Charles, AC; Piros, ET; Evans, CJ; Hales, TG			L-type Ca2+ channels and K+ channels specifically modulate the frequency and amplitude of spontaneous Ca2+ oscillations and have distinct roles in prolactin release in GH(3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; ADRENAL CHROMAFFIN CELLS; INTRACELLULAR CALCIUM; NEUROENDOCRINE CELLS; ELECTRICAL-ACTIVITY; POTASSIUM CURRENT; OPIOID RECEPTORS; GH3 CELLS; RAT; HORMONE	GH(3) cells showed spontaneous rhythmic oscillations in intracellular calcium concentration ([Ca2+](i)) and spontaneous prolactin release. The L-type Ca2+ channel inhibitor nimodipine reduced the frequency of Ca2+ oscillations at lower concentrations (100nm-1 mu M), whereas at higher concentrations (10 mu M), it completely abolished them. Ca2+ oscillations persisted following exposure to thapsigarsn, indicating that inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ stores were not required for spontaneous activity. The K+ channel inhibitors Ba2+, Cs+, and tetraethylammonium (TEA) had distinct effects on different K+ currents, as well as on Ca2+ oscillations and prolactin release. Cs+ inhibited the inward rectifier K+ current (K-IR) and increased the frequency of Ca2+ oscillations. TEA inhibited outward K+ currents activated at voltages above -40 mV (grouped within the category of Ca2+ and voltage-activated currents, K-Ca,K-V) and increased the amplitude of Ca2+ oscillations. Ba2+ inhibited both K-IR and K-Ca,K-V and increased both the amplitude and the frequency of Ca2+ oscillations. Prolactin release was increased by Ba2+ and Cs+ but not by TEA. These results indicate that L-type Ca2+ channels and K-IR channels modulate the frequency of Ca2+ oscillations and prolactin release, whereas TEA-sensitive K-Ca,K-V channels modulate the amplitude of Ca2+ oscillations without altering prolactin release. Differential regulation of these channels can produce frequency or amplitude modulation of calcium signaling that stimulates specific pituitary cell functions.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Cornell Univ, Dept Physiol, New York, NY 10021 USA; Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Dept Psychiat, Los Angeles, CA 90095 USA; George Washington Univ, Dept Pharmacol, Washington, DC 20037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cornell University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; George Washington University	Charles, AC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS002808, R29NS032283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05010, P50 DA005010] Funding Source: Medline; NINDS NIH HHS [P01-NS 02808, R29 NS32283] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barros F, 1996, PFLUG ARCH EUR J PHY, V431, P443, DOI 10.1007/BF02207284; BARROS F, 1994, PFLUG ARCH EUR J PHY, V426, P221, DOI 10.1007/BF00374775; BARROS F, 1992, PFLUG ARCH EUR J PHY, V422, P31, DOI 10.1007/BF00381510; BAUER CK, 1994, PFLUG ARCH EUR J PHY, V428, P17, DOI 10.1007/BF00374747; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUBINSKY JM, 1985, P NATL ACAD SCI USA, V82, P4282, DOI 10.1073/pnas.82.12.4282; Engisch KL, 1997, J NEUROSCI, V17, P9010; Giovannucci DR, 1997, J PHYSIOL-LONDON, V498, P735, DOI 10.1113/jphysiol.1997.sp021898; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; KUKULJAN M, 1994, J BIOL CHEM, V269, P4860; Kukuljan M, 1997, BIOPHYS J, V72, P698, DOI 10.1016/S0006-3495(97)78706-X; LI YX, 1995, BIOPHYS J, V69, P785, DOI 10.1016/S0006-3495(95)79952-0; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; MALGAROLI A, 1991, FEBS LETT, V283, P169, DOI 10.1016/0014-5793(91)80580-V; Mansvelder HD, 1998, J NEUROSCI, V18, P81; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MASUMOTO N, 1995, CELL CALCIUM, V18, P223, DOI 10.1016/0143-4160(95)90067-5; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MIKI H, 1995, ENDOCRINOLOGY, V136, P2954, DOI 10.1210/en.136.7.2954; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; OXFORD GS, 1989, J PHYSIOL-LONDON, V410, P587, DOI 10.1113/jphysiol.1989.sp017550; Piros ET, 1996, MOL PHARMACOL, V50, P947; PIROS ET, 1995, MOL PHARMACOL, V47, P1041; RITCHIE AK, 1987, J PHYSIOL-LONDON, V385, P611, DOI 10.1113/jphysiol.1987.sp016510; ROGAWSKI MA, 1989, MOL PHARMACOL, V35, P458; SCHERUBL H, 1994, ANN NY ACAD SCI, V733, P335, DOI 10.1111/j.1749-6632.1994.tb17283.x; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHANGOLD GA, 1985, LIFE SCI, V36, P2209, DOI 10.1016/0024-3205(85)90331-5; SIMASKO SM, 1991, AM J PHYSIOL, V261, pE66, DOI 10.1152/ajpendo.1991.261.1.E66; SIMASKO SM, 1988, AM J PHYSIOL, V254, pE328, DOI 10.1152/ajpendo.1988.254.3.E328; STOJILKOVIC SS, 1994, MOL PHARMACOL, V45, P1013; Thomas P, 1997, J PHYSIOL-LONDON, V504, P705, DOI 10.1111/j.1469-7793.1997.705bd.x; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; VARNEY MA, 1994, BRIT J PHARMACOL, V112, P390, DOI 10.1111/j.1476-5381.1994.tb13084.x; Varro A, 1996, BBA-MOL CELL RES, V1313, P101, DOI 10.1016/0167-4889(96)00056-0; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175	45	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7508	7515		10.1074/jbc.274.11.7508	http://dx.doi.org/10.1074/jbc.274.11.7508			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066818	hybrid			2022-12-27	WOS:000079078400090
J	Webb, DJ; Nguyen, DHD; Sankovic, M; Gonias, SL				Webb, DJ; Nguyen, DHD; Sankovic, M; Gonias, SL			The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PSEUDOMONAS EXOTOXIN-A; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; MEDIATES ENDOCYTOSIS; PROTEIN BINDS; INHIBITOR COMPLEX; EPITHELIAL-CELLS; SERPIN COMPLEXES; 39-KDA PROTEIN	The very low density lipoprotein receptor (VLDLr) binds diverse ligands, including urokinase-type plasminogen activator (uPA) and uPA-plasminogen activator inhibitor-1 (PAI-1) complex. In this study, we characterized the effects of the VLDLr on the internalization, catabolism, and function of the uPA receptor (uPAR) in MCF-7 and MDA-MB-435 breast cancer cells. When challenged with uPA . PAI-1 complex, MDA-MB-435 cells internalized uPAR; this process was inhibited by 80% when the activity of the VLDLr was neutralized with receptor-associated protein (RAP), To determine whether internalized uPAR is degraded, we studied the catabolism of [S-35]methionine-labeled uPAR. In the absence of exogenous agents, the uPAR catabolism t(1/2) was 8.2 h. uPA . PAI-1 complex accelerated uPAR catabolism (t(1/2) to 1.8 h), while RAP inhibited uPAR catabolism in the presence (t(1/2) of 7.8 h) and absence (t(1/2) of 16.9 h) of uPA . PAI-1 complex, demonstrating a critical role for the VLDLr, When MCF-7 cells were cultured in RAP, cell surface uPAR levels increased gradually, reaching a new steady-state in 3 days, The amount of uPA which accumulated in the medium also increased. Culturing in RAP for 3 days increased MCF-7 cell motility by 2.2 +/- 0.1-fold and by 4.4 +/- 0.3-fold when 1.0 nm uPA was added. The effects of RAP on MCF-7 cell motility were entirely abrogated by an antibody which binds uPA and prevents uPA binding to uPAR. MCF-7 cells that were cultured in RAP demonstrated increased levels of activated mitogen-activated protein kinases, Furthermore, the MEK inhibitor, PD098059, decreased the motility of RAP-treated cells without affecting control cultures. These studies suggest a model in which the VLDLr regulates autocrine uPAR-initiated signaling and thereby regulates cellular motility.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Box 214, Charlottesville, VA 22908 USA.	SLG2T@VIRGINIA.EDU			NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CHUCHOLOWSKI N, 1992, FIBRINOLYSIS, V6, P95; CONESE M, 1995, BAILLIERE CLIN HAEM, V8, P365, DOI 10.1016/S0950-3536(05)80273-2; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Fichtner I, 1997, ANTICANCER RES, V17, P3633; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Silvy M, 1998, ENDOCRINOLOGY, V139, P2382, DOI 10.1210/en.139.5.2382; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TELEN MJ, 1984, BLOOD, V64, P599; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Weaver AM, 1997, J LIPID RES, V38, P1841; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	55	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7412	7420		10.1074/jbc.274.11.7412	http://dx.doi.org/10.1074/jbc.274.11.7412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066806	hybrid			2022-12-27	WOS:000079078400078
J	Edwards, AS; Faux, MC; Scott, JD; Newton, AC				Edwards, AS; Faux, MC; Scott, JD; Newton, AC			Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C beta II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PHORBOL ESTERS; IN-VIVO; PERMISSIVE ACTIVATION; NEGATIVE CHARGE; ALPHA; AUTOPHOSPHORYLATION; INACTIVATION; BINDING	Protein kinase C is processed by three phosphorylation events before it is competent to respond to second messengers. Specifically, the enzyme is first phosphorylated at the activation loop by another kinase, followed by two ordered autophosphorylations at the carboxyl terminus (Keranen, L, M,, Dutil, E, M,, and Newton, A. C, (1995) Curr, Biol, 5, 1394-1403). This study examines the role of negative charge at the first conserved carboxyl-terminal phosphorylation position, Thr-641, in regulating the function and subcellular localization of protein kinase C beta II Mutation of this residue to Ala results in compensating phosphorylations at adjacent sites, so that a triple Ala mutant was required to address the function of phosphate at Thr-641, Biochemical and immunolocalization analyses of phosphorylation site mutants reveal that negative charge at this position is required for the following: 1) to process catalytically competent protein kinase C; 2) to allow autophosphorylation of Ser-660; 3) for cytosolic localization of protein kinase C; and 4) to permit phorbol ester-dependent membrane translocation. Thus, phosphorylation of Thr-641 in protein kinase C beta II is essential for both the catalytic function and correct subcellular localization of protein kinase C, The conservation of this residue in every protein kinase C isozyme, as well as other members of the kinase superfamily such as protein kinase A, suggests that carboxyl-terminal phosphorylation serves as a key molecular switch for defining kinase function.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; Oregon Health & Science University	Newton, AC (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R01GM048231, R37GM043154, R37GM048231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154, GM 48231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7564; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	46	105	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6461	6468		10.1074/jbc.274.10.6461	http://dx.doi.org/10.1074/jbc.274.10.6461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037738	hybrid			2022-12-27	WOS:000078902800060
J	Kallio, PJ; Wilson, WJ; O'Brien, S; Makino, Y; Poellinger, L				Kallio, PJ; Wilson, WJ; O'Brien, S; Makino, Y; Poellinger, L			Regulation of the hypoxia-inducible transcription factor 1 alpha by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PROTEIN-DEGRADATION; FACTOR-I; ERYTHROPOIETIN GENE; ALPHA-SUBUNIT; C-JUN; ACTIVATION; DOMAIN; STABILIZATION; LACTACYSTIN; RECRUITMENT	HIF-1 alpha (hypoxia-inducible factor 1 alpha) is a basic-helix-loop-helix PAS (Per/Arnt/Sim) transcription factor that, under hypoxic conditions, dimerizes with a partner factor, the basic-helix-loop-helix/PAS protein Arnt, to recognize hypoxia-responsive elements of target genes. It has recently been demonstrated that HLF-1 alpha protein but not mRNA levels are dramatically up-regulated in response to hypoxia, Here we show that inhibitors of 26 S proteasome activity produced a dramatic accumulation of endogenous as well as transfected HIF-1 alpha protein under normoxic conditions, whereas the levels of Amt protein were not affected. HIF-1 alpha was polyubiquitinated in vivo under normoxic conditions, indicating rapid degradation via the ubiquitin-proteasome pathway. This degradation process appeared to target a region within the C terminus of HIF-1 alpha. Importantly, HIF-1 alpha ubiquitination was drastically decreased under hypoxic conditions. Up-regulation of HIF-1 alpha protein by proteasome inhibitors did not result in transcriptional activation of reporter genes, indicating either the requirement of additional regulatory steps to induce functional activity of HIF-1 alpha: or the inability of polyubiquitinated forms of HIF-1 alpha to mediate hypoxic signal transduction, In support of both these notions, we demonstrate that HIF-1 alpha showed hypoxia-dependent translocation from the cytoplasm to the nucleus and that this regulatory mechanism was severely impaired in the presence of proteasome inhibitors. Taken together, these data demonstrate that the mechanism of hypoda-dependent activation of HIF-1 alpha is a complex multistep process and that stabilization of HIF-1 alpha protein levels is not sufficient to generate a functional form.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.		Wilson, William/A-3631-2009	Wilson, William/0000-0001-5658-0997				CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; MURAKAMI Y, 1992, NATURE, V360, P587; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pugh CW, 1997, J BIOL CHEM, V272, P11205; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609	28	658	697	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6519	6525		10.1074/jbc.274.10.6519	http://dx.doi.org/10.1074/jbc.274.10.6519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037745	hybrid			2022-12-27	WOS:000078902800067
J	Kendall, RL; Rutledge, RZ; Mao, X; Tebben, AJ; Hungate, RW; Thomas, KA				Kendall, RL; Rutledge, RZ; Mao, X; Tebben, AJ; Hungate, RW; Thomas, KA			Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; KINETIC MECHANISM; SIGNAL-TRANSDUCTION; DOMAIN; PHOSPHORYLATION; ANGIOGENESIS; INHIBITION; EXPRESSION; BINDING; IDENTIFICATION	Vascular endothelial growth factor is an important physiological regulator of angiogenesis, The function of this endothelial cell selective growth factor is mediated by two homologous tyrosine kinase receptors, fms-like tyrosine kinase 1 (Flt-1) and kinase domain receptor (KDR). Although the functional consequence of vascular endothelial growth factor binding to the Flt-1 receptor is not fully understood, it is well established that mitogenic signaling is mediated by KDR, Upon sequencing several independent cDNA clones spanning the cytoplasmic region of human KDR, we identified and confirmed the identity of a functionally required valine at position 848 in the ATP binding site, rather than the previously reported glutamic acid residue, which corresponds to an inactive tyrosine kinase, The cytoplasmic domain of recombinant native KDR, expressed as a glutathione S-transferase fusion protein, can undergo autophosphorylation in the presence of ATP. In addition, the kinase activity can be substantially increased by autophosphorylation at physiologic ATP concentrations. Mutation analysis indicates that both tyrosine residues 1054 and 1059 are required for activation, which is a consequence of an increased affinity for both ATP and the peptide substrate and has no effect on k(cat), the intrinsic catalytic activity of the enzyme. KDR kinase catalyzes phosphotransfer by formation of a ternary complex with ATP and the peptide substrate. We demonstrate that tyrosine kinase antagonists can preferentially inhibit either the unactivated or activated form of the enzyme.	Merck Res Labs, Dept Canc Res, W Point, PA 19486 USA; Merck Res Labs, Dept Mol Design & Divers, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Kendall, RL (corresponding author), Merck Res Labs, Dept Canc Res, 16-101, W Point, PA 19486 USA.							AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; APRELIKOVA O, 1992, CANCER RES, V52, P746; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; HARDIE G, 1995, PROTEIN KINASE FACTS, P7; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KNIGHT WB, 1989, BIOCHEMISTRY-US, V28, P5728, DOI 10.1021/bi00440a005; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; LONGATI P, 1994, ONCOGENE, V9, P49; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; *MOL APPL GROUP, 1995, LOOK VERS 2 0; *MOL SIM INC, 1997, QUANTA97; PARK JE, 1994, J BIOL CHEM, V269, P25646; POSNER I, 1992, J BIOL CHEM, V267, P20638; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; RONNSTRAND L, 1990, BIOCHEM BIOPH RES CO, V167, P1333, DOI 10.1016/0006-291X(90)90669-E; Segel I. H., 1975, ENZYME KINETICS, P273; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALKER DH, 1987, BIOCHEMISTRY-US, V26, P1428, DOI 10.1021/bi00379a033; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WILDEN PA, 1992, J BIOL CHEM, V267, P16660	45	102	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6453	6460		10.1074/jbc.274.10.6453	http://dx.doi.org/10.1074/jbc.274.10.6453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037737	hybrid			2022-12-27	WOS:000078902800059
J	Treuter, E; Johansson, L; Thomsen, JS; Warnmark, A; Leers, J; Pelto-Huikko, M; Sjoberg, M; Wright, APH; Spyrou, G; Gustafsson, JA				Treuter, E; Johansson, L; Thomsen, JS; Warnmark, A; Leers, J; Pelto-Huikko, M; Sjoberg, M; Wright, APH; Spyrou, G; Gustafsson, JA			Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors - Implications for the recruitment of trap and P160 coactivator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASES; CBP; ACTIVATION; DOMAIN; ACID; TRANSACTIVATION; HETERODIMERS; COREPRESSORS	Transcriptional activation by nuclear receptors (NRs) involves the concerted action of coactivators, chromatin components, and the basal transcription machinery. Crucial NR coactivators, which target primarily the conserved ligand-regulated activation (AF-2) domain, include p160 family members, such as TIF2, as well as p160-associated coactivators, such as CBP/p300. Because these coactivators possess intrinsic histone acetyltransferase activity, they are believed to function mainly by regulating chromatin-dependent transcriptional activation. Recent evidence suggests the existence of an additional NR coactivator complex, referred to as the thyroid hormone receptor-associated protein (TRAP) complex, which may function more directly as a bridging complex to the basal transcription machinery. TRAP220, the 220-kDa NR-binding subunit of the complex, has been identified in independent studies using both biochemical and genetic approaches. In light of the functional differences identified between p160 and TRAP coactivator complexes in NR activation, we have attempted to compare interaction and functional characteristics of TIF 2 and TRAP220. Our findings imply that competition between the NR-binding subunits of distinct coactivator complexes may act as a putative regulatory step in establishing either a sequential activation cascade or the formation of independent coactivator complexes.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Tampere University; Tampere University Hospital; Tampere University; Karolinska Institutet	Treuter, E (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	eckardt.treuter@csb.ki.se	Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969; thomsen, jane/0000-0002-9336-5695; Treuter, Eckardt/0000-0002-4147-8989				Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Cheng K, 1997, J ROY SOC MED, V90, P6, DOI 10.1177/014107689709031S03; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wiebel FF, 1997, MOL CELL BIOL, V17, P3977, DOI 10.1128/MCB.17.7.3977; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	56	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6667	6677		10.1074/jbc.274.10.6667	http://dx.doi.org/10.1074/jbc.274.10.6667			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037764	hybrid			2022-12-27	WOS:000078902800086
J	Araujo, FD; Knox, JD; Ramchandani, S; Pelletier, R; Bigey, P; Price, G; Szyf, M; Zannis-Hadjopoulos, M				Araujo, FD; Knox, JD; Ramchandani, S; Pelletier, R; Bigey, P; Price, G; Szyf, M; Zannis-Hadjopoulos, M			Identification of initiation sites for DNA replication in the human dnmt1 (DNA-methyltransferase) locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; C-MYC GENE; AUTONOMOUS REPLICATION; DELETION ANALYSIS; METHYLATED DNA; MONKEY DNA; ORIGIN; SEQUENCE; BINDING; CELLS	Vertebrates have developed multiple mechanisms to coordinate the replication of epigenetic and genetic information. Dnmt1 encodes the maintenance enzyme DNA-methyltransferase, which is responsible for propagating the DNA methylation pattern and the epigenetic information that it encodes during replication. Direct sequence analysis and bisulfite mapping of the 5' region of DNA-methyltransferase 1 (dnmt1) have indicated the presence of many sequence elements associated with previously characterized origins of DNA replication. This study tests the hypothesis that the dnmt1 region containing these elements is an origin of replication in human cells. First, we demonstrate that a vector containing this dnmt1 sequence is able to support autonomous replication when transfected into HeLa cells. Second, using a gel retardation assay, we show that it contains a site for binding of origin-rich sequences binding activity, a recently purified replication protein. Finally, using competitive polymerase chain reaction, we show that replication initiates in this region in vivo, Based on these lines of evidence, we propose that initiation sites for DNA replication are located between the first intron and exon 7 of the human dnmt1 locus.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.			bigey, pascal/0000-0002-6795-8569				Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; FRAPPIER L, 1987, P NATL ACAD SCI USA, V84, P6668, DOI 10.1073/pnas.84.19.6668; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HEINZEL SS, 1991, MOL CELL BIOL, V11, P2263, DOI 10.1128/MCB.11.4.2263; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KIPLING D, 1990, MOL CELL BIOL, V10, P265, DOI 10.1128/MCB.10.1.265; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; LANDRY S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P234, DOI 10.1016/0167-4781(91)90059-U; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; ORRWEAVER TL, 1991, BIOESSAYS, V13, P97, DOI 10.1002/bies.950130302; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Pelletier R, 1997, J CELL BIOCHEM, V66, P87; Ramchandani S, 1998, BIOL CHEM, V379, P535; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; RUIZ MT, 1995, J CELL BIOCHEM, V58, P221, DOI 10.1002/jcb.240580211; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; Yisraeli J., 1984, DNA METHYLATION BIOC; Zannis-Hadjopoulos M, 1998, CRIT REV EUKAR GENE, V8, P81, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.40; ZANNISHADJOPOULOS M, 1994, GENE, V151, P273, DOI 10.1016/0378-1119(94)90670-X; ZANNISHADJOPOULOS M, 1981, CELL, V27, P155, DOI 10.1016/0092-8674(81)90369-X	41	37	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9335	9341		10.1074/jbc.274.14.9335	http://dx.doi.org/10.1074/jbc.274.14.9335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092611	hybrid			2022-12-27	WOS:000079451800030
J	Forster, C; Santos, MA; Ruffert, S; Kramer, R; Revuelta, JL				Forster, C; Santos, MA; Ruffert, S; Kramer, R; Revuelta, JL			Physiological consequence of disruption of the VMA1 gene in the riboflavin overproducer Ashbya gossypii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; CATALYTIC SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MUTATIONAL ANALYSIS; SECRETORY PATHWAY; ENZYME COMPLEX; AMINO-ACIDS	The vacuolar ATPase subunit A structural gene VMA1 of the biotechnologically important riboflavin overproducer Ashbya gossypii was cloned and disrupted to prevent riboflavin retention in the vacuolar compartment and to redirect the riboflavin flux into the medium, Cloning was achieved by polymerase chain reaction using oligonucleotide primers derived form conserved sequences of the Vma1 proteins from yeast and filamentous fungi, The deduced polypeptide comprises 617 amino acids with a calculated molecular mass of 67.8 kDa. The deduced amino acid sequence is highly similar to that of the catalytic subunits of Saccharomyces cerevisiae (67 kDa), Candida tropicalis (67 kDa), and Neurospora crassa (67 kDa) with 89, 87, and 60% identity, respectively, and shows about 25% identity to the beta-subunit of the FoF1-ATPase of S. cerevisiae and Schizosaccharomyces pombe. In contrast to S. cerevisiae, however, where disruption of the VMA1 gene was conditionally lethal, and to N. crassa, where viable disruptants could not be isolated, disruption of the VMA1 gene in A. gossypii did not cause a lethal phenotype, Disruption of the AgVMA1 gene led to complete excretion of riboflavin into the medium instead of retention in the vacuolar compartment, as observed in the wild type.	Univ Cologne, Inst Biochem, D-0674 Cologne, Germany; Univ Salamanca, Dept Microbiol & Genet, Salamanca 37007, Spain	University of Cologne; University of Salamanca	Kramer, R (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-0674 Cologne, Germany.		Santos, Maria Angeles/H-2239-2015; Revuelta, Jose Luis/ABG-1502-2020; Revuelta, Jose L/C-2324-2012	Santos, Maria Angeles/0000-0002-1257-7611; Revuelta, Jose Luis/0000-0001-7838-5308; Revuelta, Jose L/0000-0001-7838-5308				Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1982, J BACTERIOL, V151, P1326, DOI 10.1128/JB.151.3.1326-1337.1982; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CARNICERO E, 1996, THESIS U SALAMANCA S; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CONONICO PG, 1969, J CELL BIOL, V43, P367; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ferea TL, 1996, GENETICS, V143, P147; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forster C, 1998, FEMS MICROBIOL LETT, V167, P209; GHISLAIN M, 1992, YEAST, V8, P791, DOI 10.1002/yea.320080913; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; GU HH, 1993, J BIOL CHEM, V268, P7372; GUILLIERMOND P, 1928, REV GEN BOT, V40, P328; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; Roos W, 1997, J BIOL CHEM, V272, P15849, DOI 10.1074/jbc.272.25.15849; RUSSO P, 1995, YEAST, V11, P447, DOI 10.1002/yea.320110507; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmidt G, 1996, MICROBIOL-SGM, V142, P419, DOI 10.1099/13500872-142-2-419; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STEINER S, 1995, GENETICS, V140, P973; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; WEISS RL, 1976, J BACTERIOL, V126, P1173, DOI 10.1128/JB.126.3.1173-1179.1976	59	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9442	9448		10.1074/jbc.274.14.9442	http://dx.doi.org/10.1074/jbc.274.14.9442			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092625	hybrid			2022-12-27	WOS:000079451800044
J	Horton, ND; Biswal, SS; Corrigan, LL; Bratta, J; Kehrer, JP				Horton, ND; Biswal, SS; Corrigan, LL; Bratta, J; Kehrer, JP			Acrolein causes inhibitor kappa B-independent decreases in nuclear factor kappa B activation in human lung adenocarcinoma (A549) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; INTRACELLULAR GLUTATHIONE; DNA; TRANSCRIPTION; TOXICITY; BINDING; THIOLS; GROWTH; P50; CYCLOPHOSPHAMIDE	Acrolein is a highly electrophilic alpha,beta-unsaturated aldehyde to which humans are exposed in various situations. In the present study, the effects of sublethal doses of acrolein on nuclear factor kappa B (NF-kappa B) activation in A549 human lung adenocarcinoma cells were investigated. Immediately following a 30-min exposure to 45 fmol of acrolein/cell, glutathione (GSH) and DNA synthesis and NF-kappa B binding mere reduced by more than 80%. All parameters returned to normal or supranormal levels by 8 h post-treatment. Pretreatment with acrolein completely blocked 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced activation of NF-kappa B. Cells treated for 1 h with 1 mM diethyl maleate (DEM) showed a 34 and 53% decrease in GSH and DNA synthesis, respectively, DEM also reduced NF-kappa B activation by 64% at 2 h post-treatment, with recovery to within 22% of control at 8 h, Both acrolein and DEM decreased NF-kappa B function similar to 50% at 2 h after treatment with TPA, as shown by a secreted alkaline phosphatase reporter assay. GSH: returned to control levels by 8 h after DEM treatment, but proliferation remained significantly depressed for 24 h, Interestingly, DEM caused a profound decrease in NF-kappa B binding, even at doses as low as 0.125 mM that had little effect on GSH. Neither acrolein nor DEM had any effect on the levels of phosphorylated or nonphosphorylated inhibitor kappa B-alpha: (I kappa B-alpha), Furthermore, acrolein decreased NF-kappa B activation in cells depleted of I kappa B-alpha by TPA stimulation in the presence of cycloheximide:, demonstrating that the decrease in NF-kappa B activation was not the result of increased binding by the inhibitory protein. This conclusion was further supported by the finding that acrolein modified NF-kappa B in the cytosol prior to chemical dissociation from I kappa B with detergent, Together, these data support the conclusion that the inhibition of NF-kappa B activation by acrolein and DEM is I kappa B-independent. The mechanism appears to be related to direct modification of thiol groups in the NF-kappa B subunits.	Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Kehrer, JP (corresponding author), Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA.	kehrerjim@mail.utexas.edu			NHLBI NIH HHS [HL48035] Funding Source: Medline; NIEHS NIH HHS [1 F32 ES05825, ES07784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, F32ES005825] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATZORI L, 1994, EXP CELL RES, V211, P115, DOI 10.1006/excr.1994.1066; Ausbel FM, 1994, CURRENT PROTOCOLS MO; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BOWES RC, 1995, ARCH BIOCHEM BIOPHYS, V323, P243, DOI 10.1006/abbi.1995.9968; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; COOPER KO, 1992, FUND APPL TOXICOL, V19, P343, DOI 10.1016/0272-0590(92)90172-E; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FRANCELEYNE M, 1982, TOXICOL LETT, V14, P143; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; GRAFSTROM RC, 1990, MUTAT RES, V238, P175, DOI 10.1016/0165-1110(90)90009-Z; GRAFSTROM RC, 1988, CANCER RES, V48, P1717; GRILLI M, 1993, INT REV CYTOL, V143, P1; KANG YJ, 1990, EXP CELL RES, V187, P177, DOI 10.1016/0014-4827(90)90134-V; KARSTEN U, 1977, ANAL BIOCHEM, V77, P464, DOI 10.1016/0003-2697(77)90259-7; KROKAN H, 1985, CARCINOGENESIS, V6, P1755, DOI 10.1093/carcin/6.12.1755; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARANO F, 1976, EXPERIENTIA, V32, P501, DOI 10.1007/BF01920821; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MOULE Y, 1971, FEBS LETT, V16, P216, DOI 10.1016/0014-5793(71)80137-0; Nath RG, 1996, CANCER RES, V56, P452; NEUSCHWANDERTETRI BA, 1989, ANAL BIOCHEM, V179, P236, DOI 10.1016/0003-2697(89)90121-8; Norton ND, 1997, TOXICOLOGY, V122, P111, DOI 10.1016/S0300-483X(97)00086-3; OHNO Y, 1985, ARCH TOXICOL, V57, P99, DOI 10.1007/BF00343118; PATEL JM, 1993, TOXICOL APPL PHARM, V122, P46, DOI 10.1006/taap.1993.1170; PERRY CS, 1995, TOXICOL IN VITRO, V9, P21, DOI 10.1016/0887-2333(94)00187-Y; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Ramu K, 1996, TOXICOL APPL PHARM, V140, P487, DOI 10.1006/taap.1996.0245; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SMITH RA, 1990, CANCER RES, V50, P3005; Snapper CM, 1996, J IMMUNOL, V156, P183; SONNENSHEIN GE, 1997, SEMIN CANCER BIOL, V8, P113; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WU HY, 1994, J BIOL CHEM, V269, P20067	51	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9200	9206		10.1074/jbc.274.14.9200	http://dx.doi.org/10.1074/jbc.274.14.9200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092592	hybrid			2022-12-27	WOS:000079451800011
J	Liochev, SI; Benov, L; Touati, D; Fridovich, I				Liochev, SI; Benov, L; Touati, D; Fridovich, I			Induction of the soxRS regulon of Escherichia coli by superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS REGULON; IN-VIVO; DISMUTASE; GENE; TRANSCRIPTION; FORM	The soxRS regulon orchestrates a multifaceted defense against oxidative stress, by inducing the transcription of similar to 15 genes. The induction of this regulon by redox agents, known to mediate O radical anion production, led to the view that O2 radical anion is one signal to which it responds. However, redox cycling agents deplete cellular reductants while producing O2 radical anion, and one may question whether the regulon responds to the depletion of some cytoplasmic reductant or to O2 radical anion, or both. We demonstrate that raising [O2 radical anion] by mutational deletion of superoxide dismutases and/or by addition of paraquat, both under aerobic conditions, causes induction of a member of the soxRS regulon and that a mutational defect in soxRS eliminates that induction. This establishes that O2 radical anion, directly or indirectly, can cause induction of this defensive regulon.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Paris 06, Dept Microbiol, Inst Jacques Monod, CNRS, F-75252 Paris 05, France; Univ Paris 07, Dept Microbiol, Inst Jacques Monod, CNRS, F-75252 Paris 05, France	Duke University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; Liochev SI, 1997, P NATL ACAD SCI USA, V94, P2891, DOI 10.1073/pnas.94.7.2891; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992	25	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9479	9481		10.1074/jbc.274.14.9479	http://dx.doi.org/10.1074/jbc.274.14.9479			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092630	hybrid			2022-12-27	WOS:000079451800049
J	Tornquist, K; Malm, AM; Pasternack, M; Kronqvist, R; Bjorklund, S; Tuominen, R; Slotte, JP				Tornquist, K; Malm, AM; Pasternack, M; Kronqvist, R; Bjorklund, S; Tuominen, R; Slotte, JP			Tumor necrosis factor-alpha, sphingomyelinase, and ceramide inhibit store-operated calcium entry in thyroid FRTL-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR-KAPPA-B; IODIDE EFFLUX; FACTOR-BETA; EPITHELIAL-CELLS; INTERFERON-GAMMA; HL-60 CELLS; CA2+ ENTRY; THYROTROPIN; SPHINGOSINE	Tumor necrosis factor alpha (TNF-alpha) is a potent inhibitor of proliferation in several cell types, including thyroid FRTL-5 cells. As intracellular free calcium ([Ca2+](i)) is a major signal in activating proliferation, we investigated the effect of TNF-alpha on calcium fluxes in FRTL-5 cells, TNF-alpha per se did not modulate resting [Ca2+](i). However, preincubation (10 min) of the cells with 1-100 ng/ml TNF-alpha decreased the thapsigargin (Tg)-evoked store-operated calcium entry in a concentration-dependent manner. TNF-alpha did not inhibit the mobilization of sequestered calcium, To investigate whether the effect of TNF-alpha on calcium entry was mediated via the sphingomyelinase pathway, the cells were pretreated with sphingomyelinase (SMase) prior to stimulation with Tg. SMase inhibited the Tg-evoked calcium entry in a concentration-dependent manner. Furthermore, an inhibition of calcium entry was obtained after preincubation of the cells with the membrane-permeable C-2-ceramide and C-6-ceramide analogues, The inactive ceramides dihydro-C-2 and dihydro-C-6 showed only marginal effects, Neither SMase, C-2-ceramide, nor C-6-ceramide affected the release of sequestered calcium. C-2- and C-6-ceramide also decreased the ATP-evoked calcium entry, without affecting the release of sequestered calcium. The effect of TNF-alpha and SMase was inhibited by the kinase inhibitor staurosporin and by the protein kinase C (PKC) inhibitor calphostin C but not by down-regulation of PKC. However, Ive were unable to measure a significant activation of PKC using TNF-alpha or C-6-ceramide, The effect of TNF-alpha was not mediated via activation of either c-Sun N-terminal kinase or p38 kinase, We were unable to detect an increase in the ceramide (or sphingosine) content of the cells after stimulation with TNF-alpha for up to 30 min, Thus, one mechanism of action of TNF-alpha; SMase, and ceramide on thyroid FRTL-5 cells is to inhibit calcium entry.	Abo Akad Univ, Dept Biol, Turku 20520, Finland; Abo Akad Univ, Dept Biochem & Pharm, Turku 20520, Finland; Univ Helsinki, Dept Pharmacol & Toxicol, Inst Biomed, Helsinki 00250, Finland; Univ Helsinki, Dept Biosci, Div Anim Physiol, Helsinki 00250, Finland; Univ Helsinki, Inst Biotechnol, Helsinki 00250, Finland; Minerva Fdn, Inst Med Res, SF-00250 Helsinki, Finland	Abo Akademi University; Abo Akademi University; University of Helsinki; University of Helsinki; University of Helsinki	Tornquist, K (corresponding author), Abo Akad Univ, Dept Biol, BioCity,Artillerigatan 6, Turku 20520, Finland.	kid.tornqvist@abo.fi						AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHEN GE, 1992, ENDOCRINOLOGY, V131, P863, DOI 10.1210/en.131.2.863; CORDA D, 1985, J BIOL CHEM, V260, P9230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Haverstick DM, 1997, J BIOL CHEM, V272, P15426, DOI 10.1074/jbc.272.24.15426; Hida H, 1998, J NEUROSCI, V18, P8712; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; Kimura T, 1997, AM J PHYSIOL-ENDOC M, V273, pE638, DOI 10.1152/ajpendo.1997.273.3.E638; KWAN CY, 1990, J BIOL CHEM, V265, P678; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; Mori K, 1996, ENDOCRINOLOGY, V137, P4994, DOI 10.1210/en.137.11.4994; Okajima F, 1997, ENDOCRINOLOGY, V138, P220, DOI 10.1210/en.138.1.220; ONGPHIPHADHANAKUL B, 1994, EUR J ENDOCRINOL, V130, P502, DOI 10.1530/eje.0.1300502; Orlati S, 1996, CELL CALCIUM, V20, P399, DOI 10.1016/S0143-4160(96)90002-0; OZAWA M, 1988, ENDOCRINOLOGY, V123, P1461, DOI 10.1210/endo-123-3-1461; PANG XP, 1993, THYROID, V3, P325, DOI 10.1089/thy.1993.3.325; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PANG XP, 1992, J BIOL CHEM, V267, P12826; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PATWARDHAN NA, 1991, SURGERY, V110, P972; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RASMUSSEN AK, 1994, J ENDOCRINOL, V143, P359, DOI 10.1677/joe.0.1430359; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAMBASIVARAO K, 1963, J LIPID RES, V4, P106; SATO K, 1990, J CLIN ENDOCR METAB, V70, P1735, DOI 10.1210/jcem-70-6-1735; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAM VK, 1988, AM J PHYSIOL, V274, pC1686; TAN KT, 1995, ENDOCRINOLOGY, V136, P881; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; Tornquist K, 1997, ENDOCRINOLOGY, V138, P4049, DOI 10.1210/en.138.10.4049; Tornquist K, 1996, J CELL PHYSIOL, V166, P241; TORNQUIST K, 1992, J CELL PHYSIOL, V150, P90, DOI 10.1002/jcp.1041500113; TUOMINEN RK, 1992, J NEUROCHEM, V58, P1652, DOI 10.1111/j.1471-4159.1992.tb10037.x; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANDERPOLL T, 1990, J CLIN ENDOCR METAB, V71, P1567; WANG XD, 1995, THYROID, V5, P137, DOI 10.1089/thy.1995.5.137; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; XU YP, 1995, J BIOL CHEM, V270, P23887, DOI 10.1074/jbc.270.41.23887; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZAKARIJA M, 1989, ENDOCRINOLOGY, V125, P1260, DOI 10.1210/endo-125-3-1260; ZHENG RQH, 1992, IMMUNOLOGY, V75, P456	62	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9370	9377		10.1074/jbc.274.14.9370	http://dx.doi.org/10.1074/jbc.274.14.9370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092616	hybrid			2022-12-27	WOS:000079451800035
J	Yamauchi, K; Nakajima, J; Hayashi, H; Horiuchi, R; Tata, JR				Yamauchi, K; Nakajima, J; Hayashi, H; Horiuchi, R; Tata, JR			Xenopus cytosolic thyroid hormone-binding protein (xCTBP) is aldehyde dehydrogenase catalyzing the formation of retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RAT-LIVER; 3,5,3'-TRIIODO-L-THYRONINE-BINDING PROTEIN; RECEPTOR SUPERFAMILY; MESSENGER-RNAS; CLONING; PURIFICATION; EXPRESSION; RETINALDEHYDE; OXIDATION	Amino acid sequencing of an internal peptide fragment derived from purified Xenopus cytosolic thyroid hormone-binding protein (xCTBP) demonstrates high similarity to the corresponding sequence of mammalian aldehyde dehydrogenase 1 (ALDH1) (Yamauchi, K., and Tata, J. R. (1994) fur. J. Biochem. 225, 1105-1112). Here we show that xCTBP was co-purified with ALDH and 3,3',5-triiodo-L-thyronine (T-3) binding activities. By photoaffinity labeling with [I-125]T-3, a T-3-binding site in the xCTBP was estimated to reside in amino acid residues 93-114, which is distinct from the active site of the enzyme but present in the NAD(+) binding domain. The amino acid sequences deduced from the two isolated xALDH1 cDNAs (xALDH1-I and xALDH1-II) were 94.6% identical to each other and very similar to those of mammalian ALDH1 enzymes. The two recombinant xALDH1 proteins exhibit both T-3 binding activity and ALDH activity converting retinal to retinoic acid (BA), which are similar to those of xCTBP. The mRNAs were present abundantly in kidney and intestine of adult female Xenopus. Interestingly, their T-3 binding activities were inhibited by NAD(+) and NADH but not by NADP(+) and NADPH, whereas NAD(+) was required for their ALDH activities. Our results demonstrate that xCTBP is identical to ALDH1 and suggest that this protein might modulate RA synthesis and intracellular level of free T-3.	Shizuoka Univ, Fac Sci, Dept Biol, Shizuoka 4228529, Japan; Gunma Univ, Sch Med, Dept Pharm, Maebashi, Gumma 3718511, Japan; Natl Inst Med Res, Lab Dev Biochem, London NW7 1AA, England	Shizuoka University; Gunma University; MRC National Institute for Medical Research	Yamauchi, K (corresponding author), Shizuoka Univ, Fac Sci, Dept Biol, 836 Ohya, Shizuoka 4228529, Japan.	sbkyama@ipc.shizuoka.ac.jp						ABRIOLA DP, 1987, BIOCHEMISTRY-US, V26, P5679, DOI 10.1021/bi00392a015; AMBROZIAK W, 1991, J BIOL CHEM, V266, P13011; ASHIZAWA K, 1992, P NATL ACAD SCI USA, V89, P9277, DOI 10.1073/pnas.89.19.9277; BARTH LG, 1959, J EMBRYOL EXP MORPH, V7, P210; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P2298; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Bhat PV, 1996, BIOCHEM CELL BIOL, V74, P695, DOI 10.1139/o96-076; BRADFORD M, 1976, ANAL BIOCHEM, V72, P112; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; CHATTERJEE VKK, 1997, MOL ENDOCRINOLOGY GE, P73; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; ELDER TD, 1962, BIOCHIM BIOPHYS ACTA, V64, P430, DOI 10.1016/0006-3002(62)90300-1; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gorbman A., 1962, TXB COMP ENDOCRINOLO; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; HASHIZUME K, 1989, J BIOL CHEM, V264, P4857; HEMPEL J, 1982, BIOCHEMISTRY-US, V21, P6834, DOI 10.1021/bi00269a032; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hennemann, 1996, THYROID ITS DIS; HSU LC, 1985, P NATL ACAD SCI USA, V82, P3771, DOI 10.1073/pnas.82.11.3771; IWASE K, 1995, BBA-GENE STRUCT EXPR, V1260, P139, DOI 10.1016/0167-4781(94)00183-4; KATO H, 1989, P NATL ACAD SCI USA, V86, P7861, DOI 10.1073/pnas.86.20.7861; KOBAYASHI M, 1991, ENDOCRINOLOGY, V129, P1701, DOI 10.1210/endo-129-4-1701; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LENNON AM, 1992, EUR J BIOCHEM, V210, P79, DOI 10.1111/j.1432-1033.1992.tb17393.x; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; MUKERJEE N, 1992, ARCH BIOCHEM BIOPHYS, V299, P23, DOI 10.1016/0003-9861(92)90239-S; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1993, RETINOIDS PROGR RES, P29; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pitt-Rivers R., 1959, THYROID HORMONES; POSCH KC, 1992, J BIOL CHEM, V267, P19676; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shambaugh G. E., 1986, WERNERS THYROID FUND, P201; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Vie MP, 1997, MOL ENDOCRINOL, V11, P1728, DOI 10.1210/me.11.11.1728; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5; Yamauchi K, 1997, COMP BIOCHEM PHYS C, V118, P27, DOI 10.1016/S0742-8413(97)00077-7; YAMAUCHI K, 1994, EUR J BIOCHEM, V225, P1105, DOI 10.1111/j.1432-1033.1994.1105b.x; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; YOSHIZATO K, 1975, J BIOL CHEM, V250, P8337; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; Zhou JZ, 1997, EUR J BIOCHEM, V245, P123, DOI 10.1111/j.1432-1033.1997.00123.x	62	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8460	8469		10.1074/jbc.274.13.8460	http://dx.doi.org/10.1074/jbc.274.13.8460			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085078	hybrid			2022-12-27	WOS:000079451600020
J	Lee, AC; Fenster, BE; Ito, H; Takeda, K; Bae, NS; Hirai, T; Yu, ZX; Ferrans, VJ; Howard, BH; Finkel, T				Lee, AC; Fenster, BE; Ito, H; Takeda, K; Bae, NS; Hirai, T; Yu, ZX; Ferrans, VJ; Howard, BH; Finkel, T			Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FIBROBLASTS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GROWTH ARREST; IN-VIVO; CELLS; GENERATION; TRANSFORMATION; INVOLVEMENT; APOPTOSIS	Human diploid fibroblasts eventually lose the capacity to replicate in culture and enter a viable but nonproliferative state of senescence. Recently, it has been demonstrated that retroviral-mediated gene transfer into primary fibroblasts of an activated ras gene (V12ras) rapidly accelerates development of the senescent phenotype, Using this in vitro system, we have sought to define the mediators of Res-induced senescence. We demonstrate that expression of V12Ras results in an increase in intracellular and in particular, mitochondrial reactive oxygen species, The ability of V12Ras to induce growth arrest and senescence is shown to be partially inhibited by coexpression of an activated rad gene. A more dramatic rescue of V12Ras-expressing cells is demonstrated when the cells are placed in a low oxygen environment, a condition in which reactive oxygen species production is inhibited. In addition, in a 1% oxygen environment, Res is unable to trigger an increase in the level of the cyclin-dependent kinase inhibitor p21 or to activate the senescent program. Under normoxic (20% O-2) conditions, the V12Ras senescent phenotype is demonstrated to be unaffected by scavengers of superoxide but rescued by scavengers of hydrogen peroxide. These results suggest that in normal diploid cells, Ras proteins regulate oxidant production and that a rise in intracellular H2O2 represents a critical signal mediating replicative senescence.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@gwgate.nhlbi.nih.gov						Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KOHL NE, 1987, ONCOGENE, V2, P41; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; YUAN HT, 1995, MECH AGEING DEV, V81, P159, DOI 10.1016/0047-6374(95)01584-M	44	510	521	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7936	7940		10.1074/jbc.274.12.7936	http://dx.doi.org/10.1074/jbc.274.12.7936			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075689	hybrid			2022-12-27	WOS:000079268100048
J	Lillig, CH; Prior, A; Schwenn, JD; Aslund, F; Ritz, D; Vlamis-Gardikas, A; Holmgren, A				Lillig, CH; Prior, A; Schwenn, JD; Aslund, F; Ritz, D; Vlamis-Gardikas, A; Holmgren, A			New thioredoxins and glutaredoxins as electron donors of 3 '-phosphoadenylylsulfate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-DEPENDENT SYNTHESIS; ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; SULFATE REDUCTION; MIXED DISULFIDE; PAPS-REDUCTASE; PROTEINS; DEOXYRIBONUCLEOTIDES; MECHANISM; MUTANT	Reduction of inorganic sulfate to sulfite in prototrophic bacteria occurs with 3'-phosphoadenylylsulfate (PAPS) as substrate for PAPS reductase and is the first step leading to reduced sulfur for cellular biosynthetic reactions. The relative efficiency as reductants of homogeneous highly active PAPS reductase of the newly identified second thioredoxin (Trx2) and glutaredoxins (Grx1, Grx2, Grx3, and a mutant Grx1C14S) was compared with the well known thioredoxin (Trx1) from Escherichia coli, Trx1, Trx2, and Grx1 supported virtually identical rates of sulfite formation with a V-max, ranging from 6.6 units mg(-1) (Trx1) to 5.1 units mg(-1) (Grx1), whereas Grx1C14S was only marginally active, and Grx2 and Grx3 had no activity. The structural difference between active reductants had no effect upon K-m (PAPS) (22.5 mu m) Grx1 effectively replaced Trx1 with essentially identical K-m-values: K-m (trx1) (13.7 mu M), K-m (grx1) (14.9 mu M), whereas the K-m (trx2) was considerably higher (34.2 mu M). The results agree with previous in vivo data suggesting that Trx1 or Grx1 is essential for sulfate reduction but not for ribonucleotide reduction in E, coli.	Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany; Harvard Med Sch, Dept Microbiol & Mol Genet, Boston, MA USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, Stockholm, Sweden	Ruhr University Bochum; Harvard University; Harvard Medical School; Karolinska Institutet	Schwenn, JD (corresponding author), Ruhr Univ Bochum, Fac Biol, POB 10 21 48, D-44780 Bochum, Germany.	jens-dirk.schwenn@ruhr-uni-bochum.de	Lillig, Christopher Horst/AAD-7098-2019; Vlamis, Alexios/AAF-5152-2020	Lillig, Christopher Horst/0000-0003-2509-5117; Vlamis, Alexios/0000-0001-5068-6459				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; Berardi MJ, 1998, BIOCHEMISTRY-US, V37, P5849, DOI 10.1021/bi972924d; BERENDT U, 1995, EUR J BIOCHEM, V233, P347, DOI 10.1111/j.1432-1033.1995.347_1.x; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; GONZALEZ.P, 1970, J BIOL CHEM, V245, P2371; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KRONE FA, 1991, MOL GEN GENET, V225, P314, DOI 10.1007/BF00269864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Sambrook J., 2002, MOL CLONING LAB MANU; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; SCHIFFMANN S, 1998, THESIS FACULTY BIOLO; SCHRIEK U, 1986, ARCH MICROBIOL, V145, P32, DOI 10.1007/BF00413024; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; SCHWENN JD, 1980, J CHROMATOGR, V139, P285; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG MLS, 1978, J BACTERIOL, V134, P131, DOI 10.1128/JB.134.1.131-138.1978; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; WAGNER W, 1978, Z NATURFORSCH C, V33, P517; Warburg O., 1942, BIOCHEM Z, V310, P384; WILSON LG, 1961, J BIOL CHEM, V236, P1822; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	35	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7695	7698		10.1074/jbc.274.12.7695	http://dx.doi.org/10.1074/jbc.274.12.7695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075658	hybrid			2022-12-27	WOS:000079268100017
J	Miele, RG; Prorok, M; Costa, VA; Castellino, FJ				Miele, RG; Prorok, M; Costa, VA; Castellino, FJ			Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; KRINGLE-2 DOMAIN; PICHIA-PASTORIS; GENE; EXPRESSION; CLONING	The properties of recombinant staphylokinase (SakSTAR) expressed in Pichia pastoris cells have been determined. The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn(28) of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides. The majority of these glycans ranged in polymerization state from Man(8)GlcNAc(2) to Man(14)GlcNAc(2), with the predominant species being Man(10)GlcNAc(2) and Man(11)GlcNAc(2). Glycosylated SakSTAR (SakSTAR(g)) did not differ from its aglycosyl form in its aggregation state in solution, its thermal denaturation properties, its ability to form a complex with human plasmin (hPm), the amidolytic properties of the respective SakSTAR-hPm complexes, or its ability to liberate the amino-terminal decapeptide required for formation of a functional SakSTAR-hPm plasminogen activator complex. However, this latter complex with SakSTAR(g) showed a greatly reduced ability to activate human plasminogen (hPg) as compared with the same complex with the aglycosyl form of SakSTAR, We conclude that glycosylation at Asn28 does not affect the structural properties of SakSTAR or its ability to participate in the formation of an active enzymatic complex with hPm, but it is detrimental to the ability of the SakSTAR-hPm complex to serve as a hPg activator. This is likely due to restricted access of hPg to the active site of the SakSTAR(g)-hPm complex.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013423, R01HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; CASTELLINO F J, 1988, Haemostasis, V18, P15; COLLEN D, 1992, FIBRINOLYSIS, V6, P226, DOI 10.1016/0268-9499(92)90075-S; COLLEN D, 1994, BLOOD, V84, P680, DOI 10.1182/blood.V84.3.680.680; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; Duman JG, 1998, BIOTECHNOL APPL BIOC, V28, P39; GASE A, 1994, EUR J BIOCHEM, V223, P303, DOI 10.1111/j.1432-1033.1994.tb18995.x; GERLACH D, 1988, ZBL BAKT-INT J MED M, V269, P314; Grella DK, 1997, BLOOD, V89, P1585, DOI 10.1182/blood.V89.5.1585.1585_1585_1589; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P143, DOI 10.1111/j.1432-1033.1994.tb20005.x; Miele RG, 1997, BIOTECHNOL APPL BIOC, V25, P151; Miele RG, 1997, BIOTECHNOL APPL BIOC, V26, P79; Nilsen SL, 1997, BIOTECHNOL APPL BIOC, V25, P63, DOI 10.1111/j.1470-8744.1997.tb00415.x; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SAKO T, 1985, EUR J BIOCHEM, V149, P557, DOI 10.1111/j.1432-1033.1985.tb08961.x; SAKO T, 1983, MOL GEN GENET, V190, P271, DOI 10.1007/BF00330650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P6463; SCHLOTT B, 1994, BBA-PROTEIN STRUCT M, V1204, P235, DOI 10.1016/0167-4838(94)90013-2; SCHLOTT B, 1994, BIO-TECHNOL, V12, P185, DOI 10.1038/nbt0294-185; Schlott B, 1997, J BIOL CHEM, V272, P6067, DOI 10.1074/jbc.272.9.6067; Ueshima S, 1996, BLOOD COAGUL FIBRIN, V7, P522, DOI 10.1097/00001721-199607000-00003	25	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7769	7776		10.1074/jbc.274.12.7769	http://dx.doi.org/10.1074/jbc.274.12.7769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075668	hybrid			2022-12-27	WOS:000079268100027
J	Steiner, H; Romig, H; Grim, MG; Philipp, U; Pesold, B; Citron, M; Baumeister, R; Haass, C				Steiner, H; Romig, H; Grim, MG; Philipp, U; Pesold, B; Citron, M; Baumeister, R; Haass, C			The biological and pathological function of the presenilin-1 Delta exon 9 mutation is independent of its defect to undergo proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID BETA-PROTEIN; IN-VIVO; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; GENE; ENDOPROTEOLYSIS; CELLS	The two homologous presenilins are key factors for the generation of amyloid beta-peptide (A beta), since Alzheimer's disease (AD)-associated mutations enhance the production of the pathologically relevant 42-amino acid A beta (A beta 42), and a gene knockout of presenilin-1 (PS1) significantly inhibits total A beta production. Presenilins undergo proteolytic processing within the domain encoded by exon 9, a process that may be closely related to their biological and pathological activity. An AD-associated mutation within the PS1 gene deletes exon 9 (PS1 Delta exon9) due to a splicing error and results in the accumulation of the uncleaved full-length protein. We now demonstrate the unexpected finding that the pathological activity of PS1 Delta exon9 is independent of its lack to undergo proteolytic processing, but is rather due to a point mutation (S290C) occurring at the aberrant exon 8/10 splice junction. Mutagenizing the cysteine residue at position 290 to the original serine residue completely inhibits the pathological activity in regard to the elevated production of A beta 42. Like PS1 Delta exon9, the resulting presenilin variant (PS1 Delta exon9 C290S) accumulates as an uncleaved protein and fully replaces endogenous presenilin fragments. Moreover, PS1 Delta exon9 C290S exhibits a significantly increased biological activity in a highly sensitive in vivo assay as compared with the AD-associated mutation. Therefore not only the increased A beta 42 production but also the decreased biological function of PS1 Delta exon9 is due to a point mutation and independent of the lack of proteolytic processing.	Cent Inst Mental Hlth, Dept Biol Mol, D-68159 Mannheim, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany; Genzentrum, D-81377 Munich, Germany; Amgen Inc, Thousand Oaks, CA 91320 USA	Central Institute of Mental Health; Boehringer Ingelheim; University of Munich; Amgen	Baumeister, R (corresponding author), Cent Inst Mental Hlth, Dept Biol Mol, J5, D-68159 Mannheim, Germany.							Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GRUNBERG J, 1997, ALZHEIMERS RES, V3, P253; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Murayama O, 1997, NEUROSCI LETT, V229, P61, DOI 10.1016/S0304-3940(97)00417-5; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349	27	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7615	7618		10.1074/jbc.274.12.7615	http://dx.doi.org/10.1074/jbc.274.12.7615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075646	hybrid			2022-12-27	WOS:000079268100005
J	Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W				Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W			Photosystem I, an improved model of the stromal subunits PsaC, PsaD, and PsaE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SYNECHOCOCCUS SP; SYNECHOCYSTIS SP PCC-6803; CROSS-LINKED COMPLEX; STRUCTURAL ORGANIZATION; ANGSTROM RESOLUTION; PSI-C; PROTEIN; FERREDOXIN; REFINEMENT; POLYPEPTIDES	An improved electron density map of photosystem I (PSI) calculated at 4-Angstrom resolution yields a more detailed structural model of the stromal subunits PsaC, PsaD, and PsaE than previously reported. The NMR structure of the subunit PsaE of PSI from Synechococcus sp, PCC7002 (Falzone, C, J., Kao, Y.-H., Zhao, J., Bryant, D. A, and Lecomte, J, T, J, (1994) Biochemistry 33, 6052-6062) has been used as a model to interpret the region of the electron density map corresponding to this subunit, The spatial orientation with respect to other subunits is described as well as the possible interactions between the stromal subunits. A first model of PsaD consisting of a four-stranded beta-sheet and an alpha-helix is suggested, indicating that this subunit partly shields PsaC from the stromal side. In addition to the improvements on the stromal subunits, the structural model of the membrane-integral region of PSI is also extended. The current electron density map allows the identification of the N and C termini of the subunits PsaA and PsaB, The 11-transmembrane alpha-helices of these subunits can now be assigned uniquely to the hydrophobic segments identified by hydrophobicity analyses.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochim, D-10623 Berlin, Germany	Free University of Berlin; Technical University of Berlin	Krauss, N (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	nkrauss@chemie.fu-berlin.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Krauss, Norbert/0000-0002-7128-4632				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADMAN ET, 1976, J BIOL CHEM, V251, P3801; Armbrust TS, 1996, PLANT PHYSIOL, V111, P1307, DOI 10.1104/pp.111.4.1307; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOTTCHER B, 1992, BIOCHIM BIOPHYS ACTA, V1100, P125, DOI 10.1016/0167-4838(92)90544-N; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; Chitnis VP, 1996, J BIOL CHEM, V271, P11772, DOI 10.1074/jbc.271.20.11772; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; Fromme P, 1998, BBA-BIOENERGETICS, V1365, P175, DOI 10.1016/S0005-2728(98)00059-0; FROMME P, 1998, THESIS TU BERLIN GER; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1996, P CCP4 STUD WEEK IS, P80; RODDAY SM, 1994, PHOTOSYNTH RES, V42, P185, DOI 10.1007/BF00018261; Rodday SM, 1996, BIOCHEMISTRY-US, V35, P11832, DOI 10.1021/bi9612834; RODDAY SM, 1995, BIOCHEMISTRY-US, V34, P6328, DOI 10.1021/bi00019a010; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Schubert WD, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P3; Setif P, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P23; Sun J, 1997, J BIOL CHEM, V272, P21793, DOI 10.1074/jbc.272.35.21793; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P743, DOI 10.1107/S0907444996001473; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; WEBER N, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204, DOI 10.1016/0005-2728(93)90144-5; Xia ZC, 1998, EUR J BIOCHEM, V255, P309, DOI 10.1046/j.1432-1327.1998.2550309.x; XU G, 1994, PLANT PHYSIOL, V106, P617; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x	49	85	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7351	7360		10.1074/jbc.274.11.7351	http://dx.doi.org/10.1074/jbc.274.11.7351			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066799	hybrid			2022-12-27	WOS:000079078400071
J	Park, SH; Liu, XW; Hennighausen, L; Davey, HW; Waxman, DJ				Park, SH; Liu, XW; Hennighausen, L; Davey, HW; Waxman, DJ			Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression - Impact of Stat5a gene disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTOSTERONE 16-ALPHA-HYDROXYLASE I-P-45016-ALPHA; GROWTH-HORMONE STIMULATION; DNA-BINDING; TYROSINE PHOSPHORYLATION; MAMMARY-GLAND; MOUSE-LIVER; RAT HEPATOCYTES; PROLACTIN; CYTOCHROME-P450; TRANSCRIPTION	Stat5b gene disruption leads to an apparent growth hormone (GH) pulse insensitivity associated with loss of male-characteristic body growth rates and male-specific liver gene expression (Udy, G, B,, Towers, R. P,, Snell, R. G,, Wilkins, R, J,, Park, S, H,, Ram, P, A., Waxman, D, J,, and Davey, H, W, (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 7239-7244). In the present study, disruption of the mouse Stat5a gene, whose coding sequence is similar to 90% identical to the Stat5b gene, resulted in no loss of expression in male mice of several sex-dependent, GH-regulated liver cytochrome P450 (CYP) enzymes. By contrast, the loss of STAT5b feminized the livers of males by decreasing expression of male-specific CYPs (CYP2D9 and testosterone 16 alpha-hydroxylase) while increasing to female levels several female-predominant liver CYPs (CYP3A, CYP2B, and testosterone 6 beta-droxylase). Since STAT5a is thus nonessential for these male GH responses, STAT5b homodimers, but not STAT5a-STAT5b heterodimers, probably mediate the sexually dimorphic effects of male GH pulses on liver CYP expression. In female mice, however, disruption of either Stat5a or Stat5b led to striking decreases in several liver CYP-catalyzed testosterone hydroxylase activities. Stat5a or Stat5b gene disruption also led to the loss of a female-specific, GH-regulated hepatic CYP2B enzyme. STAT5a, which is much less abundant in liver than STAT5b, and STAT5b are therefore both required for constitutive expression in female but not male mouse liver of certain GH-regulated CYP steroid hydroxylases, suggesting that STAT5 protein heterodimerization is an important determinant of the sex-dependent and gene-specific effects that GH has on the liver.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA; NIDDK, NIH, Bethesda, MD 20892 USA; AgResearch, Hamilton, New Zealand	Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); AgResearch - New Zealand	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bio.bu.edu		Hennighausen, Lothar/0000-0001-8319-9841; Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; DEVORE K, 1985, BIOCHEMISTRY-US, V24, P5632, DOI 10.1021/bi00341a052; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FORD HC, 1979, ENDOCRINOLOGY, V104, P857, DOI 10.1210/endo-104-4-857; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HARADA N, 1984, J BIOL CHEM, V259, P2285; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; HONKAKOSKI P, 1992, BIOCHEM J, V285, P979, DOI 10.1042/bj2850979; Jahn GA, 1997, BIOL REPROD, V57, P894, DOI 10.1095/biolreprod57.4.894; LAKSO M, 1991, EUR J BIOCHEM, V195, P477, DOI 10.1111/j.1432-1033.1991.tb15728.x; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MACLEOD JN, 1991, J ENDOCRINOL, V131, P395, DOI 10.1677/joe.0.1310395; MODE A, 1992, ADV ENZYME REGUL, V32, P255; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAGANO M, 1994, J BIOL CHEM, V269, P13337; NEGISHI M, 1991, METHOD ENZYMOL, V206, P267; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; NOSHIRO M, 1986, ARCH BIOCHEM BIOPHYS, V244, P857, DOI 10.1016/0003-9861(86)90655-7; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Paolini M, 1996, ARCH TOXICOL, V70, P451, DOI 10.1007/s002040050298; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Sharma MC, 1998, BIOCHEM PHARMACOL, V56, P1251, DOI 10.1016/S0006-2952(98)00247-0; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; STANLEY LA, 1991, BIOCHEM PHARMACOL, V42, P311, DOI 10.1016/0006-2952(91)90718-K; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Tapner M, 1996, HEPATOLOGY, V24, P367; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Waxman David J., 1995, P391; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P462; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WAXMAN DJ, 1987, MOL PHARMACOL, V32, P615; WONG G, 1987, BIOCHEMISTRY-US, V26, P8683, DOI 10.1021/bi00400a029; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672	55	96	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7421	7430		10.1074/jbc.274.11.7421	http://dx.doi.org/10.1074/jbc.274.11.7421			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066807	hybrid			2022-12-27	WOS:000079078400079
J	Schuenemann, TA; Delgado-Nixon, VM; Dalbey, RE				Schuenemann, TA; Delgado-Nixon, VM; Dalbey, RE			Direct evidence that the proton motive force inhibits membrane translocation of positively charged residues within membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M13 COAT PROTEIN; ESCHERICHIA-COLI; INNER MEMBRANE; ELECTROCHEMICAL GRADIENT; CYTOPLASMIC MEMBRANE; LEADER PEPTIDASE; PLASMA-MEMBRANE; INSERTION; TOPOLOGY; PROCOAT	The M13 phage procoat protein requires both its signal sequence and its membrane anchor sequence in the mature part of the protein for membrane insertion. Translocation of its short acidic periplasmic loop is stimulated by the proton motive force (pmf) and does not require the Sec components. We now find that the pmf becomes increasingly important for the translocation of negatively charged residues within procoat when the hydrophobicity of the signal or membrane anchor is incrementally reduced. In contrast, we find that the pmf inhibits translocation of the periplasmic loop when it contains one or two positively charged residues. This inhibitory effect of the pmf is stronger when the hydrophobicity of the inserting procoat protein is compromised. No pmf effect is observed for translocation of an uncharged periplasmic loop even when the hydrophobicity is reduced. We also show that the Delta Psi component of the pmf is necessary and sufficient for insertion of representative constructs and that the translocation effects of charged residues are primarily due to the Delta Psi component of the pmf and not the pH component.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Ohio State University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18Th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu						ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; GELLER B, 1993, J BIOL CHEM, V268, P9442; GELLER BL, 1990, J BACTERIOL, V172, P4870, DOI 10.1128/jb.172.9.4870-4876.1990; GELLER BL, 1985, J BIOL CHEM, V260, P3281; HONIG BH, 1986, ANNU REV BIOPHYS BIO, V15, P163; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KATO M, 1992, J BIOL CHEM, V267, P413; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1990, J STRUCT BIOL, V104, P38, DOI 10.1016/1047-8477(90)90055-H; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LEE E, 1994, J BIOL CHEM, V269, P28822; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Soekarjo M, 1996, BIOCHEMISTRY-US, V35, P1232, DOI 10.1021/bi951087h; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; TANI K, 1989, J BIOL CHEM, V264, P18582; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	49	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6855	6864		10.1074/jbc.274.11.6855	http://dx.doi.org/10.1074/jbc.274.11.6855			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066738	hybrid			2022-12-27	WOS:000079078400010
J	Berengian, AR; Parfenova, M; Mchaourab, HS				Berengian, AR; Parfenova, M; Mchaourab, HS			Site-directed spin labeling study of subunit interactions in the alpha-crystallin domain of small heat-shock proteins - Comparison of the oligomer symmetry in alpha A-crystallin, HSP 27, and HSP 16.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; IN-VITRO; PHOSPHORYLATION; REACTIVATION; INTERFACE; FAMILY	Site-directed spin labeling was used to investigate quaternary interactions along a conserved sequence in the Lu-crystallin domain of alpha A-crystallin, heat-shock protein 27 (HSP 27), and Mycobacterium tuberculosis heat-shock protein (HSP 16.3). In previous work, it was demonstrated that this sequence in alpha A-crystallin and HSP 27 forms a beta-strand involved in subunit contacts. In this study, the symmetry and geometry of the resulting interface were investigated. For this purpose, the pattern of spin-spin interactions was analyzed, and the number of interacting spins was determined in alpha A-crystallin and HSP 27, The results reveal a 2-fold symmetric interface consisting of two beta-strands interacting near their N termini in an antiparallel fashion. Remarkably, subunit interactions along this interface persist when the alpha-crystallin domains are expressed in isolation. Because this domain in alpha A-crystallin forms dimers and tetramers, it is inferred that interactions along this interface mediate the formation of a basic dimeric unit. In contrast, in HSP 16.3, spin-spin interactions are observed at only one site near the C terminus of the sequence. Furthermore, cysteine substitutions at residues flanking the N terminus resulted in the dissociation of the oligomeric structure. Analysis of the spin-spin interactions and size exclusion chromatography indicates a 3-fold symmetric interface. Taken together, our results demonstrate that subunit interactions in the alpha-crystallin domain of mammalian small heat-shock proteins assemble a basic building block of the oligomeric structure. Sequence divergence in this domain results in variations in the size and symmetry of the quaternary structure between distant members of the small heat-shock protein family.	Med Coll Wisconsin, Biophys Res Inst, Natl Biomed ESR Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Mchaourab, HS (corresponding author), Med Coll Wisconsin, Biophys Res Inst, Natl Biomed ESR Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	hassane@mcw.edu			NCRR NIH HHS [RR01008] Funding Source: Medline; NEI NIH HHS [EY12018] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012018, R29EY012018] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; MALEY DA, 1998, J MOL BIOL, V277, P27; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P14627, DOI 10.1021/bi971700s; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; Yuan Y., 1996, J BACTERIOL, V178, P4484, DOI DOI 10.1128/JB.178.15.4484-4492.1996	30	84	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6305	6314		10.1074/jbc.274.10.6305	http://dx.doi.org/10.1074/jbc.274.10.6305			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037719	hybrid			2022-12-27	WOS:000078902800041
J	Lamontagne, J; Papadopoulou, B				Lamontagne, J; Papadopoulou, B			Developmental regulation of spliced leader RNA gene in Leishmania donovani amastigotes is mediated by specific polyadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON GENE; PROCYCLIN MESSENGER-RNAS; TRYPANOSOMA-BRUCEI; HEAT-SHOCK; 3'-UNTRANSLATED REGION; INTERGENIC REGIONS; DISCONTINUOUS TRANSCRIPTION; DIFFERENTIAL EXPRESSION; CHAGASI PROMASTIGOTES; STABILITY	Leishmania cycles between the insect vector and its mammalian host undergoing several important changes mediated by the stage-specific expression of a number of genes. Using a genomic differential screening approach, we isolated differentially expressed cosmid clones carrying several copies of the mini-exon gene. We report that the spliced leader (SL) RNA essential for the maturation of all pre-mRNAs by trans-splicing, is developmentally regulated in Leishmania donovani amastigotes and that this regulation is rapidly induced upon parasite growth under acidic conditions. Stage-specific regulation of the SL RNA is associated with the expression of a larger similar to 170-nucleotide transcript that bears an additional 15-nucleotide sequence at its 3'-end and is polyadenylated in contrast to the mature SL RNA. The poly(A)(+) SL RNA represents 12-16% of the total SL transcript synthesized in amastigotes and is 2.5-3-fold more stable than the poly(A)(-) transcript. The poly(A)(+) SL transcript is synthesized specifically from one class of the genomic mini-exon copies. Polyadenylation of the SL RNA may control the levels of the SL mature transcript under amastigote growth and may represent an additional step in the gene regulation process during parasite differentiation.	Univ Laval, Ctr Hosp, CHUQ, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Papadopoulou, B (corresponding author), Univ Laval, Ctr Hosp, CHUQ, Ctr Rech Infectiol, Pavillon CHUL,2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.	Barbara.Papadopoulou@crchul.ulaval.ca						AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Baker EJ, 1993, CONTROL MESSENGER RN, P367; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; BELLOFATTO V, 1988, NUCLEIC ACIDS RES, V16, P7437, DOI 10.1093/nar/16.15.7437; BERSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8; FLEISCHMANN J, 1994, GENE, V144, P45, DOI 10.1016/0378-1119(94)90201-1; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; Hausler T, 1996, MOL BIOCHEM PARASIT, V76, P57, DOI 10.1016/0166-6851(95)02538-3; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; HUBEL A, 1995, MOL BIOCHEM PARASIT, V70, P107, DOI 10.1016/0166-6851(95)00012-P; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KOOTER JM, 1984, EMBO J, V3, P2387, DOI 10.1002/j.1460-2075.1984.tb02144.x; Krobitsch S, 1998, J BIOL CHEM, V273, P6488, DOI 10.1074/jbc.273.11.6488; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LAIRD PW, 1985, NUCLEIC ACIDS RES, V13, P4253, DOI 10.1093/nar/13.12.4253; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; MUHICH ML, 1989, J BIOL CHEM, V264, P7107; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; Noll TM, 1997, MOL BIOCHEM PARASIT, V84, P215, DOI 10.1016/S0166-6851(96)02801-0; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; REDDY R, 1985, J BIOL CHEM, V260, P930; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOLLER JK, 1989, NUCLEIC ACIDS RES, V17, P7999, DOI 10.1093/nar/17.19.7999; SCHURCH N, 1994, MOL CELL BIOL, V14, P3668, DOI 10.1128/MCB.14.6.3668; STURM NR, 1998, WOODS HOL MOL PAR 9, P60; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	60	47	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6602	6609		10.1074/jbc.274.10.6602	http://dx.doi.org/10.1074/jbc.274.10.6602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037755	hybrid			2022-12-27	WOS:000078902800077
J	Tsuchida, M; Knechtle, SJ; Hamawy, MM				Tsuchida, M; Knechtle, SJ; Hamawy, MM			CD28 ligation induces tyrosine phosphorylation of Pyk2 but not Fak in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RECEPTOR SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT PHOSPHORYLATION; COSTIMULATORY RECEPTOR; CD28-DEFICIENT MICE; GENE-EXPRESSION; MAST-CELLS; PROTEIN; ACTIVATION	Protein tyrosine kinases are critical for the function of CD28 in T cells. We examined whether the tyrosine kinases Pyk2 and Fak (members of the focal adhesion kinase family) are involved in CD28 signaling. We found that ligating CD28 in Jurkat T cells rapidly increases the tyrosine phosphorylation of Pyk2 but not of Fak. Paxillin, a substrate for Pyk2 and Fak, was not tyrosine-phosphorylated after CD28 ligation. CD28-induced tyrosine phosphorylation of Pyk2 was markedly reduced in the absence of external Ca2+. Previous studies have shown that the T cell antigen receptor (TCR) induces tyrosine phosphorylation of Pyk2. In this report, the concurrent ligation of CD28 and TCR increased tyrosine phosphorylation of Pyk2; however, the extent of phosphorylation by both receptors was equivalent to the sum of that induced by each receptor alone. The Syk/Zap inhibitor piceatannol blocked CD28, and TCR induced tyrosine phosphorylation of Pyk2, suggesting that Syk/ Zap is involved in Pyk2 phosphorylation. In contrast, the phosphatidylinositol 3-kinase inhibitor wortmannin blocked TCR- but not CD28-induced phosphorylation of Pyk2, suggesting that CD28 and TCR activate distinct pathways to induce tyrosine phosphorylation of Pyk2. Notably, depleting phorbol 12-myristate 13-acetate-sensitive protein kinase C did not block CD28- and CD3-induced tyrosine phosphorylation of Pyk2. These data provide evidence for the involvement of Pyk2 in the CD28 signaling cascade and suggest that neither Fak nor paxillin is involved in the signaling pathways of CD28.	Univ Wisconsin, Dept Surg, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Hamawy, MM (corresponding author), Univ Wisconsin, Dept Surg, 600 Highland Ave,H4-749, Madison, WI 53792 USA.	hamawy@surgery.wisc.edu		Knechtle, Stuart/0000-0002-1625-385X				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Astier A, 1997, J BIOL CHEM, V272, P228; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BLOEMENA E, 1994, EUR J IMMUNOL, V5, P943; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; HAMAWY MM, 1995, J BIOL CHEM, V270, P12305, DOI 10.1074/jbc.270.20.12305; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Ilic D, 1997, J CELL SCI, V110, P401; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Kaga S, 1998, J IMMUNOL, V160, P24; Kaga S, 1998, J IMMUNOL, V160, P4182; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; LEDBETTER JA, 1992, ADV EXP MED BIOL, V323, P23; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liao XC, 1997, J EXP MED, V186, P221, DOI 10.1084/jem.186.2.221; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LU YL, 1992, J IMMUNOL, V149, P24; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Marengere LEM, 1997, J IMMUNOL, V159, P3220; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pages F, 1996, J BIOL CHEM, V271, P9403, DOI 10.1074/jbc.271.16.9403; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PERI KG, 1994, CHEM IMMUNOL, V59, P19; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUNG CK, 1994, J BIOL CHEM, V269, P12503; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	77	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6735	6740		10.1074/jbc.274.10.6735	http://dx.doi.org/10.1074/jbc.274.10.6735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037772	hybrid			2022-12-27	WOS:000078902800094
J	Baburina, I; Jackowski, S				Baburina, I; Jackowski, S			Cellular responses to excess phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CHOLINE KINASE-ACTIVITY; SIGNAL-TRANSDUCTION; RAS ONCOGENE; P388D(1) MACROPHAGES; PHOSPHATIDYLCHOLINE HYDROLYSIS; A(2) ENZYMES; CELLS; EXPRESSION; MECHANISM	Phosphatidylcholine (PtdCho) is the major membrane phospholipid in mammalian cells, and its synthesis is controlled by the activity of CDP:phosphocholine cytidylyl-transferase (CCT), Enforced CCT expression accelerated the rate of PtdCho synthesis. However, the amount, of cellular PtdCho did not increase as a result of the turnover of both the choline and glycerol components of PtdCho. Metabolic labeling experiments demonstrated that cells compensated for elevated CCT activity by the degradation of PtdCho to glycerophosphocholine (GPC). Phospholipase D-mediated PtdCho hydrolysis and phosphocholine formation were unaffected, Most of the GPC produced in response to excess phospholipid production was secreted into the medium. Cells also degraded the excess membrane PtdCho to GPC when phospholipid formation was increased by exposure to exogenous lysophosphatidylcholine or lysophosphatidylethanolamine. The replacement of the acyl moiety at the 1-position of PtdCho with a non-hydrolyzable alkyl moiety prevented degradation to GPC. Accumulation of alkylacyl-PtdCho was associated with the inhibition of cell proliferation, demonstrating that alternative pathways of degradation will not substitute. GPC formation was blocked by bromoenol lactone, implicating the calcium-independent phospholipase A(2) as a key participant in the response to excess phospholipid. Owing to the fact that PtdCho is biosynthetically converted to PtdEtn, excess PtdCho resulted in overproduction and exit of GPE as well as GPC. Thus, general membrane phospholipid homeostasis is achieved by a balance between the opposing activities of CCT and phospholipase A(2).	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAUERNSCHMITT HG, 1993, BIOCHIM BIOPHYS ACTA, V1148, P331, DOI 10.1016/0005-2736(93)90147-R; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHARLES J, 1980, ANAL BIOCHEM, V104, P10; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Cornell R.B., 1996, ADV LIPOBIOLOGY, P1; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Farooqui AA, 1995, BRAIN RES REV, V21, P152, DOI 10.1016/0165-0173(95)00008-9; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Geilen CC, 1996, BBA-LIPID LIPID MET, V1299, P299, DOI 10.1016/0005-2760(95)00221-9; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HOFFMAN DR, 1984, BLOOD, V63, P545; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim TS, 1997, J BIOL CHEM, V272, P2542; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PRICE BD, 1989, J BIOL CHEM, V264, P16638; PROTILLA D, 1998, J BIOL CHEM, V271, P15451; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Sugimoto H, 1998, J BIOL CHEM, V273, P12536, DOI 10.1074/jbc.273.20.12536; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; XU XX, 1994, J BIOL CHEM, V269, P31693; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; ZABLOCKI K, 1991, P NATL ACAD SCI USA, V88, P7820, DOI 10.1073/pnas.88.17.7820	57	165	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9400	9408		10.1074/jbc.274.14.9400	http://dx.doi.org/10.1074/jbc.274.14.9400			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092620	hybrid			2022-12-27	WOS:000079451800039
J	Day, ML; Zhao, X; Vallorosi, CJ; Putzi, M; Powell, CT; Lin, C; Day, KC				Day, ML; Zhao, X; Vallorosi, CJ; Putzi, M; Powell, CT; Lin, C; Day, KC			E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADHESION MOLECULE UVOMORULIN; CANCER-CELLS; BETA-CATENIN; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; ALLELIC LOSS; ACTIVATION; GENE; EXPRESSION	E-cadherin and the retinoblastoma tumor suppressor (Rb) are traditionally associated with diverse regulatory aspects of cell growth and differentiation, However, we have discovered new evidence, which suggests that these proteins are functionally linked in a physiologic pathway required for cell survival and programmed cell death. pharmacological activation of protein kinase C (PKC) or inducible overexpression and activation of the alpha isozyme of PRC (PHC alpha) resulted in approximately 60% apoptosis of mammary and prostate epithelial cells, Interestingly, the surviving cells had undergone dramatic aggregation concurrent with increased E-cadherin expression. When aggregation was inhibited by the addition of an E-cadherin-blocking antibody, apoptosis increased synergistically, We hypothesized that survival of the aggregated population was associated with contact-inhibited growth and that apoptosis might result from aberrant growth regulatory signals in non-aggregated, cycling cells. This hypothesis was confirmed by experiments that demonstrated that E-cadherin-dependent aggregation resulted in Rb-mediated GI arrest and survival, Immunoblot analysis and Bow cytometry revealed that hypophosphorylated Rb was present in non-aggregated, S phase cultures concurrent with synergistic cell death. We have also determined that the loss of membrane E-cadherin and subsequent hypophosphorylation of Rb in luminal epithelial cells preceded apoptosis induced by castration. These findings provide compelling evidence that suggests that E-cadherin-mediated aggregation results in Rb activation and G(1), arrest that is critical for survival of prostate and mammary epithelial cells, These data also indicate that Rb can initiate a fatal growth signal conflict in non-aggregated, cycling cells when the protein is hypophosphorylated as these epithelial cells enter S phase.	Univ Michigan, Dept Surg, Urol Sect, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center	Day, ML (corresponding author), Univ Michigan, Dept Surg, Urol Sect, Box 0944,Rm 6219 CGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047650] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568] Funding Source: Medline; NIDDK NIH HHS [DK/CA47650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cooney KA, 1996, CANCER RES, V56, P1142; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; DAY ML, 1993, CANCER RES, V53, P5597; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; FABRE M, 1993, J CELL SCI, V106, P513; Fishman DD, 1998, INT J ONCOL, V12, P181; GAMALLO C, 1993, AM J PATHOL, V142, P987; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GUENETTE RS, 1994, J MOL ENDOCRINOL, V12, P47, DOI 10.1677/jme.0.0120047; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Ilyas M, 1997, J PATHOL, V182, P128; Ittmann MM, 1996, HUM PATHOL, V27, P28, DOI 10.1016/S0046-8177(96)90134-3; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEWIS JE, 1994, J CELL SCI, V107, P3615; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; Pollack A, 1990, Methods Cell Biol, V33, P19; Potter SW, 1996, J CELL PHYSIOL, V169, P1, DOI 10.1002/(SICI)1097-4652(199610)169:1<1::AID-JCP1>3.0.CO;2-S; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; SKOUDY A, 1995, FEBS LETT, V374, P415, DOI 10.1016/0014-5793(95)01167-D; Spinedi A, 1998, BIOCHEM BIOPH RES CO, V243, P852, DOI 10.1006/bbrc.1998.8184; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; UMBAS R, 1994, CANCER RES, V54, P3929; UMBAS R, 1992, CANCER RES, V52, P5104; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Wang H, 1996, ONCOGENE, V13, P373; WINKEL GK, 1990, DEV BIOL, V138, P1, DOI 10.1016/0012-1606(90)90171-E; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	52	99	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9656	9664		10.1074/jbc.274.14.9656	http://dx.doi.org/10.1074/jbc.274.14.9656			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092652	hybrid			2022-12-27	WOS:000079451800071
J	Lamberty, M; Ades, S; Uttenweiler-Joseph, S; Brookhart, G; Bushey, D; Hoffmann, JA; Bulet, P				Lamberty, M; Ades, S; Uttenweiler-Joseph, S; Brookhart, G; Bushey, D; Hoffmann, JA; Bulet, P			Insect immunity - Isolation from the lepidopteran Heliothis virescens of a novel insect defensin with potent antifungal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; 3-DIMENSIONAL SOLUTION STRUCTURE; RICH ANTIMICROBIAL PEPTIDES; DIPTERAN PHORMIA-TERRANOVAE; ANTI-BACTERIAL PROTEINS; SEQUENCE HOMOLOGY; INNATE IMMUNITY; BOMBYX-MORI; LARVAE; FAMILY	Lepidoptera have been reported to produce several antibacterial peptides in response to septic injury, However, in marked contrast to other insect groups, no inducible antifungal molecules had been described so far in this insect order. Surprisingly, also cysteine-rich antimicrobial peptides, which predominate in the antimicrobial defense of other insects, had not been discovered in Lepidoptera, Here we report the isolation from the hemolymph of immune induced larvae of the lepidopteran Heliothis virescens of a cysteine-rich molecule with exclusive antifungal activity. We have fully characterized this antifungal molecule, which has significant homology with the insect defensins, a large family of antibacterial peptides directed against Gram-positive strains. Interestingly, the novel peptide shows also similarities with the antifungal peptide drosomycin from Drosophila. Thus, Lepidoptera appear to have built their humoral immune response against bacteria on cecropins and attacins. In addition, we report that Lepidoptera have conferred antifungal properties to the well conserves structure of antibacterial insect defensins through amino acid replacements.	CNRS, Unite Propre Rech 9022, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Rhone Poulenc Agro, Res Triangle Pk, NC 27709 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bulet, P (corresponding author), CNRS, Unite Propre Rech 9022, Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	bulet@ibmc.u-strasbg.fr	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Axen A, 1997, EUR J BIOCHEM, V247, P614, DOI 10.1111/j.1432-1033.1997.00614.x; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1995, BIOCHEMISTRY-US, V34, P7394, DOI 10.1021/bi00022a012; BULET P, 1993, J BIOL CHEM, V268, P14893; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; Fant F, 1998, J MOL BIOL, V279, P257, DOI 10.1006/jmbi.1998.1767; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; HARA S, 1995, J BIOL CHEM, V270, P29923, DOI 10.1074/jbc.270.50.29923; HARA S, 1995, BIOCHEM J, V310, P651, DOI 10.1042/bj3100651; Hetru Charles, 1998, P40; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; Landon C, 1997, PROTEIN SCI, V6, P1878, DOI 10.1002/pro.5560060908; Lockey TD, 1996, EUR J BIOCHEM, V236, P263, DOI 10.1111/j.1432-1033.1996.00263.x; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Michaut L, 1996, FEBS LETT, V395, P6, DOI 10.1016/0014-5793(96)00992-1; Oerke EC., 1994, CROP PRODUCTION CROP; OURTH DD, 1994, BIOCHEM BIOPH RES CO, V200, P35, DOI 10.1006/bbrc.1994.1410; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TAMAOKI H, 1991, PROTEIN ENG, V4, P509, DOI 10.1093/protein/4.5.509; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083	36	136	160	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9320	9326		10.1074/jbc.274.14.9320	http://dx.doi.org/10.1074/jbc.274.14.9320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092609	hybrid			2022-12-27	WOS:000079451800028
J	Ness, LS; Booth, IR				Ness, LS; Booth, IR			Different foci for the regulation of the activity of the KefB and KefC glutathione-gated K+ efflux systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POTASSIUM CHANNELS; ACTIVATION; CLONING; TRANSPORT; GENE	KefB and KefC are glutathione-gated K+ efflux systems in Escherichia coti, and the proteins exhibit strong similarity at the level of both primary sequence and domain organization. The proteins are maintained closed by glutathione and are activated by binding of adducts formed between glutathione and electrophiles. By construction of equivalent mutations in each protein, this study has analyzed the control over inactive state of the proteins. A UV-induced mutation in KefB, L75S, causes rapid spontaneous K+ efflux but has only a minor effect on K+ efflux via KefC. Similarly amino acid substitutions that cause increased spontaneous activity in RefC have only small effects in RefB. Exchange of an eight amino acid region from KefC (HALESDIE) with the equivalent sequence from KefB (HELETAID) has identified a role for a group of acidic residues in controlling KefC activity. The mutations HELETALD and L74S in KefC act synergistically, and the activity of the resultant protein resembles that of KefB. We conclude that, despite the high degree of sequence similarity, KefB and KefC: exhibit different sensitivities to the same site-specific mutations.	Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Booth, IR (corresponding author), Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.							Booth I. R., 1996, HDB BIOL PHYS, V2, P693; BOOTH IR, 1985, BIOCHIMIE, V67, P83, DOI 10.1016/S0300-9084(85)80233-9; DOUGLAS RM, 1994, MOL MEMBR BIOL, V11, P55, DOI 10.3109/09687689409161030; ELMORE MJ, 1990, MOL MICROBIOL, V4, P405, DOI 10.1111/j.1365-2958.1990.tb00607.x; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FERGUSON GP, 1995, MOL MICROBIOL, V17, P1025, DOI 10.1111/j.1365-2958.1995.mmi_17061025.x; FERGUSON GP, 1993, MOL MICROBIOL, V9, P1297, DOI 10.1111/j.1365-2958.1993.tb01259.x; Ferguson GP, 1997, J BACTERIOL, V179, P1007, DOI 10.1128/jb.179.4.1007-1012.1997; Maniatis T., 1982, MOL CLONING LAB MANU; MEURY J, 1982, EMBO J, V1, P339, DOI 10.1002/j.1460-2075.1982.tb01171.x; Miller S, 1997, J BIOL CHEM, V272, P24942, DOI 10.1074/jbc.272.40.24942; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; WOOD CM, 1996, THESIS U ABERDEEN AB; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	15	27	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9524	9530		10.1074/jbc.274.14.9524	http://dx.doi.org/10.1074/jbc.274.14.9524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092637	hybrid			2022-12-27	WOS:000079451800056
J	Niswender, CM; Copeland, SC; Herrick-Davis, K; Emeson, RB; Sanders-Bush, E				Niswender, CM; Copeland, SC; Herrick-Davis, K; Emeson, RB; Sanders-Bush, E			RNA editing of the human serotonin 5-Hydroxytryptamine 2C receptor silences constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 2ND INTRACELLULAR LOOP; HORMONE RECEPTOR; 5-HT2C RECEPTOR; AMINO-ACID; ION FLOW; ACTIVATION; MUTATIONS; CHANNELS; INTERNALIZATION	RNA transcripts encoding the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor (5-HT2CR) undergo adenosine-to-inosine RNA editing events at up to five specific sites. Compared with rat brain, human brain samples expressed higher levels of RNA transcripts encoding the amino acids valine-serine-valine (5-HT2C-VSV) and valine-glycine-valine (5-HT2C-VGV) at positions 156, 158, and 160, respectively. Agonist stimulation of the nonedited human receptor (5-HT2C-INI) and the edited 5-HT2C-VSV and 5-HT2C-VGV receptor variants stably expressed in NIH-3T3 fibroblasts demonstrated that serotonergic agonists were less potent at the edited receptors, Competition binding experiments revealed a guanine nucleotide-sensitive serotonin high affinity state only for the 5-HT2C-INI receptor; the loss of high affinity agonist binding to the edited receptor demonstrates that RNA editing generates unique 5-HT(2C)Rs that couple less efficiently to G proteins. This reduced G protein coupling for the edited isoforms is primarily due to silencing of the constitutive activity of the nonedited 5-HT2CR. The distinctions in agonist potency and constitutive activity suggest that different edited 5-HT(2C)Rs exhibit distinct responses to serotonergic ligands and further imply that RNA editing represents a novel mechanism for controlling physiological signaling at serotonergic synapses.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Psychiat, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA; Albany Med Coll, Dept Pharmacol, Albany, NY 12208 USA; Albany Med Coll, Dept Neurosci, Albany, NY 12208 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Albany Medical College; Albany Medical College	Sanders-Bush, E (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.			Emeson, Ronald/0000-0002-4585-1648				Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Ausubel FM, 1988, MOL REPROD DEV; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BASS BL, 1993, RNA WORLD, P383; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; FURCHGOTT RF, 1967, ANN NY ACAD SCI, V144, P882, DOI 10.1111/j.1749-6632.1967.tb53817.x; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HerrickDavis K, 1997, J NEUROCHEM, V69, P1138; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOYER D, 1994, PHARMACOL REV, V46, P157; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MORO O, 1993, J BIOL CHEM, V268, P22273; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Perez DM, 1996, MOL PHARMACOL, V49, P112; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sanders-Bush Elaine, 1995, P431; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WONG SKF, 1990, J BIOL CHEM, V265, P6219; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397	30	296	313	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9472	9478		10.1074/jbc.274.14.9472	http://dx.doi.org/10.1074/jbc.274.14.9472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092629	hybrid			2022-12-27	WOS:000079451800048
J	Stroschein, SL; Wang, W; Luo, KX				Stroschein, SL; Wang, W; Luo, KX			Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced Smad-dependent transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR SMAD4; DPC4 GENE; SIGNAL-TRANSDUCTION; INDUCIBLE ELEMENTS; II RECEPTOR; CELLS; EXPRESSION; COMPLEX; MADR2; PHOSPHORYLATION	Transforming growth factor beta (TGF beta) activates transcription of the plasminogen activator inhibitor type-1 (PAI-1) gene through a major TGF beta-responsive region (-740 and -647) in the PAI-1 promoter. This process requires the Smad family of signaling molecules. Upon phosphorylation by the TGF beta receptors, Smad2 and Smad3 homoligomerize and heteroligomerize with Smad4, translocate to the nucleus and activate transcription of TGF beta responsive genes. Smad3 and Smad4 have been shown to bind to various sites in the PAI-1 promoter. To determine the number of Smad-binding sites within the 94-base pair major TGF beta-responsive region and the mechanism of Smad-mediated transactivation, we systematically mapped the Smad-binding sites and show that Smad4 and Smad3 bind cooperatively to two adjacent DNA elements in this region. Both elements were required for TGF beta-induced, Smad3- and Smad4-dependent activation of PAI-1 transcription. Contrary to previous reports, transactivation of the PAI-1 promoter was mediated by the amino- but not carboxyl-terminal domains of the Smads. Furthermore, oligomerization of Smad3 markedly enhanced its binding to the two binding sites, Finally, a Smad4 mutation identified in a human pancreatic carcinoma that inactivates Smad4 signaling abolished Smad4: DNA binding activity, hence preventing transactivation of TGF beta-responsive genes. These results underscore the importance of the Smad4 DNA binding activity in controlling cell growth and carcinogenesis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Sci & Technol China, Dept Biol, Hefei, Anhui, Peoples R China	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Luo, KX (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall,Mail Code 3206, Berkeley, CA 94720 USA.							Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Barrett MT, 1996, CANCER RES, V56, P4351; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BURATOWSKI S, 1997, CURRENT PROTOCOLS MO; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SK, 1996, CANCER RES, V56, P2519; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagatake M, 1996, CANCER RES, V56, P2718; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SMITH DB, 1997, CURRENT PROTOCOLS MO; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	49	108	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9431	9441		10.1074/jbc.274.14.9431	http://dx.doi.org/10.1074/jbc.274.14.9431			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092624	hybrid			2022-12-27	WOS:000079451800043
J	Fluiter, K; Sattler, W; De Beer, MC; Connell, PM; van der Westhuyzen, DR; van Berkel, TJC				Fluiter, K; Sattler, W; De Beer, MC; Connell, PM; van der Westhuyzen, DR; van Berkel, TJC			Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; SR-BI; PARENCHYMAL-CELLS; OXIDATIVE MODIFICATION; LIPID HYDROPEROXIDES; PLASMA-LIPOPROTEINS; KUPFFER CELLS; ADRENAL-GLAND; VIVO	High density lipoprotein (HDL) can protect low density lipoprotein (LDL) against oxidation, Oxidized cholesterol esters from LDL can be transferred to HDL and efficiently and selectively removed from the blood circulation by the liver and adrenal in vivo. In the present study, we investigated whether scavenger receptor BI (SR-BI) is responsible for this process. At 30 min after injection, the selective uptake of oxidized cholesterol esters from HDL for liver and adrenal was 2.3- and 2.6-fold higher, respectively, than for native cholesterol esters, whereas other tissues showed no significant difference. The selective uptake of oxidized cholesterol esters from HDL by isolated liver parenchymal cells could be blocked for 75% by oxidized LDL and for 50% by phosphatidylserine liposomes, both of which are known substrates of SR-BI, In vivo uptake of oxidized cholesterol esters from HDL by parenchymal cells decreased by 64 and 81% when rats were treated with estradiol and a high cholesterol diet, respectively, whereas Kupffer cells showed 660 and 475% increases, respectively. These contrasting changes in oxidized cholesterol ester uptake were accompanied by similar contrasting changes in SR-BI expression of parenchymal and Kupffer cells. The rates of SR-BI-mediated selective uptake of oxidized and native cholesterol esters were analyzed in SR-BI-transfected Chinese hamster ovary cells. SR-BI-mediated selective uptake was 3.4-fold higher for oxidized than for native cholesterol esters (30 min of incubation). It is concluded that in addition to the selective uptake of native cholesterol esters, SR-BI is responsible for the highly efficient Selective uptake of oxidized cholesterol esters from HDL and thus forms an essential mediator in the HDL-associated protection system for atherogenic oxidized cholesterol esters.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Graz Univ, Inst Med Biochem, A-8010 Graz, Austria; Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA	Leiden University; Leiden University - Excl LUMC; University of Graz; University of Kentucky	van Berkel, TJC (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Sylvius Labs, POB 9503, NL-2300 RA Leiden, Netherlands.		Van Berkel, Theo/ABD-7677-2021; Eckhardt, Erik/G-1567-2010; Fluiter, Kees/H-2828-2015	Fluiter, Kees/0000-0003-0898-7260	NHLBI NIH HHS [HL59376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRAF J, 1990, J HEPATOL, V10, P387, DOI 10.1016/0168-8278(90)90152-H; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sakai M, 1996, ATHEROSCLEROSIS, V119, P191, DOI 10.1016/0021-9150(95)05646-7; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1995, FREE RADICAL BIO MED, V18, P421, DOI 10.1016/0891-5849(94)00170-O; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Thuren TY, 1998, CIRCULATION, V98, P201; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1982, BIOCHEM J, V208, P493, DOI 10.1042/bj2080493; VANKUIJK FJGM, 1990, METHOD ENZYMOL, V186, P388; VanVelzen AG, 1997, BIOCHEM J, V322, P411; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WEISGRABER KH, 1980, J LIPID RES, V21, P316; Xu SZ, 1997, J LIPID RES, V38, P1289	45	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8893	8899		10.1074/jbc.274.13.8893	http://dx.doi.org/10.1074/jbc.274.13.8893			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085133	Green Published, hybrid			2022-12-27	WOS:000079451600075
J	Skiba, NP; Yang, CS; Huang, T; Bae, H; Hamm, HE				Skiba, NP; Yang, CS; Huang, T; Bae, H; Hamm, HE			The alpha-helical domain of G alpha(t) determines specific interaction with regulator of G protein signaling 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; PHOTORECEPTOR G-PROTEIN; HETEROTRIMERIC G-PROTEIN; ROD OUTER SEGMENTS; CGMP PHOSPHODIESTERASE; CRYSTAL-STRUCTURE; RGS PROTEINS; GAMMA-SUBUNIT; ACCELERATING PROTEIN; INHIBITORY SUBUNIT	RGS proteins (regulators of G protein signaling) are potent accelerators of the intrinsic GTPase activity of G protein alpha subunits (GAPs), thus controlling the response kinetics of a variety of cell signaling processes. Most RGS domains that have been studied have relatively little GTPase activating specificity especially for G proteins within the G(i) subfamily. Retinal RGS9 is unique in its ability to act synergistically with a downstream effector cGMP phosphodiesterase to stimulate the GTPase activity of the alpha subunit of transducin, G alpha(t). Here we report another unique property of RGS9: high specificity for G alpha(t). The core (RGS) domain of RGS9 (RGS9) stimulates G alpha(t) GTPase activity by 10-fold and G alpha(i1) GTPase activity by only 2-fold at a concentration of 10 mu M. Using chimeric G alpha(t)/G alpha(i1) subunits we demonstrated that the alpha-helical domain of G alpha(t) imparts this specificity. The functional effects of RGS9 were well correlated with its affinity for activated G alpha subunits as measured by a change in fluorescence of a mutant G alpha(t) (Chi6b) selectively labeled at Cys-210, K-d values for RGS9 complexes with G alpha(t) and G alpha(i1) calculated from the direct binding and competition experiments were 185 nM and 2 mu M, respectively. The gamma subunit of phosphodiesterase increases the GAP activity of RGS9, We demonstrate that this is because of the ability of P gamma to increase the affinity of RGS9 for G alpha(t). A distinct, nonoverlapping pattern of RGS and P gamma interaction with G alpha(t) suggests a unique mechanism of effector-mediated GAP function of the RGS9.	Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Dept Ophthalmol, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biol Chem, Searle Bldg,Rm 5-555,320 E Super St, Chicago, IL 60611 USA.	h-hamm@nwu.edu	Hamm, Heidi E/G-2374-2014; Bae, Hyunsu/ABH-6248-2020	Bae, Hyunsu/0000-0002-0299-3582; YANG, CHII-SHEN/0000-0002-2792-6247	NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY10291, EY06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Natochin M, 1998, BIOCHEMISTRY-US, V37, P13776, DOI 10.1021/bi981155a; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Seno K, 1998, J BIOL CHEM, V273, P22169, DOI 10.1074/jbc.273.35.22169; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Wieland T, 1997, J BIOL CHEM, V272, P8853; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379	54	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8770	8778		10.1074/jbc.274.13.8770	http://dx.doi.org/10.1074/jbc.274.13.8770			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085118	hybrid			2022-12-27	WOS:000079451600060
J	Bell, B; Xing, HM; Yan, K; Gautam, N; Muslin, AJ				Bell, B; Xing, HM; Yan, K; Gautam, N; Muslin, AJ			KSR-1 binds to G-protein beta gamma subunits and inhibits beta gamma-induced mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; GENE ENCODES; C-ELEGANS; RAS; RAF-1; INTERACTS; PATHWAY	The protein kinase KSR-1 is a recently identified participant in the Res signaling pathway. The subcellular localization of KSR-1 is variable. In serum-deprived cultured cells, KSR-1 is primarily found in the cytoplasm; in serum-stimulated cells, a significant portion of KSR-1 is found at the plasma membrane. To identify the mechanism that mediates KSR-1 translocation, we performed a yeast two-hybrid screen. Three clones that interacted with KSR-1 were found to encode the full-length gamma(10) subunit of heterotrimeric G-proteins. KSR-1 also interacted with gamma(2) and gamma(3) in a two-hybrid assay. Deletion analysis demonstrated that the isolated CA3 domain of KSR-1, which contains a cysteine-rich zinc finger-like domain, interacted with gamma subunits. Coimmunoprecipitation experiments demonstrated that KSR-1 bound to beta(1)gamma(3) subunits when all three were transfected into cultured cells. Lysophosphatidic acid treatment of cells induced KSR-1 translocation to the plasma membrane from the cytoplasm that was blocked by administration of pertussis toxin but not by dominant-negative Ras. Finally, transfection of wild-type KSR-1 inhibited beta(1)gamma(3)-induced mitogen-activated protein kinase activation in cultured cells. These results demonstrate that KSR-1 translocation to the plasma membrane is mediated, at least in part, by an interaction with beta(gamma) and that this interaction may modulate mitogen-activated protein kinase signaling.	Washington Univ, Cardiovasc Res Ctr, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), Washington Univ, Cardiovasc Res Ctr, Sch Med, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	amuslin@imgate.wustl.edu						Coso OA, 1996, J BIOL CHEM, V271, P3963; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GALLAGHER C, 1994, METHOD ENZYMOL, V237, P471; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; Pellegrino S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/jbc.272.40.25360; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X	36	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7982	7986		10.1074/jbc.274.12.7982	http://dx.doi.org/10.1074/jbc.274.12.7982			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075696	hybrid			2022-12-27	WOS:000079268100055
J	Biswas, N; Weller, SK				Biswas, N; Weller, SK			A mutation in the C-terminal putative Zn2+ finger motif of UL52 severely affects the biochemical activities of the HSV-1 helicase-primase subcomplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; ORIGIN-BINDING PROTEIN; PHOTO-CROSS-LINKING; SINGLE-STRANDED-DNA; COLI REP HELICASE; ZINC FINGERS; UL8 SUBUNIT; CRYSTAL-STRUCTURE; DEPENDENT ATPASE; GENE-PRODUCTS	Herpes simplex virus type 1 encodes a heterotrimeric helicase-primase complex that is composed of the products of the UL5, UL52, and UL8 genes. A subcomplex consisting of the UL5 and UL52 proteins retains all the enzymatic activities exhibited by the holoenzyme in vitro. The UL52 protein contains a putative zinc finger at its C terminus which is highly conserved among both prokaryotic and eukaryotic primases. We constructed a mutation in which two highly conserved cysteine residues in the zinc finger motif were replaced with alanine residues. A UL52 expression plasmid containing the mutation in the zinc finger region is unable to support the growth of a UL52 mutant virus in a transient complementation assay. Wild type and mutant UL5.UL52 subcomplexes were purified from insect cells infected with recombinant baculoviruses. Surprisingly, the mutant protein was severely affected in all biochemical activities tested; no helicase or primase activities could be detected, and the mutant protein retains only about 9% of wild type levels of single-stranded DNA-dependent ATPase activity. Gel mobility shift assays showed that DNA binding is severely affected as well; the mutant subcomplex only retains approximately 8% of wild type levels of binding to a forked substrate. On the other hand, the mutant protein retains its ability to interact with UL5 as indicated by copurification and with UL8 as indicated by a supershifted band in the gel mobility shift assay. In addition, the ability of individual subunits to bind single-stranded DNA was examined by photo crosslinking. In the wild type UL5 UL52 subcomplex, both subunits are able to bind an 18-mer of oligo(dT), The mutant subcomplex was severely compromised in the ability of both UL5 and UL52 to bind the oligonucleotide; total cross-linking was only 2% of wild type levels. These results are consistent with the proposal that the putative zinc binding motif of UL52 is required not only for binding of the UL52 subunit to DNA and for primase activity but also for optimal binding of UL5 to DNA and for the subsequent ATPase and helicase activities.	Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA	University of Connecticut	Weller, SK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA.		Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	PHS HHS [A121747] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CARMICHAEL EP, 1989, J VIROL, V63, P591, DOI 10.1128/JVI.63.2.591-599.1989; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; GAC NTL, 1996, J BIOL CHEM, V271, P21645; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GravesWoodward KL, 1997, J BIOL CHEM, V272, P4623, DOI 10.1074/jbc.272.7.4623; GravesWoodward KL, 1996, J BIOL CHEM, V271, P13629, DOI 10.1074/jbc.271.23.13629; Hamatake RK, 1997, J GEN VIROL, V78, P857, DOI 10.1099/0022-1317-78-4-857; Healy S, 1997, J BIOL CHEM, V272, P3411, DOI 10.1074/jbc.272.6.3411; Hong Z, 1996, J VIROL, V70, P4261, DOI 10.1128/JVI.70.7.4261-4268.1996; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Joo WS, 1998, MOL CELL BIOL, V18, P2677, DOI 10.1128/MCB.18.5.2677; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lukonis CJ, 1997, J VIROL, V71, P2390, DOI 10.1128/JVI.71.3.2390-2399.1997; Marsden HS, 1997, J VIROL, V71, P6390, DOI 10.1128/JVI.71.9.6390-6397.1997; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; Meisenheimer KM, 1996, NUCLEIC ACIDS RES, V24, P981, DOI 10.1093/nar/24.5.981; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OLIVO PD, 1990, HERPESVIRUS TRANSCRI; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELLER SK, 1983, J VIROL, V45, P354, DOI 10.1128/JVI.45.1.354-366.1983; WELLER SK, 1990, HERPESVIRUS TRANSCRI, P105; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WITTE MM, 1988, MOL CELL BIOL, V8, P3726, DOI 10.1128/MCB.8.9.3726; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; ZHU L, 1992, J VIROL, V66, P458, DOI 10.1128/JVI.66.1.458-468.1992; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	57	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8068	8076		10.1074/jbc.274.12.8068	http://dx.doi.org/10.1074/jbc.274.12.8068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075707	hybrid			2022-12-27	WOS:000079268100066
J	Gelman, L; Zhou, GC; Fajas, L; Raspe, E; Fruchart, JC; Auwerx, J				Gelman, L; Zhou, GC; Fajas, L; Raspe, E; Fruchart, JC; Auwerx, J			p300 interacts with the N- and C-terminal part of PPAR gamma 2 in a ligand-independent and -dependent manner, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; KINASE-MEDIATED PHOSPHORYLATION; PROTEIN-KINASE; PPAR-GAMMA; TRANSCRIPTIONAL COACTIVATOR; RETINOIC ACID; FATTY-ACIDS; CBP; EXPRESSION; THIAZOLIDINEDIONE	The nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) activates the transcription of multiple genes involved in intra- and extracellular lipid metabolism. Several cofactors are crucial for the stimulation or the silencing of nuclear receptor transcriptional activities. The two homologous cofactors p300 and CREB-binding protein (CBP) have been shown to co-activate the ligand-dependent transcriptional activities of several nuclear receptors as well as the ligand-independent transcriptional activity of the androgen receptor. We show here that the interaction between p300/CBP and PPAR gamma is complex and involves multiple domains in each protein, p300/CBP not only bind in a ligand-dependent manner to the DEF region of PPAR gamma but also bind directly in a ligand-independent manner to a region in the AB domain localized between residue 31 to 99, In transfection experiments, p300/CBP could thereby enhance the transcriptional activities of both the activating function (AF)-1 and AF-2 domains. p300/CBP displays itself at least two docking sites for PPAR gamma located in its N terminus (between residues 1 and 113 for CBP) and in the middle of the protein (between residues 1099 and 1460).	Inst Pasteur, LBRE, Unite 325,INSERM, Dept Atherosclerose, F-59019 Lille, France; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Rahway, NJ 07065 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Merck & Company	Auwerx, J (corresponding author), Inst Pasteur, LBRE, Unite 325,INSERM, Dept Atherosclerose, 1 Rue Prof Calmette, F-59019 Lille, France.		Coll, Lluis Fajas/C-8567-2014	Auwerx, Johan/0000-0002-5065-5393; Fajas, Lluis/0000-0002-1283-9503; Gelman, Laurent/0000-0003-3277-3115				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leong GM, 1998, J BIOL CHEM, V273, P2296, DOI 10.1074/jbc.273.4.2296; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schoonjans K, 1996, J LIPID RES, V37, P907; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	48	191	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7681	7688		10.1074/jbc.274.12.7681	http://dx.doi.org/10.1074/jbc.274.12.7681			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075656	hybrid			2022-12-27	WOS:000079268100015
J	Na, SY; Kang, BY; Chung, SW; Han, SJ; Ma, XJ; Trinchieri, G; Im, SY; Lee, JW; Kim, TS				Na, SY; Kang, BY; Chung, SW; Han, SJ; Ma, XJ; Trinchieri, G; Im, SY; Lee, JW; Kim, TS			Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; ESTROGEN-RECEPTOR; P65 SUBUNIT; NUCLEAR RECEPTORS; DENDRITIC CELLS; IL-12; EXPRESSION; PROTEIN; COACTIVATOR; IDENTIFICATION	Lipopolysaccharide (LPS) increases the production of interleukin-12 (IL-12) from mouse macrophages via a kappa B site within the IL-12 p40 promoter. In this study, we found that retinoids inhibit this LPS-stimulated production of IL-12 in a dose-dependent manner. The NF kappa B components p50 and p65 bound retinoid X receptor (RXR) in a ligand-independent manner in vitro, and the interaction interfaces involved the p50 residues 1-245, the p65 residues 194-441, and the N-terminal A/B/C domains of RXR, Activation of macrophages by LPS resulted in markedly enhanced binding activities to the kappa B site, which significantly decreased upon addition of retinoids, as demonstrated by the electrophoretic mobility shift assays. In cotransfections of CV-1 and HeLa cells, RXR also inhibited the NF kappa B transactivation in a ligand-dependent manner, whereas a mutant RXR lacking the AF2 transactivation domain, which serves as ligand-dependent binding sites for transcription integrators SRC-1 and p300, was without any effect. In addition, coexpression of increasing amounts of SRC-1 or p300 relieved the retinoid-mediated inhibition of the NF kappa B transactivation, From these results, we propose that retinoid-mediated suppression of the IL-12 production from LPS-activated macrophages may involve both inhibition of the NF kappa B-DNA interactions and competitive recruitment of transcription integrators between NF kappa B and RXR.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; The Wistar Institute	Kim, TS (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	taekim@chonnam.chonnam.ac.kr	Trinchieri, Giorgio/F-9369-2015	Trinchieri, Giorgio/0000-0001-5892-7464				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Benjamin D, 1996, J IMMUNOL, V156, P1626; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Caspi NR, 1998, CLIN IMMUNOL IMMUNOP, V88, P4, DOI 10.1006/clin.1998.4540; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Constantinescu CS, 1998, IMMUNOL LETT, V62, P25, DOI 10.1016/S0165-2478(98)00025-X; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; DeKruyff R, 1998, J IMMUNOL, V160, P2231; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Irving H, 1998, EUR J CANCER, V34, P111, DOI 10.1016/S0959-8049(97)10027-2; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kang KF, 1996, J IMMUNOL, V156, P1402; Kim CH, 1995, J INFLAMM, V45, P312; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim TS, 1997, J IMMUNOL, V158, P4137; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDyer JF, 1998, J ALLERGY CLIN IMMUN, V102, P11; Moller DR, 1997, IMMUNOLOGY, V91, P197, DOI 10.1046/j.1365-2567.1997.00246.x; Moller DR, 1997, J IMMUNOL, V159, P5157; Moore DD, 1995, GLOB MOB SURV; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; ONATE SA, 1995, SCIENCE, V270, P1354; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rogers MB, 1997, CURR TOP DEV BIOL, V35, P1, DOI 10.1016/S0070-2153(08)60255-0; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Tone Y, 1996, EUR J IMMUNOL, V26, P1222, DOI 10.1002/eji.1830260606; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yoshimoto T, 1996, J IMMUNOL, V156, P1082; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	55	211	214	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7674	7680		10.1074/jbc.274.12.7674	http://dx.doi.org/10.1074/jbc.274.12.7674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075655	hybrid			2022-12-27	WOS:000079268100014
J	Vacherot, F; Delbe, J; Heroult, M; Barritault, D; Fernig, DG; Courty, J				Vacherot, F; Delbe, J; Heroult, M; Barritault, D; Fernig, DG; Courty, J			Glycosaminoglycans differentially bind HARP and modulate its biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; AFFIN REGULATORY PEPTIDE; MOLECULE HB-GAM; AMINO-ACID-SEQUENCE; HEPARAN-SULFATE; CELL-SURFACE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; NEURITE OUTGROWTH; DEVELOPING BRAIN	Heparin affin regulatory peptide (HARP) is a polypeptide belonging to a family of heparin binding growth/differentiation factors. The high affinity of HARP for heparin suggests that this secreted polypeptide should also bind to heparan sulfate proteoglycans derived from cell surface and extracellular matrix defined as extracellular compartments. Using Western blot analysis, we detected HARP bound to heparan sulfate proteoglycans in the extracellular compartments of MDA-MB 231 and MC 3T3-E1 as well as NIH3T3 cells overexpressing HARP protein. Heparitinase treatment of EEL cells inhibited HARP-induced cell proliferation, and the biological activity of HARP in this system was restored by the addition of heparin, We report that heparan sulfate, dermatan sulfate, and to a lesser extent, chondroitin sulfate A, displaced HARP bound to the extracellular compartment, Binding analyses with a biosensor showed that HARP bound heparin with fast association and dissociation kinetics (k(ass) = 1.6 x 10(6) M-1 s(-1); k(diss) = 0.02 s(-1)), yielding a K-d value of 13 nM; the interaction between HARP and dermatan sulfate was characterized by slower association kinetics (k(ass) = 0.68 x 10(6) M-1 s(-1)) and a lower affinity (K-d = 51 nM). Exogenous heparin, heparan sulfate, and dermatan sulfate potentiated the growth-stimulatory activity of HARP, suggesting that corresponding proteoglycans could be involved in the regulation of the mitogenic activity of HARP.	Univ Paris 12, CNRS 7053, UPRES A,Unite Propre Rec Enseignement Superieur A, CRRET,Lab Rech Croissance Cellulaire Reparat & Re, F-94010 Creteil, France; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Liverpool	Courty, J (corresponding author), Univ Paris 12, CNRS 7053, UPRES A,Unite Propre Rec Enseignement Superieur A, CRRET,Lab Rech Croissance Cellulaire Reparat & Re, Ave Gen de Gaulle, F-94010 Creteil, France.		Delbe, Jean/R-3680-2018; Courty, Jose/Q-3702-2018; Vacherot, Francis/R-6588-2018; Fernig, David G/A-3590-2008	Vacherot, Francis/0000-0002-3677-1267; Fernig, David G/0000-0003-4875-4293				BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; Bohlen P, 1991, GROWTH FACTORS, V4, P97, DOI 10.3109/08977199109000261; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P355; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HUGHES RC, 1975, EUR J BIOCHEM, V52, P143, DOI 10.1111/j.1432-1033.1975.tb03982.x; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KUO MD, 1990, J BIOL CHEM, V265, P18749; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledoux D, 1997, J HISTOCHEM CYTOCHEM, V45, P1239, DOI 10.1177/002215549704500907; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PENG HB, 1995, J NEUROSCI, V15, P3027; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WANAKA A, 1993, DEV BRAIN RES, V72, P133, DOI 10.1016/0165-3806(93)90166-8; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YEUNG D, 1995, TRAC-TREND ANAL CHEM, V14, P49, DOI 10.1016/0165-9936(95)91472-5; ZHOU HY, 1992, BIOCHEM BIOPH RES CO, V186, P1288, DOI 10.1016/S0006-291X(05)81545-1	47	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7741	7747		10.1074/jbc.274.12.7741	http://dx.doi.org/10.1074/jbc.274.12.7741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075664	hybrid			2022-12-27	WOS:000079268100023
J	Chen, W; LoBrutto, R; Frasch, WD				Chen, W; LoBrutto, R; Frasch, WD			EPR spectroscopy of VO2+-ATP bound to catalytic site 3 of chloroplast F-1-ATPase from Chlamydomonas reveals changes in metal ligation resulting from mutations to the phosphate-binding loop threonine (beta T168)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; MITOCHONDRIAL F1-ATPASE; ESCHERICHIA-COLI; ATP; ADP; SUBUNIT; DOMAIN; SUBSTITUTION; NUCLEOTIDES; RESOLUTION	Site-directed mutations were made to the phosphate-binding loop threonine in the P-subunit of the chloroplast F-1-ATPase in Chlamydomonas (beta T168), Rates of photophosphorylation and ATPase-driven proton translocation measured in coupled thylakoids purified from beta T168D, beta T168C, and beta T168L mutants had <10% of the wild type rates, as did rates of Mg2+-ATPase activity of purified chloroplast F-1-ATPase (CF1), The EPR spectra of VO2+-ATP bound to Site 3 of CF1 from wild type and mutants showed that EPR species C, formed exclusively upon activation, was altered in CF, from each mutant in both signal intensity and in V-51 hyperfine parameters that depend on the equatorial VO2+ ligands. These data provide the first direct evidence that Site 3 is a catalytic site, No significant differences between wild type and mutants were observed in EPR species B, the predominant form of the latent enzyme. Thus, the phosphate-binding loop threonine is an equatorial metal ligand in the activated conformation but not in the latent conformation of Site 3, The metal-nucleotide conformation that gives rise to species B is consistent with the Mg2+-ADP complex that becomes entrapped in a catalytic site in a manner that regulates enzymatic activity. The lack of catalytic function of CF1 with entrapped Mg2+-ADP may be explained in part by the absence of the phosphate-binding loop threonine as a metal ligand.	Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Frasch, WD (corresponding author), Arizona State Univ, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA.	frasch@asu.edu			NIGMS NIH HHS [R01 GM050202, GM50202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; Chasteen N.D., 1981, BIOL MAGN RESON, V3, P53; DUNHAM KR, 1981, J BIOL CHEM, V256, P212; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRASCH WD, 1982, BIOCHEMISTRY-US, V21, P3636, DOI 10.1021/bi00258a017; Frasch WD, 1994, MOL BIOL CYANOBACTER, P361; Hamstra BJ, 1997, INORG CHEM, V36, P4866, DOI 10.1021/ic970284x; HOLYK N, 1979, THESIS U NEW HAMSPHI; HOUSEMAN ALP, 1995, BIOCHEMISTRY-US, V34, P3277, DOI 10.1021/bi00010a018; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P4910, DOI 10.1021/bi00182a020; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P10000, DOI 10.1021/bi00199a025; Hu CY, 1996, BIOCHEMISTRY-US, V35, P12201, DOI 10.1021/bi961105a; Hu DL, 1998, FEBS LETT, V421, P65, DOI 10.1016/S0014-5793(97)01531-7; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; MARKHAM GD, 1984, BIOCHEMISTRY-US, V23, P470, DOI 10.1021/bi00298a011; MAURICE AM, 1981, THESIS U ILLINOIS; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MUELLER DM, 1994, EUR J BIOCHEM, V222, P991, DOI 10.1111/j.1432-1033.1994.tb18950.x; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Nilges M. J., 1979, THESIS U ILLINOIS UR; OMOTE H, 1992, J BIOL CHEM, V267, P20571; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; Pal E.F., 1989, NATURE, V341, P209; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SCHUMANN J, 1980, P 5 INT PHOT C BALB, V2, P881; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SMITH DJ, 1976, P NATL ACAD SCI USA, V73, P4314, DOI 10.1073/pnas.73.12.4314; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; XIAO JP, 1989, BIOCHIM BIOPHYS ACTA, V976, P203, DOI 10.1016/S0005-2728(89)80231-2; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	40	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7089	7094		10.1074/jbc.274.11.7089	http://dx.doi.org/10.1074/jbc.274.11.7089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066766	hybrid			2022-12-27	WOS:000079078400038
J	Jobbagy, Z; Olah, Z; Petrovics, G; Eiden, MV; Leverett, BD; Dean, NM; Anderson, WB				Jobbagy, Z; Olah, Z; Petrovics, G; Eiden, MV; Leverett, BD; Dean, NM; Anderson, WB			Up-regulation of the Pit-2 phosphate transporter retrovirus receptor by protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APE LEUKEMIA-VIRUS; OSTEOBLAST-LIKE CELLS; NIH 3T3 CELLS; ECOTROPIC MURINE RETROVIRUSES; AMINO-ACID TRANSPORTER; PARATHYROID-HORMONE; SURFACE RECEPTOR; GROWTH; INVOLVEMENT; STIMULATION	The membrane receptors for the gibbon ape leukemia retrovirus and the amphotropic murine retrovirus serve normal cellular functions as sodium-dependent phosphate transporters (Pit-1 and Pit-2, respectively). Our earlier studies established that activation of protein kinase C (PKC) by treatment of cells with phorbol 12-myristate 13-acetate (PMA) enhanced sodium-dependent phosphate (Na/P-i) uptake, Studies now have been carried out to determine which type of Na/P-i transporter (Pit-1 or Pit-2) is regulated by PKC and which PKC isotypes are involved in the up-regulation of Na/P-i uptake by the Na/P-i transporter/viral receptor. It was found that the activation of short term (2-min) Na/P-i uptake by PMA is abolished when cells are infected with amphotropic murine retrovirus (binds Pit-2 receptor) but not with gibbon ape leukemia retrovirus (binds Pit-1 receptor), indicating that Pit-2 is the form of Na/P-i, transporter/viral receptor regulated by PKC, The PKC-mediated activation of Pit-2 was blocked by pretreating cells with the pan-PKC inhibitor bisindolylmaleimide but not with the conventional PKC isotype inhibitor Go 6976, suggesting that a novel PKC isotype is required to regulate Pit-2. Overexpression of PKC epsilon, but not of PKC alpha, -delta, or -zeta was found to mimic the activation of Na/P-i uptake. To further establish that PKC epsilon is involved in the regulation of Pit-2, cells were treated with PKC epsilon-selective antisense oligonucleotides, Treatment with PKC epsilon antisense oligonucleotides decreased the PMA-induced activation of Na/P-i uptake. These results indicate that PMA-induced stimulation of Na/P-i uptake by Pit-2 is specifically mediated through activation of PKC epsilon.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; ISIS Pharmaceut, Carlsbad Res Ctr, Dept Pharmacol, Carlsbad, CA 92008 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); US Food & Drug Administration (FDA); Isis Pharmaceuticals Inc	Anderson, WB (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 37,Rm 1E-14,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.			Petrovics, Gyorgy/0000-0003-3732-284X	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002592, Z01MH002592] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAO M, 1994, EUR J ENDOCRINOL, V131, P646, DOI 10.1530/eje.0.1310646; BARQUINERO J, 1995, BLOOD, V85, P1195, DOI 10.1182/blood.V85.5.1195.bloodjournal8551195; Caverzasio J, 1996, KIDNEY INT, V49, P975, DOI 10.1038/ki.1996.138; COREY JL, 1994, J BIOL CHEM, V269, P14757; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; FranchiGazzola R, 1996, J BIOL CHEM, V271, P26124, DOI 10.1074/jbc.271.42.26124; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; KARIM Z, 1995, AM J PHYSIOL-CELL PH, V269, pC134, DOI 10.1152/ajpcell.1995.269.1.C134; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Liedtke CM, 1997, AM J PHYSIOL-CELL PH, V273, pC1632, DOI 10.1152/ajpcell.1997.273.5.C1632; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; Nishizuka Yasutomi, 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS202, DOI 10.1111/j.1440-1681.1995.tb02883.x; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLAH Z, 1994, J BIOL CHEM, V269, P25426; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; Palmer G, 1997, ENDOCRINOLOGY, V138, P5202, DOI 10.1210/en.138.12.5202; QUAMME G, 1989, AM J PHYSIOL, V257, pF967, DOI 10.1152/ajprenal.1989.257.6.F967; QUAMME G, 1994, BBA-MOL CELL RES, V1223, P107, DOI 10.1016/0167-4889(94)90079-5; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Rokaw MD, 1996, J BIOL CHEM, V271, P32468, DOI 10.1074/jbc.271.50.32468; Schmid C, 1998, BIOCHEM BIOPH RES CO, V245, P220, DOI 10.1006/bbrc.1998.8403; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Veldman CM, 1997, BONE, V21, P41, DOI 10.1016/S8756-3282(97)00077-X; Veldman CR, 1998, ENDOCRINOLOGY, V139, P89, DOI 10.1210/en.139.1.89; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; WILSON CA, 1991, J VIROL, V65, P5975, DOI 10.1128/JVI.65.11.5975-5982.1991; WILSON CA, 1995, J VIROL, V69, P534, DOI 10.1128/JVI.69.1.534-537.1995; Zhen XC, 1997, J BONE MINER RES, V12, P36, DOI 10.1359/jbmr.1997.12.1.36	34	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7067	7071		10.1074/jbc.274.11.7067	http://dx.doi.org/10.1074/jbc.274.11.7067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066763	hybrid			2022-12-27	WOS:000079078400035
J	Aspinwall, CA; Lakey, JRT; Kennedy, RT				Aspinwall, CA; Lakey, JRT; Kennedy, RT			Insulin-stimulated insulin secretion in single pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEEDBACK INHIBITION; B-CELLS; RECEPTOR SUBSTRATE-1; EXOGENOUS INSULIN; CANINE PANCREAS; GLUCOSE; ISLETS; RELEASE; RESISTANCE; CA2+	Functional insulin receptors are known to occur in pancreatic beta cells; however, except for a positive feedback on insulin synthesis, their physiological effects are unknown. Amperometric measurements at single, primary pancreatic beta cells reveal that application of exogenous insulin in the presence or absence of nonstimulatory concentrations of glucose evokes exocytosis mediated by the beta cell insulin receptor. Insulin also elicits increases in intracellular Ca2+ concentration in beta cells but has minimal effects on membrane potential. Conditions where the insulin receptor is blocked or cell surface concentration of free insulin is reduced during exocytosis diminishes secretion induced by other secretagogues, providing evidence for direct autocrine action of insulin upon secretion from the same cell. These results indicate that the beta cell insulin receptor can mediate positive feedback for insulin secretion. The presence of a positive feedback mechanism for insulin secretion mediated by the insulin receptor provides a potential Link between impaired insulin secretion and insulin resistance.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Alberta, Dept Surg, Comprehens Tissue Ctr, Edmonton, AB T6G 2N8, Canada	State University System of Florida; University of Florida; University of Alberta	Kennedy, RT (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	rtkenn@chem.ufl.edu	Kennedy, Robert/G-9095-2016	Kennedy, Robert/0000-0003-2447-7471; Aspinwall, Craig/0000-0002-4359-5812	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046960] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK46960] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1976, ENDOCRINOLOGY, V99, P1468, DOI 10.1210/endo-99-6-1469; ARGOUD GM, 1987, DIABETES, V36, P959, DOI 10.2337/diabetes.36.8.959; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; BEISCHER W, 1983, DIABETOLOGIA, V25, P139; BOSCO D, 1989, EXP CELL RES, V184, P72, DOI 10.1016/0014-4827(89)90365-0; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; DRAZNIN B, 1986, ENDOCRINOLOGY, V118, P1054, DOI 10.1210/endo-118-3-1054; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HUANG L, 1995, P NATL ACAD SCI USA, V92, P9608, DOI 10.1073/pnas.92.21.9608; HURLEY LS, 1969, AM J CLIN NUTR, V22, P1332; IVERSEN J, 1971, DIABETES, V20, P1; Kennedy RT, 1996, J AM CHEM SOC, V118, P1795, DOI 10.1021/ja953271w; Komatsu M, 1997, DIABETES, V46, P1928, DOI 10.2337/diabetes.46.12.1928; Kulkarni RN, 1998, DIABETES, V47, pA57; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LI GD, 1991, J BIOL CHEM, V266, P3449; LILJENQUIST JE, 1978, DIABETES, V27, P563, DOI 10.2337/diab.27.5.563; LORETI L, 1974, DIABETOLOGIA, V10, P309; LUZI L, 1992, DIABETES, V41, P1632, DOI 10.2337/diabetes.41.12.1632; MAES E, 1984, ENDOCRINOLOGY, V114, P2205, DOI 10.1210/endo-114-6-2205; MAKI LW, 1995, AM J PHYSIOL-CELL PH, V268, pC780, DOI 10.1152/ajpcell.1995.268.3.C780; MALAISSE WJ, 1967, P SOC EXP BIOL MED, V124, P497; MARINCOLA F, 1983, DIABETES, V32, P1162, DOI 10.2337/diabetes.32.12.1162; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PACE CS, 1977, BIOCHIM BIOPHYS ACTA, V497, P408; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; SCHATZ H, 1977, J ENDOCRINOL, V74, P243, DOI 10.1677/joe.0.0740243; SCHUIT FC, 1989, DIABETOLOGIA, V32, P207, DOI 10.1007/BF00265096; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; SODOYEZ JC, 1969, P SOC EXP BIOL MED, V130, P568; STAGNER J, 1986, J CLIN INVEST, V78, P1193, DOI 10.1172/JCI112702; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANAKA R, 1980, ENDOCRINOL JAPON, V27, P343; Tang JP, 1996, AM J PHYSIOL-ENDOC M, V270, pE504, DOI 10.1152/ajpendo.1996.270.3.E504; TAYLOR SI, 1994, DIABETES, V43, P735, DOI 10.2337/diab.43.6.735; VANSCHRAVENDIJK CFH, 1990, DIABETOLOGIA, V33, P649, DOI 10.1007/BF00400565; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; WARNOCK GL, 1994, PANCREATIC ISLET TRA, V1, P81; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu G, 1998, DIABETES, V47, pA57; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498	52	179	188	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6360	6365		10.1074/jbc.274.10.6360	http://dx.doi.org/10.1074/jbc.274.10.6360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037726	hybrid			2022-12-27	WOS:000078902800048
J	Gilchrist, A; Bunemann, M; Li, A; Hosey, MM; Hamm, HE				Gilchrist, A; Bunemann, M; Li, A; Hosey, MM; Hamm, HE			A dominant-negative strategy for studying roles of G proteins in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; NUCLEOTIDE-BINDING PROTEIN; HETEROTRIMERIC G-PROTEIN; PIG ATRIAL MYOCYTES; ALPHA-SUBUNIT; K+-CHANNEL; CRYSTAL-STRUCTURE; CYTOPLASMIC DOMAINS; CELLULAR EXPRESSION; SYNTHETIC PEPTIDES	G proteins play a critical role in transducing a large variety of signals into intracellular responses, Increasingly, there is evidence that G proteins may play other roles as well. Dominant-negative constructs of the ct subunit of G proteins would be useful in studying the roles of G proteins in a variety of processes, but the currently available dominant-negative constructs, which target Mg2+-binding sites, are rather leaky. A variety of studies have implicated the carboxyl terminus of G protein alpha subunits in both mediating receptor-G protein interaction and in receptor selectivity. Thus we have made minigene plasmid constructs that encode oligonucleotide sequences corresponding to the carboxyl-terminal undecapeptide of G alpha(i), G alpha(q), Or G alpha(s) To determine whether overexpression of the carboxyl-terminal peptide would block cellular responses, we used as a test system the activation of the M-2 muscarinic receptor activated K+ channels in HEK 293 cells. The minigenes were transiently transfected along with G protein-regulated inwardly rectifying K+ channels (GIRK) into HER 293 cells that stably express the M-2 muscarinic receptor. The presence of the G alpha(i) carboxyl-terminal peptide results in specific inhibition of GIRK activity in response to agonist stimulation of the M-2 muscarinic receptor. The G alpha(i) minigene construct completely blocks agonist-mediated M-2 mAChR K+ channel response whereas the control minigene constructs (empty vector, pcDNA3,1, and the G alpha carboxyl peptide in random order, pcDNA-G alpha(i)R) had no effect on agonist-mediated M-2 muscarinic receptor GIRK response. The inhibitory effects of the G alpha i minigene construct were specific because overexpression of peptides corresponding to the carboxyl terminus of G alpha(q) Or G alpha(s) had no effect on M-2 muscarinic receptor stimulation of the K+ channel.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Mol Pharmacol & Biochem, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, 320 E Super 5-555 Searle, Chicago, IL 60611 USA.		Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014	Gilchrist, Annette/0000-0003-2386-7646; 	NEI NIH HHS [EY06062, EY10291] Funding Source: Medline; NHLBI NIH HHS [HL50121] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Breitwieser GE, 1996, J MEMBRANE BIOL, V152, P1, DOI 10.1007/s002329900080; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; BUNEMANN M, 1995, J PHYSIOL-LONDON, V482, P81; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; CARREL F, 1994, MOL BIOL CELL, V5, P7, DOI 10.1091/mbc.5.1.7; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Jan LY, 1997, CURR OPIN CELL BIOL, V9, P155, DOI 10.1016/S0955-0674(97)80057-9; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LAI J, 1991, J PHARMACOL EXP THER, V258, P938; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takano K, 1997, J PHYSIOL-LONDON, V502, P559, DOI 10.1111/j.1469-7793.1997.559bj.x; THOMAS EA, 1994, J PHARMACOL EXP THER, V271, P1042; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Ulloa-Aguirre A, 1998, ENDOCRINOLOGY, V139, P2472, DOI 10.1210/en.139.5.2472; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WINITZ S, 1994, J BIOL CHEM, V269, P1889	63	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6610	6616		10.1074/jbc.274.10.6610	http://dx.doi.org/10.1074/jbc.274.10.6610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037756	hybrid			2022-12-27	WOS:000078902800078
J	Guillen, E; Abeijon, C; Hirschberg, CB				Guillen, E; Abeijon, C; Hirschberg, CB			The genes for the Golgi apparatus N-acetylglucosaminyltransferase and the UDP-N-acetylglucosamine transporter are contiguous in Kluyveromyces lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; YEAST; BIOSYNTHESIS	The mannan chains of Kluyveromyces lactis mannoproteins are similar to those of Saccharomyces cerevisiae except that they lack mannose phosphate and have terminal alpha(1-->2)-linked N-acetylglucosamine. Previously, Smith ct al, (Smith, W, L, Nakajima, T, and Ballou, C, E. (1975) J, Biol, Chem. 250, 3426-3435) characterized two mutants, mnn2-1 and mnn2-2, which lacked terminal N-acetylglucosamine in their mannoproteins. The former mutant lacks the Golgi N-acetylglucosaminyl-transferase activity, whereas the latter one was recently found to be deficient in the Golgi UDP-GlcNAc transporter activity. Analysis of extensive crossings between the two mutants led Ballou and co-workers (reference cited above) to conclude that these genes were allelic or tightly linked. We have now cloned the gene encoding the K. lactis Golgis membrane N-acetylglucosaminyltransferase by complementation of the mnn2-1 mutation and named it GNT1. The mnn2-1 mutant was transformed with a 9.5-kilobase (kb) genomic fragment previously shown to contain the gene encoding the UDP-GlcNAc transporter; transformants were isolated, and phenotypic correction was monitored after cell surface labeling with fluorescein isothiocyanate-conjugated Griffonia simplicifolia II lectin, which binds terminal N-acetylglucosamine, and a fluorescence-activated cell sorter. The above 9.5-kb DNA fragment restored the wild-type lectin binding phenotype of the transferase mutant; further subcloning of this fragment yielded a smaller one containing an opening reading frame of 1,383 bases encoding a protein of 460 amino acids with an estimated molecular mass of 53 kDa, which also restored the wild-type phenotype. Transformants had also regained the ability to transfer N-acetylglucosamine to 3-O-alpha-D-mannopyranosyl-D-mannopyranoside. The gene encoding the above transferase was found to be approximately 1 kb upstream from the previously characterized MNN2 gene encoding the UDP-GlcNAc Golgi transporter. Each gene can be transcribed independently by their own promoter. To our knowledge this is the first demonstration of two Golgis apparatus functionally related genes being contiguous in a genome.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 700 Albany St,W200, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Brown T., 1997, CURRENT PROTOCOLS MO; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; CHEN XJ, 1991, BIOCHIMIE, V73, P1195, DOI 10.1016/0300-9084(91)90004-K; COLLART M, 1993, CURRENT PROTOCOLS MO; DOUGLAS RH, 1982, BIOCHEMISTRY-US, V21, P1561, DOI 10.1021/bi00536a015; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HERMAN A, 1963, J BACTERIOL, V85, P895, DOI 10.1128/JB.85.4.895-900.1963; Kaiser C., 1994, METHODS YEAST GENETI, P209; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NEEDLEMAN RB, 1984, P NATL ACAD SCI-BIOL, V81, P2811, DOI 10.1073/pnas.81.9.2811; RASHKE WC, 1972, BIOCHEMISTRY-US, V11, P3807; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; SMITH WL, 1975, J BIOL CHEM, V250, P3426; WESOLOWSKILOUVEL M, 1988, YEAST, V4, P71, DOI 10.1002/yea.320040108; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6641	6646		10.1074/jbc.274.10.6641	http://dx.doi.org/10.1074/jbc.274.10.6641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037760	hybrid			2022-12-27	WOS:000078902800082
J	Haeseleer, F; Sokal, I; Li, N; Pettenati, M; Rao, N; Bronson, D; Wechter, R; Baehr, W; Palczewski, K				Haeseleer, F; Sokal, I; Li, N; Pettenati, M; Rao, N; Bronson, D; Wechter, R; Baehr, W; Palczewski, K			Molecular characterization of a third member of the guanylyl cyclase-activating protein subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CA2+-BINDING PROTEIN; VERTEBRATE RODS; MESSENGER-RNAS; CLONING; CALCIUM; LOCALIZATION; EXPRESSION; RETINA; GENES	The mammalian retina contains at least two guanylyl cyclases (GC1 and GC2) and two guanylyl cyclase-activating proteins (GCAP1 and GCAP2). Here we present evidence of the presence of a new photoreceptor-specific GCAP, termed GCAP3, which is closely related to GCAP1. The sequence similarity of GCAP3 with GCAP1 and GCAP2 is 57 and 49%, respectively. Recombinant GCAP3 and GCAP2 stimulate GC1 and GC2 in low [Ca2+](free) and inhibit GCs when [Ca2+](free) is elevated, unlike GCAP1, which only stimulates GC1. GCAP3 is encoded by a distinct gene present in other mammalian species but could not be detected by genomic Southern blotting in rodents, amphibians, and lower vertebrates. The intron/exon arrangement of the GCAP3 gene is identical to that of the other GCAP genes. While the GCAP1 and GCAP2 genes are arranged in a tail-to-tail array on chromosome 6p in human, the GCAP3 gene is located on 3q13.1, suggesting an ancestral gene duplication/translocation event. The identification of multiple Ca2+-binding proteins that interact with GC is suggestive of complex regulatory mechanisms for photoreceptor GC.	Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Chem, Seattle, WA 98195 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Med Genet Sect, Winston Salem, NC 27157 USA; Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84132 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Baylor College of Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Utah System of Higher Education; University of Utah	Haeseleer, F (corresponding author), Univ Washington, Sch Med, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.				NEI NIH HHS [EY08123, EY08061] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008123, R29EY008061, R01EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Cuenca N, 1998, INVEST OPHTH VIS SCI, V39, P1243; Dizhoor A. M., 1998, IOVS, V39, pS443; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; FISCHER R, 1988, J BIOL CHEM, V263, P17055; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HOWARD A, 1992, BIOCHEM BIOPH RES CO, V185, P663, DOI 10.1016/0006-291X(92)91676-H; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; JEUNG EB, 1994, J MOL BIOL, V235, P1231, DOI 10.1006/jmbi.1994.1076; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; PETTENATI MJ, 1998, NUCL ACID HYBRIDIZAT, P81; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pozdnyakov N, 1997, BIOCHEMISTRY-US, V36, P14159, DOI 10.1021/bi971792l; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SCHNETKAMP PPM, 1995, AM J PHYSIOL-CELL PH, V269, pC1153, DOI 10.1152/ajpcell.1995.269.5.C1153; Semple-Rowland S. L., 1998, IOVS, V39, pS952; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBBARAYA I, 1994, J BIOL CHEM, V269, P31080; Surgucheva I., 1997, Investigative Ophthalmology and Visual Science, V38, pS477; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513	37	115	117	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6526	6535		10.1074/jbc.274.10.6526	http://dx.doi.org/10.1074/jbc.274.10.6526			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037746	hybrid			2022-12-27	WOS:000078902800068
J	Jungmann, J; Rayner, JC; Munro, S				Jungmann, J; Rayner, JC; Munro, S			The Saccharomyces cerevisiae protein Mnn10p/Bed1p is a subunit of a Golgi mannosyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; OUTER CHAIN ELONGATION; YEAST MANNAN STRUCTURE; CELL-WALL; SCHIZOSACCHAROMYCES-POMBE; CHEMICAL-STRUCTURE; GLYCOSYLATION DEFECTS; GENETIC-CONTROL; MUTANTS; GLYCOSYLTRANSFERASES	In the yeast Saccharomyces cerevisiae many of the N-linked glycans on cell wall and periplasmic proteins are modified by the addition of mannan, a large mannose-containing polysaccharide. Mannan comprises a backbone of approximately 50 alpha-1,6-linked mannoses to which are attached many branches consisting of alpha-1,2-linked and alpha-1,3-linked mannoses. The initiation and subsequent elongation of the mannan backbone is performed by two complexes of proteins in the cis Golgis. In this study we show that the product of the MNN10/BED1 gene is a component of one of these complexes, that which elongates the backbone. Analysis of interactions between the proteins in this complex shows that Mnn10p, and four previously characterized proteins (Anp1p, Mnn9p, Mnn11p, and Hoc1p) are indeed all components of the same large structure, Deletion of either Mnn10p, or its homologue Mnn11p, results in defects in mannan synthesis in vivo, and analysis of the enzymatic activity of the complexes isolated from mutant strains suggests that Mnn10p and Mnn11p are responsible for the majority of the alpha-1,6-polymerizing activity of the complex.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Munro, Sean/0000-0001-6160-5773; Rayner, Julian/0000-0002-9835-1014				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BALLOU L, 1980, J BIOL CHEM, V255, P5986; BALLOU L, 1989, J BIOL CHEM, V264, P11857; BARDALAYE PC, 1977, J BIOL CHEM, V252, P2584; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; Gemmill TR, 1996, J BIOL CHEM, V271, P25945, DOI 10.1074/jbc.271.42.25945; Hashimoto H, 1997, BIOCHEM BIOPH RES CO, V241, P682, DOI 10.1006/bbrc.1997.7888; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; Ikuta K, 1997, FEBS LETT, V414, P338, DOI 10.1016/S0014-5793(97)01028-4; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; JIMENEZBARBERO J, 1995, CARBOHYD RES, V272, P121, DOI 10.1016/0008-6215(95)00023-M; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; Mondesert G, 1997, GENETICS, V147, P421; NAKAJIMA T, 1994, J FERMENT BIOENG, V78, P472, DOI 10.1016/0922-338X(94)90050-7; Nakamura T, 1997, MOL GEN GENET, V256, P481, DOI 10.1007/s004380050592; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEAT S, 1961, J CHEM SOC, P3918, DOI 10.1039/jr9610003918; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Roy SK, 1998, J BIOL CHEM, V273, P2583, DOI 10.1074/jbc.273.5.2583; Sekiya-Kawasaki M, 1998, GENETICS, V150, P43; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SMITH EL, 1940, P NATL ACAD SCI USA, V26, P23658; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	47	102	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6579	6585		10.1074/jbc.274.10.6579	http://dx.doi.org/10.1074/jbc.274.10.6579			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037752	hybrid			2022-12-27	WOS:000078902800074
J	Louis, JM; Oroszlan, S; Tozser, J				Louis, JM; Oroszlan, S; Tozser, J			Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; I-ASSOCIATED MYELOPATHY; ESCHERICHIA-COLI; HIV-1 PROTEASE; RETROVIRAL PROTEINASES; BACTERIAL EXPRESSION; ASPARTIC PROTEINASE; RATIONAL DESIGN; ANEMIA VIRUS; SPECIFICITY	We have developed a system for expression and purification of wild-type human T-cell leukemia virus type 1 (HTLV-1) proteinase to attain sufficient quantities for structural, kinetic, and biophysical investigations. However, similar to the human immunodeficiency virus type 1 (HIV-1) proteinase, HTLV-1 proteinase also undergoes autoproteolysis rapidly upon renaturation to produce two products. The site of this autoproteolytic cleavage was mapped, and a resistant HTLV-1 proteinase construct (L40I) as well as another construct, wherein the two cysteine residues were exchanged to alanines, were expressed and purified. Oligopeptide substrates representing the naturally occurring cleavage sites in HTLV-1 were good substrates of the HTLV-1 proteinase. The kinetic parameters k(cat) and K-m were nearly identical for all the three enzymes. Although three of four peptides representing HTLV-1 proteinase cleavage sites were fairly good substrates of HIV-1 proteinase, only two of nine peptides representing HIV-1 proteinase cleavage sites were hydrolyzed by the HTLV-1 proteinase, suggesting substantial differences in the specificity of the two enzymes. The large difference in the specificity of the two enzymes was also demonstrated by inhibition studies. Of the several. inhibitors of HIV-1 or other retroviral proteinases that were tested on HTLV-1 proteinase, only two inhibit the enzyme with a K-i lower than 100 nM.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Debrecen Univ Med, Sch Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; NCI, Mol Virol & Carcinogenesis Lab, ABL, Basic Res Program,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Debrecen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.	jmlouis@helix.nih.gov; tozser@indi.biochem.dote.hu	Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Louis, John M/0000-0002-0052-1899; Tozser, Jozsef/0000-0001-5076-8729				BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; DAENKE S, 1994, J GEN VIROL, V75, P2233, DOI 10.1099/0022-1317-75-9-2233; Ding YS, 1998, J VIROL, V72, P3383, DOI 10.1128/JVI.72.4.3383-3386.1998; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; GESSAIN A, 1985, LANCET, V2, P407; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; GUSTCHINA A, 1995, PROTEIN SCI, V8, P1453; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HAYAKAWA T, 1991, BIOCHEM BIOPH RES CO, V181, P1281, DOI 10.1016/0006-291X(91)92077-W; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRUSKOVAHEIDING.O, 1997, LEUKEMIA S, V3, P45; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; HUI KY, 1991, FASEB J, V5, P2606, DOI 10.1096/fasebj.5.11.1868985; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; KOBAYASHI M, 1991, FEBS LETT, V293, P106, DOI 10.1016/0014-5793(91)81162-2; Laco GS, 1997, J VIROL, V71, P5505, DOI 10.1128/JVI.71.7.5505-5511.1997; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; LUUKKONEN BGM, 1995, J GEN VIROL, V76, P2169, DOI 10.1099/0022-1317-76-9-2169; MENENDEZARIAS L, 1992, J BIOL CHEM, V267, P24134; MENENDEZARIAS L, 1993, VIROLOGY, V196, P557, DOI 10.1006/viro.1993.1511; MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; OSAME M, 1986, LANCET, V1, P1031; Pettit SC, 1998, AIDS RES HUM RETROV, V14, P1007, DOI 10.1089/aid.1998.14.1007; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Powell DJ, 1996, EUR J BIOCHEM, V241, P664, DOI 10.1111/j.1432-1033.1996.00664.x; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSE JR, 1993, J BIOL CHEM, V268, P11939; SAIGA A, 1993, ARCH VIROL, V128, P195, DOI 10.1007/BF01309434; SHEREMATA WA, 1993, NEUROLOGY, V43, P2125, DOI 10.1212/WNL.43.10.2125; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; Tessmer U, 1998, J VIROL, V72, P3459, DOI 10.1128/JVI.72.4.3459-3463.1998; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480; WODAWER A, 1993, ANNU REV BIOCHEM, V62, P543; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; Wu J, 1998, BIOCHEMISTRY-US, V37, P4518, DOI 10.1021/bi972183g; Yamazaki T, 1996, PROTEIN SCI, V5, P495	50	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6660	6666		10.1074/jbc.274.10.6660	http://dx.doi.org/10.1074/jbc.274.10.6660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037763	hybrid			2022-12-27	WOS:000078902800085
J	Ganesan, AK; Mende-Mueller, L; Selzer, J; Barbieri, JT				Ganesan, AK; Mende-Mueller, L; Selzer, J; Barbieri, JT			Pseudomonas aeruginosa exoenzyme S, a double ADP-ribosyltransferase, resembles vertebrate mono-ADP-ribosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; EUKARYOTIC CELLS; RAS; RIBOSYLATION; EXPRESSION; PROTEIN; SEQUENCE; CLONING; TARGET; ACTIN	Previous data indicated that Pseudomonas aeruginosa exoenzyme S (ExoS) ADP-ribosylated Ras at multiple sites. One site appeared to be Arg(41), but the second site could not be localized. In this study, the sites of ADP-ribosylation of c-Ha-Ras by ExoS were directly determined. Under saturating conditions, ExoS ADP-ribosylated Ras to a stoichiometry of 2 mol of ADP-ribose incorporated per mol of Ras, Nucleotide occupancy did not influence the stoichiometry or velocity of ADP-ribosylation of Ras by ExoS. Edman degradation and mass spectrometry of V8 protease generated peptides of ADP-ribosylated Ras identified the sites of ADP-ribosylation to be Arg(41) and Arg(128). ExoS ADP-ribosylated the double mutant, RasR41K,R128K, to a stoichiometry of 1 mol of ADP-ribose incorporated per mol of Pas, which indicated that Ras possessed an alternative site of ADP-ribosylation. The alternative site of ADP-ribosylation on Has was identified as Arg(135), which was on the same alpha-helix as Arg(128). Arg(41) and Arg(128) are located within two different secondary structure motifs, beta-sheet and alpha-helix, respectively, and are spatially separated within the three-dimensional structure of Has. The fact that ExoS could ADP-ribosylate a target protein at multiple sites, along with earlier observations that ExoS could ADP-ribosylate numerous target proteins, were properties that have been attributed to several vertebrate ADP-ribosyltransferases, This prompted a detailed alignment study which showed that the catalytic domain of ExoS possessed considerably more primary amino acid homology with the vertebrate mono-ADP-ribosyltransferases than the bacterial ADP-ribosyltransferases. These data are consistent with the hypothesis that ExoS may represent an evolutionary link between bacterial and vertebrate mono-ADP-ribosyltransferases.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Freiburg, Inst Pharmacol & Toxicol, D-79104 Freiburg, Germany	Medical College of Wisconsin; Medical College of Wisconsin; University of Freiburg	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	toxin@mcw.edu			NIAID NIH HHS [AI-30162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BODEY GP, 1983, REV INFECT DIS, V5, P279; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; FRITZ G, 1994, EUR J BIOCHEM, V223, P909, DOI 10.1111/j.1432-1033.1994.tb19068.x; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JUST I, 1995, BIOCHEMISTRY-US, V34, P326, DOI 10.1021/bi00001a040; Klebl BM, 1997, ARCH BIOCHEM BIOPHYS, V347, P155, DOI 10.1006/abbi.1997.0330; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; KRUEGER KM, 1995, CLIN MICROBIOL REV, V8, P34, DOI 10.1128/CMR.8.1.34; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; McGuffie EM, 1998, INFECT IMMUN, V66, P2607, DOI 10.1128/IAI.66.6.2607-2613.1998; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; Olson JC, 1997, INFECT IMMUN, V65, P248, DOI 10.1128/IAI.65.1.248-256.1997; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; TERASHIMA M, 1995, EUR J BIOCHEM, V231, P242, DOI 10.1111/j.1432-1033.1995.0242f.x; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; WANG J, 1994, J IMMUNOL, V153, P4048; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; Yu YJ, 1997, DNA CELL BIOL, V16, P235, DOI 10.1089/dna.1997.16.235; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	27	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9503	9508		10.1074/jbc.274.14.9503	http://dx.doi.org/10.1074/jbc.274.14.9503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092634	hybrid			2022-12-27	WOS:000079451800053
J	Idriss, SD; Gudi, T; Casteel, DE; Kharitonov, VG; Pilz, RB; Boss, GR				Idriss, SD; Gudi, T; Casteel, DE; Kharitonov, VG; Pilz, RB; Boss, GR			Nitric oxide regulation of gene transcription via soluble guanylate cyclase and type I cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; C-FOS; EXPRESSION; CELLS; PHOSPHORYLATION; DIFFERENTIATION; STIMULATION; CLONING; SIGNAL; ALPHA	Nitric oxide (NO) regulates the expression of multiple genes but in most cases its precise mechanism of action is unclear. We used baby hamster kidney (BHK) cells, which have very low soluble guanylate cyclase and cGMP-dependent protein kinase (G-kinase) activity, and CS-54 arterial smooth muscle cells, which express these two enzymes, to study NO regulation of the human fos promoter. The NO-releasing agent Deta-NONOate (ethanamine-2,2'-(hydroxynitrosohydrazone)bis-) had no effect on a chloramphenicol acetyltransferase (CAT) reporter gene under control of the fos promoter in BHK cells transfected with an empty vector or in cells transfected with a G-kinase I beta expression vector. In BHK cells transfected with expression vectors for guanylate cyclase, Deta-NONOate markedly increased the intracellular cGMP concentration and caused a small (2-fold) increase in CAT activity; the increased CAT activity appeared to be from cGMP activation of cAMP-dependent protein kinase, In BHK cells co-transfected with guanylate cyclase and G-kinase expression vectors, CAT activity was increased 5-fold in the absence of Deta-NONOate and 7-fold in the presence of Deta-NONOate, Stimulation of CAT activity in the absence of Deta-NONOate appeared to be largely from endogenous NO since we found that: (i) BHK cells produced high amounts of NO; (ii) CAT activity was partially inhibited by a NO synthase inhibitor; and (iii) the inhibition by the NO synthase inhibitor was reversed by exogenous NO. In CS-54 cells, we found that NO increased fos promoter activity and that the increase was prevented by a guanylate cyclase inhibitor. In summary, we found that NO activates the fos promoter by a guanylate cyclase- and G-kinase-dependent mechanism.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Alliance Pharmaceut Co, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	gboss@UCSD.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CORNWELL TL, 1994, AM J PHYSIOL, pC1405; DE CR, 1995, J CLIN INVEST, V96, P60; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P173; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HABY C, 1994, J NEUROCHEM, V62, P496; IDRISS SD, 1992, BIOCHEM BIOPH RES CO, V183, P312, DOI 10.1016/0006-291X(92)91645-7; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; OHKI K, 1995, BRAIN RES, V696, P140, DOI 10.1016/0006-8993(95)00914-C; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PILZ RB, 1994, J BIOL CHEM, V269, P32155; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Whorton AR, 1997, AM J PHYSIOL-LUNG C, V272, pL1161, DOI 10.1152/ajplung.1997.272.6.L1161; WOLFE L, 1989, J BIOL CHEM, V264, P7734	34	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9489	9493		10.1074/jbc.274.14.9489	http://dx.doi.org/10.1074/jbc.274.14.9489			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092632	hybrid			2022-12-27	WOS:000079451800051
J	Collins, SP; Uhler, MD				Collins, SP; Uhler, MD			Cyclic AMP- and cyclic GMP-dependent protein kinases differ in their regulation of cyclic AMP response element-dependent gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; HUMAN-PLATELETS; C-FOS; MOLECULAR-CLONING; MAMMALIAN-CELLS; FOCAL ADHESION; SMOOTH-MUSCLE; 2 ISOFORMS; IN-VITRO; CAMP	The ability of cGMP-dependent protein kinases (cGKs) to activate cAMP response element (CRE)-dependent gene transcription was compared with that of cAMP-dependent protein kinases (cAKs). Although both the type IP cGMP-dependent protein kinase (cGKI beta) and the type II cAMP-dependent protein kinase (cAKII) phosphorylated the cytoplasmic substrate VASP (vasodilator- and A kinase-stimulated phosphoprotein) to a similar extent, cyclic nucleotide regulation of CRE-dependent transcription was at least 10-fold higher in cAKII-transfected cells than in cGKI beta-transfected cells. Overexpression of each kinase in mammalian cells resulted in a cytoplasmic localization of the unactivated enzyme. As reported previously, the catalytic (C) subunit of cAKII translocated to the nucleus following activation by 8-bromo-cyclic AMP. However, cGKI beta did not translocate to the nucleus upon activation by 8-bromocyclic GMP. Replacement of an autophosphorylated serine (Ser(79)) of cGKI beta with an aspartic acid resulted in a mutant kinase with constitutive kinase activity in vitro and in vivo. The cGKI beta S79D mutant localized to the cytoplasm and was only a weak activator of CRE-dependent gene transcription. However, an amino-terminal deletion mutant of cGKI beta was found in the nucleus as well as the cytoplasm and was a strong activator of CRE-dependent gene transcription. These data suggest that the inability of cGKs to translocate to the nucleus is responsible for the differential ability of cAKs and cGKs to activate CRE-dependent gene transcription and that nuclear redistribution of cGKs is not required for NO/cGMP regulation of gene transcription.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Uhler, MD (corresponding author), Univ Michigan, Neurosci Labs, Bldg 1103 E Huron St, Ann Arbor, MI 48104 USA.				NIGMS NIH HHS [GM 38788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038788, R29GM038788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASWAD DW, 1981, J BIOL CHEM, V256, P3487; BOERTH NJ, 1994, FEBS LETT, V342, P255, DOI 10.1016/0014-5793(94)80512-1; BROWN NA, 1990, J BIOL CHEM, V265, P13181; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; Coven E, 1998, J NEUROCHEM, V71, P1865; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; COX S, 1994, J BIOL CHEM, V269, P22614; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GEAHLEN RL, 1980, J BIOL CHEM, V255, P1164; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1982, J BIOL CHEM, V257, P1196; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HABY C, 1994, J NEUROCHEM, V62, P496; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KUO JF, 1975, P NATL ACAD SCI USA, V72, P2256, DOI 10.1073/pnas.72.6.2256; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINCOLN TM, 1993, ADV SEC MESS PHOSPH, V28, P121; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; UHLER MD, 1993, J BIOL CHEM, V268, P13586; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zimmer M, 1996, GENOMICS, V36, P227, DOI 10.1006/geno.1996.0457	76	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8391	8404		10.1074/jbc.274.13.8391	http://dx.doi.org/10.1074/jbc.274.13.8391			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085070	hybrid			2022-12-27	WOS:000079451600012
J	Egan, BS; Lane, KB; Shepherd, VL				Egan, BS; Lane, KB; Shepherd, VL			PU.1 and USF are required for macrophage-specific mannose receptor promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; TRANSCRIPTION FACTOR PU.1; LOOP-HELIX PROTEIN; DNA-BINDING; COOPERATIVE INTERACTION; REGULATES EXPRESSION; GENE-EXPRESSION; CD11B PROMOTER; MYELOID CELLS; ETS ONCOGENE	In the current study we report the isolation of 854 base pairs of the rat mannose receptor promoter. Analysis of the sequence revealed one Sp1 site, three PU.1 sites, and a potential TATA box (TTTAAA) 33 base pairs 5' of the transcriptional start site. The tissue specificity of the promoter was determined using transient transfections, The promoter was most active in the mature macrophage cell line NR8383 although the promoter also showed activity in the monocytic cell line RAW. No activity was observed in pre-monocytic cell lines or epithelial cell lines, Mutation of the TTTAAA sequence to TTGGAA resulted in a 50% decrease in activity in transient transfection assays suggesting that the promoter contains a functional TATA box, Using electrophoretic mobility shift assays and mutagenesis we established that the transcription factors Sp1, PU.1, and USF bound to the mannose receptor promoter, but only PU.1 and USF contributed to activation. Transient transfections using a dominant negative construct of USF resulted in a 50% decrease in mannose receptor promoter activity, further establishing the role of USF in activating the rat mannose receptor promoter. Comparison of the rat, mouse, and human sequence demonstrated that some binding sites are not conserved. Gel shifts were performed to investigate differences in protein binding between species. USF bound to the rat and human promoter but not to the mouse promoter, suggesting that different mechanisms are involved in regulation of mannose receptor expression in these species. From these results we conclude that, similar to other myeloid promoters, transcription of the rat mannose receptor is regulated by binding of PU.1 and a ubiquitous factor at an adjacent site. However, unlike other myeloid promoters, we have identified USF as the ubiquitous factor, and demonstrated that the promoter contains a functional TATA box.	Dept Vet Affairs Med Ctr, Res Serv, Nashville, TN 37212 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37212 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37212 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37212 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University	Shepherd, VL (corresponding author), Dept Vet Affairs Med Ctr, Res Serv, 1310 24th Ave S, Nashville, TN 37212 USA.	virginia.l.shepherd@vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY002853] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055977] Funding Source: NIH RePORTER; NEI NIH HHS [EY02853] Funding Source: Medline; NHLBI NIH HHS [HL55977] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUM JS, 1991, CARBOHYD RES, V213, P145, DOI 10.1016/S0008-6215(00)90605-0; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARRIS N, 1992, BLOOD, V80, P2363; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honda H, 1997, BIOCHEM BIOPH RES CO, V234, P376, DOI 10.1006/bbrc.1997.6650; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; HROMAS R, 1993, BLOOD, V82, P2998; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KONISH M, 1983, METHOD ENZYMOL, V98, P301; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lane KB, 1998, J LEUKOCYTE BIOL, V64, P345, DOI 10.1002/jlb.64.3.345; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Longoni D, 1998, INT J CLIN LAB RES, V28, P162, DOI 10.1007/s005990050037; MARODI L, 1991, J IMMUNOL, V146, P2783; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROULEUX F, 1994, EXP CELL RES, V214, P113, DOI 10.1006/excr.1994.1239; ROULEUXBONNIN F, 1995, BIOCHEM BIOPH RES CO, V217, P106, DOI 10.1006/bbrc.1995.2751; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779; SHEPHERD VL, 1990, AM J RESP CELL MOL, V2, P335, DOI 10.1165/ajrcmb/2.4.335; SHEPHERD VL, 1985, J BIOL CHEM, V260, P160; SHEPHERD VL, 1982, J RETICULOENDOTH SOC, V32, P423; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SPEERT DP, 1988, J CLIN INVEST, V82, P872, DOI 10.1172/JCI113692; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STEPHENSON JD, 1987, BIOCHEM BIOPH RES CO, V148, P883, DOI 10.1016/0006-291X(87)90958-2; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	63	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9098	9107		10.1074/jbc.274.13.9098	http://dx.doi.org/10.1074/jbc.274.13.9098			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085160	hybrid			2022-12-27	WOS:000079451600102
J	Haugh, JM; Schooler, K; Wells, A; Wiley, HS; Lauffenburger, DA				Haugh, JM; Schooler, K; Wells, A; Wiley, HS; Lauffenburger, DA			Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-gamma 1 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL MOTILITY; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; C ACTIVITY; PROTEIN; KINASE; TRANSDUCTION; TRAFFICKING	The epidermal growth factor receptor (EGFR) ligands, epidermal growth factor (EGF), and transforming growth factor-alpha (TGF alpha) elicit differential postendocytic processing of ligand and receptor molecules, which impacts long-term cell signaling outcomes. These differences arise from the higher affinity of the EGF-EGFR interaction versus that of TGF alpha-EGFR in the acidic conditions of sorting endosomes, To determine whether EGFR occupancy in endosomes might also affect short-term signaling events, we examined activation of the phospholipase C-gamma 1 (PLC-gamma 1) pathway, an event shown to be essential for growth factor-induced cell motility, We found that EGF continues to stimulate maximal tyrosine phosphorylation of EGFR following internalization, while, as expected, TGF alpha stimulates markedly less. The resulting higher level of receptor activation by EGF, however, did not yield higher levels of phosphatidylinositol (4,5)-bisphosphate (PIP2) hydrolysis over those stimulated by TGF alpha. By altering the ratio of activated receptors between the cell surface and the internalized compartment, we found that only cell surface receptors effectively participate in PLC function. In contrast to PIP2 hydrolysis, PLC-gamma 1 tyrosine phosphorylation correlated linearly with the total level of Tyr(P)-EGFR stimulated by either ligand, indicating that the functional deficiency of internal EGFR cannot be attributed to an inability to interact with and phosphorylate signaling proteins. We conclude that EGFR signaling through the PLC pathway is spatially restricted at a point between PLC-gamma 1 phosphorylation and PIP2 hydrolysis, perhaps because of limited access of EGFR-bound PLC-gamma 1 to its substrate in endocytic trafficking organelles.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Alabama System; University of Alabama Birmingham; Utah System of Higher Education; University of Utah	Lauffenburger, DA (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lauffen@mit.edu		Wiley, Steven/0000-0003-0232-6867; Wells, Alan/0000-0002-1637-8150; Haugh, Jason/0000-0002-2476-4027				ASCOLI M, 1982, J BIOL CHEM, V257, P13306; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Batty IH, 1998, BIOCHEM J, V330, P1069; BERTICS PJ, 1985, J CELL BIOCHEM, V29, P195, DOI 10.1002/jcb.240290304; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CHANG CP, 1993, J BIOL CHEM, V268, P19312; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Cockcroft S, 1998, BIOESSAYS, V20, P423, DOI 10.1002/(SICI)1521-1878(199805)20:5<423::AID-BIES9>3.3.CO;2-U; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GILL GN, 1988, COLD SPRING HARB SYM, V53, P467, DOI 10.1101/SQB.1988.053.01.054; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; KAY DG, 1986, J BIOL CHEM, V261, P8473; KORC M, 1989, J BIOL CHEM, V264, P14990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LUND KA, 1994, REGULATION CELLULAR, P277; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; SORKIN A, 1991, J BIOL CHEM, V266, P23453; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xie H, 1998, J CELL SCI, V111, P615	50	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8958	8965		10.1074/jbc.274.13.8958	http://dx.doi.org/10.1074/jbc.274.13.8958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085141	hybrid			2022-12-27	WOS:000079451600083
J	Kabisch, UC; Grantzdorffer, A; Schierhorn, A; Rucknagel, KP; Andreesen, JR; Pich, A				Kabisch, UC; Grantzdorffer, A; Schierhorn, A; Rucknagel, KP; Andreesen, JR; Pich, A			Identification of D-proline reductase from Clostridium sticklandii as a selenoenzyme and indications for a catalytically active pyruvoyl group derived from a cysteine residue by cleavage of a proprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE REDUCTASE; EUBACTERIUM-ACIDAMINOPHILUM; ESCHERICHIA-COLI; ENZYME INTERMEDIATE; MESSENGER-RNA; SELENOCYSTEINE; DECARBOXYLASE; PURIFICATION; THIOREDOXIN; MECHANISM	Highly active D-proline reductase was obtained from Clostridium sticklandii by a modified purification scheme. The cytoplasmic enzyme had a molecular mass of about 870 kDa and was composed of three subunits with molecular masses of 23, 26, and 45 kDa. The 23-kDa subunit contained a carbonyl group at its N terminus, which could either be labeled with fluorescein thiosemicarbazide or removed by o-phenylenediamine; thus, N-terminal sequencing became feasible for this subunit, L-[C-14]proline was covalently bound to the 23-kDa subunit if proline racemase and NaBH4 were added. Selenocysteine was detected in the 26-kDa subunit, which correlated with an observed selenium content of 10.6 g-atoms in D-proline reductase. No other non-proteinaceous cofactor was identified in the enzyme, A 4.8-kilobase pair (kb) EcoRI fragment was isolated and sequenced containing the two genes prdA and prdB. prdA coding for a 68-kDa protein was most likely translated as a proprotein that was posttranslationally cleaved at a threonine-cysteine site to give the 45-kDa subunit and most probably a pyruvoyl-containing 23-kDa subunit. The gene prdB encoded the 26-kDa subunit and contained an in frame UGA codon for selenocysteine insertion. prdA and prdB were transcribed together on a transcript of 4.5 kb; prdB was additionally transcribed as indicated by a 0.8-kb mRNA species.	Univ Halle Wittenberg, Inst Microbiol, D-6099 Halle, Germany; Max Planck Gesell, Forschunsstelle Enzymol Prot, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Max Planck Society	Andreesen, JR (corresponding author), Univ Halle Wittenberg, Inst Microbiol, Kurt Mothes Str 3, D-6099 Halle, Germany.	j.andreesen@mikrobiologie.uni-halle.de						Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Andreesen J.R., 1989, CLOSTRIDIA, P27; ANDREESEN JR, 1994, ANTON LEEUW INT J G, V66, P223, DOI 10.1007/BF00871641; ANDREESEN JR, 1999, IN PRESS BIOFACTORS; ARKOWITZ RA, 1990, J AM CHEM SOC, V112, P870, DOI 10.1021/ja00158a059; ARKOWITZ RA, 1991, BIOCHEMISTRY-US, V30, P4090, DOI 10.1021/bi00230a039; ARKOWITZ RA, 1994, ARCH BIOCHEM BIOPHYS, V311, P457, DOI 10.1006/abbi.1994.1262; ARKOWITZ RA, 1989, BIOCHEMISTRY-US, V28, P4639, DOI 10.1021/bi00437a019; BAUMAN JGJ, 1981, J HISTOCHEM CYTOCHEM, V29, P227, DOI 10.1177/29.2.6166653; BERTRAM J, 1989, ARCH MICROBIOL, V151, P551, DOI 10.1007/BF00454874; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIETRICHS D, 1991, J BACTERIOL, V173, P5983, DOI 10.1128/jb.173.19.5983-5991.1991; Dixon H B, 1972, Methods Enzymol, V25, P409, DOI 10.1016/S0076-6879(72)25036-4; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; GARCIA GE, 1992, J BACTERIOL, V174, P7080, DOI 10.1128/jb.174.22.7080-7089.1992; HACKERT ML, 1997, COMPREHENSIVE BIOL C, P201; Harms C, 1998, MICROBIOL-UK, V144, P793, DOI 10.1099/00221287-144-3-793; HODGINS DS, 1969, ARCH BIOCHEM BIOPHYS, V130, P274, DOI 10.1016/0003-9861(69)90034-4; Huttenhofer A, 1998, COLD SPRING HARBOR M, P603; Huttenhofer A, 1996, RNA, V2, P354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI QX, 1990, J BIOL CHEM, V265, P4111; LOVITT RW, 1986, FEMS MICROBIOL LETT, V36, P269; LUBBERS M, 1993, EUR J BIOCHEM, V217, P791, DOI 10.1111/j.1432-1033.1993.tb18307.x; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER T, 1992, EUR J BIOCHEM, V206, P79, DOI 10.1111/j.1432-1033.1992.tb16903.x; SCHWARTZ AC, 1980, FEMS MICROBIOL LETT, V7, P153, DOI 10.1111/j.1574-6941.1980.tb01596.x; SCHWARTZ AC, 1979, ARCH MICROBIOL, V123, P203, DOI 10.1007/BF00446821; SETO B, 1980, J BIOL CHEM, V255, P5004; SETO B, 1976, J BIOL CHEM, V251, P2435; SETO B, 1979, ANAL BIOCHEM, V95, P44, DOI 10.1016/0003-2697(79)90183-0; SETO B, 1978, J BIOL CHEM, V253, P4525; SETO B, 1980, DIVERSITY BACTERIAL, P49; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STADTMAN TC, 1957, J BACTERIOL, V73, P218, DOI 10.1128/JB.73.2.218-219.1957; STADTMAN TC, 1954, J BACTERIOL, V67, P314, DOI 10.1128/JB.67.3.314-320.1954; UHDE A, 1990, THESIS U GOTTINGEN G; Wagner M, 1999, EUR J BIOCHEM, V260, P38, DOI 10.1046/j.1432-1327.1999.00107.x; WAGNER M, 1995, ARCH MICROBIOL, V163, P286, DOI 10.1007/BF00393382; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xiong HS, 1997, J BIOL CHEM, V272, P28342, DOI 10.1074/jbc.272.45.28342; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	46	48	56	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8445	8454		10.1074/jbc.274.13.8445	http://dx.doi.org/10.1074/jbc.274.13.8445			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085076	hybrid			2022-12-27	WOS:000079451600018
J	Montessuit, C; Thorburn, A				Montessuit, C; Thorburn, A			Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MUSCLE CELL HYPERTROPHY; GENE-EXPRESSION; MAP KINASE; RAT-HEART; GROWTH-FACTOR; DEVELOPMENTAL REGULATION; TYROSINE-PHOSPHATASE; OXIDATIVE STRESS; ANGIOTENSIN-II	Myocardial hypertrophy is associated with increased basal glucose metabolism. Basal glucose transport into cardiac myocytes is mediated by the GLUT1 isoform of glucose transporters, whereas the GLUT4 isoform is responsible for regulatable glucose transport. Treatment of neonatal cardiac myocytes with the hypertrophic agonist 12-O-tetradecanoylphorbol-13-acetate or phenylephrine increased expression of Glut1 mRNA relative to Glut4 mRNA. To study the transcriptional regulation of GLUT1 expression, myocytes were transfected with luciferase reporter constructs under the control of the Glut1 promoter. Stimulation of the cells with 12-O-tetradecanoylphorbol-13-acetate or phenylephrine induced transcription from the Glut1 promoter, which was inhibited by cotransfection with the mitogen-activated protein kinase phosphatases CL100 and MKP-3. Cotransfection of the myocytes with constitutively active versions of has and MEK1 or an estrogen-inducible version of Raf1 also stimulated transcription from the Glut1 promoter. Hypertrophic induction of the Glut1 promoter was also partially sensitive to inhibition of the phosphatidylinositol 3-kinase pathway and was strongly inhibited by cotransfection with dominant-negative Ras. Thus, Ras activation and pathways downstream of Ras mediate induction of the Glut1 promoter during myocardial hypertrophy.	Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Dept Internal Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Montessuit, C (corresponding author), Univ Utah, Eccles Inst Human Genet, 15N 2030E,Rm 4220, Salt Lake City, UT 84112 USA.	christophe.montessuit@hci.utah.edu	Montessuit, Christophe/B-5650-2011	Montessuit, Christophe/0000-0002-2580-7711	NHLBI NIH HHS [HL-50210] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; ALLARD MF, 1994, AM J PHYSIOL, V267, pH742, DOI 10.1152/ajpheart.1994.267.2.H742; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; CHEN SY, 1994, ONCOGENE, V9, P2691; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ELALAOUITALIBI Z, 1992, AM J PHYSIOL, V262, pH1068, DOI 10.1152/ajpheart.1992.262.4.H1068; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NAGAO M, 1993, J BIOL CHEM, V268, P24114; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRASAD MR, 1992, BASIC RES CARDIOL, V87, P19, DOI 10.1007/BF00795386; Remondino-Mueller Andrea, 1997, Journal of Molecular and Cellular Cardiology, V29, pA85; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SCHONEKESS BO, 1995, CIRC RES, V77, P726, DOI 10.1161/01.RES.77.4.726; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; SIVITZ WI, 1991, ENDOCRINOLOGY, V128, P2387, DOI 10.1210/endo-128-5-2387; SPEAKE BK, 1993, BIOCHIM BIOPHYS ACTA, V1165, P263, DOI 10.1016/0005-2760(93)90135-V; STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796; STUDELSKA DR, 1992, AM J PHYSIOL, V263, pE102, DOI 10.1152/ajpendo.1992.263.1.E102; TARDY I, 1996, J MOL CELL CARDIOL, V28, pA16; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG C, 1991, BIOCHEM BIOPH RES CO, V177, P1095, DOI 10.1016/0006-291X(91)90651-M; WEINBERG EO, 1995, CIRCULATION, V92, P385; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X	62	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9006	9012		10.1074/jbc.274.13.9006	http://dx.doi.org/10.1074/jbc.274.13.9006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085148	hybrid			2022-12-27	WOS:000079451600090
J	Sheehy, AM; Schlissel, MS				Sheehy, AM; Schlissel, MS			Overexpression of RelA causes G(1) arrest and apoptosis in a pro-B cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C-REL; GENE-TRANSCRIPTION; DNA-BINDING; SPLENIC MICROARCHITECTURE; TRANSACTIVATION DOMAIN; TARGETED DISRUPTION; IMMUNE-RESPONSES; MICE LACKING; B/REL FAMILY	NF-kappa B/Rel family proteins form a network of posttranslationally regulated transcription factors that respond to a variety of extracellular stimuli and mediate distinct cellular responses. These responses include cytokine gene expression, regulated cell cycle activation, and both the protection from and induction of the cell death program. To examine the function of individual Rel family proteins in B cell development and resolve their role in the signaling of apoptosis, we used a tetracycline-regulated gene expression system to overexpress either c-Rel or RelA in the transformed pro-B cell line 220-8. Elevated levels of RelA, but not c-Rel, induced a G(1) cell cycle arrest followed by apoptosis. Both the DNA binding and transactivation domains of RelA were required for this effect. When RelA was overexpressed in the immature B cell line WEHI 231 or the mature B cell line M12, neither cell cycle arrest nor apoptosis was evident. The differential effects of elevated RelA levels in these cell lines suggests that susceptibility to NF-kappa B-induced apoptosis may reflect a relevant selection event during B cell development.	Johns Hopkins Univ, Sch Med, Dept Med, Grad Program Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Schlissel, MS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Grad Program Immunol, 720 Rutland Ave, Baltimore, MD 21205 USA.	mss@welchlink.welch.jhu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL48702] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang W, 1996, IMMUNITY, V4, P291, DOI 10.1016/S1074-7613(00)80437-9; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GANCHI PA, 1992, MOL CELL BIOL, V13, P1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; HANNINK M, 1990, ONCOGENE, V5, P1843; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; KALLENBACH S, 1993, EUR J IMMUNOL, V23, P1917, DOI 10.1002/eji.1830230828; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATERS C, 1991, ONCOGENE, V6, P101; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	70	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8708	8716		10.1074/jbc.274.13.8708	http://dx.doi.org/10.1074/jbc.274.13.8708			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085110	hybrid			2022-12-27	WOS:000079451600052
J	Huang, ZQ; Philippin, B; O'Leary, E; Bonventre, JV; Kriz, W; Witzgall, R				Huang, ZQ; Philippin, B; O'Leary, E; Bonventre, JV; Kriz, W; Witzgall, R			Expression of the transcriptional repressor protein Kid-1 leads to the disintegration of the nucleolus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; ZINC-FINGER PROTEINS; DNA-BINDING; FACTOR UBF; MEDIATED REPRESSION; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; NUCLEAR MATRIX; KRUPPEL-TYPE; FACTOR HUBF	The rat Kid-1 gene codes for a 66-kDa protein with KRAB domains at the NH2 terminus and two Cys(2)His(2)-zinc finger clusters of four and nine zinc fingers at the COOH terminus. It was the first KRAB-zinc finger protein for which a transcriptional repressor activity was demonstrated. Subsequently, the KRAB-A domain was identified as a widespread transcriptional repressor motif, We now present a biochemical and functional analysis of the Kid-1 protein in transfected cells. The full-length Kid-1 protein is targeted to the nucleolus and adheres tightly to as yet undefined nucleolar structures, leading eventually to the disintegration of the nucleolus. The tight adherence and nucleolar distribution can be attributed to the larger zinc finger cluster, whereas the KRAB-A domain is responsible for the nucleolar fragmentation, Upon disintegration of the nucleolus, the nucleolar transcription factor upstream binding factor disappears from the nucleolar fragments, In the absence of Kid-1, the KRIP-1 protein, which represents the natural interacting partner of zinc finger proteins with a KRAB-A domain, is homogeneously distributed in the nucleus, whereas coexpression of Kid-1 leads to a shift of KRIP-1 into the nucleolus. Nucleolar run-ons demonstrate that rDNA transcription is shut off in the nucleolar fragments. Our data demonstrate the functional diversity of the KRAB and zinc finger domains of Kid-1 and provide new functional insights into the regulation of the nucleolar structure.	Univ Heidelberg, Inst Anat & Cell Biol 1, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA	Ruprecht Karls University Heidelberg; Harvard University; Harvard University; Massachusetts General Hospital	Witzgall, R (corresponding author), Univ Heidelberg, Inst Anat & Cell Biol 1, Neuenheimer Feld 307, D-69120 Heidelberg, Germany.			Witzgall, Ralph/0000-0002-5283-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, R37DK039773] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arranz V, 1997, MOL CELL BIOL, V17, P2116, DOI 10.1128/MCB.17.4.2116; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BELL P, 1992, J CELL BIOL, V118, P1297, DOI 10.1083/jcb.118.6.1297; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BENAVENTE R, 1987, J CELL BIOL, V105, P1483, DOI 10.1083/jcb.105.4.1483; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady JP, 1997, EXP EYE RES, V64, P287, DOI 10.1006/exer.1996.0206; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEVELAND DW, 1995, TRENDS CELL BIOL, V5, P60, DOI 10.1016/S0962-8924(00)88947-3; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; Elser B, 1997, J BIOL CHEM, V272, P27908, DOI 10.1074/jbc.272.44.27908; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOESSENS G, 1984, INT REV CYTOL, V87, P107, DOI 10.1016/S0074-7696(08)62441-9; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; HOZAK P, 1995, J CELL SCI, V108, P635; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IMAI H, 1994, MOL BIOL REP, V19, P115, DOI 10.1007/BF00997157; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kamakaka RT, 1997, TRENDS BIOCHEM SCI, V22, P124, DOI 10.1016/S0968-0004(96)10074-8; KEMPF T, 1994, FEBS LETT, V354, P307, DOI 10.1016/0014-5793(94)01151-6; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Masson C, 1996, EXP CELL RES, V226, P114, DOI 10.1006/excr.1996.0209; MATHENY C, 1994, J BIOL CHEM, V269, P8176; MCSTAY B, 1991, GENE DEV, V5, P1957, DOI 10.1101/gad.5.11.1957; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Omori Y, 1997, CYTOGENET CELL GENET, V78, P285, DOI 10.1159/000134673; PASSANANTI C, 1995, CELL GROWTH DIFFER, V6, P1037; Payen E, 1998, J BIOL CHEM, V273, P9099, DOI 10.1074/jbc.273.15.9099; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Perrin L, 1998, J CELL SCI, V111, P2753; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; ROUSSEL P, 1993, J CELL SCI, V104, P327; Roussel P, 1996, J CELL BIOL, V133, P235, DOI 10.1083/jcb.133.2.235; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEER U, 1984, J CELL BIOL, V99, P672, DOI 10.1083/jcb.99.2.672; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; SU LS, 1993, GENE DEV, V7, P735, DOI 10.1101/gad.7.5.735; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WEISENBERGER D, 1993, EUR J CELL BIOL, V61, P189; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719	64	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7640	7648		10.1074/jbc.274.12.7640	http://dx.doi.org/10.1074/jbc.274.12.7640			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075651	hybrid			2022-12-27	WOS:000079268100010
J	Patel, R; Holt, M; Philipova, R; Moss, S; Schulman, H; Hidaka, H; Whitaker, M				Patel, R; Holt, M; Philipova, R; Moss, S; Schulman, H; Hidaka, H; Whitaker, M			Calcium/calmodulin-dependent phosphorylation and activation of human cdc25-c at the G(2)/M phase transition in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-II; SEA-URCHIN EMBRYOS; P80CDC25 MITOTIC INDUCER; FISSION YEAST; ASPERGILLUS-NIDULANS; CYCLIN-B; TYROSINE PHOSPHORYLATION; CALMODULIN ANTAGONIST; CATALYTIC SUBUNIT; CDK REGULATION	The human tyrosine phosphatase (p54(cdc25-c)) is activated by phosphorylation at mitosis entry. The phosphorylated p54(cdc25-c) in turn activates the p34-cyclin B protein kinase and triggers mitosis. Although the active p34-cyclin B protein kinase can itself phosphorylate and activate p54(cdc25-c), we have investigated the possibility that other kinases may initially trigger the phosphorylation and activation of p54(cdc25-c). We have examined the effects of the calcium/calmodulin-dependent protein kinase (CaM kinase II) on p54(cdc25-c). Our in vitro experiments show that CaM kinase II can phosphorylate p54(cdc25-c) and increase its phosphatase activity by 2.5-3-fold. Treatment of a synchronous population of HeLa cells with KN-93 (a water-soluble inhibitor of CaM kinase II) or the microinjection of AC3-I (a specific peptide inhibitor of CaM kinase II) results in a cell cycle block in G(2) phase. In the KN-93-arrested cells, p54(cdc25-c) is not phosphorylated, p34(cdc2) remains tyrosine phosphorylated, and there is no increase in histone H1 kinase activity. Our data suggest that a calcium-calmodulin-dependent step may be involved in the initial activation of p54(cdc25-c).	Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 466, Japan	Newcastle University - UK; University of Leicester; University of London; University College London; University of London; University College London; Stanford University; Nagoya University	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Holt, Mark/0000-0001-7775-8539				BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BARTELT DC, 1988, P NATL ACAD SCI USA, V85, P3279, DOI 10.1073/pnas.85.10.3279; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGECOMBE M, 1991, EMBO J, V10, P3769, DOI 10.1002/j.1460-2075.1991.tb04946.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Graessmann A, 1980, Methods Enzymol, V65, P816; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P286; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1985, NATURE, V316, P848, DOI 10.1038/316848a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KREIS TE, 1982, INT REV CYTOL, V75, P209, DOI 10.1016/S0074-7696(08)61005-0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LINDSAY HD, 1995, J CELL SCI, V108, P3557; LONDESBOROUGH J, 1989, J GEN MICROBIOL, V135, P3373; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MEIJER L, 1989, EMBO J, V8, P3053; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; NISHIMOTO T, 1985, EXP CELL RES, V156, P351, DOI 10.1016/0014-4827(85)90542-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PATEL R, 1991, CELL REGUL, V2, P391, DOI 10.1091/mbc.2.5.391; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SASAKI Y, 1982, BIOCHEM BIOPH RES CO, V104, P451, DOI 10.1016/0006-291X(82)90658-1; SCHATZMAN RC, 1983, BIOCHIM BIOPHYS ACTA, V755, P144, DOI 10.1016/0304-4165(83)90284-2; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; TWIGG J, 1988, NATURE, V332, P364; ULLOA RM, 1991, MOL CELL BIOCHEM, V102, P155; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WELSH MJ, 1979, J CELL BIOL, V81, P624, DOI 10.1083/jcb.81.3.624; WELSH MJ, 1978, P NATL ACAD SCI USA, V78, P1867; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; WOLNIAK SM, 1980, J CELL BIOL, V87, P23, DOI 10.1083/jcb.87.1.23; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	83	114	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7958	7968		10.1074/jbc.274.12.7958	http://dx.doi.org/10.1074/jbc.274.12.7958			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075693	hybrid			2022-12-27	WOS:000079268100052
J	Wang, B; Feng, L; Hu, Y; Huang, SH; Reynolds, CP; Wu, LT; Jong, AY				Wang, B; Feng, L; Hu, Y; Huang, SH; Reynolds, CP; Wu, LT; Jong, AY			The essential role of Saccharomyces cerevisiae CDC6 nucleotide-binding site in cell growth, DNA synthesis, and Orc1 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; REPLICATION ORIGINS; BUDDING YEAST; S-PHASE; DIRECTED MUTAGENESIS; NUCLEAR DIVISION; FISSION YEAST; MCM PROTEINS; GENE-PRODUCT; CYCLE	Saccharomyces cerevisiae Cdc6 is a protein required for the initiation of DNA replication. The biochemical function of the protein is unknown, but the primary sequence contains motifs characteristic of nucleotide-binding sites. To study the requirement of the nucleotide-binding site for the essential function of Cdc6, we have changed the conserved Lys(114) at the nucleotide-binding site to five other amino acid residues. We have used these mutants to investigate in vivo roles of the conserved lysine in the growth rate of transformant cells and the complementation of cdc6 temperature-sensitive mutant cells. Our results suggest that replacement of Lys with Glu (K114E) and Pro (K114P) leads to loss-of-function in supporting cell growth, replacement of the Lys with Gln (K114Q) or Leu (K114L) yields partially functional proteins, and replacement with Arg yields a phenotype equivalent to wild-type, a silent mutation. To investigate what leads to the growth defects derived from the mutations at the nucleotide-binding site, we evaluated its gene functions in DNA replication by the assays of the plasmid stability and chromosomal DNA synthesis. Indeed, the K114P and K114E mutants showed the complete retraction of DNA synthesis. In order to test its effect on the G(1)/S transition of the cell cycle, we have carried out the temporal and spatial studies of yeast replication complex. To do this, yeast chromatin fractions from synchronized culture were prepared to detect the Mcm5 loading onto the chromatin in the presence of the wild-type CdcG or mutant cdc6(K114E) proteins, We found that cdc6(K114E) is defective in the association with chromatin and in the loading of Mcm5 onto chromatin origins. To further investigate the molecular mechanism of nucleotide-binding function, we have demonstrated that the Cdc6 protein associates with Orc1 in vitro and in vivo, Intriguingly, the interaction between Orc1 and Cdc6 is disrupted when the cdc6(K114E) protein is used. Our results suggest that a proper molecular interaction between Orc1 and Cdc6 depends on the functional ATP-binding of Cdc6, which may be a prerequisite step to assemble the operational replicative complex at the G(1)/S transition.	Univ So Calif, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Dept Microbiol, Los Angeles, CA 90027 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90027 USA	University of Southern California; University of Southern California; University of Southern California	Jong, AY (corresponding author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,Mail Stop 57, Los Angeles, CA 90027 USA.			Reynolds, C. Patrick/0000-0002-2827-8536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048492] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BOTSTEIN D, 1985, SCIENCE, V229, P1193, DOI 10.1126/science.2994214; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; Detweiler CS, 1997, J CELL SCI, V110, P753; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Feng L, 1998, J BIOL CHEM, V273, P1298, DOI 10.1074/jbc.273.3.1298; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAVIN KA, 1995, SCIENCE, V270, P1585; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HARTWELL LH, 1985, GENETICS, V110, P381; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Jong A, 1996, DNA CELL BIOL, V15, P883, DOI 10.1089/dna.1996.15.883; JONG AY, 1995, ANAL BIOCHEM, V227, P32, DOI 10.1006/abio.1995.1249; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WHEALS AE, 1987, YEAST, P284; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; ZHOU C, 1993, DNA CELL BIOL, V12, P363, DOI 10.1089/dna.1993.12.363; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZHOU C, 1990, BIOTECHNIQUES, V8, P503; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	50	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8291	8298		10.1074/jbc.274.12.8291	http://dx.doi.org/10.1074/jbc.274.12.8291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075735	hybrid			2022-12-27	WOS:000079268100094
J	Chaudhry, AZ; Vitullo, AD; Gronostajski, RM				Chaudhry, AZ; Vitullo, AD; Gronostajski, RM			Nuclear factor I-mediated repression of the mouse mammary tumor virus promoter is abrogated by the coactivators p300/CBP and SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; BINDING-SITES; MMTV PROMOTER; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; CHROMATIN STRUCTURE; GENE-TRANSCRIPTION; TERMINAL DOMAIN; PROTEIN GENE; GLOBIN GENE	To better understand the function of nuclear factor I (NFI) proteins in transcription, we have used transient transfection assays to assess transcriptional modulation by NFI proteins on the NFI-dependent mouse mammary tumor virus (MMTV) promoter. Expression of NFI-C or NFI-X, but not NFI-A or NFI-B proteins, represses glucocorticoid induction of the MMTV promoter in HeLa cells. Repression is DNA binding-independent as a deletion construct expressing the NH2-terminal 160 residues of NFI-C represses but does not bind DNA, Repression by NFI-C is cell type-dependent and occurs in HeLa and COS-1 cells but not 293 or JEG-3 cells. NFI-C does not repress progesterone induction of the MMTV promoter in HeLa cells, suggesting that progesterone induction of the promoter differs mechanistically from glucocorticoid induction. NFI-C-mediated repression is alleviated by overexpression of glucocorticoid receptor (GR), suggesting that NFI-C represses the MMTV promoter by preventing GR function. However, repression by NFI-C occurs with only a subset of glucocorticoid-responsive promoters, as the chimeric NFIGRE beta-gal promoter that is activated by GR is not repressed by NFI-C. Since the coactivator proteins p300/CBP, SRC-1A, and RAC3 had previously been shown to function at steroid hormone-responsive promoters, we asked whether they could influence NFI-C-mediated repression of MMTV expression, Expression of p300/CBP or SRC-1A alleviates repression by NFI-C, whereas RACE has no effect. This abrogation of NFI-C-mediated repression by p300/CBP and SRC-1A suggests that repression by NFI-C may occur by interference with coactivator function at the MMTV promoter.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Gronostajski, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Vitullo, Alfredo/F-9744-2015	Vitullo, Alfredo/0000-0002-4833-5147; Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34908] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; Gorman C., 1985, DNA CLONING, V2; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LI S, 1995, MOL CELL BIOL, V15, P2063; Liu YC, 1997, J BIOL CHEM, V272, P10739; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; WADE PA, 1997, CURR BIOL, V7, P82; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	62	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7072	7081		10.1074/jbc.274.11.7072	http://dx.doi.org/10.1074/jbc.274.11.7072			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066764	hybrid			2022-12-27	WOS:000079078400036
J	Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W				Klukas, O; Schubert, WD; Jordan, P; Krauss, N; Fromme, P; Witt, HT; Saenger, W			Localization of two phylloquinones, Q(K) and Q(K)', in an improved electron density map of photosystem I at 4-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; PHOTOSYNTHETIC REACTION-CENTER; BACTERIAL REACTION CENTERS; SINGLE-CRYSTALS; STRUCTURAL ORGANIZATION; OXYGENIC PHOTOSYNTHESIS; ANGSTROM RESOLUTION; RADICAL PAIRS; CHLOROPHYLL-A; EPR	An improved electron density map of photosystem I from Synechococcus elongatus calculated at 4-Angstrom resolution for the first time reveals a second phylloquinone molecule and thereby completes the set of cofactors constituting the electron transfer system of this iron-sulfur type photosynthetic reaction center: six chlorophyll a, two phylloquinones, and three Fe4S4 clusters. The location of the newly identified phylloquinone pair, the individual plane orientations of these molecules, and the resulting distances to other cofactors of the electron transfer system are discussed and compared with those determined by magnetic resonance techniques.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10623 Berlin, Germany	Free University of Berlin; Technical University of Berlin	Krauss, N (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	nkrauss@chemie.fu-berlin.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Krauss, Norbert/0000-0002-7128-4632				ADMAN ET, 1976, J BIOL CHEM, V251, P3801; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bittl R, 1997, BIOCHEMISTRY-US, V36, P12001, DOI 10.1021/bi971645n; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Dzuba SA, 1997, CHEM PHYS LETT, V264, P238, DOI 10.1016/S0009-2614(96)01302-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fischer N, 1998, EMBO J, V17, P849, DOI 10.1093/emboj/17.4.849; GLOUX J, 1994, J AM CHEM SOC, V116, P1953, DOI 10.1021/ja00084a040; GUIGLIARELLI B, 1993, J BIOL CHEM, V268, P900; Iwaki M, 1996, J PHYS CHEM-US, V100, P10802, DOI 10.1021/jp960221k; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamlowski A, 1998, J PHYS CHEM B, V102, P8266, DOI 10.1021/jp9817022; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P185, DOI 10.1016/S0005-2728(96)00161-2; Kass H, 1996, CHEM PHYS LETT, V251, P193, DOI 10.1016/0009-2614(96)00129-7; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nugent JHA, 1996, EUR J BIOCHEM, V237, P519, DOI 10.1111/j.1432-1033.1996.00519.x; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RIUS G, 1989, J AM CHEM SOC, V111, P2464, DOI 10.1021/ja00189a015; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Schubert WD, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P3; SETIF P, 1989, BIOCHEMISTRY-US, V28, P2689, DOI 10.1021/bi00432a049; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; SNYDER SW, 1991, P NATL ACAD SCI USA, V88, P9895, DOI 10.1073/pnas.88.21.9895; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; Witt HT, 1996, BER BUNSEN PHYS CHEM, V100, P1923, DOI 10.1002/bbpc.19961001202; Zech SG, 1996, BER BUNSEN PHYS CHEM, V100, P2041, DOI 10.1002/bbpc.19961001220	37	71	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7361	7367		10.1074/jbc.274.11.7361	http://dx.doi.org/10.1074/jbc.274.11.7361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066800	hybrid			2022-12-27	WOS:000079078400072
J	Rudgers, GW; Palzkill, T				Rudgers, GW; Palzkill, T			Identification of residues in beta-lactamase critical for binding beta-lactamase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-CLAVULIGERUS; ESCHERICHIA-COLI; RESISTANCE; CEPHALOSPORINS; DETERMINANTS; CEFTAZIDIME; EFFICIENCY; MUTANTS; GENES; ACID	beta-Lactamase inhibitory protein (BLIP) is a potent inhibitor of several beta-lactamases including TEM-1 beta-lactamase (K-i = 0.1 nM), The co-crystal structure of TEM-1 beta-lactamase and BLIP has been solved, revealing the contact residues involved in the interface between the enzyme and inhibitor. To determine which residues in TEM-1 beta-lactamase are critical for binding BLIP, the method of monovalent phage display was employed. Random mutants of TEM-1 beta-lactamase in the 99-114 loop-helix and 235-240 B3 beta-strand regions were displayed as fusion proteins on the surface of the M13 bacteriophage. Functional mutants were selected based on the ability to bind BLIP, After three rounds of enrichment, the sequences of a collection of functional beta-lactamase mutants revealed a consensus sequence for the binding of BLIP. Seven loop-helix residues including Asp-101, Leu-102, Val-103, Ser-106, Pro-107, Thr-109, and His-112 and three B3 beta-strand residues including Ser-235, Gly-236, and Gly-238 were found to be critical for tight binding of BLIP, In addition, the selected beta-lactamase mutants A113L/T114R and E240K were found to increase binding of BLIP by over 6- and 11-fold, respectively. Combining these substitutions resulted in 550-fold tighter binding between the enzyme and BLIP with a K-i of 0.40 pM. These results reveal that the binding between TEM-1 beta-lactamase and BLIP can be improved and that there are a large number of sequences consistent with tight binding between BLIP and beta-lactamase.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956, R56AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P259, DOI 10.1128/AAC.33.3.259; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; Gibson T. J., 1984, THESIS CAMBRIDGE U C; HANKE M, 1994, BIOTECHNIQUES, V17, P858; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Huang WZ, 1998, ANTIMICROB AGENTS CH, V42, P2893, DOI 10.1128/AAC.42.11.2893; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; IMTIAZ U, 1994, ANTIMICROB AGENTS CH, V38, P1134, DOI 10.1128/AAC.38.5.1134; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MATTHEW M, 1979, J ANTIMICROB CHEMOTH, V5, P349, DOI 10.1093/jac/5.4.349; MEDEIROS AA, 1984, BRIT MED BULL, V40, P18, DOI 10.1093/oxfordjournals.bmb.a071942; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PALZKILL T, 1991, METHODS COMPANION ME, V3, P155; PARKER RH, 1987, INFECT CONT HOSP EP, V8, P36, DOI 10.1017/S0195941700066972; PerezLlarena F, 1997, J BACTERIOL, V179, P6035, DOI 10.1128/jb.179.19.6035-6040.1997; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	35	27	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6963	6971		10.1074/jbc.274.11.6963	http://dx.doi.org/10.1074/jbc.274.11.6963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066750	hybrid			2022-12-27	WOS:000079078400022
J	Ozawa, K; Kuwabara, K; Tamatani, M; Takatsuji, K; Tsukamoto, Y; Kaneda, S; Yanagi, H; Stern, DM; Eguchi, Y; Tsujimoto, Y; Ogawa, S; Tohyama, M				Ozawa, K; Kuwabara, K; Tamatani, M; Takatsuji, K; Tsukamoto, Y; Kaneda, S; Yanagi, H; Stern, DM; Eguchi, Y; Tsujimoto, Y; Ogawa, S; Tohyama, M			150-kDa oxygen-regulated protein (ORP150) suppresses hypoxia-induced apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; STRESS PROTEIN; ASTROCYTES; INDUCTION; INTERLEUKIN-6; REOXYGENATION; ACTIVATION; EXPOSURE	To determine the contribution of 180-kDa oxygen-regulated protein (ORP150) to cellular processes underlying adaptation to hypoxia, a cell line stably transfected to overexpress ORP150 antisense RNA was created. In human embryonic kidney (HEK) cells stably overexpressing ORP150 antisense RNA, ORP150 antigen and transcripts were suppressed to low levels in normoxia and hypoxia, whereas wild-type cells showed induction of ORP150 with oxygen deprivation. Inhibition of ORP150 in antisense transfectants was selective, as hypoxia-mediated enhancement of glucose-regulated protein (GRP) 78 and GRP94 was maintained. However, antisense ORP150 transfectants displayed reduced viability when subjected to hypoxia, compared with wildtype and sense-transfected HEK cells. In contrast, diminished levels of ORP150 had no effect on cytotoxicity induced by other stimuli, including oxygen-free radicals and sodium arsenate. Although cellular ATP content was similar in hypoxia, compared with ORP150 antisense transfectants and wild-type HEK cells, suppression of ORP150 expression was associated with accelerated apoptosis, Hypoxia-mediated cell death in antisense HEK transfectants did not cause an increase in caspase activity or in cytoplasmic cytochrome c antigen. A well recognized inducer of apoptosis in HEK cells, staurosporine, caused increased caspase activity and cytoplasmic cytochrome c levels in both wild-type and antisense cells. These data indicate that ORP150 has an important cytoprotective role in hypoxia-induced cellular perturbation and that ORP150-associated inhibition of apoptosis may involve mechanisms distinct from those triggered by other apoptotic stimuli.	Osaka Univ, Sch Med, Ctr Biomed Res, Dept Anat & Neurosci, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Ctr Biomed Res, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med 1, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Ctr Biomed Res, Dept Med Genet, Suita, Osaka 565, Japan; HSP Res Inst, Kyoto 610, Japan; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Osaka University; Osaka University; Osaka University; Osaka University; Columbia University	Ozawa, K (corresponding author), Osaka Univ, Sch Med, Ctr Biomed Res, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	ozawa@anat2.med.osaka-u.ac.jp						BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; Despres P, 1996, J VIROL, V70, P4090; Du YS, 1997, J NEUROCHEM, V69, P1382; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Harkness RA, 1997, ACTA PAEDIATR, V86, P1, DOI 10.1111/j.1651-2227.1997.tb08820.x; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HORI O, 1994, J NEUROCHEM, V62, P1489; Hori O, 1996, J NEUROCHEM, V66, P973; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEIST M, 1994, J IMMUNOL, V153, P1778; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; SHCREENIWAS R, 1991, J CELL PHYSL, V146, P8; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tsukamoto Y, 1998, LAB INVEST, V78, P699; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; UEDA H, 1988, J BIOCHEM, V104, P81, DOI 10.1093/oxfordjournals.jbchem.a122427; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9	40	152	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6397	6404		10.1074/jbc.274.10.6397	http://dx.doi.org/10.1074/jbc.274.10.6397			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037731	hybrid			2022-12-27	WOS:000078902800053
J	Schnappinger, D; Schubert, P; Berens, C; Pfleiderer, K; Hillen, W				Schnappinger, D; Schubert, P; Berens, C; Pfleiderer, K; Hillen, W			Solvent-exposed residues in the Tet repressor (TetR) four-helix bundle contribute to subunit recognition and dimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; GENE-EXPRESSION; DNA-BINDING; TETRACYCLINE; MUTAGENESIS; SPECIFICITY; COMPLEX; MOTIF; DIMERIZATION	Dimerization specificity of Tet repressor (TetR) can be altered by changes in the core of the four-helix bundle that mediates protein-protein recognition. We demonstrate here that the affinity of subunit interaction depends also on the solvent-exposed residues at positions 128 and 179'-184', which interact across the dimerization surface. TetR(B) and (D), two naturally occurring sequence variants, differ at position 128 with respect to the monomer-monomer distances in the crystal structures and the charge of the amino acids, being glutamate in TetR(B) and arginine in TetR(D), In vivo analysis of chimeric TetR(B/D) variants revealed that the single E128R exchange does not alter the dimerization specificity of TetR(B) to the one of TetR(D), When combined with specificity mutations in (alpha 10, it is, however, able to increase dimerization efficiency of the TetR(B/D) chimera with TetR(D), A loss of contact analysis revealed a positive interaction between Arg-128 and residues located at positions 179'-184' of the second monomer, We constructed a hyperstable TetR(B) variant by replacing residues 128 and 179-184 by the respective TetR(D) sequence. These results establish that in addition to a region in the hydrophobic core residues at the solvent-exposed periphery of the dimerization surface participate in protein-protein recognition in the TetR four-helix bundle.	Univ Erlangen Nurnberg, Inst Mikrobiol Biochem & Genet, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Hillen, W (corresponding author), Univ Erlangen Nurnberg, Inst Mikrobiol Biochem & Genet, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.	whillen@biologie.uni-erlangen.de						ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; Backes H, 1997, BIOCHEMISTRY-US, V36, P5311, DOI 10.1021/bi961527k; Berens C, 1997, J BIOL CHEM, V272, P6936, DOI 10.1074/jbc.272.11.6936; BERENS C, 1995, MOL MICROBIOL, V18, P437, DOI 10.1111/j.1365-2958.1995.mmi_18030437.x; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Ettner N, 1996, J CHROMATOGR A, V742, P95, DOI 10.1016/0021-9673(96)00232-4; Gatz C, 1997, ANNU REV PLANT PHYS, V48, P89, DOI 10.1146/annurev.arplant.48.1.89; GREENBLATT J, 1992, TRANSCRIPTIONAL REGU, P203; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIN M, 1995, IMMUNOTECHNOLOGY, V1, P151, DOI 10.1016/1380-2933(95)00016-X; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Miller JH., 1992, SHORT COURSE BACTERI, P72; NICOLLS A, 1991, PROTEINS, V11, P281; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schnappinger D, 1998, EMBO J, V17, P535, DOI 10.1093/emboj/17.2.535; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WISSMANN A, 1991, GENETICS, V128, P225; Zeng XG, 1997, PROTEIN SCI, V6, P2218; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	31	12	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6405	6410		10.1074/jbc.274.10.6405	http://dx.doi.org/10.1074/jbc.274.10.6405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037732	hybrid			2022-12-27	WOS:000078902800054
J	Driscoll, B; T'Ang, A; Hu, YH; Yan, CL; Fu, Y; Luo, Y; Wu, KJ; Wen, SM; Shi, XH; Barsky, L; Weinberg, K; Murphree, AL; Fung, YK				Driscoll, B; T'Ang, A; Hu, YH; Yan, CL; Fu, Y; Luo, Y; Wu, KJ; Wen, SM; Shi, XH; Barsky, L; Weinberg, K; Murphree, AL; Fung, YK			Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; FACTOR-BETA; RB PROTEIN; TGF-BETA; NEGATIVE REGULATION; EPITHELIAL-CELLS; T-ANTIGEN; PHOSPHORYLATION; BINDING	The conformation and activity of pRb, the product of the retinoblastoma susceptibility gene, is dependent on the phosphorylation status of one or more of its 16 potential cyclin-dependent kinase (cdk) sites. However, it is not clear whether the phosphorylation status of one or more of these sites contributes to the determination of the various conformations and activity of pRb. Moreover, whether and how the conformation of pRb may regulate the phosphorylation of the cdk sites is also unclear. In the process of analyzing the function and regulation of pRb, we uncovered the existence of an unusual structural motif, m89 (amino acids 880-900), the mutation of which confers upon pRb a hypophosphorylated conformation. Mutation of this structural domain activates, rather than inactivates, the growth suppressor function of pRb. In order to understand the effect of the mutation of m89 on the phosphorylation of cdk sites, we identified all the cdk sites (Thr-356, Ser-807/Ser-811, and Thr821) the phosphorylation of which drastically modify the conformation of pRb. Mutation of each of these four sites alone or in combinations results in the different conformations of pRb, the migration pattern of which, on SDS-polyacrylamide gel electrophoresis, resembles various in vivo hypophosphorylated forms. Each of these hypophosphorylated forms of pRb has enhanced growth suppressing activity relative to the wild type. Our data revealed that the m89 structural motif controls the exposure of the cdk sites Ser-807/Ser-811 in vitro and in vivo. Moreover, the m89 mutant has enhanced growth suppressing activity, similar to a mutant with alanine substitutions at Ser-807/Ser-811, Our recent finding, that the m89 region is part of a structural domain, p5, conserved antigenically and functionally between pRb and p53, suggests that the evolutionarily conserved p5 domain may play a role in the coordinated regulation of the activity of these two tumor suppressors, under certain growth conditions.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Div Ophthalmol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Div Pathol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Div Res Immunol Bone Marrow Transplant, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Dept Immunol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Children's Hospital Los Angeles	Fung, YK (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, MS94,4650 Sunset Blvd,Smith Res Tower, Los Angeles, CA 90027 USA.				NCI NIH HHS [R01-CA44754] Funding Source: Medline; NHLBI NIH HHS [R01-HL 54850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Driscoll Barbara, 1995, Molecular and Cellular Differentiation, V3, P361; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FUNG YKT, 1993, ONCOGENE, V8, P2659; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GHABRIAL SA, 1973, VIROLOGY, V51, P485, DOI 10.1016/0042-6822(73)90447-9; Giannini G, 1997, J BIOL CHEM, V272, P5313, DOI 10.1074/jbc.272.8.5313; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES JA, 1991, EMBO J, V10, P857; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; TANG A, 1995, CHALLENGES MODERN ME, V10, P73; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TUNG JS, 1971, BIOCHEM BIOPH RES CO, V42, P1117, DOI 10.1016/0006-291X(71)90020-9; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	47	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9463	9471		10.1074/jbc.274.14.9463	http://dx.doi.org/10.1074/jbc.274.14.9463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092628	hybrid			2022-12-27	WOS:000079451800047
J	Manfred, G; Gupta, N; Vazquez-Memije, ME; Sadlock, JE; Spinazzola, A; De Vivo, DC; Schon, EA				Manfred, G; Gupta, N; Vazquez-Memije, ME; Sadlock, JE; Spinazzola, A; De Vivo, DC; Schon, EA			Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEIGH-SYNDROME; WILD-TYPE; DNA; CELLS; MTDNA; FIBROBLASTS; SEGREGATION; RESPIRATION; SUBUNIT-6; NT-8993	AT --> G mutation at position 8993 in human mitochondrial DNA is associated with the syndrome neuropathy, ataxia, and retinitis pigmentosa and with a maternally inherited form of Leigh's syndrome. The mutation substitutes an arginine for a leucine at amino acid position 156 in ATPase 6, a component of the F-0 portion of the mitochondrial ATP synthase complex Fibroblasts harboring high levels of the T8993G mutation have decreased ATP synthesis activity, hut do not display any growth defect under standard culture conditions, Combining the notions that cells with respiratory chain defects grow poorly in medium containing galactose as the major carbon source, and that resistance to oligomycin, a mitochondrial inhibitor, is associated with mutations in the ATPase 6 gene in the same transmembrane domain where the T8993G amino acid substitution is located, we created selective culture conditions using galactose and oligomycin that elicited a pathological phenotype in T8993G: cells and that allowed for the rapid selection of wild-type over T8993G mutant cells. We then generated cytoplasmic hybrid clones containing heteroplasmic levels of the T8993G mutation, and showed that selection in galactose-oligomycin caused a significant increase in the fraction of wild-type molecules (from 16 to 28%) in these cells.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, H Houston Merritt Clin Res Ctr Muscular Dystrophy, New York, NY 10032 USA; Bronx High Sch Sci, Bronx, NY USA; IMSS, Ctr Med Nacl, Hosp Pediat, Unidad Invest Genet Humana, Mexico City 06725, DF, Mexico	Columbia University; Columbia University; Instituto Mexicano del Seguro Social	Manfred, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, Rm 4-431,630 W 168th St, New York, NY 10032 USA.		Spinazzola, Antonella/P-5298-2017; Spinazzola, Antonella/P-5791-2019	Spinazzola, Antonella/0000-0003-4242-8091; Spinazzola, Antonella/0000-0003-4242-8091	NINDS NIH HHS [NS32527, NS28828, NS11766] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032527, P50NS011766, P01NS011766, R01NS028828] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453; BREEN GAM, 1982, MOL CELL BIOL, V2, P772, DOI 10.1128/MCB.2.7.772; BREEN GAM, 1986, J BIOL CHEM, V261, P1680; HOLT IJ, 1990, AM J HUM GENET, V46, P428; JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; MILLIS AJT, 1973, BIOCHIM BIOPHYS ACTA, V292, P73, DOI 10.1016/0005-2728(73)90251-X; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; SANTORELLI FM, 1992, ANN NEUROL, V32, P467; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Spelbrink JN, 1997, CURR GENET, V32, P115, DOI 10.1007/s002940050255; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TONSGARD JH, 1990, BIOCHEM J, V270, P511, DOI 10.1042/bj2700511; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; TULINIUS MH, 1995, HUM GENET, V96, P290; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZEVIANI M, 1988, NEUROLOGY, V38, P1339	26	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9386	9391		10.1074/jbc.274.14.9386	http://dx.doi.org/10.1074/jbc.274.14.9386			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092618	hybrid			2022-12-27	WOS:000079451800037
J	Osaka, H; Malany, S; Kanter, JR; Sine, SM; Taylor, P				Osaka, H; Malany, S; Kanter, JR; Sine, SM; Taylor, P			Subunit interface selectivity of the alpha-neurotoxins for the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING SITES; TORPEDO-CALIFORNICA; DELTA-SUBUNIT; CHOLINERGIC RECEPTOR; MOLECULAR DISSECTION; CROSS-LINKING; SNAKE TOXINS; RESIDUES; IDENTIFICATION	Peptide toxins selective for particular subunit interfaces of the nicotinic acetylcholine receptor have proven invaluable in assigning candidate residues located in the two binding sites and for determining probable orientations of the bound peptide. We report here on a short alpha-neurotoxin from Naja mossambica mossambica (NmmI) that, similar to other alpha-neurotoxins, binds with high affinity to alpha gamma and alpha delta subunit interfaces (K-D similar to 100 pM) but binds with markedly reduced affinity to the alpha epsilon interface (K-D similar to 100 nM). By constructing chimeras composed of portions of the gamma and epsilon subunits and coexpressing them with wild type alpha, beta, and delta subunits in HEK 293 cells, we identify a region of the subunit sequence responsible for the difference in affinity. Within this region, gamma Pro-175 and gamma Glu-176 confer high affinity, whereas Thr and Ala, found at homologous positions in epsilon, confer low affinity. To identify an interaction between gamma Glu-176 and residues in NmmI, we have examined cationic residues in the central loop of the toxin and measured binding of mutant toxin-receptor combinations. The data show strong pairwise interactions or coupling between gamma Glu-176 and Lys-27 of NmmI and progressively weaker interactions with Arg-33 and Arg-36 in loop II of this three-loop toxin, Thus, loop II of NmmI, and in particular the face of this loop closest to loop III, appears to come into close apposition with Glu-176 of the gamma subunit surface of the binding site interface.	Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA; Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	University of California System; University of California San Diego; Mayo Clinic	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM 18360] Funding Source: Medline; NINDS NIH HHS [NS 31744] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; Arias HR, 1997, BRAIN RES REV, V25, P133, DOI 10.1016/S0165-0173(97)00020-9; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; CHATRENET B, 1990, P NATL ACAD SCI USA, V87, P3378, DOI 10.1073/pnas.87.9.3378; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; Faiman GA, 1996, PROTEIN ENG, V9, P315, DOI 10.1093/protein/9.3.315; Galzi JL, 1996, EMBO J, V15, P5824, DOI 10.1002/j.1460-2075.1996.tb00969.x; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; HAMILTON SL, 1985, BIOCHEMISTRY-US, V24, P2210, DOI 10.1021/bi00330a015; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1992, BIOCHEMISTRY-US, V31, P8239, DOI 10.1021/bi00150a017; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MARCHOT P, 1988, EUR J BIOCHEM, V174, P537, DOI 10.1111/j.1432-1033.1988.tb14132.x; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; Molles B. E., 1998, Journal of Physiology Paris, V92, P470, DOI 10.1016/S0928-4257(99)80086-2; Osaka H, 1998, J BIOL CHEM, V273, P12758, DOI 10.1074/jbc.273.21.12758; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; PILLET L, 1993, J BIOL CHEM, V268, P909; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; SINE S, 1979, J BIOL CHEM, V254, P3315; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Utkin YN, 1998, EUR J BIOCHEM, V253, P229, DOI 10.1046/j.1432-1327.1998.2530229.x; WITZEMANN V, 1979, BIOCHEMISTRY-US, V18, P5511, DOI 10.1021/bi00591a039	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9581	9586		10.1074/jbc.274.14.9581	http://dx.doi.org/10.1074/jbc.274.14.9581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092644	hybrid			2022-12-27	WOS:000079451800063
J	Sangha, N; Kaur, S; Sharma, V; Krishnasastry, MV				Sangha, N; Kaur, S; Sharma, V; Krishnasastry, MV			Importance of the carboxyl terminus in the folding and function of alpha-hemolysin of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CIRCULAR-DICHROISM; TRANSMEMBRANE PORE; ESCHERICHIA-COLI; KEY RESIDUES; PROTEIN; STATE; TRANSLOCATION; MUTAGENESIS; BINDING	The physical state of two model mutants of alpha-hemolysin (alpha HL), alpha HL(1-289), a carboxyl-terminal deletion mutant (CDM), and alpha HL(1-331), a carboxyl-terminal extension mutant (CEM), were examined in detail to identify the role of the carboxyl terminus in the folding and function of native alpha HL, Denatured alpha HL can be refolded efficiently with nearly total recovery of its activity upon restoration of nondenaturing conditions. Various biophysical and biochemical studies on the three proteins have revealed the importance of an intact carboxyl terminus in the folding of alpha HL. The CDM exhibits a marked increase in susceptibility to proteases as compared with alpha HL, alpha HL and CEM exhibit similar fluorescence emission maxima, and that of the CDM is red-shifted by 9 nm, which indicates a greater solvent exposure of the tryptophan residues of the CDM, In addition, the CDM binds 8-anilino-1-naphthalene sulfonic acid (ANS) and increases its fluorescence intensity significantly unlike alpha HL and GEM, which show marginal binding. The circular dichroism studies point that the CDM possesses significant secondary structure, but its tertiary structure is greatly diminished as compared with alpha HL, These data show that the CDM has several of the features that characterize a molten globule state. Experiments with freshly translated mutants, using coupled in vitro transcription and translation, have further supported our observations that deletion at the carboxyl terminus leads to major structural perturbations in the water-soluble form of alpha HL. The studies demonstrate a critical role of the carboxyl terminus of alpha HL in attaining the native folded state.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Krishnasastry, MV (corresponding author), Natl Ctr Cell Sci, Univ Pune Campus, Pune 411007, Maharashtra, India.	infonccs@giaspn01.vsnl.net.in						Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; Fink A L, 1995, Methods Mol Biol, V40, P343; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND I, 1987, ANAL BIOCHEM, V164, P84, DOI 10.1016/0003-2697(87)90371-X; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMJEN BV, 1996, J BIOL CHEM, V271, P8655; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; Valeva A, 1997, BBA-BIOMEMBRANES, V1325, P281, DOI 10.1016/S0005-2736(96)00266-0; Vandana S, 1997, J BIOL CHEM, V272, P24858, DOI 10.1074/jbc.272.40.24858; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALLACE BA, 1984, P NATL ACAD SCI-BIOL, V81, P1406, DOI 10.1073/pnas.81.5.1406	25	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9193	9199		10.1074/jbc.274.14.9193	http://dx.doi.org/10.1074/jbc.274.14.9193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092591	hybrid			2022-12-27	WOS:000079451800010
J	Brown, JD; DiChiara, MR; Anderson, KR; Gimbrone, MA; Topper, JN				Brown, JD; DiChiara, MR; Anderson, KR; Gimbrone, MA; Topper, JN			MEKK-1, a component of the stress (stress-activated protein kinase c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; FLUID MECHANICAL STIMULI; VASCULAR ENDOTHELIUM; SIGNAL-TRANSDUCTION; SHEAR-STRESS; KAPPA-B; SMAD2; PHOSPHORYLATION; RECEPTOR; IDENTIFICATION	Smad proteins are essential components of the intracellular signaling pathways utilized by members of the transforming growth factor-beta (TGF-beta) superfamily of growth factors. Certain Smad proteins (e.g. Smad1, -2, and -3) can act as regulated transcriptional activators, a process that involves phosphorylation of these proteins by activated TGF-beta superfamily receptors, We demonstrate that the intracellular kinase mitogen-activated protein kinase kinase kinase-1 (MEKK-1), an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase pathway, can participate in Smad2-dependent transcriptional events in cultured endothelial cells, A constitutively active form of MEKK-1 but not mitogen-activated protein kinase kinase-1 (MEK-1) or TGF-beta-activated kinase-1, two distinct intracellular kinases, can specifically activate a Gal4-Smad2 fusion protein, and this effect correlates with an increase in the phosphorylation state of the Smad2 protein. These effects do not require the presence of the C-terminal SSXS motif of Smad2 that is the site of TGF-beta type 1 receptor-mediated phosphorylation. Activation of Smad2 by active MEKK-1 results in enhanced Smad2-Smad4 interactions, nuclear localization of Smad2 and Smad4, and the stimulation of Smad protein-transcriptional coactivator interactions in endothelial cells, Overexpression of Smad7 can inhibit the MEKK-1-mediated stimulation of Smad2 transcriptional activity, A physiological level of fluid shear stress, a known activator of endogenous MEKK-1 activity in endothelial cells, can stimulate Smad2-mediated transcriptional activity. These data demonstrate a novel mechanism for activation of Smad protein-mediated signaling in endothelial cells and suggest that Smad2 may act as an integrator of diverse stimuli in these cells.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Dept Med,Div Cardiovasc, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Div Vasc Res, Boston, MA 02115 USA	Stanford University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Topper, JN (corresponding author), Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Dept Med,Div Cardiovasc, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL051150, P50HL056985] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL56985, R37-HL51150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Frey RS, 1997, CANCER RES, V57, P628; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gimbrone MA, 1997, J CLIN INVEST, V99, P1809, DOI 10.1172/JCI119346; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li YS, 1996, MOL CELL BIOL, V16, P5947; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Topper JN, 1998, CIRCULATION, V98, P2396, DOI 10.1161/01.CIR.98.22.2396; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	34	138	143	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8797	8805		10.1074/jbc.274.13.8797	http://dx.doi.org/10.1074/jbc.274.13.8797			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085121	hybrid			2022-12-27	WOS:000079451600063
J	Gadal, O; Shpakovski, GV; Thuriaux, P				Gadal, O; Shpakovski, GV; Thuriaux, P			Mutants in ABC10 beta, a conserved subunit shared by all three yeast RNA polymerases, specifically affect RNA polymerase I assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; COMMON SUBUNITS; III MUTATIONS; ACTIVE-SITE; GENE; SUPPRESSOR; SEQUENCE; VECTORS; NOPP140; ENZYMES	ABC10 beta, a small polypeptide common to the three yeast RNA polymerases, has close homology to the N subunit of the archaeal enzyme and is remotely related to the smallest subunit of vaccinial RNA polymerase, The eucaryotic, archaeal, and viral polypeptides share an invariant motif CX,C.., CC that is strictly essential for yeast growth, as shown by site-directed mutagenesis, whereas the rest of the ABC10 beta sequence is fairly tolerant to amino acid replacements. ABC10 beta has Zn2+ binding properties in vitro, and the CX2C ... CC motif may therefore define an atypical metal-chelating site. Hybrid subunits that derive most of their amino acids from the archaeal subunit are functional in yeast, indicating that the archaeal and eucaryotic polypeptides have a largely equivalent role in the organization of their respective transcription complexes. However, all eucaryotic forms of ABC10 beta harbor a HVDLIEK motif that, when mutated or replaced by its archaeal counterpart, leads to a polymerase I-specific lethal defect in vivo. This is accompanied by a specific lack in the largest subunit of RNA polymerase I (A190) in cell-free extracts, showing that the mutant enzyme is not properly assembled in vivo.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia	CEA; UDICE-French Research Universities; Universite Paris Saclay; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Thuriaux, P (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.		Shpakovski, George V. Вячеславович/AAU-7443-2020; Gadal, Olivier/A-4731-2008	Shpakovski, George V. Вячеславович/0000-0003-2851-7020; Gadal, Olivier/0000-0001-9421-0831				AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; ARCHAMBAULT J, 1990, MOL CELL BIOL, V10, P6123, DOI 10.1128/MCB.10.12.6123; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHEDIN S, 1998, IN PRESS COLD SPRING; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Ikonomova R, 1997, DNA CELL BIOL, V16, P1161, DOI 10.1089/dna.1997.16.1161; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LANZENDORFER M, 1994, SYST APPL MICROBIOL, V16, P656; LANZENDORFER M, 1997, GENE DEV, V11, P1033; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; MCKUNE K, 1994, J BACTERIOL, V176, P4754, DOI 10.1128/JB.176.15.4754-4756.1994; Meier UT, 1996, J BIOL CHEM, V271, P19376; MEIER UT, 1992, CELL, V70, P127; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Moss B, 1996, FIELDS VIROLOGY, V2, P2637; MUKERJEE K, 1997, EUR J BIOCHEM, V247, P884; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Nouraini S, 1996, MOL CELL BIOL, V16, P5985; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1982, J BIOL CHEM, V257, P4570; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; Shpakovski GV, 1997, BIOORG KHIM+, V23, P110; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; THURIAUX P, 1995, METH MOL G, V6, P227; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TREICH I, 1991, J BIOL CHEM, V266, P21971; Treich Isabelle, 1992, Gene Expression, V2, P31; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1994, TRANSCRIPTION MECH R, P227; Woychik Nancy A., 1993, Gene Expression, V3, P77; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8421	8427		10.1074/jbc.274.13.8421	http://dx.doi.org/10.1074/jbc.274.13.8421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085073	hybrid			2022-12-27	WOS:000079451600015
J	Shenoy, SK; Yu, L; Yu, CA				Shenoy, SK; Yu, L; Yu, CA			Identification of quinone-binding and heme-ligating residues of the smallest membrane-anchoring subunit (QPs3) of bovine heart mitochondrial succinate : ubiquinone reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-REDUCTASE; ESCHERICHIA-COLI; COMPLEX-II; RECOMBINANT PROTEIN; OXIDOREDUCTASE; CLONING; RECONSTITUTION; EXPRESSION; LIGANDS; DOMAIN	The smallest membrane-anchoring subunit (QPs3) of bovine heart succinate:ubiquinone reductase was overexpressed in Escherichia coli JM109 as a glutathione S-transferase fusion protein using the expression vector pGEX2T/QPs3. The yield of soluble active recombinant glutathione S-transferase-QPs3 fusion protein was isopropyl-1-thio-beta-D-galactopyranoside concentration-, induction growth time-, temperature-, and medium-dependent. Maximum yield of soluble recombinant fusion protein was obtained from cells harvested 3.5 h post-isopropyl-1-thio-beta-D-galactopyranos (0.4 mM)-induction growth at 25 degrees C in 2.0% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mm KCl, 10 mM MgCl2, 20 mM glucose (SOC medium) containing 440 mM sorbitol and 2.5 mM betaine. QPs3 was released from the fusion protein by proteolytic cleavage with thrombin. Isolated recombinant QPs3 shows one protein band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis that corresponds to subunit V of mitochondrial succinate: ubiquinone reductase. Although purified recombinant QPs3 is dispersed in 0.01% dodecylmaltoside, it is in a highly aggregated form, with an apparent molecular mass of more than 1 million. The recombinant QPs3 binds ubiquinone, causing a spectral blue shift. Upon titration of the recombinant protein with ubiquinone, a saturation behavior is observed, suggesting that the binding is specific and that recombinant QPs3 may be in the functionally active state. Two amino acid residues, serine 33 and tyrosine 37, in the putative ubiquinone binding domain of QPs3 are involved in ubiquinone binding because the S33A- or Y37A-substituted recombinant QPs3s do not cause the spectral blue shift of ubiquinone. Although recombinant QPs3 contains little cytochrome b(560) heme, the spectral characteristics of cytochrome b(560) are reconstituted upon addition of hemin chloride. Reconstituted cytochrome b(560) in recombinant QPs3 shows a EPR signal at g = 2.92. Histidine residues at positions 46 and 60 are responsible for heme ligation because the H46N- or H60N-substituted QPs3 fail to restore cytochrome b560 upon addition of hemin chloride.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okway.okstate.edu	Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1986, IRON SULFUR PROTEIN, P40; Chen YR, 1996, J BIOL CHEM, V271, P2057, DOI 10.1074/jbc.271.4.2057; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; Lee GY, 1998, BBA-BIOENERGETICS, V1363, P35, DOI 10.1016/S0005-2728(97)00089-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; ROSE CT, 1998, BIOCHEMISTRY-US, V37, P4148; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1980, BIOCHIM BIOPHYS ACTA, V593, P24, DOI 10.1016/0005-2728(80)90005-5; YU L, 1992, J BIOL CHEM, V267, P24508	26	21	22	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8717	8722		10.1074/jbc.274.13.8717	http://dx.doi.org/10.1074/jbc.274.13.8717			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085111	hybrid			2022-12-27	WOS:000079451600053
J	Zhao, Q; Lee, FS				Zhao, Q; Lee, FS			Mitogen-activated protein kinase ERK kinase kinases 2 and 3 activate nuclear factor-kappa B through I kappa B kinase-alpha and I kappa B kinase-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEK KINASES; IKK-ALPHA; PATHWAYS; COMPLEX; INDUCTION; JNK; IDENTIFICATION; INTERACT	Recent evidence indicates that nuclear factor-kappa B (NF-kappa B), a transcription factor critically important for immune and inflammatory responses, is activated by a protein kinase cascade. The essential features of this cascade are that a mitogen-activated protein kinase kinase kinase (MAP3K) activates an I kappa B kinase (IKK) that site-specifically phosphorylates I kappa B. The I kappa B protein, which ordinarily sequesters NF-kappa B in the cytoplasm, is subsequently degraded by the ubiquitin-proteasome pathway, thereby allowing the nuclear translocation of NF-kappa B. Thus far, only two MAP3Ks, NIK and MEKK1, have been identified that can activate this pathway. We now show that MEKK2 and MEKK3 can in vivo activate IKK-alpha and IKK-beta, induce site-specific I kappa B alpha phosphorylation, and, relatively modestly, activate an NF-kappa B reporter gene. In addition, dominant negative versions of either IKK-alpha or IKK-beta abolish NF-kappa B activation induced by MEKK2 or MEKK3, thereby providing evidence that these IKKs mediate the NF-kappa B-inducing activities of these MEKKs, In contrast, other MAP3Ks, including MEKK4, ASK1, and MLK3, fail to show evidence of activation of the NF-kappa B pathway. We conclude that a distinct subset of MAP3Ks can activate NF-kappa B.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, FS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 218 John Morgan Bldg, Philadelphia, PA 19104 USA.			Lee, Frank/0000-0003-2511-1834				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; EZOE K, 1994, ONCOGENE, V9, P935; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sambrook J., 2002, MOL CLONING LAB MANU; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	36	240	258	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8355	8358		10.1074/jbc.274.13.8355	http://dx.doi.org/10.1074/jbc.274.13.8355			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085062	hybrid			2022-12-27	WOS:000079451600004
J	Zhang, FX; Kirschning, CJ; Mancinelli, R; Xu, XP; Jin, YP; Faure, E; Mantovani, A; Rothe, M; Muzio, M; Arditi, M				Zhang, FX; Kirschning, CJ; Mancinelli, R; Xu, XP; Jin, YP; Faure, E; Mantovani, A; Rothe, M; Muzio, M; Arditi, M			Bacterial lipopolysaccharide activates nuclear factor-kappa B through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; DROSOPHILA TOLL PROTEIN; SOLUBLE CD14; KINASE; ENDOTOXIN; MACROPHAGES; REQUIRES; PATHWAY; IRAK	Bacterial lipopolysaccharide (LPS)-mediated immune responses, including activation of monocytes, macrophages, and endothelial cells, play an important role in the pathogenesis of Gram-negative bacteria-induced sepsis syndrome. Activation of NF-kappa B is thought to be required for cytokine release from LPS-responsive cells, a critical step for endotoxic effects. Here we investigated the role and involvement of interleukin-l (IL-1) and tumor necrosis factor (TNF-alpha) signal transducer molecules in LPS signaling in human dermal microvessel endothelial cells (HDMEC) and THP-1 monocytic cells. LPS stimulation of HDMEC and THP-1 cells initiated an IL-l receptor-like NF-kappa B signaling cascade, In transient cotransfection experiments, dominant negative mutants of the IL-1 signaling pathway, including MyD88, IRAK, IRAK2, and TRAF6 inhibited both IL-1- and LPS-induced NF-kappa B-luciferase activity. LPS-induced NF-kappa B activation was not inhibited by a dominant negative mutant of TRAF2 that is involved in TNF signaling. LPS-induced activation of NF-kappa B-responsive reporter gene was not inhibited by IL-1 receptor antagonist. TLR2 and TLR4 were expressed on the cell surface of HDMEC and THP-1 cells. These findings suggest that a signal transduction molecule in the LPS receptor complex may belong to the IL-1 receptor/toll-like receptor (TLR) super family, and the LPS signaling cascade uses an analogous molecular framework for signaling as IL-I in mononuclear phagocytes and endothelial cells.	Steven Spielberg Pediat Res Ctr, Div Pediat Infect Dis, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Tularik Inc, San Francisco, CA USA; Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, I-20157 Milan, Italy	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Arditi, M (corresponding author), Cedars Sinai Med Ctr, Dept Pediat, 8700 Beverly Blvd,Rm 4310, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Mantovani, Alberto/HCI-7449-2022; Muzio, Marta/J-9360-2018	Mantovani, Alberto/0000-0001-5578-236X; Muzio, Marta/0000-0002-7761-759X	NIAID NIH HHS [AI40275] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040275] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDITI M, 1995, J IMMUNOL, V155, P3994; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CAO Z, 1996, SCIENCE, V383, P443; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Haeffner A, 1997, J IMMUNOL, V158, P1310; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; REIMANN T, 1994, J IMMUNOL, V153, P5740; RIETSCHEL ET, 1996, CURR TOP MICROBIOL I, V216, P40; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Schumann RR, 1996, BLOOD, V87, P2805, DOI 10.1182/blood.V87.7.2805.bloodjournal8772805; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	39	529	552	2	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7611	7614		10.1074/jbc.274.12.7611	http://dx.doi.org/10.1074/jbc.274.12.7611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075645	hybrid			2022-12-27	WOS:000079268100004
J	Brunati, AM; Donella-Deana, A; James, P; Quadroni, M; Contri, A; Marin, O; Pinna, LA				Brunati, AM; Donella-Deana, A; James, P; Quadroni, M; Contri, A; Marin, O; Pinna, LA			Molecular features underlying the sequential phosphorylation of HS1 protein and its association with c-Fgr protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-LINEAGE; SRC FAMILY; MEDIATED APOPTOSIS; LYMPHOMA-CELLS; SH2 DOMAINS; TPK-IIB; RECEPTOR; SUBSTRATE; SYK; IDENTIFICATION	The hematopoietic lineage cell-specific protein HS1 was shown to undergo a process of sequential phosphorylation both in vitro and in vitro, which is synergistically mediated by Syk and Src family protein-tyrosine kinases and essential for B cell antigen receptor-mediated apoptosis, We have now identified tyrosine 222 as the HS1 residue phosphorylated by the Src family protein kinases c-Fgr and Lyn, and we show that a truncated form of HS1 (HS1-208-401) lacking the N-terminal putative DNA binding region and the C-terminal Src homology 3 (SH3) domain is still able to undergo all the steps of sequential phosphorylation as efficiently as full-length HS1. We also show that a stable association of phospho-HS1 with c-Fgr through its SH2 domain requires previous autophosphorylation of the kinase and is prevented by subsequent phosphorylation of Tyr-222. Kinetic studies with HS1 and its truncated forms previously phosphorylated by Syk and with a peptide substrate reproducing the sequence around tyrosine 222 support the view that efficient phosphorylation of HS1 by Src family protein kinases entirely relies on TyrP SH2 domain interaction with negligible, if any, contribution of local specificity determinants. Our data indicate that the proline-rich region of HS1 bordered by tyrosyl residues affected by Syk and Src family kinases represents a functional domain designed to undergo a process of sequential phosphorylation.	Univ Padua, Dipartimento Chim Biol, CNR, Ctr Studio Biomembrane, I-35121 Padua, Italy; Univ Padua, Ctr Ric Interdipartimentale Biotechnol Innovat, I-35121 Padua, Italy; Swiss Fed Inst Technol Zentrum, Prot Chem Lab, CH-8090 Zurich, Switzerland; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of British Columbia	Pinna, LA (corresponding author), Univ Padua, Dipartimento Chim Biol, CNR, Ctr Studio Biomembrane, Via Colombo 3, I-35121 Padua, Italy.		Brunati, Anna Maria/I-8136-2018	Brunati, Anna Maria/0000-0002-3481-9503; Quadroni, Manfredo/0000-0002-2720-4084				BENHAMOU LE, 1994, EUR J IMMUNOL, V24, P1993, DOI 10.1002/eji.1830240909; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P111; Brunati AM, 1998, BIOCHEM BIOPH RES CO, V243, P700, DOI 10.1006/bbrc.1998.8153; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; DonellaDeana A, 1996, EUR J BIOCHEM, V235, P18, DOI 10.1111/j.1432-1033.1996.00018.x; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; HATA D, 1993, IMMUNOL LETT, V40, P65; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Suzuki Y, 1997, J IMMUNOL, V158, P2736; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387	31	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7557	7564		10.1074/jbc.274.11.7557	http://dx.doi.org/10.1074/jbc.274.11.7557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066823	hybrid			2022-12-27	WOS:000079078400095
J	Littman, SJ; Fang, WH; Modrich, P				Littman, SJ; Fang, WH; Modrich, P			Repair of large insertion/deletion heterologies in human nuclear extracts is directed by a 5 ' single-strand break and is independent of the mismatch repair system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERODUPLEX DNA-MOLECULES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; TUMOR-CELLS; LOOPS; REPLICATION; SEQUENCES; CANCER; HETERODIMER; SPECIFICITY	The repair of 12-, 27-, 62-, and 216-nucleotide unpaired insertion/deletion heterologies has been demonstrated in nuclear extracts of human cells. When present in covalently closed circular heteroduplexes or heteroduplexes containing a single-strand break 3' to the heterology, such structures are subject to a low level repair reaction that occurs with little strand bias. However, the presence of a single-strand break 5' to the insertion/deletion heterology greatly increases the efficiency of rectification and directs repair to the incised DNA strand. Because nick direction of repair is independent of the strand in which a particular heterology is placed, the observed strand bias is not due to asymmetry imposed on the heteroduplex by the extrahelical DNA segment. Strand-specific repair by this system requires ATP and the four dNTPs and is inhibited by aphidicolin, Repair is independent of the mismatch repair proteins MSH2, MSH6, MLH1, and PMS2 and occurs by a mechanism that is distinct from that of the conventional mismatch repair system. Large heterology repair in nuclear extracts of human cells is also independent of the XPF gene product, and extracts of Chinese hamster ovary cells deficient in the ERCC1 and ERCC4 gene products also support the reaction.	Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Med Oncol, Durham, NC 27710 USA; Natl Taiwan Univ, Coll Med, Sch Med Technol, Taipei 10002, Taiwan	Duke University; Howard Hughes Medical Institute; Duke University; National Taiwan University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Rm 150,POB 3711, Durham, NC 27710 USA.			FANG, WOEI-HORNG/0000-0003-4728-5931; Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [K08CA071554] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA71554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; DEPAMPHILIS ML, 1980, ANNU REV BIOCHEM, V49, P627, DOI 10.1146/annurev.bi.49.070180.003211; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; EDENBERG HJ, 1978, J BIOL CHEM, V253, P3273; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PUKKILA PJ, 1983, GENETICS, V104, P571; REENAN RAG, 1992, GENETICS, V132, P975; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VANDERVLIET PC, 1978, NATURE, V276, P532, DOI 10.1038/276532a0; WEISS U, 1988, NUCLEIC ACIDS RES, V16, P2313, DOI 10.1093/nar/16.5.2313; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7474	7481		10.1074/jbc.274.11.7474	http://dx.doi.org/10.1074/jbc.274.11.7474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066813	hybrid			2022-12-27	WOS:000079078400085
J	Persechini, A; Cronk, B				Persechini, A; Cronk, B			The relationship between the free concentrations of Ca2+ and Ca2+-calmodulin in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CALMODULIN-BINDING DOMAIN; ADENYLYL-CYCLASE; FLUORESCENT INDICATORS; CALCIUM; PROTEINS; LOCALIZATION; ACTIVATION; SITES; CA2+/CALMODULIN	Using stably expressed fluorescent indicator proteins, we have determined for the first time the relationship between the free Ca2+ and Ca2+-calmodulin concentrations in intact cells. A similar relationship is obtained when the free Ca2+ concentration is externally buffered or when it is transiently increased in response to a Ca2+-mobilizing agonist, Below a free Ca2+ concentration of 0.2 mu M, no Ca2+-calmodulin is detectable. A global maximum free Ca2+-calmodulin concentration of similar to 45 nM is produced when the free Ca2+ concentration exceeds 3 mu M, and a half-maximal concentration is produced at a free Ca2+ concentration of 1 mu M. Data for fractional saturation of the indicators suggest that the total concentration of calmodulin-binding proteins is similar to 2-fold higher than the total calmodulin concentration. We conclude that high-affinity calmodulin targets (K-d less than or equal to 10 nM) are efficiently activated throughout the cell, but efficient activation of low-affinity targets (K-d greater than or equal to 100 nM) occurs only where free Ca2+-calmodulin concentrations can be locally enhanced.	Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Persechini, A (corresponding author), Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, 601 Elmwood Ave,Box 711, Rochester, NY 14642 USA.				NIDDK NIH HHS [DK44322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauer PJ, 1996, J PHYSIOL-LONDON, V494, P675, DOI 10.1113/jphysiol.1996.sp021523; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BJORK J, 1995, EUR J CELL BIOL, V66, P200; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; KATADA T, 1987, J BIOL CHEM, V262, P11897; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Medvedeva MV, 1996, BIOCHEM J, V315, P1021, DOI 10.1042/bj3151021; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Nicol S, 1997, BIOCHEMISTRY-US, V36, P11487, DOI 10.1021/bi970709r; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Shupnik MA, 1996, MOL ENDOCRINOL, V10, P90, DOI 10.1210/me.10.1.90; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2	41	132	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6827	6830		10.1074/jbc.274.11.6827	http://dx.doi.org/10.1074/jbc.274.11.6827			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066733	hybrid			2022-12-27	WOS:000079078400005
J	Tsuji, Y; Moran, E; Torti, SV; Torti, FM				Tsuji, Y; Moran, E; Torti, SV; Torti, FM			Transcriptional regulation of the mouse ferritin H gene - Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HEAVY-CHAIN; MOLECULAR-CLONING; ADENOVIRUS E1A; FUNCTIONAL COLLABORATION; CELLULAR PROTEINS; BREAST-CARCINOMA; IRON-METABOLISM; SERUM FERRITIN; MESSENGER-RNA	We previously identified a major enhancer of the mouse ferritin H gene (FER-1) that is central to repression of the ferritin H gene by the adenovirus E1A oncogene (Tsuji, Y,, Akebi, N,, Lam, T, K,, Nakabeppu, Y,, Torti, S. V,, and Torti, F, M, (1995) Mel. Cell. Biol, 15, 5152-5164), To dissect the molecular mechanism of transcriptional regulation of ferritin H, E1A mutants were tested for their ability to repress FER-1 enhancer activity using cotransfection with ferritin H-chloramphenicol acetyltransferase (CAT) reporter constructs. Here we report that p300/CBP transcriptional adaptor proteins are involved in the regulation of ferritin H transcription through the FER-1 enhancer element. Thus, ELA mutants that failed to bind p300/CBP lost the ability to repress FER-1, whereas mutants of E1A that abrogated its interaction with Rb, p107, or p130 were fully functional in transcriptional repression. Transfection with EIA did not affect endogenous p300/CBP levels, suggesting that repression of FER-1 by E1A is not due to repression of p300/CBP synthesis, but to E1A and p300/CBP interaction. In addition, we have demonstrated that transfection of a p300 expression plasmid significantly activated ferritin H-CAT containing the FER-1 enhancer, but had a marginal effect on ferritin H-CAT with FER-1 deleted, Furthermore, both wild-type p300 and a p300 mutant that failed to bind E1A but retained an adaptor function restored FER-1 enhancer activity repressed by E1A. Sodium butyrate, an inhibitor of histone deacetylase, mimicked p300/CBP function in activation of ferritin H-CAT and elevation of endogenous ferritin H mRNA, suggesting that the histone acetyltransferase activity of p300/CBP or its associated proteins may contribute to the activation of ferritin H transcription, Recruitment of these broadly active transcriptional adaptor proteins for ferritin H synthesis may represent an important mechanism by which changes in iron metabolism are coordinated with other cellular responses mediated by p300/CBP.	Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsuji, Y (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.				NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [CA12197] Funding Source: Medline; NIDDK NIH HHS [DK-42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BECK GR, 1997, J CELL BIOCHEM, V68, P1; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BLATT J, 1992, J LAB CLIN MED, V119, P139; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CAIRO G, 1986, BIOCHEM BIOPH RES CO, V139, P652, DOI 10.1016/S0006-291X(86)80040-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COX F, 1988, J BIOL CHEM, V263, P7060; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELLIOTT RL, 1993, ANN NY ACAD SCI, V698, P159, DOI 10.1111/j.1749-6632.1993.tb17204.x; GUNER G, 1992, CANCER LETT, V67, P103, DOI 10.1016/0304-3835(92)90132-F; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KIKYO N, 1994, CANCER RES, V54, P268; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; Mymryk JS, 1996, ONCOGENE, V13, P1581; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1993, EXP CELL RES, V209, P175, DOI 10.1006/excr.1993.1299; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1998, J BIOL CHEM, V273, P2984, DOI 10.1074/jbc.273.5.2984; VAUGHN CB, 1987, CANCER INVEST, V5, P7, DOI 10.3109/07357908709020300; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; WILLIAMS MR, 1990, EUR J SURG ONCOL, V16, P22; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	57	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7501	7507		10.1074/jbc.274.11.7501	http://dx.doi.org/10.1074/jbc.274.11.7501			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066817	hybrid			2022-12-27	WOS:000079078400089
J	Zhang, YL; Hervio, L; Strandberg, L; Madison, EL				Zhang, YL; Hervio, L; Strandberg, L; Madison, EL			Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; SITE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; CORONARY THROMBOLYSIS; MYOCARDIAL-INFARCTION; INHIBITOR; ENZYME; DETERMINANTS; SUBSTITUTION; EFFICIENT	Archetypal members of the chymotrypsin family of serine proteases, such as trypsin, chymotrypsin, and elastase, exhibit relatively broad substrate specificity. However, the successful development of efficient proteolytic cascades, such as the blood coagulation and fibrinolytic systems, required the evolution of proteases that displayed restricted specificity. Tissue-type plasminogen activator (t-PA), for example, possesses exquisitely stringent substrate specificity, and the molecular basis of this important biochemical property of t-PA remains obscure. Previous investigations of related serine proteases, which participate in the blood coagulation cascade, have focused attention on the residue that occupies position 192 (chymotrypsin numbering system), which plays a pivotal role in determining both the inhibitor and substrate specificity of these enzymes, Consequently, we created and characterized the kinetic properties of new variants of t-PA that contained point mutations at position 192. These studies demonstrated that, unlike in coagulation serine proteases, Gln-192 does not contribute significantly to the substrate or inhibitor specificity of t-PA in physiologically relevant reactions. Replacement of Gln-192 with a glutamic acid residue did, however, decrease the catalytic efficiency of mature, two-chain t-PA toward plasminogen in the absence of a fibrin co-factor.	Corvas Int, Dept Mol Biol, San Diego, CA 92121 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Madison, EL (corresponding author), Corvas Int, Dept Mol Biol, 3030 Sci Pk Rd, San Diego, CA 92121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475, P01HL031950] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BELL LD, 1988, GENE, V63, P155, DOI 10.1016/0378-1119(88)90521-5; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERGMANN SR, 1983, SCIENCE, V220, P1181; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; Cannon CP, 1997, CIRCULATION, V95, P351; Castellino F. J, 1995, MOL BASIS THROMBOSIS, P495; COLLEN D, 1988, SEMIN THROMB HEMOST, V14, P95, DOI 10.1055/s-2007-1002761; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COLLEN D, 1992, HEART CARDIOVASCULAR, V1, P275; COLLEN DC, 1990, THROMB RES, P105; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; Ke SH, 1997, J BIOL CHEM, V272, P1811, DOI 10.1074/jbc.272.3.1811; Keyt Bruce A., 1996, P435; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MCCLUSKEY ER, 1997, NEW THERAPEUTIC AGEN, P475; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P8701, DOI 10.1021/bi00027a020; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1995, J BIOL CHEM, V270, P16176, DOI 10.1074/jbc.270.27.16176; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; Tachias K, 1997, J BIOL CHEM, V272, P28; Tachias K, 1997, J BIOL CHEM, V272, P14580, DOI 10.1074/jbc.272.23.14580; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1984, NEW ENGL J MED, V310, P609; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	45	8	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7153	7156		10.1074/jbc.274.11.7153	http://dx.doi.org/10.1074/jbc.274.11.7153			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066774	hybrid			2022-12-27	WOS:000079078400046
J	Holzfeind, PJ; Ambrose, HJ; Newey, SE; Nawrotzki, RA; Blake, DJ; Davies, KE				Holzfeind, PJ; Ambrose, HJ; Newey, SE; Nawrotzki, RA; Blake, DJ; Davies, KE			Tissue-selective expression of alpha-dystrobrevin is determined by multiple promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTRIC ORGAN; OPEN READING FRAMES; MUSCULAR-DYSTROPHY; TRANSLATIONAL CONTROL; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; MUSCLE; BRAIN; TRANSCRIPT	alpha-Dystrobrevin, the mammalian orthologue of the Torpedo 87-kDa postsynaptic protein, is a dystrophin-associated and dystrophin-related protein. Knockout of the gene in the mouse results in muscular dystrophy. The control of the alpha-dystrobrevin gene in the various tissues is therefore of interest. Multiple dystrobrevin isoforms differing in their domain content are generated by alternative splicing of a single gene. The data presented here demonstrate that expression of alpha-dystrobrevin from three promoters, that are active in a tissue-selective manner, also plays a role in the function of the protein in different tissues. The most proximal promoter A is active in brain and to a lesser extent in lung, whereas the most distal promoter B, which possesses several Sp1 binding sites, is restricted to brain. Promoter C, which contains multiple consensus myogenic binding sites, is up-regulated during in vitro myoblast differentiation. interestingly, the organization and the activity of the alpha-dystrobrevin promoters is reminiscent of those in the dystrophin gene. Taken together we suggest that the multipromoter system, distributed over a region of 270 kilobases at the 5'-end of the alpha-dystrobrevin gene, has been developed to allow the regulation of this gene in different cell types and/or different developmental stages.	Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.							Ambrose HJ, 1997, GENOMICS, V39, P359, DOI 10.1006/geno.1996.4515; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; KESSEL M, 1988, NATURE, V332, P117, DOI 10.1038/332117c0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Nawrotzki R, 1998, J CELL SCI, V111, P2595; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Roberts RG, 1998, HUM MOL GENET, V7, P589, DOI 10.1093/hmg/7.4.589; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; TINSLEY JM, 1993, HUM MOL GENET, V2, P521, DOI 10.1093/hmg/2.5.521; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; Zhou H., 1998, Society for Neuroscience Abstracts, V24, P1534; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	38	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6250	6258		10.1074/jbc.274.10.6250	http://dx.doi.org/10.1074/jbc.274.10.6250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037712	hybrid			2022-12-27	WOS:000078902800034
J	Kennedy, KA; Traxler, B				Kennedy, KA; Traxler, B			MalK forms a dimer independent of its assembly into the MalFGK(2) ATP-binding cassette transporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-BINDING; PROTEIN; SYSTEM; PURIFICATION; SUBUNIT; COMPLEX; DIMERIZATION; REQUIREMENTS; EXPRESSION	The maltose transport complex (MTC) is a member of the ATP-binding cassette superfamily of membrane transport proteins and is a model for understanding the folding and assembly of hetero oligomeric membrane protein complexes. The MTC is made up of two integral membrane proteins, MalF and MalG, and a peripheral membrane protein, MalK, These proteins associate with a stoichiometry of 1:1:2 to form the complex MalFGK(2). In our studies of the oligomerization of this complex, we have shown that the ATP-binding component, MalK, forms a dimer in the absence of MalF and MalG, Epitope-tagged MalK coimmunoprecipitated with wild-type MalK, indicating that the MalK protein forms an oligomer, The relative amounts of tagged and wild-type MalK that were present in the whole cell extracts and in the immunoprecipitated complexes show that the MalK oligomer is a dimer, These hetero-oligomers can also be formed in vitro by mixing two extracts, each containing either tagged or wild-type MalK. The dimerization of MalK was also demonstrated in vivo using the bacteriophage lambda repressor fusion assay. The formation of a MalK dimer in the absence of MalF and MalG may represent an initial step in the assembly pathway of the MTC.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Traxler, B (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.							AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BALBAS P, 1986, VECTORS, P5; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEAN DA, 1990, J BIOL CHEM, V265, P21005; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Lippincott J, 1997, J BACTERIOL, V179, P1337, DOI 10.1128/jb.179.4.1337-1343.1997; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; Miller J.H., 1972, EXPT MOL GENETICS; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; Sambrook J., 2002, MOL CLONING LAB MANU; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; WALTER C, 1992, J BIOL CHEM, V267, P8863	22	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6259	6264		10.1074/jbc.274.10.6259	http://dx.doi.org/10.1074/jbc.274.10.6259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037713	hybrid			2022-12-27	WOS:000078902800035
J	Wiley, JC; Wailes, LA; Idzerda, RL; McKnight, GS				Wiley, JC; Wailes, LA; Idzerda, RL; McKnight, GS			Role of regulatory subunits and protein kinase inhibitor (PKI) in determining nuclear localization and activity of the catalytic subunit of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A ANCHORING PROTEIN; SIGNAL-TRANSDUCTION; GOLGI-COMPLEX; EXPORT; EXPRESSION; MUTATIONS; GENE; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION	Regulation of protein kinase A by subcellular localization may be critical to target catalytic subunits to specific substrates. We employed epitope-tagged catalytic subunit to correlate subcellular localization and gene-inducing activity in the presence of regulatory subunit or protein kinase inhibitor (PKI). Transiently expressed catalytic subunit distributed throughout the cell and induced gene expression. Go-expression of regulatory subunit or PKI blocked gene induction and prevented nuclear accumulation. A mutant PKI lacking the nuclear export signal blocked gene induction but not nuclear accumulation, demonstrating that nuclear export is not essential to inhibit gene induction. When the catalytic subunit was targeted to the nucleus with a nuclear localization signal, it was not sequestered in the cytoplasm by regulatory subunit, although its activity was completely inhibited. PKI redistributed the nuclear catalytic subunit to the cytoplasm and blocked gene induction, demonstrating that the nuclear export signal of PKI can override a strong nuclear localization signal. With increasing PKI, the export process appeared to saturate, resulting in the return of catalytic subunit to the nucleus. These results demonstrate that both the regulatory subunit and PKI are able to completely inhibit the gene-inducing activity of the catalytic subunit even when the catalytic subunit is forced to concentrate in the nuclear compartment.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	McKnight, GS (corresponding author), Univ Washington, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD033057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM032875] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33057] Funding Source: Medline; NIGMS NIH HHS [GM32875, 2T32-GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TAYLOR SS, 1993, RECEPTOR, V3, P165; THOMAS J, 1991, J BIOL CHEM, V266, P10906; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	31	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6381	6387		10.1074/jbc.274.10.6381	http://dx.doi.org/10.1074/jbc.274.10.6381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037729	hybrid			2022-12-27	WOS:000078902800051
J	Brodbeck, D; Cron, P; Hemmings, BA				Brodbeck, D; Cron, P; Hemmings, BA			A human protein kinase B gamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHOINOSITIDE-3-OH KINASE; AKT; INSULIN; PDK1; BETA; TRANSLOCATION; EXPRESSION	We have cloned human protein kinase B gamma (PKB gamma) and found that it contains two regulatory phosphorylation sites, Thr(305) and Ser(472), which correspond to Thr(308) and Ser(473) Of PKB alpha. Thus it differs significantly from the previously published rat PKB gamma. We have also isolated a similar clone from a mouse cDNA library. In human tissues, PKB gamma is widely expressed as two transcripts. A mutational analysis of the two regulatory sites of human PKB gamma showed that phosphorylation of both sites, occurring in a phosphoinositide 3-kinase-dependent manner, is required for full activity. Our results suggest that the two phosphorylation sites act in concert to produce full activation of PKB gamma, similar to PKB alpha. This contrasts with rat PKB gamma, which is thought to be regulated by 3-phosphoinositide-dependent protein kinase 1 alone.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299	29	154	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9133	9136		10.1074/jbc.274.14.9133	http://dx.doi.org/10.1074/jbc.274.14.9133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092583	hybrid			2022-12-27	WOS:000079451800002
J	Gurezka, R; Laage, R; Brosig, B; Langosch, D				Gurezka, R; Laage, R; Brosig, B; Langosch, D			A heptad motif of leucine residues found in membrane proteins can drive self-assembly of artificial transmembrane segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS-E5 TRANSFORMING PROTEIN; FOCUS-FORMING VIRUS; GROWTH-FACTOR RECEPTOR; ERYTHROPOIETIN RECEPTOR; ALPHA-HELICES; COILED COILS; GP55 GLYCOPROTEIN; STOP-TRANSFER; AMINO-ACIDS; ACTIVATION	Specific interactions between cu-helical transmembrane segments are important for folding and/or oligomerization of membrane proteins. Previously, we have shown that most transmembrane helix-helix interfaces of a set of crystallized membrane proteins are structurally equivalent to soluble leucine zipper interaction domains. To establish a simplified model of these membrane-spanning leucine zippers, we studied the homophilic interactions of artificial transmembrane segments using different experimental approaches. Importantly, an oligoleucine, but not an oligoalanine, sequence efficiently self-assembled in membranes as well as in detergent solution. Self-assembly was maintained when a leucine zipper type of heptad motif consisting of leucine residues was grafted onto an alanine host sequence. Analysis of point mutants or of a random sequence confirmed that the heptad motif of leucines mediates self-recognition of our artificial transmembrane segments. Further, a data base search identified degenerate versions of this leucine motif within transmembrane segments of a variety of functionally different proteins. For several of these natural transmembrane segments, self-interaction was experimentally verified. These results support various lines of previously reported evidence where these transmembrane segments were implicated in the oligomeric assembly of the corresponding proteins.	Univ Heidelberg, Inst Neurobiol, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Langosch, D (corresponding author), Univ Heidelberg, Inst Neurobiol, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.							ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; Brosig B, 1998, PROTEIN SCI, V7, P1052; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P142; Dieckmann GR, 1997, CURR OPIN STRUC BIOL, V7, P486, DOI 10.1016/S0959-440X(97)80111-X; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; HEIDIN CH, 1995, CELL, V80, P213; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LOEB JA, 1987, J BIOL CHEM, V262, P3022; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MCGINNES L, 1993, VIROLOGY, V196, P101, DOI 10.1006/viro.1993.1458; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; SCHRAUBER H, 1993, J MOL BIOL, V230, P592, DOI 10.1006/jmbi.1993.1172; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Subczynski WK, 1998, BIOCHEMISTRY-US, V37, P3156, DOI 10.1021/bi972148+; Tarr K, 1997, J BIOL CHEM, V272, P9099; VERREY F, 1993, BIOCHEM J, V292, P149, DOI 10.1042/bj2920149; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITLEY P, 1994, NAT STRUCT BIOL, V1, P858, DOI 10.1038/nsb1294-858; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; WOLFF L, 1985, J VIROL, V53, P570, DOI 10.1128/JVI.53.2.570-578.1985; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11579, DOI 10.1021/bi00161a042; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	57	161	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9265	9270		10.1074/jbc.274.14.9265	http://dx.doi.org/10.1074/jbc.274.14.9265			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092601	hybrid			2022-12-27	WOS:000079451800020
J	Sharma, P; Steinbach, PJ; Sharma, M; Amin, ND; Barchi, JJ; Pant, HC				Sharma, P; Steinbach, PJ; Sharma, M; Amin, ND; Barchi, JJ; Pant, HC			Identification of substrate binding site of cyclin-dependent kinase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CDK5 ACTIVATOR; CRYSTAL-STRUCTURE; PROTEIN-KINASE; PHOSPHORYLASE-KINASE; CATALYTIC SUBUNIT; CELL-CYCLE; COMPLEX; RECOGNITION; DYNAMICS; PROGRAM	Cyclin-dependent kinase 5 (CDK5), unlike other CDKs, is active only in neuronal cells where its neuron-specific activator p35 is present. However, it phosphorylates serines/threonines in S/TPXK/R-type motifs Like other CDKs. The tail portion of neurofilament-H contains more than 50 KSP repeats, and CDK5 has been shown to phosphorylate S/T specifically only in KS/ TPXK motifs, indicating highly specific interactions in substrate recognition. CDKs have been shown to have a high preference for a basic residue (lysine or arginine) as the n+3 residue, n being the location in the primary sequence of a phosphoacceptor serine or threonine, Because of the lack of a crystal structure of a CDK-substrate complex, the structural basis for this specific interaction is unknown, me have used site-directed mutagenesis ("charged to alanine") and molecular modeling techniques to probe the recognition interactions for substrate peptide (PKTPKKAKKL) derived from histone H1 docked in the active site of CDK5, The experimental data and computer simulations suggest that Asp(86) and Asp(91) are key residues that interact with the lysines at positions n+2 and/or n+3 of the substrates.	NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA; NINDS, Ctr Mol Modeling, Ctr Informat Technol, NIH, Bethesda, MD 20892 USA; NINDS, Med Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Pant, HC (corresponding author), NINDS, Neurochem Lab, NIH, Bldg 36,Rm 4D20, Bethesda, MD 20892 USA.	hcp@codon.nih.gov	Barchi, Joseph J/N-3784-2014	Barchi, Joseph/0000-0001-9906-0799	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000265, ZIACT000265] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT))		BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noble MEM, 1997, TRENDS BIOCHEM SCI, V22, P482, DOI 10.1016/S0968-0004(97)01144-4; Pavelites JJ, 1997, J COMPUT CHEM, V18, P221, DOI 10.1002/(SICI)1096-987X(19970130)18:2<221::AID-JCC7>3.0.CO;2-X; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SHARMA P, 1998, BIOCHEMISTRY-US, V371, P419; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STEINBACH PJ, 1994, J COMPUT CHEM, V15, P667, DOI 10.1002/jcc.540150702; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Veeranna, 1998, J NEUROSCI, V18, P4008; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	31	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9600	9606		10.1074/jbc.274.14.9600	http://dx.doi.org/10.1074/jbc.274.14.9600			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092646	hybrid			2022-12-27	WOS:000079451800065
J	Wurmser, AE; Gary, JD; Emr, SD				Wurmser, AE; Gary, JD; Emr, SD			Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN SORTING PATHWAYS; LYSOSOME-LIKE VACUOLE; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; PHOSPHOLIPASE-C; PI 3-KINASE; TRANSPORT; GENE		Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Emr, SD (corresponding author), Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA.				NCI NIH HHS [CA58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Bonangelino CJ, 1997, MOL CELL BIOL, V17, P6847, DOI 10.1128/MCB.17.12.6847; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Bryant NJ, 1998, J CELL BIOL, V142, P651, DOI 10.1083/jcb.142.3.651; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1998, SEMIN CELL DEV BIOL, V9, P527, DOI 10.1006/scdb.1998.0255; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; COWLES CR, 1994, J CELL SCI, V107, P3449; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANEKO Y, 1982, MOL CELL BIOL, V2, P127, DOI 10.1128/MCB.2.2.127; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PETERSON MR, 1999, IN PRESS CURR BIOL; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; VOLINIA, 1995, EMBO J, V14, P3339; Wada Y, 1997, J CELL SCI, V110, P1299; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	71	193	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9129	9132		10.1074/jbc.274.14.9129	http://dx.doi.org/10.1074/jbc.274.14.9129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092582	hybrid			2022-12-27	WOS:000079451800001
J	Cartwright, JL; McLennan, AG				Cartwright, JL; McLennan, AG			The Saccharomyces cerevisiae YOR163w gene encodes a diadenosine 5 ',5 '''-P-1,P-6-hexaphosphate (Ap(6)A) hydrolase member of the MutT motif (nudix hydrolase) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASES; P-1,P-4-BIS(5'-ADENOSYL) TETRAPHOSPHATE; BIS(5'-NUCLEOSIDYL) TETRAPHOSPHATES; ADENOSINE 5'-TETRAPHOSPHATE; ESCHERICHIA-COLI; AP4A; HYDROLYSIS; PYROPHOSPHOHYDROLASES; PHOSPHODIESTERASE; 5'-PENTAPHOSPHATE	The YOR163w open reading frame on chromosome XV of the Saccharomyces cerevisiae genome encodes a member of the MutT motif (nudix hydrolase) family of enzymes of M-r 21,443. By cloning and expressing this gene in Escherichia coli and S. cerevisiae, we have shown the product to be a (di)adenosine polyphosphate hydrolase with a previously undescribed substrate specificity. Diadenosine 5',5'''-P-1,P-6-hexaphosphate is the preferred substrate, and hydrolysis in (H2O)-O-18 shows that ADP and adenosine 5'-tetraphosphate are produced by attack at P beta and AMP and adenosine 5'-pentaphosphate are produced by attack at P-alpha with a K-m of 56 mu m and k(cat) of 0.4 s(-1). Diadenosine 5',5'''-P-1,P-5-pentaphosphate, adenosine 5'-pentaphosphate, and adenosine 5'-tetraphosphate are also substrates, but not diadenosine 5',5"-P-1,P-4-tetraphosphate or other dinucleotides, mononucleotides, nucleotide sugars, or nucleotide alcohols. The enzyme, which was shown to be expressed in log phase yeast cells by immunoblotting, displays optimal activity at pH 6.9, 50 degrees C, and 4-10 mM Mg2+ (or 200 mu M Mn2+). It has an absolute requirement for a reducing agent, such as dithiothreitol (1 mM), and is inhibited by Ca2+ with an IC50 of 3.3 mM and F- (noncompetitively) with a K-i of 80 mu M. Its function may be to eliminate potentially toxic dinucleoside polyphosphates during sporulation.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	McLennan, AG (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,POB 147, Liverpool L69 7ZB, Merseyside, England.	agmclen@liv.ac.uk						Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BLACKBURN GM, 1987, NUCLEIC ACIDS RES, V15, P6991, DOI 10.1093/nar/15.17.6991; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; Cartwright JL, 1997, BIOCHEM SOC T, V25, pS580, DOI 10.1042/bst025s580; DIXON RM, 1989, J BIOL CHEM, V264, P2069; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; GURANOWSKI A, 1994, BIOCHEMISTRY-US, V33, P235, DOI 10.1021/bi00167a031; GURANOWSKI A, 1994, J BACTERIOL, V176, P2986, DOI 10.1128/JB.176.10.2986-2990.1994; GURANOWSKI A, 1985, J BIOL CHEM, V260, P3542; GURANOWSKI A, 1990, FEBS LETT, V262, P205, DOI 10.1016/0014-5793(90)80190-T; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; JAKUBOWSKI H, 1983, J BIOL CHEM, V258, P9982; JAKUBOWSKI H, 1986, P NATL ACAD SCI USA, V83, P2378, DOI 10.1073/pnas.83.8.2378; KAUSHAL V, 1990, GENE, V95, P79, DOI 10.1016/0378-1119(90)90416-O; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MCLENNAN AG, 1989, BIOCHEMISTRY-US, V28, P3868, DOI 10.1021/bi00435a036; MCLENNAN AG, 1989, BIOMED ENVIRON MASS, V18, P450, DOI 10.1002/bms.1200180615; MCLENNAN AG, 1994, BIOCHEM J, V300, P183, DOI 10.1042/bj3000183; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NG KME, 1987, NUCLEIC ACIDS RES, V15, P3573, DOI 10.1093/nar/15.8.3573; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PLATEAN P, 1982, BIOCHEMISTRY-US, V20, P4654; PLATEAU P, 1990, J BACTERIOL, V172, P6892, DOI 10.1128/jb.172.12.6892-6899.1990; PRESCOTT M, 1992, INT J BIOCHEM, V24, P565, DOI 10.1016/0020-711X(92)90328-X; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3984, DOI 10.1073/pnas.73.11.3984; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6; Theoclitou M. E., 1996, J CHEM SOC P1, V16; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018	36	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8604	8610		10.1074/jbc.274.13.8604	http://dx.doi.org/10.1074/jbc.274.13.8604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085096	hybrid			2022-12-27	WOS:000079451600038
J	Nielsen, MS; Jacobsen, C; Olivecrona, G; Gliemann, J; Petersen, CM				Nielsen, MS; Jacobsen, C; Olivecrona, G; Gliemann, J; Petersen, CM			Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ALPHA(2)-MACROGLOBULIN RECEPTOR; TERMINAL DOMAIN; PROTEIN BINDS; IN-VITRO; DENSITY; FAMILY; CELLS; INTERNALIZATION; FORMS	Lipoprotein lipase and the receptor-associated protein (RAP) bind to overlapping sites on the low density Lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP), We have investigated if lipoprotein lipase interacts with the RAP binding but structurally distinct receptor sortilin/neurotensin receptor-3, We show, by chemical cross-linking and surface plasmon resonance analysis, that soluble sortilin binds lipoprotein lipase with an affinity similar to that of LRP. The binding was inhibited by heparin and RAP and by the newly discovered sortilin ligand neurotensin. In S-35-labeled 3T3-L1 adipocytes treated with the cross-linker dithiobis(succinimidyl propionate), lipoprotein lipase-containing complexes were isolated by anti-sortilin antibodies. To elucidate function in cells, sortilin-negative Chinese hamster ovary cells were transfected with full-length sortilin and shown to express about 8% of the receptors on the cell surface. These cells degraded I-125-labeled lipoprotein lipase much faster than the wildtype cells. The degradation was inhibited by unlabeled lipoprotein lipase, indicating a saturable pathway, and by RAP and heparin. Moreover, inhibition by the weak base chloroquine suggested that degradation occurs in an acidic vesicle compartment. The results demonstrate that sortilin is a multifunctional receptor that binds lipoprotein lipase and, when expressed on the cell. surface, mediates its endocytosis and degradation.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Aarhus University; Umea University	Nielsen, MS (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.	mn@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694				BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; FernandezBorja M, 1996, J LIPID RES, V37, P464; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gerdes C, 1997, CIRCULATION, V96, P733; Gliemann J, 1998, BIOL CHEM, V379, P951; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; MASUNO H, 1992, J LIPID RES, V33, P1343; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; Tauris J, 1998, FEBS LETT, V429, P27, DOI 10.1016/S0014-5793(98)00559-6; VILELLA E, 1993, J LIPID RES, V34, P1555; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Weaver AM, 1997, J LIPID RES, V38, P1841; Willnow TE, 1998, BIOL CHEM, V379, P1025; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323	37	164	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8832	8836		10.1074/jbc.274.13.8832	http://dx.doi.org/10.1074/jbc.274.13.8832			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085125	hybrid			2022-12-27	WOS:000079451600067
J	Sionov, RV; Moallem, E; Berger, M; Kazaz, A; Gerlitz, O; Ben-Neriah, Y; Oren, M; Haupt, Y				Sionov, RV; Moallem, E; Berger, M; Kazaz, A; Gerlitz, O; Ben-Neriah, Y; Oren, M; Haupt, Y			c-Abl neutralizes the inhibitory effect of Mdm2 on p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; TYROSINE KINASE; DNA-DAMAGE; APOPTOSIS; DEGRADATION; PATHWAY; GROWTH; SIGNALS; ARREST	Upon exposure to stress signals, the p53 tumor suppressor protein is stabilized and induces growth suppression. p53 activities are efficiently inhibited by the Mdm2 oncoprotein through an autoregulatory feedback loop. In addition, Mdm2 promotes p53 degradation, thereby terminating its growth inhibitory signal. Hence, p53 exerts its effects during the interval between p53 activation and the subsequent inhibition by Mdma. Modulation of this interval by regulatory proteins may determine the extent and duration of p53 activity, Recent studies have shown that the c-Abl protein-tyrosine kinase binds p53 and enhances its transcriptional activity. Here we provide an explanation for the cooperation between these proteins. We demonstrate that c-Abl increases the expression level of the p53 protein, The enhanced expression is achieved by inhibiting Mdm2-mediated degradation of p53, This provides a likely mechanistic explanation for the findings that c-Abl overcomes the inhibitory effects of Mdma on p53-mediated transcriptional activation and apoptosis. These results suggest that c-Abl modulates the time window within which p53 remains active. The ability of c-Abl to neutralize the inhibitory effects of Mdma on p53 may be important for its growth inhibitory function.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il	Ben-Neriah, Yinon/L-6285-2019	Haupt, Ygal/0000-0001-5925-0096; Oren, Moshe/0000-0003-4311-7172; Gerlitz, Offer/0000-0002-1574-2088				Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOGA A, 1995, ONCOGENE, V11, P791; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Momand J, 1997, J CELL BIOCHEM, V64, P343; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	25	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8371	8374		10.1074/jbc.274.13.8371	http://dx.doi.org/10.1074/jbc.274.13.8371			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085066	hybrid			2022-12-27	WOS:000079451600008
J	Biscardi, JS; Maa, MC; Tice, DA; Cox, ME; Leu, TH; Parsons, SJ				Biscardi, JS; Maa, MC; Tice, DA; Cox, ME; Leu, TH; Parsons, SJ			c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr(845) and Tyr(1101) is associated with modulation of receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; MITOGENIC RESPONSIVENESS; INSULIN-RECEPTOR; EGF RECEPTOR	Accumulating evidence indicates that interactions between the epidermal growth factor receptor (EGFR) and the nonreceptor tyrosine kinase c-Src may contribute to an aggressive phenotype in multiple human tumors. Previous work from our laboratory demonstrated that murine fibroblasts which overexpress both these tyrosine kinases display synergistic increases in DNA synthesis, soft agar growth, and tumor formation in nude mice, and increased phosphorylation of the receptor substrates Shc and phospholipase gamma as compared with single overexpressors, These parameters correlated with the ability of c-Src and EGFR to form an EGF-dependent heterocomplex in vivo, Here we provide evidence that association between c-Src and EGFR can occur directly, as shown by receptor overlay experiments, and that it results in the appearance of two novel tyrosine phosphorylations on the receptor that are seen both in vitro and in vivo following EGF stimulation. Edman degradation analyses and co-migration of synthetic peptides with EGFR-derived tryptic phosphopeptides identify these sites as Tyr(845) and Tyr(1101). Tyr(1101) lies within the carboxyl-terminal region of the EGFR among sites of receptor autophosphorylation, while Tyr845 resides in the catalytic domain, in a position analogous to Tyr(416) Of c-Src, Phosphorylation of Tyr(416) and homologous residues in other tyrosine kinase receptors has been shown to be required for or to increase catalytic activity, suggesting that c-Src can influence EGFR activity by mediating phosphorylation of Tyr(845). Indeed, EGF-induced phosphorylation of Tyr(845) was increased in MDA468 human breast cancer cells engineered to overexpress c-Src as compared with parental MDA 468 cells. Furthermore, transient expression of a Y845F variant EGFR in murine fibroblasts resulted in an ablation of EGF-induced DNA synthesis to nonstimulated levels. Together, these data support the hypothesis that c-Src-mediated phosphorylation of EGFR Tyr(845) is involved in regulation of receptor function, as well as in tumor progression.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.	sap@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NCI NIH HHS [CA71449, CA3948] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BISCARDI JS, 1998, IN PRESS ADV CANC RE; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHANG JH, 1993, ONCOGENE, V8, P959; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; LONGATI P, 1994, ONCOGENE, V9, P49; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; Stewart JM, 1984, SOLID PHASE PEPTIDE; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TICE DA, 1999, IN PRESS P NATL ACAD; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	56	538	558	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8335	8343		10.1074/jbc.274.12.8335	http://dx.doi.org/10.1074/jbc.274.12.8335			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075741				2022-12-27	WOS:000079268100100
J	Ma, JY; Simonovic, M; Qian, R; Colley, KJ				Ma, JY; Simonovic, M; Qian, R; Colley, KJ			Sialyltransferase isoforms are phosphorylated in the cis-medial Golgi on serine and threonine residues in their luminal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; RAT MAMMARY-GLAND; ENDOPLASMIC-RETICULUM; CASEIN KINASE; BREFELDIN-A; MEMBRANE-PROTEINS; N-ACETYLGALACTOSAMINYLTRANSFERASE; DETERMINES EXPRESSION; BINDING PROTEIN; SIGNAL ANCHOR	ST6Gal-I (alpha 2,6-sialyltransferase) is expressed as two isoforms, STTyr and STCys, which exhibit differences in catalytic activity, trafficking through the secretory pathway, and proteolytic processing and secretion. We have found that the ST6Gal-I isoforms are phosphorylated on luminal Ser and Thr residues. Immunoprecipitation of S-35- and P-32-labeled proteins expressed in COS-1 cells suggests that the STTyr isoform is phosphorylated to a greater extent than the STTyr isoform. Analysis of domain deletion mutants revealed that STTyr is phosphorylated on stem and catalytic domain amino acids, whereas STTyr is phosphorylated on catalytic domain amino acids. An endoplasmic reticulum retained/retrieved chimeric Iip33-ST protein demonstrates drastically lower phosphorylation than does the wild type STTyr isoform. This suggests that the bulk of the ST6Gal-I phosphorylation is occurring in the Golgi. Treatment of cells with the ionophore monensin does not significantly block phosphorylation of the STTyr isoform, suggesting that phosphorylation is occurring in the cis-medial Golgi prior to the monensin block. This study demonstrates the presence of kinase activities in the cia-medial Golgi and the substantial phosphorylation of the luminal sequences of a glycosyltransferase.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,M-C 536, Chicago, IL 60612 USA.	karenc@uic.edu		Simonovic, Miljan/0000-0002-1576-2222	NIGMS NIH HHS [GM48134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134, R29GM048134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; BARTHOLOMEW BA, 1973, J BIOL CHEM, V248, P5751; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1985, J BIOL CHEM, V260, P4879; Cho SK, 1997, GLYCOCONJUGATE J, V14, P809, DOI 10.1023/A:1018533804015; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; EIPPER BA, 1982, J BIOL CHEM, V257, P4907; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GU XB, 1995, J NEUROCHEM, V64, P2295; HATHAWAY H J, 1991, Glycobiology, V1, P211, DOI 10.1093/glycob/1.2.211; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HUDGIN RL, 1971, CAN J BIOCHEM CELL B, V49, P829, DOI 10.1139/o71-117; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KRESSE H, 1986, CIBA F SYMP, V124, P89; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; Lasa M, 1997, BIOCHEM BIOPH RES CO, V240, P602, DOI 10.1006/bbrc.1997.7702; LasaBenito M, 1996, FEBS LETT, V382, P149, DOI 10.1016/0014-5793(96)00136-6; LIBERTI JP, 1985, BIOCHEM BIOPH RES CO, V128, P713, DOI 10.1016/0006-291X(85)90105-6; Ma JY, 1997, J BIOL CHEM, V272, P672; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OETTING WS, 1986, J BIOL CHEM, V261, P1649; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PAUL JI, 1984, J BIOL CHEM, V259, P3477; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Ridgway ND, 1998, BBA-LIPID LIPID MET, V1390, P37, DOI 10.1016/S0005-2760(97)00167-7; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; SCHEIDELER MA, 1986, J NEUROCHEM, V46, P1639, DOI 10.1111/j.1471-4159.1986.tb01787.x; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STROUS GJ, 1987, EUR J BIOCHEM, V169, P307, DOI 10.1111/j.1432-1033.1987.tb13613.x; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; Swift LL, 1996, J BIOL CHEM, V271, P31491; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VARRO A, 1994, J BIOL CHEM, V269, P20764; VARRO A, 1993, BIOCHEM J, V295, P813, DOI 10.1042/bj2950813; VEGH M, 1994, BBA-PROTEIN STRUCT M, V1205, P49, DOI 10.1016/0167-4838(94)90090-6; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; WANG SY, 1982, J BIOL CHEM, V257, P3837; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEST DW, 1983, EUR J BIOCHEM, V137, P215, DOI 10.1111/j.1432-1033.1983.tb07817.x; WU CB, 1995, CALCIFIED TISSUE INT, V57, P285, DOI 10.1007/BF00298884; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	57	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8046	8052		10.1074/jbc.274.12.8046	http://dx.doi.org/10.1074/jbc.274.12.8046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075704	hybrid			2022-12-27	WOS:000079268100063
J	Pereira, MS; Mulloy, B; Mourao, PAS				Pereira, MS; Mulloy, B; Mourao, PAS			Structure and anticoagulant activity of sulfated fucans - Comparison between the regular, repetitive, and linear fucans from echinoderms with the more heterogeneous and branched polymers from brown algae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; SEAWEED ECKLONIA-KUROME; DERMATAN SULFATE; ANTITHROMBIN ACTIVITY; PENTOSAN POLYSULFATE; CHONDROITIN SULFATE; CELL-PROLIFERATION; FUCOIDAN FRACTION; SEA-CUCUMBER; POLYSACCHARIDES	Sulfated fucans are among the most widely studied of all the sulfated polysaccharides of non-mammalian origin that exhibit biological activities in mammalian systems. Examples of these polysaccharides extracted from echinoderms have simple structures, composed of oligosaccharide repeating units within which the residues differ by specific patterns of sulfation among different species. In contrast the algal fucans may have some regular repeating structure but are clearly more heterogeneous when compared with the echinoderm fucans. The structures of the sulfated fucans from brown algae also vary from species to species. We compared the anticoagulant activity of the regular and repetitive fucans from echinoderms with that of the more heterogeneous fucans from three species of brown algae. Our results indicate that different structural features determine not only the anticoagulant potency of the sulfated fucans but also the mechanism by which they exert this activity. Thus, the branched fucans from brown algae are direct inhibitors of thrombin, whereas the linear fucans from echinoderms require the presence of antithrombin or heparin cofactor II for inhibition of thrombin, as reported for mammalian glycosaminoglycans, The linear sulfated fucans from echinoderms have an anticoagulant action resembling that of mammalian dermatan sulfate and a modest action through antithrombin. A single difference of one sulfate ester per tetrasaccharide repeating unit modifies the anticoagulant activity of the polysaccharide markedly. Possibly the spatial arrangements of sulfate esters in the repeating tetrasaccharide unit of the echinoderm fucan mimics the site in dermatan sulfate with high affinity for heparin cofactor II.	Univ Hosp, Lab Tecido Conjunt, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control	Mourao, PAS (corresponding author), Univ Hosp, Lab Tecido Conjunt, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.	mourao@server.bioqmed.ufrj.br	Mourao, Paulo/AAA-5386-2020; Pereira, Mariana/GSE-3546-2022; Sá Pereira, Mariana/C-2211-2015					AHUJA KK, 1982, EXP CELL RES, V140, P353, DOI 10.1016/0014-4827(82)90124-0; ALBANO RM, 1990, CARBOHYD RES, V208, P163, DOI 10.1016/0008-6215(90)80096-L; Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARK GF, 1992, FASEB J, V6, pA233; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; DANISHEFSKY I, 1969, J BIOL CHEM, V244, P1741; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; DISCHE Z, 1948, J BIOL CHEM, V175, P595; DISCHE Z, 1947, J BIOL CHEM, V167, P189; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FERRAO AV, 1993, BIOCHIM BIOPHYS ACTA, V1180, P225, DOI 10.1016/0925-4439(93)90042-Y; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GARCIAVILLALON D, 1991, ANTIVIR RES, V15, P139, DOI 10.1016/0166-3542(91)90031-L; GRAUFFEL V, 1989, BIOMATERIALS, V10, P363, DOI 10.1016/0142-9612(89)90127-0; HAHNENBERGER R, 1991, GLYCOCONJUGATE J, V8, P350, DOI 10.1007/BF00731347; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KAKKAR VV, 1989, HEPARIN CHEM BIOL PR, P455; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; Lefebvre R, 1997, BIOL REPROD, V56, P1198, DOI 10.1095/biolreprod56.5.1198; Logeart D, 1997, EUR J CELL BIOL, V74, P376; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MAURAY S, 1995, THROMB HAEMOSTASIS, V74, P1280; MCCAFFREY TA, 1992, BIOCHEM BIOPH RES CO, V184, P773, DOI 10.1016/0006-291X(92)90657-7; MCCLURE MO, 1992, AIDS RES HUM RETROV, V8, P19, DOI 10.1089/aid.1992.8.19; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NISHINO T, 1991, THROMB RES, V62, P765, DOI 10.1016/0049-3848(91)90380-F; NISHINO T, 1991, THROMB RES, V64, P723, DOI 10.1016/0049-3848(91)90072-5; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; Percival E., 1967, CHEM ENZYMOLOGY MARI, P157; PETERSON RN, 1984, J EXP ZOOL, V231, P137, DOI 10.1002/jez.1402310118; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; RIOV D, 1996, ANTICANCER RES, V16, P1213; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x; SCULLY MF, 1983, THROMB RES, V31, P87, DOI 10.1016/0049-3848(83)90010-5; SINNIGER V, 1993, J CHROMATOGR-BIOMED, V615, P215, DOI 10.1016/0378-4347(93)80335-2; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530	50	309	349	3	90	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7656	7667		10.1074/jbc.274.12.7656	http://dx.doi.org/10.1074/jbc.274.12.7656			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075653	hybrid			2022-12-27	WOS:000079268100012
J	Ahmed, M; Taylor, W; Smith, PR; Becker, MA				Ahmed, M; Taylor, W; Smith, PR; Becker, MA			Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-GLOBIN GENE; SUBUNIT-I; PYROPHOSPHATE SYNTHETASE; HUMAN-FIBROBLASTS; PURINE OVERPRODUCTION; SUPERACTIVITY; EXPRESSION; THALASSEMIA; MUTATION; PROMOTER	Phosphoribosylpyrophosphate (PRPP) synthetase (PRS) superactivity is an X-linked disorder characterized by gout with overproduction of purine nucleotides and uric acid. Study of the two X-linked PRS isoforms (PRS1 and PRS2) in cells from certain affected individuals has shown selectively increased concentrations of structurally normal PRS1 transcript and isoform, suggesting that this form of the disorder involves pretranslational dysregulation of PRPS1 expression and might be more appropriately termed overactivity of normal PRS. We applied Southern and Northern blot analyses and slot blotting of nuclear runoffs to delineate the process underlying aberrant PRPS1 expression in fibroblasts and lymphoblasts from patients with overactivity of normal PRS, Neither PRPS1 amplification nor altered stability or processing of PRS1 mRNA was identified, but PRPS1 transcription was increased relative to GAPDH (3- to 4-fold normal in fibroblasts; 1.9 to 2.4-fold in lymphoblasts) and PRPS2, Nearly coordinate relative increases in each process mediating transfer of genetic information from PRPS1 transcription to maximal PRS1 isoform expression in patient fibroblasts further supported the idea that accelerated PRPS1 transcription is the major aberration leading to PRS1 overexpression. In addition, modulated relative increases in PRS activities at suboptimal Pi concentration and in rates of PRPP and purine nucleotide synthesis in intact patient fibroblasts indicate that despite an intact allosteric mechanism of regulation of PRS activity, PRPS1 transcription is a major determinant of PRPP and purine synthesis. The genetic basis of disordered PRPS1 transcription remains unresolved; normal- and patient-derived PRPS1s share nucleotide sequence identity at least 850 base pairs 5' to the consensus transcription initiation site.	Univ Chicago, Dept Med, Rheumatol Sect, Chicago, IL 60637 USA	University of Chicago	Becker, MA (corresponding author), Univ Chicago, Med Ctr, 5841 S Maryland Ave,MC 0930, Chicago, IL 60637 USA.	mbecker@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028554] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28554] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; ARANOW BJ, 1992, MOL CELL BIOL, V12, P4170; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Becker M.A., 1990, GENOMICS, V8, P550; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BECKER MA, 1976, J CLIN INVEST, V57, P308, DOI 10.1172/JCI108282; BECKER MA, 1980, J CLIN INVEST, V65, P109, DOI 10.1172/JCI109640; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1986, BIOCHIM BIOPHYS ACTA, V882, P168, DOI 10.1016/0304-4165(86)90151-0; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; Becker MA, 1996, J BIOL CHEM, V271, P19894, DOI 10.1074/jbc.271.33.19894; BECKER MA, 1987, J BIOL CHEM, V262, P14531; Becker MA, 1998, ADV EXP MED BIOL, V431, P215; BECKER MA, 1988, AM J MED, V85, P383, DOI 10.1016/0002-9343(88)90591-8; BECKER MA, 1973, SCIENCE, V179, P1123, DOI 10.1126/science.179.4078.1123; BECKER MA, 1982, J LAB CLIN MED, V99, P485; BERG PE, 1991, AM J HEMATOL, V36, P42, DOI 10.1002/ajh.2830360109; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; FOX IH, 1972, J BIOL CHEM, V247, P2126; FOX IH, 1971, J BIOL CHEM, V246, P5739; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOLMES EW, 1973, J BIOL CHEM, V248, P6035; HOLMES EW, 1973, J BIOL CHEM, V248, P144; ISHIJIMA S, 1991, J BIOL CHEM, V266, P15693; ISHIZUKA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P139, DOI 10.1016/0167-4781(92)90521-Z; KORNBERG A, 1955, J BIOL CHEM, V215, P389; LOSMAN MJ, 1985, J CLIN INVEST, V76, P1657, DOI 10.1172/JCI112151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARZLUFF WF, 1988, TRANSCRIPTION TRANSL, P89; MATSUDA M, 1992, BLOOD, V80, P1347; MOI P, 1992, BLOOD, V79, P512; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; SIMMONDS HA, 1985, NEUROPEDIATRICS, V16, P106, DOI 10.1055/s-2008-1052552; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; SPERLING O, 1972, EUR J CLIN BIOL RES, V17, P703; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; Tatibana M, 1972, Adv Enzyme Regul, V10, P249, DOI 10.1016/0065-2571(72)90017-9; YEN RCK, 1981, J BIOL CHEM, V256, P1839; YEN RCK, 1978, P NATL ACAD SCI USA, V75, P482, DOI 10.1073/pnas.75.1.482; ZOREF E, 1975, J CLIN INVEST, V56, P1093, DOI 10.1172/JCI108183	46	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7482	7488		10.1074/jbc.274.11.7482	http://dx.doi.org/10.1074/jbc.274.11.7482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066814	hybrid			2022-12-27	WOS:000079078400086
J	Barry, OP; Kazanietz, MG; Pratico, D; FitzGerald, GA				Barry, OP; Kazanietz, MG; Pratico, D; FitzGerald, GA			Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C mitogen-activated protein kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RAT MESANGIAL CELLS; PHORBOL ESTER; MAP KINASE; GENE-EXPRESSION; H SYNTHASE-2; ENDOPEROXIDE SYNTHASE-2; DIFFERENTIAL INHIBITION; STIMULATED PLATELETS; TRANSCRIPTION FACTOR	Activation of platelets results in shedding of membrane microparticles (RIP) with potentially bioactive properties. Platelet MP modulate platelet, monocyte, and vascular endothelial cell function, both by direct effects of MP arachidonic acid (AA) and by its metabolism to bioactive prostanoids. We have previously reported that platelet MP induce expression of cyclooxygenase (COX)-2 and prostacyclin production in monocytes and endothelial cells. To elucidate further the molecular mechanisms that underlie RIP-induced upregulation of COX-2 expression, we investigated the response of a human monocytoid (U-937) cell line to platelet MP stimulation, In U-937 cells, RIP-induced COX-2 expression and eicosanoid formation is prevented by pharmacological inhibitors of protein kinase C (PKC), PI 3-kinase, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase, and p38 kinase, Treatment with the PI 3-kinase inhibitors wortmannin and LY294002 also blocked RIP-induced p42/p44 MAPK, p38, and JNK1 phosphorylation. Conversely, platelet RIP stimulation of U-937 cells results in direct activation of PKC, p42/p44 MAPK, p38 kinase, and c-Jun N-terminal kinase (JNK) as well as activation of the transcription factors c-Jun and Elk-l, However, MP failed to activate the cAMP response element. Activation of U-937 cells by MP induces translocation of classical (PKC beta), novel (PKC delta) and atypical (PKC zeta and PKC lambda) isozymes of PKC from the cytosol to the membrane, with concomitant activation of downstream MAPK. While RIP-induced activation of p42/p44 MAPK and p38 kinase is transient, a sustained activation of JNK1 was observed. Although PKC activation is required for RIP-induced p42/p44 MAPK, activation of the stress kinases p38 and JNK1 was PKC-independent, The fatty acid fraction of the MP accounted for these effects, which were mimicked by MP Ak Rather than acting directly via nuclear receptors, MP AA activates COX-2-dependent prostaglandin production by a PKC/p42/p44 MAPK/p38 kinase-sensitive pathway in which PI 3-kinase plays a significant role. RIP AA also stimulates transcriptional activation of COX-2 as well as c-Jun and Elk-1.	Univ Penn, Sch Med, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA	University of Pennsylvania	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Barry, Orla/0000-0001-6364-3642	NCI NIH HHS [CA74197] Funding Source: Medline; NHLBI NIH HHS [HL57847, HL50400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; BIZIOS R, 1988, J CELL PHYSIOL, V134, P275, DOI 10.1002/jcp.1041340214; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DEVAUX PF, 1993, CURR OPIN STRUC BIOL, V3, P489, DOI 10.1016/0959-440X(93)90072-S; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin RA, 1996, CLIN IMMUNOL IMMUNOP, V80, P116, DOI 10.1006/clin.1996.0104; GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HABIB A, 1993, J BIOL CHEM, V268, P23448; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Holme PA, 1997, ARTERIOSCL THROM VAS, V17, P646, DOI 10.1161/01.ATV.17.4.646; ISSEKUTZ TB, 1981, AM J PATHOL, V103, P47; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KESTER M, 1994, J BIOL CHEM, V269, P22574; KILEY SC, 1995, J CELL SCI, V108, P1003; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE YJ, 1993, THROMB RES, V72, P295, DOI 10.1016/0049-3848(93)90138-E; LI Q, 1994, J BIOL CHEM, V269, P17508; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Miyazaki Y, 1996, BLOOD, V88, P3456, DOI 10.1182/blood.V88.9.3456.bloodjournal8893456; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; OHKI S, 1979, J BIOL CHEM, V254, P829; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; RAO GN, 1994, J BIOL CHEM, V269, P32586; Ridley SH, 1997, J IMMUNOL, V158, P3165; RIZZO MT, 1995, BLOOD, V86, P2967, DOI 10.1182/blood.V86.8.2967.bloodjournal8682967; SHEARMAN MS, 1991, FEBS LETT, V279, P261, DOI 10.1016/0014-5793(91)80163-W; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; Siljander P, 1996, BLOOD, V87, P4651, DOI 10.1182/blood.V87.11.4651.bloodjournal87114651; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Singh N, 1995, CAN J CARDIOL, V11, P1015; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; TANS G, 1991, BLOOD, V77, P2641; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; WAYS DK, 1987, CANCER RES, V47, P3344; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YANG ZH, 1994, CIRCULATION, V89, P2266, DOI 10.1161/01.CIR.89.5.2266; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	73	202	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7545	7556		10.1074/jbc.274.11.7545	http://dx.doi.org/10.1074/jbc.274.11.7545			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066822	hybrid			2022-12-27	WOS:000079078400094
J	Fu, WM; Begley, JG; Killen, MW; Mattson, MP				Fu, WM; Begley, JG; Killen, MW; Mattson, MP			Anti-apoptotic role of telomerase in pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; AMPLIFICATION PROTOCOL TRAP; OXIDATIVE STRESS; DOWN-REGULATION; IMMORTAL CELLS; BCL-2; PROTEASES; CANCER; DEATH; DIFFERENTIATION	Telomerase is a protein-RNA enzyme complex that adds a six-base DNA sequence (TTAGGG) to the ends of chromosomes and thereby prevents their shortening. Reduced telomerase activity is associated with cell differentiation and accelerated cellular senescence, whereas increased telomerase activity is associated with cell transformation and immortalization, Because many types of cancer have been associated with reduced apoptosis, whereas cell differentiation and senescence have been associated with increased apoptosis, we tested the hypothesis that telomerase activity is mechanistically involved in the regulation of apoptosis. Levels of telomerase activity in cultured pheochromocytoma cells decreased prior to cell death in cells undergoing apoptosis, Treatment of cells with the oligodeoxynucleotide TTAGGG or with 3,3'-diethyloxadicarbocyanine, agents that inhibit telomerase activity in a concentration-dependent manner, significantly enhanced mitochondrial dysfunction and apoptosis induced by staurosporine, Fe2+ (an oxidative insult), and amyloid beta-peptide (a cytotoxic peptide linked to neuronal apoptosis in Alzheimer's disease). Overexpression of Bcl-2 and the caspase inhibitor zVAD-fmk protected cells against apoptosis in the presence of telomerase inhibitors, suggesting a site of action of telomerase prior to caspase activation and mitochondrial dysfunction, Telomerase activity decreased in cells during the process of nerve growth factor-induced differentiation, and such differentiated cells exhibited increased sensitivity to apoptosis, Our data establish a role for telomerase in suppressing apoptotic signaling cascades and suggest a mechanism whereby telomerase may suppress cellular senescence and promote tumor formation.	Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Res Ctr Aging, 211 Sanders Brown Bldg, Lexington, KY 40536 USA.	mmattson@aging.coa.uky.edu	Mattson, Mark P/F-6038-2012					Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen Q, 1996, P NATL ACAD SCI USA, V93, P2635, DOI 10.1073/pnas.93.7.2635; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; D'Mello SR, 1998, CURR TOP DEV BIOL, V39, P187, DOI 10.1016/S0070-2153(08)60456-1; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1997, J NEUROSCI, V17, P4212; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Higuchi Y, 1997, FREE RADICAL BIO MED, V23, P90, DOI 10.1016/S0891-5849(96)00589-8; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Keller JN, 1998, J NEUROSCI, V18, P687; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman I, 1997, J NEUROSCI, V17, P5089; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MacManus J P, 1996, Hum Cell, V9, P197; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Martin DS, 1997, CANCER INVEST, V15, P372, DOI 10.3109/07357909709039742; Mata JE, 1997, TOXICOL APPL PHARM, V144, P189, DOI 10.1006/taap.1997.8103; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reichman TW, 1997, J CELL BIOCHEM, V67, P13, DOI 10.1002/(SICI)1097-4644(19971001)67:1<13::AID-JCB2>3.0.CO;2-Z; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Sabbah HN, 1998, PROG CARDIOVASC DIS, V40, P549, DOI 10.1016/S0033-0620(98)80003-0; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stern G, 1996, ADV NEUROL, V69, P101; Strahl C, 1996, MOL CELL BIOL, V16, P53; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takeda M, 1997, ARCH TOXICOL, V71, P612, DOI 10.1007/s002040050434; Warner HR, 1997, CURR TOP CELL REGUL, V35, P107, DOI 10.1016/S0070-2137(97)80004-0; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yegorov YE, 1996, FEBS LETT, V389, P115, DOI 10.1016/0014-5793(96)00533-9; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	55	222	246	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7264	7271		10.1074/jbc.274.11.7264	http://dx.doi.org/10.1074/jbc.274.11.7264			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066788	hybrid			2022-12-27	WOS:000079078400060
J	Haug, LS; Jensen, V; Hvalby, O; Walaas, SI; Ostvold, AC				Haug, LS; Jensen, V; Hvalby, O; Walaas, SI; Ostvold, AC			Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic nucleotide-dependent kinases in vitro and in rat cerebellar slices in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RECONSTITUTED LIPID VESICLES; LONG-TERM DEPRESSION; PROTEIN-KINASE; TRISPHOSPHATE RECEPTOR; CA2+ RELEASE; MAMMALIAN BRAIN; CALCIUM; CELLS; PURIFICATION	We have examined cyclic nucleotide-regulated phosphorylation of the neuronal type I inositol 1,4,5-trisphosphate (IP3) receptor immunopurified from rat cerebellar membranes in vitro and in rat cerebellar slices in situ, The isolated IP(3)eceptor protein was phosphorylated by both cAMP- and cGMP-dependent protein kinases on two distinct sites as determined by thermolytic phosphopeptide mapping, phosphopeptide 1, representing Ser-1589, and phosphopeptide 2, representing Ser-1756 in the rat protein (Ferris, C, D,, Cameron, A M,, Bredt, D, S,, Huganir, R, L,, and Snyder, S, H. (1991) Biochem. Biophys, Res. Commun. 175, 192-198), Phosphopeptide maps show that cAMP-dependent protein kinase (PKA) labeled both sites with the same time course and same stoichiometry, whereas cGMP-dependent protein kinase (PKG) phosphorylated Ser-1756 with a higher velocity and a higher stoichiometry than Ser-1589, Synthetic decapeptides corresponding to the two phosphorylation sites (peptide 1, AARRD (S) under bar VLAA (Ser-1589), and peptide 2, SGRRE (S) under bar LTSF (Ser-1756)) were used to determine kinetic constants for the phosphorylation by PKG and PKA, and the catalytic efficiencies were in agreement with the results obtained by in vitro phosphorylation of the intact protein. In cerebellar slices prelabeled with [P-32]orthophosphate, activation of endogenous kinases by incubation in the presence of cAMP/cGMP analogues and specific inhibitors of PKG and PKA induced in both cases a 3-fold increase in phosphorylation of the IP(3)eceptor. Thermolytic phosphopeptide mapping of in situ labeled IP(3)eceptor by PKA showed labeling on the same sites (Ser-1589 and Ser-1756) as in vitro. In contrast to the findings in vitro, PKG preferentially phosphorylated Ser-1589 in situ, Because both PKG and the IP(3)eceptor are specifically enriched in cerebellar Purkinje cells, PKG may be an important IP(3)eceptor regulator irt vivo.	Univ Oslo, Neurochem Lab, N-0317 Oslo, Norway; Univ Oslo, Dept Neurophysiol, N-0317 Oslo, Norway; Univ Oslo, Dept Grp Basic Med Sci, N-0317 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Ostvold, AC (corresponding author), Univ Oslo, Neurochem Lab, POB 1115 Blindern, N-0317 Oslo, Norway.							BALTENSPERGER K, 1990, BIOCHEMISTRY-US, V29, P9753, DOI 10.1021/bi00493a035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; CASNELLIE JE, 1980, J BIOL CHEM, V255, P3770; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; Chatton JY, 1998, BIOCHEM J, V330, P1411, DOI 10.1042/bj3301411; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Guihard G, 1996, BIOCHEM J, V318, P849, DOI 10.1042/bj3180849; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; Haug LS, 1998, NEUROCHEM INT, V33, P109, DOI 10.1016/S0197-0186(98)00021-7; Haug LS, 1996, NEURODEGENERATION, V5, P169, DOI 10.1006/neur.1996.0024; HAUG LS, 1994, J NEUROCHEM S1, V63; HAUG LS, 1998, J NEUROCHEM S, V71; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; IVES HE, 1980, J BIOL CHEM, V255, P3777; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MATTER N, 1993, J BIOL CHEM, V268, P732; NAKADE S, 1994, J BIOL CHEM, V269, P6735; PARKS TP, 1987, ARCH BIOCHEM BIOPHYS, V255, P361, DOI 10.1016/0003-9861(87)90404-8; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; Quinton TM, 1996, BIOCHEMISTRY-US, V35, P6865, DOI 10.1021/bi960128m; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; WALAAS SI, 1983, J NEUROSCI, V3, P291; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; WALAAS SI, 1996, NEUROMETHODS, V30, P1; WEEKS G, 1988, SYNAPSE, V2, P89, DOI 10.1002/syn.890020112; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h	56	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7467	7473		10.1074/jbc.274.11.7467	http://dx.doi.org/10.1074/jbc.274.11.7467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066812	hybrid			2022-12-27	WOS:000079078400084
J	Lagree, V; Froger, A; Deschamps, S; Hubert, JF; Delamarche, C; Bonnec, G; Thomas, D; Gouranton, J; Pellerin, I				Lagree, V; Froger, A; Deschamps, S; Hubert, JF; Delamarche, C; Bonnec, G; Thomas, D; Gouranton, J; Pellerin, I			Switch from an aquaporin to a glycerol channel by two amino acids substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; WATER CHANNEL; MOLECULAR-CLONING; ESCHERICHIA-COLI; XENOPUS-OOCYTES; MIP FAMILY; EXPRESSION; PROTEINS; SEQUENCE; CELLS	The MIP (major intrinsic protein) proteins constitute a channel family of currently 150 members that have been identified in cell membranes of organisms ranging from bacteria to man. Among these proteins, two functionally distinct subgroups are characterized: aquaporins that allow specific water transfer and glycerol channels that are involved in glycerol and small neutral solutes transport. Since the flow of small molecules across cell membranes is vital for every living organism, the study of such proteins is of particular interest, For instance, aquaporins located in kidney cell membranes are responsible for reabsorption of 150 liters of water/ day in adult human. To understand the molecular mechanisms of solute transport specificity, we analyzed mutant aquaporins in which highly conserved residues have been substituted by amino acids located at the same positions in glycerol channels. Here, we show that substitution of a tyrosine and a tryptophan by a proline and a leucine, respectively, in the sixth transmembrane helix of an aquaporin leads to a switch in the selectivity of the channel, from water to glycerol.	Univ Rennes 1, CNRS, UPRES A 6026, Equipe Canaux & Recepteurs Membranaires, F-35042 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Pellerin, I (corresponding author), Univ Rennes 1, CNRS, UPRES A 6026, Equipe Canaux & Recepteurs Membranaires, Batiment 13,Campus Beaulieu, F-35042 Rennes, France.		THOMAS, Danniel/AAJ-5033-2020; DELAMARCHE, Christian/A-2138-2010	THOMAS, Danniel/0000-0002-9650-0434; DELAMARCHE, Christian/0000-0002-8963-0062				BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1998, NEWS PHYSIOL SCI, V13, P137; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagree V, 1998, J BIOL CHEM, V273, P12422, DOI 10.1074/jbc.273.20.12422; Lagree V, 1998, J BIOL CHEM, V273, P33949, DOI 10.1074/jbc.273.51.33949; LeCaherec F, 1996, EUR J BIOCHEM, V241, P707, DOI 10.1111/j.1432-1033.1996.00707.x; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; MA TH, 1994, J BIOL CHEM, V269, P21845; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512	25	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6817	6819		10.1074/jbc.274.11.6817	http://dx.doi.org/10.1074/jbc.274.11.6817			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066730	hybrid			2022-12-27	WOS:000079078400002
J	Moriyama, H; Horiuchi, H; Koga, R; Fukuhara, T				Moriyama, H; Horiuchi, H; Koga, R; Fukuhara, T			Molecular characterization of two endogenous double-stranded RNAs in rice and their inheritance by interspecific hybrids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MALE-STERILITY; VICIA-FABA; SACCHAROMYCES-CEREVISIAE; RIBONUCLEIC-ACID; REPLICON; TRANSMISSION; CULTIVARS; BARLEY	We completely sequenced 13,936 nucleotides (nt) of a double-stranded RNA (dsRNA) of wild rice (W-dsRNA). A single long open reading frame (13,719 nt) containing the conserved motifs of RNA-dependent RNA polymerase and RNA helicase was located in the coding strand. The identity between entire nucleotide sequence of W-dsRNA and that of the dsRNA of temperate japonica rice (J-dsRNA, 13,952 nt) was 75.5%. A site-specific discontinuity (nick) was identified at nt 1,197 from the 5' end of the coding strand of W-dsRNA. This nick is also located at nt 1,211 from the 5' end in the coding strand of J-dsRNA. The dsRNA copy number was increased more than 10-fold in pollen grains of both rice plants. This remarkable increase may be responsible for the highly efficient transmission of J-dsRNA via pollen that we already reported. J-dsRNA and W-dsRNA were also efficiently transmitted to interspecific F1 hybrids. Seed-mediated dsRNA transmission to F2 plants was also highly efficient when the maternal parent was wild rice. The efficiency of dsRNA transmission to F2 plants was reduced when the maternal parent was temperate japonica rice; however, the reduced rates in F2 plants were returned to high levels in F3 plants.	Tokyo Univ Agr & Technol, Fac Agr, Mol & Cellular Biol Lab, Tokyo 1838509, Japan	Tokyo University of Agriculture & Technology	Fukuhara, T (corresponding author), Tokyo Univ Agr & Technol, Fac Agr, Mol & Cellular Biol Lab, 3-5-8 Fuchu, Tokyo 1838509, Japan.	fuku@cc.tuat.ac.jp	Fukuhara, T./C-3208-2013; Moriyama, Hiromitsu/F-9256-2013					BROWN GG, 1989, INT REV CYTOL, V117, P1; FAIRBANKS DJ, 1988, THEOR APPL GENET, V76, P619, DOI 10.1007/BF00260917; FROHMAN MA, 1990, PCR PROTOCOLS GUIDE, P25; FUKUHARA T, 1995, J BIOL CHEM, V270, P18147, DOI 10.1074/jbc.270.30.18147; FUKUHARA T, 1993, PLANT MOL BIOL, V21, P1121, DOI 10.1007/BF00023608; GABRIEL CJ, 1987, PHYTOPATHOLOGY, V77, P92, DOI 10.1094/Phyto-77-92; GRILL LK, 1981, P NATL ACAD SCI-BIOL, V78, P7043, DOI 10.1073/pnas.78.11.7043; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; LEFEBVRE A, 1990, PLANT MOL BIOL, V14, P477, DOI 10.1007/BF00027494; MACKENZIE SA, 1988, THEOR APPL GENET, V76, P59, DOI 10.1007/BF00288832; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; Matsuo T., 1997, SCI RICE PLANT, V3; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; MORIYAMA H, 1995, MOL GEN GENET, V248, P364, DOI 10.1007/BF02191603; Moriyama H, 1996, PLANT MOL BIOL, V31, P713, DOI 10.1007/BF00019459; MORIYAMA H, 1999, IN PRESS PLANT MOL B; MORRIS TJ, 1979, PHYTOPATHOLOGY, V69, P854, DOI 10.1094/Phyto-69-854; PFEIFFER P, 1993, J GEN VIROL, V74, P1167, DOI 10.1099/0022-1317-74-6-1167; Pfeiffer P, 1998, J GEN VIROL, V79, P2349, DOI 10.1099/0022-1317-79-10-2349; TURPEN T, 1988, PLANT MOL BIOL, V10, P489, DOI 10.1007/BF00033604; VALVERDE RA, 1990, PLANT SCI, V67, P195, DOI 10.1016/0168-9452(90)90243-H; VALVERDE RA, 1991, J AM SOC HORTIC SCI, V116, P903, DOI 10.21273/JASHS.116.5.903; WAKARCHUK DA, 1985, PLANT MOL BIOL, V5, P55, DOI 10.1007/BF00017873; WANG B, 1990, THEOR APPL GENET, V79, P556, DOI 10.1007/BF00226167; WANG ZY, 1989, PLANT SCI, V61, P227, DOI 10.1016/0168-9452(89)90229-X; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; ZABALGOGEAZCOA I, 1993, PLANT SCI, V91, P45, DOI 10.1016/0168-9452(93)90187-5; ZABALGOGEAZCOA IA, 1992, PLANT SCI, V83, P187, DOI 10.1016/0168-9452(92)90078-Z	29	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6882	6888		10.1074/jbc.274.11.6882	http://dx.doi.org/10.1074/jbc.274.11.6882			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066741	hybrid			2022-12-27	WOS:000079078400013
J	Pahan, K; Raymond, JR; Singh, I				Pahan, K; Raymond, JR; Singh, I			Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C-6 glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; C6 GLIOMA-CELLS; SELECTIVE INHIBITOR; MULTIPLE-SCLEROSIS; MOLECULAR-CLONING; GLUCOSE-TRANSPORT; MAMMALIAN-CELLS; IN-VITRO; EXPRESSION; INDUCTION	Nitric oxide (NO) produced by inducible nitric-oxide synthase (iNOS) in different cells including brain cells in response to proinflammatory cytokines plays an important role in the pathophysiology of demyelinating and neurodegenerative diseases, The present study underlines the importance of phosphatidylinositol 3-kinase (PI 3-kinase) in the expression of iNOS in C-6 glial cells and rat primary astrocytes. Bacterial lipopolysaccharide (LPS) or interleukin-1 beta (IL-1 beta) was unable to induce the expression of iNOS and the production of NO in rat C-6 glial cells. Similarly, wortmannin and LY294002, compounds that inhibit PI3-kinase, were also unable to induce the expression of NOS and the production of NO. However, a combination of wortmannin or LY294002 with LPS or IL-1 beta induced the expression of iNOS and the production of NO in C-6 glial cells. Consistent with the induction of iNOS, wortmannin also induced iNOS promoter-derived chloramphenicol acetyltransferase activity in LPS- or IL-1 beta-treated C-6 glial cells. The expression of iNOS by LPS in C-6 glial cells expressing a dominant-negative mutant of p85 alpha, the regulatory subunit of PI 3-kinase, further supports the conclusion that inhibition of PI 3-kinase provides a necessary signal for the induction of iNOS, Next we examined the effect of wortmannin on the activation of mitogen-activated protein (MAP) kinase and nuclear factor NF-kappa B in LPS- or IL-1 beta-stimulated C-6 glial cells. In contrast to the inability of LPS and IL-1 beta alone to induce the expression of iNOS, both LPS and IL-1 beta individually stimulated MAP kinase activity and induced DNA binding and transcriptional activity of NF-kappa B, Wortmannin alone was unable to activate MAP kinase and NF-kappa B. Moreover, wortmannin had no effect on LPS- or IL-1 beta-mediated activation of MAP kinase and NF-kappa B, suggesting that wortmannin induced the expression of iNOS in LPS- or IL-1 beta-stimulated C-6 glial cells without modulating the activation of MAP kinase and NF-kappa B, Similar to C-6 glial cells, wortmannin also stimulated LPS-mediated expression of iNOS and production of NO in astrocytes without affecting the LPS-mediated activation of NF-kappa B, Taken together, the results from specific chemical inhibitors and dominant-negative mutant expression studies demonstrate that apart from the activation of NF-kappa B, inhibition of PI 3-kinase is also necessary for the expression of iNOS and production of NO.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.				NINDS NIH HHS [NS-37766, NS-34741, NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS037766, R01NS022576, R01NS034741] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobashi K, 1997, J NEUROCHEM, V68, P1896; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P811; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hu SX, 1995, GLIA, V15, P491, DOI 10.1002/glia.440150412; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Liu Q, 1997, J IMMUNOL, V159, P829; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Minshall C, 1996, J IMMUNOL, V156, P939; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; POWIS G, 1994, CANCER RES, V54, P2419; Salkowski CA, 1997, J IMMUNOL, V158, P905; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; WARD SG, 1992, J BIOL CHEM, V267, P23862; Xie KP, 1997, ONCOGENE, V15, P771, DOI 10.1038/sj.onc.1201239; XIE QW, 1994, J BIOL CHEM, V269, P4705	41	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7528	7536		10.1074/jbc.274.11.7528	http://dx.doi.org/10.1074/jbc.274.11.7528			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066820	hybrid			2022-12-27	WOS:000079078400092
J	Fjellstrom, O; Axelsson, M; Bizouarn, T; Hu, X; Johansson, C; Meuller, J; Rydstrom, J				Fjellstrom, O; Axelsson, M; Bizouarn, T; Hu, X; Johansson, C; Meuller, J; Rydstrom, J			Mapping of residues in the NADP(H)-binding site of proton-translocating nicotinamide nucleotide transhydrogenase from Escherichia coli - A study of structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; ADENINE-DINUCLEOTIDE; BINDING DOMAINS; PUMPING TRANSHYDROGENASE; DIRECTED MUTAGENESIS; BETA-SUBUNIT; MOBILE LOOP; PROTEIN; PREDICTION; ACID	Conformational changes in proton pumping transhydrogenases have been suggested to be dependent on binding of NADP(H) and the redox state of this substrate. Based on a detailed amino acid sequence analysis, it is argued that a classical beta alpha beta alpha beta dinucleotide binding fold is responsible for binding NADP(H). A model defining beta A, alpha B, beta B, beta D, and beta E of this domain is presented. To test this model, four single cysteine mutants (cf beta A348C, cf beta A390C, cf beta K424C, and cf beta RA25C) were introduced into a functional cysteine-free transhydrogenase. Also, five cysteine mutants were constructed in the isolated domain III of Escherichia coli transhydrogenase (ecIIIH345C, ecIIIA348C, ecIIIR350C, ecIIID392C, and ecIIIK424C). In addition to kinetic characterizations, effects of sulfhydryl-specific labeling with N-ethylmaleimide, 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid, and diazotized 3-aminopyridine adenine dinucleotide (phosphate) were examined. The results are consistent with the view that, in agreement with the model, beta-Ala(348), beta-Arg(350), beta-Ala(390), beta-Asp(392), and beta-Lys(424) are located in or close to the NADP(H) site. More specifically, beta-Ala(348) succeeds beta B. The remarkable reactivity of beta R350C toward NNADP suggests that this residue is close to the nicotinamide moiety of NADP(H). beta-Ala(390) and beta-Asp(392) terminate or succeed beta D, and are thus, together with the region following PA, creating the switch point crevice where NADP(H) binds. beta-Asp(392) is particularly important for the substrate affinity,but it could also have a more complex role in the coupling mechanism for transhydrogenase.	Univ Gothenburg, Dept Biochem & Biophys, S-40530 Gothenburg, Sweden; Chalmers Univ Technol, S-40530 Gothenburg, Sweden	University of Gothenburg; Chalmers University of Technology	Rydstrom, J (corresponding author), Univ Gothenburg, Dept Biochem & Biophys, Box 462, S-40530 Gothenburg, Sweden.		bizouarn, tania/W-6782-2019; Rydström, Jan/A-7683-2010					ADAMS MJ, 1970, NATURE, V227, P1098, DOI 10.1038/2271098a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMY NK, 1977, BIOCHIM BIOPHYS ACTA, V480, P83; ANDERSON BM, 1978, ARCH BIOCHEM BIOPHYS, V188, P214, DOI 10.1016/0003-9861(78)90374-0; Baker PJ, 1998, NAT STRUCT BIOL, V5, P561, DOI 10.1038/817; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; Bizouarn T, 1997, BBA-BIOENERGETICS, V1320, P265, DOI 10.1016/S0005-2728(97)00030-3; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; Bragg PD, 1997, ARCH BIOCHEM BIOPHYS, V338, P57, DOI 10.1006/abbi.1996.9797; Bragg PD, 1996, EUR J BIOCHEM, V241, P611, DOI 10.1111/j.1432-1033.1996.00611.x; CHAN JK, 1975, J BIOL CHEM, V250, P67; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; EBEL RE, 1981, ARCH BIOCHEM BIOPHYS, V211, P227, DOI 10.1016/0003-9861(81)90448-3; FISHER TL, 1973, J BIOL CHEM, V248, P4298; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; FJELLSTROM O, 1995, PROTEINS, V21, P91, DOI 10.1002/prot.340210203; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; *GEN COMP GROUP, 1996, GCG SEQ AN SOFTW PAC; GLAVAS N, 1993, J BIOL CHEM, V268, P14125; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P49; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HU X, 1999, IN PRESS BIOCHEMISTR; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBISTA M, 1994, ANALYST, V119, P417, DOI 10.1039/an9941900417; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Meuller J, 1996, BBA-BIOENERGETICS, V1273, P191, DOI 10.1016/0005-2728(95)00154-9; Meuller J, 1997, BIOCHEM J, V324, P681, DOI 10.1042/bj3240681; NIEFIND K, 1991, J MOL BIOL, V219, P481, DOI 10.1016/0022-2836(91)90188-C; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; PALMER T, 1992, BIOCHIM BIOPHYS ACTA, V1099, P157, DOI 10.1016/0304-4173(92)90022-7; REST B, 1994, PROTEINS, V20, P216; Rossmann M. G., 1975, ENZYMES, V11, P62; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; WOOLF JH, 1977, MOL CELL BIOCHEM, V15, P19, DOI 10.1007/BF01731286; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	49	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6350	6359		10.1074/jbc.274.10.6350	http://dx.doi.org/10.1074/jbc.274.10.6350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037725	hybrid			2022-12-27	WOS:000078902800047
J	Hausser, A; Storz, P; Link, G; Stoll, H; Liu, YC; Altman, A; Pfizenmaier, K; Johannes, FJ				Hausser, A; Storz, P; Link, G; Stoll, H; Liu, YC; Altman, A; Pfizenmaier, K; Johannes, FJ			Protein kinase C mu is negatively regulated by 14-3-3 signal transduction proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PHOSPHORYLATION; PHORBOL ESTER; T-CELLS; DOWN-REGULATION; NUCLEAR-FACTOR; IN-VITRO; ACTIVATION; ASSOCIATION; BINDING; DOMAIN	Recent studies have documented direct interaction between 14-3-3 proteins and hey molecules in signal transduction pathways like Ras, Cbl, and protein kinases, In T cells, the 14-3-3 tau isoform has been shown to associate with protein kinase C theta and to negatively regulate interleukin-2 secretion, Here we present data that 14-3-3 tau interacts with protein kinase C mu (PKC mu), a subtype that differs from other PKC members in structure and activation mechanisms. Specific interaction of PKC mu and 14-3-3 tau can be shown in the T cell line Jurkat by immunocoprecipitiation and by pulldown assays of either endogenous or overexpressed proteins using PKC mu-specific antibodies and GST-14-3-3 fusion proteins, respectively. Using PKC mu, deletion mutants, the 14-3-3 tau binding region is mapped within the regulatory C1 domain. Binding of 14-3-3 tau to PKC mu is significantly enhanced upon phorbol ester stimulation of PKC mu kinase activity in Jurkat cells and occurs via a Cbl-like serine containing consensus motif, However, 14-3-3 tau is not a substrate of PKC mu, In contrast 14-3-3 tau strongly down-regulates PKC mu kinase activity in vitro. Moreover, overexpression of 14-3-3 tau significantly reduced phorbol ester induced activation of PKC mu kinase activity in intact cells. We therefore conclude that 14-3-3 tau is a negative regulator of PKC mu in T cells.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; La Jolla Inst Allergy & Immunol, Div Cell Biol & Immunol, San Diego, CA 92121 USA	University of Stuttgart; La Jolla Institute for Immunology	Johannes, FJ (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Franz-Josef.Johannes@po.uni-stuttgart.de	Hausser, Angelika/AAC-4531-2021	LIU, YUN-CAI/0000-0002-0996-7109				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; delPeso L, 1997, SCIENCE, V278, P687; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; WheelerJones CPD, 1996, BIOCHEM J, V315, P41, DOI 10.1042/bj3150041; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	43	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9258	9264		10.1074/jbc.274.14.9258	http://dx.doi.org/10.1074/jbc.274.14.9258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092600	hybrid			2022-12-27	WOS:000079451800019
J	Arabshahi, A; Frey, PA				Arabshahi, A; Frey, PA			Standard free energy for the hydrolysis of adenylylated T4 DNA ligase and the apparent pK(a) of lysine 159	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDES; ATP	Equilibrium constants for the adenylylation of T4 DNA Ligase have been measured at 10 pH values. The values, when plotted against pH, fit a titration curve corresponding to a pK(a) of 8.4 +/- 0.1. The simplest interpretation is that the apparent pK(a) is that of the B-amino group of the AMP-aceepting residue Lys(159). Based on the pH dependence of the equilibrium constants, the value at pH 7.0 is 0.0213 at 25 degrees C, corresponding to Delta G'(o) = +2.3 kcal mol(-1). From this value and the standard free energy change of -10.9 kcal mol(-1) for the hydrolysis of ATP to AMP and PPi, we calculate that Delta G'(o) for the hydrolysis of the adenylyl-DNA ligase is -13.2 kcal mol(-1). The presence of conserved basic amino acid residues in the catalytic domain, which are proximal to the active site in the homologous catalytic domain of T7 DNA ligase, suggests that the pK(a) of Lys159 is perturbed downward by the electrostatic effects of nearby positively charged amino acid side chains. The lower than normal pK(a) 8.4 compared with 10.5 for the 6-amino group of lysine and the high energy of the alpha,beta-phosphoanhydride linkage in ATP significantly facilitate adenylylation of the enzyme.	Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53705 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53705 USA.				NIGMS NIH HHS [GM 30480] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTY RA, 1994, PURE APPL CHEM, V66, P1641, DOI 10.1351/pac199466081641; Arabshahi A, 1996, BIOCHEMISTRY-US, V35, P3426, DOI 10.1021/bi952983w; BECKER A, 1967, P NATL ACAD SCI USA, V58, P1996, DOI 10.1073/pnas.58.5.1996; COZZARELLI NR, 1967, BIOCHEM BIOPH RES CO, V28, P578, DOI 10.1016/0006-291X(67)90353-1; DAVIS RW, 1980, ADV BACTERIAL GENET, P196; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FREY PA, 1995, BIOCHEMISTRY-US, V34, P11307, DOI 10.1021/bi00036a001; GEFTER ML, 1976, P NATL ACAD SCI USA, V58, P240; GELLERT M, 1967, P NATL ACAD SCI USA, V57, P148, DOI 10.1073/pnas.57.1.148; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; LEHMAN IR, 1974, ENZYMES, V10, P237; LIDE DR, 1997, CRC HDB CHEM PHYSICS; MODRICH P, 1973, J BIOL CHEM, V248, P7502; OLIVERA BM, 1967, P NATL ACAD SCI USA, V57, P1426, DOI 10.1073/pnas.57.5.1426; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; Rossi R, 1997, NUCLEIC ACIDS RES, V25, P2106, DOI 10.1093/nar/25.11.2106; Sarasin A, 1997, CANCER DETECT PREV, V21, P406; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; WEISS B, 1967, P NATL ACAD SCI USA, V57, P1021, DOI 10.1073/pnas.57.4.1021; YU GL, 1990, MOL CELL BIOL, V10, P2070, DOI 10.1128/MCB.10.5.2070	22	11	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8586	8588		10.1074/jbc.274.13.8586	http://dx.doi.org/10.1074/jbc.274.13.8586			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085093	hybrid			2022-12-27	WOS:000079451600035
J	Holtz, KM; Stec, B; Kantrowitz, ER				Holtz, KM; Stec, B; Kantrowitz, ER			A model of the transition state in the alkaline phosphatase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-MECHANISM; CRYSTAL-STRUCTURES; VANADATE	A high resolution crystal structure of Escherichia coli alkaline phosphatase in the presence of vanadate has been refined to 1.9 Angstrom resolution. The vanadate ion takes on a trigonal bipyramidal geometry and is covalently bound by the active site serine nucleophile. A coordinated water molecule occupies the axial position opposite the serine nucleophile, whereas the equatorial oxygen atoms of the vanadate ion are stabilized by interactions with both Arg-166 and the zinc metal ions of the active site. This structural complex supports the in-line displacement mechanism of phosphomonoester hydrolysis by alkaline phosphatase and provides a model for the proposed transition state in the enzyme-catalyzed reaction.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02167 USA	Boston College	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02167 USA.			Stec, Boguslaw/0000-0002-8696-0349	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; BRUNGER AT, 1992, X PLOR VERSION 3 1; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; Crans DC, 1996, PHOSPHORUS SULFUR, V109, P245, DOI 10.1080/10426509608545136; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; LOPEZ V, 1976, ARCH BIOCHEM BIOPHYS, V175, P31, DOI 10.1016/0003-9861(76)90482-3; Murphy JE, 1997, NAT STRUCT BIOL, V4, P618, DOI 10.1038/nsb0897-618; MURPHY JE, 1995, J MOL BIOL, V253, P604, DOI 10.1006/jmbi.1995.0576; PAULING L, 1960, NATURE CHEM BOND STR, P251; Reid T.W., 1971, ENZYMES, V4, P373	13	146	151	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8351	8354		10.1074/jbc.274.13.8351	http://dx.doi.org/10.1074/jbc.274.13.8351			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085061	hybrid			2022-12-27	WOS:000079451600003
J	Compagno, D; Lampe, JN; Bourget, C; Kutyavin, IV; Yurchenko, L; Lukhtanov, EA; Gorn, VV; Gamper, HB; Toulme, JJ				Compagno, D; Lampe, JN; Bourget, C; Kutyavin, IV; Yurchenko, L; Lukhtanov, EA; Gorn, VV; Gamper, HB; Toulme, JJ			Antisense oligonucleotides containing modified bases inhibit in vitro translation of Leishmania amazonensis mRNAs by invading the mini-exon hairpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOME MESSENGER-RNAS; SPLICED LEADER SEQUENCE; MODIFIED OLIGODEOXYNUCLEOTIDES; LEPTOMONAS-COLLOSOMA; SECONDARY STRUCTURE; GENE-EXPRESSION; COMMON; COMPLEMENTARY; PARASITES; BINDING	Complementary oligodeoxynucleotides (ODNs) that contain 2-aminoadenine and 2-thiothymine interact weakly with each other but form stable hybrids with unmodified complements, These selectively binding complementary (SBC) agents can invade duplex DNA and hybridize to each strand (Kutyavin, I. V., Rhinehart, R, L,, Lukhtanov, E, A, Gorn, V, V,, Meyer, R, B,, and Camper, H. B, (1996) Biochemistry 35, 11170-11176), Antisense ODNs with similar properties should be less encumbered by RNA secondary structure. Here we show that SEC ODNs strand invade a hairpin in the mini-exon RNA of Leishmania amazonensis and that the resulting heteroduplexes are substrates for Escherichia coli RNase H. SEC ODNs either with phosphodiester or phosphorothioate backbones form more stable hybrids with RNA than normal base (NB) ODNs, Optimal binding was observed when the entire hairpin sequence was targeted. Translation of L, amazonensis mRNA in a cell-free extract was more efficiently inhibited by SEC ODNs complementary to the mini-exon hairpin than by the corresponding NE ODNs, Nonspecific protein binding in the cell-free extract by phosphorothioate SEC ODNs rendered them ineffective as antisense agents in vitro. SEC phosphorothioate ODNs displayed a modest but significant improvement of leishmanicidal properties compared with NE phosphorothioate ODNs.	Univ Victor Segalen, INSERM, U 386, IFR Pathol Infect, F-33076 Bordeaux, France; Epoch Pharmaceut Inc, Bothell, WA 98021 USA; Inst Biorgan Chem, Novosibirsk, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Toulme, JJ (corresponding author), Univ Victor Segalen, INSERM, U 386, IFR Pathol Infect, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jean-jacques.toulme@bordeaux.inserm.fr	Lampe, Jed N./J-8930-2019	Lampe, Jed N./0000-0003-0794-2263; Compagno, Daniel/0000-0002-7589-7217; Toulme, Jean-jacques/0000-0002-8432-5034				BANGS JD, 1992, J BIOL CHEM, V267, P9805; BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1993, BIOCHIMIE, V75, P113, DOI 10.1016/0300-9084(93)90032-N; Chastain M, 1993, ANTISENSE RES APPL, P55; CHEONG C, 1988, NUCLEIC ACIDS RES, V16, P5115, DOI 10.1093/nar/16.11.5115; CONNOLLY BA, 1989, NUCLEIC ACIDS RES, V17, P4957, DOI 10.1093/nar/17.13.4957; CORNELISSEN AWCA, 1986, NUCLEIC ACIDS RES, V14, P5605, DOI 10.1093/nar/14.14.5605; DEDIONISIO L, 1995, J CHROMATOGR B, V669, P125, DOI 10.1016/0378-4347(95)00153-A; Ecker DJ, 1993, ANTISENSE RES APPL, P387; GAMPER HB, 1993, NUCLEIC ACIDS RES, V21, P145, DOI 10.1093/nar/21.1.145; GARRIGA P, 1993, BIOCHEMISTRY-US, V32, P1067, DOI 10.1021/bi00055a011; HARRIS KA, 1995, RNA, V1, P351; HOWARD FB, 1984, BIOCHEMISTRY-US, V23, P6723, DOI 10.1021/bi00321a068; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; Kutyavin IV, 1996, BIOCHEMISTRY-US, V35, P11170, DOI 10.1021/bi960626v; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; PASCOLO E, 1993, BIOCHIMIE, V75, P43, DOI 10.1016/0300-9084(93)90023-L; PASCOLO E, 1994, BBA-GENE STRUCT EXPR, V1219, P98, DOI 10.1016/0167-4781(94)90251-8; Pascolo E, 1996, J BIOL CHEM, V271, P24187, DOI 10.1074/jbc.271.39.24187; RAMAZEILLES C, 1994, P NATL ACAD SCI USA, V91, P7859, DOI 10.1073/pnas.91.17.7859; Toulme J. J., 1992, Antisense RNA and DNA., P175; Toulme JJ, 1996, BIOCHIMIE, V78, P663, DOI 10.1016/S0300-9084(96)80012-5; Toulme JJ, 1997, PARASITOLOGY, V114, pS45; UHLENBECK OC, 1995, RNA, V1, P4; VERSPIEREN P, 1987, GENE, V61, P307, DOI 10.1016/0378-1119(87)90194-6; VERSPIEREN P, 1990, NUCLEIC ACIDS RES, V18, P4711, DOI 10.1093/nar/18.16.4711; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; Woo JS, 1996, NUCLEIC ACIDS RES, V24, P2470, DOI 10.1093/nar/24.13.2470	39	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8191	8198		10.1074/jbc.274.12.8191	http://dx.doi.org/10.1074/jbc.274.12.8191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075723	hybrid			2022-12-27	WOS:000079268100082
J	Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T				Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T			Modulation of the remote heme site geometry of recombinant mouse neuronal nitric-oxide synthase by the N-terminal hook region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN ACTIVATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CYTOCHROME P-450-CAM; L-ARGININE; TETRAHYDROBIOPTERIN; EXPRESSION; COMPLEXES; DOMAIN; LIGAND	The role of two essential residues at the N-terminal hook region of neuronal nitric-oxide synthase (nNOS) in nitric-oxide synthase activity was investigated. Full-length mouse nNOS proteins containing single-point mutations of Thr-315 and Asp-314 to alanine were produced in the Escherichia coli and baculovirus-insect cell expression systems, The molecular properties of the mutant proteins were analyzed in detail by biochemical, optical, and electron paramagnetic resonance spectroscopic techniques and compared with those of the wildtype enzyme. Replacement of Asp-314 by Ala altered the geometry around the heme site and the substrate-binding pocket of the heme domain and abrogated the ability of nNOS to form catalytically active dimers, Replacement of Thr-315 by Ala reduced the protein stability and altered the geometry around the heme site, especially in the absence of bound (6R)-5,6,7,8-tetrahydro-L-biopterin cofactor. These results suggest that Asp-314 and Thr-315 both play critical structural roles in stabilizing the heme domain and subunit interactions in mouse nNOS.	Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan	Nippon Medical School	Iwasaki, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.			Iwasaki, Toshio/0000-0001-9562-4649				ANDERSSON LA, 1991, STRUCT BOND, V74, P1; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; Hori H, 1997, BIOCHEM BIOPH RES CO, V234, P476, DOI 10.1006/bbrc.1997.6664; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; IWASAKI T, 1997, J INORG BIOCHEM, V67, P103; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; Possee RD., 1992, BACULOVIRUS EXPRESSI; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; Poulos TL, 1995, CURR OPIN STRUC BIOL, V5, P767, DOI 10.1016/0959-440X(95)80009-3; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Rietjens IMCM, 1996, J BIOL INORG CHEM, V1, P372, DOI 10.1007/s007750050068; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Summers MD, 1987, TEXAS AGR EXPT STATI; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014	59	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7705	7713		10.1074/jbc.274.12.7705	http://dx.doi.org/10.1074/jbc.274.12.7705			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075660	hybrid			2022-12-27	WOS:000079268100019
J	Orii, KE; Orii, KO; Souri, M; Orii, T; Kondo, N; Hashimoto, T; Aoyama, T				Orii, KE; Orii, KO; Souri, M; Orii, T; Kondo, N; Hashimoto, T; Aoyama, T			Genes for the human mitochondrial trifunctional protein alpha- and beta-subunits are divergently transcribed from a common promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXYACYL-COA DEHYDROGENASE-DEFICIENCY; DIHYDROFOLATE-REDUCTASE GENE; PSEUDOMONAS-FRAGI B-0771; FATTY-ACID OXIDATION; MULTIENZYME COMPLEX; ENZYME COMPLEX; EXPRESSION; DNA; IDENTIFICATION; SEQUENCE	Human HADHA and HADHB genes encode the subunits of an enzyme complex, the trifunctional protein, involved in mitochondrial beta-oxidation of fatty acids. Both genes are located in the same region of chromosome 2p23. We isolated genomic clones, including 5' flanking regions, for HADHA and HADHB. Sequencing revealed that both of these genes are linked in a head-to-head arrangement on opposite strands and have in common a 350-bp 5' flanking region. The 5' flanking region has bidirectional promoter activity within this region; two cis elements proved critical for the activity. Transcription factor Sp1 functions as an activator for the bidirectional promoter by binding to both elements. Therefore, expression of trifunctional protein subunits are probably coordinately regulated by a common promoter and by Sp1.	Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Shinshu Univ, Sch Med, Dept Biochem, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Aging Biochem, Res Ctr Aging & Adaptat, Matsumoto, Nagano 3908621, Japan; Chubu Gakuin Univ, Dept Human Welfare, Fac Human Welfare, Seki 5013936, Japan	Gifu University; Shinshu University; Shinshu University	Orii, KE (corresponding author), Gifu Univ, Sch Med, Dept Pediat, 40 Tsukasa Machi, Gifu 5008076, Japan.	kenjior-gif@umin.u-tokyo.ac.jp	Orii, Kenji/AAJ-9069-2020					Aoyama T, 1997, CYTOGENET CELL GENET, V79, P221, DOI 10.1159/000134727; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; CARPENTER K, 1992, BIOCHEM BIOPH RES CO, V183, P443, DOI 10.1016/0006-291X(92)90501-B; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; Ijlst L, 1996, J CLIN INVEST, V98, P1028, DOI 10.1172/JCI118863; ISHII N, 1987, J BIOL CHEM, V262, P8144; JACKSON S, 1992, J CLIN INVEST, V90, P1219, DOI 10.1172/JCI115983; KAMIJO T, 1994, J CLIN INVEST, V93, P1740, DOI 10.1172/JCI117158; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302; KANO M, 1991, GENE, V109, P285, DOI 10.1016/0378-1119(91)90623-J; LENNARD AC, 1991, MOL CELL BIOL, V11, P1281, DOI 10.1128/MCB.11.3.1281; LEONE TC, 1995, J BIOL CHEM, V270, P24622; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; Orii KE, 1997, HUM MOL GENET, V6, P1215, DOI 10.1093/hmg/6.8.1215; Orii KE, 1996, BIOCHEM BIOPH RES CO, V219, P773, DOI 10.1006/bbrc.1996.0309; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; OSUMI T, 1987, J BIOL CHEM, V262, P8138; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SATO S, 1994, J BIOCHEM, V115, P286, DOI 10.1093/oxfordjournals.jbchem.a124330; SCHILLING LJ, 1989, MOL CELL BIOL, V9, P4568, DOI 10.1128/MCB.9.10.4568; SEWELL AC, 1994, EUR J PEDIATR, V153, P745, DOI 10.1007/BF01954492; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SOININEN R, 1988, J BIOL CHEM, V263, P17217; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Ushikubo S, 1996, AM J HUM GENET, V58, P979; WANDERS RJA, 1989, LANCET, V2, P52, DOI 10.1016/S0140-6736(89)90300-0; ZHANG QX, 1994, BBA-GENE STRUCT EXPR, V1219, P567, DOI 10.1016/0167-4781(94)90091-4	33	43	44	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8077	8084		10.1074/jbc.274.12.8077	http://dx.doi.org/10.1074/jbc.274.12.8077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075708	hybrid			2022-12-27	WOS:000079268100067
J	Tung, SF; Chuang, JY; Lin, CT; Lai, MY; Wu, CW; Lin, YS				Tung, SF; Chuang, JY; Lin, CT; Lai, MY; Wu, CW; Lin, YS			Inhibition of hTAF(II)32-binding implicated in the transcriptional repression by central regions of mutant p53 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR PROTEIN; STEROID-BINDING DOMAINS; VP16 ACTIVATION DOMAIN; WILD-TYPE; NUCLEAR-LOCALIZATION; FACTOR-TFIIB; MECHANISM; GROWTH; PURIFICATION; EXPRESSION	We previously identified a movable and regulable inactivation function within the central region (CRts247) Of a temperature-sensitive p53 (p53(ts)) mutant, p53(N247I). Here we showed that central regions from several p53(ts) mutants behaved similarly, i,e, they repressed a neighboring activation domain only when existing in the mutant status. Using chimeric protein GAL4VP16-CRts247 as an example, we demonstrated that de novo protein synthesis was not required for the reactivation of the chimeric protein, indicating that a post-translational mechanism was involved in the control of CRts247 activity. The CRts247-conferred thermo-regulability did not work via a mechanism demanding either an alteration of the subcellular compartmentalization of or the inactivation of DNA-binding activity of the GAL4 chimera. Further, CRts247 did not function in trans, eliminating the possibility that the observed repression was because of the competition for a putative factor(s) by the mutant p53 domain. Rather, CRts247 bestowed temperature-dependent interaction with hTAF(II)32 to the VP16 activation domain. In a parallel experiment, CRts247 also caused a large reduction in the affinity of hTAF(II)32 to the p53 activation domain at the nonpermissive temperature. These results strongly suggested that inhibition of hTAF(II)32 binding could be one of the mechanisms responsible for the transcriptional repression by mutant p53 central regions.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 100, Taiwan; China Med Coll, Sch Med Technol, Taichung 404, Taiwan; Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; China Medical University Taiwan; National Taiwan University; National Taiwan University	Lin, YS (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.							CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUANG JY, 1995, J BIOL CHEM, V270, P23899, DOI 10.1074/jbc.270.41.23899; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tantin D, 1996, METHOD ENZYMOL, V274, P133; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310	39	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7748	7755		10.1074/jbc.274.12.7748	http://dx.doi.org/10.1074/jbc.274.12.7748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075665	hybrid			2022-12-27	WOS:000079268100024
J	Wu-Wong, JSR; Berg, CE; Wang, JH; Chiou, WJ; Fissel, B				Wu-Wong, JSR; Berg, CE; Wang, JH; Chiou, WJ; Fissel, B			Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN RELEASE; ADIPOSE-CELLS; PURIFICATION; MEMBRANE; CLONING; MUSCLE; SIGNAL; NIDDM; RAT	Endothelin-1 (ET-1) is a al-amino acid peptide that binds to G-protein-coupled receptors to evoke biological responses. This report studies the effect of ET-1 on regulating glucose transport in 3T3-L1 adipocytes. ET-1, but not angiotensin II, stimulated glucose uptake in a dose-dependent manner with an EC50 value of 0.29 nM and a 2.47-fold stimulation at 100 nM. ET-1 stimulated glucose uptake in differentiated 3T3-L1 cells but had no effect in undifferentiated cells, although ET-1 stimulated phosphatidylinositol hydrolysis to a similar degree in both. The 3T3-L1 cells expressed similar to 560,000 sites/cell of ETA receptor, which was not altered during differentiation. Western blot analysis and immunofluorescence staining show that ET-1 stimulated the translocation of insulin-responsive aminopeptidase and GLUT4 to the plasma membrane, The effect of ET-I on glucose uptake was blocked by A-216546, an antagonist selective for the ETA receptor. ET-1 treatment did not induce phosphorylation of insulin receptor beta-subunit, insulin receptor substrate-1, or Akt but stimulated the tyrosyl phosphorylation of a 75-kDa protein. Genistein (100 mu M), an inhibitor of tyrosine kinases, inhibited ET-1-stimulated glucose uptake. Our results show that ET-1 stimulates GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes via activation of ETA receptor.	Abbott Labs, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wu-Wong, JSR (corresponding author), Abbott Labs, Div Pharmaceut Prod, 100 Abbott Pk Rd,D47V,AP9A, Abbott Pk, IL 60064 USA.	ruth.r.wuwong@abbott.com						ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BALDINI G, 1991, J BIOL CHEM, V266, P4037; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Douglas SA, 1997, J VASC RES, V34, P152, DOI 10.1159/000159219; ECHEL J, 1990, BIOCHEM J, V272, P691; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; FISHER Y, 1996, AM J PHYSIOL, V270, pC1204; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Hansen PA, 1998, J APPL PHYSIOL, V85, P1218, DOI 10.1152/jappl.1998.85.4.1218; Holloszy John O., 1998, Frontiers in Bioscience, V3, pD1011; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; Juan CC, 1996, BIOCHEM BIOPH RES CO, V227, P694, DOI 10.1006/bbrc.1996.1571; KAWAMURA M, 1992, DIABETES CARE, V15, P1396, DOI 10.2337/diacare.15.10.1396; Kishi K, 1996, J BIOL CHEM, V271, P26561, DOI 10.1074/jbc.271.43.26561; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; Lenz T, 1998, AM J HYPERTENS, V11, P1028, DOI 10.1016/S0895-7061(98)00086-7; Maeda S, 1998, J APPL PHYSIOL, V85, P425, DOI 10.1152/jappl.1998.85.2.425; Maeda S, 1998, J CARDIOVASC PHARM, V31, pS392, DOI 10.1097/00005344-199800001-00112; Maeda S, 1997, LIFE SCI, V61, P419, DOI 10.1016/S0024-3205(97)00399-8; NERI SGG, 1997, EUR J CLIN INVEST, V27, P761; OPGENORTH TJ, 1997, 5 INT C END KYOT JAP; Rosendorff C, 1997, CARDIOVASC DRUG THER, V10, P795, DOI 10.1007/BF00053038; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sarman B, 1998, DIABETES METAB REV, V14, P171, DOI 10.1002/(SICI)1099-0895(199806)14:2<171::AID-DMR207>3.0.CO;2-G; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; WADA K, 1990, BIOCHEM BIOPH RES CO, V167, P251, DOI 10.1016/0006-291X(90)91758-K; Wu-Wong JR, 1998, J CARDIOVASC PHARM, V31, pS185, DOI 10.1097/00005344-199800001-00053; WuWong JR, 1996, AM J PHYSIOL-CELL PH, V271, pC869, DOI 10.1152/ajpcell.1996.271.3.C869; WUWONG JR, 1994, AM J PHYSIOL-CELL PH, V267, pC1185, DOI 10.1152/ajpcell.1994.267.5.C1185; WUWONG JR, 1998, AM DIAB ASS 58 SCI S; WUWONG JR, 1999, IN PRESS EUR J PHARM; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zimmerman RS, 1995, METABOLISM, V44, P1532, DOI 10.1016/0026-0495(95)90070-5; ZIMMERMAN RS, 1995, METABOLISM, V44, P1321, DOI 10.1016/0026-0495(95)90037-3	38	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8103	8110		10.1074/jbc.274.12.8103	http://dx.doi.org/10.1074/jbc.274.12.8103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075711	hybrid			2022-12-27	WOS:000079268100070
J	Asturias, FJ; Kornberg, RD				Asturias, FJ; Kornberg, RD			Protein crystallization on lipid layers and structure determination of the RNA polymerase II transcription initiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							START SITE SELECTION; ELECTRON CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; 2-DIMENSIONAL CRYSTALLIZATION; CRYSTALS; RESOLUTION; RECONSTRUCTION; CONFORMATIONS; GROWTH		Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.							Asturias FJ, 1998, ULTRAMICROSCOPY, V70, P133, DOI 10.1016/S0304-3991(97)00108-3; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; ASTURIAS FJ, 1995, J STRUCT BIOL, V114, P60, DOI 10.1006/jsbi.1995.1005; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; BRISSON A, 1994, BIOL CELL, V80, P221, DOI 10.1016/0248-4900(94)90045-0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROWTHER RA, 1975, ANNU REV BIOCHEM, V44, P161, DOI 10.1146/annurev.bi.44.070175.001113; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1988, J MOL BIOL, V203, P269, DOI 10.1016/0022-2836(88)90107-6; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)80223-H; EDWARDS AM, 1994, NAT STRUCT BIOL, V1, P195, DOI 10.1038/nsb0394-195; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FRANK J, 1993, ULTRAMICROSCOPY, V49, P387, DOI 10.1016/0304-3991(93)90244-R; HEMMING SA, 1995, J MOL BIOL, V246, P308, DOI 10.1006/jmbi.1994.0086; HENDERSON R, 1995, Q REV BIOPHYS, V28, P171, DOI 10.1017/S003358350000305X; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; Kornberg RD, 1991, CURR OPIN STRUC BIOL, V1, P642, DOI 10.1016/S0959-440X(05)80090-9; KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; MORGAN DG, 1992, J STRUCT BIOL, V108, P245, DOI 10.1016/1047-8477(92)90025-6; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REIDLER J, 1986, HDB EXPT IMMUNOLOGY, V1; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; Wilson-Kubalek EM, 1998, P NATL ACAD SCI USA, V95, P8040, DOI 10.1073/pnas.95.14.8040	29	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6813	6816		10.1074/jbc.274.11.6813	http://dx.doi.org/10.1074/jbc.274.11.6813			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066729	hybrid			2022-12-27	WOS:000079078400001
J	Brown, CT; Nugent, MA; Lau, FW; Trinkaus-Randall, V				Brown, CT; Nugent, MA; Lau, FW; Trinkaus-Randall, V			Characterization of proteoglycans synthesized by cultured corneal fibroblasts in response to transforming growth factor beta and fetal calf serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN RECEPTOR; CYCLIN-DEPENDENT KINASES; CELL-ADHESION MOLECULES; DECORIN GENE-EXPRESSION; HAMSTER OVARY CELLS; HEPARAN-SULFATE; BASEMENT-MEMBRANE; CORE PROTEIN; DOMAIN-I	A culture system was developed to analyze the relationship between proteoglycans and growth factors during corneal injury. Specifically, the effects of transforming growth factor beta-1 (TGF-beta 1) and fetal calf serum on proteoglycan synthesis in corneal fibroblasts were examined. Glycosaminoglycan synthesis and sulfation were determined using selective polysaccharidases, Proteoglycan core proteins were analyzed using gel electrophoresis and Western blotting, Cells cultured in 10% dialyzed fetal calf serum exhibited decreased synthesis of more highly sulfated chondroitin sulfate and heparan sulfate compared with cells cultured in 1% dialyzed fetal calf serum. The amount and sulfation of the glycosaminoglycans was not significantly influenced by TGF-beta 1, The major proteoglycan species secreted into the media were decorin and perlecan, Decorin was glycanated with chondroitin sulfate, Perlecan was linked to either chondroitin sulfate, heparan sulfate, or both chondroitin sulfate and heparan sulfate. Decorin synthesis was reduced by either TGF-beta 1 or serum. At early time points, both TGF-beta 1 and serum induced substantial increases in perlecan bearing chondroitin sulfate and/or heparan sulfate chains. In contrast, after extended periods in culture, the amount of perlecan bearing heparan sulfate chains was unaffected by TGF-beta 1 and decreased by serum. The levels of perlecan bearing chondroitin sulfate chains were elevated with TGF-PI treatment and were decreased with serum. Because both decorin and perlecan bind growth factors and are proposed to modulate their activity, changes in the expression of either of these proteoglycans could substantially affect the cellular response to injury.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Trinkaus-Randall, V (corresponding author), Boston Univ, Sch Med, Dept Biochem, Rm L903,80 E Concord St, Boston, MA 02118 USA.			Nugent, Matthew/0000-0002-8630-4712; Trinkaus-Randall, Vickery/0000-0002-8573-9108	NEI NIH HHS [EY110004] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; AXELSSON I, 1978, BIOCHEM J, V169, P517, DOI 10.1042/bj1690517; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BROWN CT, 1995, J CELL BIOCHEM, V59, P57, DOI 10.1002/jcb.240590108; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; CINTRON C, 1978, J ULTRA MOL STRUCT R, V65, P13, DOI 10.1016/S0022-5320(78)90017-5; CONRAD GW, 1977, J BIOL CHEM, V252, P6861; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; DAHL IMS, 1978, EXP EYE RES, V27, P175, DOI 10.1016/0014-4835(78)90087-8; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Doege K, 1997, MATRIX BIOL, V16, P211, DOI 10.1016/S0945-053X(97)90010-X; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P435; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GREGORY JD, 1982, J BIOL CHEM, V257, P6965; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HASSELL JR, 1979, J BIOL CHEM, V254, P2346; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HAYASHI K, 1989, INVEST OPHTH VIS SCI, V30, P239; HEIMER R, 1995, J MOL CELL CARDIOL, V27, P2191, DOI 10.1016/S0022-2828(95)91479-X; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; KOKENYESI R, 1995, BIOCHEM BIOPH RES CO, V211, P262, DOI 10.1006/bbrc.1995.1805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nietfeld J J, 1994, EXS, V70, P215; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; SCHWARZ W, 1969, VIRCHOWS ARCH A, V347, P115, DOI 10.1007/BF00544113; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Tiedemann K, 1997, MATRIX BIOL, V15, P469, DOI 10.1016/S0945-053X(97)90020-2; Trinkaus-Randall V, 1998, J CONTROL RELEASE, V53, P205, DOI 10.1016/S0168-3659(97)00254-X; TRINKAUSRANDALL V, 1990, INVEST OPHTH VIS SCI, V31, P1321; TRNKAUSRANDALL V, 1997, PRINCIPLES TISSUE EN, P386; WILSON SE, 1992, INVEST OPHTH VIS SCI, V33, P1756; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; YUE BYJ, 1976, J BIOCH, V158, P567	68	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7111	7119		10.1074/jbc.274.11.7111	http://dx.doi.org/10.1074/jbc.274.11.7111			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066769	hybrid			2022-12-27	WOS:000079078400041
J	Hinkle, A; Goranson, A; Butters, CA; Tobacman, LS				Hinkle, A; Goranson, A; Butters, CA; Tobacman, LS			Roles for the troponin tail domain in thin filament assembly and regulation - A deletional study of cardiac troponin T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; ACTIN-TROPOMYOSIN; COOPERATIVE INTERACTIONS; LABELED TROPOMYOSIN; CA2+ SENSITIVITY; CALCIUM-BINDING; ATPASE ACTIVITY	Striated muscle contraction is regulated by Ca2+ binding to troponin, which has a globular domain and an elongated tail attributable to the NH2-terminal portion of the bovine cardiac troponin T (TnT) subunit. Truncation of the bovine cardiac troponin tail was investigated using recombinant TnT fragments and subunits TnI and TnC. Progressive truncation of the troponin tail caused progressively weaker binding of troponin-tropomyosin to actin and of troponin to actin-tropomyosin. A sharp drop-off in affinity occurred with NH2-terminal deletion of 119 rather than 94 residues. Deletion of 94 residues had no effect on Ca2+-activation of the myosin subfragment 1-thin filament MgATPase rate and did not eliminate cooperative effects of Ca2+ binding. Troponin tail peptide TnT1-153 strongly promoted tropomyosin binding to actin in the absence of TnI or TnC. The results show that the anchoring function of the troponin tail involves interactions with actin as well as with tropomyosin and has comparable importance in the presence or absence of Ca2+. Residues 95-153 are particularly important for anchoring, and residues 95-119 are crucial for function or local folding. Because striated muscle regulation involves switching among the conformational states of the thin filament, regulatory significance for the troponin tail may arise from its prominent contribution to the protein-protein interactions within these conformations.	Univ Iowa, Dept Internal Med, GH, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, GH, 200 Hawkins Dr SE610, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu						ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; Bing W, 1997, BIOCHEM J, V327, P335, DOI 10.1042/bj3270335; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; BYERS DM, 1979, FEBS LETT, V104, P106, DOI 10.1016/0014-5793(79)81093-5; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; Chandra M, 1998, BIOPHYS J, V74, pA52; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; Forissier JF, 1996, CIRCULATION, V94, P3069, DOI 10.1161/01.CIR.94.12.3069; FUJITA S, 1992, J BIOCHEM-TOKYO, V112, P306, DOI 10.1093/oxfordjournals.jbchem.a123896; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hammell RL, 1997, J BIOL CHEM, V272, P22409, DOI 10.1074/jbc.272.36.22409; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; ISHII Y, 1991, J BIOL CHEM, V266, P6894; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MATSUSHITA M, 1993, CLIN CHIM ACTA, V216, P103, DOI 10.1016/0009-8981(93)90143-R; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MEEDEL TH, 1993, J BIOL CHEM, V268, P6755; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; OHTSUKI I, 1984, J BIOCHEM, V95, P1337, DOI 10.1093/oxfordjournals.jbchem.a134740; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PAN BS, 1991, J BIOL CHEM, V266, P12432; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1977, J BIOL CHEM, V252, P983; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Sorensen BR, 1996, BIOPHYS J, V71, P3407, DOI 10.1016/S0006-3495(96)79535-8; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WALSH TP, 1984, J MOL BIOL, V182, P265; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	73	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7157	7164		10.1074/jbc.274.11.7157	http://dx.doi.org/10.1074/jbc.274.11.7157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066775	hybrid			2022-12-27	WOS:000079078400047
J	Marsischky, GT; Lee, S; Griffith, J; Kolodner, RD				Marsischky, GT; Lee, S; Griffith, J; Kolodner, RD			Saccharomyces cerevisiae MSH2/6 complex interacts with Holliday junctions and facilitates their cleavage by phage resolution enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR SYSTEM; DNA-BASE PAIRS; GENETIC-RECOMBINATION; CROSSING-OVER; MUTS HOMOLOG; HOMEOLOGOUS RECOMBINATION; DUPLEX OLIGONUCLEOTIDES; SPECIFICALLY BINDS; ESCHERICHIA-COLI; PROTEIN	Genetic and biochemical studies have indicated that mismatch repair proteins can interact with recombination intermediates. In this study, gel shift assays and electron microscopic analysis were used to show that the Saccharomyces cerevisiae MSH2/6 complex binds to Holliday junctions and has an affinity and specificity for them that is at least as high as it has as for mispaired bases. Under equilibrium binding conditions, the MSH2/6 complex had a K-d of binding to Holliday junctions of 0.5 nm. The MSH2/6 complex enhanced the cleavage of Holliday junctions by T4 endonuclease VII and T7 endonuclease I. This is consistent with the view that the MSH2/6 complex can function in both mismatch repair and the resolution of recombination intermediates as predicted by genetic studies.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, CMME-3080,9500 Gilman Dr, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM31819, GM50006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006, R01GM031819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; Alani E, 1996, MOL CELL BIOL, V16, P5604; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; CHI NW, 1994, J BIOL CHEM, V269, P29984; Datta A, 1996, MOL CELL BIOL, V16, P1085; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; DETLOFF P, 1992, GENETICS, V132, P113; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOUTRIAUX MP, 1986, P NATL ACAD SCI USA, V83, P2576, DOI 10.1073/pnas.83.8.2576; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FEINSTEIN SI, 1986, GENETICS, V113, P13; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MATIC I, 1995, CELL, V80, P507, DOI 10.1016/0092-8674(95)90501-4; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; PETIT MA, 1991, GENETICS, V129, P327; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P975; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Saparbaev M, 1996, GENETICS, V142, P727; Selva EM, 1997, MOL GEN GENET, V257, P71; SELVA EM, 1995, GENETICS, V139, P1175; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	46	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7200	7206		10.1074/jbc.274.11.7200	http://dx.doi.org/10.1074/jbc.274.11.7200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066781	hybrid, Green Published			2022-12-27	WOS:000079078400053
J	Wang, Y; Guo, W; Liang, LZ; Esselman, WJ				Wang, Y; Guo, W; Liang, LZ; Esselman, WJ			Phosphorylation of CD45 by casein kinase 2 - Modulation of activity and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE-COMMON ANTIGEN; T-CELLS; PHOSPHOTYROSINE PHOSPHATASE; LYMPHOCYTE-ACTIVATION; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; MURINE LYMPHOMA; EXPRESSION; DOMAIN	CD45 is a receptor-type protein-tyrosine phosphatase (PTP) that is required for antigen-specific stimulation and proliferation in lymphocytes, This study was designed to determine the nature of specific kinases in lymphocytes that phosphorylate CD45 and to determine the effect of phosphorylation on CD45 PTP activity. A major cytoplasmic lymphocyte kinase that phosphorylated CD45 was identified as casein kinase 2 (CK2) by use of an in-gel kinase assay in combination with immunoprecipitation, immunodepletion, and specific inhibition. Mutational analysis of CK2 consensus sites showed that the target for CK2 was in an acidic insert of 19 amino acids in the D2 domain, and Ser to Ala mutations at amino acids 965, 968, 969, and 973 abrogated CK2 phosphorylation of CD45, CK2 phosphorylation increased CD45 activity S-fold toward phosphorylated myelin basic protein, and this increase was reversible by PP2A treatment. Mutation of Ser to Glu at the CK2 sites had the same effect as phosphorylation and also tripled the V-max of CD45. CD45 isolated in vivo was highly phosphorylated and could not be phosphorylated by CK2 without prior dephosphorylation with phosphatase PP2A. We conclude that CK2 is a major lymphocyte kinase that is responsible for in vivo phosphorylation of CD45, and phosphorylation at specific CK2 sites regulates CD45 PTP activity.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA	Michigan State University	Esselman, WJ (corresponding author), Michigan State Univ, Dept Microbiol, Rm 344 Giltner Hall, E Lansing, MI 48824 USA.	esselman@pilot.msu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042794] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/GM42794] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Bretz J D, 1992, Dev Immunol, V2, P249, DOI 10.1155/1992/34586; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHANG HL, 1991, J IMMUNOL, V147, P1687; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Doro U, 1996, MOL CELL BIOL, V16, P4996; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; GONZATTIHACES MI, 1982, J BIOL CHEM, V257, P6642; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kang SM, 1997, J BIOL CHEM, V272, P11588; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Litchfield DW, 1996, BIOCHEM CELL BIOL, V74, P541, DOI 10.1139/o96-458; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MELKERSONWATSON LJ, 1994, J IMMUNOL, V153, P2004; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; NG DHW, 1995, J IMMUNOL METHODS, V179, P177, DOI 10.1016/0022-1759(94)00281-Z; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SELDIN DC, 1994, BLOOD, V84, P376; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Stover David R., 1993, P193; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; TAWFIC S, 1995, J BIOL CHEM, V270, P21009, DOI 10.1074/jbc.270.36.21009; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TUAZON PT, 1991, ADV 2 MESS PHOSPHOPR, V23, P123; Ulyanova T, 1997, IMMUNOL RES, V16, P101, DOI 10.1007/BF02786326; VALENTINE MA, 1991, EUR J IMMUNOL, V21, P913, DOI 10.1002/eji.1830210409; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386	46	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7454	7461		10.1074/jbc.274.11.7454	http://dx.doi.org/10.1074/jbc.274.11.7454			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066810	hybrid			2022-12-27	WOS:000079078400082
J	Mackay, K; Mochly-Rosen, D				Mackay, K; Mochly-Rosen, D			An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; TERMINAL KINASES; REPERFUSION; APOPTOSIS; HEART; PHOSPHORYLATION; CELLS; STIMULATION	Cellular ischemia results in activation of a number of kinases, including p38 mitogen-activated protein kinase (MAPK); however, it is not yet clear whether p38 MAPK activation plays a role in cellular damage or is part of a protective response against ischemia, We have developed a model to study ischemia in cultured neonatal rat cardiac myocytes. In this model, two distinct phases of p38 MAPK activation were observed during ischemia. The first phase began within 10 min and lasted less than 1 h, and the second began after 2 h and lasted throughout the ischemic period. Similar to previous studies using in vivo models, the nonspecific activator of p38 MAPK and c-Jun NH2-terminal kinase, anisomycin, protected cardiac myocytes from ischemic injury, decreasing the release of cytosolic lactate dehydrogenase by approximately 25%. We demonstrated, however, that a selective inhibitor of p38 MAPK, SB 203580, also protected cardiac myocytes against extended ischemia in a dose-dependent manner. The protective effect was seen even when the inhibitor was present during only the second, sustained phase of p38 MAPK activation. We found that ischemia induced apoptosis in neonatal rat cardiac myocytes and that SE 203580 reduced activation of caspase-3, a key event in apoptosis. These results suggest that p38 MAPK induces apoptosis during ischemia in cardiac myocytes and that selective inhibition of p58 MAPK could be developed as a potential therapy for ischemic heart disease.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL-52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bradham CA, 1997, HEPATOLOGY, V25, P1128, DOI 10.1002/hep.510250514; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Downey JM, 1997, ADV EXP MED BIOL, V430, P39; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Kajstura J, 1996, LAB INVEST, V74, P86; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KHANDOUDI N, 1998, 6 ANTW JOLL KYOT RES; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MAULIK N, 1998, VASCULAR MYOCARDIAL; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tombes RM, 1998, BIOCHEM J, V330, P1451; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	41	262	276	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6272	6279		10.1074/jbc.274.10.6272	http://dx.doi.org/10.1074/jbc.274.10.6272			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037715	hybrid			2022-12-27	WOS:000078902800037
J	Vollmer, W; von Rechenberg, M; Holtje, JV				Vollmer, W; von Rechenberg, M; Holtje, JV			Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING-PROTEINS; OUTER-MEMBRANE PROTEIN; CONTROLLED OVEREXPRESSION; AFFINITY-CHROMATOGRAPHY; CELL-ENVELOPE; GENE; CLONING; WALL; LOCALIZATION; PURIFICATION	Enlargement of the stress-bearing murein sacculus of bacteria depends on the coordinated interaction of murein synthases and hydrolases. To understand the mechanism of interaction of these two classes of proteins affinity chromatography and surface plasmon resonance (SPR) studies were performed. The membrane-bound lytic transglycosylase MltA when covalently linked to CNBr-activated Sepharose specifically retained the penicillin-binding proteins (PBPs) 1B, 1C, 2, and 3 from a crude Triton X-100 membrane extract of Escherichia coli. In the presence of periplasmic proteins also PBP1A was specifically bound. At least five different non-PBPs showed specificity for MltA-Sepharose. The amino-terminal amino acid sequence of one of these proteins could be obtained, and the corresponding gene was mapped at 40 min on the E. coli genome. This MltA-interacting protein, named MipA, in addition binds to PBP1B, a bifunctional murein transglycosylase/ transpeptidase. SPR studies with PBP1B immobilized to ampicillin-coated sensor chips showed an oligomerization of PBP1B that may indicate a dimerization, Simultaneous application of MipA and MltA onto a PBP1B sensor chip surface resulted in the formation of a trimeric complex, The dissociation constant was determined to be about 10(-6) M, The formation of a complex between a murein polymerase (PBP1B) and a murein hydrolase (MltA) in the presence of MipA represents a first step in a reconstitution of the hypothetical murein-synthesizing holoenzyme, postulated to be responsible for controlled growth of the stress-bearing sacculus of E. coli.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Holtje, JV (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	joachim-volker.hoeltje@tuebingen.mpg.de						BARBAS JA, 1986, J BACTERIOL, V165, P269, DOI 10.1128/jb.165.1.269-275.1986; BAYER ME, 1968, J GEN MICROBIOL, V53, P395, DOI 10.1099/00221287-53-3-395; BAYER MH, 1990, J BACTERIOL, V172, P125, DOI 10.1128/JB.172.1.125-135.1990; Beguin P, 1996, CRIT REV BIOCHEM MOL, V31, P201, DOI 10.3109/10409239609106584; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHOP RE, 1993, FEMS MICROBIOL LETT, V114, P349, DOI 10.1111/j.1574-6968.1993.tb06597.x; BURMAN LG, 1984, P NATL ACAD SCI-BIOL, V81, P1844, DOI 10.1073/pnas.81.6.1844; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EHLERT K, 1995, MOL MICROBIOL, V16, P761, DOI 10.1111/j.1365-2958.1995.tb02437.x; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; Ghuysen JM, 1997, INT J ANTIMICROB AG, V8, P45, DOI 10.1016/S0924-8579(96)00358-5; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Holtje JV, 1996, MICROBIOL-SGM, V142, P1911, DOI 10.1099/13500872-142-8-1911; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KELLENBERGER E, 1990, MOL MICROBIOL, V4, P697, DOI 10.1111/j.1365-2958.1990.tb00640.x; KOCH AL, 1985, J THEOR BIOL, V117, P137, DOI 10.1016/S0022-5193(85)80169-7; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORAT B, 1991, MOL MICROBIOL, V5, P675, DOI 10.1111/j.1365-2958.1991.tb00739.x; KUSSER W, 1980, EUR J BIOCHEM, V103, P277, DOI 10.1111/j.1432-1033.1980.tb04312.x; Lommatzsch J, 1997, J BACTERIOL, V179, P5465, DOI 10.1128/jb.179.17.5465-5470.1997; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MACKMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Miller J.H., 1972, EXPT MOL GENETICS; NAKAGAWA J, 1979, AGR BIOL CHEM TOKYO, V43, P1379, DOI 10.1080/00021369.1979.10863634; PARK JT, 1973, BIOCHEM BIOPH RES CO, V51, P863, DOI 10.1016/0006-291X(73)90006-5; Park JT, 1996, ESCHERICHIA COLI SAL, P48; ROMEIS T, 1994, J BIOL CHEM, V269, P21603; ROMEIS T, 1994, EUR J BIOCHEM, V224, P597, DOI 10.1111/j.1432-1033.1994.00597.x; SCHMIDT LS, 1981, J BACTERIOL, V145, P632, DOI 10.1128/JB.145.1.632-637.1981; SCHWARZ U, 1981, FEMS MICROBIOL LETT, V10, P107, DOI 10.1111/j.1574-6968.1981.tb06217.x; Shockman GD., 1994, BACTERIAL CELL WALL, P131, DOI 10.1016/S0167-7306(08)60410-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; STEVENSON G, 1985, EUR J BIOCHEM, V148, P385, DOI 10.1111/j.1432-1033.1985.tb08850.x; TEMPLIN MF, 1992, J BIOL CHEM, V267, P20039; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vonRechenberg M, 1996, MICROB DRUG RESIST, V2, P155, DOI 10.1089/mdr.1996.2.155; WACHI M, 1989, J BACTERIOL, V171, P3123, DOI 10.1128/jb.171.6.3123-3127.1989; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; ZIJDERVELD CAL, 1991, J BACTERIOL, V173, P5740, DOI 10.1128/jb.173.18.5740-5746.1991	48	149	153	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6726	6734		10.1074/jbc.274.10.6726	http://dx.doi.org/10.1074/jbc.274.10.6726			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037771	hybrid			2022-12-27	WOS:000078902800093
J	Blaise, R; Grober, J; Rouet, P; Tavernier, G; Daegelen, D; Langin, D				Blaise, R; Grober, J; Rouet, P; Tavernier, G; Daegelen, D; Langin, D			Testis expression of hormone-sensitive lipase is conferred by a specific promoter that contains four regions binding testicular nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR-4 ENHANCER; CONVERTING ENZYME ACE; DNA-BINDING; GENE; SRY; SEQUENCE; SPERMATOGENESIS; CREM; MOUSE; CELLS	The testicular isoform of hormone-sensitive lipase (HSLtes) is encoded by a testis-specific exon and 9 exons common to the testis and adipocyte isoforms. In mouse, HSLtes mRNA appeared during spermiogenesis in round spermatids. Two constructs containing 1.4 and 0.5 kilobase pairs (kb) of the human HSLtes gene 5'-flanking region cloned upstream of the chloramphenicol acetyltransferase gene were microinjected into mouse oocytes. Analyses of enzyme activity in male and female transgenic mice showed that 0.5 kb of the HSLtes promoter was sufficient to direct expression only in testis, Cell transfection experiments showed that CREM tau, a testis-specific transcriptional activator, does not transactivate the HSLtes promoter. Using gel retardation assays, four testis-specific binding regions (TSBR) were identified using testis and liver nuclear extracts. The testis-specific protein binding on TSBR4 was selectively competed by a probe containing a SRY/Sox protein DNA recognition site. Sox5 and Sox6 which are expressed in post-meiotic germ cells bound TSBR4. Mutation of the AACAAAG motif in TSBR4 abolished the binding. Moreover, binding of the high mobility group domain of Sox5 induced a bend within TSBR4. Together, our results showed that 0.5 kb of the human HSLtes promoter bind Sox proteins and contain cis-acting elements essential for the testis specificity of HSL.	Univ Toulouse 3, Hop Rangueil, Inst Louis Bugnard, INSERM U317, F-31403 Toulouse 4, France; Fac Med, Inst Cochin Genet Mol, INSERM U129, F-75014 Paris, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Langin, D (corresponding author), CHU Rangueil, INSERM U317, Inst Louis Bugnard, Batiment L3, F-31403 Toulouse 4, France.			Tavernier, Genevieve/0000-0002-0214-0344; Blaise, Regis/0000-0001-7759-3244; Langin, Dominique/0000-0002-2669-7825; Rouet, Philippe/0000-0001-6204-2079				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; Grober J, 1997, BIOCHEM J, V328, P453, DOI 10.1042/bj3280453; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HOGAN B, 1994, MANIPULATING MOUSE E, P226; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HOLST LS, 1994, FEBS LETT, V355, P125, DOI 10.1016/0014-5793(94)01185-0; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; LAURELL H, 1995, INT J OBESITY, V19, P590; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHTA ND, 1994, ENDOCRINOLOGY, V135, P1543, DOI 10.1210/en.135.4.1543; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TAKAMATSU N, 1995, MOL CELL BIOL, V15, P3759; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	51	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9327	9334		10.1074/jbc.274.14.9327	http://dx.doi.org/10.1074/jbc.274.14.9327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092610	hybrid			2022-12-27	WOS:000079451800029
J	Cervoni, N; Bhattacharya, S; Szyf, M				Cervoni, N; Bhattacharya, S; Szyf, M			DNA demethylase is a processive enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EMBRYO; METHYLATION PATTERNS; 5-METHYLCYTOSINE; GENE; DIFFERENTIATION	DNA methylation patterns are generated during development by a sequence of methylation and demethylation events. We have recently demonstrated that mammals bear a bona fide demethylase enzyme that removes methyl groups from methylated cytosines. A general genome wide demethylation occurs early in development and in differentiating cell lines. This manuscript tests the hypothesis that the demethylase enzyme is a processive enzyme. Using bisulfite mapping, this report demonstrates that demethylase is a processive enzyme and that the rate limiting step in demethylation is the initiation of demethylation. Initiation of demethylation is determined by the properties of the sequence. Once initiated, demethylation progresses processively. We suggest that these data provide a molecular explanation for global hypomethylation.	McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; BENVENISTY N, 1985, P NATL ACAD SCI USA, V82, P267, DOI 10.1073/pnas.82.2.267; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; FEINBERG AP, 1988, CANCER RES, V48, P1159; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; MONK M, 1987, DEVELOPMENT, V99, P371; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4	20	41	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8363	8366		10.1074/jbc.274.13.8363	http://dx.doi.org/10.1074/jbc.274.13.8363			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085064	hybrid			2022-12-27	WOS:000079451600006
J	Dell, H; Hadzopoulou-Cladaras, M				Dell, H; Hadzopoulou-Cladaras, M			CREB-binding protein is a transcriptional coactivator for hepatocyte nuclear factor-4 and enhances apolipoprotein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; RETINOID-X-RECEPTOR; HUMAN APOCIII GENE; RNA-POLYMERASE-II; DNA-BINDING; TRANSACTIVATION DOMAIN; HORMONE RECEPTORS; HISTONE ACETYLTRANSFERASES; PROXIMAL PROMOTER; RESPONSE ELEMENT	Hepatocyte nuclear factor-4 (HNF-4) is a liver-enriched transcription factor that is crucial in the regulation of a large number of genes involved in glucose, cholesterol, and fatty acid metabolism and in determining the hepatic phenotype. We have previously shown that HNF-4 contains transcription activation functions at the N terminus (AF-1) and the C terminus (AF-2) which work synergistically to confer full HNF-4 activity. Here, we show that HNF-4 recruits the CREB-binding protein (CBP) coactivator on promoters of genes that contain functional HNF-4 sites. HNF-4 interacts with the N-terminal region of CBP (amino acids 1-771) and the C-terminal region of CBP (amino acids 1812-2441). The two activating functions of HNF-4, AF-1 and AF-2, interact with the N terminus and the N and C terminus of CBP, respectively. In addition, we show that in contrast to the other nuclear hormone receptors the interaction between HNF-4 and CBP is ligand-independent. Recruitment of CBP by HNF-4 results in an enhancement of the transcriptional activity of the latter. CBP does not activate gene expression in the absence of HNF-4, and dominant negative forms of HNF-4 prevent transcriptional activation by CBP, suggesting that the mere recruitment of CBP by HNF-4 is not sufficient for enhancement of gene expression. These findings demonstrate that CBP acts as a transcriptional coactivator for HNF-4 and provide new insights into the regulatory function of HNF-4.	Boston Univ, Sch Med, Dept Med, Ctr Adv Biomed Res,Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA	Boston University	Hadzopoulou-Cladaras, M (corresponding author), Boston Univ, Sch Med, Dept Med, Ctr Adv Biomed Res,Cardiovasc Inst,Sect Mol Genet, 715 Albany St, Boston, MA 02118 USA.	cladaras@bu.edu			NHLBI NIH HHS [HL56104] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056104] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Drewes T, 1996, MOL CELL BIOL, V16, P925; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Fraser JD, 1998, NUCLEIC ACIDS RES, V26, P2702, DOI 10.1093/nar/26.11.2702; Furuta H, 1997, DIABETES, V46, P1652, DOI 10.2337/diabetes.46.10.1652; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HATA S, 1995, BBA-GENE STRUCT EXPR, V1260, P55, DOI 10.1016/0167-4781(94)00177-5; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Holewa B, 1997, MOL CELL BIOL, V17, P687, DOI 10.1128/MCB.17.2.687; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jiang GQ, 1997, J BIOL CHEM, V272, P1218, DOI 10.1074/jbc.272.2.1218; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAVRENTIADOU SN, 1998, IN PRESS BIOCHEMISTR; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakhei H, 1998, NUCLEIC ACIDS RES, V26, P497, DOI 10.1093/nar/26.2.497; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yoshida E, 1998, GENE, V208, P307, DOI 10.1016/S0378-1119(98)00008-0; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	63	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9013	9021		10.1074/jbc.274.13.9013	http://dx.doi.org/10.1074/jbc.274.13.9013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085149	hybrid			2022-12-27	WOS:000079451600091
J	Frazier, WA; Gao, AG; Dimitry, J; Chung, J; Brown, EJ; Lindberg, FP; Linder, ME				Frazier, WA; Gao, AG; Dimitry, J; Chung, J; Brown, EJ; Lindberg, FP; Linder, ME			The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric G(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; LIGAND-BINDING; ALPHA(V)BETA(3); SPECIFICITY; EXPRESSION; MIGRATION; DOMAIN; ALPHA	Integrin-associated protein (IAP; CD47) is a thrombospondin receptor that forms a signaling complex with beta(3) integrins resulting in enhanced alpha(v)beta(3)-dependent cell spreading and chemotaxis and, in platelets, alpha(IIb)beta(3)-dependent spreading and aggregation. These actions of CD47 are all specifically abrogated by pertussis toxin treatment of cells. Here we report that CD47, its beta(3) integrin partner, and G(i) proteins form a stable, detergent-soluble complex that can be recovered by immunoprecipitation and affinity chromatography, G(i alpha) is released from this complex by treatment with GTP or AlF4. GTP and AlF4 also reduce the binding of CD47 to its agonist peptide (4N1K) derived from thrombospondin, indicating a direct association of CD47 with G(i). 4N1K peptide causes a rapid decrease in intraplatelet cyclic AMP levels, a G(i)-dependent event necessary for aggregation. Finally, 4N1K stimulates the binding of GTP gamma(35)S to membranes from cells expressing IAP and alpha(v)beta(3). This functional coupling of CD47 to heterotrimeric G proteins provides a mechanistic explanation for the biological effects of CD47 in a wide variety of systems.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Infect Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Frazier, WA (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	frazier@biochem.wustl.edu	Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL CANCER INSTITUTE [R01CA065872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054390, R01GM051466] Funding Source: NIH RePORTER; NCI NIH HHS [CA65872] Funding Source: Medline; NIGMS NIH HHS [GM54390, GM51466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J. C., 1995, THROMBOSPONDIN GENE; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KRAUSE JE, 1994, TACHYKININ RECEPTORS, P165; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MCLEISH KR, 1993, GTPASE BIOL, V2, P363; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PEROUTKA SJ, 1994, HDB RECEPTORS CHANNE; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Suchard SJ, 1996, J CELL PHYSIOL, V168, P217, DOI 10.1002/(SICI)1097-4652(199607)168:1<217::AID-JCP26>3.0.CO;2-2; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865	29	136	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8554	8560		10.1074/jbc.274.13.8554	http://dx.doi.org/10.1074/jbc.274.13.8554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085089	hybrid			2022-12-27	WOS:000079451600031
J	Her, S; Bell, RA; Bloom, AK; Siddall, BJ; Wong, DL				Her, S; Bell, RA; Bloom, AK; Siddall, BJ; Wong, DL			Phenylethanolamine N-methyltransferase gene expression - SP1 and MAZ potential for tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REGULATION; C-MYC; PROMOTER; ACTIVATION; EGR-1; MOUSE; ELEMENTS; KINASE	Phenylethanolamine N-methyltransferase (PNMT) promoter-luciferase reporter gene constructs (pGL3RP863, pGL3RP444, and pGL3RP392) transfected into COS1, RS1, PC12, NIH/3T3, or Neuro2A cells showed the highest basal luciferase activity in the Neuro2A cells. DNase I footprinting with Neuro2A cell nuclear extract identified protected PNMT promoter regions spanning the -168/-165 and -48/-45 base pair Sp1/Egr-1 binding sites. Gel mobility shift assays and transient transfection assays using site-directed mutant PNMT promoter-luciferase reporter gene constructs indicated that the elevated basal luciferase activity in the Neuro2A cells was mediated by Sp-1. Furthermore, activation of the PNMT promoter by Sp1 depends on both its binding affinity for its cognate target sequences and its intracellular concentrations. When Sp1 levels were increased through an expression plasmid, luciferase reporter gene expression rose well beyond basal wild-type levels, even with either Sp1 binding element mutated. Finally, another transcription factor expressed in the Neuro2A cells competes with Sp1 by interacting with DNA sequences 3' to the -48 base pair Sp1 site to prevent Sp1 binding and induction of the PNMT promoter. The DNA consensus sequence, Southwestern analysis, and gel mobility shift assays with antibodies identify MAZ as the competitive factor. These findings suggest that Sp1 may potentially contribute to the tissue-specific expression of the PNMT gene, with the competition between Sp1 and MAZ conferring additional tissue-specific control.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Stanford University	Wong, DL (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, MSLS Bldg,Rm P106, Stanford, CA 94305 USA.	ms.dlw@forsythe.stanford.edu						ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BATTER DK, 1988, J NEUROSCI RES, V19, P367, DOI 10.1002/jnr.490190313; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATIGNANIKENNED.G, 1992, P NATL ACAD SCI USA, V89, P11498; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EBERT SN, 1994, J BIOL CHEM, V269, P20885; Ebert SN, 1998, J NEUROCHEM, V70, P2286; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; EBERT SN, 1990, J VIROL, V64, P4059, DOI 10.1128/JVI.64.9.4059-4066.1990; EVINGER MJ, 1998, CATECHOLAMINES BRIDG, V42, P73; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANEDA N, 1988, J BIOL CHEM, V263, P7672; LI Y, 1993, J BIOL CHEM, V268, P3563; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; PYRE JJ, 1992, BIOCHEMISTRY-US, V31, P4102; ROSS ME, 1990, J NEUROSCI, V10, P520; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67	31	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8698	8707		10.1074/jbc.274.13.8698	http://dx.doi.org/10.1074/jbc.274.13.8698			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085109	hybrid			2022-12-27	WOS:000079451600051
J	Leahy, P; Crawford, DR; Grossman, G; Gronostajski, RM; Hanson, RW				Leahy, P; Crawford, DR; Grossman, G; Gronostajski, RM; Hanson, RW			CREB binding protein coordinates the function of multiple transcription factors including nuclear factor I to regulate phosphoenolpyruvate carboxykinase (GTP) gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE UNIT; MAMMARY-TUMOR VIRUS; DNA-BINDING; TRANSGENIC MICE; PROMOTER; ELEMENTS; IDENTIFICATION; EXPRESSION; RECEPTOR; REGION	Nuclear factor I (NFI) binds to a region of the phosphoenolpyruvate carboxykinase (GTP) (PEPCK) gene promoter adjacent to the cAMP regulatory element (CRE) and inhibits the induction of transcription from the gene promoter caused by the catalytic subunit of protein kinase A. In vivo footprinting studies demonstrated that both the CRE and the NFI-binding site are occupied by transcription factors, regardless of the presence of factors that stimulate (dibutyryl cAMP or dexamethasone) or inhibit (insulin) transcription from the PEPCK gene promoter. The NFI effects on transcription from the PEPCK gene promoter were observed even in the absence of the NFI binding site, suggesting the possibility of other weaker binding sites on the promoter or an interaction of NFI with a transcriptional co-activator. A mammalian two-hybrid system was used to demonstrate direct interaction between the transactivation domain of NFI-C and the CREB binding domain of the CREB-binding protein (CBP), Overexpression of a gene fragment encoding the CREB binding domain of CBP stimulates transcription from the PEPCK gene promoter. The inhibitory effect of NFI on transcription of the PEPCK gene induced by the catalytic subunit of protein kinase A appears to be the result of an interaction between NFI and the CREB-binding protein in which NFI competes with CREB for binding to the CREB-binding site on CBP, In contrast, glucocorticoids and thyroid hormone use the steroid hormone receptor binding domain of CBP to stimulate transcription from the PEPCK gene promoter. NFI-A combines with dexamethasone or thyroid hormone in an additive manner to stimulate PEPCK gene transcription. We conclude that CBP coordinates the action of the multiple factors known to control transcription of the PEPCK gene.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Cleveland Clinic Foundation	Leahy, P (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.			Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34908] Funding Source: Medline; NIDDK NIH HHS [DK-25541, DK-07319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V1, P101; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Becker MM, 1993, FOOTPRINTING NUCL AC, P129; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHEN H, 1997, CELL, V90, P669; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V181, P367, DOI 10.1016/S0006-291X(05)81428-7; Crawford DR, 1998, J BIOL CHEM, V273, P13387, DOI 10.1074/jbc.273.22.13387; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; CUIF MH, 1993, J BIOL CHEM, V268, P13769; FABER S, 1993, J BIOL CHEM, V268, P24976; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Klemm DJ, 1996, J BIOL CHEM, V271, P8082, DOI 10.1074/jbc.271.14.8082; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; LEAHY P, 1995, BIOTECHNIQUES, V19, P894; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MANDEL HG, 1995, ANAL BIOCHEM, V230, P191, DOI 10.1006/abio.1995.1460; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; ZAR JH, 1974, BIOSTAT ANAL, P101	59	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8813	8822		10.1074/jbc.274.13.8813	http://dx.doi.org/10.1074/jbc.274.13.8813			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085123	hybrid			2022-12-27	WOS:000079451600065
J	Farinas, J; Verkman, AS				Farinas, J; Verkman, AS			Receptor-mediated targeting of fluorescent probes in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; PH; PROTEIN; TRANSPORT	A strategy was developed to label specified sites in living cells with a wide selection of fluorescent or other probes and applied to study pH regulation in Golgis. cDNA transfection was used to target a single-chain antibody to a specified site such as an organelle lumen. The targeted antibody functioned as a high affinity receptor to trap cell-permeable hapten-fluorophore conjugates. Synthesized conjugates of a hapten (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, phOx) and fluorescent probes (Bodipy Fl, tetramethylrhodamine, fluorescein) were bound with high affinity (similar to 5 nM) and specific localization to the single-chain antibody expressed in the endoplasmic reticulum, Golgi, and plasma membrane of living Chinese hamster ovary cells. Using the pH-sensitive phOx-fluorescein conjugate and ratio imaging microscopy, pH was measured in the lumen of Golgi (pH 6.25 +/- 0.06). Measurements of pH-dependent vacuolar H+/ATPase pump activity and H+ leak in Golgi provided direct evidence that resting Golgi pH is determined by balanced leak-pump kinetics rather than the inability of the H+/ATPase to pump against an electrochemical gradient. Like expression of the green fluorescent protein, the receptor-mediated fluorophore targeting approach permits specific intracellular fluorescence labeling. A significant advantage of the new approach is the ability to target chemical probes with custom-designed spectral and indicator properties.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Farinas, J (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK043840, R37DK035124] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI K, 1993, J BIOL CHEM, V268, P5649; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSOMER VA, 1997, J BIOL CHEM, V272, P13270; Rybak SL, 1997, BIOPHYS J, V73, P674, DOI 10.1016/S0006-3495(97)78102-5; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TSIEN RY, 1992, AM J PHYSIOL, V263, pC723, DOI 10.1152/ajpcell.1992.263.4.C723; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429	25	85	100	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7603	7606		10.1074/jbc.274.12.7603	http://dx.doi.org/10.1074/jbc.274.12.7603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075643	hybrid			2022-12-27	WOS:000079268100002
J	Nagamatsu, S; Watanabe, T; Nakamichi, Y; Yamamura, C; Tsuzuki, K; Matsushima, S				Nagamatsu, S; Watanabe, T; Nakamichi, Y; Yamamura, C; Tsuzuki, K; Matsushima, S			alpha-soluble N-ethylmaleimide-sensitive factor attachment protein is expressed in pancreatic beta cells and functions in insulin but not gamma-aminobutyric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; FUSION PROTEIN; RECOMBINANT ADENOVIRUS; REGULATED EXOCYTOSIS; VESICULAR TRANSPORT; ENDOCRINE-CELLS; ATPASE ACTIVITY; SNAP RECEPTORS; IN-VITRO; T-SNARE	The function of soluble N-ethylmaleimide-sensitive attachment protein-alpha (alpha-SNAP) in exocytosis still remains obscure. This study was conducted to determine the physiological role of alpha-SNAP in the secretion of insulin and gamma-aminobutryric acid (GABA) from pancreatic beta cells. Reverse transcriptase-polymerase chain reaction analysis of total RNA isolated from rat islets disclosed alpha-SNAP, but not beta-SNAP, mRNA expression, and an immunofluorescence study of rat pancreas showed that alpha-SNAP was present predominantly in the cytoplasm of the islets of Langerhans, alpha-SNAP overexpression in rat islets enhanced insulin release relative to the control levels. An in, vitro binding study showed that both wildtype alpha-SNAP and C-terminal-deleted alpha-SNAP mutant (1-285) can bind to syntaxin 1A. alpha-SNAP mutant (1-285) was overexpressed to evaluate its activity as dominant-negative effector on insulin release. Overexpression of alpha-SNAP mutant (1-285) in rat islets and MING cells decreased glucose-stimulated insulin release to about 50% of the control levels. Suppression of endogeneous alpha-SNAP in MIN6 cells by treatment with an antisense phosphorothioate oligonucleotide resulted in inhibition of insulin release. In order to examine if alpha-SNAP functions in exocytosis from synaptic-like microvesicles in pancreatic beta cells, the functional role of alpha-SNAP in GABA release from MIN6 cells was studied. The data showed no effect of alpha-SNAP mutant (1-285) overexpression on GABA release. We conclude that 1) alpha-SNAP plays a crucial role in insulin exocytosis via large dense core vesicles, but not GABA released via synaptic-like microvesicles, in pancreatic beta cells; and 2) the interaction of alpha-SNAP and syntaxin 1A may play an important role in the insulin exocytotic process.	Kyorin Univ, Sch Med, Dept Biochem, Mitaka, Tokyo 1818611, Japan; Kyorin Univ, Sch Med, Dept Clin Pathol, Mitaka, Tokyo 1818611, Japan	Kyorin University; Kyorin University	Nagamatsu, S (corresponding author), Kyorin Univ, Sch Med, Dept Biochem, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	shinya@kyorin-u.ac.jp						Barnard RJO, 1996, MOL BIOL CELL, V7, P693, DOI 10.1091/mbc.7.5.693; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BETY WM, 1992, SCIENCE, V255, P200; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gaskins HR, 1995, J BIOL CHEM, V270, P30286, DOI 10.1074/jbc.270.51.30286; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kayo T, 1996, J BIOL CHEM, V271, P10731, DOI 10.1074/jbc.271.18.10731; KEHR J, 1988, J NEUROCHEM, V51, P1308, DOI 10.1111/j.1471-4159.1988.tb03101.x; KiralyBorri CE, 1996, BIOCHEM J, V314, P199, DOI 10.1042/bj3140199; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LING ZD, 1994, ENDOCRINOLOGY, V134, P2614, DOI 10.1210/en.134.6.2614; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nagamatsu S, 1997, DIABETOLOGIA, V40, P1396, DOI 10.1007/s001250050841; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SEINO S, 1996, DIABETES REV, V4, P177; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sudlow AW, 1996, FEBS LETT, V393, P185, DOI 10.1016/0014-5793(96)00880-0; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	55	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8053	8060		10.1074/jbc.274.12.8053	http://dx.doi.org/10.1074/jbc.274.12.8053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075705	hybrid			2022-12-27	WOS:000079268100064
J	Halford, MM; Oates, AC; Hibbs, ML; Wilks, AF; Stacker, SA				Halford, MM; Oates, AC; Hibbs, ML; Wilks, AF; Stacker, SA			Genomic structure and expression of the mouse growth factor receptor related to tyrosine kinases (Ryk)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INSULIN-RECEPTOR; CPG ISLANDS; SEQUENCE-ANALYSIS; GENE STRUCTURE; FACTOR-I; NUCLEOTIDE-SEQUENCE; CONSERVED FEATURES; MOLECULAR-CLONING; CATALYTIC DOMAIN; C-MET	We report the genomic organization of the mouse orphan receptor related to tyrosine kinases (Ryk), a structurally unclassified member of the growth factor receptor family. The mouse RYK protein is encoded by 15 exons distributed over a minimum of 81 kilobases, Genomic DNA sequences encoding a variant protein tyrosine kinase ATP-binding motif characteristic of RYK are unexpectedly found in two separate exons, A feature of the gene is an unmethylated CpG island spanning exon 1 and flanking sequences, including a TATA box-containing putative promoter and single transcription start site. Immunohistochemical examination of RYK protein distribution revealed widespread but developmentally regulated expression, which was spatially restricted within particular adult organs. Quantitative reduction of Southern blotting stringency for the detection of Ryk-related sequences provided evidence for a retroprocessed mouse pseudogene and a more distantly related gene paralogue. Extensive cross-species reactivity of a mouse Ryk kinase subdomain probe and the cloning of a Ryk orthologue from Caenorhabditis elegans demonstrate that Ryk and its relatives encode widely conserved members of a novel receptor tyrosine kinase subfamily.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	Steven.Stacker@ludwig.edu.au	Wilks, Andrew F/R-5542-2019; Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273; Wilks, Andrew F/0000-0002-8554-2399				ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andre C, 1997, GENOMICS, V39, P216, DOI 10.1006/geno.1996.4482; ANDRE C, 1992, ONCOGENE, V7, P685; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BICKMORE WA, 1992, METHOD ENZYMOL, V216, P224; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Blumenthal T, 1996, CURR OPIN GENET DEV, V6, P692, DOI 10.1016/S0959-437X(96)80022-0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Burmeister M, 1996, TRENDS GENET, V12, P389, DOI 10.1016/S0168-9525(96)90092-X; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOUGH NM, 1995, MAMM GENOME, V6, P255, DOI 10.1007/BF00352411; Greco A, 1996, ONCOGENE, V13, P2463; Gurniak CB, 1996, ONCOGENE, V13, P777; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; IMBERT A, 1994, CYTOGENET CELL GENET, V67, P175, DOI 10.1159/000133817; KAWASAKI K, 1988, JPN J CANCER RES, V79, P1174, DOI 10.1111/j.1349-7006.1988.tb01542.x; KELMAN Z, 1993, ONCOGENE, V8, P37; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LARSSONBLOMBERG L, 1994, FEBS LETT, V348, P119, DOI 10.1016/0014-5793(94)00577-X; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lin JC, 1998, ONCOGENE, V16, P833, DOI 10.1038/sj.onc.1201599; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; MOSSIE K, 1995, ONCOGENE, V11, P2179; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STACKER SA, 1991, J IMMUNOL, V146, P648; STACKER SA, 1993, ONCOGENE, V8, P1347; STACKER SA, 1985, J NATL CANCER I, V75, P801, DOI 10.1093/jnci/75.5.801; SZABO P, 1994, DEVELOPMENT, V120, P1651; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YEE K, 1993, BLOOD, V82, P1335	74	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7379	7390		10.1074/jbc.274.11.7379	http://dx.doi.org/10.1074/jbc.274.11.7379			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066802	hybrid			2022-12-27	WOS:000079078400074
J	Harada, H; Tagashira, S; Fujiwara, M; Ogawa, S; Katsumata, T; Yamaguchi, A; Komori, T; Nakatsuka, M				Harada, H; Tagashira, S; Fujiwara, M; Ogawa, S; Katsumata, T; Yamaguchi, A; Komori, T; Nakatsuka, M			Cbfa1 isoforms exert functional differences in osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOCALCIN GENE-TRANSCRIPTION; ALKALINE-PHOSPHATASE GENE; CLEIDOCRANIAL DYSPLASIA; BINDING PROTEIN; RUNT DOMAIN; ELEMENTS CONTROL; MESSENGER-RNA; DNA-BINDING; EXPRESSION	Cbfa1 is an essential transcription factor for osteoblast differentiation and bone formation. We investigated functional differences among three isoforms of Cbfa1: Type I (originally reported as Pebp2 alpha A by Ogawa et al. (Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., and Ito, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6859-6863), Type II (originally reported as til-l by Stewart ef al. (Stewart, M., Terry, A, Hu, M., O'Hara, M., Blyth, K., Baxter, E., Cameron, E., Onions, D. E., and Neil, J. C. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 8646-8651), and Type III (originally reported as Osf2/Cbfa1 by Ducy ef al. (Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, C. (1997) Cell 89, 747-754). A reverse transcriptase-polymerase chain reaction analysis demonstrated that these isoforms were expressed in adult mouse bones. The transient transfection of Type I or Type II Cbfa1 in a mouse fibroblastic cell line, C3H10T1/2, induced the expression of alkaline phosphatase (ALP) activity. This induction was synergistically enhanced by the co-introduction of Xenopus BMP-4 cDNA. In contrast, the transient transfection of Type III cDNA induced no ALP activity. In C3H10T1/2 cells stably transfected with each isoform of Cbfa1, the gene expression of ALP was also strongly induced in cells transfected with Type I and Type II Cbfa1 but not in cells with Type III Cbfa1. Osteocalcin, osteopontin,and type I collagen gene expressions were induced or up-regulated in all of the cells stably transfected with each isoform of Cbfa1, and Type II transfected cells exhibited the highest expression level of osteocalcin gene. A luciferase reporter gene assay using a 6XOSE2-SV40 promoter (6 tandem binding elements for Cbfa1 ligated in front of the SV40 promoter sequence), a mouse osteocalcin promoter, and a mouse osteopontin promoter revealed the differences in the transcriptional induction of target genes by each Cbfa1 isoform with or without its beta-subunit. These results suggest that all three of the Cbfa1 isoforms used in the present study are involved in the stimulatory action of osteoblast differentiation, but they exert different functions in the process of osteoblast differentiation.	Sumitomo Pharmaceut Res Ctr, Konohana Ku, Osaka 5540022, Japan; Nagasaki Univ, Sch Dent, Dept Oral Pathol, Nagasaki 8528588, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 5650871, Japan	Nagasaki University; Osaka University	Nakatsuka, M (corresponding author), Sumitomo Pharmaceut Res Ctr, Konohana Ku, 3-1-98 Kasugade-naka, Osaka 5540022, Japan.							Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASLAM F, 1995, MOL ENDOCRINOL, V9, P679, DOI 10.1210/me.9.6.679; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; EscalanteAlcalde D, 1996, MECH DEVELOP, V57, P21, DOI 10.1016/0925-4773(96)00524-2; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Harada H, 1998, ENDOCRINOLOGY, V139, P204, DOI 10.1210/en.139.1.204; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kobayashi T, 1998, BIOCHEM MOL BIOL INT, V44, P683; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169-6009(08)80056-6; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; TERAO M, 1987, P NATL ACAD SCI USA, V84, P7051, DOI 10.1073/pnas.84.20.7051; TERAO M, 1990, BIOCHEM J, V268, P641, DOI 10.1042/bj2680641; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; [No title captured]	50	393	416	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6972	6978		10.1074/jbc.274.11.6972	http://dx.doi.org/10.1074/jbc.274.11.6972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066751	hybrid			2022-12-27	WOS:000079078400023
J	Hu, MCT; Wang, YP; Mikhail, A; Qiu, WR; Tan, TH				Hu, MCT; Wang, YP; Mikhail, A; Qiu, WR; Tan, TH			Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; MAP KINASE; C-JUN; INSITU HYBRIDIZATION; MAMMALIAN-CELLS; GENE-EXPRESSION; PHOSPHORYLATION; CASCADE; DOMAIN	The p38 mitogen-activated protein kinases (MAPK) play a crucial role in stress and inflammatory responses and are also involved in activation of the human immunodeficiency virus gene expression. We have isolated the murine cDNA clones encoding p38-delta MAPK, and we have localized the p38-delta gene to mouse chromosome 17A3-B and human chromosome 6p21.3. By using Northern and in situ hybridization, we have examined the expression of p38-delta in the mouse adult tissues and embryos, p38-delta was expressed primarily in the lung, testis, kidney, and gut epithelium in the adult tissues. Although p38-delta was expressed predominantly in the developing gut and the septum transversum in the mouse embryo at 9.5 days, its expression began to be expanded to many specific tissues in the 12.5-day embryo. At 15.5 days, p38-delta was expressed virtually in most developing epithelia in embryos, suggesting that p38-delta is a developmentally regulated MAPK. Interestingly, p38-delta and p38-alpha were similar serine/threonine kinases but differed in substrate specificity. Overall, p38-delta resembles p38-gamma, whereas p38-beta resembles p38-alpha. Moreover, p38-delta is activated by environmental stress, extracellular stimulants, and MAPK kinase-3, -4, -6, and -7, suggesting that p38-delta is a unique stress-responsive protein kinase.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Phylogeny Inc, Columbus, OH 43212 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Amgen; Baylor College of Medicine	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA.	Mickey_Hu_99@yahoo.com	Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170				BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCDONNELL PC, 1995, GENOMICS, V29, P301, DOI 10.1006/geno.1995.1252; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	56	86	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7095	7102		10.1074/jbc.274.11.7095	http://dx.doi.org/10.1074/jbc.274.11.7095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066767	hybrid			2022-12-27	WOS:000079078400039
J	Yamazaki, M; Gong, Z; Fukuchi-Mizutani, M; Fukui, Y; Tanaka, Y; Kusumi, T; Saito, K				Yamazaki, M; Gong, Z; Fukuchi-Mizutani, M; Fukui, Y; Tanaka, Y; Kusumi, T; Saito, K			Molecular cloning and biochemical characterization of a novel anthocyanin 5-O-glucosyltransferase by mRNA differential display for plant forms regarding anthocyanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETUNIA-HYBRIDA; GENETIC-CONTROL; UDP-GLUCOSE; SILENE-DIOICA; FLOWERS; LOCUS; IDENTIFICATION; BIOSYNTHESIS; PROTEIN; PETALS	UDP-glucose: anthocyanin 5-O-glucosyltransferase (5-GT) is responsible for the modification of anthocyanins to more stable molecules in complexes for co-pigmentation, supposedly resulting in a purple hue. The cDNA encoding 5-GT was isolated by a differential display applied to two different forms of anthocyanin production in Perilla frutescens var. crispa, Differential display was carried out for mRNA from the leaves of reddish-purple and green forms of P. frutescens, resulting in the isolation of five cDNA clones predominantly expressed in the red form. The cDNA encoded a polypeptide of 460 amino acids, exhibiting a low homology with the sequences of several glucosyltransferases including UDP-glucose: anthocyanidin 3-O-glucosyltransferase. By using this cDNA as the probe, we also isolated a homologous cDNA clone from a petal cDNA library of Verbena hybrida, To identify the biochemical function of the encoded proteins, these cDNAs were expressed in Saccharomyces cerevisiae cells. The recombinant proteins in the yeast extracts catalyzed the conversion of anthocyanidin 3-O-glucosides into the corresponding anthocyanidin 3,5-di-O-glucosides using UDP-glucose as a cofactor, indicating the identity of the cDNAs encoding 5-GT, Several biochemical properties (optimum pH, K-m values, and sensitivity to inhibitors) were similar to those reported previously for 5-GTs, Southern blot analysis indicated the presence of two copies of 5-GT genes in the genome of both red and green forms of P, frutescens. The mRNA accumulation of the 5-GT gene was detected in the leaves of the red form but not in those of the green form and was induced by illumination of light, as observed for other structural genes for anthocyanin biosynthesis in P, frutescens.	Chiba Univ, Fac Pharmaceut Sci, Res Ctr Med Resources, Lab Mol Biol & Biotechnol,Inage Ku, Chiba 2638522, Japan; Suntory Ltd, Inst Fundamental Res, Osaka 6188503, Japan	Chiba University; Suntory Holdings Ltd	Saito, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Res Ctr Med Resources, Lab Mol Biol & Biotechnol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.		Saito, Kazuki/D-2670-2009; Yamazaki, Mami/A-9050-2010; Gong, Zhizhong/AAS-4796-2021	Saito, Kazuki/0000-0001-6310-5342; Yamazaki, Mami/0000-0001-6157-5287; 				ASHIKARI T, 1989, APPL MICROBIOL BIOT, V32, P129, DOI 10.1007/BF00165875; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGLIERA F, 1994, PLANT J, V5, P81, DOI 10.1046/j.1365-313X.1994.5010081.x; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; FEDOROFF NV, 1984, P NATL ACAD SCI-BIOL, V81, P3825, DOI 10.1073/pnas.81.12.3825; FORKMANN G, 1993, GENETICS FLAVONOIDS, P537; Gong ZZ, 1997, PLANT MOL BIOL, V35, P915, DOI 10.1023/A:1005959203396; Heller W, 1993, BIOSYNTHESIS FLAVONO, V1986, P499; HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071; Horvath DM, 1996, PLANT MOL BIOL, V31, P1061, DOI 10.1007/BF00040724; Imanishi S, 1998, PLANT CELL PHYSIOL, V39, P202, DOI 10.1093/oxfordjournals.pcp.a029358; Ito M., 1996, J PHYTOGEOGR TAXON, V44, P43; JONSSON LMV, 1984, PLANTA, V160, P341, DOI 10.1007/BF00393415; KAMSTEEG J, 1980, Z PFLANZENPHYSIOL, V96, P87, DOI 10.1016/S0044-328X(80)80104-8; KAMSTEEG J, 1978, BIOCHEM GENET, V16, P1059, DOI 10.1007/BF00484526; KONDO T, 1989, AGR BIOL CHEM TOKYO, V53, P797; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTIN C, 1992, CONTROL FLOWER COLOR, P219; Matsune T., 1997, ENGEIGAKU ZASSHI S2, V66, P92; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SEYFFERT W, 1982, BIOL ZBL, V101, P465; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; TEUSCH M, 1986, PLANTA, V168, P586, DOI 10.1007/BF00392280; TOKI K, 1995, PHYTOCHEMISTRY, V38, P515, DOI 10.1016/0031-9422(94)00698-S; YOSHIDA K, 1997, PERILLA GENUS PERILL, P149	29	110	142	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7405	7411		10.1074/jbc.274.11.7405	http://dx.doi.org/10.1074/jbc.274.11.7405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066805	hybrid			2022-12-27	WOS:000079078400077
J	Svensson, M; Sabharwal, H; Hakansson, A; Mossberg, AK; Lipniunas, P; Leffler, H; Svanborg, C; Linse, S				Svensson, M; Sabharwal, H; Hakansson, A; Mossberg, AK; Lipniunas, P; Leffler, H; Svanborg, C; Linse, S			Molecular characterization of alpha-lactalbumin folding variants that induce apoptosis in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRION PROTEIN; MOLTEN-GLOBULE STATE; HUMAN-MILK; CONFORMATIONAL TRANSITIONS; SCRAPIE; BINDING; INTERMEDIATE; MEMBRANES; ZINC	This study characterized a protein complex in human milk that induces apoptosis in tumor cells but spares healthy cells. The active fraction was purified from casein by anion exchange chromatography. Unlike other casein components the active fraction was retained by the ion exchanger and eluted after a high salt gradient. The active fraction showed N-terminal amino acid sequence identity with human milk alpha-lactalbumin and mass spectrometry ruled out post-translational modifications. Size exclusion chromatography resolved monomers and oligomers of alpha-lactalbumin that were characterized using UV absorbance, fluorescence, and circular dichroism spectroscopy. The high molecular weight oligomers were kinetically stable against dissociation into monomers and were found to have an essentially retained secondary structure but a less well organized tertiary structure. Comparison with native monomeric and molten globule alpha-lactalbumin showed that the active fraction contains oligomers of alpha-lactalbumin that have undergone a conformational switch toward a molten globule-like state. Oligomerization appears to conserve alpha-lactalbumin in a state with molten globule-like properties at physiological conditions. The results suggest differences in biological properties between folding variants of alpha-lactalbumin.	Univ Lund, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden; Rockefeller Univ, Dept Clin Microbiol & Immunol, New York, NY 10021 USA; Univ Lund, Dept Physiol Chem 2, S-22362 Lund, Sweden; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Lund University; Rockefeller University; Lund University; University of California System; University of California San Francisco	Svensson, M (corresponding author), Univ Lund, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, Solvegatan 23, S-22362 Lund, Sweden.		Hakansson, Anders/H-8190-2014; Leffler, Hakon/A-2416-2019; Hakansson, Anders P/AAX-1225-2020	Hakansson, Anders/0000-0002-2834-6009; Hakansson, Anders P/0000-0002-2834-6009; Leffler, Hakon/0000-0003-4482-8945; Linse, Sara/0000-0001-9629-7109				ACHARYA KR, 1991, J MOL BIOL, V221, P571; ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559; Aramini JM, 1996, BBA-PROTEIN STRUCT M, V1293, P72, DOI 10.1016/0167-4838(95)00223-5; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Brew K., 1992, Advanced dairy chemistry-1: Proteins., P191; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; DAVIS MK, 1988, LANCET, V2, P365; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; HAKANSSON A, 1999, IN PRESS EXP CELL RE, V246; HEINE WE, 1991, J NUTR, V121, P277, DOI 10.1093/jn/121.3.277; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; KUWAJIMA K, 1985, PROTEIN-STRUCT FUNCT, V6, P87; LONNERDAL B, 1985, AM J CLIN NUTR, V41, P113; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P6945, DOI 10.1021/bi00345a029; PFEIL W, 1987, BIOCHIM BIOPHYS ACTA, V911, P114, DOI 10.1016/0167-4838(87)90277-9; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; REDHEAD K, 1990, FEMS MICROBIOL LETT, V70, P269, DOI 10.1016/S0378-1097(05)80006-0; REN JS, 1993, J BIOL CHEM, V268, P19292; SAERKAR NH, 1973, CANCER RES, V33, P626; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHMIDT DV, 1972, BIOCHIM BIOPHYS ACTA, V263, P714, DOI 10.1016/0005-2795(72)90055-4; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMISOTNOV GV, 1987, FEBS LETT, V244, P9; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Svanborg C, 1991, Adv Exp Med Biol, V310, P167; Wu LC, 1996, BIOCHEMISTRY-US, V35, P859, DOI 10.1021/bi951408p; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281	38	180	191	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6388	6396		10.1074/jbc.274.10.6388	http://dx.doi.org/10.1074/jbc.274.10.6388			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037730	hybrid			2022-12-27	WOS:000078902800052
J	Lambert, H; Charette, SJ; Bernier, AF; Guimond, A; Landry, J				Lambert, H; Charette, SJ; Bernier, AF; Guimond, A; Landry, J			HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-A-CRYSTALLIN; P38 MAP KINASE; B-CRYSTALLIN; CELL-DEATH; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; ACTIN POLYMERIZATION; H-1-NMR SPECTROSCOPY; QUATERNARY STRUCTURE	Distinct biochemical activities have been reported for small and large molecular complexes of heat shock protein 27 (HSP27), respectively. Using glycerol gradient ultracentrifugation and chemical cross-linking, we show here that Chinese hamster HSP27 is expressed in cells as homotypic multimers ranging from dimers up to 700-kDa oligomers. Treatments with arsenite, which induces phosphorylation on Ser(15) and Ser(90) provoked a major change in the size distribution of the complexes that shifted from oligomers to dimers, Ser(90) phosphorylation was sufficient and necessary for causing this change in structure. Dimer formation was severely inhibited by replacing Ser(90) with Ala(90) but not by replacing Ser(15) with Ala(15). Using the yeast two-hybrid system, two domains were identified that were responsible for HSP27 intermolecular interactions. One domain was insensitive to phosphorylation and corresponded to the C-terminal alpha-crystallin domain. The other domain was sensitive to serine 90 phosphorylation and was located in the N-terminal region of the protein. Fusion of this N-terminal domain to firefly luciferase conferred luciferase with the capacity to form multimers that dissociated into monomers upon phosphorylation. A deletion within this domain of residues Arg(5)-Tyr(23), which contains a WDPF motif found in most proteins of the small heat shock protein family, yielded a protein that forms only phosphorylation-insensitive dimers. We propose that HSP27 forms stable dimers through the alpha-crystallin domain. These dimers further multimerize through intermolecular interactions mediated by the phosphorylation-sensitive N-terminal domain.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Landry, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 11 Cote du Palais, Quebec City, PQ G1R 2J6, Canada.		Charette, Steve/GYJ-3058-2022					ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Beresford PJ, 1998, J IMMUNOL, V161, P161; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1998, MOL CHAPERONES LIFE, P533; Farnsworth PN, 1998, INT J BIOL MACROMOL, V22, P175, DOI 10.1016/S0141-8130(98)00015-4; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Garrido C, 1997, CANCER RES, V57, P2661; Guay J, 1997, J CELL SCI, V110, P357; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Harrison CJ, 1997, STRUCTURE, V5, P1261, DOI 10.1016/S0969-2126(97)00277-3; HICKEY E, 1986, GENE, V43, P147, DOI 10.1016/0378-1119(86)90018-1; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; LANDRY J, 1992, J BIOL CHEM, V267, P794; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; vandenIjssel PRLA, 1996, OPHTHALMIC RES, V28, P39, DOI 10.1159/000267941; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	68	275	285	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9378	9385		10.1074/jbc.274.14.9378	http://dx.doi.org/10.1074/jbc.274.14.9378			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092617	hybrid			2022-12-27	WOS:000079451800036
J	Motoike, HK; Bodi, I; Nakayama, H; Schwartz, A; Varadi, G				Motoike, HK; Bodi, I; Nakayama, H; Schwartz, A; Varadi, G			A region in IVS5 of the human cardiac L-type calcium channel is required for the use-dependent block by phenylalkylamines and benzothiazepines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MOLECULAR DETERMINANTS; CA2+ CHANNEL; ALPHA(1) SUBUNIT; 1,4-DIHYDROPYRIDINE SENSITIVITY; SODIUM-CHANNELS; DIHYDROPYRIDINE BINDING; RECEPTOR-SITE; INACTIVATION; SEGMENT	Mutations in motif IVS5 and IVS6 of the human cardiac calcium channel were made using homologous residues from the rat brain sodium channel 2a, [H-3]PN200-110 and allosteric binding assays revealed that the dihydropyridine and benzothiazepine receptor sites maintained normal coupling in the chimeric mutant channels. Whole cell voltage clamp recording from Xenopus oocytes showed a dramatically slowed inactivation and a complete loss of use-dependent block for mutations in the cytoplasmic connecting link to IVS5 (HHT-5371) and in IVS5 transmembrane segment (HHT-5411) with both diltiazem and verapamil, However, the use-dependent block by isradipine was retained by these two mutants. For mutants HHT-5411 and HHT-5371, the residual current appeared associated with a loss of voltage dependence in the rate of inactivation indicating a destabilization of the inactivated state. Furthermore, both HHT-5371 and -5411 recovered from inactivation significantly faster after drug block than that of the wild type channel. Our data demonstrate that accelerated recovery of HHT-5371 and HHT-5411 decreased accumulation of these channels in inactivation during pulse trains and suggest a close link between inactivation gating of the channel and use-dependent block by phenylalkylamines and benzothiazepines and provide evidence of a role for the transmembrane and cytoplasmic regions of IVS5 in the use-dependent block by diltiazem and verapamil.	Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Kumamoto Univ, Fac Pharmaceut Sci, Kumamoto 862, Japan	University of Cincinnati; Kumamoto University	Varadi, G (corresponding author), Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, 231 Bethesda Ave,POB 670828, Cincinnati, OH 45267 USA.	varadig@email.uc.edu			NHLBI NIH HHS [5R37-HL43231, P01-HL22619, T32-HL07382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, T32HL007382, R37HL043231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cai DM, 1997, MOL PHARMACOL, V51, P872, DOI 10.1124/mol.51.5.872; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; Kraus RL, 1998, J BIOL CHEM, V273, P27205, DOI 10.1074/jbc.273.42.27205; Mikala G, 1998, MOL CELL BIOCHEM, V185, P95, DOI 10.1023/A:1006878106672; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; MIYAZAKI J, 1989, GENE, V79, P269; Mori Y, 1996, JPN J PHARMACOL, V72, P83, DOI 10.1254/jjp.72.83; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1994, J BIOL CHEM, V269, P1635; YATANI A, 1988, AM J PHYSIOL, V254, pH140, DOI 10.1152/ajpheart.1988.254.1.H140; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	40	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9409	9420		10.1074/jbc.274.14.9409	http://dx.doi.org/10.1074/jbc.274.14.9409			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092621	hybrid			2022-12-27	WOS:000079451800040
J	Hoenderop, JGJ; van der Kemp, AWCM; Hartog, A; van de Graaf, SFJ; van Os, CH; Willems, PHGM; Bindels, RJM				Hoenderop, JGJ; van der Kemp, AWCM; Hartog, A; van de Graaf, SFJ; van Os, CH; Willems, PHGM; Bindels, RJM			Molecular identification of the apical Ca2+ channel in 1,25-dihydroxyvitamin D-3-responsive epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CALCIUM-TRANSPORT; RECEPTOR; GENE; MUTATIONS; PROTEINS; RICKETS; KIDNEY; SODIUM; CELLS	In mammals, the extracellular calcium concentration is maintained within a narrow range despite large variations in daily dietary input and body demand. The small intestine and kidney constitute the influx pathways into the extracellular Ca2+ pool and, therefore, play a primary role in Ca2+ homeostasis, We identified an apical Ca2+ influx channel, which is expressed in proximal small intestine, the distal part of the nephron and placenta. This novel epithelial Ca2+ channel (ECaC) of 730 amino acids contains six putative membrane-spanning domains with an additional hydrophobic stretch predicted to be the pore region. ECaC resembles the recently cloned capsaicin receptor and the transient receptor potential-related ion channels with respect to its predicted topology but shares less than 30% sequence homology with these channels. In kidney, ECaC is abundantly present in the apical membrane of Ca2+ transporting cells and colocalizes with 1,25-dihydroxyvitamin D-3-dependent calbindin-D-28K. ECaC expression in Xenopus oocytes confers Ca2+ influx with properties identical to those observed in distal renal cells. Thus, ECaC has the expected properties for being the gatekeeper of 1,25-dihydroxyvitamin D-3-dependent active transepithelial Ca2+ transport.	Catholic Univ Nijmegen, Dept Cell Physiol, Inst Cellular Signaling, NL-6500 HB Nijmegen, Netherlands; Catholic Univ Nijmegen, Dept Biochem, Inst Cellular Signaling, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Bindels, RJM (corresponding author), Catholic Univ Nijmegen, Dept Cell Physiol, Inst Cellular Signaling, POB 9101, NL-6500 HB Nijmegen, Netherlands.	reneb@sci.kun.nl	Willems, P.H.G.M./L-4759-2015; Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013	Willems, P.H.G.M./0000-0002-0915-1599; Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; van de Graaf, Stan/0000-0003-4238-4359				BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; BINDELS RJM, 1991, J AM SOC NEPHROL, V2, P1122; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Colbert HA, 1997, J NEUROSCI, V17, P8259; Favus MJ, 1996, KIDNEY, V2, P1893; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; GROSS M, 1990, AM J PHYSIOL, V259, pF195, DOI 10.1152/ajprenal.1990.259.2.F195; HAGIWARA S, 1982, J PHYSIOL-LONDON, V331, P231, DOI 10.1113/jphysiol.1982.sp014371; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; POLLAK MR, 1993, CELL, V75, P1237; Raber G, 1997, CELL CALCIUM, V22, P157, DOI 10.1016/S0143-4160(97)90009-9; SUKI WN, 1996, KIDNEY, V1, P472; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; VANOS CH, 1987, BIOCHIM BIOPHYS ACTA, V906, P195, DOI 10.1016/0304-4157(87)90012-8; WASSERMAN RH, 1982, CALCIUM CELL FUNCTIO, V2, P175; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	22	446	478	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8375	8378		10.1074/jbc.274.13.8375	http://dx.doi.org/10.1074/jbc.274.13.8375			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085067	hybrid, Green Published			2022-12-27	WOS:000079451600009
J	Otto, JC; Kim, E; Young, SG; Casey, PJ				Otto, JC; Kim, E; Young, SG; Casey, PJ			Cloning and characterization of a mammalian prenyl protein-specific protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-FACTOR; PARTIAL-PURIFICATION; IN-VITRO; SACCHAROMYCES-CEREVISIAE; ISOPRENYLATED PEPTIDES; BOVINE BRAIN; RAS; ENDOPROTEASE; PROTEOLYSIS; METHYLATION	Proteins containing C-terminal "CAAX" sequence motifs undergo three sequential post-translational processing steps: modification of the cysteine with either a 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenyl lipid, proteolysis of the C-terminal. -AAX tripeptide, and methylation of the carboxyl group of the now C-terminal prenylcysteine. A putative prenyl protein protease in yeast, designated Rce1p, was recently identified. In this study, a portion of a putative human homologue of RCE1 (hRCE1) was identified in a human expressed sequence tag data base, and the corresponding cDNA was cloned, Expression of hRCE1 was detected in all tissues examined. Both yeast and human RCE1 proteins were produced in Sf9 insect cells by infection with a recombinant baculovirus; membrane preparations derived from the infected Sf9 cells exhibited a high level of prenyl protease activity. Recombinant hRCE1 so produced recognized both farnesylated and geranylgeranylated proteins as substrates, including farnesyl-Ki-Ras, farnesyl-N-Ras, farnesyl-Ha-Ras, and the farnesylated heterotrimeric G protein G(gamma 1) subunit, as well, as geranylgeranyl Ki-Ras and geranylgeranyl-Rap1b. The protease activity of hRCE1 activity was specific for prenylated proteins, because unprenylated peptides did not compete for enzyme activity. hRCE1 activity was also exquisitely sensitive to a prenyl peptide analogue that had been previously described as a potent inhibitor of the prenyl protease activity in mammalian tissues. These data indicate that both the yeast and the human RCE1 gene products are bona fide prenyl protein proteases and suggest that they play a major role in the processing of CAAX-type prenylated proteins.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Duke University; Duke University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOPYAN TN, 1994, BIOCHEM BIOPH RES CO, V198, P787, DOI 10.1006/bbrc.1994.1113; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; Hitz AM, 1996, FEBS LETT, V391, P310, DOI 10.1016/0014-5793(96)00766-1; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jang GF, 1998, BIOCHEMISTRY-US, V37, P4473, DOI 10.1021/bi972289b; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; MA YT, 1993, BIOCHEMISTRY-US, V32, P2386, DOI 10.1021/bi00060a033; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; Nishii W, 1997, J BIOCHEM-TOKYO, V122, P402; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	36	139	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8379	8382		10.1074/jbc.274.13.8379	http://dx.doi.org/10.1074/jbc.274.13.8379			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085068	hybrid			2022-12-27	WOS:000079451600010
J	Yarwood, SJ; Sale, EM; Sale, GJ; Houslay, MD; Kilgour, E; Anderson, NG				Yarwood, SJ; Sale, EM; Sale, GJ; Houslay, MD; Kilgour, E; Anderson, NG			Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ADIPOCYTE DIFFERENTIATION; ADIPOSE CONVERSION; GENE-EXPRESSION; 3T3-L1 CELLS; MAP KINASE; FACTOR-I; INSULIN; RECEPTOR; JAK2	The signals mediating growth hormone (GH)-dependent differentiation of 3T3-F442A preadipocytes under serum-free conditions have been studied. GH priming of cells was required before the induction of terminal differentiation by a combination of epidermal growth factor, tri-iodothyronine, and insulin. Cellular depletion of Janus kinase-2 (JAK-2) using antisense oligodeoxynucleotides (ODNs) prevented GH-stimulated JAK-2 and signal transducer and activator of transcription (STAT)-5 tyrosine phosphorylation and severely attenuated the ability of GH to promote differentiation. Although p42(MAPK)/p44(MAPK) mitogen-activated protein kinases were activated during GH priming, treatment of cells with PD 098059, which prevented activation of these kinases, did not block GH priming. However, antisense ODN-mediated depletion of mitogen-activated protein kinases from the cells showed that their expression was necessary for terminal differentiation. Similarly, although p70(s6k) was activated during GH priming, pretreatment of cells with rapamycin, which prevented the activation of p70(s6k), had no effect on GH priming. However, rapamycin did partially block epidermal growth factor, tri-iodothyronine, and insulin-stimulated terminal differentiation. By contrast, cellular depletion of STAT-B with antisense ODNs completely abolished the ability of GH to promote differentiation. These results indicate that JAK-2, acting specifically via STAT-5, is necessary for GH-dependent differentiation of 3T3-F442A preadipocytes. Activation of p42(MAPK)/p44(MAPK) and p70(s6k) is not essential for the promotion of differentiation by GH, although these signals are required for GH-independent terminal differentiation.	Univ Manchester, Sch Biol Sci, Dept Surg, Manchester M13 9PT, Lancs, England; Univ Glasgow, Inst Biol & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Southampton, Dept Biochem, Southampton SO16 7PX, Hants, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	University of Manchester; University of Glasgow; University of Southampton	Anderson, NG (corresponding author), Univ Manchester, Sch Biol Sci, Dept Surg, Rm G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Yarwood, Stephen/0000-0001-9489-9253; Houslay, Miles/0000-0002-3826-8091				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; FLINT DJ, 1993, J ENDOCRINOL, V137, P203, DOI 10.1677/joe.0.1370203; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; KILGOUR E, 1994, FEBS LETT, V343, P205, DOI 10.1016/0014-5793(94)80556-3; KILGOUR E, 1993, FEBS LETT, V328, P271, DOI 10.1016/0014-5793(93)80942-N; LAI E, 1981, J BIOL CHEM, V256, P2866; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MADON RJ, 1986, J ENDOCRINOL, V111, P117, DOI 10.1677/joe.0.1110117; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MORIKAWA M, 1986, J CELL PHYSIOL, V128, P293, DOI 10.1002/jcp.1041280222; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WABITSCH M, 1995, METABOLISM, V44, P45, DOI 10.1016/0026-0495(95)90220-1; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WISE LS, 1979, J BIOL CHEM, V254, P273; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; ZEZULAK KM, 1986, SCIENCE, V233, P551, DOI 10.1126/science.3726546	34	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8662	8668		10.1074/jbc.274.13.8662	http://dx.doi.org/10.1074/jbc.274.13.8662			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085104	hybrid			2022-12-27	WOS:000079451600046
J	Dong, LQ; Zhang, RB; Langlais, P; He, HL; Clark, M; Zhu, L; Liu, F				Dong, LQ; Zhang, RB; Langlais, P; He, HL; Clark, M; Zhu, L; Liu, F			Primary structure, tissue distribution, and expression of mouse phosphoinositide-dependent protein kinase-1, a protein kinase that phosphorylates and activates protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; AKT; INSULIN; IDENTIFICATION; ADIPOCYTES; SURVIVAL; BINDING	Phosphoinositide-dependent protein kinase-l (PDK1) is a recently identified serine/threonine kinase that phosphorylates and activates Akt and p70(S6K), two downstream kinases of phosphatidylinositol S-kinase, To further study the potential role of PDK1, we have screened a mouse liver cDNA library and identified a cDNA encoding the enzyme. The predicted mouse PDK1 (mPDK1) protein contained 559 amino acids and a COOH-terminal pleckstrin homology domain. A 7-kilo-base mPDK1 mRNA was broadly expressed in mouse tissues and in embryonic cells. In the testis, a high level expression of a tissue-specific S-kilobase transcript was also detected. Anti-mPDK1 antibody recognized multiple proteins in mouse tissues with molecular masses ranging from 60 to 180 kDa. mPDK1 phosphorylated the conserved threonine residue (Thr(402)) in, the activation loop of protein kinase C-zeta and activated the enzyme in vitro and in cells. Our findings suggest that there may be different isoforms of mPDK1 and that the protein is an upstream kinase that activates divergent pathways downstream of phosphatidylinositol 3-kinase.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	liuf@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI H, 1994, J BIOL CHEM, V269, P28098; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315	31	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8117	8122		10.1074/jbc.274.12.8117	http://dx.doi.org/10.1074/jbc.274.12.8117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075713	hybrid			2022-12-27	WOS:000079268100072
J	Faniello, MC; Bevilacqua, MA; Condorelli, G; de Crombrugghe, B; Maity, SN; Avvedimento, VE; Cimino, F; Costanzo, F				Faniello, MC; Bevilacqua, MA; Condorelli, G; de Crombrugghe, B; Maity, SN; Avvedimento, VE; Cimino, F; Costanzo, F			The B subunit of the CAAT-binding factor NFY binds the central segment of the co-activator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-FERRITIN TRANSCRIPTION; ENCODING GENE FERH; DNA COMPLEX; FACTOR BBF; CBF-B; CELLS; MOTIF; CAMP; MOLECULE; PROMOTER	We report that the heterotrimeric transcription factor NFY or "CAAT-binding factor" binds the -60 region of the human H ferritin promoter, the B site. DNA binding analysis with specific antibodies demonstrates that NFY/B/C subunits tightly bind this site and that NFY/C subunit is masked in vivo by binding with other protein(s). NFY binds the co-activator p300. Specifically, the NFY/B subunit interacts with the central segment of p300 in vivo and in vitro. cAMP substantially increases the formation of the NFY.p300 complex. Taken together these data provide a general model of cAMP induction of non-CRE-containing promoters and suggest that the NFY-B.p300 complex is located at the 5' end of the promoter and the NFY-B.C.TFIIB on the 3' end toward the transcription start site.	Univ Naples, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Magna Graecia University of Catanzaro	Costanzo, F (corresponding author), Univ Naples, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		Costanzo, Francesco Saverio/K-3168-2018; Condorelli, Gianluigi/Q-6736-2017	Costanzo, Francesco Saverio/0000-0002-3096-9416; Condorelli, Gianluigi/0000-0003-0481-6843; Maity, Sankar/0000-0002-2387-6545; FANIELLO, Concetta Maria/0000-0001-6938-2754				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; Bevilacqua MA, 1997, BIOCHEM BIOPH RES CO, V240, P179, DOI 10.1006/bbrc.1997.7632; BEVILACQUA MA, 1994, GENE, V141, P287, DOI 10.1016/0378-1119(94)90587-8; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; QIAO L, 1998, EMBO J, V17, P6300; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SUSHMA EA, 1993, ONCOGENE, V8, P1639	21	79	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7623	7626		10.1074/jbc.274.12.7623	http://dx.doi.org/10.1074/jbc.274.12.7623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075648	hybrid			2022-12-27	WOS:000079268100007
J	Giasson, BI; Uryu, K; Trojanowski, JQ; Lee, VMY				Giasson, BI; Uryu, K; Trojanowski, JQ; Lee, VMY			Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; OLIGODENDROGLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; LEWY BODIES; OLIVOPONTOCEREBELLAR ATROPHY; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; PROTEIN; COMPONENT; EPITOPES	alpha-Synuclein is a soluble presynaptic protein which is pathologically redistributed within intracellular lesions characteristic of several neurodegenerative diseases. Here we demonstrate that wild type and two mutant forms of alpha-synuclein linked to familial Parkinson's disease (Ala(30) --> Pro and Ala(53) --> Thr) self-aggregate and assemble into 10-19-nm-wide filaments with distinct morphologies under defined in vitro conditions. Immunogold labeling demonstrates that the central region of all these filaments are more robustly labeled than the N-terminal or C-terminal regions, suggesting that the latter regions are buried within the filaments. Since in vitro generated alpha-synuclein filaments resemble the major ultrastructural elements of authentic Lewy bodies that are hallmark lesions of Parkinson's disease, we propose that self-aggregating alpha-synuclein is the major subunit protein of these filamentous lesions.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Maloney 3, Philadelphia, PA 19104 USA.		Shahmoradian, Sarah H/C-7465-2015	Shahmoradian, Sarah H/0000-0001-9752-7287				ABE H, 1992, ACTA NEUROPATHOL, V84, P273; ARIMA K, 1992, ACTA NEUROPATHOL, V83, P453, DOI 10.1007/BF00310020; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Baba M, 1998, AM J PATHOL, V152, P879; BALIN BJ, 1991, BRAIN RES, V556, P181, DOI 10.1016/0006-8993(91)90306-G; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DALE GE, 1992, ACTA NEUROPATHOL, V83, P525, DOI 10.1007/BF00310030; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; GOLDMAN JE, 1983, SCIENCE, V221, P1082, DOI 10.1126/science.6308771; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; Hong L, 1998, NEUROREPORT, V9, P1239, DOI 10.1097/00001756-199804200-00051; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IZIZARRY MC, 1998, J NEUROPATHOL EXP NE, V57, P334; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; KATO S, 1990, ACTA NEUROPATHOL, V79, P584, DOI 10.1007/BF00294235; KATO S, 1991, ACTA NEUROPATHOL, V82, P488, DOI 10.1007/BF00293383; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MURAYAMA S, 1992, ACTA NEUROPATHOL, V84, P32, DOI 10.1007/BF00427212; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SCHMIDT ML, 1991, AM J PATHOL, V139, P53; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	43	440	453	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7619	7622		10.1074/jbc.274.12.7619	http://dx.doi.org/10.1074/jbc.274.12.7619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075647	hybrid			2022-12-27	WOS:000079268100006
J	Reddy, LG; Autry, JM; Jones, LR; Thomas, DD				Reddy, LG; Autry, JM; Jones, LR; Thomas, DD			Co-reconstitution of phospholamban mutants with the Ca-ATPase reveals dependence of inhibitory function on phospholamban structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; SODIUM DODECYL-SULFATE; PROTEIN-KINASE; CALCIUM-PUMP; CA2+-ATPASE; PHOSPHORYLATION; IDENTIFICATION; CA-2+-ATPASE; SEQUENCE; MUSCLES	Phospholamban (PLB), a 52-amino acid integral membrane protein, regulates the Ca-ATPase (calcium pump) in cardiac sarcoplasmic reticulum through PLB phosphorylation mediated by beta-adrenergic stimulation. Based on site-directed mutagenesis and coexpression with Ca-ATPase (SERCA2a) in Sf21 insect cells or in HEK 293 cells, and on spin label detection of PLB oligomeric state in lipid bilayers, it has been proposed that the monomeric form of PLB is the inhibitory species, and depolymerization of PLB is essential for its regulatory function. Here we have studied the relationship between PLB oligomeric state and function by in vitro co-reconstitution of PLB and its mutants with purified Ca-ATPase, We compared wild type-PLB (wt-PLB), which is primarily a pentamer on SDS-polyacrylamide gel electrophoresis (PAGE) at 25 degrees C, with two of its mutants, C41L-PLB and L37A-PLB, that are primarily tetramer and monomer, respectively. We found that the monomeric mutant L37A-PLB is a more potent inhibitor than wt-PLB, supporting the previous proposal that PLB monomer is the inhibitory species. On the other hand, C41L-PLB, which has a monomeric fraction comparable to that of wt-PLB on SDS-PAGE at 25 degrees C, has no inhibitory activity when assayed at 25 degrees C, However, at 37 degrees C, a 3-fold increase in the monomeric fraction of C41L-PLB on SDS-PAGE resulted in inhibitory activity comparable to that of wt-PLB, Upon increasing the temperature from 25 to 37 degrees C, no change in fraction monomer or inhibitory activity for wt-PLB and L37A-PLB was observed. Based on these results, the extent of inhibition of Ca-ATPase by PLB or its mutants appears to depend not only on the propensity of PLB to dissociate into monomers but also on the relative potency of the particular PLB monomer when interacting with the Ca-ATPase.	Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Indiana Univ, Krannert Inst Cardiol, Indianapolis, IN 46202 USA	University of Minnesota System; University of Minnesota Twin Cities; Indiana University System; Indiana University-Purdue University Indianapolis	Thomas, DD (corresponding author), Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.		Autry, Joseph M./X-6839-2019; Thomas, David D/B-4257-2012	Autry, Joseph M./0000-0002-1144-725X; Thomas, David D./0000-0002-8822-2040	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032961, R01AR032961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027906] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06308] Funding Source: Medline; NIAMS NIH HHS [AR32961] Funding Source: Medline; NIGMS NIH HHS [GM27906] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Autry JM, 1998, ANN NY ACAD SCI, V853, P92, DOI 10.1111/j.1749-6632.1998.tb08259.x; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Ferrington DA, 1998, BIOPHYS J, V74, pA356; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; JONES LR, 1985, J BIOL CHEM, V260, P7721; JORGENSEN AO, 1987, J CELL BIOL, V104, P1343, DOI 10.1083/jcb.104.5.1343; Kargacin ME, 1998, BIOCHEM J, V331, P245, DOI 10.1042/bj3310245; Karim CB, 1998, BIOCHEMISTRY-US, V37, P12074, DOI 10.1021/bi980642n; KIM HW, 1990, J BIOL CHEM, V265, P1702; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; REDDY L, 1999, IN PRESS BIOCHEMISTR; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Stokes DL, 1997, CURR OPIN STRUC BIOL, V7, P550, DOI 10.1016/S0959-440X(97)80121-2; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SZYMANSKA K, 1991, MEMBRANE BIOCHEM, V9, P191; TADA M, 1989, BIOESSAYS, V10, P163; Thomas DD, 1998, ANN NY ACAD SCI, V853, P186, DOI 10.1111/j.1749-6632.1998.tb08266.x; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; WATANABE Y, 1991, J BIOCHEM, V110, P40, DOI 10.1093/oxfordjournals.jbchem.a123540; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	43	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7649	7655		10.1074/jbc.274.12.7649	http://dx.doi.org/10.1074/jbc.274.12.7649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075652	hybrid			2022-12-27	WOS:000079268100011
J	Watts, BA; George, T; Good, DW				Watts, BA; George, T; Good, DW			Nerve growth factor inhibits HCO3- absorption in renal thick ascending limb through inhibition of basolateral membrane Na+/H+ exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NA-H EXCHANGE; APICAL MEMBRANE; INTRACELLULAR-PH; BICARBONATE ABSORPTION; RECEPTOR EXPRESSION; METABOLIC-ACIDOSIS; PROXIMAL TUBULE; MESANGIAL CELLS; MESSENGER-RNA	Nerve growth factor (NGF) inhibits transepithelial HCO, absorption in the rat medullary thick ascending limb (MTAL), To investigate the mechanism of this inhibition, MTALs were perfused in vitro in Na+-free solutions, and apical and basolateral membrane Na+/H+ exchange activities were determined from rates of pH(i) recovery after lumen or bath Na+ addition. NGF (0.7 nM in the bath) had no effect on apical Na+/H+ exchange activity, but inhibited basolateral Na+/H+ exchange activity by 50%. Inhibition of basolateral Na+/H+ exchange activity with ethylisopropyl amiloride (EIPA) secondarily reduces apical Na+/H+ exchange activity and HCO3- absorption in the MTAL (Good, D, W,, George, T,, and Watts, B, A, III (1995) Proc. Natl. Acad. Sci, U,S.A. 92, 12525-12529). To determine whether a similar mechanism could explain inhibition of HCO3- absorption by NGF, apical Na+/H+ exchange activity was assessed in physiological solutions (146 mM Na+) by measurement of the initial rate of cell acidification after lumen EIPA addition. Under these conditions, in which basolateral Na+/H+ exchange activity is present, NGF inhibited apical Na+/H+ exchange activity. Inhibition of HCO3- absorption by NGF was eliminated in the presence of bath EIPA or in the absence of bath Na+. Also, NGF blocked inhibition of HCO3- absorption by bath EIPA. We conclude that NGF inhibits basolateral Na+/H+ exchange activity in the MTAL, an effect opposite from the stimulation of Na+/H+ exchange by growth factors in other systems. NGF inhibits transepithelial HCO3- absorption through inhibition of basolateral Na+/H+ exchange, most likely as the result of functional coupling in which primary inhibition of basolateral Na+/H+ exchange activity results secondarily in inhibition of apical Na+/H+ exchange activity. These findings establish a role for basolateral Na+/H+ exchange in the regulation of renal tubule HCO3- absorption.	Univ Texas, Med Branch, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Good, DW (corresponding author), Univ Texas, Med Branch, Dept Med, 4-200 John Sealy Annex 0562,301 Univ Blvd, Galveston, TX 77555 USA.				NIDDK NIH HHS [DK-38217] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038217] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1995, KIDNEY INT, V48, P1386, DOI 10.1038/ki.1995.427; ALPERN RJ, 1996, KIDNEY, V1, P408; ALPERS CE, 1993, LAB INVEST, V69, P703; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AttmaneElakeb A, 1996, KIDNEY INT, V50, P1051, DOI 10.1038/ki.1996.408; Bianchini L, 1997, J BIOL CHEM, V272, P271; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pC736; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BORENSZTEIN P, 1995, AM J PHYSIOL-RENAL, V268, pF1224, DOI 10.1152/ajprenal.1995.268.6.F1224; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; Chambrey R, 1998, AM J PHYSIOL-RENAL, V275, pF379, DOI 10.1152/ajprenal.1998.275.3.F379; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V273, pC1064, DOI 10.1152/ajpcell.1997.273.3.C1064; GANZ MB, 1994, AM J PHYSIOL, V266, pF576, DOI 10.1152/ajprenal.1994.266.4.F576; Good David W., 1998, Journal of the American Society of Nephrology, V9, p6A; Good DW, 1996, AM J PHYSIOL-RENAL, V270, pF691, DOI 10.1152/ajprenal.1996.270.4.F691; Good DW, 1998, AM J PHYSIOL-CELL PH, V274, pC931, DOI 10.1152/ajpcell.1998.274.4.C931; GOOD DW, 1995, J BIOL CHEM, V270, P9883, DOI 10.1074/jbc.270.17.9883; GOOD DW, 1993, SEMIN NEPHROL, V13, P225; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; GOOD DW, 1997, J AM SOC NEPHROL S, V8, pA6; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUERRA L, 1993, J MEMBRANE BIOL, V135, P209; HAMMERMAN MR, 1993, ANNU REV PHYSIOL, V55, P305, DOI 10.1146/annurev.physiol.55.1.305; HEBERT SC, 1986, AM J PHYSIOL, V250, pC920, DOI 10.1152/ajpcell.1986.250.6.C920; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; Laghmani K, 1997, J CLIN INVEST, V99, P24, DOI 10.1172/JCI119128; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MA YH, 1994, J BIOL CHEM, V269, P30734; MACKOVICBASIC M, 1990, SEMIN NEPHROL, V10, P122; MALY K, 1989, J BIOL CHEM, V264, P11839; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PREISIG PA, 1991, KIDNEY INT, V39, P1077, DOI 10.1038/ki.1991.137; SALIDO EC, 1986, J NEUROSCI RES, V16, P457, DOI 10.1002/jnr.490160302; SCHLATTER E, 1995, J AM SOC NEPHROL, V6, P1223; SUN AM, 1992, AM J PHYSIOL, V262, pF241, DOI 10.1152/ajprenal.1992.262.2.F241; Sun AM, 1997, J MEMBRANE BIOL, V160, P85, DOI 10.1007/s002329900297; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V422, P9, DOI 10.1007/BF00381507; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WALKER P, 1980, BRAIN RES, V186, P331, DOI 10.1016/0006-8993(80)90979-8; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; WATTS BA, 1994, J BIOL CHEM, V269, P20250; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	58	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7841	7847		10.1074/jbc.274.12.7841	http://dx.doi.org/10.1074/jbc.274.12.7841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075676	hybrid			2022-12-27	WOS:000079268100035
J	Gupta, N; Scharenberg, AM; Fruman, DA; Cantley, LC; Kinet, JP; Long, EO				Gupta, N; Scharenberg, AM; Fruman, DA; Cantley, LC; Kinet, JP; Long, EO			The SH2 domain-containing inositol 5 '-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during Fc gamma RIIb1-mediated inhibition of B cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; PHOSPHATIDYLINOSITOL 3-KINASE; POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE PHOSPHORYLATION; PHOSPHATASE SHIP; ACTIVATION; ANTIGEN; KINASE; IMMUNOGLOBULIN; LYMPHOCYTES	Coligation of Fc gamma RIIb1 with the B cell receptor (BCR) or Fc epsilon RI on mast cells inhibits B cell or mast cell activation, Activity of the inositol phosphatase SHIP is required for this negative signal. In vitro, SHIP catalyzes the conversion of the phosphoinositide 3-kinase (PI3K) product phosphatidylinositol 3,4,5-trisphosphate (PIP3) into phosphatidylinositol 3,4-bisphosphate. Recent data demonstrate that coligation of Fc gamma RIIb1 with BCR inhibits PIP3-dependent Btk (Bruton's tyrosine kinase) activation and the Btk-dependent generation of inositol trisphosphate that regulates sustained calcium influx, In this study, we provide evidence that coligation of Fc gamma RIIb1 with BCR induces binding of PI3K to SHIP, This interaction is mediated by the binding of the SH2 domains of the p85 subunit of PI3K to a tyrosine-based motif in the C-terminal region of SHIP. Furthermore, the generation of phosphatidylinositol 3,4-bisphosphate was only partially reduced during coligation of BCR with Fc gamma RIIb1 despite a drastic reduction in PIP3. In contrast to the complete inhibition of Tec kinase-dependent calcium signaling, activation of the serine/threonine kinase Akt was partially preserved during BCR and Fc gamma RIIb1 coligation, The association of PI3K with SHIP may serve to activate PI3K and to regulate downstream events such as B cell activation-induced apoptosis.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Beth Israel Deaconess Med Ctr, Lab Allergy & Immunol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Lab Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Long, EO (corresponding author), NIAID, Immunogenet Lab, NIH, Twinbrook II,12441 Parklawn Dr, Rockville, MD 20852 USA.	elong@nih.gov	Long, Eric O/G-5475-2011; Cantley, Lewis C/D-1800-2014	Long, Eric O/0000-0002-7793-3728; Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashman RF, 1996, J IMMUNOL, V157, P5; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHAN PL, 1971, IMMUNOLOGY, V21, P967; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; EARL PL, 1988, CURRENT PROTOCOLS MO; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WENG WK, 1994, J BIOL CHEM, V269, P32514; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON HA, 1987, J IMMUNOL, V138, P1712; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7489	7494		10.1074/jbc.274.11.7489	http://dx.doi.org/10.1074/jbc.274.11.7489			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066815	hybrid			2022-12-27	WOS:000079078400087
J	Manes, S; Llorente, M; Lacalle, RA; Gomez-Mouton, C; Kremer, L; Mira, E; Martinez-A, C				Manes, S; Llorente, M; Lacalle, RA; Gomez-Mouton, C; Kremer, L; Mira, E; Martinez-A, C			The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; FACTOR-I RECEPTOR; BREAST-CANCER-CELLS; PROSTATE EPITHELIAL-CELLS; FACTOR IGF; MONOCLONAL-ANTIBODIES; SOMATOMEDIN RECEPTOR; MITOGENIC RESPONSE; NUDE-MICE; EXPRESSION	The androgen-independent human prostate adenocarcinoma cell line DU-145 proliferates in serum-free medium and produces insulin-like growth factors (IGF)-I, IGF-IZ, and the IGF type-1 receptor (IGF-1R), They also secrete three IGF-binding proteins (IGFBP), IGFBP-2, -3, and -4, Of these, immunoblot analysis revealed selective proteolysis of IGFBP-3, yielding fragments of 31 and 19 kDa, By using an anti-IGF-I-specific monoclonal antibody (mAb), we detect surface receptor-bound IGF-I on serum-starved DU-145 cells, which activates IGF-IR and triggers a mitogenic signal. Incubation of DU-145 cells with blocking anti-IGF-I, anti-IGF-II, or anti-IGF-I plus anti-IGF-II mAb does not, however, inhibit serum-free growth of DU-145, Conversely, anti-IGF-1R mAb and IGFBP-3 inhibit DNA synthesis. IGFBP-3 also modifies the DU-145 cell cycle, decreases p34(cdc2) levels, and IGF-IR autophosphorylation. The antiproliferative IGFBP-3 activity is not IGF-independent, since des-(1-3)IGF-I, which does not bind to IGFBP-3, reverses its inhibitory effect. DU-145 also secretes the matrix metalloproteinase (MMP)-9, which can be detected in both a soluble and a membrane-bound form. Matrix metalloproteinase inhibitors, but not serpins, abrogate DNA synthesis in DU-145 associated with the blocking of IGFBP-3 proteolysis. Overexpression of an antisense cDNA for MMP-9 inhibits 80% of DU-145 cell proliferation that can be reversed by IGF-I in a dose-dependent manner. Inhibition of MMP-9 expression is also associated with a decrease in IGFBP-3 proteolysis and with reduced signaling through the IGF-1R, Our data indicate an IGF autocrine loop operating in DU-145 cells, specifically modulated by IGFBP-3, whose activity may in turn be regulated by IGFBP-3 proteases such as MMP-9.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Manes, S (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Kremer, Leonor/L-5445-2015; Llorente, Mercedes/AAA-7646-2021; Manes, Santos/E-4725-2011; MIRA, EMILIA/K-2456-2014	Kremer, Leonor/0000-0002-2235-2010; MIRA, EMILIA/0000-0002-4226-1829; Manes, Santos/0000-0001-8023-957X; GOMEZ-MOUTON, CONCEPCION/0000-0002-1595-6027; Lacalle, Rosa Ana/0000-0003-0082-167X; Llorente Gomez, Mercedes/0000-0001-8759-9148				ADASHI EY, 1992, J CLIN INVEST, V90, P1593, DOI 10.1172/JCI116028; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BICKETT DM, 1993, ANAL BIOCHEM, V212, P58, DOI 10.1006/abio.1993.1291; BIRNBAUM RS, 1994, J ENDOCRINOL, V141, P535, DOI 10.1677/joe.0.1410535; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CONNOLLY JM, 1994, PROSTATE, V24, P167, DOI 10.1002/pros.2990240402; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; EMONARD HP, 1992, CANCER RES, V52, P5845; FIGUEROA JA, 1995, J CLIN ENDOCR METAB, V80, P3476, DOI 10.1210/jc.80.12.3476; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KALEBIC T, 1994, CANCER RES, V54, P5531; KATO H, 1993, J BIOL CHEM, V268, P2655; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LI CY, 1995, ONCOGENE, V11, P1885; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Manes S, 1997, J ENDOCRINOL, V154, P293, DOI 10.1677/joe.0.1540293; Manes S, 1997, ENDOCRINOLOGY, V138, P905, DOI 10.1210/en.138.3.905; MARCELLI M, 1995, ENDOCRINOLOGY, V136, P1040, DOI 10.1210/en.136.3.1040; MICKEY DD, 1977, CANCER RES, V37, P4049; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OH Y, 1993, J BIOL CHEM, V268, P26045; Oh Y, 1997, ENDOCRINE, V7, P111, DOI 10.1007/BF02778076; OH YM, 1993, J BIOL CHEM, V268, P14964; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Quesada AR, 1997, CLIN EXP METASTAS, V15, P26; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; RAIBOWOL K, 1989, CELL, V57, P393; RESNICOFF M, 1994, CANCER RES, V54, P2218; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 1998, CANCER RES, V58, P4127; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SINGH P, 1994, CANCER RES, V54, P6563; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; XIONG LM, 1992, P NATL ACAD SCI USA, V89, P5356, DOI 10.1073/pnas.89.12.5356; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329	74	149	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					6935	6945		10.1074/jbc.274.11.6935	http://dx.doi.org/10.1074/jbc.274.11.6935			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066747	hybrid			2022-12-27	WOS:000079078400019
J	Gutsche-Perelroizen, I; Lepault, J; Ott, A; Carlier, MF				Gutsche-Perelroizen, I; Lepault, J; Ott, A; Carlier, MF			Filament assembly from profilin-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ATP HYDROLYSIS; ACANTHAMOEBA PROFILIN; SKELETAL-MUSCLE; BARBED ENDS; BETA-ACTIN; POLYMERIZATION; PROTEIN; MYOSIN; PURIFICATION	Profilin plays a major role in the assembly of actin filament at the barbed ends. The thermodynamic and kinetic parameters for barbed end assembly from profilin-actin have been measured turbidimetrically. Filament growth from profilin-actin requires MgATP to be bound to actin. No assembly is observed from profilin-CaATP-actin. The rate constant for association of profilin-actin to barbed ends is 30% lower than that of actin, and the critical concentration for F-actin assembly from profilin-actin units is 0.3 mu M under physiological ionic conditions. Barbed ends grow from profilin-actin with an ADP-P-i cap. Profilin does not cap the barbed ends and is not detectably incorporated into filaments. The EDC-cross-linked profilin-actin complex (PA(cov)) both copolymerizes with F-actin and undergoes spontaneous self-assembly, following a nucleation-growth process characterized by a critical concentration of 0.2 mu M under physiological conditions. The PA(cov) polymer is a helical filament that displays the same diffraction pattern as F-actin, with layer lines at 6 and 36 nm. The PA(cov) filaments bound phalloidin with the same kinetics as F-actin, bound myosin subfragment-1, and supported actin-activated ATPase of myosin subfragment-1, but they did not translocate in vitro along myosin-coated glass surfaces. These results are discussed in light of the current models of actin structure.	Inst Curie, Phys Sect, F-75005 Paris, France; Ctr Mol Genet, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Carlier, MF (corresponding author), Inst Curie, Phys Sect, 11 Rue Pierre & Marie Curie, F-75005 Paris, France.	carlier@lebs.cnrs-gif.fr	Lepault, Jean/AAN-8859-2020					Allen PG, 1996, BIOCHEMISTRY-US, V35, P14062, DOI 10.1021/bi961326g; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASELLA JF, 1986, J BIOL CHEM, V261, P915; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; DETMERS P, 1981, J BIOL CHEM, V256, P99; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Fievez S, 1997, BIOCHEMISTRY-US, V36, P11843, DOI 10.1021/bi971206o; Fievez S, 1997, BIOCHEMISTRY-US, V36, P11837, DOI 10.1021/bi971205w; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1995, J STRUCT BIOL, V115, P186, DOI 10.1006/jsbi.1995.1043; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1	40	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6234	6243		10.1074/jbc.274.10.6234	http://dx.doi.org/10.1074/jbc.274.10.6234			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037710	hybrid			2022-12-27	WOS:000078902800032
J	Kim, CH; Kim, HS; Cubells, JF; Kim, KS				Kim, CH; Kim, HS; Cubells, JF; Kim, KS			A previously undescribed intron and extensive 5 ' upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; RAT ADRENAL-MEDULLA; NERVE GROWTH-FACTOR; TRANSGENIC MICE; TYROSINE-HYDROXYLASE; MESSENGER-RNA; REGULATORY ELEMENTS; NEUROTRANSMITTER TRANSPORTERS; NORADRENALINE TRANSPORTER; SEROTONIN TRANSPORTER	The synaptic action of norepinephrine is terminated by NaCl-dependent uptake into presynaptic noradrenergic nerve endings, mediated by the norepinephrine transporter (NET), NET is expressed only in neuronal tissues that synthesize and secrete norepinephrine and in most cases is co-expressed with the norepinephrine-synthetic enzyme dopamine beta-hydroxylase (DBH), To understand the molecular mechanisms regulating human NET (hNET) gene expression, we isolated and characterized an hNET genomic clone encompassing approximately 9.5 kilobase pairs of the 5' upstream promoter region. Here we demonstrate that the hNET gene contains an as-yet-unidentified intron of 476 base pairs within the 5'-untranslated region. Furthermore, both primer extension and 5'-rapid amplification of cDNA ends analyses identified multiple transcription start sites from mRNAs expressed only in NET-expressing cell lines. The start sites clustered in two subdomains, each preceded by a TATA-like sequence motif, As expected for mature mRNAs, transcripts from most of these sites each contained an additional G residue at the 5' position. Together, the data strongly support the authenticity of these sites as the transcriptional start sites of hNET. We assembled hNET-chloramphenicol acetyltransferase reporter constructs containing different lengths of hNET 5' sequence in the presence or the absence of the first intron, Transient transfection assays indicated that the combination of the 5' upstream sequence and the first intron supported the highest level of noradrenergic cell-specific transcription. Forced expression of the paired-like homeodomain transcription factor Phox2a did not affect hNET promoter activity in NET-negative cell lines, in marked contrast to its effect on a DBH-chloramphenicol acetyltransferase reporter construct. Together with our previous studies suggesting a critical role of Phox2a for noradrenergic-specific expression of the DBH gene, these data support a model in which distinct, or partially distinct, molecular mechanisms regulate cell-specific expression of the NET and DBH genes.	Univ Tennessee, Coll Med, Dept Neurol, Memphis, TN 38163 USA; Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Vet Affairs Connecticut Hlth Care Syst, Dept Psychiat, West Haven, CT 06516 USA; Yale Univ, Sch Med, West Haven, CT 06516 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Kim, KS (corresponding author), Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, 115 Mill St, Belmont, MA 02178 USA.	kskim@mclean.harvard.edu	Cubells, Joe F./V-2543-2018		NIDA NIH HHS [DA 00167] Funding Source: Medline; NIMH NIH HHS [MH48866] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048866, R29MH048866] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amara S G, 1998, Adv Pharmacol, V42, P164; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Axelrod J, 1969, Prog Brain Res, V31, P21; Barker Eric L., 1995, P321; Bengel D, 1997, MOL BRAIN RES, V44, P286, DOI 10.1016/S0169-328X(96)00234-3; Bonisch H, 1998, Adv Pharmacol, V42, P183; Bradley CC, 1997, J NEUROCHEM, V69, P1356; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bruss M, 1997, MOL BRAIN RES, V52, P257, DOI 10.1016/S0169-328X(97)00267-2; CICCARONE V, 1989, CANCER RES, V49, P219; CUBELLS JF, 1995, J NEUROCHEM, V65, P502; CUBELLS JF, 1995, NEUROSCI LETT, V193, P189, DOI 10.1016/0304-3940(95)11699-W; DONOVAN DM, 1995, MOL BRAIN RES, V30, P327, DOI 10.1016/0169-328X(95)00018-N; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; Fritz JD, 1998, J NEUROCHEM, V70, P2241; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; Hormuzdi SG, 1998, MOL CELL BIOL, V18, P3368, DOI 10.1128/MCB.18.6.3368; HOYLE GW, 1994, J NEUROSCI, V14, P2455; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; ISRAEL Y, 1973, ANN NY ACAD SCI, V215, P38, DOI 10.1111/j.1749-6632.1973.tb28246.x; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; Kawarai T, 1997, GENE, V195, P11, DOI 10.1016/S0378-1119(97)00131-5; Kim HS, 1998, J NEUROSCI, V18, P8247; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1995, PRACTICAL APPROACH G, V2, P151; KIM KT, 1993, J NEUROCHEM, V60, P946, DOI 10.1111/j.1471-4159.1993.tb03241.x; KIRSHNER N, 1957, J BIOL CHEM, V226, P207; Klimek V, 1997, J NEUROSCI, V17, P8451; KOBAYASHI K, 1992, P NATL ACAD SCI USA, V89, P1631, DOI 10.1073/pnas.89.5.1631; KOBAYASHI K, 1994, J BIOL CHEM, V269, P29725; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LIN AMY, 1993, NEUROSCI LETT, V164, P71, DOI 10.1016/0304-3940(93)90860-N; LINGEN B, 1994, FEBS LETT, V342, P235, DOI 10.1016/0014-5793(94)80508-3; LORANG D, 1994, J NEUROSCI, V14, P4903; Lu D, 1996, ENDOCRINOLOGY, V137, P763, DOI 10.1210/en.137.2.763; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Markel PD, 1997, GENOME RES, V7, P92, DOI 10.1101/gr.7.2.92; Marks D F, 1996, J Health Psychol, V1, P7, DOI 10.1177/135910539600100102; Matsuoka I, 1997, BRAIN RES, V776, P181, DOI 10.1016/S0006-8993(97)01016-0; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MORITA S, 1993, MOL BRAIN RES, V17, P239, DOI 10.1016/0169-328X(93)90007-C; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Porzgen P, 1998, BBA-GENE STRUCT EXPR, V1398, P365, DOI 10.1016/S0167-4781(98)00072-4; PORZGEN P, 1995, BIOCHEM BIOPH RES CO, V215, P1145, DOI 10.1006/bbrc.1995.2582; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; REIS DJ, 1975, J PHARMACOL EXP THER, V193, P775; REIS DJ, 1974, BRAIN RES, V81, P380, DOI 10.1016/0006-8993(74)90956-1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Seo HM, 1996, J NEUROSCI, V16, P4102; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; SURI C, 1993, J NEUROSCI, V13, P1280; Tiveron MC, 1996, J NEUROSCI, V16, P7649; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Wakade AR, 1996, J PHYSIOL-LONDON, V494, P67, DOI 10.1113/jphysiol.1996.sp021476; Yang CY, 1998, J NEUROCHEM, V71, P1813	71	77	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6507	6518		10.1074/jbc.274.10.6507	http://dx.doi.org/10.1074/jbc.274.10.6507			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037744	hybrid			2022-12-27	WOS:000078902800066
J	Freyssenet, D; Di Carlo, M; Hood, DA				Freyssenet, D; Di Carlo, M; Hood, DA			Calcium-dependent regulation of cytochrome c gene expression in skeletal muscle cells - Identification of a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE ACTIVITY; MITOCHONDRIAL BIOGENESIS; SIGNAL-TRANSDUCTION; CHRONIC STIMULATION; ENERGY-METABOLISM; MESSENGER-RNAS; CYCLIC-AMP; NUCLEAR; RAT; CA2+	Mitochondrial biogenesis can occur rapidly in mammalian skeletal muscle subjected to a variety of physiological conditions. However, the intracellular signal(s) involved in regulating this process remain unknown. Using nuclearly encoded cytochrome c, we show that its expression in muscle cells is increased by changes in cytosolic Ca2+ using the ionophore A23187. Treatment of myotubes with A23187 increased cytochrome c mRNA expression up to 1.7-fold. Transfection experiments using promoter-chloramphenicol acetyltransferase constructs revealed that this increase could be transcriptionally mediated since A23187 increased chloramphenicol acetyltransferase activity by 2.5-fold. This increase was not changed by KN62, an inhibitor of Ca2+/calmodulin-dependent kinases II and IV, and it was not modified by overexpression of protein kinase A and cAMP response element-binding protein, demonstrating that the A23187 effect was not mediated through Ca2+/calmodulin-dependent kinase- or protein kinase A-dependent pathways. However, treatment of myotubes with staurosporine or 12-O-tetradecanoylphorbol-13-acetate reduced the effect of A23187 on cytochrome c transactivation by 40-50%. Coexpression of the Ca2+-sensitive protein kinase C isoforms alpha and beta(II), but not the Ca2+-insensitive delta isoform, exaggerated the A23187-mediated response. The short-term effect of A23187 was mediated in part by mitogen-activated protein kinase (extracellular signal-regulated kinases 1 and 2) since its activation peaked 2 h after A23187 treatment, and cytochrome c transactivation was reduced by PD98089, a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor. These results demonstrate the existence of a Ca2+-sensitive, protein kinase C-dependent pathway involved in cytochrome c expression and implicate Ca2+ as a signal in the up-regulation of nuclear genes encoding mitochondrial proteins.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; York Univ, Dept Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada	York University - Canada; York University - Canada	Hood, DA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	dhood@yorku.ca						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLELAND PJF, 1989, J BIOL CHEM, V264, P17704; Connor MK, 1996, ARCH BIOCHEM BIOPHYS, V333, P103, DOI 10.1006/abbi.1996.0369; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; Essig D A, 1996, Exerc Sport Sci Rev, V24, P289; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; Freyssenet D, 1996, ARCH PHYSIOL BIOCHEM, V104, P129, DOI 10.1076/apab.104.2.129.12878; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; HOOD DA, 1989, AM J PHYSIOL, V256, pC1092, DOI 10.1152/ajpcell.1989.256.5.C1092; HOOD DA, 1994, CAN J APPL PHYSIOL, V19, P12, DOI 10.1139/h94-002; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAWRENCE JC, 1983, AM J PHYSIOL, V244, pC348, DOI 10.1152/ajpcell.1983.244.5.C348; LI WWF, 1993, J BIOL CHEM, V268, P12003; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCCORMACK JG, 1994, NEWS PHYSIOL SCI, V9, P71; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MUCHARDT C, 1990, J VIROL, V64, P4296, DOI 10.1128/JVI.64.9.4296-4305.1990; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; Orrenius S, 1996, ADV NEUROL, V71, P137; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Robey RB, 1996, BIOTECHNIQUES, V20, P40; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHUDT C, 1975, EUR J BIOCHEM, V60, P579, DOI 10.1111/j.1432-1033.1975.tb21036.x; SEEDORF U, 1986, BIOCHEM J, V239, P115, DOI 10.1042/bj2390115; STEVENS RJ, 1995, MOL CELL BIOCHEM, V143, P119, DOI 10.1007/BF01816945; STRETER FA, 1987, AM J PHYSIOL, V253, pC296; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Takahashi M, 1998, AM J PHYSIOL-CELL PH, V274, pC1380, DOI 10.1152/ajpcell.1998.274.5.C1380; Thompson MG, 1997, J BIOL CHEM, V272, P10910; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WALKE W, 1994, J BIOL CHEM, V269, P19447; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593	49	87	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9305	9311		10.1074/jbc.274.14.9305	http://dx.doi.org/10.1074/jbc.274.14.9305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092607	hybrid			2022-12-27	WOS:000079451800026
J	Pou, S; Keaton, L; Surichamorn, W; Rosen, GM				Pou, S; Keaton, L; Surichamorn, W; Rosen, GM			Mechanism of superoxide generation by neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO-CENTER-DOT; L-ARGININE; AROMATIC HYDROXYLATION; GUANYLATE-CYCLASE; REDUCTASE DOMAIN; RELAXING FACTOR; IN-VIVO; PEROXYNITRITE; CELLS; TETRAHYDROBIOPTERIN	Neuronal nitric-oxide synthase (NOS I) in the absence of L-arginine has previously been shown to generate superoxide (O-2(radicalanion)) (Pou, S., Pou, W. S., Bredt, D. S., Snyder, S. H., and Rosen, G. M. (1992) J. Biol. Chem. 267, 24173-24176). In the presence of L-arginine, NOS I produces nitric oxide (NO.). Yet the competition between O-2 and L-arginine for electrons, and by implication formation of O-2(radicalanion), has until recently remained undefined. Herein, we investigated this relationship, observing O-2(radicalanion) generation even at saturating levels of L-arginine. Of interest was the finding that the frequently used NOS inhibitor N-G-monomethyl L-arginine enhanced O-2(radicalanion) production in the presence of L-arginine because this antagonist attenuated NO. formation. Whereas diphenyliodonium chloride inhibited O-2(radicalanion), blockers of heme such as NaCN, 1-phenylimidazole, and imidazole likewise prevented the formation of O-2(radicalanion) at concentrations that inhibited NO. formation from L-arginine, Taken together these data demonstrate that NOS I generates O-2(radicalanion) and the formation of this free radical occurs at the heme domain.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Rosen, GM (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 725 W Lombard St, Baltimore, MD 21201 USA.	grosen@umaryland.edu			NCI NIH HHS [CA-69538] Funding Source: Medline; NIA NIH HHS [AG-14829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG014829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; BANCI L, 1994, J AM CHEM SOC, V116, P4866, DOI 10.1021/ja00090a035; BONNETT R, 1959, J CHEM SOC, P2094, DOI 10.1039/jr9590002094; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DEGUCHI T, 1982, J BIOL CHEM, V257, P147; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; Fukuto JM, 1997, ACCOUNTS CHEM RES, V30, P149, DOI 10.1021/ar960010y; FURCHGOTT R F, 1988, P401; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Kaur H, 1997, FREE RADICAL RES, V26, P71, DOI 10.3109/10715769709097786; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; MAKINO K, 1992, CAN J CHEM, V70, P2818, DOI 10.1139/v92-358; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MIKI N, 1977, BIOCHEM BIOPH RES CO, V75, P851, DOI 10.1016/0006-291X(77)91460-7; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POU S, 1995, BBA-GEN SUBJECTS, V1244, P62, DOI 10.1016/0304-4165(94)00197-6; POU S, 1992, J BIOL CHEM, V267, P24173; POU S, 1989, J BIOL CHEM, V264, P12299; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; Tierney DL, 1998, J AM CHEM SOC, V120, P2983, DOI 10.1021/ja973648t; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; WHITE RE, 1994, CYTOCHROME P450, P333; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; YANG G, 1992, FREE RADICAL BIO MED, V12, P327, DOI 10.1016/0891-5849(92)90120-6	54	166	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9573	9580		10.1074/jbc.274.14.9573	http://dx.doi.org/10.1074/jbc.274.14.9573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092643	hybrid			2022-12-27	WOS:000079451800062
J	Bachand, F; Yao, XJ; Hrimech, M; Rougeau, N; Cohen, EA				Bachand, F; Yao, XJ; Hrimech, M; Rougeau, N; Cohen, EA			Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 Gag precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID PROTEIN NCP7; CELL-CYCLE ARREST; VIRION INCORPORATION; NUCLEAR-LOCALIZATION; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; HELICAL STRUCTURE; VIRAL EXPRESSION; T-CELLS; GENE	The 96-amino acid Vpr protein is the major virion-associated accessory protein of the human immunodeficiency virus type 1 (HIV-1), As Vpr is not part of the p55 Gag polyprotein precursor (Pr55(gag)), its incorporation requires an anchor to associate with the assembling viral particles. Although the molecular mechanism is presently unclear, the C-terminal region of the Pr55(gag) corresponding to the p6 domain appears to constitute such an anchor essential for the incorporation of the Vpr protein. In order to clarify the mechanism by which the Vpr accessory protein is trans-incorporated into progeny virion particles, we tested whether HIV-1 Vpr interacted with the Pr55(gag) using the yeast two-hybrid system and the maltose-binding protein pull-down assay. The present study provides genetic and biochemical evidence indicating that the Pr55(gag) can physically interact with the Vpr protein. Furthermore, point mutations affecting the integrity of the conserved L-X-S-L-F-G motif of P6(gag) completely abolish the interaction between Vpr and the Pr55(gag) and, as a consequence, prevent Vpr virion incorporation. In contrast to other studies, mutations affecting the integrity of the NCp7 zinc fingers impaired neither Vpr virion incorporation nor the binding between Vpr and the Pr55(gag). Conversely, amino acid substitutions in Vpr demonstrate that an intact N-terminal alpha-helical structure is essential for the Vpr-Pr55(gag) interaction. Vpr and the Pr55(gag) demonstrate a strong interaction in vitro as salt concentrations as high as 900 mM could not disrupt the interaction. Finally, the interaction is efficiently competed using anti-Vpr sera. Together, these results strongly suggest that Vpr trans-incorporation into HIV-1 particles requires a direct interaction between its N-terminal region and the C-terminal region of p6(gag). The development of Pr55(gag)-Vpr interaction assays may allow the screening of molecules that can prevent the incorporation of the Vpr accessory protein into HIV-1 virions, and thus inhibit its early functions.	Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Cohen, EA (corresponding author), Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada.			Yao, Xiaojian/0000-0002-5022-1309				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kewalramani VN, 1996, VIROLOGY, V218, P159, DOI 10.1006/viro.1996.0176; Kobinger GP, 1998, J VIROL, V72, P5441, DOI 10.1128/JVI.72.7.5441-5448.1998; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LAVALLEE C, 1993, J ACQ IMMUN DEF SYND, V6, P529, DOI 10.1097/00126334-199305000-00014; LAVALLEE C, 1994, J VIROL, V68, P1926; Li MS, 1996, BIOCHEM BIOPH RES CO, V218, P352, DOI 10.1006/bbrc.1996.0061; Li XQ, 1997, J VIROL, V71, P5624, DOI 10.1128/JVI.71.7.5624-5630.1997; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; MAHALINGAM S, 1995, VIROLOGY, V207, P297, DOI 10.1006/viro.1995.1081; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SATO A, 1995, MICROBIOL IMMUNOL, V39, P1015, DOI 10.1111/j.1348-0421.1995.tb03293.x; Sato A, 1996, VIROLOGY, V220, P208, DOI 10.1006/viro.1996.0302; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WANG JJ, 1994, J GEN VIROL, V75, P2607, DOI 10.1099/0022-1317-75-10-2607; WU XY, 1994, J VIROL, V68, P6161, DOI 10.1128/JVI.68.10.6161-6169.1994; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; YAO XJ, 1992, J VIROL, V66, P5119, DOI 10.1128/JVI.66.8.5119-5126.1992; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0	52	90	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9083	9091		10.1074/jbc.274.13.9083	http://dx.doi.org/10.1074/jbc.274.13.9083			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085158	hybrid			2022-12-27	WOS:000079451600100
J	Huang, LE; Willmore, WG; Gu, J; Goldberg, MA; Bunn, HF				Huang, LE; Willmore, WG; Gu, J; Goldberg, MA; Bunn, HF			Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide - Implications for oxygen sensing and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; ARNT TRANSCRIPTION FACTOR; LACTATE-DEHYDROGENASE-A; DNA-BINDING ACTIVITY; FACTOR-I; ERYTHROPOIETIN GENE; PHOSPHOGLYCERATE KINASE-1; RESPONSIVE ELEMENT; SYNTHASE PROMOTER	It has been proposed that cells sense hypoxia by a heme protein, which transmits a signal that activates the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1), thereby inducing a number of physiologically relevant genes such as erythropoietin (Epo), We have investigated the mechanism by which two heme-binding ligands, carbon monoxide and nitric oxide, affect oxygen sensing and signaling, Two concentrations of CO (10 and 80%) suppressed the activation of HIF-1 and induction of Epo mRNA by hypoxia in a dose-dependent manner. In contrast, CO had no effect on the induction of HIF-1 activity and Epo expression by either cobalt chloride or the iron chelator desferrioxamine, The affinity of CO for the putative sensor was much lower than that of oxygen (Haldane coefficient, similar to 0.5). Parallel experiments were done with 100 mu M sodium nitroprusside, a nitric oxide donor. Both NO and CO inhibited HIF-1 DNA binding by abrogating hypoxia-induced accumulation of HIF-1 alpha protein. Moreover, both NO and CO specifically targeted the internal oxygen-dependent degradation domain of HIF-1 alpha, and also repressed the C-terminal transactivation domain of HIF-1 alpha. Thus, NO and CO act proximally, presumably as heme ligands binding to the oxygen sensor, whereas desferrioxamine and perhaps cobalt appear to act at a site downstream.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bunn, HF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol Oncol, LMRC-2,221 Longwood Ave, Boston, MA 02115 USA.	bunn@calvin.bwh.harvard.edu		Huang, Eric/0000-0002-6444-1708	NIDDK NIH HHS [F32-DK09365, R01-DK45098, R01-DK41234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009365, R01DK045098, R01DK041234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER H, 1994, ANN NY ACAD SCI, V718, P3; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BICKAR D, 1984, J BIOL CHEM, V259, P777; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; FANDREY J, 1993, BLOOD, V81, P617; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GARBERS DL, 1992, CELL, V71, P1; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOPFERT T, 1995, AM J PHYSIOL-REG I, V269, pR995, DOI 10.1152/ajpregu.1995.269.5.R995; GORLACH A, 1994, FEBS LETT, V348, P216, DOI 10.1016/0014-5793(94)00607-5; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Negelein E, 1931, BIOCHEM Z, V243, P386; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Srinivas V, 1998, J BIOL CHEM, V273, P18019, DOI 10.1074/jbc.273.29.18019; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WARBURG O, 1949, HEAVY METAL PROSTHET, P1; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; YONETANI T, 1972, J BIOL CHEM, V247, P2447	51	263	283	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9038	9044		10.1074/jbc.274.13.9038	http://dx.doi.org/10.1074/jbc.274.13.9038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085152	hybrid			2022-12-27	WOS:000079451600094
J	Jacob, R; Preuss, U; Panzer, P; Alfalah, M; Quack, S; Roth, MG; Naim, H; Naim, HY				Jacob, R; Preuss, U; Panzer, P; Alfalah, M; Quack, S; Roth, MG; Naim, H; Naim, HY			Hierarchy of sorting signals in chimeras of intestinal lactase-phlorizin hydrolase and the influenza virus hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMYLOID PRECURSOR PROTEIN; AMINO-ACID CHANGE; MDCK CELLS; CYTOPLASMIC DOMAIN; PHLORHIZIN HYDROLASE; INTERNALIZATION SIGNALS; HIPPOCAMPAL-NEURONS	Lactase-phlorizin hydrolase (LPH) is an apical protein in intestinal cells, The location of sorting signals in LPR was investigated by preparing a series of mutants that lacked the LPH cytoplasmic domain or had the cytoplasmic domain of LPH replaced by sequences that comprised basolateral targeting signals and overlapping internalization signals of various potency. These signals are mutants of the cytoplasmic domain of the influenza hemagglutinin (HA), which have been shown to be dominant in targeting HA to the basolateral membrane. The LPH-HA chimeras were expressed in Madin-Darby canine kidney (MDCK) and colon carcinoma (Caco-2) cells, and their transport to the cell surface was analyzed. All of the LPH mutants were targeted correctly to the apical membrane, Furthermore, the LPH-HA chimeras were internalized, indicating that the HA tails were available to interact with the cytoplasmic components of clathrin-coated pits. The introduction of a strong basolateral sorting signal into LPH was not sufficient to override the strong apical signals of the LPH external domain or transmembrane domains. These results show that basolateral sorting signals are not always dominant over apical sorting signals in proteins that contain each and suggest that sorting of basolateral from apical proteins occurs within a common compartment where competition for sorting signals can occur.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany; Univ Dusseldorf, Prot Secret Grp, D-40225 Dusseldorf, Germany; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Zurich, Inst Mol Biol Div 1, CH-8057 Zurich, Switzerland	University of Veterinary Medicine Hannover, Foundation; Heinrich Heine University Dusseldorf; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Zurich	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011; Al Falah, Dr. Marwan/C-6281-2011	Roth, Michael/0000-0002-9056-332X				Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Ball JM, 1997, AIDS RES HUM RETROV, V13, P665, DOI 10.1089/aid.1997.13.665; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DEHOOP M, 1995, J CELL BIOL, V130, P1447, DOI 10.1083/jcb.130.6.1447; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang XF, 1997, J BIOL CHEM, V272, P27598, DOI 10.1074/jbc.272.44.27598; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 1996, EUR J BIOCHEM, V236, P789, DOI 10.1111/j.1432-1033.1996.t01-1-00789.x; JACOB R, 1994, J BIOL CHEM, V269, P2712; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; LOW SH, 1991, J BIOL CHEM, V266, P13391; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; Moolenaar CEC, 1997, J CELL SCI, V110, P557; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; NAIM HY, 1994, METHOD CELL BIOL, V43, P113; NAIM HY, 1995, J CELL BIOL, V129, P1241, DOI 10.1083/jcb.129.5.1241; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Naim HY, 1996, EUR J CELL BIOL, V70, P198; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ouwendijk J, 1998, J BIOL CHEM, V273, P6650, DOI 10.1074/jbc.273.12.6650; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAGNO P, 1992, EXP CELL RES, V203, P236, DOI 10.1016/0014-4827(92)90060-L; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTH MG, 1983, CELL, V33, P435, DOI 10.1016/0092-8674(83)90425-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOOLE KL, 1992, J CELL SCI, V102, P495; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	62	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8061	8067		10.1074/jbc.274.12.8061	http://dx.doi.org/10.1074/jbc.274.12.8061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075706	hybrid			2022-12-27	WOS:000079268100065
J	Lai, CF; Ripperger, J; Wang, YP; Kim, H; Hawley, RB; Baumann, H				Lai, CF; Ripperger, J; Wang, YP; Kim, H; Hawley, RB; Baumann, H			The STAT3-independent signaling pathway by glycoprotein 130 in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; CYTOKINE RECEPTOR SUPERFAMILY; INHIBITORY FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; GROWTH-FACTOR; HEMATOPOIETIN RECEPTORS; INTERLEUKIN-6 RECEPTOR; SERINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN	Interleukin (IL)-6 is a major regulator of hepatic acute-phase plasma protein (APP) genes. The membrane-proximal 133-amino acid cytoplasmic domain of glycoprotein (gp) 130, containing one copy of the Box3 motif, is sufficient to transmit a productive signal to endogenous APP genes in rat hepatoma H-35 cells. In contrast, a mutant gp130 domain lacking the Box3 motif activates Janus kinases to a normal level but fails to activate signal transducer and activator of transcription 3 and to up-regulate a number of APP genes, including thiostatin, fibrinogen, hemopexin, and haptoglobin. However, in the absence of Box3, gp130 still stimulates the expression of alpha(2)-macroglobulin and synergizes with IL-1 to up-regulate alpha(1)-acid glycoprotein, The Box3 motif is not required for activation of the SH2-containing protein tyrosine phosphatase 2 or the mitogen-activated protein kinase (MAPK), nor is the immediate induction of egr-1 and junB significantly altered. Surprisingly, gp130 without any functional Box3 stimulates prolonged activation of MAPK, leading to an extended period of up-regulation of egr-1 and to an extracellularly regulated kinase-mediated reduction in the IL-B-stimulated production of thiostatin, IL-6 reduces proliferation of H-35 cells through signaling by the Box3, In addition, cells expressing Box3-deficient gp130 showed distinct morphologic changes upon receptor activation. Taken together, these results indicate that Box3-derived and Box3-independent signals cooperate in the control of hepatic APP genes and that Box3 may be involved in the modulation of MAPK activity in gp130 signaling.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada	Roswell Park Cancer Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	baumann@sc3101.med.buffalo.edu		Hawley, Robert/0000-0003-3512-5818; Kim, Hongkyun/0000-0002-4879-7122	NCI NIH HHS [CA26122, CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hirano T, 1998, Int Rev Immunol, V16, P249; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MILLAND J, 1990, AM J PHYSIOL, V259, pG340, DOI 10.1152/ajpgi.1990.259.3.G340; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROKITA H, 1990, COMP BIOCHEM PHYS A, V95, P41, DOI 10.1016/0300-9629(90)90007-F; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503	63	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7793	7802		10.1074/jbc.274.12.7793	http://dx.doi.org/10.1074/jbc.274.12.7793			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075671	hybrid			2022-12-27	WOS:000079268100030
J	Lareyre, JJ; Thomas, TZ; Zheng, WL; Kasper, S; Ong, DE; Orgebin-Crist, MC; Matusik, RJ				Lareyre, JJ; Thomas, TZ; Zheng, WL; Kasper, S; Ong, DE; Orgebin-Crist, MC; Matusik, RJ			A 5-kilobase pair promoter fragment of the murine epididymal retinoic acid-binding protein gene drives the tissue-specific, cell-specific, and androgen-regulated expression of a foreign gene in the epididymis of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT EPIDIDYMIS; MOUSE EPIDIDYMIS; MOLECULAR-CLONING; PROBASIN GENE; VAS-DEFERENS; IN-VIVO; DNA; PROSTATE; ADULT; NITROCELLULOSE	The murine epididymis synthesizes and secretes a retinoic acid-binding protein (mE-RABP) that belongs to the lipocalin superfamily, The gene encoding mE-RABP is specifically expressed in the mouse mid/distal caput epididymidis under androgen control. In transgenic mice, a 5-kilobase pair (kb) promoter fragment, but not a 0.6-kb fragment, of the mE-RABP gene driving the chloramphenicol acetyltransferase (CAT) reporter gene restricted high level of transgene expression to the caput epididymidis, No transgene expression was detected in any other male or female tissues. Immunolocalization of the CAT protein and in situ hybridization of the corresponding CAT mRNA indicated that transgene expression occurred in the principal cells of the mid/distal caput epididymidis, thereby mimicking the spatial endogenous mE-RABP gene expression. Transgene and mE-RABP gene expression was detected from 30 days and progressively increased until 60 days of age. Castration, efferent duct ligation, and hormone replacement studies demonstrated that transgene expression was specifically regulated by androgen but not by any other testicular factors. Altogether, our results demonstrate that the 5-kb promoter fragment of the mE-RABP gene contains all of the information required for the hormonal regulation and the spatial and temporal expression of the mE-RABP gene in the epididymis.	Vanderbilt Univ, Ctr Reprod Biol Res, Sch Med, Med Ctr N, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Obstet & Gynecol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Orgebin-Crist, MC (corresponding author), Vanderbilt Univ, Ctr Reprod Biol Res, Sch Med, Med Ctr N, Room D2303, Nashville, TN 37232 USA.	m-c.orgebin-crist@mcmail.vanderbilt.edu		Matusik, Robert/0000-0003-2057-9892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD003820, R01HD036900, P30HD005797, R01HD003820] Funding Source: NIH RePORTER; NICHD NIH HHS [HD03820, HD05797, HD36900] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUHAILA A, 1984, ANAT REC, V209, P197, DOI 10.1002/ar.1092090207; ASTRAUDO C, 1995, ARCH ANDROLOGY, V35, P247, DOI 10.3109/01485019508987877; BEDFORD JM, 1967, J EXP ZOOL, V166, P271, DOI 10.1002/jez.1401660210; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BROOKS DE, 1986, J BIOL CHEM, V261, P4956; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; DOUGLASS J, 1991, ANN NY ACAD SCI, V637, P384, DOI 10.1111/j.1749-6632.1991.tb27324.x; DYSON ALMB, 1973, ENDOCRINOLOGY, V93, P391, DOI 10.1210/endo-93-2-391; FAURE J, 1991, BIOL REPROD, V44, P13, DOI 10.1095/biolreprod44.1.13; GALLON C, 1989, J ANDROL, V10, P188; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; JEANFAUCHER C, 1985, INT J ANDROL, V8, P44, DOI 10.1111/j.1365-2605.1985.tb00817.x; Lan ZJ, 1998, BIOL REPROD, V58, P197, DOI 10.1095/biolreprod58.1.197; Lareyre JJ, 1998, MOL REPROD DEV, V50, P387, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;387::AID-MRD2&gt;3.0.CO;2-E; Lareyre JJ, 1998, ENDOCRINOLOGY, V139, P2971, DOI 10.1210/en.139.6.2971; LAREYRE JJ, 1998, 10 EUR WORKSH MOL CE; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NEWCOMER ME, 1990, J BIOL CHEM, V265, P12876; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; ONG DE, 1988, ARCH BIOCHEM BIOPHYS, V267, P474, DOI 10.1016/0003-9861(88)90053-7; ORGEBINCRIST MC, 1967, NATURE, V216, P816, DOI 10.1038/216816a0; OrgebinCrist MC, 1996, PHARMACOLOGY, BIOLOGY, AND CLINICAL APPLICATIONS OF ANDROGENS, P27; PALMITER RD, 1985, CELL, V41, P343, DOI 10.1016/S0092-8674(85)80004-0; PERRY ACF, 1993, BIOCHEM J, V293, P21, DOI 10.1042/bj2930021; RANKIN TL, 1992, BIOL REPROD, V46, P767, DOI 10.1095/biolreprod46.5.767; RANKIN TL, 1992, BIOL REPROD, V46, P747, DOI 10.1095/biolreprod46.5.747; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SKUDLAREK MD, 1986, BIOL REPROD, V35, P167, DOI 10.1095/biolreprod35.1.167; SKUDLAREK MD, 1992, BIOCHEM J, V286, P907, DOI 10.1042/bj2860907; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONEY TW, 1989, ENDOCRINOLOGY, V125, P243, DOI 10.1210/endo-125-1-243; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428	43	37	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8282	8290		10.1074/jbc.274.12.8282	http://dx.doi.org/10.1074/jbc.274.12.8282			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075734	hybrid, Green Published			2022-12-27	WOS:000079268100093
J	Cupillard, L; Mulherkar, R; Gomez, N; Kadam, S; Valentin, E; Lazdunski, M; Lambeau, G				Cupillard, L; Mulherkar, R; Gomez, N; Kadam, S; Valentin, E; Lazdunski, M; Lambeau, G			Both group IB and group IIA secreted phospholipases A(2) are natural ligands of the mouse 180-kDa M-type receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-NECROSIS-FACTOR; AMINO-ACID-SEQUENCE; ENHANCING FACTOR; MEMBRANE-RECEPTOR; PANCREATIC PHOSPHOLIPASE-A2; TOXIC PHOSPHOLIPASES-A2; STRUCTURAL ELEMENTS; CHROMOSOME 1P35-36	Snake venom and mammalian secreted phospholipases A(2) (sPLA(2)s) have been associated with toxic (neurotoxicity, myotoxicity, etc.), pathological (inflammation, cancer, etc.), and physiological (proliferation, contraction, secretion, etc.) processes. Specific membrane receptors (M and N types) for sPLA(2)s have been initially identified with snake venom sPLA(2)s as ligands, and the M-type 180-kDa receptor was cloned from different animal species. This paper addresses the problem of the endogenous ligands of the M-type receptor. Recombinant group IB and group ILA. sPLA(2)s from human and mouse species have been prepared and analyzed for their binding properties to M-type receptors from differ ent animal species. Both mouse group IB and group ILA sPLA(2)s are high affinity ligands (in the 1-10 nM range) for the mouse M-type receptor. These two sPLA(2)s are expressed in the mouse tissues where the M-type receptor is also expressed, making it likely that both types of sPLA(2)s are physiological ligands of the mouse M-type receptor. This conclusion does not hold for human group IB and IIA sPLA(2)s and the cloned human M-type receptor. The two mouse sPLA(2)s have relatively high affinities for the mouse M-type receptor, but they can have much lower affinities for receptors from other animal species, indicating that species specificity exists for sPLA(2) binding to M-type receptors, Caution should thus be exerted in avoiding mixing sPLA(2)s, cells, or tissues from different animal species in studies of the biological roles of mammalian sPLA(2)s associated with an action through their membrane receptors.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; Tata Mem Ctr, Canc Res Inst, Lab Genet Engn, Parel 400012, Mumbai, India	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Tata Memorial Centre (TMC)	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				Abe T, 1997, INT J CANCER, V74, P245, DOI 10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BROUCKAERT P, 1993, IMMUNOBIOLOGY, V187, P317, DOI 10.1016/S0171-2985(11)80347-5; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DESAI SJ, 1991, HISTOCHEMISTRY, V96, P371, DOI 10.1007/BF00271359; Dobbie Z, 1997, HUM GENET, V99, P653, DOI 10.1007/s004390050423; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Fan QS, 1997, MOL CELL BIOL, V17, P4238, DOI 10.1128/MCB.17.8.4238; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gandolfo G, 1996, PHARMACOL TOXICOL, V78, P341, DOI 10.1111/j.1600-0773.1996.tb01386.x; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Haluska FG, 1997, INT J CANCER, V72, P337, DOI 10.1002/(SICI)1097-0215(19970717)72:2<337::AID-IJC22>3.0.CO;2-B; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hara N, 1997, ADV EXP MED BIOL, V407, P109; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Kadam Shilpa, 1998, Indian Journal of Experimental Biology, V36, P553; Kennedy BP, 1998, CANCER RES, V58, P500; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; Lambeau G, 1997, VENOM PHOSPHOLIPASE, P389; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Minami T, 1997, J GASTROENTEROL, V32, P431, DOI 10.1007/BF02934505; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MULHERKAR R, 1986, FEBS LETT, V207, P142, DOI 10.1016/0014-5793(86)80028-X; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1986, J CELL PHYSIOL, V127, P183, DOI 10.1002/jcp.1041270122; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURATA K, 1993, BRIT J CANCER, V68, P103, DOI 10.1038/bjc.1993.294; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; OHARA O, 1986, J BIOCHEM-TOKYO, V99, P733, DOI 10.1093/oxfordjournals.jbchem.a135532; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; OLIVIER JL, 1994, BIOCHEMISTRY-US, V33, P7134, DOI 10.1021/bi00189a017; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; Rae D., 1996, SCAND J GASTROENTE S, V219, P24; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIGGINS GJ, 1995, CANCER RES, V55, P5184; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; Spirio LN, 1996, CANCER RES, V56, P955; Taylor ME, 1997, GLYCOBIOLOGY, V7, pR5; THIEME TR, 1987, J IMMUNOL, V139, P1173; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VERHEIJ HM, 1983, BIOCHIM BIOPHYS ACTA, V747, P93, DOI 10.1016/0167-4838(83)90126-7; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0	80	121	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7043	7051		10.1074/jbc.274.11.7043	http://dx.doi.org/10.1074/jbc.274.11.7043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066760	hybrid			2022-12-27	WOS:000079078400032
J	Lai, K; Willis, AC; Elsas, LJ				Lai, K; Willis, AC; Elsas, LJ			The biochemical role of glutamine 188 in human galactose-1-phosphate uridyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; URIDYL TRANSFERASE; URIDYLYLTRANSFERASE; GALACTOSE; SEQUENCE; MUTATION; ENZYME; GENE; IDENTIFICATION; HISTIDINE-166	The substitution of arginine for glutamine at amino acid 188 (Q188R) ablates the function of human galactose-1-phosphate uridyltransferase (GALT) and is the most common mutation causing galactosemia in the white population. GALT catalyzes two consecutive reactions. The first reaction binds UDP-glucose (UDP-Glu), displaces glucose-1-phosphate (glu-1-P), and forms the UMP-GALT intermediate, In the second reaction, galactose-1-phosphate (gal-1-P) is bound, UDP-galactose (UDP-Gal) is released, and the free enzyme is recycled, In this study, we modeled glutamine, asparasne, and a common mutation arginine at amino acid 188 on the three-dimensional model of the Escherichia coli GALT-UMP protein crystal, We found that the amide group of the glutamine side chain could provide two hydrogen bonds to the phosphoryl oxygens of UMP with lengths of 2.52 and 2.82 Angstrom. Arginine and asparasne could provide only one hydrogen bond of 2.52 and 3.02 Angstrom respectively. To test this model, we purified recombinant human Gln(188)-, Arg(188)., and Asn(188)-GALT and analyzed the first reaction in the absence of gal-1-P by quantitating glu-1-P released using enzyme-linked methods. Gln(188)-GALT displaced 80 +/- 7.0 nmol glu-1-P/mg GALT/min in the first reaction. By contrast, both Arg(188). and Asn(188)-GALT released more glu-1-P (170 +/- 8.0 and 129 +/- 28.4 nmol/mg GALT/min, respectively). The overall, double displacement reaction was quantitated in the presence of gall-P, Gln(188)-GALT produced 80,030 +/- 5,910 nmol glu-1-P/mg GALT/min, whereas the mutant Arg(188). and Asn(188) GALT released only 600 +/- 71.2 and 2960 +/- 283.6 nmole glu-1-P/mg GALT/min, respectively, We conclude from these data that glutamine at position 188 stabilizes the UMP-GALT intermediate through hydrogen bonding and enables the double displacement of both glu-1-P and UDP-Gal, The substitution of arginine or asparagine at position 188 reduces hydrogen bonding and destabilizes UMP-GALT, The unstable UMP-GALT allows single displacement of glu-1-P with release of free GALT but impairs the subsequent binding of gal-1-P and displacement of UDP-Gal.	Emory Univ, Sch Med, Dept Biochem, Div Med Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Div Med Genet, Atlanta, GA 30322 USA	Emory University; Emory University	Elsas, LJ (corresponding author), Emory Univ, Sch Med, Dept Biochem, Div Med Genet, 2040 Ridgewood Dr Bldg, Atlanta, GA 30322 USA.	lje@rw.ped.emory.edu		Amara, Amy/0000-0003-0762-9656	NCRR NIH HHS [M01-RR00039] Funding Source: Medline; NICHD NIH HHS [P0-1 HD29847-04] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD029847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000039] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CORNWELL TL, 1987, NUCLEIC ACIDS RES, V15, P8116, DOI 10.1093/nar/15.19.8116; Elsas LJ, 1998, GENET MED, V1, P40; ELSAS LJ, 1995, EUROPEAN J PEDS, V154, P21; Elsevier JP, 1996, J BIOL CHEM, V271, P32002, DOI 10.1074/jbc.271.50.32002; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; FLACH JE, 1990, MOL BIOL MED, V7, P365; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; FREY PA, 1992, ENZYMES, V20, P141; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; Hochuli E, 1990, Genet Eng (N Y), V12, P87; INDGE KJ, 1976, BIOCHEM J, V155, P567, DOI 10.1042/bj1550567; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; Lai K, 1998, HUM MUTAT, V11, P28; Lai K, 1996, J PEDIATR-US, V128, P89, DOI 10.1016/S0022-3476(96)70432-8; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LELOIR LF, 1951, ARCH BIOCHEM BIOPHYS, V33, P186, DOI 10.1016/0003-9861(51)90096-3; LESLIE ND, 1992, GENOMICS, V14, P474, DOI 10.1016/S0888-7543(05)80244-7; MARKUS HB, 1977, J BIOL CHEM, V252, P5363; Moore DD, 1995, GLOB MOB SURV; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; REICHARDT JKV, 1991, AM J HUM GENET, V49, P860; RUNYAN KR, 1989, METHOD ENZYMOL, V171, P164; RUZICKA FJ, 1993, BIOORG CHEM, V21, P238, DOI 10.1006/bioo.1993.1020; SAITO S, 1967, J BIOL CHEM, V242, P2362; Segal S, 1995, METABOLIC MOL BASIS, P967; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; WEDEKIND JE, 1994, ACTA CRYSTALLOGR D, V50, P329, DOI 10.1107/S0907444993012958; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WELLS L, 1996, J INHERIT METAB DIS, V20, P633; WILLIAMS VP, 1978, ARCH BIOCHEM BIOPHYS, V191, P182, DOI 10.1016/0003-9861(78)90080-2; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1974, BIOCHEMISTRY-US, V13, P3889, DOI 10.1021/bi00716a011; [No title captured]	37	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6559	6566		10.1074/jbc.274.10.6559	http://dx.doi.org/10.1074/jbc.274.10.6559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037750	hybrid			2022-12-27	WOS:000078902800072
J	Olafsdottir, S; Martinez, A				Olafsdottir, S; Martinez, A			The accessibility of iron at the active site of recombinant human phenylalanine hydroxylase to water as studied by H-1 NMR paramagnetic relaxation - Effect of L-Phe and comparison with the rat enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; SUBSTRATE-BINDING; FUSION PROTEIN; ACTIVATION; H-1-NMR; 4-MONOOXYGENASE; PURIFICATION; STATE	The high-spin (S = 5/2) Fe(III) ion at the active site of recombinant human phenylalanine hydroxylase (PAH) has a paramagnetic effect on the longitudinal relaxation rate of water protons. This effect is proportional to the concentration of enzyme, with a paramagnetic molar-relaxivity value at 400 MHz and 25 degrees C of 1.3 (+/- 0.03) x 10(3) s(-1) M-1. The value of the Arrhenius activation energy (E-a) for the relaxation rate was -14.4 +/- 1.1 kJ/mol for the resting enzyme, indicating a fast exchange of water protons in the paramagnetic environment. The frequency dependence of the relaxation rate also supported this hypothesis. Thus, the recombinant human PAH appears to have a more solvent-accessible catalytic iron than the rat enzyme, in which the water coordinated to the metal is slowly exchanging with the solvent, These findings may be related to the level of basal activity before activation for these enzymes, which is higher for human than for rat PAH, In the presence of saturating (5 mM) concentrations of the substrate L-Phe, the paramagnetic molar relaxivity for human PAH decreased to 0.72 (+/- 0.05) x 10(3) s(-1) M-1 with no significant change in the E-a. Effective correlation times (tau(C)) of 1.8 (+/- 0.3) x 10(-10) and 1.25 (+/- 0.2) x 10(-10) s(-1) were calculated for the enzyme and the enzyme-substrate complex, respectively, and most likely represent the electron spin relaxation rate (tau(S)) for Fe(III) in each case. Together with the paramagnetic molar-relaxivity values, the tau(C) values were used to estimate Fe(III)-water distances. It seems that at least one of the three water molecules coordinated to the iron in the resting rat and human enzymes is displaced from coordination on the binding of L-Phe at the active site.	Univ Bergen, Dept Biochem, N-5009 Bergen, Norway	University of Bergen	Martinez, A (corresponding author), Univ Bergen, Dept Biochem, Arstadveien 19, N-5009 Bergen, Norway.		Martinez, Aurora/M-3088-2019	Martinez, Aurora/0000-0003-1643-6506				Blair D., 1961, TALANTA LONDON, V7, P163; BLOEMBERGEN N, 1957, J CHEM PHYS, V27, P572, DOI 10.1063/1.1743771; BLOOM LM, 1986, BIOCHEMISTRY-US, V25, P4204, DOI 10.1021/bi00363a006; BURTON DR, 1979, PROG NUCL MAG RES SP, V13, P1, DOI 10.1016/0079-6565(79)80012-6; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; CITRON BA, 1992, PROTEIN EXPRES PURIF, V3, P93, DOI 10.1016/S1046-5928(05)80024-5; Doskeland AP, 1996, BIOCHEM J, V313, P409, DOI 10.1042/bj3130409; DWEK RA, 1975, APPL ENZYME SYSTEMS, P247; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; HERSHBERG RD, 1975, BIOCHEMISTRY-US, V14, P3885, DOI 10.1021/bi00688a023; JARORI GK, 1989, BIOCHEMISTRY-US, V28, P9343, DOI 10.1021/bi00450a015; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Knappskog PM, 1997, FEBS LETT, V409, P7, DOI 10.1016/S0014-5793(97)00465-1; Kowlessur D, 1996, ARCH BIOCHEM BIOPHYS, V333, P85, DOI 10.1006/abbi.1996.0367; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; Loeb KE, 1997, J AM CHEM SOC, V119, P1901, DOI 10.1021/ja962269h; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MARTINEZ A, 1991, EUR J BIOCHEM, V198, P675, DOI 10.1111/j.1432-1033.1991.tb16066.x; MARTINEZ A, 1990, EUR J BIOCHEM, V193, P211, DOI 10.1111/j.1432-1033.1990.tb19325.x; MARTINEZ A, 1993, EUR J BIOCHEM, V211, P259, DOI 10.1111/j.1432-1033.1993.tb19894.x; MILDVAN AS, 1980, METHODS DETERMINING, P211; QUE L, 1977, BIOCHIM BIOPHYS ACTA, V485, P60; Scriver C.R., 1995, METABOLIC MOL BASIS, V7th ed, P1015; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; [No title captured]	32	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6280	6284		10.1074/jbc.274.10.6280	http://dx.doi.org/10.1074/jbc.274.10.6280			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037716	hybrid			2022-12-27	WOS:000078902800038
J	Viale, A; Ortola, C; Hervieu, G; Furuta, M; Barbero, P; Steiner, DF; Seidah, NG; Nahon, JL				Viale, A; Ortola, C; Hervieu, G; Furuta, M; Barbero, P; Steiner, DF; Seidah, NG; Nahon, JL			Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; MICROINJECTED XENOPUS OOCYTES; PROPROTEIN CONVERTASE; SECRETORY PATHWAY; PUTATIVE NEUROPEPTIDES; CDNA STRUCTURE; YEAST KEX2; RAT; EXPRESSION; PC2	Melanin concentrating hormone (MCH) and neuropeptide EI (NEI) are two peptides produced from the same precursor in mammals, by cleavage at the Arg(145) Arg(146) Site and the Lys(129)-Arg(130) site, respectively. We performed co-localization studies to reveal simultaneously the expression of MCH mRNA and proconvertases (PCs) such as PC1/3 or PC2. In the rat hypothalamus, PC2 was present in all MCH neurons, and PC1/3 was present in about 15-20% of these cells. PC1/3 or PC2 was not found in MCH-positive cells in the spleen. In GH(4)C(1) cells co-infected with vaccinia virus (VV):pro-MCH along with VV:furin, PACE4, PC1/3, PC2, PC5/6A, PC5/6B, or PC7, we observed only efficient cleavage at the Arg(145)-Arg(146) Site to generate mature MCH. Co-expression of pro-MCH together with PC2 and 7B2 resulted in very weak processing to NEI. Comparison of pro-MCH processing patterns in PC1/3- or PC2-transfected PC12 cells showed that PC2 but not PC1/3 generated NEI. Finally, we analyzed the pattern of pro-MCH processing in PC2 null mice. In the brain of homozygotic mutants, the production of mature NEI was dramatically reduced. In contrast, MCH content was increased in the hypothalamus of PC2 null mice. In the spleen, a single large MCH-containing peptide was identified in both wild type and PC2 nub mice, Together, our data suggest that pra-MCH is processed differently in the brain and in peripheral organs of mammals. PC2 is the key enzyme that produces NEI, whereas several PCs may cleave at the Arg(145)-Arg(146) Site to generate MCH in neuronal cell types.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Nahon, JL (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	Nahonjl@ipmc.cnrs.fr	NAHON, Jean-Louis/O-7977-2016; Seidah, Nabil/I-3596-2013	NAHON, Jean-Louis/0000-0001-9572-7779; Seidah, Nabil/0000-0001-6503-9342	NIDDK NIH HHS [DK 13914, DK 20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, P60DK020595, R37DK013914, P30DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER BI, 1994, TRENDS ENDOCRIN MET, V5, P120, DOI 10.1016/1043-2760(94)90093-0; Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Grillon S, 1997, NEUROPEPTIDES, V31, P131, DOI 10.1016/S0143-4179(97)90081-0; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hervieu G, 1996, ENDOCRINOLOGY, V137, P561, DOI 10.1210/en.137.2.561; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; Hervieu G, 1996, BIOL REPROD, V54, P1161, DOI 10.1095/biolreprod54.6.1161; Johanning K, 1996, J NEUROCHEM, V66, P898; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; Laslop A, 1998, J NEUROCHEM, V70, P374; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARCINKIEWICZ M, 1993, P NATL ACAD SCI USA, V90, P4922, DOI 10.1073/pnas.90.11.4922; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PARKES D, 1992, ENDOCRINOLOGY, V131, P1826, DOI 10.1210/en.131.4.1826; Presse F, 1997, MOL BRAIN RES, V52, P270, DOI 10.1016/S0169-328X(97)00273-8; PRESSE F, 1992, ENDOCRINOLOGY, V131, P1241, DOI 10.1210/en.131.3.1241; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; RISOLD PY, 1992, NEUROSCI LETT, V136, P145, DOI 10.1016/0304-3940(92)90035-6; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Rothenberg ME, 1996, MOL ENDOCRINOL, V10, P331, DOI 10.1210/me.10.4.331; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; SEIDAH NG, 1993, ANN NY ACAD SCI, V680, P135, DOI 10.1111/j.1749-6632.1993.tb19680.x; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEIDAH NG, 1998, MOL B INT U, V2, P49; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI K, 1995, NEUROENDOCRINOLOGY, V61, P493, DOI 10.1159/000126872; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; Viale A, 1997, MOL BRAIN RES, V46, P243, DOI 10.1016/S0169-328X(97)00018-1; Wang W, 1998, BIOCHEM BIOPH RES CO, V248, P538, DOI 10.1006/bbrc.1998.9006; Yoon J, 1997, ENDOCRINOLOGY, V138, P3620, DOI 10.1210/en.138.9.3620; ZHENG M, 1994, J NEUROSCI, V14, P4656; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	58	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6536	6545		10.1074/jbc.274.10.6536	http://dx.doi.org/10.1074/jbc.274.10.6536			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037747	hybrid			2022-12-27	WOS:000078902800069
J	Jones, JM; Nau, K; Geraghty, MT; Erdmann, R; Gould, SJ				Jones, JM; Nau, K; Geraghty, MT; Erdmann, R; Gould, SJ			Identification of peroxisomal acyl-CoA thioesterases in yeast and humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAT-LIVER; LONG-CHAIN; BIOGENESIS DISORDERS; BETA-OXIDATION; GENE; PURIFICATION; MEMBRANE; PROLIFERATORS; BINDING	A computer-based screen of the Saccharomyces cerevisiae genome identified YJR019C as a candidate oleate-induced gene. YJR019C mRNA levels were increased significantly during growth on fatty acids, suggesting that; it may play a role in fatty acid metabolism, The YJR019C product is highly similar to tesB, a bacterial acyl-CoA thioesterase, and carries a tripeptide sequence, alanine-lysine-phenylalanine(COOH), that closely resembles the consensus sequence for type-1 peroxisomal targeting signals. YJR019C directed green fluorescence protein to peroxisomes, and biochemical studies revealed that YJR019C is an abundant component of purified yeast peroxisomes, Disruption of the YJR019C gene caused a significant decrease in total cellular thioesterase activity, and recombinant YJR019C was found to exhibit intrinsic acyl-CoA thioesterase activity of 6 units/mg, YJR019C also shared significant sequence similarity with hTE, a human thioesterase that was previously identified because of its interaction with human immunodeficiency virus-Nef in the yeast two-hybrid assay. We report here that hTE is also a peroxisomal protein, demonstrating that thioesterase activity is a conserved feature of peroxisomes, We propose that YJR019C and hTE be renamed as yeast, and human PTE1 to reflect the fact that they encode peroxisomal thioesterases. The physical segregation of yeast and human PTE1 from the cytosolic fatty acid synthase suggests that these enzymes are unlikely to play a role in formation of fatty acids. Instead, the observation that PTE1 contributes to growth on fatty acids implicates this thioesterase in fatty acid oxidation.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Ruhr Univ Bochum, Dept Physiol Chem, D-44780 Bochum, Germany	Johns Hopkins University; Johns Hopkins University; Ruhr University Bochum	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	Stephen.Gould@qmail.bs.jhu.edu			NIDDK NIH HHS [DK45787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKERBRACHMANN C, 1998, YEAST, V14, P115; CRANE DI, 1994, J BIOL CHEM, V269, P21835; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P569; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; KUNAU WH, 1992, PROG CLIN BIOL RES, V375, P9; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LEE KY, 1979, J BIOL CHEM, V254, P4516; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Mannaerts GP, 1996, ANN NY ACAD SCI, V804, P99, DOI 10.1111/j.1749-6632.1996.tb18611.x; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; Sambrook J., 2002, MOL CLONING LAB MANU; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	30	68	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9216	9223		10.1074/jbc.274.14.9216	http://dx.doi.org/10.1074/jbc.274.14.9216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092594	hybrid			2022-12-27	WOS:000079451800013
J	Shi, JY; Zhu, HF; Arvidson, DN; Woldegiorgis, G				Shi, JY; Zhu, HF; Arvidson, DN; Woldegiorgis, G			A single amino acid change (substitution of glutamate 3 with alanine) in the N-terminal region of rat liver carnitine palmitoyltransferase I abolishes malonyl-CoA inhibition and high affinity binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART; YEAST; SENSITIVITY; EXPRESSION; ENZYME; SITES; CDNA; POLYPEPTIDE; ISOFORM; PROTEIN	We have recently shown by deletion mutation analysis that the conserved first 18 N-terminal amino acid residues of rat liver carnitine palmitoyltransferase I (L-CPTI) are essential for malonyl-CoA inhibition and binding (Shi, J., Zhu, H,, Arvidson, D, N,, Cregg, J, M,, and Woldegiorgis, G, (1998) Biochemistry 37, 11033-11038), To identify specific residue(s) involved in malonyl-CoA binding and inhibition of L-CPTI, we constructed two more deletion mutants, Delta 12 and Delta 6, and three substitution mutations within the conserved first six amino acid residues. Mutant L-CPTI, lacking either the first six N-terminal amino acid residues or with a change of glutamic acid 3 to alanine, was expressed at steady-state levels similar to wild type and had near wild type catalytic activity, However, malonyl-CoA inhibition of these mutant enzymes was reduced 100-fold, and high affinity malonyl-CoA binding was lost, A mutant L-CPTI with a change of histidine 5 to alanine caused only partial loss of malonyl-CoA inhibition, whereas a mutant L-CPTI with a change of glutamine 6 to alanine had wild type properties. These results demonstrate that glutamic acid 3 and histidine 5 are necessary for malonyl-CoA binding and inhibition of L-CPTI by malonyl-CoA but are not required for catalysis.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR 97291 USA		Woldegiorgis, G (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, POB 91000, Portland, OR 97291 USA.	gwoldeg@bmb.ogi.edu			NHLBI NIH HHS [HL52571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P26438; COOK GA, 1994, J BIOL CHEM, V269, P8803; COOK GA, 1987, J BIOL CHEM, V262, P2050; CORR PB, 1995, HERZ, V20, P156; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Hamel FG, 1997, BIOCHEM BIOPH RES CO, V234, P671, DOI 10.1006/bbrc.1997.6693; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; KASHFI K, 1995, LIPIDS, V30, P383, DOI 10.1007/BF02536295; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1987, BIOCHIM BIOPHYS ACTA, V878, P243; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; PAULY DF, 1988, J BIOL CHEM, V263, P18160; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; STEPHENS TW, 1983, BIOCHEM J, V212, P521, DOI 10.1042/bj2120521; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	35	59	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9421	9426		10.1074/jbc.274.14.9421	http://dx.doi.org/10.1074/jbc.274.14.9421			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092622	hybrid			2022-12-27	WOS:000079451800041
J	Svensson, L; Aszodi, A; Reinholt, FP; Fassler, R; Heinegard, D; Oldberg, A				Svensson, L; Aszodi, A; Reinholt, FP; Fassler, R; Heinegard, D; Oldberg, A			Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; LEUCINE-RICH REPEATS; TARGETED DISRUPTION; ARTICULAR-CARTILAGE; MATRIX PROTEINS; SKIN FRAGILITY; BIGLYCAN GENE; STEM-CELLS; DECORIN; FIBRILLOGENESIS	Fibromodulin is a member of a family of connective tissue glycoproteins/proteoglycans containing leucine-rich repeat motifs. Several members of this gene family bind to fibrillar collagens and are believed to function in the assembly of the collagen network in connective tissues. Here we show that mice lacking a functional fibromodulin gene exhibit an altered morphological phenotype in tail tendon with fewer and abnormal collagen fiber bundles. In fibromodulin-null animals virtually all collagen fiber bundles are disorganized and have an abnormal morphology. Also 10-20% of the bundles in heterozygous mice are similar to the abnormal bundles in fibromodulin-null tail tendon. Ultrastructural analysis of Achilles tendon from fibromodulin-null mice show collagen fibrils with irregular and rough outlines in cross-section. Morphometric analysis show that fibromodulin-null mice have on the average thinner fibrils than wild type animals as a result of a larger preponderance of very thin fibrils in an overall similar range of fibril diameters. Protein and RNA analyses show an approximately 4-fold increase in the content of lumican in fibromodulin-null as compared with wild type tail tendon, despite a decrease in lumican mRNA These results demonstrate a role for fibromodulin in collagen fibrillogenesis and suggest that the orchestrated action of several leucine-rich repeat glycoproteins/proteoglycans influence the architecture of collagen matrices.	Univ Lund, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden; Natl Hosp Norway, Dept Pathol, Lab Electron Microscopy, N-0027 Oslo, Norway	Lund University; Lund University; Skane University Hospital; University of Oslo; National Hospital Norway	Oldberg, A (corresponding author), Univ Lund, Dept Cell & Mol Biol, POB 94, S-22100 Lund, Sweden.	ake.oldberg@medkem.lu.se						ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; ASZODI A, 1994, MATRIX BIOL, V14, P181, DOI 10.1016/0945-053X(94)90007-8; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIRK DE, 1989, P NATL ACAD SCI USA, V86, P4549, DOI 10.1073/pnas.86.12.4549; BJORCK L, 1977, SCAND J IMMUNOL, V6, P1063; Blevins FT, 1997, ORTHOP CLIN N AM, V28, P1, DOI 10.1016/S0030-5898(05)70260-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; GLOSSL J, 1983, BIOCHEM J, V215, P295; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kadler KE, 1996, BIOCHEM J, V316, P1; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LARSSON T, 1991, J BIOL CHEM, V266, P20428; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NEUFELD EF, 1973, LYSOSOMES STORAGE DI, P261; Nurminskaya MV, 1998, ARCH BIOCHEM BIOPHYS, V350, P1, DOI 10.1006/abbi.1997.0498; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; REINHOLT FP, 1982, J ULTRA MOL STRUCT R, V80, P270, DOI 10.1016/S0022-5320(82)80040-3; ROUGHLEY PJ, 1996, OSTEOARTHR CARTILAGE, V4, P229; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	54	348	361	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9636	9647		10.1074/jbc.274.14.9636	http://dx.doi.org/10.1074/jbc.274.14.9636			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092650	hybrid			2022-12-27	WOS:000079451800069
J	Waldron, RT; Iglesias, T; Rozengurt, E				Waldron, RT; Iglesias, T; Rozengurt, E			The pleckstrin homology domain of protein kinase D interacts preferentially with the eta isoform of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MOLECULAR-CLONING; PHORBOL ESTERS; GROWTH-FACTORS; INTACT-CELLS; PH DOMAINS; ACTIVATION; DIACYLGLYCEROL; TARGET; ASSOCIATION	The results presented here demonstrate that protein kinase D (PKD) and PKC eta transiently coexpressed in COS-7 cells form complexes that can be immunoprecipitated from cell lysates using specific antisera to PKD or PKC eta. The presence of PKC eta in PKD immune complexes was initially detected by in vitro kinase assays which reveal the presence of an 80-kDa phosphorylated band in addition to the 110-kDa band corresponding to autophosphorylated PHD. The association between PKD and PKC eta was further verified by Western blot analysis and peptide phosphorylation assays that exploited the distinct substrate specificity between PKCs and PKD. By the same criteria, PKD formed complexes only very weakly with PKC epsilon, and did not bind PKC zeta. When PKC eta was coexpressed with PHD mutants containing either complete or partial deletions of the PH domain, both PKC eta immunoreactivity and PKC activity in PHD immunoprecipitates were sharply reduced. In contrast, deletion of an amino-terminal portion of the molecule, either cysteine-rich region, or the entire cysteine-rich domain did not interfere with the association of PBD with PKC eta. Furthermore, a glutathione S-transferase-PKDPH fusion protein bound preferentially to PKC eta, These results indicate that the PHD PH domain can discriminate between closely related structures of a single enzyme family, e.g. novel PKCs epsilon and eta, thereby revealing a previously undetected degree of specificity among protein-protein interactions mediated by PH domains.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, London WC2A 3PX, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Warren Hall,Room 11-124, Los Angeles, CA 90095 USA.		Vacas, Teresa Iglesias/ABF-8663-2020; Waldron, Richard Taliesin/ABF-2773-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Waldron, Richard Taliesin/0000-0003-3151-6002				Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1995, CANCER SURV, V24, P81; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	31	104	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9224	9230		10.1074/jbc.274.14.9224	http://dx.doi.org/10.1074/jbc.274.14.9224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092595	hybrid			2022-12-27	WOS:000079451800014
J	Loihl, AK; Whalen, S; Campbell, IL; Mudgett, JS; Murphy, S				Loihl, AK; Whalen, S; Campbell, IL; Mudgett, JS; Murphy, S			Transcriptional activation following cerebral ischemia in mice of a promoter-deleted nitric oxide synthase-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACKING; LIPOPOLYSACCHARIDE; SUPEROXIDE; OXYGENASE; RESPONSES; DOMAINS; CELLS	Nitric oxide synthase (NOS)-2 is transcriptionally activated in a wide variety of injurious conditions, including cerebral ischemia, and the resulting nitric oxide is implicated both in tissue damage and recovery. Studies in vitro suggest that the proximal region of the NOS-2 promoter is obligatory for gene activation by proinflammatory cytokines, However, following cerebral ischemia in a NOS-2 gene-deficient mouse in which this region and exons 1-4 have been deleted, we find temporal and spatial expression, identical to wild-type, from a previously unidentified promoter region. The resulting protein is predicted to lack the first 113 amino acids and is NOS-S-incompetent, Fortuitously, this gene-deficient mouse presents a unique opportunity to determine more about the mechanisms of NOS-2 gene regulation in vivo.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Neurosci Program, Iowa City, IA 52242 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Merck Res Labs, Dept Mol Pharmacol Immunol & Rheumatol, Rahway, NJ 07065 USA	University of Iowa; University of Iowa; Scripps Research Institute; Merck & Company	Murphy, S (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-530 Bowen Sci Bldg, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029226] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-29226] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRONSON SK, 1994, J BIOL CHEM, V269, P27155; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; KIM HH, 1994, J BIOL CHEM, V269, P24747; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Loihl AK, 1998, PROG BRAIN RES, V118, P253; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MURPHY S, 1990, P33; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; POU S, 1992, J BIOL CHEM, V267, P24173; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	29	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8844	8849		10.1074/jbc.274.13.8844	http://dx.doi.org/10.1074/jbc.274.13.8844			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085127	hybrid			2022-12-27	WOS:000079451600069
J	Sanchez, M; Calzada, A; Bueno, A				Sanchez, M; Calzada, A; Bueno, A			The Cdc6 protein is ubiquitinated in vivo for proteolysis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL CYCLE; DNA-REPLICATION; BUDDING YEAST; FISSION YEAST; S-PHASE; CDK INHIBITOR; SCHIZOSACCHAROMYCES-POMBE; DEPENDENT PROTEOLYSIS; INITIATION; DEGRADATION	The Saccharomyces cerevisiae Cdc6 protein is necessary for the formation of pre-replicative complexes that are required for firing DNA replication at origins at the beginning of S phase. Cdc6p protein levels oscillate during the cell cycle. In a normal cell cycle the presence of this protein is restricted to G(1), partly because the CDC6 gene is transcribed only during G(1) and partly because the Cdc6p protein is rapidly degraded at late G(1)/early S phase, We report here that the Cdc6p protein is degraded in a Cdc4-dependent manner, suggesting that phosphorylated Cdc6 is specifically recognized by the ubiquitin-mediated proteolysis machinery. Indeed, we have found that Cdc6 is ubiquitinated in vivo and degraded by a Cdc4-dependent mechanism. Our data, together with previous observations regarding Cdc6 stability, suggest that under physiological conditions budding yeast cells degrade ubiquitinated Cdc6 every cell cycle at the beginning of S phase.	Univ Salamanca, CSIC, Inst Microbiol Bioquim,Edificio Dept, Ctr Invest Canc,Dept Microbiol & Genet, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bueno, A (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim,Edificio Dept, Ctr Invest Canc,Dept Microbiol & Genet, Campus Miguel de Unamuno, Salamanca 37007, Spain.	abn@gugu.usal.es	SANCHEZ, MAR/L-1898-2017; Calzada, Arturo/M-1168-2014; Bueno, Avelino/A-9505-2016	Calzada, Arturo/0000-0002-3190-688X; Bueno, Avelino/0000-0002-0362-4391; Sanchez, Maria del Mar/0000-0003-4438-0722				[Anonymous], 1991, Methods Enzymol, V194, P1; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WHITBREAD LA, 1995, GENE, V155, P113, DOI 10.1016/0378-1119(94)00925-I; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	40	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9092	9097		10.1074/jbc.274.13.9092	http://dx.doi.org/10.1074/jbc.274.13.9092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085159	hybrid			2022-12-27	WOS:000079451600101
J	Schaubach, OL; Dombroski, AJ				Schaubach, OL; Dombroski, AJ			Transcription initiation at the flagellin promoter by RNA polymerase carrying sigma(28) from Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; LAC UV5 PROMOTER; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; AMINO-ACIDS; START-SITE; NONTEMPLATE STRAND; SIGMA-70 SUBUNIT; TETR PROMOTER; BINDING	The sigma subunit of RNA polymerase is a critical factor in positive control of transcription initiation. Primary a factors are essential proteins required for vegetative growth, whereas alternative sigma factors mediate transcription in response to various stimuli. Late gene expression during flagellum biosynthesis in Salmonella typhimurium is dependent upon an alternative a factor, sigma(28), the product of the fliA gene. We have characterized the intermediate complexes formed by sigma(28) holoenzyme on the pathway to open complex formation. Interactions with the promoter for the flagellin gene fliC were analyzed using DNase I and KMnO4 footprinting over a range of temperatures. We propose a model in which closed complexes are established in the upstream region of the promoter, including the -35 element, but with little significant contact in the -10 element or downstream regions of the promoter. An isomerization event extends the DNA contacts into the -10 element and the start site, with loss of the most distal upstream contacts accompanied by DNA melting to form open complexes, Melting occurs efficiently even at 16 degrees C. Once open complexes have formed, they are unstable to heparin challenge even in the presence of nucleoside triphosphates, which have been observed to stabilize open complexes at rRNA promoters.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Dombroski, AJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.	dombros@utmmg.med.uth.tmc.edu			NIGMS NIH HHS [GM56453-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; CHEN YF, 1992, P NATL ACAD SCI USA, V89, P5123, DOI 10.1073/pnas.89.11.5123; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DUVALVALENTIN G, 1987, NUCLEIC ACIDS RES, V15, P575, DOI 10.1093/nar/15.2.575; DUVALVALENTIN G, 1986, NUCLEIC ACIDS RES, V14, P1967, DOI 10.1093/nar/14.5.1967; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Fredrick K, 1997, P NATL ACAD SCI USA, V94, P4982, DOI 10.1073/pnas.94.10.4982; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GRALLA JD, 1993, FOOTPRINTING TECHNIQ, P107; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; Johnson BD, 1997, J BIOL CHEM, V272, P31029, DOI 10.1074/jbc.272.49.31029; JONES CH, 1992, J BACTERIOL, V174, P6815, DOI 10.1128/JB.174.21.6815-6821.1992; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; MELANCON P, 1982, BIOCHEMISTRY-US, V21, P4318, DOI 10.1021/bi00261a022; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OHNISHI K, 1990, MOL GEN GENET, V221, P139, DOI 10.1007/BF00261713; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SHORENSTEIN RG, 1973, J BIOL CHEM, V248, P6170; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TAYLOR WE, 1979, GENE, V6, P331, DOI 10.1016/0378-1119(79)90073-8; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Zaychikov E, 1997, J BIOL CHEM, V272, P2259; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	57	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8757	8763		10.1074/jbc.274.13.8757	http://dx.doi.org/10.1074/jbc.274.13.8757			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085116	hybrid			2022-12-27	WOS:000079451600058
J	Worthylake, R; Opresko, LK; Wiley, HS				Worthylake, R; Opresko, LK; Wiley, HS			ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; POSTENDOCYTIC TRAFFICKING; ENDOCYTIC SYSTEM; EGF RECEPTORS; NEU; INTERNALIZATION; FAMILY; HETERODIMERIZATION	ErbB-2/HER2 is an important signaling partner for the epidermal growth factor receptor (EGFR), Overexpression of erbB-2 is also associated with poor prognosis in breast cancer. To investigate how erbB-2 amplification affects its interactions with the EGFR, we used a human mammary epithelial cell system in which erbB-2 expression was increased 7-20-fold by gene transfection. We found that amplification of erbB-2 caused constitutive activation of erbB-2 as well as ligand-independent activation of the EGFR. Overexpression of erbB-2 strongly inhibited erbB-2 down-regulation following transactivation by EGFR. Significantly, down-regulation of activated EGFR was also inhibited by erbB-2 amplification, resulting in enhanced ligand-dependent activation of the EGFR. The rate of EGFR endocytosis was not affected by erbB-2 overexpression, but the rate of lysosomal targeting was significantly reduced. In addition, erbB-2 overexpression promoted rapid recycling of activated EGFR back to the cell surface and decreased ligand dissociation from the EGFR. Our data suggest that overexpression of erbB-2 inhibits both its downregulation and that of the EGFR. The net effect is increased signaling through the EGFR system.	Univ Utah, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Wiley, HS (corresponding author), Univ Utah, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.	Wiley@path.med.utah.edu		Wiley, Steven/0000-0003-0232-6867				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Baulida J, 1996, J BIOL CHEM, V271, P5251; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; DSOUZA B, 1993, ONCOGENE, V8, P1797; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GILL GN, 1984, J BIOL CHEM, V259, P7755; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAIGLER HT, 1985, J CELL PHYSIOL, V124, P322, DOI 10.1002/jcp.1041240223; Harlow E., 1988, ANTIBODIES LAB MANUA; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1992, ONCOGENE, V7, P511; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1993, REGULATION CELLULAR, V3, P277; MAIER LA, 1991, CANCER RES, V51, P5361; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tan M, 1997, CANCER RES, V57, P1199; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILEY HS, 1985, J BIOL CHEM, V260, P5290; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	56	258	268	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8865	8874		10.1074/jbc.274.13.8865	http://dx.doi.org/10.1074/jbc.274.13.8865			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085130	hybrid			2022-12-27	WOS:000079451600072
J	El-Jack, AK; Hamm, JK; Pilch, PF; Farmer, SR				El-Jack, AK; Hamm, JK; Pilch, PF; Farmer, SR			Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPAR gamma and C/EBP alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED MEMBRANE AMINOPEPTIDASE; BINDING-PROTEIN-ALPHA; NECROSIS-FACTOR-ALPHA; 3T3-L1 ADIPOCYTES; ECTOPIC EXPRESSION; GENE-EXPRESSION; ADIPOGENESIS; GLUT4; CELLS; VESICLES	Adipocyte differentiation is regulated by at least two major transcription factors, CCAAT/enhancer-binding protein alpha (C/EBP alpha) and peroxisome proliferator-activated receptor gamma (PPAR gamma), Expression of PPAR gamma in fibroblasts converts them to fat-laden cells with an adipocyte-like morphology. Here, we investigate the ability of PPAR gamma to confer insulin-sensitive glucose transport to a variety of murine fibroblast cell lines. When cultured in the presence of a PPAR gamma ligand, Swiss-3T3 and BALB/c-3T3 cells ectopically expressing PPAR gamma accumulate lipid droplets, express C/EBP alpha, aP2, insulin-responsive aminopeptidase, and glucose transporter isoform 4 (GLUT4), and exhibit highly insulin-responsive 2-deoxyglucose uptake. In contrast, PPAR gamma-expressing NIH-3T3 cells, despite similar lipid accumulation, adipocyte morphology, and aP2 expression, do not express C/EBP alpha or GLUT4 and fail to acquire insulin sensitivity. In cells ectopically expressing PPAR gamma, the development of insulin-responsive glucose uptake correlates with C/EBP alpha expression. Furthermore, ectopic expression of C/EBP alpha in NIH-3T3 cells converts them to the adipocyte phenotype and restores insulin-sensitive glucose uptake. We propose that the pathway(s) leading to fat accumulation and morphological changes are distinct from that leading to insulin-dependent glucose transport. Our results suggest that although PPAR gamma is sufficient to trigger the adipogenic program, C/EBP alpha is required for establishment of insulin-sensitive glucose transport.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@med-biochem.bu.edu		Farmer, Stephen/0000-0003-2483-2795; Pilch, Paul/0000-0003-1997-0499; El Jack, Amr/0000-0002-5892-5538	NIDDK NIH HHS [DK30425, DK35424, DK51586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK051586, R01DK030425, R01DK051586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shulman RG, 1996, MOL MED, V2, P533, DOI 10.1007/BF03401638; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	41	164	176	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7946	7951		10.1074/jbc.274.12.7946	http://dx.doi.org/10.1074/jbc.274.12.7946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075691	hybrid			2022-12-27	WOS:000079268100050
J	Morishige, K; Inanobe, A; Yoshimoto, Y; Kurachi, H; Murata, Y; Tokunaga, Y; Maeda, T; Maruyama, Y; Kurachi, Y				Morishige, K; Inanobe, A; Yoshimoto, Y; Kurachi, H; Murata, Y; Tokunaga, Y; Maeda, T; Maruyama, Y; Kurachi, Y			Secretagogue-induced exocytosis recruits G protein-gated K+ channels to plasma membrane in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANTERIOR-PITUITARY; POTASSIUM CHANNEL; MOLECULAR-PROPERTIES; INWARD RECTIFIER; EXPRESSION; BRAIN; GIRK1; LOCALIZATION; ACTIVATION; LACTOTROPHS	Stimulation-regulated fusion of vesicles to the plasma membrane is an essential step for hormone secretion but may also serve for the recruitment of functional proteins to the plasma membrane. While studying the distribution of G protein-gated K+ (K-G) channels in the anterior pituitary lobe, we found K-G channel subunits Kir3.1 and Kir3.4 localized on the membranes of intracellular dense core vesicles that contained thyrotropin. Stimulation of these thyrotroph cells with thyrotropin-releasing hormone provoked fusion of vesicles to the plasma membrane, increased expression of Kir3.1 and Kir3.4 subunits in the plasma membrane, and markedly enhanced K-G currents stimulated by dopamine and somatostatin, These data indicate a novel mechanism for the rapid insertion of functional ion channels into the plasma membrane, which could form a new type of negative feedback control loop for hormone secretion in the endocrine system.	Osaka Univ, Dept Pharmacol 2, Fac Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Obstet & Gynecol, Fac Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Shiga Univ Med Sci, Dept Anat 1, Otsu, Shiga 5202120, Japan; Tohoku Univ, Grad Sch Med, Dept Physiol, Sendai, Miyagi 9800872, Japan	Osaka University; Osaka University; Osaka University; Shiga University of Medical Science; Tohoku University	Kurachi, Y (corresponding author), Osaka Univ, Dept Pharmacol 2, Fac Med, Suita, Osaka 5650871, Japan.							CROYLE ML, 1986, DNA-J MOLEC CELL BIO, V5, P299, DOI 10.1089/dna.1986.5.299; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; EINHORN LC, 1993, J PHYSIOL-LONDON, V462, P563, DOI 10.1113/jphysiol.1993.sp019569; FERRER J, 1995, J BIOL CHEM, V270, P26086, DOI 10.1074/jbc.270.44.26086; FOMINA AF, 1995, J NEUROSCI, V15, P4982; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Iizuka M, 1997, NEUROSCIENCE, V77, P1, DOI 10.1016/S0306-4522(96)00460-5; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Ishii M, 1997, J NEUROSCI, V17, P7725; Karschin C, 1996, J NEUROSCI, V16, P3559; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Liao YJ, 1996, J NEUROSCI, V16, P7137; MARTIN JB, 1970, SCIENCE, V168, P1366, DOI 10.1126/science.168.3937.1366; Maruyama Y, 1996, J PHYSIOL-LONDON, V492, P807, DOI 10.1113/jphysiol.1996.sp021347; Morishige K, 1996, BIOCHEM BIOPH RES CO, V220, P300, DOI 10.1006/bbrc.1996.0400; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OZAWA H, 1989, ANAT EMBRYOL, V180, P207, DOI 10.1007/BF00309773; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; PENNEFATHER PS, 1988, BRAIN RES, V444, P346, DOI 10.1016/0006-8993(88)90944-4; Ponce A, 1996, J NEUROSCI, V16, P1990; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; SUCHER NJ, 1995, NEURON, V14, P1095, DOI 10.1016/0896-6273(95)90257-0; TADOKORO C, 1995, BIOCHEM BIOPH RES CO, V214, P1211, DOI 10.1006/bbrc.1995.2415; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WOJTOWICZ JM, 1994, J NEUROSCI, V14, P3688; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	33	31	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7969	7974		10.1074/jbc.274.12.7969	http://dx.doi.org/10.1074/jbc.274.12.7969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075694	hybrid			2022-12-27	WOS:000079268100053
J	Qazi, U; Gettins, PGW; Strickland, DK; Stoops, JK				Qazi, U; Gettins, PGW; Strickland, DK; Stoops, JK			Structural details of proteinase entrapment by human alpha(2)-macroglobulin emerge from three-dimensional reconstructions of Fab labeled native, half-transformed, and transformed molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR RECOGNITION SITE; HUMAN ALPHA-2-MACROGLOBULIN; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; ALPHA-MACROGLOBULINS; BAIT REGION; METHYLAMINE; LOCALIZATION; COMPLEXES; IMAGES	Three-dimensional electron microscopy reconstructions of native, half-transformed, and transformed alpha(2)-macroglobulins (alpha(2)Ms) labeled with a monoclonal Fab Fab offer new insight into the mechanism of its proteinase entrapment. Each alpha(2)M binds four Fabs, two at either end of its dimeric protomers approximately 145 Angstrom apart. in the native structure, the epitopes are near the base of its two chisel-like features, laterally separated by 129 Angstrom whereas in the methylamine-transformed alpha(2)M, the epitopes are at the base of its four arms, laterally separated by 160 A. Upon thiol ester cleavage, the chisels on the native alpha(2)M appear to split with a separation and rotation to give the four arm-like extensions on transformed alpha(2)M. Thus, the receptor binding domains previously enclosed within the chisels are exposed. The labeled structures further indicate that the two protomeric strands that constitute the native and transformed molecules are related and reside one on each side of the major axes of these structures. The half-transformed structure shows that the two Fabs at one end of the molecule have an arrangement similar to those on the native alpha(2)M, whereas on its transformed end, they have rotated. The rotation is associated with a partial untwisting of the strands and an enlargement of the openings to the cavity, We propose that the enlarged openings permit the entrance of the proteinase. Then cleavage of the remaining bait domains by a second proteinase occurs with its entrance into the cavity, This is followed by a retwisting of the strands to encapsulate the proteinases and expose the receptor binding domains associated with the transformed alpha(2)M.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Univ Illinois, Dept Biochem, Chicago, IL 60612 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Texas System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; American Red Cross	Stoops, JK (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, 6431 Fannin St, Houston, TX 77030 USA.	stoops@casper.med.uth.tmc.edu			NHLBI NIH HHS [HL 42886, HL 50744] Funding Source: Medline; NIGMS NIH HHS [GM 54414] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1974, BAYER S, V5, P72; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BOISSET N, 1993, J MOL BIOL, V232, P522, DOI 10.1006/jmbi.1993.1408; Boisset N, 1996, J BIOL CHEM, V271, P25762, DOI 10.1074/jbc.271.42.25762; Bowen ME, 1998, J BIOL CHEM, V273, P1825, DOI 10.1074/jbc.273.3.1825; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; DELAIN E, 1988, J BIOL CHEM, V263, P2981; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; FIGLER NL, 1991, J STRUCT BIOL, V106, P237, DOI 10.1016/1047-8477(91)90073-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1985, NEW METHODOLOGIES ST, P36; GETTINS P, 1989, BIOCHEMISTRY-US, V28, P5613, DOI 10.1021/bi00439a041; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; Kolodziej SJ, 1998, J STRUCT BIOL, V123, P124, DOI 10.1006/jsbi.1998.4027; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; MIDDAUGH CR, 1993, BIOCHIM BIOPHYS ACTA, V1161, P328, DOI 10.1016/0167-4838(93)90233-H; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Penczek PA, 1996, ULTRAMICROSCOPY, V63, P205, DOI 10.1016/0304-3991(96)00037-X; Qazi U, 1998, J BIOL CHEM, V273, P8987, DOI 10.1074/jbc.273.15.8987; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Starkey P. M., 1977, PROTEINASES MAMMALIA, P663; Stoops James K., 1998, Microscopy and Microanalysis, V4, P986, DOI 10.1017/S1431927600025058; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VLAICU R, 1985, ATHEROSCLEROSIS, V55, P35, DOI 10.1016/0021-9150(85)90164-9	40	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8137	8142		10.1074/jbc.274.12.8137	http://dx.doi.org/10.1074/jbc.274.12.8137			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075716	hybrid			2022-12-27	WOS:000079268100075
J	Rallapalli, R; Strachan, G; Cho, B; Mercer, WE; Hall, DJ				Rallapalli, R; Strachan, G; Cho, B; Mercer, WE; Hall, DJ			A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MEDIATED TRANSCRIPTION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; ONCOPROTEIN MDM2; BINDING DOMAIN; ACTIVATION; MUTATIONS; APOPTOSIS; DELETION	The MDMX gene product is related to the MDM2 oncoprotein, both of which interact with the p53 tumor suppressor. We have identified a novel transcript of the MDMX gene that is expressed in a variety of cell lines, and in particular, in growing and transformed cells. This transcript is identical to the published sequence yet it has a short internal deletion of 68 base pairs. This deletion produces a shift in the reading frame after codon 114, resulting in the inclusion of a stop codon at amino acid residue 127 (full-length MDMX is 489 residues). This truncated MDMX protein is termed MDMX-S ("short form"), represents only the p53-binding domain, and appears to bind p53 better than full-length MDMX The MDMX-S protein can be detected in cell extracts and when overexpressed is much more effective than MDMX at inhibiting p53-mediated transcriptional activation and induction of apoptosis, Since MDMX-S lacks the central and carboxyl-terminal regions contained within full length MDMX, it is likely to play a key role in the regulation of cell proliferation and apoptosis ina way distinct from MDMX.	Thomas Jefferson Univ, Jefferson Canc Inst, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Hall, DJ (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 501 Curtis Bldg, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD M, 1997, CANCER RES, V57, P614; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FREBOURG T, 1992, CANCER RES, V52, P6976; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Harlow E., 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOGAN TJ, 1995, CANCER RES, V55, P2883; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOBERG KH, 1992, ONCOGENE, V7, P411; Momand J, 1997, J CELL BIOCHEM, V64, P343; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schlott T, 1997, J PATHOL, V182, P54; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	38	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8299	8308		10.1074/jbc.274.12.8299	http://dx.doi.org/10.1074/jbc.274.12.8299			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075736	hybrid			2022-12-27	WOS:000079268100095
J	Sadar, MD				Sadar, MD			Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; LNCAP CELLS; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; STEROID-RECEPTORS; TERMINAL DOMAIN; PHOSPHORYLATION; BINDING	Transcription of the prostate-specific antigen (PSA) gene escapes regulation by androgens in advanced prostate cancer. To determine the molecular mechanism(s) of androgen-independent regulation of the PSA gene, the possibility that the androgen receptor (AR) is activated in the absence of androgen by stimulation of protein kinase A (PKA) was investigated. Activation of PKA by forskolin resulted in elevated expression of the PSA gene in androgen-depleted LNCaP cells, an effect that was blocked by the antiandrogen, bicalutamide, Further evidence that induction of PSA gene expression was dependent on AR was obtained from experiments using PC3 cells devoid of AR. Neither PSA, PB, nor ARR(3) androgen-responsive reporters could be induced by activation of PKA in the absence of transfected AR. In addition, when nuclear AR from forskolin-treated LNCaP cells was incubated with oligonucleotides encoding an androgen response element of the PSA promoter and examined by electromobility shift assay, an increase in AR-androgen response element complex formation was observed. Lastly, cotransfection of an expression vector for a chimeric protein encoding the amino-terminal domain of the human AR linked to Gal4 and a 5xGal4UAS reporter gene construct resulted in activation of the amino-terminal domain of the AR by stimulation of PKA activity. These results demonstrate androgen-independent induction of PSA gene expression in prostate cancer cells by an AR-dependent pathway.	British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Dept Canc Endocrinol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.		Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215	NIDDK NIH HHS [P50 DK47656] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047656] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PE, 1992, CANCER RES, V52, P1525; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CULIG Z, 1994, CANCER RES, V54, P5474; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; GOUELI SA, 1984, BIOCHEM BIOPH RES CO, V123, P778, DOI 10.1016/0006-291X(84)90297-3; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JENSEN N, 1995, J CLIN ANESTH, V7, P270, DOI 10.1016/0952-8180(95)90006-3; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; KUIPER GGJM, 1995, BIOCHEMISTRY-US, V34, P1851, DOI 10.1021/bi00006a005; KUIPER GGJM, 1992, J STEROID BIOCHEM, V41, P697, DOI 10.1016/0960-0760(92)90407-A; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Sato N, 1996, J STEROID BIOCHEM, V58, P139, DOI 10.1016/0960-0760(96)00018-0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Snoek R, 1998, PROSTATE, V36, P256; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TURGEON JL, 1994, MOL ENDOCRINOL, V8, P860, DOI 10.1210/me.8.7.860; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VELSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P253; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WILSON EM, 1976, J BIOL CHEM, V251, P5620; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389; ZOPPI S, 1993, J CLIN INVEST, V91, P1105, DOI 10.1172/JCI116269	45	224	246	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7777	7783		10.1074/jbc.274.12.7777	http://dx.doi.org/10.1074/jbc.274.12.7777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075669	hybrid			2022-12-27	WOS:000079268100028
J	Walter, T; Aronson, A				Walter, T; Aronson, A			Specific binding of the E2 subunit of pyruvate dehydrogenase to the upstream region of Bacillus thuringiensis protoxin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL PROTEIN GENE; DELTA-ENDOTOXIN GENE; GLUTATHIONE-S-TRANSFERASE; ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; MULTIENZYME COMPLEX; EXPRESSION; TRANSFORMATION; TRANSCRIPTION	During sporulation, Bacillus thuringiensis produces inclusions comprised of different amounts of several related protoxins, each with a unique specificity profile for insect larvae. A major class of these genes designated cry1 have virtually identical dual overlapping promoters, but the upstream sequences differ. A gel retardation assay was used to purify a potential regulatory protein which bound with different affinities to these sequences in three cry1 genes. It was identified as the E2 subunit of pyruvate dehydrogenase. There was specific competition for binding by homologous gene sequences but not by pUC nor Bacillus subtilis DNA; calf thymus DNA competed at higher concentrations. The B. thuringiensis gene encoding E2 was cloned, and the purified glutathione S-transferase-Ea fusion protein footprinted to a consensus binding sequence within an inverted repeat and to a potential bend region, both sites 200-300 base pairs upstream of the promoters. Mutations of these sites in the cry1A gene resulted in decreased binding of the E2 protein and altered kinetics of expression of a fusion of this regulatory region with the lacZ gene. Recruitment of the E2 subunit as a transcription factor could couple the change in post exponential catabolism to the initiation of protoxin synthesis.	Purdue Univ, Dept Sci Biol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Walter, T (corresponding author), Purdue Univ, Dept Sci Biol, W Lafayette, IN 47907 USA.	twalter@bilbo.bio.purdue.edu			NIGMS NIH HHS [GM 34035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS LF, 1991, J BACTERIOL, V173, P3846, DOI 10.1128/JB.173.12.3846-3854.1991; AGAISSE H, 1995, J BACTERIOL, V177, P6027, DOI 10.1128/jb.177.21.6027-6032.1995; ARONSON A, 1995, APPL ENVIRON MICROB, V61, P4057, DOI 10.1128/AEM.61.11.4057-4060.1995; ARONSON AI, 1971, J BACTERIOL, V106, P1016, DOI 10.1128/JB.106.3.1016-1025.1971; ARONSON AI, 1994, FEMS MICROBIOL LETT, V117, P21, DOI 10.1111/j.1574-6968.1994.tb06737.x; ARONSON AI, 1993, MOL MICROBIOL, V7, P489, DOI 10.1111/j.1365-2958.1993.tb01139.x; BAUM JA, 1995, MOL MICROBIOL, V18, P1, DOI 10.1111/j.1365-2958.1995.mmi_18010001.x; BIETLOT HPL, 1990, BIOCHEM J, V267, P309, DOI 10.1042/bj2670309; BRIZZARD BL, 1991, MOL GEN GENET, V231, P59, DOI 10.1007/BF00293822; BULLA LA, 1980, CRC CR REV MICROBIOL, V8, P147, DOI 10.3109/10408418009081124; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; DULMAGE HT, 1970, J INVERTEBR PATHOL, V16, P80, DOI 10.1016/0022-2011(70)90209-0; ECKDAHL TT, 1987, NUCLEIC ACIDS RES, V15, P8531; EIDENTWILKINSON B, 1992, J BACTERIOL, V174, P477, DOI 10.1128/jb.174.2.477-485.1992; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIACOMINI A, 1992, FEMS MICROBIOL LETT, V100, P87, DOI 10.1111/j.1574-6968.1992.tb05687.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hederstedt Lars, 1993, P181; HEMILA H, 1990, J BACTERIOL, V172, P5052, DOI 10.1128/jb.172.9.5052-5063.1990; HOFTE H, 1990, NUCLEIC ACIDS RES, V18, P5545; HOFTE H, 1989, MICROBIOL REV, V53, P242; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; LAFFAN JJ, 1988, P NATL ACAD SCI USA, V85, P7452, DOI 10.1073/pnas.85.20.7452; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lee MK, 1996, APPL ENVIRON MICROB, V62, P583, DOI 10.1128/AEM.62.2.583-586.1996; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miller J. H, 1972, EXPT MOL GENETICS; NAKATA HM, 1960, J BACTERIOL, V80, P801, DOI 10.1128/JB.80.6.801-810.1960; RUSSELL GC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P225, DOI 10.1016/0167-4838(91)90271-Z; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHIS V, 1989, MOL MICROBIOL, V3, P229, DOI 10.1111/j.1365-2958.1989.tb01812.x; SCHURTER W, 1989, MOL GEN GENET, V218, P177, DOI 10.1007/BF00330581; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH GP, 1993, NUCLEIC ACIDS RES, V16, P6240; TABASHNIK BE, 1992, APPL ENVIRON MICROB, V58, P3343, DOI 10.1128/AEM.58.10.3343-3346.1992; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WALTER T, 1995, THESIS PURDUE U; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	41	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					7901	7906		10.1074/jbc.274.12.7901	http://dx.doi.org/10.1074/jbc.274.12.7901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075684	hybrid			2022-12-27	WOS:000079268100043
J	Park, CY; Hayman, MJ				Park, CY; Hayman, MJ			The tyrosines in the bidentate motif of the env-sea oncoprotein are essential for cell transformation and are binding sites for Grb2 and the tyrosine phosphatase SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; AVIAN ERYTHROBLASTOSIS VIRUS; SCATTER FACTOR-RECEPTOR; GROWTH-FACTOR RECEPTOR; TPR-MET ONCOPROTEIN; POINT MUTATION; PROTEIN-KINASE; SH3 DOMAINS; ONCOGENE; ACTIVATION	The transforming gene product of the S13 avian erythroblastosis virus, the env-sea protein, is a member of the hepatocyte growth factor receptor family of tyrosine kinases comprising Met, Ron, and Sea. Like all three members of this family, the env-sea protein has a so-called bidentate motif (Y(557)INMAVTY(564)VNL) composed of two tandemly arranged tyrosines in the carboxyl terminus. To investigate whether the tyrosine residues in this motif are essential for the env-sea-mediated transformation, we generated tyrosine to phenylalanine mutations. Substitutions of both tyrosine residues resulted in complete loss of the transforming activity. In contrast, single mutations at either tyrosine did not inhibit transformation of Rat1 cells, and mutation of tyrosine 564 actually increased transformation of Rat 1 cells. To define signaling pathways activated by the env-sea protein, we looked for protein-protein interactions mediated by these tyrosine residues. We show that the bidentate motif is responsible for interaction with the adapter protein Grb2, phosphatidylinositol 3-kinase, and the tyrosine phosphatase SHP-2, Furthermore, we show that microinjected Src homology 2 domains from either Grb2 or SHP-2 blocked the transforming activity of the env-sea protein. Together, these results suggest that the tyrosines within the bidentate motif are essential for the env-sea transformation.	SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	hayman@asterix.bio.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; CROWE AJ, 1994, ONCOGENE, V9, P537; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Keegan K, 1996, ONCOGENE, V12, P1537; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONSIN C, 1993, ONCOGENE, V8, P1195; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7583	7590		10.1074/jbc.274.11.7583	http://dx.doi.org/10.1074/jbc.274.11.7583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066827	hybrid			2022-12-27	WOS:000079078400099
J	Hagen, FK; Hazes, B; Raffo, R; deSa, D; Tabak, LA				Hagen, FK; Hazes, B; Raffo, R; deSa, D; Tabak, LA			Structure-function analysis of the UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase - Essential residues lie in a predicted active site cleft resembling a lactose repressor fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE ALIGNMENT; CRYSTAL-STRUCTURE; BINDING-SITES; PURIFICATION; GALNAC; GALACTOSYLTRANSFERASE; IDENTIFICATION; RECOGNITION; EXPRESSION; DOMAINS	Mucin-type O-glycosylation is initiated by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (ppGaNTases), Based on sequence relationships with divergent proteins, the ppGaNTases can be subdivided into three putative domains: each putative domain contains a characteristic sequence motif. The 112-amino acid glycosyltransferase (1) under bar (GT1) motif represents the first half of the catalytic unit and contains a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence. Secondary structure predictions and structural threading suggest that the GT1 motif forms a 5-stranded parallel beta-sheet flanked by 4 alpha-helices, which resembles the first domain of the lactose repressor. Four invariant carboxylates and a histidine residue are predicted to lie at the C-terminal end of three beta-strands and line the active site cleft. Site-directed mutagenesis of murine ppGaNTase-T1 reveals that conservative mutations at these 5 positions result in products with no detectable enzyme activity (D156Q, D209N, and H211D) or <1% activity (E127Q and E213Q). The second half of the catalytic unit contains a DXXYXXWGGENXE motif (positions 310-322) which is also found in beta 1,4-galactosyltransferases (termed the Gal/GaLNAc-T motif), Mutants of carboxylates within this motif express either no detectable activity, 1% or 2% activity (F319Q, E322Q, and D310N, respectively). Mutagenesis of highly conserved (but not invariant) carboxylates produces only modest alterations in enzyme activity. Mutations in the C-terminal 128-amino acid ricin-like lectin motif do not alter the enzyme's catalytic properties.	Univ Rochester, Rochester Inst Biomed Sci, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada	University of Rochester; University of Alberta	Tabak, LA (corresponding author), Univ Rochester, Rochester Inst Biomed Sci, Ctr Oral Biol, 601 Elmwood Ave, Rochester, NY 14642 USA.	Lawrence_Tabak@urmc.rochester.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108, T35DE007189] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08108, T35 DE07189] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BOEGGEMAN EE, 1995, GLYCOCONJUGATE J, V12, P865, DOI 10.1007/BF00731249; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; Breton C, 1998, J BIOCHEM, V123, P1000; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; Frankel AE, 1996, BIOCHEMISTRY-US, V35, P14749, DOI 10.1021/bi960798s; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG YC, 1992, J BIOL CHEM, V267, P2728; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wragg S, 1997, BIOCHEM J, V328, P193, DOI 10.1042/bj3280193; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	32	101	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1999	274	10					6797	6803		10.1074/jbc.274.10.6797	http://dx.doi.org/10.1074/jbc.274.10.6797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172BQ	10037781	hybrid, Green Submitted			2022-12-27	WOS:000078902800103
